PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	WANG, J; KLEIN, JR				WANG, J; KLEIN, JR			THYMUS-NEUROENDOCRINE INTERACTIONS IN EXTRATHYMIC T-CELL DEVELOPMENT	SCIENCE			English	Article							INTESTINAL INTRAEPITHELIAL LYMPHOCYTES; BONE-MARROW ORIGIN; GROWTH-HORMONE; RADIATION CHIMERAS; NEGATIVE SELECTION; EPITHELIAL-CELLS; ATHYMIC MICE; ALPHA-BETA; RECEPTOR; MOUSE	Studies of the development of murine intestinal intraepithelial lymphocytes (IELs) have yielded markedly different results depending on the experimental system used. In athymic radiation chimeras, IELs consist of all subsets found in euthymic mice; adult mice that were athymic at birth have only IELs that are positive for T cell receptor gamma delta and CD8 alpha alpha. These differences are resolved by the finding that administration of the neuropeptide thyrotropin-releasing hormone to adult mice thymectomized as neonates leads to the development of all IEL T cells. Thus, a neuroendocrine signal initiated by the thymus during fetal or neonatal life appears to be required for subsequent extrathymic maturation of gut alpha beta T cells.	UNIV TULSA, DEPT BIOL SCI, TULSA, OK 74104 USA; UNIV TULSA, CTR STUDIES MOLEC BIOL & BIOTECHNOL, TULSA, OK 74104 USA	University of Tulsa; University of Tulsa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035566, R23DK035566] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK035566, DK35566] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BANDEIRA A, 1991, P NATL ACAD SCI USA, V88, P43, DOI 10.1073/pnas.88.1.43; BEN E, 1991, LIFE SCI, V48, P2141, DOI 10.1016/0024-3205(91)90147-4; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; DARDENNE M, 1992, ANN NY ACAD SCI, V650, P85; FARBIS N, 1992, INT J IMMUNOPATH PH, V5, P93; GOFF BL, 1987, CLIN EXP IMMUNOL, V68, P580; GOFF BL, 1990, CLIN EXP IMMUNOL, V48, P2141; GUYGRAND D, 1991, IMMUNOL RES, V10, P296, DOI 10.1007/BF02919710; GUYGRAND D, 1993, CURR OPIN IMMUNOL, V5, P247, DOI 10.1016/0952-7915(93)90012-H; GUYGRAND D, 1991, J EXP MED, V173, P471, DOI 10.1084/jem.173.2.471; HENDERSON RS, 1981, THYMUS, V3, P359; HOLUB M, 1989, IMMUNOLOGY NUDE MICE, P141; KAISERLIAN D, 1989, EUR J IMMUNOL, V19, P1513, DOI 10.1002/eji.1830190827; KAISERLIAN D, 1993, EUR J IMMUNOL, V23, P2717, DOI 10.1002/eji.1830231053; KENAI H, 1993, EUR J IMMUNOL, V23, P1818, DOI 10.1002/eji.1830230813; KIYONO H, 1994, MUCOSAL IMMUNOLOGY I, P1; KLEIN JR, 1987, J IMMUNOL, V138, P58; KLEIN JR, 1986, J EXP MED, V164, P309, DOI 10.1084/jem.164.1.309; KLEIN JR, 1992, IMMUNOL TODAY, V13, P148, DOI 10.1016/0167-5699(92)90114-M; LEFRANCOIS L, 1991, IMMUNOL TODAY, V12, P436, DOI 10.1016/0167-5699(91)90015-L; LEFRANCOIS L, 1991, J IMMUNOL, V147, P1746; LIN T, 1993, EUR J IMMUNOL, V23, P1968, DOI 10.1002/eji.1830230836; LONDON SD, 1987, J EXP MED, V165, P830, DOI 10.1084/jem.165.3.830; MALOY KJ, 1991, IMMUNOLOGY, V72, P555; MAYRHOFER G, 1983, INT ARCH ALLER A IMM, V71, P317, DOI 10.1159/000233414; MAYRHOFER G, 1980, BLOOD, V55, P532; MISHELL BS, 1980, SELECTED METHODS CEL, P326; MOSLEY RL, 1992, J IMMUNOL METHODS, V156, P19; MOSLEY RL, 1994, DEV COMP IMMUNOL, V18, P155, DOI 10.1016/0145-305X(94)90243-7; MOSLEY RL, 1990, J IMMUNOL, V145, P1369; MOSLEY RL, 1992, TRANSPLANTATION, V53, P868, DOI 10.1097/00007890-199204000-00030; MURPHY WJ, 1993, J EXP MED, V178, P231, DOI 10.1084/jem.178.1.231; MURPHY WJ, 1992, J IMMUNOL, V149, P3851; PIERPAOL.W, 1972, EXPERIENTIA, V28, P1386; PIERPAOLI W, 1972, NATURE-NEW BIOL, V238, P282, DOI 10.1038/newbio238282a0; PIERPAOLI W, 1990, J NEUROIMMUNOL, V27, P99, DOI 10.1016/0165-5728(90)90059-V; PIERPAOLI W, 1975, CLIN EXP IMMUNOL, V20, P323; PIERPAOLI W, 1977, CELL IMMUNOL, V29, P16, DOI 10.1016/0008-8749(77)90271-4; POUSSIER P, 1992, J EXP MED, V176, P187, DOI 10.1084/jem.176.1.187; POUSSIER P, 1994, ANNU REV IMMUNOL, V12, P521, DOI 10.1146/annurev.immunol.12.1.521; POUSSIER P, 1993, J EXP MED, V178, P1947, DOI 10.1084/jem.178.6.1947; ROCHA B, 1992, IMMUNOL TODAY, V13, P449, DOI 10.1016/0167-5699(92)90074-H; ROCHA B, 1991, J EXP MED, V173, P483, DOI 10.1084/jem.173.2.483; SAKABE K, 1986, THYMUS, V8, P97; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; STICKNEY D, 1993, MOL IMMUNOL, V30, P813, DOI 10.1016/0161-5890(93)90004-U; VIDAL K, 1993, J IMMUNOL, V151, P4642; VINEY JL, 1989, IMMUNOLOGY, V66, P583; WEIHE WH, 1984, EXP CELL BIOL, V52, P140; WHETSELL M, 1991, MOL CELL BIOL, V11, P5902, DOI 10.1128/MCB.11.12.5902	51	83	84	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 23	1994	265	5180					1860	1862		10.1126/science.8091211	http://dx.doi.org/10.1126/science.8091211			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	8091211				2022-12-24	WOS:A1994PH25800031
J	RIVARA, FP; KOEPSELL, TD; JURKOVICH, GJ; GURNEY, JG; SODERBERG, R				RIVARA, FP; KOEPSELL, TD; JURKOVICH, GJ; GURNEY, JG; SODERBERG, R			THE EFFECTS OF ALCOHOL-ABUSE ON READMISSION FOR TRAUMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SCREENING-TEST; INJURIES; INTOXICATION; EMERGENCY; ACCIDENTS	Objective.-To determine the effect of admission for trauma with concurrent acute alcohol intoxication or chronic alcohol abuse on the risk of subsequent recurrence of trauma. Design.-Prospective cohort study. Setting.-Level I regional trauma center. Patients.-A total of 2578 patients 18 years or older admitted with blunt or penetrating trauma within 24 hours of injury and surviving to discharge. All patients had a blood alcohol concentration (BAC) test, a gamma-glutamyltransferase (GGT) test, and the short Michigan Alcohol Screening Test (SMAST) performed on admission. Main Outcome Measurement.-Readmission to the trauma center for new trauma. Average follow-up was 28 months (range, 16 to 40 months). Results.-The overall rate of readmission for new injuries was 1.3 per 1000 patient-months of follow-up. Patients who were intoxicated on the initial admission (BAC >22 mmol/L [100 mg/dL]) were 2.5-fold as likely to be readmitted than those not intoxicated (95% confidence limits, 1.6, 3.9). The relative risks for patients with positive SMAST scores and abnormal GGT values were 2.2 (95% confidence limits, 1.4, 3.5) and 3.5 (95% confidence limits, 2.2, 5.5), respectively. The increased risks remained significant for intoxication and abnormal GGT values after adjustment for gender, race, Medicaid status, and mechanism of injury. Conclusion.-Alcohol abuse is associated with an increased risk of readmission for new trauma. Trauma patients should be screened for alcohol problems; referral of problem drinkers for appropriate care may decrease their risk of admission for subsequent trauma.	UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT SURG, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	RIVARA, FP (corresponding author), HARBORVIEW INJURY PREVENT & RES CTR, 325 9TH AVE, ZX-10, SEATTLE, WA 98104 USA.							BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; CESARE J, 1990, J TRAUMA, V30, P176, DOI 10.1097/00005373-199002000-00007; CHANG G, 1988, JAMA-J AM MED ASSOC, V260, P2533, DOI 10.1001/jama.260.17.2533; COX DR, 1972, J R STAT SOC B, V34, P187; DEVGUN MS, 1985, ALCOHOL CLIN EXP RES, V9, P235, DOI 10.1111/j.1530-0277.1985.tb05742.x; GENTILELLO LM, 1988, AM J SURG, V156, P558, DOI 10.1016/S0002-9610(88)80553-1; JURKOVICH GJ, 1992, ANN EMERG MED, V21, P704, DOI 10.1016/S0196-0644(05)82783-0; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LOWENFELS AB, 1984, ANN EMERG MED, V13, P1056, DOI 10.1016/S0196-0644(84)80070-0; MACKENZIE EJ, 1988, ICDMAP DETERMINING I; PAPOZ L, 1986, BRIT MED J, V292, P1234, DOI 10.1136/bmj.292.6530.1234; PATEL S, 1975, J CLIN PATHOL, V28, P414, DOI 10.1136/jcp.28.5.414; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; ROSKALI S, 1974, CLIN CHEM, V20, P1121; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SMITH GS, 1988, ANNU REV PUBL HEALTH, V9, P99; SODERSTROM CA, 1987, ARCH SURG-CHICAGO, V122, P1067; SODERSTROM CA, 1989, ADV TRAUMA, V4, P211; Swan KG, 1989, J TRAUMA, V29, P947; WATSON RR, 1986, ALCOHOL CLIN EXP RES, V10, P364, DOI 10.1111/j.1530-0277.1986.tb05108.x; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; 1990, BROADENING BASE TREA; 1985, INJURY AM CONTINUING	26	173	175	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1993	270	16					1962	1964		10.1001/jama.270.16.1962	http://dx.doi.org/10.1001/jama.270.16.1962			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC513	8105114				2022-12-24	WOS:A1993MC51300028
J	DEBRE, M; BONNET, MC; FRIDMAN, WH; CAROSELLA, E; PHILIPPE, N; REINERT, P; VILMER, E; KAPLAN, C; TEILLAUD, JL; GRISCELLI, C				DEBRE, M; BONNET, MC; FRIDMAN, WH; CAROSELLA, E; PHILIPPE, N; REINERT, P; VILMER, E; KAPLAN, C; TEILLAUD, JL; GRISCELLI, C			INFUSION OF FC-GAMMA-FRAGMENTS FOR TREATMENT OF CHILDREN WITH ACUTE IMMUNE THROMBOCYTOPENIC PURPURA	LANCET			English	Article							IMMUNOGLOBULIN-BINDING FACTORS; INTRAVENOUS IMMUNOGLOBULIN; ANTIBODY-PRODUCTION; GLOBULIN; RECEPTORS; CELLS; IGG; CHILDHOOD	Treatment of acute immune thrombocytopenic purpura (ITP) with intravenous immunoglobulin (IVIG) induces partial or complete responses, shown by transient or persistent increases in platelet count. The clinical benefit could be due to blockade of the Fcgamma receptor (FcgammaR); platelets sensitised by IgG could not be cleared by cells of the reticuloendothelial system if FcgammaR on these cells was blocked with IVIG. To find out whether this putative mechanism is correct, we treated twelve children who had acute ITP with intravenous infusions of Fcgamma fragments. Eleven children showed rapid increases in platelet counts to above the critical value of 50 x 10(9)/L, thereby avoiding major haemorrhagic risk. The response was stable in six patients and transient in five. No adverse reactions were observed. In responders who had detectable platelet-associated IgG before treatment (> 1500 IgG per platelet), platelet IgG fell substantially with treatment. Serum soluble CD16 (sCD16 or sFcgammaRIII) concentrations, measured in five children, showed transient or stable increases that correlated with the rise in platelet count. No sCD16 was detected in the Fcgamma preparation used. We conclude that the infusion of Fcgamma fragments is an efficient treatment of acute ITP in children. The efficacy of Fcgamma fragments strengthens the hypothesis that FcgammaR blockade is the main mechanism of action of IVIG in ITP, although other immunoregulatory mechanisms triggered by the presence of increased sCD16 concentrations in serum could be involved in the clinical benefit observed.	DIRECT MED IMMUNOPROT PASTEUR MERLEUX SERUMS & VAC, MARCY LETOILE, FRANCE; INST CURIE, INSERM, U255, F-75231 PARIS 05, FRANCE; HOP INTERCOMMUNAL CRETEIL, CRETEIL, FRANCE; HOP ROBERT DEBRE, PARIS, FRANCE; HOP ST LOUIS, CTR HAYEM, CEA, DSV, F-75475 PARIS 10, FRANCE; HOP DEBROUSSE, F-69005 LYON, FRANCE; INST NATL TRANSFUS SANGUINE, PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; CEA; UDICE-French Research Universities; Universite Paris Cite; CHU Lyon	DEBRE, M (corresponding author), HOP NECKER ENFANTS MALAD, UNITE IMMUNOHEMATOL, 149 RUE SEVRES, F-75748 PARIS, FRANCE.			fridman, wolf herman/0000-0002-1332-0973; Teillaud, Jean-Luc/0000-0003-4442-9565				ANDERSON CL, 1989, CHEM IMMUNOL, V47, P1; ASTIER A, IN PRESS J IMMUNOL M; BARANDUN S, 1975, VOX SANG, V28, P157, DOI 10.1111/j.1423-0410.1975.tb02755.x; BEARDSLEY DS, 1993, HEMATOLOGY INFANCY C, P1561; BURDACH SEG, 1986, J PEDIATR-US, V109, P770, DOI 10.1016/S0022-3476(86)80691-6; BUSSEL JB, 1987, VOX SANG, V52, P206, DOI 10.1111/j.1423-0410.1987.tb03029.x; BUSSEL JB, 1989, J ALLERGY CLIN IMMUN, V84, P566, DOI 10.1016/0091-6749(89)90193-0; CLARKSON SB, 1986, NEW ENGL J MED, V314, P1236, DOI 10.1056/NEJM198605083141907; COHN EJ, 1946, J AM CHEM SOC, V68, P459, DOI 10.1021/ja01207a034; FEHR J, 1982, NEW ENGL J MED, V306, P1254, DOI 10.1056/NEJM198205273062102; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; FOLLEA G, 1985, NOUV REV FR HEMATOL, V27, P5; FRIDMAN WH, 1986, MOL IMMUNOL, V23, P1141, DOI 10.1016/0161-5890(86)90144-6; FRIDMAN WH, 1988, NOUV REV FR HEMATOL, V30, P311; FRIDMAN WH, 1974, J IMMUNOL, V113, P1008; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P3189; HUIZINGA TWJ, 1988, NATURE, V333, P667, DOI 10.1038/333667a0; IMBACH P, 1981, LANCET, V1, P1228; KAVERI SV, 1991, CLIN EXP IMMUNOL, V86, P192; KHAYAT D, 1987, J IMMUNOL METHODS, V100, P235, DOI 10.1016/0022-1759(87)90194-3; LANIER LL, 1989, EUR J IMMUNOL, V19, P775, DOI 10.1002/eji.1830190431; LOWY I, 1983, P NATL ACAD SCI-BIOL, V80, P2323, DOI 10.1073/pnas.80.8.2323; MULLER JY, 1983, REV FR TRANSFUS IMMU, V26, P173, DOI 10.1016/S0338-4535(83)80091-9; ONCLEY JL, 1949, J AM CHEM SOC, V71, P541, DOI 10.1021/ja01170a048; SALAMA A, 1983, LANCET, V2, P193; SOLALCELIGNY P, 1983, SCAND J HAEMATOL, V31, P39; SOUBRANE C, 1993, BLOOD, V81, P15; TEILLAUD JL, 1990, MOL IMMUNOL, V27, P1209, DOI 10.1016/0161-5890(90)90024-T; VARIN N, 1989, EUR J IMMUNOL, V19, P2263, DOI 10.1002/eji.1830191213	29	274	282	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	1993	342	8877					945	949		10.1016/0140-6736(93)92000-J	http://dx.doi.org/10.1016/0140-6736(93)92000-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105212				2022-12-24	WOS:A1993MC00500007
J	RIGGS, JE				RIGGS, JE			SMOKING AND ALZHEIMERS-DISEASE - PROTECTIVE EFFECT OR DIFFERENTIAL SURVIVAL BIAS	LANCET			English	Editorial Material							CIGARETTE-SMOKING				RIGGS, JE (corresponding author), W VIRGINIA UNIV,HLTH SCI CTR,DEPT NEUROL,POB 9180,MORGANTOWN,WV 26506, USA.							AU WW, 1991, MUTAT RES, V260, P137, DOI 10.1016/0165-1218(91)90001-3; BARON JA, 1986, NEUROLOGY, V36, P1490, DOI 10.1212/WNL.36.11.1490; BOERRIGTER ME, 1992, J GERONTOL, V47, P177; BRENNER DE, 1993, NEUROLOGY, V43, P293, DOI 10.1212/WNL.43.2.293; CONNEALLY PM, 1991, ADV NEUROL, V56, P233; FARRER LA, 1984, AM J MED GENET, V18, P115, DOI 10.1002/ajmg.1320180115; FIELDING JE, 1985, NEW ENGL J MED, V313, P555, DOI 10.1056/NEJM198508293130906; GRAVES AB, 1991, INT J EPIDEMIOL S2, V20, P48; Gusella J F, 1991, Adv Hum Genet, V20, P125; PINCHEIRA J, 1993, MUTAT RES, V295, P55, DOI 10.1016/0921-8734(93)90001-J; RIGGS JE, 1992, CLIN NEUROPHARMACOL, V15, P88, DOI 10.1097/00002826-199204000-00002; RIGGS JE, 1992, MECH AGEING DEV, V65, P217, DOI 10.1016/0047-6374(92)90037-E; RIGGS JE, 1993, MECH AGEING DEV, V66, P249, DOI 10.1016/0047-6374(93)90012-G; VANDUIJN CM, 1991, BRIT MED J, V302, P1491, DOI 10.1136/bmj.302.6791.1491	14	71	71	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 25	1993	342	8874					793	794		10.1016/0140-6736(93)91547-Y	http://dx.doi.org/10.1016/0140-6736(93)91547-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103882				2022-12-24	WOS:A1993LY86800016
J	CAMPBELL, G; WEAVER, T; TOMLINSON, A				CAMPBELL, G; WEAVER, T; TOMLINSON, A			AXIS SPECIFICATION IN THE DEVELOPING DROSOPHILA APPENDAGE - THE ROLE OF WINGLESS, DECAPENTAPLEGIC, AND THE HOMEOBOX GENE ARISTALESS	CELL			English	Article							SEGMENT-POLARITY GENE; IMAGINAL DISKS; XENOPUS EMBRYOS; HALTERE DEVELOPMENT; ECTOPIC EXPRESSION; FROG EMBRYOS; BETA FAMILY; PATTERN; ORGANIZER; WNT	The wingless (wg) and decapentaplegic (dpp) genes of Drosophila encode homologs of secreted growth factors and are required for the correct patterning of the appendages. We show that the presumptive tips of both the leg and wing, the distal extreme of the proximodistal axis, are characterized by the close association of cells expressing wg, dpp, and the homeobox gene aristaless (al). Ectopic expression of wg can induce both ectopic al expression and a duplication of the proximodistal axis (the development of supernumerary legs), but only in regions expressing high levels of dpp. Ectopic al expression can induce a duplication of the proximodistal axis in the wing, suggesting that it may also be directly involved in axis specification. The proximodistal axis may be specified via a mechanism involving a direct interaction between cells expressing wg, dpp, and possibly al.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology				Campbell, Gerard/0000-0002-7631-4394				ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1992, DEVELOPMENT, V116, P81; BAKER NE, 1988, DEVELOPMENT, V102, P489; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BATE M, 1991, DEVELOPMENT, V112, P755; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; Bryant P.J., 1978, P230; Bryant PJ, 1987, GENETIC REGULATION D, P339; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN B, 1991, MECH DEVELOP, V33, P229, DOI 10.1016/0925-4773(91)90030-A; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; CONDIC ML, 1991, DEVELOPMENT, V111, P23; DAVIS LG, 1986, METHODS MOL BIOL; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; GELBART WM, 1989, DEVELOPMENT, V107, P65; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; Grigliati T., 1986, DROSOPHILA PRACTICAL, P39; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; LEWIS EB, 1945, GENETICS, V30, P137; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MEINHARDT H, 1982, DEV ORDER ITS ORIGIN, P439; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; POODRY CA, 1970, ROUX ARCH DEV BIOL, V166, P1, DOI 10.1007/BF00576805; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; POSTLETHWAIT JH, 1978, GENETICS BIOL DROS C, V2, P359; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; SCHUBIGER G, 1968, ROUX ARCH DEV BIOL, V160, P9; SHARMA RP, 1976, DEV BIOL, V48, P461, DOI 10.1016/0012-1606(76)90108-1; SMITH JC, 1989, DEVELOPMENT, V107, P149; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SOKOL SY, 1992, DEV BIOL, V154, P348, DOI 10.1016/0012-1606(92)90073-P; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Stern C, 1926, GENETICS, V11, P503; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481	59	246	247	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					1113	1123		10.1016/0092-8674(93)90732-6	http://dx.doi.org/10.1016/0092-8674(93)90732-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8104704				2022-12-24	WOS:A1993LY49300017
J	STEINHOFF, MC				STEINHOFF, MC			DEVELOPING AND DEPLOYING PNEUMOCOCCAL AND HAEMOPHILUS VACCINES	LANCET			English	Editorial Material											STEINHOFF, MC (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD 21218, USA.							FUNKHOUSER A, 1991, REV INFECT DIS, V13, P542; MASTRO TD, 1991, LANCET, V337, P156, DOI 10.1016/0140-6736(91)90813-5; RILEY ID, 1991, REV INFECT DIS, V13, P535; ROBBINS JB, 1983, J INFECT DIS, V148, P1136, DOI 10.1093/infdis/148.6.1136; STEINHOFF MC, 1992, 32ND INT C ANT AG CH, P325; 1986, NEW VACCINE DEV ESTA, V2, P357	6	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					630	631		10.1016/0140-6736(93)91754-A	http://dx.doi.org/10.1016/0140-6736(93)91754-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103141				2022-12-24	WOS:A1993LX27200005
J	XUE, D; TU, Y; CHALFIE, M				XUE, D; TU, Y; CHALFIE, M			COOPERATIVE INTERACTIONS BETWEEN THE CAENORHABDITIS-ELEGANS HOMEOPROTEINS UNC-86 AND MEC-3	SCIENCE			English	Article							DROSOPHILA HOMEODOMAIN PROTEINS; DNA-BINDING SPECIFICITY; TOUCH RECEPTOR NEURONS; POU-DOMAIN PROTEINS; C-ELEGANS; RNA-POLYMERASE; TRANSCRIPTION FACTORS; CELL IDENTITY; GENE; EXPRESSION	The POU-type homeodomain protein UNC-86 and the LIM-type homeodomain protein MEC-3, which specify neuronal cell fate in the nematode Caenorhabditis elegans, bind cooperatively as a heterodimer to the mec-3 promoter. Heterodimer formation increases DNA binding stability and, therefore, increases DNA binding specificity. The in vivo significance of this heterodimer formation in neuronal differentiation is suggested by (i) a loss-of-function mec-3 mutation whose product in vitro binds DNA well but forms heterodimers with UNC-86 poorly and (ii) a mec-3 mutation with wild-type function whose product binds DNA poorly but forms heterodimers well.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University				XUE, DING/0000-0002-8429-8136	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030997, R37GM030997] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30997] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHALFIE M, 1981, CELL, V24, P59, DOI 10.1016/0092-8674(81)90501-8; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; FRITSCH EFJ, 1989, MOL CLONING LABORATO; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MITANI S, IN PRESS DEVELOPMENT; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TREISMAN J, 1989, CELL, V59, P553; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WAY JC, 1991, GENE DEV, V5, P2199, DOI 10.1101/gad.5.12a.2199; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WILLIAMS BD, 1992, GENETICS, V131, P609; XUE D, 1992, EMBO J, V11, P4969, DOI 10.1002/j.1460-2075.1992.tb05604.x; XUE DF, UNPUB; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	51	194	201	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 3	1993	261	5126					1324	1328		10.1126/science.8103239	http://dx.doi.org/10.1126/science.8103239			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV656	8103239				2022-12-24	WOS:A1993LV65600029
J	CINQUE, P; BRYTTING, M; VAGO, L; CASTAGNA, A; PARRAVICINI, C; ZANCHETTA, N; MONFORTE, AD; WAHREN, B; LAZZARIN, A; LINDE, A				CINQUE, P; BRYTTING, M; VAGO, L; CASTAGNA, A; PARRAVICINI, C; ZANCHETTA, N; MONFORTE, AD; WAHREN, B; LAZZARIN, A; LINDE, A			EPSTEIN-BARR-VIRUS DNA IN CEREBROSPINAL-FLUID FROM PATIENTS WITH AIDS-RELATED PRIMARY LYMPHOMA OF THE CENTRAL-NERVOUS-SYSTEM	LANCET			English	Article							POLYMERASE CHAIN-REACTION; AMPLIFICATION; DIAGNOSIS	Epstein-Barr virus (EBV) is constantly associated with AIDS-related primary lymphomas of the central nervous system (CNS). To assess whether EBV DNA in cerebrospinal fluid (CSF) could be used as a tumour marker, CSF samples that had been taken within 180 days before death from 85 patients with HIV infection and neurological disorders at necropsy were examined retrospectively by nested polymerase chain reaction (PCR) for EBV. Histologically evident primary CNS lymphomas were found in 17 patients, and EBV was shown in tissue by in-situ hybridisation in 16 of the 16 cases examined. All 17 patients with primary CNS lymphoma had EBV DNA in CSF. EBV DNA was found in CSF from 1 of 68 HIV-infected patients without histologically detectable lymphoma at necropsy. PCR for EBV DNA in CSF was 100% sensitive and 98.5% specific for AIDS-associated primary CNS lymphoma, and may be useful as a diagnostic tumour marker.	UNIV MILAN,S RAFFAELE HOSP,DEPT INFECT DIS,I-20122 MILAN,ITALY; NATL BACTERIOL LAB,DEPT VIROL,S-10521 STOCKHOLM,SWEDEN; KAROLINSKA INST,S-10401 STOCKHOLM 60,SWEDEN; UNIV MILAN,L SACCO HOSP,DEPT PATHOL 5,I-20122 MILAN,ITALY; UNIV MILAN,L SACCO HOSP,CENT ANAL LAB,I-20122 MILAN,ITALY; UNIV MILAN,L SACCO HOSP,INFECT DIS CLIN,I-20122 MILAN,ITALY	University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Karolinska Institutet; University of Milan; Luigi Sacco Hospital; University of Milan; Luigi Sacco Hospital; University of Milan; Luigi Sacco Hospital			Castagna, Antonella/K-3280-2018; Cinque, Paola/AAA-1227-2019; LAZZARIN, Adriano/K-3607-2018	Castagna, Antonella/0000-0002-8338-9714; LAZZARIN, Adriano/0000-0003-2551-7754; Cinque, Paola/0000-0003-2448-5957				[Anonymous], 1982, CANCER, V49, P2112; AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BRYTTING M, 1992, J CLIN MICROBIOL, V30, P1937, DOI 10.1128/JCM.30.8.1937-1941.1992; CHAPPELL ET, 1992, NEUROSURGERY, V30, P825, DOI 10.1227/00006123-199206000-00001; CINQUE P, 1992, J INFECT DIS, V166, P1408, DOI 10.1093/infdis/166.6.1408; CINQUE P, 1993, 4TH INT C CYT PAR; GULLEY ML, 1992, CANCER, V70, P185, DOI 10.1002/1097-0142(19920701)70:1<185::AID-CNCR2820700129>3.0.CO;2-J; HAMILTONDUTOIT SJ, 1991, AM J PATHOL, V138, P149; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HSIA K, 1989, J CLIN MICROBIOL, V27, P1802, DOI 10.1128/JCM.27.8.1802-1809.1989; KATZ BZ, 1992, AM J PATHOL, V140, P1247; MACMAHON EME, 1991, LANCET, V338, P969, DOI 10.1016/0140-6736(91)91837-K; Maniatis T., 1982, MOL CLONING; PARRAVICINI CL, 1988, AIDS, V2, P171; SUMAYA CV, 1986, J INFECT DIS, V154, P864, DOI 10.1093/infdis/154.5.864	16	263	272	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					398	401		10.1016/0140-6736(93)92814-A	http://dx.doi.org/10.1016/0140-6736(93)92814-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101902				2022-12-24	WOS:A1993LR90000010
J	RAMSAY, MEB; RAO, M; BEGG, NT; REDHEAD, K; ATTWELL, AM				RAMSAY, MEB; RAO, M; BEGG, NT; REDHEAD, K; ATTWELL, AM			ANTIBODY-RESPONSE TO ACCELERATED IMMUNIZATION WITH DIPHTHERIA, TETANUS, PERTUSSIS-VACCINE	LANCET			English	Article							PERFORMANCE; AFFINITY	From May, 1990, a new schedule of immunisation against diphtheria, tetanus, and pertussis (at 2, 3, and 4 months) replaced the previous more widely spaced schedule. A report that children had lower concentrations of diphtheria and tetanus antibodies a month after an accelerated schedule led us to undertake a controlled study to assess antibody response and the persistence of antibodies a year after immunisation in children receiving vaccine according to widely spaced and accelerated schedules. Concentrations of antibodies to diphtheria and tetanus toxoids and to Bordetella pertussis filamentous haemagglutinin (FHA) were measured by solid-phase radioimmunoassay (SP-RIA). We studied 57 children who received accelerated immunisation at median ages of 11, 16, and 21 weeks and two control cohorts (total n = 82) who received vaccine at median ages of 15, 21, and 45 weeks. 6-8 weeks after the third dose the accelerated-schedule group had lower (p<0.0001) geometric mean concentrations of antibody to tetanus (0.522 [95% CI 0.383-0.710] vs 3.43 [2.45-4.81] IU/mL), diphtheria (0.266 [0.179-0.396] vs 2.39 [0.616-3.53] IU/mL), and FHA (0.044 10.030-0.063] vs 0.270 [0.196-0.374] units/mL) than the longer-schedule group. 12 months after the third dose the differences between the groups had narrowed (tetanus 0.197 vs 0.341 IU/mL, p=0.29; diphtheria 0.100 vs 0.131 IU/mL, p=0.64; FHA 0.014 vs 0.016 units/mL, p=0.72). At that time all children had tetanus antibody concentrations above protective levels (0.01 IU/mL); only 2 of 31 in the accelerated-schedule group and 3 of 31 in the longer-schedule group had diphtheria antibody concentrations below the protective level. The use of an accelerated schedule of diphtheria, tetanus, and pertussis vaccination is unlikely to lead to an increase in the proportion of children unprotected against these diseases before the preschool booster.	PHLS,CTR COMMUNICABLE DIS SURVEILLANCE,DIV IMMUNISAT,LONDON,ENGLAND; NE ESSEX HLTH AUTHOR,COLCHESTER,ESSEX,ENGLAND; NATL INST BIOL STAND & CONTROLS,POTTERS BAR,HERTS,ENGLAND	National Institute for Biological Standards & Control			Ramsay, Mary Elizabeth/S-8281-2016	Ramsay, Mary Elizabeth/0000-0002-7156-7640				[Anonymous], 1988, LANCET, Vi, P955; BOOY R, 1992, LANCET, V339, P507, DOI 10.1016/0140-6736(92)90336-2; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC; Miller E, 1992, Commun Dis Rep CDR Rev, V2, pR152; NIMMO GR, 1984, J IMMUNOL METHODS, V72, P177, DOI 10.1016/0022-1759(84)90446-0; RAMSAY MEB, 1991, BRIT MED J, V302, P1489, DOI 10.1136/bmj.302.6791.1489; SESARDIC D, 1992, LANCET, V340, P737, DOI 10.1016/0140-6736(92)92284-M; SMITH JWG, 1969, BRIT MED BULL, V25, P177, DOI 10.1093/oxfordjournals.bmb.a070689; STEWARD MW, 1985, J IMMUNOL METHODS, V78, P173, DOI 10.1016/0022-1759(85)90074-2; WHITE JM, 1992, BRIT MED J, V304, P682, DOI 10.1136/bmj.304.6828.682; 1990, IMMUNISATION INFECTI; 1989, CANADIAN IMMUNIZATIO; 1988, IMMUNISATION INFECTI; 1990, REPORT WHO M COPENHA	14	21	21	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					203	205		10.1016/0140-6736(93)92298-8	http://dx.doi.org/10.1016/0140-6736(93)92298-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100929				2022-12-24	WOS:A1993LN62200011
J	ALLEN, CMC				ALLEN, CMC			CONSCIOUS BUT PARALYZED - RELEASING THE LOCKED-IN	LANCET			English	Editorial Material											ALLEN, CMC (corresponding author), ADDENBROOKES HOSP,DEPT NEUROL,CAMBRIDGE CB2 2QQ,ENGLAND.							BERNAT JL, 1993, NEUROLOGY, V43, P224, DOI 10.1212/WNL.43.1_Part_1.224; BRAHAMS D, 1992, LANCET, V340, P1534, DOI 10.1016/0140-6736(92)92777-D; HOWARD RS, 1989, BRAIN, V112, P1155, DOI 10.1093/brain/112.5.1155; MOSS AH, 1993, NEUROLOGY, V43, P438, DOI 10.1212/WNL.43.2.438; PATTERSON JR, 1986, STROKE, V17, P758, DOI 10.1161/01.STR.17.4.758; THADANI VM, 1991, NEUROLOGY, V41, P498, DOI 10.1212/WNL.41.4.498; 1993, NEUROLOGY, V43, P222	7	10	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					130	131		10.1016/0140-6736(93)91340-R	http://dx.doi.org/10.1016/0140-6736(93)91340-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101251				2022-12-24	WOS:A1993LN04200006
J	VENDRELL, JP; REYNES, J; HUGUET, MF; NGOU, J; MICHARD, C; ATOUI, N; PRATLONG, F; SEGONDY, M; SERRE, A				VENDRELL, JP; REYNES, J; HUGUET, MF; NGOU, J; MICHARD, C; ATOUI, N; PRATLONG, F; SEGONDY, M; SERRE, A			IN-VITRO SYNTHESIS OF ANTIBODIES TO TOXOPLASMA-GONDII BY LYMPHOCYTES FROM HIV-1-INFECTED PATIENTS	LANCET			English	Note							HIV-1 INFECTION; SECRETION; CELLS	Toxoplasma-specific in-vitro antibody production by peripheral blood lymphocytes (PBL) was investigated in 124 adults infected with human immunodeficiency virus (HIV-1). PBL from 20 of 21 patients with cerebral toxoplasmosis showed spontaneous in-vitro secretion of antibodies to Toxoplasma gondii antigens. Among 103 HIV-1-infected patients without signs or symptoms of toxoplasmosis, PBL from 19 produced toxoplasma-specific antibodies in vitro; 5 of these patients, who discontinued prophylaxis for toxoplasmic encephalitis, showed in-vitro antibody production 3-15 months before the diagnosis of toxoplasmic encephalitis. In-vitro production of toxoplasma-specific antibodies could improve the diagnosis of toxoplasmic encephalitis in HIV-1-infected patients.	CHR MONTPELLIER,DEPT PARASITOL,MONTPELLIER,FRANCE; FAC MED MONTPELLIER,F-34000 MONTPELLIER,FRANCE; CHR MONTPELLIER,DEPT INFECT DIS,MONTPELLIER,FRANCE; FAC MED MONTPELLIER,F-34000 MONTPELLIER,FRANCE; CHR MONTPELLIER,DEPT IMMUNOL,MONTPELLIER,FRANCE; CHR MONTPELLIER,DEPT VIROL,MONTPELLIER,FRANCE	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier	VENDRELL, JP (corresponding author), INST BIOL,DEPT IMMUNOL,INSERM,U249,4 BLVD HENRI IV,F-34060 MONTPELLIER,FRANCE.							AMADORI A, 1989, J IMMUNOL, V143, P2146; [Anonymous], MMWR; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; PAHWA S, 1989, P NATL ACAD SCI USA, V86, P7532, DOI 10.1073/pnas.86.19.7532; PORTER SB, 1992, NEW ENGL J MED, V327, P1643, DOI 10.1056/NEJM199212033272306; RIECKMANN P, 1991, J IMMUNOL, V147, P2922; STEPICKBIEK P, 1990, J INFECT DIS, V162, P270, DOI 10.1093/infdis/162.1.270; STEVENS RH, 1979, J IMMUNOL, V122, P2498; VENDRELL JP, 1992, CLIN EXP IMMUNOL, V89, P126, DOI 10.1111/j.1365-2249.1992.tb06890.x; VENDRELL JP, 1991, CLIN EXP IMMUNOL, V83, P197, DOI 10.1111/j.1365-2249.1991.tb05614.x	10	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					22	23		10.1016/0140-6736(93)91883-N	http://dx.doi.org/10.1016/0140-6736(93)91883-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100291				2022-12-24	WOS:A1993LK98500012
J	LOWRY, S				LOWRY, S			ONCOLOGY - MOLECULAR-BASIS FOR HORMONE-RELATED CANCER	LANCET			English	Editorial Material											LOWRY, S (corresponding author), BELFAST CITY HOSP,DEPT ONCOL,BELFAST BT9 7AD,ANTRIM,NORTH IRELAND.							FATHALLA MF, 1971, LANCET, V2, P163; FUTREAL PA, 1992, CANCER RES, V52, P2624; JACOBS IJ, 1993, CANCER RES, V53, P1218; LOWRY WS, 1992, OVARIAN CANC, V2, P35; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P689, DOI 10.1093/nar/19.3.689; SKOLNICK HM, 1992, AM J HUM GENET, V51, P4; TULINIUS H, 1992, BRIT MED J, V305, P855, DOI 10.1136/bmj.305.6858.855	7	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1630	1630		10.1016/0140-6736(93)90767-B	http://dx.doi.org/10.1016/0140-6736(93)90767-B			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099999				2022-12-24	WOS:A1993LJ72700013
J	LOGAN, A				LOGAN, A			MOLECULAR MEDICINE - MAKING CALCIUM SIGNALS SELECTIVE	LANCET			English	Note											LOGAN, A (corresponding author), UNIV BIRMINGHAM,DEPT CLIN CHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.			Logan, Ann/0000-0003-3215-5042				ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1248	1248		10.1016/0140-6736(93)91151-B	http://dx.doi.org/10.1016/0140-6736(93)91151-B			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098397				2022-12-24	WOS:A1993LC49700009
J	HURLEY, JC				HURLEY, JC			REAPPRAISAL OF THE ROLE OF ENDOTOXIN IN THE SEPSIS SYNDROME	LANCET			English	Article							RESPIRATORY-DISTRESS SYNDROME; ASSOCIATION; INFECTIONS; SEPTICEMIA; MORTALITY; PREDICTOR; FAILURE; DISEASE; DEATH; TRACT	There is strong evidence to implicate endotoxin released from gram negative bacteria in the pathogenesis of the sepsis syndrome and related conditions, but equally compelling data bring the role of endotoxin into doubt. Reappraisal of endotoxin and its release from gram negative bacteria suggests that it is not directly responsible for the complications of sepsis syndrome. Rather, release of endotoxin is a marker for the transition of gram negative organisms to cell-wall-deficient forms (L-forms) that may persist undetected despite antibiotic therapy directed against the parental form. This transition has two consequences in compromised patients: L-forms cause organ failure, and they serve as a sanctuary from which cell-wall-intact revertants may arise.			HURLEY, JC (corresponding author), CHILDRENS HOSP & MED CTR,DIV INFECT DIS,4800 SAND POINT WAY NE,POB C5371,SEATTLE,WA 98105, USA.			Hurley, James/0000-0002-5885-2084				ANDERSEN BM, 1984, SCAND J INFECT DIS, V16, P247, DOI 10.3109/00365548409070397; BELL RC, 1983, ANN INTERN MED, V99, P293, DOI 10.7326/0003-4819-99-3-293; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BOUCEK MM, 1984, J PEDIATR-US, V105, P538, DOI 10.1016/S0022-3476(84)80416-3; BRANDTZAEG P, 1992, J CLIN INVEST, V89, P816, DOI 10.1172/JCI115660; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; CASSELL GH, 1993, CLIN MICROBIOL REV, V6, P69, DOI 10.1128/CMR.6.1.69-87.1993; CASSELL GH, 1988, LANCET, V2, P240; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; FEIN AM, 1983, CHEST, V83, P40, DOI 10.1378/chest.83.1.40; FEINGOLD DS, 1969, NEW ENGL J MED, V281, P1159, DOI 10.1056/NEJM196911202812106; FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593; GUTMAN LT, 1965, J CLIN INVEST, V44, P1945, DOI 10.1172/JCI105300; HURLEY JC, 1992, CLIN INFECT DIS, V15, P840, DOI 10.1093/clind/15.5.840; HURLEY JC, IN PRESS J INFECT DI; HURLEY JC, 1991, THESIS MELBOURNE U M; KAPLAN RL, 1979, ARCH INTERN MED, V139, P867, DOI 10.1001/archinte.139.8.867; KORVICK JA, 1992, ANTIMICROB AGENTS CH, V36, P620, DOI 10.1128/AAC.36.3.620; KREGER BE, 1980, AM J MED, V68, P344, DOI 10.1016/0002-9343(80)90102-3; Madoff S, 1986, BACTERIAL L FORMS; MARTIN MA, 1992, CLIN INFECT DIS, V14, P1213, DOI 10.1093/clinids/14.6.1213; MCKAY KA, 1966, NATURE, V212, P359, DOI 10.1038/212359a0; MIYATA T, 1989, LANCET, V2, P189; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MOORE RD, 1987, J INFECT DIS, V155, P93, DOI 10.1093/infdis/155.1.93; NIEDERMAN MS, 1990, CLIN CHEST MED, V11, P633; OGNIBENE FP, 1986, NEW ENGL J MED, V315, P547, DOI 10.1056/NEJM198608283150904; PARSONS PE, 1992, AM REV RESPIR DIS, V146, P694, DOI 10.1164/ajrccm/146.3.694; PARSONS PE, 1989, AM REV RESPIR DIS, V140, P294, DOI 10.1164/ajrccm/140.2.294; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; SEIDENFELD JJ, 1986, AM REV RESPIR DIS, V134, P12; TANIMOTO H, 1991, ANTIBIOT CHEMOTHER, V44, P94; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; VANDEVENTER SJH, 1988, LANCET, V1, P605; WORTEL CH, 1992, J INFECT DIS, V166, P1367, DOI 10.1093/infdis/166.6.1367; YAMAMOTO A, 1979, JPN J EXP MED, V49, P361; 1992, LANCET, V340, P1323; 1985, LANCET, V2, P594	38	37	38	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1133	1135		10.1016/0140-6736(93)93139-R	http://dx.doi.org/10.1016/0140-6736(93)93139-R			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097815				2022-12-24	WOS:A1993KZ68700015
J	MACFARLANE, JT; COLVILLE, A; GUION, A; MACFARLANE, RM; ROSE, DH				MACFARLANE, JT; COLVILLE, A; GUION, A; MACFARLANE, RM; ROSE, DH			PROSPECTIVE-STUDY OF ETIOLOGY AND OUTCOME OF ADULT LOWER-RESPIRATORY-TRACT INFECTIONS IN THE COMMUNITY	LANCET			English	Article							ACUTE BRONCHITIS; PNEUMONIA; CHLAMYDIA; ETIOLOGY; STRAIN; TWAR	Community-acquired adult lower-respiratory-tract infections (LRTI) are generally thought to be caused by atypical and viral infections. We have studied 480 adults presenting to a single general practice with community-acquired LRTI between November, 1990, and December, 1991. The overall incidence was 44 cases per 1000 population per year, the incidence was 2-4 times higher in people aged 60 and over than in those aged less than 50.206 patients were studied in detail; among this group 91 (44%) had 113 pathogens identified. There were 92 bacteria (Streptococcus pneumoniae in 62 and Haemophilus influenzae in 16), 19 viruses (influenza virus in 12), and only 2 atypical pathogens (Mycoplasma pneumoniae and Coxiella burnetii). Pneumococcal infection was common in people who were 60 or older, those who had underlying chronic disease, or people with both features. There was moderate morbidity in terms of time in bed, time to return to normal activities, and days off work. 25% of patients returned for a second consultation with the general practitioner, in most because of unsatisfactory clinical progress. Community-acquired LRTI are very common,and the range of causative pathogens is similar to that for community-acquired pneumonia. Existing management strategies seem inadequate.	CITY HOSP,DEPT RADIOL,NOTTINGHAM NG5 1PB,ENGLAND; UNIV NOTTINGHAM HOSP,PUBL HLTH LAB SERV,NOTTINGHAM NG7 2UH,ENGLAND; STENHOUSE MED CTR,NOTTINGHAM,ENGLAND	University of Nottingham; University of Nottingham	MACFARLANE, JT (corresponding author), CITY HOSP,DEPT RESP MED,HUCKLAND RD,NOTTINGHAM NG5 1PB,ENGLAND.							BLACK DAK, 1975, BRIT J PREV SOC MED, V29, P222; BROOME CV, 1991, NEW ENGL J MED, V325, P1506, DOI 10.1056/NEJM199111213252109; DUNLAY J, 1984, J FAM PRACTICE, V18, P719; GRAYSTON JT, 1989, CHEST, V95, P664, DOI 10.1378/chest.95.3.664; HAGER H, 1987, REV INFECT DIS, V9, P1140; Howie J G, 1973, J R Coll Gen Pract, V23, P895; HOWIE JGR, 1978, BRIT MED J, V2, P1342, DOI 10.1136/bmj.2.6148.1342; MACFARLANE JT, 1982, LANCET, V2, P255; MARRIE TJ, 1987, ANN INTERN MED, V106, P507, DOI 10.7326/0003-4819-106-4-507; MURRAY HW, 1975, AM J MED, V58, P229, DOI 10.1016/0002-9343(75)90574-4; RODNICK JE, 1988, WESTERN J MED, V149, P347; SILLIS M, 1992, J INFECTION, V25, P77, DOI 10.1016/0163-4453(92)92130-B; SIMPSON REH, 1973, POSTGRAD MED J, V49, P763; VENKATESAN P, 1992, THORAX, V47, P329, DOI 10.1136/thx.47.5.329; VERHEIJ TJM, 1989, FAM PRACT, V6, P66, DOI 10.1093/fampra/6.1.66; Wallace R J Jr, 1988, Semin Respir Infect, V3, P49; WOODHEAD MA, 1987, LANCET, V1, P671; 1991, COMMUNICAB DIS REP, V1, P49; 1992, IMMUNISATION INFECTI; 1974, BMJ, V3, P1; 1987, Q J MED, V62, P195	21	292	306	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					511	514		10.1016/0140-6736(93)90275-L	http://dx.doi.org/10.1016/0140-6736(93)90275-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094769				2022-12-24	WOS:A1993KP08300002
J	DISANTO, JP; BONNEFOY, JY; GAUCHAT, JF; FISCHER, A; DESAINTBASILE, G				DISANTO, JP; BONNEFOY, JY; GAUCHAT, JF; FISCHER, A; DESAINTBASILE, G			CD40 LIGAND MUTATIONS IN X-LINKED IMMUNODEFICIENCY WITH HYPER-IGM	NATURE			English	Article							TUMOR NECROSIS FACTOR; HYPERIMMUNOGLOBULINEMIA-M; SWITCH; RECEPTOR; CLONING; CELLS	SIGNALLING for the B-cell immunoglobulin isotype switch requires T-cell-derived cytokines and T-B cell interaction, which operates primarily through the CD40 molecule on B cells with its ligand (CD40L) on activated T cells (reviewed in ref. 1). The CD40L is a type II membrane protein2-5 with homology to tumour necrosis factor-alpha and -beta6,7, and has important functions in B-cell activation and differentiation2,4,8. Human CD40L maps on Xq26.3-27.1 (ref. 3), the region where a primary immunodeficiency characterized by an immunoglobulin isotype switch defect (the hyper-IgM immunodeficiency syndrome, HIGM1) has been localized9,10. The hypothesis that HIGM1 involves an abnormality of the CD40L has been tested. We report here the lack of CD40L expression in four unrelated male children with the hyper-IgM syndrome. CD40L transcripts in these patients showed either deletions or point mutations clustered within a limited region of the CD40L. extracellular domain. These genetic alterations with abnormal CD40L expression provide a molecular basis for immunoglobulin isotype switch defects observed in this immunodeficiency.	GLAXO INST MOLEC BIOL,GENEVA 674,SWITZERLAND	GlaxoSmithKline	DISANTO, JP (corresponding author), HOP NECKER ENFANTS MALAD,INSERM,U132,149 RUE SEVRES,F-75743 PARIS 15,FRANCE.		Di Santo, James P/M-4298-2014; de Saint Basile, Genevieve/G-9731-2017	Di Santo, James P/0000-0002-7146-1862; de Saint Basile, Genevieve/0000-0002-1913-5269				ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; DEVRIES JE, 1991, CURR OPIN IMMUNOL, V3, P851, DOI 10.1016/S0952-7915(05)80003-2; DISANTO JP, 1993, EUR J IMMUNOL, V23, P320, DOI 10.1002/eji.1830230203; ECK MJ, 1989, J BIOL CHEM, V264, P17595; GAUCHAT JF, 1993, FEBS LETT, V315, P259, DOI 10.1016/0014-5793(93)81175-Y; GEHA RS, 1979, J CLIN INVEST, V64, P385, DOI 10.1172/JCI109473; GOUGEON ML, 1992, J CLIN IMMUNOL, V12, P92, DOI 10.1007/BF00918138; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0; HENDRIKS RW, 1990, EUR J IMMUNOL, V20, P2603, DOI 10.1002/eji.1830201212; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; MAYER L, 1986, NEW ENGL J MED, V314, P409, DOI 10.1056/NEJM198602133140703; MENSINK EJBM, 1987, HUM GENET, V76, P96; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P650; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; PADAYACHEE M, 1992, GENOMICS, V14, P551, DOI 10.1016/S0888-7543(05)80270-8; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266	21	644	661	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					541	543		10.1038/361541a0	http://dx.doi.org/10.1038/361541a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8094231				2022-12-24	WOS:A1993KL71400062
J	BARRES, BA; RAFF, MC				BARRES, BA; RAFF, MC			PROLIFERATION OF OLIGODENDROCYTE PRECURSOR CELLS DEPENDS ON ELECTRICAL-ACTIVITY IN AXONS	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; GLIAL PROGENITOR-CELL; RAT OPTIC-NERVE; NEURONS; CHAIN; PDGF; LOCALIZATION; TETRODOTOXIN	OLIGODENDROCYTES myelinate axons in the vertebrate central nervous system. It would, therefore, make sense if axons played a part in controlling the number of oligodendrocytes that develop in a myelinated tract. Although oligodendrocytes themselves normally do not divide, the precursor cells that give rise to them do. Here we show that the proliferation of oligodendrocyte precursor cells in the developing rat optic nerve depends on electrical activity in neighbouring axons, and that this activity-dependence can be circumvented by experimentally increasing the concentration of platelet-derived growth factor, which is present in the optic nerve and stimulates these cells to proliferate in culture. These findings suggest that axonal electrical activity normally controls the production and/or release of the growth factors that are responsible for proliferation of oligodendrocyte precursor cells and thereby helps to control the number of oligodendrocytes that develop in the region.			BARRES, BA (corresponding author), UNIV LONDON UNIV COLL,DEPT BIOL,MRC,DEV NEUROBIOL PROGRAMME,MEDAWAR BLDG,LONDON WC1E 6BT,ENGLAND.		Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763				ANDERTON BH, 1980, J NEUROCYTOL, V9, P835, DOI 10.1007/BF01205022; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1990, NEURON, V4, P507, DOI 10.1016/0896-6273(90)90109-S; CURRIE J, 1974, J COMP NEUROL, V156, P123, DOI 10.1002/cne.901560202; DELONG GR, 1962, J COMP NEUROL, V118, P205, DOI 10.1002/cne.901180207; EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913; FRIEDMAN S, 1990, EUR J NEUROSCI, V2, P243, DOI 10.1111/j.1460-9568.1990.tb00416.x; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; GYLLENSTEN L, 1963, J EMBRYOL EXP MORPH, V11, P255; MAGUAD JP, 1988, J IMMUNOL METHODS, V106, P95; ORKAND RK, 1966, J NEUROPHYSIOL, V29, P788, DOI 10.1152/jn.1966.29.4.788; PERRY VH, 1991, EUR J NEUROSCI, V3, P102, DOI 10.1111/j.1460-9568.1991.tb00815.x; PERRY VH, 1992, BIOESSAYS, V14, P401, DOI 10.1002/bies.950140610; PRINGLE N, 1989, EMBO J, V8, P1049, DOI 10.1002/j.1460-2075.1989.tb03472.x; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RASMINSKY M, 1972, J PHYSIOL-LONDON, V227, P323, DOI 10.1113/jphysiol.1972.sp010035; RICCIO RV, 1985, NEUROSCIENCE, V16, P1027, DOI 10.1016/0306-4522(85)90113-7; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; SALZER JL, 1980, J CELL BIOL, V84, P767, DOI 10.1083/jcb.84.3.767; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; TAUBER H, 1980, NEUROSCI LETT, V16, P235, DOI 10.1016/0304-3940(80)90003-8; WEINREICH D, 1975, BRAIN RES, V84, P137, DOI 10.1016/0006-8993(75)90807-0; WHEELER DD, 1966, J CELL PHYSIOL, V67, P141, DOI 10.1002/jcp.1040670116; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K	24	477	494	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 21	1993	361	6409					258	260		10.1038/361258a0	http://dx.doi.org/10.1038/361258a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	8093806				2022-12-24	WOS:A1993KH61400059
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA SEEKS COMMENTS ON HOW TO ENHANCE FOOD SAFETY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1994, JAMA-J AM MED ASSOC, V271, P812; 1994, FED REGISTER, V59, P39888	2	22	22	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					995	995		10.1001/jama.272.13.995	http://dx.doi.org/10.1001/jama.272.13.995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089899				2022-12-24	WOS:A1994PH77500008
J	GENEWEIN, A; TELENTI, A; BERNASCONI, C; MORDASINI, C; WEISS, S; MAURER, AM; RIEDER, HL; SCHOPFER, K; BODMER, T				GENEWEIN, A; TELENTI, A; BERNASCONI, C; MORDASINI, C; WEISS, S; MAURER, AM; RIEDER, HL; SCHOPFER, K; BODMER, T			MOLECULAR APPROACH TO IDENTIFYING ROUTE OF TRANSMISSION OF TUBERCULOSIS IN THE COMMUNITY	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MYCOBACTERIUM-TUBERCULOSIS; EPIDEMIOLOGY; OUTBREAK; TOOL; ELEMENT; POLYMORPHISMS; INFECTION; COMPLEX; STRAINS	There is growing concern that tuberculosis is spread in Europe in the way that it is in the USA. We have used DNA ''fingerprinting'' in a systematic evaluation of tuberculosis cases notified in our community to uncover foci of transmission. An IS6110 probe was used to test all isolates from culture-confirmed tuberculosis cases (163 patients) notified in 1991-92 in the Canton of Berne. In total, 45 patients (27.6%), potentially linked on the basis of restriction fragment length polymorphism, were investigated edepidemiologically. The largest group (n = 22) included members of a defined social group (drug addicts, homeless persons, alcoholics), from whom tuberculosis spread to the general population. A key patient developed multidrug-resistant tuberculosis during the surveillance period. This population study showed that (i) extensive transmission of Mycobacterium tuberculosis is now taking place in Europe in the same social setting as in the USA; (ii) there is definite ''spillover'' to the general population; (iii) the dimensions of the problem cannot be recognised easily by routine public health service activities because of the complexity of the transmission network; and (iv) multidrug-resistant tuberculosis develops in this setting.	UNIV BERN,INST MED MICROBIOL,FRIEDBUEHLSTR 51,CH-3010 BERN,SWITZERLAND; TIEFENAU HOSP,BERN,SWITZERLAND; CANTONAL LEAGUE AGAINST TB & LUNG DIS,BERN,SWITZERLAND; CANTONAL OFF PUBL HLTH,BERN,SWITZERLAND; FED OFF PUBL HLTH,LIEBEFELD,SWITZERLAND	University of Bern			Telenti, Amalio/AAY-1674-2021					ANNAS GJ, 1993, NEW ENGL J MED, V328, P585, DOI 10.1056/NEJM199302253280825; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; ISERMAN MD, 1993, NEW ENGL J MED, V328, P576; LAGUNA F, 1991, J INFECTION, V23, P139, DOI 10.1016/0163-4453(91)92016-X; MCADAM RA, 1990, MOL MICROBIOL, V4, P1607, DOI 10.1111/j.1365-2958.1990.tb02073.x; MULLER M, 1992, ZWANGSMASSNAHMEN INS; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; REVES R, 1981, AM J EPIDEMIOL, V113, P423, DOI 10.1093/oxfordjournals.aje.a113110; RIEDER HL, 1992, TUBERCLE LUNG DIS, V73, P181, DOI 10.1016/0962-8479(92)90082-U; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; THIERRY D, 1990, NUCLEIC ACIDS RES, V18, P188, DOI 10.1093/nar/18.1.188; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; VANSOOLINGEN D, 1992, RFLP ANAL MYCOBACTER; ZHANG YS, 1992, J CLIN MICROBIOL, V30, P1551, DOI 10.1128/JCM.30.6.1551-1556.1992; 1992, MMWR, V41, P1; 1991, MMWR, V40, P585; 1991, MMWR, V40, P869; 1991, B OFF FED SANTE PUBL, V35, P546	27	203	207	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					841	844		10.1016/0140-6736(93)92698-S	http://dx.doi.org/10.1016/0140-6736(93)92698-S			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104275				2022-12-24	WOS:A1993MA02500012
J	CHRISTAKIS, NA; ASCH, DA				CHRISTAKIS, NA; ASCH, DA			BIASES IN HOW PHYSICIANS CHOOSE TO WITHDRAW LIFE-SUPPORT	LANCET			English	Article							SUSTAINING TREATMENT; ADVANCE DIRECTIVES; DECISION-MAKING; CRITICALLY ILL; CARE; PREFERENCES; EUTHANASIA; ATTITUDES	We have investigated biases in physicians' decisions regarding the form of life support to withdraw from critically ill patients in whom the decision to withdraw has already been made. Using a specially designed instrument that solicited both self-reported preferences and also responses to experimentally varied clinical vignettes, we surveyed 862 American internists, of whom 481 (56%) responded. Physicians do have preferences about the form of life support withdrawn. From most likely to least likely the order is: blood products, haemodialysis, intravenous vasopressors, total parenteral nutrition, antibiotics, mechanical ventilation, tube feedings, and intravenous fluids. Four biases in decision making were also identified. Physicians prefer to withdraw forms of therapy supporting organs that failed for natural rather than iatrogenic reasons, to withdraw recently instituted rather than longstanding interventions, to withdraw forms of therapy resulting in immediate death rather than delayed death, and to withdraw forms of therapy resulting in delayed death when confronted with diagnostic uncertainty. Because these biases may have clinical, social, and ethical consequences counter to patient goals, and because they may affect the underlying decision whether to withdraw life support at all, they may represent impediments to rational and compassionate decision making in critical care.	UNIV PENN, LEONARD DAVIS INST HLTH ECON, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DIV FISIOL VEGETAL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT SOCIOL, PHILADELPHIA, PA 19104 USA; VET AFFAIRS MED CTR, PHILADELPHIA, PA USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Philadelphia Veterans Affairs Medical Center			Christakis, Nicholas A/C-3205-2009; Christakis, Nicholas A/B-6690-2008	Asch, David/0000-0002-7970-286X				[Anonymous], 1983, PRESIDENTS COMMISSIO; BOSK CL, 1980, NEW ENGL J MED, V303, P71, DOI 10.1056/NEJM198007103030203; BRETT AS, 1991, JAMA-J AM MED ASSOC, V266, P825, DOI 10.1001/jama.266.6.825; CARALIS PV, 1992, CRIT CARE MED, V20, P683, DOI 10.1097/00003246-199205000-00023; Cassell EJ, 1991, NATURE SUFFERING GOA; CHARLSON ME, 1986, JAMA-J AM MED ASSOC, V255, P1316, DOI 10.1001/jama.255.10.1316; COHEN BJ, 1992, MED DECIS MAKING, V12, P350; CRANE D, 1977, SANCTITY SOCIAL LIFE; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; EMANUEL EJ, 1988, LANCET, V1, P106; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FABERLANGENDOEN K, 1992, CRIT CARE MED, V20, P570, DOI 10.1097/00003246-199205000-00005; HOLLANDER M, 1973, NONPARAMETRIC STATIS; LYNN J, 1989, BY NO EXTRAORDINARY; MOWER WR, 1993, ARCH INTERN MED, V153, P375, DOI 10.1001/archinte.153.3.375; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; NIGHTINGALE SD, 1988, CHEST, V93, P684, DOI 10.1378/chest.93.4.684; PEARLMAN RA, 1982, ANN INTERN MED, V97, P420, DOI 10.7326/0003-4819-97-3-420; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; Samuelson W., 1988, J RISK UNCERTAINTY, V1, P7, DOI [10.1007/BF00055564, DOI 10.1007/BF00055564]; SCHNEIDERMAN LJ, 1988, NEW ENGL J MED, V318, P984, DOI 10.1056/NEJM198804143181509; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; UHLMANN RF, 1991, ARCH INTERN MED, V151, P495, DOI 10.1001/archinte.151.3.495; VONPREYSSFRIEDMAN SM, 1992, J GEN INTERN MED, V7, P46, DOI 10.1007/BF02599102; WEIR RF, 1989, ABATING TREATMENT CR; WILSON W C, 1992, Journal of the American Medical Association, V267, P949, DOI 10.1001/jama.267.7.949; Zussman Robert, 1992, INTENSIVE CARE MED E; 1991, LANCET, V337, P96	30	143	146	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1993	342	8872					642	646		10.1016/0140-6736(93)91759-F	http://dx.doi.org/10.1016/0140-6736(93)91759-F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103146				2022-12-24	WOS:A1993LX27200010
J	HERMANN, E; YU, DTY; ZUMBUSCHENFELDE, KHM; FLEISCHER, B				HERMANN, E; YU, DTY; ZUMBUSCHENFELDE, KHM; FLEISCHER, B			HLA-B27-RESTRICTED CD8 T-CELLS DERIVED FROM SYNOVIAL-FLUIDS OF PATIENTS WITH REACTIVE ARTHRITIS AND ANKYLOSING-SPONDYLITIS	LANCET			English	Article							REITERS-SYNDROME; CLONES; HLA-B27; LYMPHOCYTES; DISEASE; SELF	Ankylosing spondylitis and seronegative spondylarthropathies such as Reiter's syndrome and reactive arthritis are strongly associated with HLA-B27. However, the mechanisms by which HLA-B27 is involved in disease susceptibility and pathogenesis are unknown. If the disease association is a consequence of HLA-B27's physiological function in antigen presentation, the disease should be mediated by cytotoxic T lymphocytes (CTLs) that recognise bacterial or self peptides presented by HLA-B27. Proof of this arthritogenic peptide model requires isolation of B27-restricted CD8 T cells from arthritic joints of patients with spondylarthropathies. An important question is whether ''arthritogenic'' bacteria such as yersinia or salmonella can generate HLA-B27-restricted bacteria-specific CTLs. We describe such HLA-B27-restricted CTLs. We tested a panel of 354 alphabeta-TCR CD8 T lymphocyte clones (TLCs) that had been derived from the synovial fluid of 4 patients with reactive arthritis and 2 patients with ankylosing spondylitis. In 1 patient with yersinia-induced arthritis, 2 TLCs were identified that killed specifically yersinia-infected B27 target cells. In another patient with salmonella-induced arthritis, 1 B27-restricted CD8 TLC that recognised both salmonella and yersinia was identified. In 5 of the 6 patients autoreactive CTLs were found, 5 of which showed B27-restricted killing of uninfected cell lines. B27-restricted CTLs with specificity for arthritogenic bacteria or autoantigens provide a missing link in the pathogenesis of the HLA-B27-associated spondylarthropathies.	UNIV CALIF LOS ANGELES,DEPT MED,DIV RHEUMATOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	HERMANN, E (corresponding author), JOHANNES GUTENBERG UNIV,DEPT MED 1,LANGENBECKSTR 1,D-55101 MAINZ,GERMANY.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR040919] Funding Source: NIH RePORTER; NIAMS NIH HHS [NIAMS P01 AR40919] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahvonen P, 1969, Acta Rheumatol Scand, V15, P232; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BENJAMIN R, 1992, RHEUM DIS CLIN N AM, V18, P11; BIJLSMA JWJ, 1988, ANN RHEUM DIS, V47, P350, DOI 10.1136/ard.47.4.350-b; BRANCATO L, 1989, RHEUMATOL INT, V9, P137; BUCHMEIER NA, 1990, SCIENCE, V248, P730, DOI 10.1126/science.1970672; EDWARDS PAW, 1982, EUR J IMMUNOL, V12, P641, DOI 10.1002/eji.1830120804; GAMMON G, 1991, IMMUNOL TODAY, V12, P193, DOI 10.1016/0167-5699(91)90052-U; GUMPEL JM, 1981, ANN RHEUM DIS, V40, P64, DOI 10.1136/ard.40.1.64; HASSELL AB, 1992, CLIN EXP IMMUNOL, V88, P442; HERMANN E, 1992, CLIN EXP IMMUNOL, V89, P427; HERMANN E, 1992, J RHEUMATOL, V19, P1243; HERMANN E, 1990, SCAND J RHEUMATOL, V19, P350, DOI 10.3109/03009749009096790; HERMANN E, 1992, CELL IMMUNOL, V143, P253, DOI 10.1016/0008-8749(92)90023-I; HERMANN E, 1989, CLIN EXP IMMUNOL, V75, P365; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KAPASI K, 1992, J IMMUNOL, V148, P3554; KEAT A, 1983, NEW ENGL J MED, V309, P1606, DOI 10.1056/NEJM198312293092604; KINGSLEY G, 1992, RHEUM DIS CLIN N AM, V18, P49; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; SCHLAAK J, 1992, EUR J IMMUNOL, V22, P2771, DOI 10.1002/eji.1830221103; VARTIAINEN J, 1964, ACTA MED SCAND, V175, P771; VINER NJ, 1991, ARTHRITIS RHEUM, V34, P1151, DOI 10.1002/art.1780340911	24	304	309	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					646	650		10.1016/0140-6736(93)91760-J	http://dx.doi.org/10.1016/0140-6736(93)91760-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103147				2022-12-24	WOS:A1993LX27200011
J	MCGRATH, R				MCGRATH, R			TRADING IN DEATH - ANTI-PERSONNEL MINES	LANCET			English	Editorial Material											MCGRATH, R (corresponding author), MINES ADVISORY GRP,COCKERMOUTH,CUMBRIA,ENGLAND.								0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					628	629		10.1016/0140-6736(93)91751-7	http://dx.doi.org/10.1016/0140-6736(93)91751-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103138				2022-12-24	WOS:A1993LX27200002
J	HARRIS, DN; BAILEY, SM; SMITH, PLC; TAYLOR, KM; OATRIDGE, A; BYDDER, GM				HARRIS, DN; BAILEY, SM; SMITH, PLC; TAYLOR, KM; OATRIDGE, A; BYDDER, GM			BRAIN-SWELLING IN 1ST HOUR AFTER CORONARY-ARTERY BYPASS-SURGERY	LANCET			English	Note							RESONANCE	Six patients undergoing routine coronary artery bypass surgery were examined by magnetic resonance imaging of the brain before surgery, immediately afterwards, and 6-18 days later. Brain swelling was visible in all six patients on the immediate postoperative scan. In five patients who had later scans the swelling had subsided. No major neurological deficits were seen, and the patients were extubated successfully within 3 h of the operation. The mechanism of the cerebral swelling is uncertain, but it may provide insight into the cause of neurophysiological deficits seen after coronary artery surgery.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CARDIAC SURG,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT DIAGNOST RADIOL,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London	HARRIS, DN (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT ANAESTHESIA,LONDON W12 0NN,ENGLAND.							BLAUTH CI, 1988, J THORAC CARDIOV SUR, V95, P668; DECOENE B, 1992, AM J NEURORADIOL, V13, P1555; HIS JH, 1991, AJR, V157, P1291; MOODY DM, 1990, ANN NEUROL, V28, P477, DOI 10.1002/ana.410280403; SCHMIDT R, 1993, NEUROLOGY, V43, P775, DOI 10.1212/WNL.43.4.775; SELLMAN M, 1992, ANN THORAC SURG, V53, P807, DOI 10.1016/0003-4975(92)91441-B; SHAW PJ, 1987, Q J MED, V62, P259; SMITH PLC, 1986, LANCET, V1, P823; VIK A, 1991, NEURORADIOLOGY, V33, P396, DOI 10.1007/BF00598610; WHITFIELD A, 1989, BRIT J ANAESTH, V62, P694, DOI 10.1093/bja/62.6.694	10	194	197	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					586	587		10.1016/0140-6736(93)91412-F	http://dx.doi.org/10.1016/0140-6736(93)91412-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102722				2022-12-24	WOS:A1993LV96300012
J	AOKI, TT; BENBARKA, MM; OKIMURA, MC; ARCANGELI, MA; WALTER, RM; WILSON, LD; TRUONG, MP; BARBER, AR; KUMAGAI, LF				AOKI, TT; BENBARKA, MM; OKIMURA, MC; ARCANGELI, MA; WALTER, RM; WILSON, LD; TRUONG, MP; BARBER, AR; KUMAGAI, LF			LONG-TERM INTERMITTENT INTRAVENOUS INSULIN THERAPY AND TYPE-1 DIABETES-MELLITUS	LANCET			English	Article							CARBOHYDRATE EXCHANGE; GLUCOSE-HOMEOSTASIS; GLYCEMIC INDEX; RESTORATION; INFUSION; MUSCLE; FOODS	An important defect in insulin-dependent diabetes mellitus (IDDM) is that the liver does not meet its full fuel-processing function, because many of the enzymes involved depend on high insulin concentrations in the portal vein. We tried to reactivate the liver by long-term treatment of IDDM patients with intravenous insulin in pulses, with the aim of achieving high portal-vein concentrations during and after a glucose meal. We studied 20 IDDM patients with brittle disease; despite use of a four-injection regimen with manipulation of insulin doses, diet, and physical activity, and frequent clinic visits for at least a year, these patients still had wide swings in blood glucose and frequent hypoglycaemic reactions. The intermittent therapy consisted of 7-10 pulses of intravenous insulin, infused while the patient was ingesting carbohydrate, primarily glucose, during the first hour of a 3 h treatment; three treatments were given in a day. After 2 consecutive days' treatment, patients were treated for 1 day per week. No patient was withdrawn from the study. At the time of this analysis the duration of intermittent treatment ranged from 7 to 71 months (mean 41 [SE 5] months). Haemoglobin A1C concentrations declined from 8.5 (0.4)% at the end of the stabilisation phase to 7.0 (0.2)% at the analysis point (p = 0.0003). During the same time the frequencies of major and minor hypoglycaemic events also fell significantly (major 3.0 [1.1] to 0.1 [0], minor 13.0 [2.6] to 2.4 [0.8] per month; both p < 0.0001). Because the use of saline rather than insulin pulses would have led to unacceptable hyperglycaemia we opted for a historical control design. The absence of a true control group limits the interpretation of these preliminary results, but we believe further studies of hepatic and muscle metabolism before and after long-term intermittent intravenous insulin therapy would be worth while.			AOKI, TT (corresponding author), UNIV CALIF DAVIS,SACRAMENTO MED CTR,DEPT INTERNAL MED,DIV ENDOCRINOL,4301 X ST,BLDG FOLB II-C,SACRAMENTO,CA 95817, USA.							AOKI TT, 1983, J CLIN INVEST, V71, P837, DOI 10.1172/JCI110837; BERGER W, 1973, HORM METAB RES, V5, P4, DOI 10.1055/s-0028-1093991; CAHILL GF, 1959, AM J MED, V26, P264, DOI 10.1016/0002-9343(59)90316-X; FOSS MC, 1982, DIABETES, V31, P46, DOI 10.2337/diabetes.31.1.46; HEINEMANN L, 1989, J INTERN MED, V226, P325, DOI 10.1111/j.1365-2796.1989.tb01403.x; HERS HG, 1982, BIOCHEM J, V206, P2; ISHIDA T, 1984, DIABETES, V33, P984, DOI 10.2337/diabetes.33.10.984; JENKINS DJA, 1983, DIABETOLOGIA, V24, P257, DOI 10.1007/BF00282710; JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362; KARAM JH, 1991, BASIC CLIN ENDOCRINO, P592; KELLEY D, 1988, J CLIN INVEST, V81, P1563, DOI 10.1172/JCI113489; MEISTAS MT, 1985, DIABETES, V34, P960, DOI 10.2337/diabetes.34.10.960; PILKIS SJ, 1968, P SOC EXP BIOL MED, V129, P681; RUDERMAN NB, 1968, DIABETES, V17, P611, DOI 10.2337/diab.17.10.611; STORER AC, 1976, BIOCHEM J, V159, P7, DOI 10.1042/bj1590007; WALDHAUSL W, 1982, DIABETOLOGIA, V23, P6, DOI 10.1007/BF00257722; Weinhouse S, 1976, CURRENT TOPICS CELLU, P1; WESSON DE, 1988, JPEN-PARENTER ENTER, V12, P237, DOI 10.1177/0148607188012003237	18	18	27	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					515	518		10.1016/0140-6736(93)91645-3	http://dx.doi.org/10.1016/0140-6736(93)91645-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102666				2022-12-24	WOS:A1993LU58200008
J	MUKADI, Y; PERRIENS, JH; STLOUIS, ME; BROWN, C; PRIGNOT, J; WILLAME, JC; POUTHIER, F; KABOTO, M; RYDER, RW; PORTAELS, F; PIOT, P				MUKADI, Y; PERRIENS, JH; STLOUIS, ME; BROWN, C; PRIGNOT, J; WILLAME, JC; POUTHIER, F; KABOTO, M; RYDER, RW; PORTAELS, F; PIOT, P			SPECTRUM OF IMMUNODEFICIENCY IN HIV-1-INFECTED PATIENTS WITH PULMONARY TUBERCULOSIS IN ZAIRE	LANCET			English	Article							CLINICAL CASE-DEFINITION; VIRUS-INFECTION; IMMUNE-DEFICIENCY; HIV-INFECTION; AIDS; COHORT; RISK; DISEASE	Tuberculosis (TB) is the most common opportunistic infection in African patients who die from AIDS, yet the stage of immunodeficiency at which TB develops is uncertain. We studied the immune status of HIV-infected outpatients with pulmonary TB in relation to their clinical presentation in a cross-sectional study of 216 HIV-seropositive and 146 HIV-seronegative ambulatory incident cases of smear-positive and culture-positive pulmonary TB in Kinshasa, Zaire. HIV-seropositive and seronegative patients had median CD4 lymphocyte counts of 316.5/muL and 830.5/muL, respectively. Of the HIV-seropositive patients, 32 9% had less than 200 CD4 lymphocytes/muL, 37% between 200 and 499, and 30.1% 500 or more. Clinical AIDS, as defined by the WHO clinical case-definition ora modified version, was of similar limited use as a predictor of immunodeficiency. Among HIV-seropositive patients, oral candidosis, lymphopenia, a negative tuberculin purified protein derivative test, and cutaneous anergy were strongly associated with CD4 counts of less than 200/muL, and seemed to be better markers of immune dysfunction. We conclude that pulmonary TB develops across a broad spectrum of HIV-induced immunodeficiency and that a diagnosis of pulmonary TB is of limited use as a marker of stage of HIV disease in African HIV-infected outpatients.	PROJET SIDA, KINSHASA, DEM REP CONGO; BELGIAN ADM DEV & COOPERAT, BRUSSELS, BELGIUM; UNIV CATHOLIQUE LOUVAIN, MT GODINNE, BELGIUM; BUR NATL TB, KINSHASA, DEM REP CONGO; INST TROP MED PRINCE LEOPOLD, B-2000 ANTWERP, BELGIUM; CDC, NCID, DIV HIV AIDS, ATLANTA, GA USA; CTR DEPISTAGE TB, KINSHASA, DEM REP CONGO	Universite Catholique Louvain; Institute of Tropical Medicine (ITM); Centers for Disease Control & Prevention - USA								[Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BATUNGWANAGO J, 1990, 5TH INT C AIDS AFR K; BRAUN MM, 1991, AM REV RESPIR DIS, V143, P501, DOI 10.1164/ajrccm/143.3.501; BURCHAM J, 1991, AIDS, V5, P365, DOI 10.1097/00002030-199104000-00002; COLEBUNDERS R, 1987, LANCET, V1, P492; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; JORDAN TJ, 1987, CHEST, V92, P234, DOI 10.1378/chest.92.2.234; KASLOW RA, 1987, ANN INTERN MED, V107, P474, DOI 10.7326/0003-4819-107-4-474; KLEIN NC, 1989, CHEST, V95, P1190, DOI 10.1378/chest.95.6.1190; KLEIN RS, 1984, NEW ENGL J MED, V311, P354, DOI 10.1056/NEJM198408093110602; MODILEVSKY T, 1989, ARCH INTERN MED, V149, P2201, DOI 10.1001/archinte.149.10.2201; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; OKONDA L, 1991, 7 INT C AIDS FLOR; PAPE JW, 1992, 8 INT C AIDS 3 STD W; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; ROYCE RA, 1991, AIDS, V5, P355, DOI 10.1097/00002030-199104000-00001; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SHAFER RW, 1991, AIDS, V5, P399, DOI 10.1097/00002030-199104000-00007; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; WADHAWAN D, 1992, 8 INT C AIDS 3 STD W; WALLIS RS, 1993, J INFECT DIS, V167, P43, DOI 10.1093/infdis/167.1.43; WIDYWIRSKI R, 1988, JAMA-J AM MED ASSOC, V260, P3286, DOI 10.1001/jama.260.22.3286; 1963, WHO TB TECH GUIDE, V3; 1986, WKLY EPIDEMIOL REC, V61, P69; 1991, MMWR, V40, P27	27	118	121	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	1993	342	8864					143	146		10.1016/0140-6736(93)91346-N	http://dx.doi.org/10.1016/0140-6736(93)91346-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101257				2022-12-24	WOS:A1993LN04200012
J	COHEN, MV; DOWNEY, JM				COHEN, MV; DOWNEY, JM			ISCHEMIC PRECONDITIONING - CAN THE PROTECTION BE BOTTLED	LANCET			English	Letter							ISCHEMIA				COHEN, MV (corresponding author), UNIV SO ALABAMA,DEPT PHYSIOL,MOBILE,AL 36688, USA.							DEUTSCH E, 1990, CIRCULATION, V82, P2044, DOI 10.1161/01.CIR.82.6.2044; LAWSON CS, 1993, CARDIOVASC RES, V27, P542, DOI 10.1093/cvr/27.4.542; LIU GS, 1991, CIRCULATION, V84, P350, DOI 10.1161/01.CIR.84.1.350; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; THORNTON JD, 1993, J MOL CELL CARDIOL, V25, P311, DOI 10.1006/jmcc.1993.1037; THORNTON JD, IN PRESS CIRC RES; TSUCHIDA A, IN PRESS J MOL CELL; YANG XM, 1993, CARDIOVASC RES, V27, P556, DOI 10.1093/cvr/27.4.556; YTREHUS K, 1993, FASEB J, V7, pA418	9	80	80	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					6	6		10.1016/0140-6736(93)91878-P	http://dx.doi.org/10.1016/0140-6736(93)91878-P			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100337				2022-12-24	WOS:A1993LK98500007
J	BONYHADI, ML; RABIN, L; SALIMI, S; BROWN, DA; KOSEK, J; MCCUNE, JM; KANESHIMA, H				BONYHADI, ML; RABIN, L; SALIMI, S; BROWN, DA; KOSEK, J; MCCUNE, JM; KANESHIMA, H			HIV INDUCES THYMUS DEPLETION INVIVO	NATURE			English	Article							SCID-HU MOUSE; HUMAN IMMUNODEFICIENCY VIRUS; T-CELLS; INFECTION; APOPTOSIS; DIFFERENTIATION; MODEL; DEATH	HUMAN immunodeficiency virus (HIV) disease is typified by declining CD4+ T lymphocyte counts in the peripheral circulation, a loss which may be secondary to accelerated destruction, to suppressed differentiation, and/or to sequestration of circulating cells into tissue spaces. As it is hard to distinguish between these possibilities in human subjects, the pathogenic mechanisms associated with HIV infection are unclear. In particular, little is known about the events that occur within infected lymphoid organs in which most CD4 T lymphocytes mature and function1,2. To obtain a better description of HIV pathogenesis in vivo, we have implanted human haematolymphoid organs into the immunodeficient SCID mouse to create the SCID-hu mouse3,4. We have previously shown that these organ systems promote long-term multilineage human haematopoiesis and are permissive for infection with HIV5,6. Here we report that human thymopoiesis is suppressed by HIV infection, thereby precluding regeneration of the peripheral T-cell compartment.	VET ADM MED CTR, PALO ALTO, CA 94304 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	BONYHADI, ML (corresponding author), SYSTEMIX INC, DIV NEW ENTERPRISE RES, 3155 PORTER DR, PALO ALTO, CA 94304 USA.							BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BASKIN GB, 1991, LAB INVEST, V65, P400; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; DIVE C, 1992, J IMMUNOL, V148, P1595; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; JOSHI VV, 1986, ARCH PATHOL LAB MED, V110, P837; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; KROWKA JF, 1991, J IMMUNOL, V146, P3751; LIN YS, 1992, J IMMUNOL, V149, P1156; MCCUNE J, 1991, ANNU REV IMMUNOL, V9, P399, DOI 10.1146/annurev.iy.09.040191.002151; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MCCUNE JM, 1991, CELL, V64, P351, DOI 10.1016/0092-8674(91)90644-E; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MOCARSKI ES, 1993, P NATL ACAD SCI USA, V90, P104, DOI 10.1073/pnas.90.1.104; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; NAMIKAWA R, 1990, J EXP MED, V172, P1055, DOI 10.1084/jem.172.4.1055; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUMAZAKI K, 1989, CLIN IMMUNOL IMMUNOP, V51, P185, DOI 10.1016/0090-1229(89)90018-4; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PAPIERNIK M, 1992, PEDIATRICS, V89, P297; SCHUURMAN HJ, 1989, AM J PATHOL, V134, P1329; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SELLINS KS, 1991, J IMMUNOL, V147, P795; SHI YF, 1991, J IMMUNOL, V146, P3340; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; Steinmann G G, 1986, Curr Top Pathol, V75, P43; TELFORD WG, 1992, CYTOMETRY, V13, P137, DOI 10.1002/cyto.990130205; VANDEKERCKHOVE BAE, 1991, J IMMUNOL, V146, P4173; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; Wyllie A H, 1980, Int Rev Cytol, V68, P251	31	361	366	0	3	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 24	1993	363	6431					728	732		10.1038/363728a0	http://dx.doi.org/10.1038/363728a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8100043				2022-12-24	WOS:A1993LJ33900058
J	BONITA, R				BONITA, R			CARDIOVASCULAR-DISEASE - CARDIOVASCULAR-DISEASE IN OKINAWA	LANCET			English	Editorial Material							HEART-DISEASE; RISK-FACTORS; JAPAN; STROKE				BONITA, R (corresponding author), UNIV AUCKLAND,DEPT MED,AUCKLAND,NEW ZEALAND.							BLACKBURN H, 1989, CIRCULATION, V79, P718, DOI 10.1161/01.CIR.79.3.718; BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989; KINJO K, 1991, HYPERTENS RES, V15, P111; MARMOT MG, 1989, BRIT MED J, V299, P1547, DOI 10.1136/bmj.299.6715.1547; SHI FL, 1989, STROKE, V20, P1581, DOI 10.1161/01.STR.20.11.1581; SHIMAMOTO T, 1989, CIRCULATION, V79, P503, DOI 10.1161/01.CIR.79.3.503; SUZUKI K, 1987, STROKE, V18, P402, DOI 10.1161/01.STR.18.2.402; TANAKA H, 1981, STROKE, V12, P460, DOI 10.1161/01.STR.12.4.460; UEDA K, 1981, STROKE, V12, P154, DOI 10.1161/01.STR.12.2.154; UESHIMA H, 1987, AM J EPIDEMIOL, V125, P62, DOI 10.1093/oxfordjournals.aje.a114512	10	5	5	2	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1185	1185		10.1016/0140-6736(93)91007-9	http://dx.doi.org/10.1016/0140-6736(93)91007-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098080				2022-12-24	WOS:A1993LB01700009
J	BURNS, A				BURNS, A			BRAIN IMAGING - COMPUTED-TOMOGRAPHY IN ALZHEIMERS-DISEASE	LANCET			English	Editorial Material							DEMENTIA				BURNS, A (corresponding author), UNIV MANCHESTER,SCH PSYCHIAT & BEHAV SCI,MANCHESTER M13 9PL,LANCS,ENGLAND.			Burns, Alistair/0000-0002-9837-0645				BURNS A, 1991, BRIT J PSYCHIAT, V159, P609, DOI 10.1192/bjp.159.5.609; BURNS A, 1991, BIOL PSYCHIAT, V29, P383, DOI 10.1016/0006-3223(91)90224-A; DECARLI C, 1990, NEUROLOGY, V40, P872, DOI 10.1212/WNL.40.6.872; DELEON MJ, 1993, LANCET, V341, P125, DOI 10.1016/0140-6736(93)92610-6; JACOBY RJ, 1980, BRIT J PSYCHIAT, V136, P256, DOI 10.1192/bjp.136.3.256; JOBST KA, 1992, LANCET, V340, P1179; LUXENBERG JS, 1987, NEUROLOGY, V37, P1135, DOI 10.1212/WNL.37.7.1135	7	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					601	602		10.1016/0140-6736(93)90360-S	http://dx.doi.org/10.1016/0140-6736(93)90360-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094836				2022-12-24	WOS:A1993KQ23400012
J	EVANS, I				EVANS, I			NEUROSCIENCE - NO COWORKER	LANCET			English	Editorial Material																		EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					414	414		10.1016/0140-6736(93)93001-H	http://dx.doi.org/10.1016/0140-6736(93)93001-H			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094181				2022-12-24	WOS:A1993KM41600016
J	SHAM, MH; VESQUE, C; NONCHEV, S; MARSHALL, H; FRAIN, M; DASGUPTA, R; WHITING, J; WILKINSON, D; CHARNAY, P; KRUMLAUF, R				SHAM, MH; VESQUE, C; NONCHEV, S; MARSHALL, H; FRAIN, M; DASGUPTA, R; WHITING, J; WILKINSON, D; CHARNAY, P; KRUMLAUF, R			THE ZINC FINGER GENE KROX20 REGULATES HOXB2 (HOX2.8) DURING HINDBRAIN SEGMENTATION	CELL			English	Article							HOMEOBOX-CONTAINING GENES; CRANIAL NEURAL CREST; DNA-BINDING DOMAINS; RETINOIC ACID; TRANSCRIPTIONAL ACTIVATOR; EXPRESSION PATTERN; VERTEBRATE HEAD; MOUSE HINDBRAIN; CULTURED-CELLS; NERVOUS-SYSTEM	The zinc finger gene Krox20 and many Hox homeobox genes are expressed in segment-restricted domains in the hindbrain. The restricted expression patterns appear before morphological segmentation, suggesting that these transcription factors may play an early role in the establishment and identity of rhombomeric segments. In this paper, we show that the HoxB2 (Hox2.8) gene is normally upregulated in rhombomeres (r) 3, 4, and 5, and we identify an enhancer region upstream of the gene that imposes r3/r5 expression in transgenic mice. This enhancer contains three Krox20-binding sites required in vitro for complex formation with Krox20 protein and in vivo for rhombomere-restricted expression. In transgenic mice, Krox20 expressed in ectopic domains can transactivate a reporter construct containing the HoxB2 r3/r5 enhancer. These data demonstrate that Krox20 is a part of the upstream transcriptional cascade that directly regulates HoxB2 expression during hindbrain segmentation.	ECOLE NORM SUPER,GENET MOLEC LAB,CNRS,URA 1302,F-75230 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS)	SHAM, MH (corresponding author), NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.		Vesque, Christine/L-9839-2017; Vesque, Christine/Q-8461-2019; Sham, Mai Har/AAX-3781-2020; Krumlauf, Robb/AAH-5012-2019	Sham, Mai Har/0000-0003-1179-7839; Krumlauf, Robb/0000-0001-9102-7927; Vesque, Christine/0000-0001-7983-4953; Charnay, Patrick/0000-0002-3847-6042	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKAM M, 1987, DEVELOPMENT, V101, P1; AWGULEWITSCH A, 1992, NATURE, V358, P341, DOI 10.1038/358341a0; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CONLON RA, 1992, DEVELOPMENT, V116, P357; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GALLIOT B, 1989, DEVELOPMENT, V107, P343; GILARDI P, 1991, BIOCHIMIE, V73, P85, DOI 10.1016/0300-9084(91)90079-G; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; Hogan B., 1986, MANIPULATING MOUSE E; HUNT P, 1991, CELL, V66, P1075, DOI 10.1016/0092-8674(91)90029-X; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cb.08.110192.001303; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNT P, 1991, DEVELOPMENT, V112, P43; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; KRAUSS S, 1991, NATURE, V353, P267, DOI 10.1038/353267a0; KRUMLAUF R, 1992, BIOESSAYS, V14, P245, DOI 10.1002/bies.950140408; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Le Douarin N., 1999, DEV CELL BIOL SERIES, V2nd, DOI [10.1017/CBO9780511897948, DOI 10.1017/CBO9780511897948, 10.1017/cbo9780511897948]; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEMAIRE P, 1990, THESIS U PARIS 6 PAR; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1990, TRENDS NEUROSCI, V13, P329, DOI 10.1016/0166-2236(90)90144-Y; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; Lumsden A.G.S., 1990, Seminars in Developmental Biology, V1, P117; MADEN M, 1992, MECH DEVELOP, V37, P13, DOI 10.1016/0925-4773(92)90011-8; MADEN M, 1991, DEVELOPMENT, V111, P35; MALICKI J, 1992, NATURE, V358, P345, DOI 10.1038/358345a0; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MORRISSKAY G, 1987, TRENDS GENET, V3, P257, DOI 10.1016/0168-9525(87)90260-5; MORRISSKAY G, 1991, SEMINARS DEV BIOL, V2, P211; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; NODEN DM, 1988, DEVELOPMENT, V103, P121; PATWARDHAN S, 1991, ONCOGENE, V6, P917; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; REGULSKI M, 1991, GENE DEV, V5, P278, DOI 10.1101/gad.5.2.278; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SECHRIST J, 1992, IN PRESS DEVELOPMENT, V116; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; SMITH SM, 1991, DEVELOPMENT, V111, P245; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; VESQUE C, 1992, NUCLEIC ACIDS RES, V20, P2485, DOI 10.1093/nar/20.10.2485; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1990, TRENDS NEUROSCI, V13, P335, DOI 10.1016/0166-2236(90)90145-Z; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WILKINSON DG, 1990, SEMINARS DEV BIOL, V1, P127	69	289	289	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 29	1993	72	2					183	196		10.1016/0092-8674(93)90659-E	http://dx.doi.org/10.1016/0092-8674(93)90659-E			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	8093858				2022-12-24	WOS:A1993KK03800004
J	AREND, WP				AREND, WP			INTERLEUKINS AND ARTHRITIS - IL-1 ANTAGONISM IN INFLAMMATORY ARTHRITIS	LANCET			English	Editorial Material											AREND, WP (corresponding author), UNIV COLORADO,HLTH SCI CTR,DIV RHEUMATOL,DENVER,CO 80262, USA.							AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; DINARELLO CA, 1991, BLOOD, V77, P1627; FIRESTEIN GS, 1992, J IMMUNOL, V149, P1054; MALYAK M, IN PRESS ARTHRITIS R	4	20	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					155	156		10.1016/0140-6736(93)90014-8	http://dx.doi.org/10.1016/0140-6736(93)90014-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093754				2022-12-24	WOS:A1993KG62700014
J	GREENWOOD, D				GREENWOOD, D			HONEY FOR SUPERFICIAL WOUNDS AND ULCERS	LANCET			English	Editorial Material											GREENWOOD, D (corresponding author), UNIV NOTTINGHAM HOSP,DEPT MICROBIOL,NOTTINGHAM NG7 2UH,ENGLAND.							ALLEN KL, 1991, J PHARM PHARMACOL, V43, P817, DOI 10.1111/j.2042-7158.1991.tb03186.x; CHIRIFE J, 1982, LANCET, V1, P560; Milne A. A., 1926, WINNIE THE POOH; WILLIX DJ, 1992, J APPL BACTERIOL, V73, P388, DOI 10.1111/j.1365-2672.1992.tb04993.x; ZUMLA A, 1989, J ROY SOC MED, V82, P374	5	25	29	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					90	91		10.1016/0140-6736(93)92564-A	http://dx.doi.org/10.1016/0140-6736(93)92564-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093411				2022-12-24	WOS:A1993KF87000011
J	NIGHTINGALE, SL				NIGHTINGALE, SL			REPORTS OF PROBLEMS WITH USE OF LIQUID-DOSING DEVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	22	22	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					995	995		10.1001/jama.272.13.995	http://dx.doi.org/10.1001/jama.272.13.995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089899				2022-12-24	WOS:A1994PH77500006
J	MARIAN, AJ; YU, QT; WORKMAN, R; GREVE, G; ROBERTS, R				MARIAN, AJ; YU, QT; WORKMAN, R; GREVE, G; ROBERTS, R			ANGIOTENSIN-CONVERTING ENZYME POLYMORPHISM IN HYPERTROPHIC CARDIOMYOPATHY AND SUDDEN CARDIAC DEATH	LANCET			English	Note							INSERTION DELETION POLYMORPHISM; HEAVY-CHAIN GENE; MUTATION	We determined the distribution frequency of angiotensin converting enzyme (ACE) polymorphism in 100 patients with hypertrophic cardiomyopathy and 106 of their unaffected siblings and offspring. The distribution of ACE genotypes was different in the two groups: allele D frequency of 0.69 in patients and 0 57 in relatives (p = 0.021). The frequency of allele D was also higher in hypertrophic cardiomyopathy families with a high incidence of sudden cardiac death than those with a low incidence (0.74 vs 0.55, p = 0.011). In 25 hypertrophic cardiomyopathy patients with a strong family history of sudden cardiac death the frequency of allele D was 0.82 (p = 0.001 vs normals).	BAYLOR COLL MED,6535 FANNIN,MS F905,HOUSTON,TX 77030	Baylor College of Medicine				Marian, AJ/0000-0002-1252-7120	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042267] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50-HL42267-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAN R, IN PRESS J CLIN INVE; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; HEJTMANCIK JF, 1991, CIRCULATION, V83, P1592, DOI 10.1161/01.CIR.83.5.1592; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; MARIAN AJ, 1992, CIRCULATION, V86, P16; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SCHUNKERT H, 1993, CIRCULATION, V87, P1328, DOI 10.1161/01.CIR.87.4.1328	9	350	362	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1085	1086		10.1016/0140-6736(93)92064-Z	http://dx.doi.org/10.1016/0140-6736(93)92064-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105312				2022-12-24	WOS:A1993ME82200010
J	PETRICCIANI, JC				PETRICCIANI, JC			ONGOING TRAGEDY OF RABIES	LANCET			English	Editorial Material											PETRICCIANI, JC (corresponding author), GENET INST INC,CAMBRIDGE,MA, USA.							BROWN A, 1974, J VIROL, V14, P840, DOI 10.1128/JVI.14.4.840-845.1974; Grachev V, 1989, Dev Biol Stand, V70, P215; MORGEAUX S, 1993, VACCINE, V11, P82, DOI 10.1016/0264-410X(93)90343-V; NICHOLSON KG, 1990, LANCET, V335, P1201, DOI 10.1016/0140-6736(90)92710-Y; PETRICCIANI JC, 1991, DEV BIOL STAND, V76, P5; PETRICCIANI JC, 1979, CELL SUBSTRATES, P9; SEHGAL S, 1992, GELBEN HELTE, V38, P126; SWADDIWUTHIPONG W, 1988, T ROY SOC TROP MED H, V82, P472, DOI 10.1016/0035-9203(88)90167-8; 1992, WORLD SURVEY RABIES	9	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1067	1068		10.1016/0140-6736(93)92058-2	http://dx.doi.org/10.1016/0140-6736(93)92058-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105306				2022-12-24	WOS:A1993ME82200004
J	WOTHERSPOON, AC; DOGLIONI, C; DISS, TC; PAN, LX; MOSCHINI, A; DEBONI, M; ISAACSON, PG				WOTHERSPOON, AC; DOGLIONI, C; DISS, TC; PAN, LX; MOSCHINI, A; DEBONI, M; ISAACSON, PG			REGRESSION OF PRIMARY LOW-GRADE B-CELL GASTRIC LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE TYPE AFTER ERADICATION OF HELICOBACTER-PYLORI	LANCET			English	Article							CAMPYLOBACTER-PYLORI; IMMUNE-RESPONSE; MONOCLONALITY	Certain features of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue (MALT) suggest the tumour is antigen-responsive. Given the close association between gastric MALT lymphoma and Helicobacter pylori, these organisms might be evoking the immunological response, and eradication of H pylori might inhibit the tumour. 6 patients in whom biopsies showed histological and molecular-genetic evidence of low-grade gastric B-cell MALT lymphoma with H pylori infection were treated with antibiotics. In all cases H pylori was eradicated and in 5, repeated biopsies showed no evidence of lymphoma. These results suggest that eradication of H pylori causes regression of low-grade B-cell gastric MALT lymphoma, and that anti-H-pylori treatment should be given for this lymphoma.	UCL,SCH MED,DEPT HISTOPATHOL,UNIV ST,LONDON WC1E 6JJ,ENGLAND; OSPED CIVILE,FELTRE,ITALY	University of London; University College London; UCL Medical School				DOGLIONI, Claudio/0000-0002-4969-5216				BENAYED F, 1989, CANCER, V63, P1251, DOI 10.1002/1097-0142(19890401)63:7<1251::AID-CNCR2820630704>3.0.CO;2-H; DISS TC, 1993, J PATHOL, V169, P291, DOI 10.1002/path.1711690303; GENTA RM, 1993, HUM PATHOL, V24, P577, DOI 10.1016/0046-8177(93)90235-9; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; ISAACSON PG, 1991, AM J SURG PATHOL, V15, P819, DOI 10.1097/00000478-199109000-00001; ISAACSON PG, 1987, HISTOPATHOLOGY, V11, P445, DOI 10.1111/j.1365-2559.1987.tb02654.x; Maniatis T., 1982, MOL CLONING; RAMASAMY I, 1992, J CLIN PATHOL, V45, P770, DOI 10.1136/jcp.45.9.770; STOLTE M, 1992, LANCET, V339, P745, DOI 10.1016/0140-6736(92)90645-J; STOLTE M, 1989, J CLIN PATHOL, V42, P1269, DOI 10.1136/jcp.42.12.1269; TRAINOR KJ, 1990, BLOOD, V75, P2220; WAN JH, 1990, J CLIN PATHOL, V43, P888, DOI 10.1136/jcp.43.11.888; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; WYATT JI, 1988, SCAND J GASTROENTERO, V23, P44, DOI 10.3109/00365528809091712	14	1757	1803	1	33	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					575	577		10.1016/0140-6736(93)91409-F	http://dx.doi.org/10.1016/0140-6736(93)91409-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102719				2022-12-24	WOS:A1993LV96300009
J	OKA, Y; KATAGIRI, H; YAZAKI, Y; MURASE, T; KOBAYASHI, T				OKA, Y; KATAGIRI, H; YAZAKI, Y; MURASE, T; KOBAYASHI, T			MITOCHONDRIAL GENE MUTATION IN ISLET-CELL-ANTIBODY-POSITIVE PATIENTS WHO WERE INITIALLY NON-INSULIN-DEPENDENT DIABETICS	LANCET			English	Note							MELLITUS	Autoimmunity is thought to lead to islet-cell-antibody (ICA) formation in diabetes mellitus. However, we found a mitochondrial gene mutation at nucleotide pair 3243 in 3 of 27 Japanese ICA-positive, initially non-insulin-dependent diabetic patients. All 3 progressed to insulin-dependency within 13-31 months, whereas 5 of the other 24 are non-insulin-dependent after 54-90 months. ICA, at least in these 3 patients, may follow gradual beta-cell destruction due to mitochondrial gene mutation, although the possibility of beta-cells with the mutation being susceptible to autoimmune destruction cannot be excluded.	TORANOMON GEN HOSP,DEPT ENDOCRINOL & METAB,TOKYO 107,JAPAN	Toranomon Hospital	OKA, Y (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN.							GERBITZ KD, 1993, FEBS LETT, V321, P194, DOI 10.1016/0014-5793(93)80106-5; KOBAYASHI T, 1993, DIABETES CARE, V16, P780, DOI 10.2337/diacare.16.5.780; KOBAYASHI T, 1987, DIABETES, V36, P510, DOI 10.2337/diabetes.36.4.510; LOHR M, 1987, DIABETOLOGIA, V30, P757; NAKANISHI K, 1993, METABOLISM, V42, P196, DOI 10.1016/0026-0495(93)90035-M; REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3; SRIKANTA S, 1983, NEW ENGL J MED, V308, P322, DOI 10.1056/NEJM198302103080607; SRIKANTA S, 1985, NEW ENGL J MED, V313, P4611; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; WARRAM JH, 1984, NEW ENGL J MED, V311, P149, DOI 10.1056/NEJM198407193110304	10	109	111	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					527	528		10.1016/0140-6736(93)91649-7	http://dx.doi.org/10.1016/0140-6736(93)91649-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102670				2022-12-24	WOS:A1993LU58200012
J	NEVEN, P				NEVEN, P			TAMOXIFEN AND ENDOMETRIAL LESIONS	LANCET			English	Editorial Material							BODY-FAT DISTRIBUTION; BREAST-CANCER				NEVEN, P (corresponding author), ALGEMENE KLIN ST JAN,DEPT OBSTET & GYNAECOL,BRUSSELS,BELGIUM.							COHEN I, 1993, BRIT J OBSTET GYNAEC, V100, P567, DOI 10.1111/j.1471-0528.1993.tb15310.x; COHEN I, 1992, LANCET, V340, P312, DOI 10.1016/0140-6736(92)92409-9; FORNANDER T, 1989, LANCET, V1, P117; LAHTI E, 1993, OBSTET GYNECOL, V81, P660; NEVEN P, 1990, EUR J OBSTET GYN R B, V35, P235, DOI 10.1016/0028-2243(90)90167-Y; SCHAPIRA DV, 1991, CANCER, V67, P523, DOI 10.1002/1097-0142(19910115)67:2<523::AID-CNCR2820670234>3.0.CO;2-O; SCHAPIRA DV, 1991, JAMA-J AM MED ASSOC, V266, P1808, DOI 10.1001/jama.266.13.1808	7	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					452	452		10.1016/0140-6736(93)91590-I	http://dx.doi.org/10.1016/0140-6736(93)91590-I			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102426				2022-12-24	WOS:A1993LU07500007
J	BRODSKY, M; KAMENKER, E; ORLOV, M; ALLEN, B				BRODSKY, M; KAMENKER, E; ORLOV, M; ALLEN, B			CARDIAC EFFECT OF PROLONGED BETA-BLOCKER THERAPY FOR MIGRAINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											BRODSKY, M (corresponding author), UNIV CALIF IRVINE,IRVINE MED CTR,ORANGE,CA 92668, USA.							FRISHMAN WH, 1988, MED CLIN N AM, V72, P37, DOI 10.1016/S0025-7125(16)30786-6; GORDON NF, 1991, MED SCI SPORT EXER, V23, P668; ROSEN JA, 1983, ANN NEUROL, V13, P92, DOI 10.1002/ana.410130119; SABLE DL, 1982, CIRCULATION, V65, P679, DOI 10.1161/01.CIR.65.4.679; WALDEN RJ, 1982, AM HEART J, V104, P515, DOI 10.1016/0002-8703(82)90149-1	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					880	880						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	8101882				2022-12-24	WOS:A1993LR61200041
J	OGRADY, JG; SCHALM, SW; WILLIAMS, R				OGRADY, JG; SCHALM, SW; WILLIAMS, R			ACUTE LIVER-FAILURE - REDEFINING THE SYNDROMES	LANCET			English	Article							HEPATIC-FAILURE; FULMINANT; PROGNOSIS	Existing definitions of clinical syndromes in acute liver failure do not accurately reflect important differences in clinical features and prognosis. Based on a large series of patients with acute liver failure treated at King's College Hospital, London between 1972 and 1985, we propose a new terminology. Hyperacute liver failure is our suggested term for cases in which encephalopathy occurs within 7 days of the onset of jaundice; this group includes the sizeable cohort likely to survive with medical management despite the high incidence of cerebral oedema. We suggest the term acute liver failure for cases with an interval of between 8 and 28 days from jaundice to encephalopathy; they also have a high incidence of cerebral oedema, but have a much poorer prognosis without liver transplantation. The term subacute liver failure is suggested to describe cases with encephalopathy that occurs within 5 to 12 weeks of the onset of jaundice; these patients are characterised by a law incidence of cerebral oedema, but have a poor prognosis. Adoption of this terminology should help in the management of these patients, in addition to standardising the structure and interpretation of controlled trials of therapies.	KINGS COLL,SCH MED & DENT,INST LIVER STUDIES,LONDON SE5 8RS,ENGLAND; ST JAMES UNIV HOSP,LIVER UNIT,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; UNIV HOSP ROTTERDAM,DEPT INTERNAL MED 2,ROTTERDAM,NETHERLANDS	University of London; King's College London; Saint James's University Hospital; Erasmus University Rotterdam; Erasmus MC				opoku, anita/0000-0001-7243-8157				BERNUAU J, 1993, LANCET, V342, P252, DOI 10.1016/0140-6736(93)91809-Z; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; GIMSON AES, 1986, HEPATOLOGY, V6, P288, DOI 10.1002/hep.1840060222; LUCKE B, 1946, AM J PATHOL, V22, P867; MATHIESEN LR, 1980, GUT, V21, P72, DOI 10.1136/gut.21.1.72; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; TAKAHASHI Y, 1991, J GASTROEN HEPATOL, V6, P159, DOI 10.1111/j.1440-1746.1991.tb01458.x; Trey C, 1970, Prog Liver Dis, V3, P282; 1989, GUT, V20, P620	9	628	645	1	25	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					273	275						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101303				2022-12-24	WOS:A1993LQ16300011
J	WANG, BB; MULLERIMMERGLUCK, MM; AUSTIN, J; ROBINSON, NT; CHISHOLM, A; KENYON, C				WANG, BB; MULLERIMMERGLUCK, MM; AUSTIN, J; ROBINSON, NT; CHISHOLM, A; KENYON, C			A HOMEOTIC GENE-CLUSTER PATTERNS THE ANTEROPOSTERIOR BODY AXIS OF C-ELEGANS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DROSOPHILA HEAD DEVELOPMENT; ANTERIOR POSTERIOR AXIS; HOMEOBOX GENES; EMBRYONIC EXPRESSION; BITHORAX COMPLEX; EMPTY SPIRACLES; DISTAL-LESS; HOMEODOMAIN; SEQUENCE	In insects and vertebrates, clusters of Antennapedia class homeobox (HOM-C) genes specify anteroposterior body pattern. The nematode C. elegans also contains a small cluster of HOM-C genes, one of which has been shown to specify positional identity. Here we show that two additional C. elegans HOM-C genes also specify positional identity and that together these three HOM-C genes function along the anteroposterior axis in the same order as their homologs in other organisms. Thus, HOM-C-based pattern formation has been conserved in nematodes despite the many differences in morphology and embryology that distinguish them from other phyla. Each C. elegans HOM-C gene is responsible for a distinct body region; however, where their domains overlap, two HOM-C genes can act together to specify the fates of individual cells.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	WANG, BB (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Chisholm, Andrew/0000-0001-5091-0537				AKAM M, 1988, DEVELOPMENT, V104, P123; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; CELNIKER SE, 1989, GENE DEV, V3, P1424, DOI 10.1101/gad.3.9.1424; CHALFIE M, 1983, SCIENCE, V221, P61, DOI 10.1126/science.6857263; CHISHOLM A, 1991, DEVELOPMENT, V111, P921; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; COSTA M, 1988, CELL, V55, P747, DOI 10.1016/0092-8674(88)90131-6; COWING DW, 1992, DEVELOPMENT, V116, P481; CRIBBS DL, 1992, EMBO J, V11, P1437, DOI 10.1002/j.1460-2075.1992.tb05188.x; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DIEDERICH RJ, 1989, GENE DEV, V3, P399, DOI 10.1101/gad.3.3.399; ELLIS H, 1985, THESIS MIT CAMBRIDGE; FIBI M, 1988, DEVELOPMENT, V102, P349; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FRANCIS R, 1991, J CELL BIOL, V114, P465, DOI 10.1083/jcb.114.3.465; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GALLIOT B, 1989, DEVELOPMENT, V107, P343; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; HAWKINS NC, 1990, NUCLEIC ACIDS RES, V18, P6101, DOI 10.1093/nar/18.20.6101; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HORVITZ HR, 1982, NEUROSCI COMMENT, V1, P56; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KENYON C, 1991, SCIENCE, V253, P516, DOI 10.1126/science.1677487; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; LAUGHON A, 1986, MOL CELL BIOL, V6, P4676, DOI 10.1128/MCB.6.12.4676; LEMOTTE PK, 1989, EMBO J, V8, P219, DOI 10.1002/j.1460-2075.1989.tb03367.x; LOER CM, 1993, IN PRESS NEUROSCIENC; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MEIJLINK F, 1987, NUCLEIC ACIDS RES, V15, P6773, DOI 10.1093/nar/15.17.6773; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; SCHALLER D, 1990, NUCLEIC ACIDS RES, V18, P2033, DOI 10.1093/nar/18.8.2033; SCHUGHART K, 1988, P NATL ACAD SCI USA, V85, P5582, DOI 10.1073/pnas.85.15.5582; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SIMEONE A, 1992, EMBO J, V11, P2541, DOI 10.1002/j.1460-2075.1992.tb05319.x; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TAN DP, 1992, P NATL ACAD SCI USA, V89, P6280, DOI 10.1073/pnas.89.14.6280; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WOOD WB, 1988, NEMATODE CAENORHABDI, P491	50	283	294	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					29	42		10.1016/0092-8674(93)90292-X	http://dx.doi.org/10.1016/0092-8674(93)90292-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8101474				2022-12-24	WOS:A1993LN62500005
J	OBRIEN, SJ; BHOPAL, RS				OBRIEN, SJ; BHOPAL, RS			LEGIONNAIRES-DISEASE - THE INFECTIVE DOSE PARADOX	LANCET			English	Editorial Material							LEGIONELLA-PNEUMOPHILA; AEROSOLS; SURVIVAL; EXPOSURE		MED SCH NEWCASTLE UPON TYNE,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE,ENGLAND	Newcastle University - UK	OBRIEN, SJ (corresponding author), UNIV BIRMINGHAM SCH MED,DEPT INFECT,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.		OBRIEN, STEPHEN/ABD-1346-2020					BASKERVILLE A, 1981, LANCET, V2, P1389; BHOPAL RS, 1993, J INFECTION, V26, P239, DOI 10.1016/0163-4453(93)95215-5; BHOPAL RS, 1991, BRIT MED J, V302, P378, DOI 10.1136/bmj.302.6773.378; BREIMAN RF, 1990, J INFECT DIS, V161, P1257, DOI 10.1093/infdis/161.6.1257; COLBOURNE JS, 1989, J INST WATER ENV MAN, V3, P345; DENNIS PJL, 1984, J HYG-CAMBRIDGE, V93, P349, DOI 10.1017/S0022172400064901; HAMBLETON P, 1983, J HYG-CAMBRIDGE, V90, P451, DOI 10.1017/S0022172400029090; MOFFAT JF, 1992, INFECT IMMUN, V60, P296, DOI 10.1128/IAI.60.1.296-301.1992; TYNDALL RL, 1985, LEGIONNAIRES DISEASE; VICKERS RM, 1992, J CLIN MICROBIOL, V30, P537, DOI 10.1128/JCM.30.3.537-539.1992; YAMAMOTO Y, 1992, J IMMUNOL, V148, P584	11	46	48	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					5	6		10.1016/0140-6736(93)91877-O	http://dx.doi.org/10.1016/0140-6736(93)91877-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100317				2022-12-24	WOS:A1993LK98500006
J	BUELER, H; AGUZZI, A; SAILER, A; GREINER, RA; AUTENRIED, P; AGUET, M; WEISSMANN, C				BUELER, H; AGUZZI, A; SAILER, A; GREINER, RA; AUTENRIED, P; AGUET, M; WEISSMANN, C			MICE DEVOID OF PRP ARE RESISTANT TO SCRAPIE	CELL			English	Article							CREUTZFELDT-JAKOB DISEASE; PRION PROTEIN; AMYLOID PLAQUES; INFECTIVITY; LINKAGE; VIRUS; GENE; IDENTIFICATION; POLYMORPHISM; PURIFICATION	S. B. Prusiner proposed that the infectious agent of scrapie, the prion, is PrP(Sc), a modified form of the normal host protein PrP(C). Prn-p0/0 mice devoid of PrP(C) showed normal development and behavior. When inoculated with mouse scrapie prions, they remained free of scrapie symptoms for at least 13 months while wild-type controls all died within 6 months. Surprisingly, heterozygous Prn-p0/+ mice also showed enhanced resistance to scrapie. After introduction of Syrian hamster PrP transgenes, Prn-P0/0 mice became highly susceptible to hamster but not to mouse prions. These experiments show that PrP(C), possibly at close to normal levels, is required for the usual susceptibility to scrapie and that lack of homology between incoming prions and the host's PrP genes retards disease.	UNIV HOSP ZURICH,INST NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND; UNIV HOSP ZURICH,BIOL ZENT LAB,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	BUELER, H (corresponding author), UNIV ZURICH,INST MOLEK BIOL 1,CH-8093 ZURICH,SWITZERLAND.		Aguzzi, Adriano/A-3351-2008; Büeler, Hansruedi/J-6965-2017; Sailer, Andreas/M-9913-2016	Büeler, Hansruedi/0000-0002-4892-7177; Aguzzi, Adriano/0000-0002-0344-6708; Sailer, Andreas/0000-0002-9015-7946	NINDS NIH HHS [NS22786-07] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022786] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baker H. F., 1992, Neurodegeneration, V1, P3; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BOLTON DC, 1988, NOVEL INFECTIOUS AGE, P164; BROWN P, 1990, NEUROLOGY, V40, P887, DOI 10.1212/WNL.40.6.887; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAIRNS HJF, 1950, NATURE, V166, P910, DOI 10.1038/166910b0; CARLSON GA, 1989, P NATL ACAD SCI USA, V86, P7475, DOI 10.1073/pnas.86.19.7475; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CARLSON GA, 1988, MOL CELL BIOL, V8, P5528, DOI 10.1128/MCB.8.12.5528; CHANDLER RL, 1961, LANCET, V1, P1378; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; DIRINGER H, 1988, CIBA F SYMP, V135, P135; EKLUND CM, 1967, J INFECT DIS, V117, P15, DOI 10.1093/infdis/117.1.15; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GAJDUSEK DC, 1991, EUR J EPIDEMIOL, V7, P567, DOI 10.1007/BF00143141; HILMERT H, 1984, BIOSCIENCE REP, V4, P165, DOI 10.1007/BF01120313; HOTCHIN J, 1983, INTERVIROLOGY, V19, P205, DOI 10.1159/000149362; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HUNTER N, 1987, J GEN VIROL, V68, P2711, DOI 10.1099/0022-1317-68-10-2711; KELLINGS K, 1992, J GEN VIROL, V73, P1025, DOI 10.1099/0022-1317-73-4-1025; Kimberlin R.H., 1990, SE VIROL, V1, P153; KINGSBURY DT, 1990, ANNU REV GENET, V24, P115, DOI 10.1146/annurev.ge.24.120190.000555; KITAMOTO T, 1986, ANN NEUROL, V20, P204, DOI 10.1002/ana.410200205; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANUELIDIS L, 1988, CIBA F SYMP, V135, P117; MEYER N, 1991, J GEN VIROL, V72, P37, DOI 10.1099/0022-1317-72-1-37; MILLSON GC, 1993, VET MICROBIOL 1979, P89; OESCH B, 1988, CIBA F SYMP, V135, P209; PATTISON IH, 1966, RES VET SCI, V7, P207; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; RACE RE, 1990, J GEN VIROL, V71, P493, DOI 10.1099/0022-1317-71-2-493; Rohwer R G, 1991, Curr Top Microbiol Immunol, V172, P195; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0	40	1706	1768	2	101	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 2	1993	73	7					1339	1347		10.1016/0092-8674(93)90360-3	http://dx.doi.org/10.1016/0092-8674(93)90360-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	LL209	8100741	Bronze			2022-12-24	WOS:A1993LL20900009
J	MATONDO, P				MATONDO, P			INFECTIOUS-DISEASE - ANTENATAL INTERVENTIONS AGAINST SEXUALLY-TRANSMITTED DISEASE IN AFRICA	LANCET			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; ERYTHROMYCIN TREATMENT				MATONDO, P (corresponding author), UNIV TEACHING HOSP,LUSAKA,ZAMBIA.							BRADDICK MR, 1990, GENITOURIN MED, V66, P622; ELLIOT G, 1990, J INFECT DIS, V161, P5321; ESCHENBACH DA, 1991, AM J OBSTET GYNECOL, V164, P734, DOI 10.1016/0002-9378(91)90506-M; HIRA SK, 1990, GENITOURIN MED, V66, P159; MATONDO P, 1989, MED J ZAMBIA, V24, P3; MCCORMACK WM, 1987, OBSTET GYNECOL, V69, P202; MCGREGOR JA, 1986, AM J OBSTET GYNECOL, V154, P98, DOI 10.1016/0002-9378(86)90401-1; Ratnam A V, 1980, Med J Zambia, V14, P71; VANDYCK E, 1992, GENITOURIN MED, V68, P111; 1992, WHOMSM92 DOC	10	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 19	1993	341	8860					1565	1566		10.1016/0140-6736(93)90701-H	http://dx.doi.org/10.1016/0140-6736(93)90701-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099644				2022-12-24	WOS:A1993LH55000008
J	BRODIE, MJ				BRODIE, MJ			EPILEPSY - FELBAMATE - A NEW ANTIEPILEPTIC DRUG	LANCET			English	Editorial Material							PARTIAL SEIZURES; CLINICAL-TRIAL; CARBAMAZEPINE				BRODIE, MJ (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,EPILEPSY RES UNIT,GLASGOW G11 6NT,SCOTLAND.							ALBANI F, 1991, EPILEPSIA, V32, P130, DOI 10.1111/j.1528-1157.1991.tb05624.x; FAUGHT E, IN PRESS NEUROLOGY; FUERST RH, 1988, EPILEPSIA, V29, P448; GRAVES NM, 1989, EPILEPSIA, V30, P225, DOI 10.1111/j.1528-1157.1989.tb05458.x; LEPPIK I E, 1990, Neurology, V40, P158; LEPPIK IE, 1991, NEUROLOGY, V41, P1785, DOI 10.1212/WNL.41.11.1785; PALMER KJ, IN PRESS DRUGS; SACHDEO R, 1992, ANN NEUROL, V32, P386, DOI 10.1002/ana.410320313; THEODORE WH, 1991, EPILEPSIA, V32, P392, DOI 10.1111/j.1528-1157.1991.tb04668.x; WAGNER M L, 1991, Epilepsia, V32, P15; WAGNER ML, 1990, EPILEPSIA, V31, P642; WARD D L, 1991, Epilepsia, V32, P8; 1992, SCRIP           1222, P26; 1993, NEW ENGL J MED, V328, P29	14	24	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 5	1993	341	8858					1445	1446		10.1016/0140-6736(93)90888-N	http://dx.doi.org/10.1016/0140-6736(93)90888-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099147				2022-12-24	WOS:A1993LF84100010
J	JHA, PKS; BERAL, V; PETO, J; HACK, S; HERMON, C; DEACON, J; MANT, D; CHILVERS, C; VESSEY, MP; PIKE, MC; MULLER, M; GISSMANN, L				JHA, PKS; BERAL, V; PETO, J; HACK, S; HERMON, C; DEACON, J; MANT, D; CHILVERS, C; VESSEY, MP; PIKE, MC; MULLER, M; GISSMANN, L			ANTIBODIES TO HUMAN PAPILLOMAVIRUS AND TO OTHER GENITAL INFECTIOUS AGENTS AND INVASIVE CERVICAL-CANCER RISK	LANCET			English	Article								Human papillomaviruses (HPVs) play an important part in the development of cervical cancer, but the role of other infectious agents, such as herpes simplex virus (HSV), is not clear. We assayed serum samples collected from 219 women with cervical cancer and from 387 controls for antibody to infectious agents. HPV 16-E7 and/or HPV 18-E7 antibodies were significantly related to cervical cancer risk (RR 1.9, 95% CI 1.2-3.2). Antibodies to HSV types 1 and 2, Chlamydia trachomatis, and to multiple infectious agents were associate with cervical cancer when seroprevalence rates in all cases and controls were compared, but when HPV-seropositive cases and controls were compared these associations were weaker and non-significant. This finding suggests that past infections with sexually transmitted infections other than HPV may be surrogate markers of exposure to HPV, and of no separate aetiological significance.	IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,OXFORD,ENGLAND; GERMAN CANC RES CTR,W-6900 HEIDELBERG 1,GERMANY; INST CANC RES,EPIDEMIOL SECT,SUTTON SM2 5PX,SURREY,ENGLAND; UNIV NOTTINGHAM,DEPT EPIDEMIOL,NOTTINGHAM NG7 2RD,ENGLAND; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,OXFORD,ENGLAND	University of Oxford; Helmholtz Association; German Cancer Research Center (DKFZ); University of London; Institute of Cancer Research - UK; University of Nottingham; University of Oxford			Gissmann, Lutz/H-4688-2011; Mant, David CA/C-7763-2009					BLEUL C, 1991, J CLIN MICROBIOL, V29, P1579, DOI 10.1128/JCM.29.8.1579-1588.1991; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; HILDESHEIM A, 1991, INT J CANCER, V49, P335, DOI 10.1002/ijc.2910490304; KOUTSKY L, 1991, JNCI-J NATL CANCER I, V83, P978, DOI 10.1093/jnci/83.14.978; LEY C, 1991, JNCI-J NATL CANCER I, V83, P997, DOI 10.1093/jnci/83.14.997; LORINCZ AT, 1992, OBSTET GYNECOL, V79, P328, DOI 10.1097/00006250-199203000-00002; MANDELSON MT, 1992, CANCER EPIDEM BIOMAR, V1, P281; MANN VM, 1990, CANCER RES, V50, P7815; MULLER M, 1992, VIROLOGY, V187, P508; SCHIFFMAN MH, 1992, JNCI-J NATL CANCER I, V84, P394, DOI 10.1093/jnci/84.6.394; SCHMAUZ R, 1989, INT J CANCER, V43, P805, DOI 10.1002/ijc.2910430511; SCHMIDT NJ, 1989, DIAGNOSTIC PROCEDURE, P265; SVENNERHOLM B, 1984, J CLIN MICROBIOL, V19, P235, DOI 10.1128/JCM.19.2.235-239.1984; TREHARNE JD, 1977, J CLIN PATHOL, V30, P510, DOI 10.1136/jcp.30.6.510	14	56	58	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1116	1118		10.1016/0140-6736(93)93128-N	http://dx.doi.org/10.1016/0140-6736(93)93128-N			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097804				2022-12-24	WOS:A1993KZ68700004
J	CHAN, SH; COSGROVE, D; WALTZINGER, C; BENOIST, C; MATHIS, D				CHAN, SH; COSGROVE, D; WALTZINGER, C; BENOIST, C; MATHIS, D			ANOTHER VIEW OF THE SELECTIVE MODEL OF THYMOCYTE SELECTION	CELL			English	Article							T-CELL RECEPTOR; TRANSGENIC MICE; ANTIGEN RECEPTOR; POSITIVE SELECTION; LYMPHOCYTES-T; NEGATIVE SELECTION; MHC MOLECULES; CD8 LINEAGE; THYMUS; EXPRESSION	Thymocyte commitment to the CD4 helper versus CD8 cytotoxic lineage has not been satisfactorily established. Two models have been elaborated: one based on instruction, the other on selection. Most previous results support the instructive model, but our comparison of thymocyte differentiation in MHC class II-, class I- and double-deficient mice provides data challenging it. There exists a significant population of CD4 single positive cells in class II-deficient animals that is intermediate in maturity between CD4+CD8+ and end-stage CD4+CD8- thymocytes and is selected on class I molecules; an equivalent CD8+CD4- population occurs in class I-deficient animals. We propose a selective model entailing two TCR-MHC molecule engagements: the first provokes random down-modulation of either CD4 or CD8 and a degree of differentiation; the second, requiring participation of the appropriate coreceptor, permits end-stage differentiation.			CHAN, SH (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE.							BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BOGUE M, 1992, P NATL ACAD SCI USA, V89, P11011, DOI 10.1073/pnas.89.22.11011; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; CANDEIAS S, 1991, P NATL ACAD SCI USA, V88, P6167, DOI 10.1073/pnas.88.14.6167; CHANG JF, 1991, J IMMUNOL, V147, P860; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; CROMPTON T, 1992, INT IMMUNOL, V4, P153, DOI 10.1093/intimm/4.2.153; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HAUGHN L, 1992, NATURE, V358, P328, DOI 10.1038/358328a0; HAYAKAWA K, 1988, J EXP MED, V168, P1825, DOI 10.1084/jem.168.5.1825; HAYAKAWA K, 1991, IMMUNOL REV, V123, P145, DOI 10.1111/j.1600-065X.1991.tb00609.x; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; JANEWAY CA, 1988, NATURE, V335, P208, DOI 10.1038/335208a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KUBO RT, 1989, J IMMUNOL, V142, P2736; KYEWSKI B, 1992, IMMUNOL TODAY, V13, P288, DOI 10.1016/0167-5699(92)90038-9; MACPHAIL S, 1987, J IMMUNOL, V139, P4007; MCKISIC MD, 1991, J IMMUNOL, V147, P2868; NIKOLICZUGIC J, 1990, INT IMMUNOL, V2, P135, DOI 10.1093/intimm/2.2.135; NIKOLICZUGIC J, 1991, IMMUNOL TODAY, V12, P65, DOI 10.1016/0167-5699(91)90160-U; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RAMSDELL F, 1991, J IMMUNOL, V147, P1779; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHORES EW, 1991, EUR J IMMUNOL, V21, P1657, DOI 10.1002/eji.1830210711; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SURH CD, 1992, J EXP MED, V176, P611, DOI 10.1084/jem.176.2.611; SWAT W, 1992, EUR J IMMUNOL, V22, P2367, DOI 10.1002/eji.1830220928; SWAT W, 1993, IN PRESS EUR J IMMUN; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; VANOERS NSC, 1992, EUR J IMMUNOL, V22, P735, DOI 10.1002/eji.1830220317; VERNACHIO J, 1989, J IMMUNOL, V142, P48; VONBOEHMER H, 1986, IMMUNOL TODAY, V7, P333; WILSON A, 1988, CELL IMMUNOL, V117, P312, DOI 10.1016/0008-8749(88)90121-9; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	52	283	286	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 23	1993	73	2					225	236		10.1016/0092-8674(93)90225-F	http://dx.doi.org/10.1016/0092-8674(93)90225-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8097430				2022-12-24	WOS:A1993KY50500006
J	MILLER, E; GOLDACRE, M; PUGH, S; COLVILLE, A; FARRINGTON, P; FLOWER, A; NASH, J; MACFARLANE, L; TETTMAR, R				MILLER, E; GOLDACRE, M; PUGH, S; COLVILLE, A; FARRINGTON, P; FLOWER, A; NASH, J; MACFARLANE, L; TETTMAR, R			RISK OF ASEPTIC-MENINGITIS AFTER MEASLES, MUMPS, AND RUBELLA VACCINE IN UK CHILDREN	LANCET			English	Article							SURVEILLANCE	Cases of aseptic meningitis associated with measles/mumps/rubella vaccine were sought in thirteen UK health districts following a reported cluster in Nottingham which suggested a risk of 1 in 4000 doses, substantially higher than previous estimates based on cases reported by paediatricians (4 per million). Cases were ascertained by obtaining vaccination records of children with aseptic meningitis diagnosed from cerebrospinal fluid samples submitted to Public Health Laboratories or discharged from hospital with a diagnosis of viral meningitis. Both methods identified vaccination 15-35 days before onset as a significant risk factor and therefore indicative of a causal association. With both, half the aseptic meningitis cases identified in children aged 12-24 months were vaccine-associated with onset 15-35 days after vaccine. The study confirmed that the true risk was substantially higher than suggested by case reports from paediatricians, probably about 1 in 11 000 doses. However, the possibility that the aseptic meningitis induced by vaccination was largely asymptomatic and a chance laboratory finding in children investigated for other clinical conditions, particularly febrile convulsions, could not be excluded. Comparison of national reports of virus-positive mumps meningitis cases before and after the introduction of this vaccine indicated that the risk from wild mumps was about 4-fold higher than from vaccine. Altogether, 28 vaccine-associated cases were identified, all in recipients of vaccines containing the Urabe mumps strain. The absence of cases in recipients of vaccine containing the Jeryl Lynn strain, despite its 14% market share, suggested a higher risk from Urabe vaccine. A prospective adverse event surveillance system using the study methods is currently being established to assess the risk, if any, from the Jeryl Lynn strain which is now the only mumps vaccine used in the UK.	PUBL HLTH LAB,LEICESTER,ENGLAND; PUBL HLTH LAB,NOTTINGHAM,ENGLAND; PUBL HLTH LAB,ASHFORD,ENGLAND; PUBL HLTH LAB,KENT,ENGLAND; UNIV OXFORD,DEPT PUBL HLTH MED,HLTH CARE EPIDEMIOL UNIT,OXFORD OX3 7LE,ENGLAND; PUBL HLTH LAB,PRESTON,ENGLAND; PUBL HLTH LAB,CHELMSFORD,ENGLAND	University of Oxford	MILLER, E (corresponding author), PUBL HLTH LAB SERV,DIV IMMUNISAT,61 COLINDALE AVE,LONDON NW9 5EQ,ENGLAND.			Farrington, Conor Patrick/0000-0002-7148-2612				AHRONHEIM GA, 1991, PEDIATR RES, V29, pA166; [Anonymous], 1989, LANCET, V2, P1015; BEGG NT, 1989, PUBLIC HEALTH, V103, P81, DOI 10.1016/S0033-3506(89)80021-6; BOTTIGER M, 1987, BRIT MED J, V295, P1264, DOI 10.1136/bmj.295.6608.1264; COLVILLE A, 1992, LANCET, V340, P786, DOI 10.1016/0140-6736(92)92322-7; FORSEY T, 1990, J GEN VIROL, V71, P987, DOI 10.1099/0022-1317-71-4-987; FUJINAGA T, 1991, PEDIATR INFECT DIS J, V10, P204, DOI 10.1097/00006454-199103000-00007; HOCKIN JC, 1988, CANADIAN DISEASES WE, V14, P210; MAGUIRE HC, 1991, CDR, pR60; MILLER C, 1989, PRACTITIONER, V233, P69; MORGANCAPNER P, 1988, BRIT MED J, V297, P770, DOI 10.1136/bmj.297.6651.770; NOKES DJ, 1991, LANCET, V338, P1309, DOI 10.1016/0140-6736(91)92601-W; Ocklitz H W, 1976, Kinderarztl Prax, V44, P145; PRENTICE RL, 1984, BIOMETRICS, V40, P445, DOI 10.2307/2531397; SUGIURA A, 1991, PEDIATR INFECT DIS J, V10, P209, DOI 10.1097/00006454-199103000-00008; WEIRSBITZKY S, 1983, LANCET, V341, P379; 1989, MMWR, V38, P388; 1992, PLCMO9211 DEP HLTH	18	136	140	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					979	982		10.1016/0140-6736(93)91069-X	http://dx.doi.org/10.1016/0140-6736(93)91069-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096942				2022-12-24	WOS:A1993KY36800002
J	HORAN, MA				HORAN, MA			IMMUNOSENESCENCE AND MUCOSAL IMMUNITY	LANCET			English	Editorial Material							AGED MICE; RESPONSIVENESS; CELLS				HORAN, MA (corresponding author), UNIV HOSP S MANCHESTER,MANCHESTER M20 8LR,LANCS,ENGLAND.							ARRANZ E, 1992, GUT, V33, P882, DOI 10.1136/gut.33.7.882; ASTLE CM, 1984, J IMMUNOL, V132, P673; AVERILL LE, 1985, J IMMUNOL, V134, P3859; ERNST DN, 1987, J IMMUNOL, V138, P26; LIGHTHART GJ, 1984, MECH AGEING DEV, V28, P47; RUSSO C, 1990, Aging Immunology and Infectious Disease, V2, P211; TAYLOR L D, 1990, Aging Immunology and Infectious Disease, V2, P205; WADE A W, 1988, Aging Immunology and Infectious Disease, V1, P65; WADE AW, 1984, ADV IMMUNOL, V36, P143, DOI 10.1016/S0065-2776(08)60901-3; ZHARHARY D, 1986, EUR J IMMUNOL, V16, P1175, DOI 10.1002/eji.1830160924; ZHARHARY D, 1983, J EXP MED, V157, P1300, DOI 10.1084/jem.157.4.1300	11	7	7	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					793	794		10.1016/0140-6736(93)90566-Y	http://dx.doi.org/10.1016/0140-6736(93)90566-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096004				2022-12-24	WOS:A1993KU90000009
J	ASCHER, MS; SHEPPARD, HW; WINKELSTEIN, W; VITTINGHOFF, E				ASCHER, MS; SHEPPARD, HW; WINKELSTEIN, W; VITTINGHOFF, E			DOES DRUG-USE CAUSE AIDS	NATURE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; KAPOSIS SARCOMA; EPIDEMIOLOGY; COHORT; MEN		UNIV CALIF BERKELEY,SCH PUBL HLTH,DEPT BIOMED & ENVIRONM HLTH SCI,BERKELEY,CA 94720	University of California System; University of California Berkeley	ASCHER, MS (corresponding author), CALIF DEPT HLTH SERV,VIRAL & RICKETTSIAL DIS LAB,BERKELEY,CA 94704, USA.							ASCHER MS, 1990, J ACQ IMMUN DEF SYND, V3, P177; DUESBERG PH, 1987, CANCER RES, V47, P1199; DUESBERG PH, 1991, P NATL ACAD SCI USA, V88, P1575, DOI 10.1073/pnas.88.4.1575; DUESBERG PH, 1992, PHARMACOL THERAPEUT, V55, P201, DOI 10.1016/0163-7258(92)90052-2; FRIDLAND G, 1989, EPIDEMIOLOGY AIDS, P153; HAVERKOS HW, 1988, HLTH HAZARDS NITRITE, P96; JAFFE HW, 1983, ANN INTERN MED, V99, P145, DOI 10.7326/0003-4819-99-2-145; KASLOW RA, 1989, JAMA-J AM MED ASSOC, V261, P3424, DOI 10.1001/jama.261.23.3424; LIFSON AR, 1990, AM J EPIDEMIOL, V131, P221, DOI 10.1093/oxfordjournals.aje.a115492; PINCHING AJ, 1990, NATURE, V347, P328; SHEPPARD HW, 1992, J ACQ IMMUN DEF SYND, V5, P143; WEISS RA, 1990, NATURE, V345, P659, DOI 10.1038/345659a0; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; 1981, MORTAL WKLY RPT, V30, P250; 1987, MORTAL WKLY RPT, V36, pS3	15	34	34	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					103	104		10.1038/362103a0	http://dx.doi.org/10.1038/362103a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	8095697				2022-12-24	WOS:A1993KR02800018
J	PENTLAND, B				PENTLAND, B			REHABILITATION - QUADRIPLEGIA AND CARDIORESPIRATORY FITNESS	LANCET			English	Editorial Material											PENTLAND, B (corresponding author), ASTLEY AINSLIE HOSP,REHABIL STUDIES UNIT,EDINBURGH,SCOTLAND.							DAVIS G, 1990, KEY ISSUES NEUROLOGI, P155; HOFFMAN MD, 1986, SPORTS MED, V3, P312, DOI 10.2165/00007256-198603050-00002; HOOKER SP, 1992, J REHABIL RES DEV, V29, P1, DOI 10.1682/JRRD.1992.07.0001; NASH MS, 1991, PARAPLEGIA, V29, P590, DOI 10.1038/sc.1991.87; WEBER RJ, 1992, DISEASES SPINAL CORD, P429	5	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					413	414		10.1016/0140-6736(93)93000-Q	http://dx.doi.org/10.1016/0140-6736(93)93000-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094180				2022-12-24	WOS:A1993KM41600015
J	DELACHAPELLE, A; SISTONEN, P; LEHVASLAIHO, H; IKKALA, E; JUVONEN, E				DELACHAPELLE, A; SISTONEN, P; LEHVASLAIHO, H; IKKALA, E; JUVONEN, E			FAMILIAL ERYTHROCYTOSIS GENETICALLY LINKED TO ERYTHROPOIETIN RECEPTOR GENE	LANCET			English	Note								Familial erythrocytosis is heterogeneous with diverse causes. Using a highly informative, simple sequence repeat polymorphism in the 5' region of the erythropoietin receptor gene (EPOR), we did linkage analysis in a large family whose clinical and genealogical features were known. There were no recombinations between the disease phenotype and the polymorphism, the logarithm of odds score for linkage at zero recombination being 6.37. This highly significant linkage indicates that a mutation in EPOR is most probably responsible for the disease phenotype in this family.	UNIV HELSINKI,DEPT MED 2,SF-00290 HELSINKI 29,FINLAND; UNIV HELSINKI,DEPT MED 3,SF-00290 HELSINKI 29,FINLAND	University of Helsinki; University of Helsinki	DELACHAPELLE, A (corresponding author), UNIV HELSINKI,DEPT MED GENET,HAARTMANINKATU 3,SF-00290 HELSINKI 29,FINLAND.							ADAMSON JW, 1975, SEMIN HEMATOL, V12, P383; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; EMANUEL PD, 1992, BLOOD, V79, P3019; JUVONEN E, 1991, BLOOD, V78, P3066; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; PENNY LA, 1991, GENOMICS, V11, P974, DOI 10.1016/0888-7543(91)90022-7	6	68	68	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					82	84		10.1016/0140-6736(93)92558-B	http://dx.doi.org/10.1016/0140-6736(93)92558-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093406				2022-12-24	WOS:A1993KF87000005
J	CORTI, MC; GURALNIK, JM; SALIVE, ME; SORKIN, JD				CORTI, MC; GURALNIK, JM; SALIVE, ME; SORKIN, JD			SERUM-ALBUMIN LEVEL AND PHYSICAL-DISABILITY AS PREDICTORS OF MORTALITY IN OLDER PERSONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; HOSPITAL STAY; COMPLICATIONS; AGE	Objectives.-To study the relationship between serum albumin level and all-cause mortality in an elderly population and to evaluate the role of albumin level in combination with physical disability status in predicting mortality. Design.-Cohort study with a mean follow-up of 3.7 years. Setting.-Three communities: East Boston, Mass, New Haven, Conn, and Iowa and Washington counties, Iowa. Subjects.-A total of 1486 men and 2630 women aged 71 years and older who consented to have blood drawn. Results.-During follow-up, 447 men and 488 women died. In both sexes, there was a graded increase in mortality rate with decreasing albumin level. After adjusting for age, race, education, chronic conditions, and disability status, hypoalbuminemia (<35 g/L) was associated with a significantly increased risk of mortality in comparison with the reference group tie, those with albumin levels greater than 43 g/L) (men: relative risk [RR], 1.9; 95% confidence interval [Cl], 1.1 to 3.1; women: RR, 3.7; 95% Cl, 2.5 to 5.5). Among those with albumin levels in the range usually considered normal (35 g/L to 50 g/L), there was a graded increase in mortality risk from the highest normal to the lowest normal groups. For women, results were similar in separate analyses that considered deaths occurring during the first year end 1 year or more after baseline, while for men the relationship decreased after 1 year. Lower albumin level was associated with an elevated risk of mortality for all categories of causes of death. A 15-lever measure that characterized participants according to albumin level and disability status demonstrated that mortality increased with decreasing albumin level and increasing disability lever. Conclusions.-Serum albumin level is an independent risk factor for all-cause mortality in older persons. A combined measure of albumin and disability reveals a strong gradient in mortality risk and may serve as a simple but useful index of frailty that can identify a high-risk group of older men and women who could be targeted for preventive and treatment efforts.			CORTI, MC (corresponding author), NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,7201 WISCONSIN AVE,ROOM 3C-309,BETHESDA,MD 20892, USA.				NATIONAL INSTITUTE ON AGING [N01AG002105, N01AG002107, N01AG002106] Funding Source: NIH RePORTER; NIA NIH HHS [N01-AG-0-2107, N01-AG-0-2105, N01-AG-0-2106] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON CF, 1984, MAYO CLIN PROC, V59, P477, DOI 10.1016/S0025-6196(12)60437-6; [Anonymous], 1988, INT CLASSIFICATION D; BADLEY EM, 1986, INT REHABIL MED, V8, P118; BRAY GA, 1978, INT J OBESITY, V2, P99; Buchner D M, 1992, Clin Geriatr Med, V8, P1; BUSH TL, 1989, AM J PUBLIC HEALTH, V79, P1554, DOI 10.2105/AJPH.79.11.1554; CAMPION EW, 1988, J GERONTOL, V43, pM18, DOI 10.1093/geronj/43.1.M18; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; DELORGERIL M, 1990, LANCET, V335, P349; DOUMAS BT, 1971, CLIN CHIM ACTA, V31, P87, DOI 10.1016/0009-8981(71)90365-2; DOWEIKO JP, 1991, JPEN-PARENTER ENTER, V15, P207, DOI 10.1177/0148607191015002207; FRIED LP, 1992, AGING-CLIN EXP RES, V4, P251, DOI 10.1007/BF03324099; FRIEDMAN P J, 1985, Journal of Clinical and Experimental Gerontology, V7, P191; GILLUM RF, 1992, AM HEART J, V123, P507, DOI 10.1016/0002-8703(92)90667-K; GRIMBLE R, 1990, LANCET, V335, P350; GURALNIK JM, 1993, AM J EPIDEMIOL, V137, P845, DOI 10.1093/oxfordjournals.aje.a116746; GURALNIK JM, 1991, REDUCING FRAILTY FAL; HALLIWELL B, 1988, BIOCHEM PHARMACOL, V37, P569, DOI 10.1016/0006-2952(88)90126-8; HERMANN FR, 1992, ARCH INTERN MED, V152, P125; HEYMSFIELD SB, 1988, MODERN NUTRITION HLT; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASL SV, 1981, AGING BIOL BEHAVIOR, P345; KEHOE R, 1994, AM J EPIDEMIOL, V139, P813, DOI 10.1093/oxfordjournals.aje.a117078; KLONOFFCOHEN H, 1992, J CLIN EPIDEMIOL, V45, P207, DOI 10.1016/0895-4356(92)90080-7; KULLER LH, 1991, AM J EPIDEMIOL, V134, P1266, DOI 10.1093/oxfordjournals.aje.a116030; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; MANTON KG, 1988, J GERONTOL, V43, pS153, DOI 10.1093/geronj/43.5.S153; MCLAREN DS, 1988, NUTRITION, V4, P1; PHILLIPS A, 1989, LANCET, V2, P1434; RICH MW, 1989, AM J CARDIOL, V63, P714, DOI 10.1016/0002-9149(89)90257-9; ROSOW I, 1966, J GERONTOL, V39, P686; ROTSCHILD MA, 1988, HEPATOLOGY, V8, P385; SALIVE ME, 1992, J CLIN EPIDEMIOL, V45, P213, DOI 10.1016/0895-4356(92)90081-W; SOETERS PB, 1990, LANCET, V335, P348, DOI 10.1016/0140-6736(90)90633-G; WILLIAMS TF, 1992, J CLIN EPIDEMIOL, V45, P205; WILLIAMS WR, 1990, LANCET, V335, P348; 1991, SAS P217 SAS I INC T; 1991, NIH91397 PUBL	38	460	465	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					1036	1042		10.1001/jama.272.13.1036	http://dx.doi.org/10.1001/jama.272.13.1036			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089886				2022-12-24	WOS:A1994PH77500029
J	BARONI, MD; MONTI, P; ALBERGHINA, L				BARONI, MD; MONTI, P; ALBERGHINA, L			REPRESSION OF GROWTH-REGULATED G1 CYCLIN EXPRESSION BY CYCLIC-AMP IN BUDDING YEAST	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; POSITIVE FEEDBACK; SIGNALING PATHWAY; PROTEIN-SYNTHESIS; S-CEREVISIAE; SIZE; GENE; CLN1; DIVISION	YEAST cell becomes committed to the cell division cycle only if it grows to a critical size(1-4) and reaches a critical rate of protein synthesis(5,6). The coordination between growth and division takes place at a control step during the G1 phase of the cell cycle called Start(4). It relies on the G1-specific cyclins encoded by CLN1, 2 and 3, which trigger Start through the activation of the Cdc28 protein kinase. In fact, the Cln cyclins are rate-limiting for Start execution and depend on growth. Here we report that the cyclic AMP signal pathway(11) modulates the dependency of Cln cyclins on growth. In particular, more growth is required to trigger Start because CLN1 and CLN2 are repressed by the cAMP signal, thus explaining the previously observed cAMP-dependent increase of the critical size and critical rate of protein synthesis(12). Cln3 is not inhibited by the cAMP pathway and counteracts this mechanism by partially mediating the growth-dependent expression of other G1 cyclins.			BARONI, MD (corresponding author), UNIV MILAN,DIPARTIMENTO FISIOL & BIOCHIM GEN,BIOCHIM COMPARATA SEZ,VIA CELORIA 26,I-20133 MILAN,ITALY.		Baroni, Maurizio David/AAL-8064-2021	Baroni, Maurizio David/0000-0001-6355-9950; Alberghina, Lilia/0000-0003-1694-931X				BARONI MD, 1992, EXP CELL RES, V201, P299, DOI 10.1016/0014-4827(92)90277-F; BARONI MD, 1989, MOL CELL BIOL, V9, P2715, DOI 10.1128/MCB.9.6.2715; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; CHEREST H, 1985, GENE, V34, P269; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HUBLER L, 1993, MOL CELL BIOL, V13, P6274, DOI 10.1128/MCB.13.10.6274; IIDA H, 1984, J CELL BIOL, V98, P1185, DOI 10.1083/jcb.98.4.1185; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; JOHNSTON GC, 1979, J BACTERIOL, V137, P1; KLEIN C, 1994, MOL CELL BIOL, V14, P1920, DOI 10.1128/MCB.14.3.1920; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; LORINCZ A, 1979, J GEN MICROBIOL, V113, P287, DOI 10.1099/00221287-113-2-287; MARTEGANI E, 1984, EUR J BIOCHEM, V144, P205, DOI 10.1111/j.1432-1033.1984.tb08450.x; MOORE SA, 1988, J BIOL CHEM, V263, P9674; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; POPOLO L, 1982, EXP CELL RES, V142, P69, DOI 10.1016/0014-4827(82)90410-4; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; REED SI, 1980, GENETICS, V95, P561; SMITH ME, 1990, YEAST, V6, P53, DOI 10.1002/yea.320060106; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; THEVELEIN JM, 1991, MOL MICROBIOL, V5, P1301, DOI 10.1111/j.1365-2958.1991.tb00776.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; WILSON RB, 1993, FEBS LETT, V325, P191, DOI 10.1016/0014-5793(93)81071-7	31	135	136	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					339	342		10.1038/371339a0	http://dx.doi.org/10.1038/371339a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	8090203				2022-12-24	WOS:A1994PH25400054
J	MIKO, TL; LEMAITRE, C; KINFU, Y				MIKO, TL; LEMAITRE, C; KINFU, Y			DAMAGE AND REGENERATION OF PERIPHERAL-NERVES IN ADVANCED TREATED LEPROSY	LANCET			English	Article							REPAIR; GRAFT	Despite the rapidly falling prevalence of leprosy, the disability and handicap resulting from loss of protective sensation, due to irreversible nerve damage, will remain a huge medical problem for many years. To elucidate the location and consequences of permanent nerve damage in treated leprosy, a prospective study involving nine patients who underwent leg amputation was conducted. Full-length nerves dissected from amputated legs were studied with histological and immunohistochemical methods. Our main findings were that: in both lepromatous and tuberculoid leprosy nerve damage increased distally, culminating in total destruction of dermal nerves and sensory nerve endings; after the therapy-related decrease of inflammation large-scale nerve regeneration took place; and that regenerating axons persisted for decades and in tuberculoid leprosy they might reach the subcutaneous fat of the plantar skin. We conclude that nerve regeneration was blocked by fibrous replacement of the distal-most nerves and nerve endings, and that the theoretical basis of nerve grafting in leprosy is in need of further clarification. In some patients, autologous transplantation of skin flaps, probably irrespective of the duration of loss of sensation, might help in regaining protective sensation.	ALL AFRICA LEPROSY & REHABIL TRAINING CTR,ARMAUER HANSEN RES INST,ADDIS ABABA,ETHIOPIA; UNIV ADDIS ABABA,FAC MED,DEPT ANAT,ADDIS ABABA,ETHIOPIA	Addis Ababa University								ADEYMO O, 1957, TRANSPLAN B, V4, P152; Carayon A, 1970, J Chir (Paris), V99, P235; Dastur D K, 1970, Int J Lepr Other Mycobact Dis, V38, P30; Dastur D K, 1983, Neurosurg Rev, V6, P139, DOI 10.1007/BF01742765; DASTUR DK, 1955, BRAIN, V78, P615, DOI 10.1093/brain/78.4.615; DAYAN AD, 1970, J NEUROL NEUROSUR PS, V33, P586, DOI 10.1136/jnnp.33.5.586; ERMAKOVA NINA, 1936, INTERNAL JOUR LEPROSY, V4, P325; FAWCETT JW, 1986, J NEUROSURG, V65, P354, DOI 10.3171/jns.1986.65.3.0354; HASTINGS R C, 1968, Leprosy Review, V39, P71; Job C K, 1968, Int J Lepr Other Mycobact Dis, V36, P257; KARANTH SS, 1989, J PATHOL, V157, P15, DOI 10.1002/path.1711570104; MACKINNON SE, 1988, SURGERY PERIPHERAL N; MANNERFELT L, 1962, Br J Plast Surg, V15, P136, DOI 10.1016/S0007-1226(62)80019-8; MIKO TL, IN PRESS BIOTECHNIC; MIKO TL, IN PRESS LEPR REV; NOORDEEN SK, 1992, B WORLD HEALTH ORGAN, V70, P7; NORRIS RW, 1988, J BONE JOINT SURG BR, V70, P530, DOI 10.1302/0301-620X.70B4.3403592; PEREIRA JH, 1991, LANCET, V338, P1239, DOI 10.1016/0140-6736(91)92105-B; PFALTZGRAFF RE, 1985, LEPROSY; REDDY DG, 1962, INDIAN J MED RES, V50, P692; Ridley DS., 1988, PATHOGENESIS LEPROSY; SABIN TD, 1969, ARCH NEUROL-CHICAGO, V20, P257, DOI 10.1001/archneur.1969.00480090045006; SABIN TD, 1984, PERIPHERAL NEUROPATH; SMITH WCS, 1993, LANCET, V341, P89, DOI 10.1016/0140-6736(93)92563-9; SMITH WCS, 1992, LEPROSY REV, V63, P23; SUNDERLAND S, 1973, BRAIN, V96, P865, DOI 10.1093/brain/96.4.865; VIEREGGE P, 1985, LEPROSY REV, V56, P5; WATERS MFR, 1993, LANCET, V341, P489, DOI 10.1016/0140-6736(93)90238-C; 1991, ELIMINATION LEPROSY	29	22	22	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					521	525		10.1016/0140-6736(93)91647-5	http://dx.doi.org/10.1016/0140-6736(93)91647-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102668				2022-12-24	WOS:A1993LU58200010
J	FELICIELLO, A; PORCELLINI, A; CIULLO, I; BONAVOLONTA, G; AVVEDIMENTO, EV; FENZI, G				FELICIELLO, A; PORCELLINI, A; CIULLO, I; BONAVOLONTA, G; AVVEDIMENTO, EV; FENZI, G			EXPRESSION OF THYROTROPIN-RECEPTOR MESSENGER-RNA IN HEALTHY AND GRAVES-DISEASE RETRO-ORBITAL TISSUE	LANCET			English	Note							MOLECULAR-CLONING; OPHTHALMOPATHY; FIBROBLASTS	It is not clear whether the ophthalmopathy present in Graves' disease is related to autoimmune reactions to common thyroid/orbit components or is due to specific ocular antigens unrelated to the thyroid. In Graves' disease, serum antibodies to the thyrotropin receptor (TSH-R) can stimulate thyroid function, but no link between the TSH-R and ocular tissues has been found. We have shown, by polymerase chain reaction amplification of specific cDNA, that mature TSH-R mRNA is expressed in the retro-orbital tissue of both healthy subjects and patients with Graves' disease. Of other tissues and cells tested (fibroblasts, lymphocytes, muscle, and thyroid), only thyroid tissue expressed the TSH-R mRNA.	UNIV NAPLES,FAC MED,CATTEDRA ENDOCRINOL,VIA S PANSINI 5,I-80131 NAPLES,ITALY; UNIV NAPLES,FAC MED,CATTEDRA PATOL ORBITARIA,I-80131 NAPLES,ITALY; UNIV NAPLES,FAC MED,DIPARTIMENTO BIOL & PATOL MOLEC & CELLULARE,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,CATANZARO,ITALY	University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria			Porcellini, Antonio/AAC-6097-2019; Porcellini, Antonio/E-1900-2011	Porcellini, Antonio/0000-0001-6882-9518; Feliciello, Antonio/0000-0002-7932-2170				ATKINSON S, 1984, LANCET, V2, P374; Francis T, 1991, Thyroid, V1, P223, DOI 10.1089/thy.1991.1.223; HEUFELDER AE, 1991, J CLIN ENDOCR METAB, V73, P307, DOI 10.1210/jcem-73-2-307; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; SMITH TJ, 1989, J CLIN ENDOCR METAB, V69, P1019, DOI 10.1210/jcem-69-5-1019; WEETMAN AP, 1991, LANCET, V338, P25, DOI 10.1016/0140-6736(91)90013-F	7	241	249	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					337	338		10.1016/0140-6736(93)91475-2	http://dx.doi.org/10.1016/0140-6736(93)91475-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101586				2022-12-24	WOS:A1993LQ86800013
J	HENDERSON, AH; JONES, CJH				HENDERSON, AH; JONES, CJH			REVERSIBLE ENDOTHELIAL DYSFUNCTION IN EPICARDIAL CORONARY-ARTERIES	LANCET			English	Editorial Material							RESISTANCE VESSELS; MICROCIRCULATION; ATHEROSCLEROSIS				HENDERSON, AH (corresponding author), UNIV WALES COLL MED,DEPT CARDIOL,CARDIFF CF4 4XN,S GLAM,WALES.							CHILIAN WM, 1990, AM J PHYSIOL, V258, pH529, DOI 10.1152/ajpheart.1990.258.2.H529; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; GRIFFITH TM, 1987, NATURE, V329, P442, DOI 10.1038/329442a0; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; HENDERSON AH, 1991, BRIT HEART J, V65, P116; LEUNG WH, 1993, LANCET, V341, P1496, DOI 10.1016/0140-6736(93)90634-S; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0	8	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					253	253		10.1016/0140-6736(93)91810-9	http://dx.doi.org/10.1016/0140-6736(93)91810-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101295				2022-12-24	WOS:A1993LQ16300003
J	LOGAN, S; STANTON, A				LOGAN, S; STANTON, A			SCREENING FOR BILIARY ATRESIA	LANCET			English	Editorial Material									MARSTON GREEN HOSP,COMMUNITY MENTAL HLTH SERV UNIT,BIRMINGHAM,ENGLAND		LOGAN, S (corresponding author), INST CHILD HLTH,DIV PUBL HLTH,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND.			Logan, Stuart/0000-0002-9279-261X				DICK MC, 1985, ARCH DIS CHILD, V60, P512, DOI 10.1136/adc.60.6.512; HENRIKSEN NT, 1981, ARCH DIS CHILD, V56, P622, DOI 10.1136/adc.56.8.622; KIVLAHAN C, 1984, PEDIATRICS, V74, P364; MACKINLAY GA, 1993, BRIT MED J, V306, P1426, DOI 10.1136/bmj.306.6890.1426; MATTHEW PM, 1981, ARCH DIS CHILD, V56, P949; MIELIVERGANI G, 1989, LANCET, V1, P421; WILSON JMG, 1968, 34 PUBL HLTH PAP	7	10	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					256	256		10.1016/0140-6736(93)91814-3	http://dx.doi.org/10.1016/0140-6736(93)91814-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101299				2022-12-24	WOS:A1993LQ16300007
J	CHAUHAN, A; PETCH, MC; SCHOFIELD, PM				CHAUHAN, A; PETCH, MC; SCHOFIELD, PM			EFFECT OF ESOPHAGEAL ACID INSTILLATION ON CORONARY BLOOD-FLOW	LANCET			English	Note							RESERVE	To assess whether gastrointestinal factors can cause chest pain (''linked angina''), we studied the effect of oesophageal stimulation with acid on coronary blood flow in 20 syndrome X patients. Coronary blood flow velocity (CBFV) was measured with an intracoronary doppler catheter positioned in the proximal left anterior descending coronary artery. Acid stimulation produced typical anginal, pain in 11 patients. Mean CBFV was significantly reduced from 7.3 (SD 4.0) to 4.4 (2.8) cm/s. Gastro-oesophageal reflux leading to reduced coronary blood flow may be a mechanism to explain linked angina.			CHAUHAN, A (corresponding author), PAPWORTH HOSP, CARDIAC UNIT, CAMBRIDGE CB3 8RE, ENGLAND.							BENNETT JR, 1966, LANCET, V2, P1150; CHAUHAN A, 1992, European Heart Journal, V13, P266; DAVIES HA, 1985, LANCET, V1, P1011; Gilbert NC, 1940, AM HEART J, V20, P519, DOI 10.1016/S0002-8703(40)90930-9; MCGINN AL, 1990, CIRCULATION, V81, P1319, DOI 10.1161/01.CIR.81.4.1319; MELLOW MH, 1983, GASTROENTEROLOGY, V85, P306; MULLINS PA, 1992, BRIT HEART J, V68, P253; SMITH KS, 1962, BRIT MED J, P1425, DOI 10.1136/bmj.2.5317.1425; THORPE A, 1984, CARDIOLOGY PRACTICE, V2, P35; von Bergmann G, 1932, DEUT MED WOCHENSCHR, V58, P605; WILSON RF, 1985, CIRCULATION, V72, P82, DOI 10.1161/01.CIR.72.1.82	11	57	58	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	1993	341	8856					1309	1310		10.1016/0140-6736(93)90817-Z	http://dx.doi.org/10.1016/0140-6736(93)90817-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098450				2022-12-24	WOS:A1993LD25300005
J	ZAMBON, A; TORRES, A; BIJVOET, S; GAGNE, C; MOORJANI, S; LUPIEN, PJ; HAYDEN, MR; BRUNZELL, JD				ZAMBON, A; TORRES, A; BIJVOET, S; GAGNE, C; MOORJANI, S; LUPIEN, PJ; HAYDEN, MR; BRUNZELL, JD			PREVENTION OF RAISED LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN A PATIENT WITH FAMILIAL HYPERCHOLESTEROLEMIA AND LIPOPROTEIN-LIPASE DEFICIENCY	LANCET			English	Note								Raised low-density lipoprotein (LDL) cholesterol is believed to predispose to development of atherosclerosis and coronary heart disease. Increased plasma LDL concentrations and premature coronary heart disease are present in familial hypercholesterolemia (FH), and the enzyme lipoprotein lipase (LPL) seems to have a key role in production of LDL. We describe a unique French Canadian individual who is both heterozygous for FH and homozygous for LPL deficiency (FH/LPL). In this patient, LDL cholesterol was strikingly low compared with both his FH (0.65 vs 5.84 mmol/L) and normolipidaemic (2.77 mmol/L) age-matched relatives despite the defect of LDL-receptor-mediated removal. No LDL peak was present in the cholesterol profile of the FH/LPL-deficient subject, as determined by density-gradient ultracentrifugation. Our results suggest that most LDL particles, in vivo, originate from triglyceride-rich lipoproteins, that LPL plays a vital part in this process, and that absence of LPL activity protects FH subjects against the increase in LDL cholesterol.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; LAVAL UNIV HOSP,LIPID RES CTR,QUEBEC CITY,PQ,CANADA; UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V6T 1W5,BC,CANADA	University of Washington; University of Washington Seattle; Laval University; University of British Columbia			Hayden, Michael R/D-8581-2011; Zambon, Alberto/J-2122-2012	Hayden, Michael R/0000-0001-5159-1419; 	NHLBI NIH HHS [HL30086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BRUNZELL JD, 1989, METABOLIC BASIS INHE, V1, P1165; GOLDBERG IJ, 1988, J CLIN INVEST, V81, P561, DOI 10.1172/JCI113354; GOLDSTEIN JL, 1989, METABOLIC BASIS INHE, V1, P1215; HAVEL RJ, 1989, METABOLIC BASIS INHE, V1, P1129; KANE JP, 1989, METABOLIC BASIS INHE, V1, P1139; LEITERSDORF E, 1990, J CLIN INVEST, V85, P1014, DOI 10.1172/JCI114531; MA YH, 1991, NEW ENGL J MED, V324, P1761, DOI 10.1056/NEJM199106203242502; MONSALVE MV, 1990, J CLIN INVEST, V86, P728, DOI 10.1172/JCI114769; VERNE N, 1986, METHOD ENZYMOL, V128, P155	10	28	31	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1119	1121		10.1016/0140-6736(93)93129-O	http://dx.doi.org/10.1016/0140-6736(93)93129-O			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097805				2022-12-24	WOS:A1993KZ68700005
J	JADRESIC, D				JADRESIC, D			PSYCHIATRY - OBSESSIONALITY IN TOURETTE SYNDROME	LANCET			English	Editorial Material							OBSESSIVE-COMPULSIVE DISORDER				JADRESIC, D (corresponding author), UNIV MANCHESTER,MANCHESTER ROYAL INFIRM,DEPT PSYCHIAT,MANCHESTER M13 9WL,LANCS,ENGLAND.							BAXTER LR, 1990, J CLIN PSYCHIAT, V51, P61; PAULS DL, 1990, J AM ACAD CHILD PSY, V29, P195, DOI 10.1097/00004583-199003000-00007; PITMAN RK, 1987, AM J PSYCHIAT, V144, P1166; ROBERTSON MM, 1993, BRIT J PSYCHIAT, V162, P114, DOI 10.1192/bjp.162.1.114; ROBERTSON MM, 1988, BRIT J PSYCHIAT, V152, P383, DOI 10.1192/bjp.152.3.383	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1063	1063		10.1016/0140-6736(93)92420-X	http://dx.doi.org/10.1016/0140-6736(93)92420-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KZ018	8096967				2022-12-24	WOS:A1993KZ01800013
J	MARCHAL, G; SERRATI, C; RIOUX, P; PETITTABOUE, MC; VIADER, F; DELASAYETTE, V; LEDOZE, F; LOCHON, P; DERLON, JM; ORGOGOZO, JM; BARON, JC				MARCHAL, G; SERRATI, C; RIOUX, P; PETITTABOUE, MC; VIADER, F; DELASAYETTE, V; LEDOZE, F; LOCHON, P; DERLON, JM; ORGOGOZO, JM; BARON, JC			PET IMAGING OF CEREBRAL PERFUSION AND OXYGEN-CONSUMPTION IN ACUTE ISCHEMIC STROKE - RELATION TO OUTCOME	LANCET			English	Note							INFARCTION	We used positron emission tomography (PET) to assess the relation between combined imaging of cerebral blood flow and oxygen consumption 5-18 h after first middle cerebral artery (MCA) stroke and neurological outcome at 2 months. All 18 patients could be classified into three visually defined PET patterns of perfusion and oxygen consumption changes. Pattern I (7 patients) suggested extensive irreversible damage and was consistently associated with poor outcome. Pattern II (5) suggested continuing ischaemia and was associated with variable outcome. Pattern III (6), with hyperperfusion and little or no metabolic alteration, was associated with excellent recovery, which suggests that early reperfusion is beneficial. This relation between PET and outcome was highly significant (p<0.0005). The results suggest that within 5-18 h of stroke onset, PET is a good predictor of outcome in patterns I and III, for which therapy seems limited. The absence of predictive value for pattern II suggests that it is due to a reversible ischaemic state that is possibly amenable to therapy. These findings may have important implications for acute MCA stroke management and for patients' selection for therapeutic trials.	CYCERON,INSERM,U320,BI BECQUEREL,BP 5027,F-14021 CAEN,FRANCE; UNIV GENOA,NEUROL CLIN,I-16126 GENOA,ITALY; CTR HOSP REG & UNIV COTE NACRE,CAEN,FRANCE; CEA,DSV DPTE,CAEN,FRANCE; CAC F BACLESSE,CAEN,FRANCE; CHU PELLEGRIN,BORDEAUX,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Caen Normandie; University of Genoa; CHU de Caen NORMANDIE; CEA; CHU Bordeaux			Derlon, Jean-Michel/L-1721-2015	baron, jean-claude/0000-0002-5264-2588				BOGOUSSLAVSKY J, 1991, CEREBROVASC DIS, V1, P1; GIUBILEI F, 1990, STROKE, V21, P895, DOI 10.1161/01.STR.21.6.895; LIMBURG M, 1991, J NUCL MED, V32, P382; MARCHAL G, 1992, ARCH NEUROL-CHICAGO, V49, P1013, DOI 10.1001/archneur.1992.00530340029014; MARCHAL G, 1992, CEREBROVASC DIS, V2, P235; MARTINEZVILA E, 1990, STROKE, V21, P1023, DOI 10.1161/01.STR.21.7.1023; RINGELSTEIN EB, 1992, NEUROLOGY, V42, P289, DOI 10.1212/WNL.42.2.289; WADE DT, 1989, HDB CLIN NEUROLOGY, V11, P233; WARDLAW JM, 1992, STROKE, V23, P1826, DOI 10.1161/01.STR.23.12.1826; WISE RJS, 1983, BRAIN, V106, P197, DOI 10.1093/brain/106.1.197	10	209	218	3	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					925	927		10.1016/0140-6736(93)91214-7	http://dx.doi.org/10.1016/0140-6736(93)91214-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096267				2022-12-24	WOS:A1993KW98100006
J	DOWNIE, AC; FROST, PG; FIELDEN, P; JOSHI, D; DANCY, CM				DOWNIE, AC; FROST, PG; FIELDEN, P; JOSHI, D; DANCY, CM			BEDSIDE MEASUREMENT OF CREATINE-KINASE TO GUIDE THROMBOLYSIS ON THE CORONARY-CARE UNIT	LANCET			English	Article								Thrombolysis is effective in treating patients with acute myocardial infarction when started within 12 h of onset, and thus is in widespread use. Early diagnosis is essential but some patients admitted to the coronary care unit with myocardial infarction do not meet the diagnostic criteria on arrival, and thus do not undergo thrombolysis. We studied 117 patients admitted consecutively to our coronary care unit with suspected but unproven myocardial infarction; normally none would have received thrombolytic agents. In each patient creatine kinase levels were measured on admission and after intervals by nurses using capillary blood samples and a dry chemistry system. Infarction was subsequently confirmed in 29 patients. Of these, 17 (59%) were correctly diagnosed and underwent thrombolysis within 12 h on the basis of a raised creatine kinase measured at the bedside. Our findings suggest that use of a bedside assay by nurses allows additional patients with myocardial infarction to receive the benefit of thrombolytic therapy within the first 12 h.	CENT MIDDLESEX HOSP, NHS TRUST, LONDON NW10, ENGLAND									[Anonymous], 1988, LANCET, V2, P349; COLLINSON PO, 1989, J CLIN PATHOL, V42, P1126, DOI 10.1136/jcp.42.11.1126; GIBB I, 1985, BRIT MED J, V290, P1381, DOI 10.1136/bmj.290.6479.1381; TIMMIS AD, 1990, BMJ-BRIT MED J, V301, P941, DOI 10.1136/bmj.301.6758.941	4	8	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 20	1993	341	8843					452	454		10.1016/0140-6736(93)90205-U	http://dx.doi.org/10.1016/0140-6736(93)90205-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094486				2022-12-24	WOS:A1993KN13700002
J	NORRIS, R				NORRIS, R			ACUTE CORONARY-CARE - WHO SHOULD GO TO THE CCU IN 1993	LANCET			English	Editorial Material											NORRIS, R (corresponding author), TRAFFORD CTR MED RES, BRIGHTON, E SUSSEX, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BETT J H N, 1989, Australian and New Zealand Journal of Medicine, V19, P572; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; CERQUEIRA MD, 1992, CIRCULATION, V86, P643; ROLLAG A, 1992, J INTERN MED, V232, P299, DOI 10.1111/j.1365-2796.1992.tb00589.x; WEAVER WD, 1992, CIRCULATION, V86, P16	7	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 23	1993	341	8839					212	212		10.1016/0140-6736(93)90073-P	http://dx.doi.org/10.1016/0140-6736(93)90073-P			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093504				2022-12-24	WOS:A1993KJ21900011
J	SMITH, WCS; JESUDASAN, K				SMITH, WCS; JESUDASAN, K			ELIMINATION OF LEPROSY AND PROSPECTS FOR REHABILITATION	LANCET			English	Editorial Material											SMITH, WCS (corresponding author), LEPROSY MISSION,SINGAPORE,SINGAPORE.							NOORDEEN SK, 1991, B WORLD HEALTH ORGAN, V69, P263; NOORDEEN SK, 1992, B WORLD HEALTH ORGAN, V70, P7; PETTIT JHS, 1964, LANCET, V2, P673, DOI 10.1016/S0140-6736(64)92482-1; SMITH WCS, 1992, LEPR REV S, V62, P23; 1982, WHO TECH REP SER, V675; 1991, ELIMINATION LEPROSY; 1985, WHO TECH REP SER, V716	7	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					89	90		10.1016/0140-6736(93)92563-9	http://dx.doi.org/10.1016/0140-6736(93)92563-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093410				2022-12-24	WOS:A1993KF87000010
J	BROWN, RH				BROWN, RH			CLINICAL IMPLICATIONS OF BASIC RESEARCH - A TRANSGENIC-MOUSE MODEL OF AMYOTROPHIC-LATERAL-SCLEROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUPEROXIDE-DISMUTASE				BROWN, RH (corresponding author), MASSACHUSETTS GEN HOSP E,BOSTON,MA 02129, USA.							BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; ROSEN DR, 1994, HUM MOL GENET, V3, P981, DOI 10.1093/hmg/3.6.981; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0	6	13	14	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	1994	331	16					1091	1092		10.1056/NEJM199410203311613	http://dx.doi.org/10.1056/NEJM199410203311613			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL560	8090173				2022-12-24	WOS:A1994PL56000013
J	LEW, J; HUANG, QQ; QI, Z; WINKFEIN, RJ; AEBERSOLD, R; HUNT, T; WANG, JH				LEW, J; HUANG, QQ; QI, Z; WINKFEIN, RJ; AEBERSOLD, R; HUNT, T; WANG, JH			A BRAIN-SPECIFIC ACTIVATOR OF CYCLIN-DEPENDENT KINASE-5	NATURE			English	Article							DIRECTED PROTEIN-KINASE; TAU-PROTEIN; PHOSPHORYLATION; SEQUENCE; IDENTIFICATION; NEUROFILAMENTS; CDC2; P34(CDC2); SUBUNIT; SITES	PHOSPHORYLATION of the neurofilament proteins of high and medium relative molecular mass, as well as of the Alzheimer's tau protein, is thought to be catalysed by a protein kinase with Cdc2-like substrate specificity(1-7). We have purified a novel Cdc2-like kinase from bovine brain(8) capable of phosphorylating both the neurofilament proteins(9) and tau(10). The purified enzyme is a heterodimer of cyclin-dependent kinase 5 (Cdk5)(9) and a novel regulatory subunit, p25 (ref. 8). When overexpressed and purified from Escherichia coli, p25 can activate Cdk5 in vitro. Unlike Cdk5, which is ubiquitously expressed in human tissue, the p25 transcript is expressed only in brain. A full-length complementary DNA clone showed that p25 is a truncated form of a larger protein precursor, p35, which seems to be the predominant form of the protein in crude brain extract. Cdk5/p35 is the first example of a Cdc2-like kinase with neuronal function.	UNIV CALGARY,MRC,SIGNAL TRANSDUCT GRP,CALGARY T2N 4N1,AB,CANADA; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER,BC,CANADA; IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND	University of Calgary; University of British Columbia; University of British Columbia								ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN RJ, 1992, J NEUROCHEM, V58, P1365, DOI 10.1111/j.1471-4159.1992.tb11351.x; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HAYES TE, 1991, NEW BIOL, V3, P259; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HISANAGA S, 1991, J BIOL CHEM, V266, P21798; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; MAWALDEWAN M, 1992, J BIOL CHEM, V267, P19705; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VULLIET R, 1992, J BIOL CHEM, V267, P22570; XIONG Y, 1992, CELL, V71, P504; XU ZS, 1992, J BIOL CHEM, V267, P4467	25	540	561	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 29	1994	371	6496					423	426		10.1038/371423a0	http://dx.doi.org/10.1038/371423a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	8090222				2022-12-24	WOS:A1994PJ28500044
J	CRISPINO, JD; BLENCOWE, BJ; SHARP, PA				CRISPINO, JD; BLENCOWE, BJ; SHARP, PA			COMPLEMENTATION BY SR PROTEINS OF PRE-MESSENGER-RNA SPLICING REACTIONS DEPLETED OF U1 SNRNP	SCIENCE			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; MESSENGER-RNA; SITE SELECTION; U6 SNRNA; SPLICEOSOME; COMPLEXES; YEAST; REGULATORS; SEQUENCE; REVEALS	Individual small nuclear ribonucleoproteins (snRNPs) U1, U2, and U4/U6 were removed from nuclear extracts of HeLa cells by antisense affinity depletion. Addition of a highly purified preparation of SR proteins fully restored splicing activity in reactions depleted of U1 snRNP but did not reconstitute splicing in reactions depleted of the other snRNPs. Affinity selection experiments revealed that spliceosomes lacking U1 snRNA formed in the U1 snRNP-depleted reactions reconstituted with SR proteins. Thus, high concentrations of SR proteins facilitate the assembly of precursor messenger RNA (pre-mRNA) into a spliceosome in the absence of interactions with U1 snRNP.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)				Crispino, John/0000-0002-8182-8306	NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034277] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA14051] Funding Source: Medline; NIAID NIH HHS [R01-AI32486] Funding Source: Medline; NIGMS NIH HHS [R01-GM34277] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; CRISPINO JD, UNPUB; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; GRABOWSKI PJ, 1986, SCIENCE, V233, P1294, DOI 10.1126/science.3638792; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M., 1993, RNA WORLD, P303; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; RYDER U, 1990, NUCLEIC ACIDS RES, V18, P7373, DOI 10.1093/nar/18.24.7373; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SONTHEIMER E, 1982, SCIENCE, V262, P1989; TARN WY, UNPUB; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER KM, 1983, MOL CELL BIOL, V13, P4023; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363	30	148	150	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1994	265	5180					1866	1869		10.1126/science.8091213	http://dx.doi.org/10.1126/science.8091213			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	8091213				2022-12-24	WOS:A1994PH25800033
J	WHITE, TD; SUWA, G; ASFAW, B				WHITE, TD; SUWA, G; ASFAW, B			AUSTRALOPITHECUS RAMIDUS, A NEW SPECIES OF EARLY HOMINID FROM ARAMIS, ETHIOPIA	NATURE			English	Article							MIDDLE PLIOCENE; KENYA; EVOLUTION; TABARIN; BARINGO; CHIMP; DNA	Seventeen hominoid fossils recovered from Pliocene strata at Aramis, Middle Awash, Ethiopia make up a series comprising dental, cranial and postcranial specimens dated to around 4.4 million years ago. When compared with Australopithecus afarensis and with modern and fossil apes the Aramis fossil hominids are recognized as a new species of Australopithecus-A. ramidus sp. nov. The antiquity and primitive morphology of A. ramidus suggests that it represents a long-sought potential root species for the Hominidae.	UNIV TOKYO, DEPT ANTHROPOL, BUNKYO KU, TOKYO 113, JAPAN; ETHIOPIAN MINIST CULTURE & SPORTS AFFAIRS, PALEOANTHROPOL LAB, ADDIS ABABA, ETHIOPIA	University of Tokyo	WHITE, TD (corresponding author), UNIV CALIF BERKELEY, HUMAN EVOLUTIONARY STUDIES LAB, BERKELEY, CA 94720 USA.		Klein, Richard G/B-5910-2009					ANDREWS P, 1991, PHILOS T R SOC B, V334, P199, DOI 10.1098/rstb.1991.0109; ANDREWS P, 1992, NATURE, V360, P641, DOI 10.1038/360641a0; BEGUN DR, 1992, SCIENCE, V257, P1929, DOI 10.1126/science.1411507; CLARK WEQ, 1950, J BEOL SOC, V105, P225; COFFING K, 1994, AM J PHYS ANTHROPOL, V93, P55, DOI 10.1002/ajpa.1330930104; Dart R. A., 1934, Folia Anatomica Japonica, V12, P207; DEAN D, 1992, NATURE, V359, P676, DOI 10.1038/359676a0; FERGUSON W W, 1983, Primates, V24, P397, DOI 10.1007/BF02381984; FERGUSON W W, 1984, Primates, V25, P519, DOI 10.1007/BF02381673; FERGUSON WW, 1989, PRIMATES, V30, P383, DOI 10.1007/BF02381261; FERGUSON WW, 1987, PRIMATES, V28, P258; FLEAGLE JG, 1991, J HUM EVOL, V21, P145, DOI 10.1016/0047-2484(91)90005-G; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; HEINRICH RE, 1993, AM J PHYS ANTHROPOL, V92, P139, DOI 10.1002/ajpa.1330920203; HILL A, 1988, YEARB PHYS ANTHROPOL, V31, P49; HILL A, 1992, J HUM EVOL, V22, P439, DOI 10.1016/0047-2484(92)90079-O; HILL A, 1985, NATURE, V315, P222, DOI 10.1038/315222a0; JOHANSON DC, 1979, SCIENCE, V203, P321, DOI 10.1126/science.104384; KRAMER A, 1986, AM J PHYS ANTHROPOL, V70, P457, DOI 10.1002/ajpa.1330700406; LOVEJOY CO, 1993, ORIGIN AND EVOLUTION OF HUMANS AND HUMANNESS, P1; LOVEJOY CO, 1981, SCIENCE, V211, P341, DOI 10.1126/science.211.4480.341; PATTERSON B, 1970, NATURE, V226, P918, DOI 10.1038/226918a0; PICKFORD M, 1983, AM J PHYS ANTHROPOL, V60, P337, DOI 10.1002/ajpa.1330600306; PILBEAM D, 1986, AM ANTHROPOL, V88, P295, DOI 10.1525/aa.1986.88.2.02a00010; ROBINSON J. T., 1956, TRANSVAAL MUS MEM, V9, P1; SARICH VM, 1989, CLADISTICS, V5, P3, DOI 10.1111/j.1096-0031.1989.tb00480.x; SARICH VM, 1967, SCIENCE, V158, P1200, DOI 10.1126/science.158.3805.1200; WALKER A, 1984, AM J PHYS ANTHROPOL, V65, P47, DOI 10.1002/ajpa.1330650108; WARD S, 1987, AM J PHYS ANTHROPOL, V72, P21, DOI 10.1002/ajpa.1330720104; WHITE TD, 1993, NATURE, V366, P261, DOI 10.1038/366261a0; WHITE TD, 1986, ANTHROPOS BRNO, V23, P79; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0	32	402	418	0	63	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 22	1994	371	6495					306	312		10.1038/371306a0	http://dx.doi.org/10.1038/371306a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	8090200				2022-12-24	WOS:A1994PH25400044
J	BOLINDER, J; UNGERSTEDT, U; ARNER, P				BOLINDER, J; UNGERSTEDT, U; ARNER, P			LONG-TERM CONTINUOUS GLUCOSE MONITORING WITH MICRODIALYSIS IN AMBULATORY INSULIN-DEPENDENT DIABETIC-PATIENTS	LANCET			English	Article							BLOOD-GLUCOSE; SUBCUTANEOUS TISSUE; ADIPOSE-TISSUE; INSTABILITY; GLYCEMIA; INVIVO	The glucose concentration in the extracellular space of subcutaneous adipose tissue closely mirrors the blood glucose concentration. With a microdialysis technique, we undertook continuous ambulatory monitoring of adipose tissue glucose in 17 insulin-dependent diabetic patients with labile glycaemic control. The aims of the study were to investigate performance of the microdialysis device and to evaluate whether consecutive 24 h glucose profiles could be used to adjust insulin therapy. A microdialysis probe was implanted subcutaneously, perfused by a portable microinfusion pump, and dialysate fractions were collected every 1 or 2 h for 75 h. The mean (SE) tissue dialysate glucose concentration was 93 (3)% of the concentration in venous plasma, and variations in adipose tissue glucose closely paralleled changes in plasma glucose. Mean 24 h tissue glucose concentration correlated significantly with glycosylated haemoglobin (HbA1c; r=0.62, p < 0.01). Most patients had a reproducible daily pattern of glucose swings, and in more than half the patients consecutive ambulatory glucose profiles were almost superimposed. When patients' insulin therapy was adjusted on the basis of ambulatory glucose monitoring, HbA1c decreased by almost 2% (p < 0.01), and this decrease lasted for at least 9 months. Microdialysis of adipose tissue can be used for continuous long-term monitoring of glucose concentrations in diabetic patients during ordinary daily life. Daily glucose profiles are often reproducible and the recordings may thus be used for individual tailoring of insulin therapy to improve glycaemic control.	HUDDINGE UNIV HOSP,DEPT MED,S-14186 HUDDINGE,SWEDEN; HUDDINGE UNIV HOSP,RES CTR,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,DEPT PHARMACOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet				Bolinder, Jan/0000-0003-0035-0142				ALBISSER AM, 1990, DIABETES CARE, V13, P393, DOI 10.2337/diacare.13.4.393; ARNER P, 1991, J INTERN MED, V230, P381, DOI 10.1111/j.1365-2796.1991.tb00461.x; BOLINDER J, 1992, DIABETOLOGIA, V35, P1177, DOI 10.1007/BF00401374; FISCHER U, 1987, DIABETOLOGIA, V30, P940, DOI 10.1007/BF00295878; JANSSON PA, 1988, AM J PHYSIOL, V255, pE218, DOI 10.1152/ajpendo.1988.255.2.E218; KADDISH AH, 1968, CLIN CHEM, V14, P116; LONNROTH P, 1987, AM J PHYSIOL, V253, pE3228; MAZZE RS, 1987, DIABETES CARE, V10, P111, DOI 10.2337/diacare.10.1.111; MEYERHOFF C, 1992, DIABETOLOGIA, V35, P1087, DOI 10.1007/BF02221686; MOATTISIRAT D, 1992, DIABETOLOGIA, V35, P224, DOI 10.1007/BF00400921; MOLNAR GD, 1972, DIABETOLOGIA, V8, P342, DOI 10.1007/BF01218495; PERNICK NL, 1986, DIABETES CARE, V9, P61, DOI 10.2337/diacare.9.1.61; PICKUP JC, 1985, LANCET, V2, P817; SCHIFFRIN A, 1982, DIABETES CARE, V5, P479, DOI 10.2337/diacare.5.5.479; SCHLICHTKRULL J, 1965, ACTA MED SCAND, V177, P95; SERVICE FJ, 1970, DIABETES, V19, P644, DOI 10.2337/diab.19.9.644; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V128, P9, DOI 10.1111/j.1748-1716.1986.tb07943.x; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; WATFORD M, 1991, TRENDS BIOCHEM SCI, V16, P201, DOI 10.1016/0968-0004(91)90082-7; WILSON DE, 1983, DIABETES CARE, V6, P604, DOI 10.2337/diacare.6.6.604; WORTH R, 1982, BRIT MED J, V285, P1233, DOI 10.1136/bmj.285.6350.1233; 1992, LANCET, V339, P1326	22	103	104	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1080	1085		10.1016/0140-6736(93)92063-Y	http://dx.doi.org/10.1016/0140-6736(93)92063-Y			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105311				2022-12-24	WOS:A1993ME82200009
J	GREENWOOD, D				GREENWOOD, D			LACKING BLOOD FOR CULTURE	LANCET			English	Editorial Material							BACTEREMIA				GREENWOOD, D (corresponding author), UNIV NOTTINGHAM HOSP,DEPT MICROBIOL,NOTTINGHAM NG7 2UH,ENGLAND.							ISPAHANI P, 1989, MED LAB SCI, V46, P295; ISPAHANI P, 1987, Q J MED, V63, P427; MERMEL LA, 1993, ANN INTERN MED, V119, P270, DOI 10.7326/0003-4819-119-4-199308150-00003; Pulvertaft RJV, 1930, LANCET, V1, P821; SHANSON DC, 1984, J CLIN PATHOL, V37, P568, DOI 10.1136/jcp.37.5.568; SHANSON DC, 1989, SEPTICAEMIA ENDOCARD; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P54	7	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1006	1006		10.1016/0140-6736(93)92875-T	http://dx.doi.org/10.1016/0140-6736(93)92875-T			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105261				2022-12-24	WOS:A1993MD06600006
J	MACMILLAN, JC; SNELL, RG; TYLER, A; HOULIHAN, GD; FENTON, I; CHEADLE, JP; LAZAROU, LP; SHAW, DJ; HARPER, PS				MACMILLAN, JC; SNELL, RG; TYLER, A; HOULIHAN, GD; FENTON, I; CHEADLE, JP; LAZAROU, LP; SHAW, DJ; HARPER, PS			MOLECULAR ANALYSIS AND CLINICAL CORRELATIONS OF THE HUNTINGTONS-DISEASE MUTATION	LANCET			English	Article							MYOTONIC-DYSTROPHY; ANTICIPATION; REPEAT	The genetic mutation underlying Huntington's disease (HD) has been identified as an expansion and instability of a specific CAG repeat sequence in a gene (IT15) on chromosome 4. We have investigated the relation of the phenotype of HD to this molecular defect and assessed the feasibility of HD mutation analysis in diagnosis and prediction. Analysis of DNA from 449 HD patients (351 familial and 98 apparently isolated cases) revealed the mutation in more than 95% of patients from both groups. No molecular difference was found between patients presenting with psychiatric symptoms and those in whom chorea or other motor defects were the principal features; additionally, there was a wide range of age at onset for any specific repeat number, though the small group with juvenile onset and presenting with rigidity showed the largest expansions. The findings suggest that molecular analysis will be an accurate and specific diagnostic test for HD and valuable in presymptomatic detection in individuals at risk. However, such testing will require considerable caution to avoid serious difficulties; the well-established guidelines developed for the use of linked markers in relation to the prediction of HD should continue to be followed, though they will require reassessment in relation to use in diagnosis.	UNIV WALES COLL MED, INST MED GENET, HEATH PK, CARDIFF CF4 4XN, S GLAM, WALES	Cardiff University			MacMillan, John C/C-9591-2011	Snell, Russell/0000-0002-8166-4014	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CRAUFURD D, 1992, J MED GENET, V29, P915, DOI 10.1136/jmg.29.12.915; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HARLEY HG, 1992, LANCET, V339, P1125, DOI 10.1016/0140-6736(92)90729-M; HARPER PS, 1992, AM J HUM GENET, V51, P10; Harper PS, 1991, HUNTINGTONS DISEASE; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; QUARRELL OWJ, 1988, J MED GENET, V25, P191, DOI 10.1136/jmg.25.3.191; QUARRELL OWJ, 1986, CLIN GENET, V30, P433; RIDLEY RM, 1991, J MED GENET, V28, P224, DOI 10.1136/jmg.28.4.224; SHAW DJ, 1992, NEUROMUSCULAR DISORD, V2, P241, DOI 10.1016/0960-8966(92)90055-B; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; VANDIJK JG, 1986, HUM GENET, V73, P235, DOI 10.1007/BF00401235; WENT L, 1990, J MED GENET, V27, P34, DOI 10.1136/jmg.27.1.34	16	84	89	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	1993	342	8877					954	958		10.1016/0140-6736(93)92002-B	http://dx.doi.org/10.1016/0140-6736(93)92002-B			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105214				2022-12-24	WOS:A1993MC00500009
J	ALMIND, K; BJORBAEK, C; VESTERGAARD, H; HANSEN, T; ECHWALD, S; PEDERSEN, O				ALMIND, K; BJORBAEK, C; VESTERGAARD, H; HANSEN, T; ECHWALD, S; PEDERSEN, O			AMINO-ACID POLYMORPHISMS OF INSULIN-RECEPTOR SUBSTRATE-1 IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Article							C-PEPTIDE; PROTEIN; GLUCOSE; EXPRESSION; GENETICS; MUSCLE; NIDDM; SERUM; RNA	Since relative or absolute insulin deficiency and insulin insensitivity are involved in the aetiology of non-insulin-dependent diabetes mellitus (NIDDM), we examined whether patients with NIDDM exhibit genetic variability in the coding region of insulin receptor substrate-1 (IRS-1), a candidate gene that is ubiquitous in insulin-sensitive and insulin-like growth factor 1 (IGF1) sensitive tissues, including those that determine glucose production and clearance and those with regulatory effects on pancreatic beta-cell function. IRS-1 has a central role as an adaptor molecule that links the insulin-receptor and IGF1-receptor kinases with enzymes that regulate cellular metabolism and growth. Single-stranded conformation polymorphism analysis and direct nucleotide sequencing were applied to genomic DNA from 86 unrelated patients with NIDDM and 76 normoglycaemic controls. 10 of the patients with NIDDM and 3 of the controls were heterozygous at codon 972 for a polymorphism in which glycine was substituted with arginine. Moreover, at codon 513, 6 patients with NIDDM and 2 controls had a heterozygous polymorphism with a transition from alanine to proline. None of the polymorphism carriers had both aminoacid variants and the total allelic frequency of IRS-1 polymorphisms was about three times higher in patients with NIDDM than in controls (p=0.02). Both aminoacid substitutions were located close to tyrosine phosphorylation motifs that are putative recognition sites for insulin and IGF1 signal transmission proteins. Analysis of the phenotypes showed that patients with NIDDM who had IRS-1 variants did not differ in their degree of insulin resistance compared with patients without known IRS-1 polymorphisms. However, carriers of the codon 972 variant had significantly lower plasma levels of fasting insulin and C-peptide. Our results suggest that aminoacid polymorphisms in IRS-1 may be involved in the aetiology of a subset of late-onset NIDDM.	STENO DIABET CTR,DK-2820 GENTOFTE,DENMARK; HAGEDORN RES INST,DK-2820 GENTOFTE,DENMARK	Steno Diabetes Center; Novo Nordisk; Hagedorn Research Institute			Pedersen, Oluf/Z-1731-2019; Pedersen, Oluf/AAG-8015-2020; Bjorbaek, Christian/S-4727-2019	Pedersen, Oluf/0000-0002-3321-3972; Hansen, Torben/0000-0001-8748-3831; Vestergaard, Henrik/0000-0003-3090-269X				CERASI E, 1972, DIABETES, V21, P224, DOI 10.2337/diab.21.4.224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAMSGAARD EM, 1987, DIABETES CARE, V10, P26, DOI 10.2337/diacare.10.1.26; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; HEDING LG, 1975, DIABETOLOGIA, V11, P541, DOI 10.1007/BF01222104; HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569; HITMAN GA, 1991, BAILLIERE CLIN ENDOC, V5, P455, DOI 10.1016/S0950-351X(05)80142-9; HOLLENBECK C, 1987, J CLIN ENDOCR METAB, V64, P1169, DOI 10.1210/jcem-64-6-1169; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAYLOR SI, 1991, J CLIN ENDOCR METAB, V73, P1158, DOI 10.1210/jcem-73-6-1158; VESTERGAARD H, 1991, DIABETES, V40, P1740, DOI 10.2337/diabetes.40.12.1740; 1979, DIABETES, V28, P1039	22	302	316	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					828	832		10.1016/0140-6736(93)92694-O	http://dx.doi.org/10.1016/0140-6736(93)92694-O			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104271				2022-12-24	WOS:A1993MA02500008
J	MURGATROYD, F				MURGATROYD, F			MALIGNANT ARRHYTHMIAS - TRIBULATIONS POST ESVEM	LANCET			English	Editorial Material							SURVIVAL				MURGATROYD, F (corresponding author), ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON,ENGLAND.							[Anonymous], 1989, CIRCULATION, V79, P1354; GRABOYS TB, 1982, AM J CARDIOL, V50, P437, DOI 10.1016/0002-9149(82)90307-1; MASON JW, 1993, NEW ENGL J MED, V329, P452, DOI 10.1056/NEJM199308123290702; MASON JW, 1993, NEW ENGL J MED, V329, P445, DOI 10.1056/NEJM199308123290701; SHENASA M, 1993, LANCET, V341, P1512, DOI 10.1016/0140-6736(93)90642-T; SWERDLOW CD, 1983, NEW ENGL J MED, V308, P1436, DOI 10.1056/NEJM198306163082402; WARD DE, 1993, NEW ENGL J MED, V329, P498, DOI 10.1056/NEJM199308123290710	7	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					569	569		10.1016/0140-6736(93)91405-B	http://dx.doi.org/10.1016/0140-6736(93)91405-B			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102715				2022-12-24	WOS:A1993LV96300005
J	TOMOTSUNE, D; SHOJI, H; WAKAMATSU, Y; KONDOH, H; TAKAHASHI, N				TOMOTSUNE, D; SHOJI, H; WAKAMATSU, Y; KONDOH, H; TAKAHASHI, N			A MOUSE HOMOLOG OF THE DROSOPHILA TUMOR-SUPPRESSOR GENE L(2)GL CONTROLLED BY HOX-C8 IN-VIVO	NATURE			English	Article							HOMEOTIC GENES; EXPRESSION; PROTEIN; ULTRABITHORAX; ORGANIZATION; MELANOGASTER; CAPACITIES; DISRUPTION; POLYMERASE; SEQUENCE	THE homeobox is a 183-base-pair DNA sequence originally found in Drosophila segmentation and homeotic genes1,2. In Drosophila, homeotic genes are clustered in the Antennapedia and Bithorax complexes, collectively called the homeotic gene complex (HOM-C)3. In the mouse genome, about 40 homeobox genes (Hox) are clustered in four chromosomal regions (Hox A to D). The Hox genes are arranged in the same order and have the same antero-posterior pattern of expression as their structural homologue in the HOM-C4,5, suggesting that they control mouse pattern formation in the same way that HOM-C members do in Drosophila. Homeobox gene products are believed to be transcription factors that regulate expression of target genes. A few candidate target genes have been identified in Drosophila by various approaches6 but the Hox gene targets are poorly understood, mostly because of limitations in the available approaches. Here we identify several candidate Hox gene targets, including a mouse homologue of the Drosophila tumour-suppressor gene l(2)gl, by immunopurification of DNA sequences bound to a Hox protein in native chromatin.	NAGOYA UNIV,SCH SCI,DEPT MOLEC BIOL,NAGOYA,AICHI 464,JAPAN	Nagoya University								AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; ANDREW DJ, 1992, NEW BIOL, V4, P5; ARCIONI L, 1992, EMBO J, V11, P265, DOI 10.1002/j.1460-2075.1992.tb05049.x; AWGULEWITSCH A, 1990, DEVELOPMENT, V108, P411; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; GATEFF E, 1974, ROUX ARCH DEV BIOL, V176, P23, DOI 10.1007/BF00577830; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; GRABA Y, 1992, EMBO J, V11, P3375, DOI 10.1002/j.1460-2075.1992.tb05416.x; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; JACKSON V, 1974, BIOCHEMISTRY-US, V19, P3952; JACOB L, 1987, CELL, V50, P215, DOI 10.1016/0092-8674(87)90217-0; KENNISON JA, 1992, NEW BIOL, V4, P91; KLAMBT C, 1989, DEV BIOL, V133, P425, DOI 10.1016/0012-1606(89)90046-8; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; WAKAMATSU Y, 1990, ACTA HISTOCHEM CYTOC, V23, P367, DOI 10.1267/ahc.23.367; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x	29	105	108	1	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					69	72		10.1038/365069a0	http://dx.doi.org/10.1038/365069a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8103190				2022-12-24	WOS:A1993LV64600056
J	HAMILTON, JA				HAMILTON, JA			RHEUMATOID-ARTHRITIS - OPPOSING ACTIONS OF HEMATOPOIETIC GROWTH-FACTORS AND SLOW-ACTING ANTIRHEUMATIC DRUGS	LANCET			English	Article							COLONY-STIMULATING FACTOR; CHRONIC INFLAMMATORY ARTHRITIS; TUMOR-NECROSIS-FACTOR; BONE-MARROW ADJACENT; D-PENICILLAMINE; GM-CSF; FACTOR-ALPHA; GOLD SALTS; CELLS; INTERLEUKIN-1	The pathogenesis of rheumatoid arthritis and the mode of action of anti-rheumatic drugs are unknown. This hypothesis proposes that haemopoietic growth factors (colony stimulating factors [CSFs]) have an important role in rheumatoid arthritis as regulators of myelopoiesis and as activators of inflammatory leucocytes. It also suggests that slow-acting anti-rheumatic drugs may work by inhibiting myelopoiesis. This opposition to one of the actions of the CSFs would result in fewer inflammatory cells in the inflamed joints.			HAMILTON, JA (corresponding author), UNIV MELBOURNE, ROYAL MELBOURNE HOSP, DEPT MED, PARKVILLE, VIC 3050, AUSTRALIA.			Hamilton, John A/0000-0002-9493-9224				ABD AHA, 1991, LYMPHOKINE CYTOK RES, V10, P43; ALLISON AC, IN PRESS AG ACT; ALVAROGRACIA JM, 1991, J IMMUNOL, V146, P3365; BRANDES ME, 1991, J CLIN INVEST, V87, P1108, DOI 10.1172/JCI115073; BUCHAN GS, 1985, J LEUKOCYTE BIOL, V37, P221, DOI 10.1002/jlb.37.2.221; CAMPBELL IK, 1991, J IMMUNOL, V147, P1238; CAMPBELL IK, IN PRESS BIOCH BIOPH; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; DREHER R, 1986, IMMUN INFEKT, V14, P100; FIRESTEIN GS, 1988, J EXP MED, V168, P1573, DOI 10.1084/jem.168.5.1573; FIRESTEIN GS, 1990, ARTHRITIS RHEUM, V33, P768, DOI 10.1002/art.1780330602; GERATZ JD, 1988, ARTHRITIS RHEUM, V31, P1156; HAMILTON JA, 1993, IMMUNOL TODAY, V14, P18, DOI 10.1016/0167-5699(93)90319-G; HAMILTON JA, 1991, J RHEUMATOL, V18, P106; HAMILTON JA, 1985, J RHEUMATOL, V12, P892; HAMILTON JA, 1987, J RHEUMATOL, V14, P216; HAMILTON JA, IN PRESS GROWTH FACT; HAYASHIDA K, 1992, ARTHRITIS RHEUM, V35, P241, DOI 10.1002/art.1780350219; HAZENBERG BPC, 1989, BLOOD, V74, P2769, DOI 10.1182/blood.V74.8.2769.2769; HOWELL A, 1975, BRIT MED J, V1, P432, DOI 10.1136/bmj.1.5955.432; KAY AGL, 1979, ANN RHEUM DIS, V38, P232, DOI 10.1136/ard.38.3.232; KAY AGL, 1976, BRIT MED J, V1, P1266, DOI 10.1136/bmj.1.6020.1266; KOTAKE S, 1992, J RHEUMATOL, V19, P1511; KUIPERS EJ, 1992, J RHEUMATOL, V19, P621; LEIZER T, 1990, BLOOD, V76, P1989, DOI 10.1182/blood.V76.10.1989.1989; LIPSKY PE, 1989, SPRINGER SEMIN IMMUN, V11, P123; LIPSKY PE, 1982, ADV INFLAMMAT RES, V3, P219; LOWENTHAL RM, 1993, J RHEUMATOL, V20, P137; METCALF D, 1987, EXP HEMATOL, V15, P1; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; OCHI T, 1988, J RHEUMATOL, V15, P1609; OWAKI H, 1989, J RHEUMATOL, V16, P572; SEITZ M, 1982, CLIN IMMUNOL IMMUNOP, V25, P405, DOI 10.1016/0090-1229(82)90205-7; SEITZ M, 1992, J RHEUMATOL, V19, P1038; THOMAS D, 1984, ANN RHEUM DIS, V43, P402, DOI 10.1136/ard.43.3.402; VERNONROBERTS B, 1979, J RHEUMATOL, V6, P120; WIKTORJEDRZEJCZAK W, 1991, EXP HEMATOL, V19, P1049; XU WD, 1989, J CLIN INVEST, V83, P876, DOI 10.1172/JCI113971; YANNI G, 1992, ARTHRITIS RHEUM, V35, pS108; ZSEBO KM, 1988, BLOOD, V71, P99	40	93	98	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1993	342	8870					536	539		10.1016/0140-6736(93)91653-4	http://dx.doi.org/10.1016/0140-6736(93)91653-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102674				2022-12-24	WOS:A1993LU58200016
J	DUBOW, MS				DUBOW, MS			ANTITUBERCULOSIS DRUG SCREENING	LANCET			English	Editorial Material											DUBOW, MS (corresponding author), MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL H3A 2T5,QUEBEC,CANADA.							GUZZO J, 1992, TOXICOL LETT, V64-5, P687, DOI 10.1016/0378-4274(92)90248-I; JACOBS WR, 1993, SCIENCE, V260, P819, DOI 10.1126/science.8484123; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; RAMSAY S, 1993, LANCET, V341, P1340, DOI 10.1016/0140-6736(93)90843-6; STEWART GSA, 1909, ASM NEWS, V59, P241; ULITZUR S, 1987, BIOLUMINESCENCE CHEM, P463	7	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					448	449		10.1016/0140-6736(93)91586-B	http://dx.doi.org/10.1016/0140-6736(93)91586-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102422				2022-12-24	WOS:A1993LU07500003
J	HARRISON, P				HARRISON, P			ANTISENSE - INTO THE BRAIN	LANCET			English	Editorial Material							EXPRESSION; INVIVO		RADCLIFFE INFIRM,DEPT NEUROPATHOL,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary	HARRISON, P (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7J,ENGLAND.			Harrison, Paul/0000-0002-6719-1126				Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2; CHIASSON BJ, 1992, EUR J PHARM-MOLEC PH, V227, P451, DOI 10.1016/0922-4106(92)90167-T; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; JIRIKOWSKI GF, 1992, SCIENCE, V255, P996, DOI 10.1126/science.1546298; PRUSINER SB, 1992, CURR OPINION NEUROBI, V5, P638; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; WAHLESTEDT C, 1993, SCIENCE, V259, P528, DOI 10.1126/science.8380941; WHITESELL L, 1993, P NATL ACAD SCI USA, V90, P4665, DOI 10.1073/pnas.90.10.4665; 1991, LANCET, V338, P1427	11	9	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					254	255		10.1016/0140-6736(93)91812-Z	http://dx.doi.org/10.1016/0140-6736(93)91812-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101297				2022-12-24	WOS:A1993LQ16300005
J	DURANDZALESKI, I; RYMER, JC; ROUDOTTHORAVAL, F; REVUZ, J; ROSA, J				DURANDZALESKI, I; RYMER, JC; ROUDOTTHORAVAL, F; REVUZ, J; ROSA, J			REDUCING UNNECESSARY LABORATORY USE WITH NEW TEST REQUEST FORM - EXAMPLE OF TUMOR-MARKERS	LANCET			English	Article							CLINICAL DECISION-MAKING; TEST-ORDERING BEHAVIOR; CONTROLLED TRIAL; COST; STRATEGIES; EDUCATION; PHYSICIANS; FAILURE; MODIFY	To limit the ordering of serum tumour marker tests that are clinically irrelevant, we designed a new request form. This is a matrix of boxes, rows being individual markers and columns body organs. The box at the intersection of line and column is colour-coded to indicate whether the test is appropriate or not. These ratings were allocated on the basis of published data and local consensus. This new form replaced the form in use at our hospital at the beginning of 1992, and resulted in a 25% decrease in the ordering of tumour markers. Adapting the design of the test request form is a low-cost intervention that combines both economic and clinical requirements in reducing the prescription of tests that are useless in a given clinical situation.	HOP HENRI MONDOR,DEPT BIOCHEM,F-94010 CRETEIL,FRANCE; HOP HENRI MONDOR,DERMATOL SERV,F-94010 CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	DURANDZALESKI, I (corresponding author), HOP HENRI MONDOR,PUBL HLTH SERV,51 AVE MARECHAL DE LATTRE DE TASSIGNY,F-94010 CRETEIL,FRANCE.							BATES SE, 1991, ANN INTERN MED, V115, P623, DOI 10.7326/0003-4819-115-8-623; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; DAVIDOFF F, 1989, MED CARE, V27, P45, DOI 10.1097/00005650-198901000-00005; DEVINE GW, 1989, J GEN INTERN MED, V7, P623; EVERITT DE, 1990, INFECT CONT HOSP EP, V11, P578; FOWKES FGR, 1986, BRIT MED J, V292, P883, DOI 10.1136/bmj.292.6524.883; FRASER CG, 1987, ANN CLIN BIOCHEM, V24, P223, DOI 10.1177/000456328702400301; GOLDMAN L, 1990, NEW ENGL J MED, V322, P1524, DOI 10.1056/NEJM199005243222110; GORTMAKER SL, 1988, MED CARE, V26, P631, DOI 10.1097/00005650-198806000-00011; GRINER PF, 1982, NEW ENGL J MED, V307, P1336, DOI 10.1056/NEJM198211183072109; GRINER PF, 1979, ANN INTERN MED, V90, P243, DOI 10.7326/0003-4819-90-2-243; GROSSMAN RM, 1983, MED CARE, V21, P783, DOI 10.1097/00005650-198308000-00003; HARRINGTON JT, 1985, NEW ENGL J MED, V312, P785; HENDERSON AR, 1982, J CLIN PATHOL, V35, P986, DOI 10.1136/jcp.35.9.986; HERSHEY JC, 1987, MED DECIS MAKING, V7, P212, DOI 10.1177/0272989X8700700403; KASSIRER JP, 1986, JAMA-J AM MED ASSOC, V256, P256, DOI 10.1001/jama.256.2.256; LEPAGE EF, 1992, TRANSFUSION, V32, P253, DOI 10.1046/j.1537-2995.1992.32392213810.x; MARTIN AR, 1980, NEW ENGL J MED, V303, P1330, DOI 10.1056/NEJM198012043032304; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; SCHROEDER S, 1973, JAMA-J AM MED ASSOC, V225, P996; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P225, DOI 10.1001/jama.252.2.225; SILVER H, 1992, TRANSFUSION, V32, P260, DOI 10.1046/j.1537-2995.1992.32392213811.x; SOMERAI SB, 1990, QUAL ASSUR HLTH CARE, V2, P37; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; WICKENNS R, 1992, BMJ, V304, P1093; WONES RG, 1987, MED CARE, V25, P78, DOI 10.1097/00005650-198701000-00009; WONG ET, 1983, JAMA-J AM MED ASSOC, V249, P3076, DOI 10.1001/jama.249.22.3076; WONG ET, 1983, JAMA-J AM MED ASSOC, V250, P2510, DOI 10.1001/jama.250.18.2510; YOUNG D, 1981, BMJ, V282, P1610; ZAAT JOM, 1992, MED CARE, V30, P189, DOI 10.1097/00005650-199203000-00001	31	56	56	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					150	153		10.1016/0140-6736(93)91349-Q	http://dx.doi.org/10.1016/0140-6736(93)91349-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101259				2022-12-24	WOS:A1993LN04200015
J	KOCOVA, M; SIEGEL, SF; WENGER, SL; LEE, PA; TRUCCO, M				KOCOVA, M; SIEGEL, SF; WENGER, SL; LEE, PA; TRUCCO, M			DETECTION OF Y-CHROMOSOME SEQUENCES IN TURNERS-SYNDROME BY SOUTHERN BLOT ANALYSIS OF AMPLIFIED DNA	LANCET			English	Article							MARKER CHROMOSOMES; MOSAICISM; GONADOBLASTOMA; GROWTH	Only about half of all patients with Turner's syndrome are monosomy 45,X on karyotyping and there are grounds for supposing that cryptic mosaicism for at least part of the Y chromosome may be present in some patients. If so this would be clinically important because of the risk to patients of gonadal neoplasms and virilisation. We have used a very sensitive method to detect Y chromosomal segments in eighteen patients with Turner's syndrome, none of whom had evidence of Y chromosomal material by cytogenetic analysis. In DNA from peripheral blood lymphocytes and/or fibroblasts we looked for specific nucleotide sequences from the sex-determining region of the Y chromosome (SRY gene) and repetitive sequences located at the centromeric region (DYZ3). By polymerase chain amplification (PCR) one patient had a definite positive signal and two patients had faintly positive signals for the SRY gene. Southern blot analysis of PCR material with a SRY-specific probe confirmed that these patients were positive for SRY and revealed another three. No patient was positive for DYZ3, suggesting that only a small portion of Y was present. These results suggest that ''pure'' 45,X monosomy is less frequent than previously supposed. Long-term follow-up of patients with Y sequences is needed to determine their risk for subsequent gonadal neoplasms and virilisation.	UNIV PITTSBURGH,CHILDRENS HOSP PITTSBURGH,DEPT PEDIAT,PITTSBURGH,PA 15213; UNIV PITTSBURGH,CHILDRENS HOSP PITTSBURG,RANGOES RES CTR,DIV ENDOCRINOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,CHILDRENS HOSP PITTSBURGH,RANGOES CTR,DIV MED GENET,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ARANOFF GS, 1988, J ADOLESCENT HEALTH, V9, P501, DOI 10.1016/S0197-0070(88)80011-1; BONAKDAR MI, 1980, OBSTET GYNECOL, V56, P748; BOSZE P, 1989, GYNECOL OBSTET INVES, V28, P113, DOI 10.1159/000293544; DEARCE MA, 1992, CLIN GENET, V41, P28; DOMINGUEZ CJ, 1962, AM J OBSTET GYNECOL, V83, P674, DOI 10.1016/S0002-9378(16)35898-7; GEMMILL RM, 1987, AM J HUM GENET, V41, P157; HASSOLD T, 1988, AM J HUM GENET, V42, P534; HELD KR, 1992, HUM GENET, V88, P288; HOOK EB, 1983, HUM GENET, V64, P24, DOI 10.1007/BF00289473; JACOBS PA, 1990, ANN HUM GENET, V54, P209, DOI 10.1111/j.1469-1809.1990.tb00379.x; LIN CC, 1990, AM J MED GENET, V37, P71, DOI 10.1002/ajmg.1320370117; LINDSAY AN, 1981, AM J MED GENET, V10, P21, DOI 10.1002/ajmg.1320100104; MAGENIS RE, 1984, J PEDIATR-US, V105, P916, DOI 10.1016/S0022-3476(84)80077-3; MAGENIS RE, 1980, AM J HUM GENET, V32, pA79; MEDLEJ R, 1922, J CLIN ENDOCR METAB, V75, P1289; MULLER U, 1987, HUM GENET, V75, P109, DOI 10.1007/BF00591069; NAKAGOME Y, 1991, AM J MED GENET, V41, P112, DOI 10.1002/ajmg.1320410127; PAGE DC, 1987, DEVELOPMENT, V101, P151; PARK E, 1983, PEDIATR RES, V17, P1; RANKE MB, 1983, EUR J PEDIATR, V141, P81, DOI 10.1007/BF00496795; ROSEN GF, 1988, OBSTET GYNECOL, V71, P677; SHAH KD, 1988, AM J CLIN PATHOL, V90, P622, DOI 10.1093/ajcp/90.5.622; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SINISI AA, 1988, CLIN ENDOCRINOL, V28, P187, DOI 10.1111/j.1365-2265.1988.tb03655.x; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V; WARBURTON PE, 1991, GENOMICS, V11, P325	26	53	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					140	143		10.1016/0140-6736(93)91345-M	http://dx.doi.org/10.1016/0140-6736(93)91345-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101256				2022-12-24	WOS:A1993LN04200011
J	OSULLIVAN, C; LEWIS, CE; HARRIS, AL; MCGEE, JO				OSULLIVAN, C; LEWIS, CE; HARRIS, AL; MCGEE, JO			SECRETION OF EPIDERMAL GROWTH-FACTOR BY MACROPHAGES ASSOCIATED WITH BREAST-CARCINOMA	LANCET			English	Note							CANCER; CELLS	By means of a cytokine release assay we have shown that in cell populations derived from primary breast carcinoma, epidermal growth factor (EGF) is secreted by cells with the characteristic morphological and immunophenotypic profile of activated macrophages (positive for CD68, CD16, CD25). EGF secretion was observed in 11 (31%) of 35 primary tumours. Secretion of EGF by normal or malignant epithelial cells was not observed. We found no association between EGF secretion by the primary tumour and recognised clinical indices of prognosis.	JOHN RADCLIFFE HOSP,INST MOLEC MED,ICRF,CLIN ONCOL UNIT,OXFORD OX3 9DU,ENGLAND	University of Oxford	OSULLIVAN, C (corresponding author), JOHN RADCLIFFE HOSP,DEPT PATHOL & BACTERIOL,LEVEL 4,OXFORD OX3 9DU,ENGLAND.		Sroka, Isis C/A-2949-2009; Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BURGESS AW, 1989, BRIT MED BULL, V45, P401, DOI 10.1093/oxfordjournals.bmb.a072331; DOTZLAW H, 1990, CANCER RES, V50, P4204; Harris A L, 1989, Recent Results Cancer Res, V113, P70; LEWIS CE, 1990, J IMMUNOL METHODS, V127, P51, DOI 10.1016/0022-1759(90)90340-2; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; MIZUKAMI Y, 1991, ANTICANCER RES, V11, P1485; WHALEN GF, 1990, LANCET, V336, P1489, DOI 10.1016/0140-6736(90)93188-U	8	117	120	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					148	149		10.1016/0140-6736(93)91348-P	http://dx.doi.org/10.1016/0140-6736(93)91348-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101258				2022-12-24	WOS:A1993LN04200014
J	EITAN, S; SCHWARTZ, M				EITAN, S; SCHWARTZ, M			A TRANSGLUTAMINASE THAT CONVERTS INTERLEUKIN-2 INTO A FACTOR CYTOTOXIC TO OLIGODENDROCYTES	SCIENCE			English	Article							HAIR FOLLICLE TRANSGLUTAMINASES; CROSS-LINKING; CELL-LINE; GROWTH; REGENERATION; ENZYMES; CULTURE; INVITRO; INJURY; MYELIN	Regenerating optic nerves from fish produce a factor that is cytotoxic to oligodendrocytes. The cytotoxic factor is recognized by antibodies to interleukin-2 (IL-2) and has the apparent molecular size of a dimer of IL-2. An enzyme, identified as a nerve transglutaminase, was purified from regenerating optic nerves of fish and was found to catalyze dimerization of human IL-2. The dimerized IL-2, unlike monomeric IL-2, is cytotoxic to oligodendrocytes from rat brain in culture. The results suggest that posttranslational modification of a cytokine can alter its activity. Under conditions in which oligodendrocytes inhibit neuronal regeneration, dimerization of IL-2 might provide a mechanism to permit nerve growth.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								Aguayo A., 1979, ADV CELL NEUROBIOL, V3, P215; BASTMEYER M, 1991, J NEUROSCI, V11, P626; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRD JC, 1987, J BIOL CHEM, V262, P11699; CAJAL SRY, 1954, DEGENERATION REGENER, V1; CARBONETTO S, 1987, J NEUROSCI, V7, P610; CHAKRABORTY G, 1987, J NEUROCHEM, V48, P669, DOI 10.1111/j.1471-4159.1987.tb05567.x; COHEN A, 1990, BRAIN RES, V537, P24, DOI 10.1016/0006-8993(90)90335-9; EITAN S, 1992, P NATL ACAD SCI USA, V89, P5442, DOI 10.1073/pnas.89.12.5442; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GILAD GM, 1985, J NEUROCHEM, V44, P1385, DOI 10.1111/j.1471-4159.1985.tb08774.x; GILLIS S, 1982, IMMUNOL REV, V63, P167, DOI 10.1111/j.1600-065X.1982.tb00415.x; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; KIERNAN JA, 1979, BIOL REV, V54, P155, DOI 10.1111/j.1469-185X.1979.tb00871.x; LORAND L, 1981, METHOD ENZYMOL, V80, P333; MARTINET N, 1988, J BIOL CHEM, V263, P4236; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MELINO G, 1988, EXP CELL RES, V179, P429, DOI 10.1016/0014-4827(88)90281-9; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PAONESSA G, 1984, SCIENCE, V226, P852, DOI 10.1126/science.6149619; PETERSON LL, 1984, MOL CELL BIOCHEM, V58, P99, DOI 10.1007/BF00240609; SAVIO T, 1989, J NEUROSCI, V9, P1126; SCHWAB ME, 1990, EXP NEUROL, V109, P2, DOI 10.1016/S0014-4886(05)80003-2; SCHWARTZ M, 1989, FASEB J, V3, P2371, DOI 10.1096/fasebj.3.12.2676680; SCHWARTZ M, 1985, SCIENCE, V228, P601; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; SIVRON T, 1991, GLIA, V4, P591, DOI 10.1002/glia.440040606; SIVRON T, UNPUB; TETZLAFF W, 1988, BRAIN RES, V445, P142, DOI 10.1016/0006-8993(88)91083-9; WATSON J, 1979, J EXP MED, V150, P1510, DOI 10.1084/jem.150.6.1510	31	131	137	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	1993	261	5117					106	108		10.1126/science.8100369	http://dx.doi.org/10.1126/science.8100369			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8100369				2022-12-24	WOS:A1993LK43400044
J	BAIRD, KS; ALWAN, WH; CROSSAN, JF; WOJCIAK, B				BAIRD, KS; ALWAN, WH; CROSSAN, JF; WOJCIAK, B			T-CELL-MEDIATED RESPONSE IN DUPUYTRENS DISEASE	LANCET			English	Note								The cause of Dupuytren's disease is unknown, but inflammatory cells might have a role. Enzymatic digestion of diseased tissue permits identification and immunofluorescent labelling of a cell subset displaying inflammatory cell morphology. Cytofluorimetry of this cell population demonstrated the presence of CD3-positive lymphocytes and expression of major histocompatibility complex (MHC) class II proteins. These results raise the possibility that Dupuytren's disease is a T-cell-mediated autoimmune disorder. The development of medical treatment on this basis may reduce the need for surgery, with its associated morbidity and high recurrence rates.	UNIV GLASGOW,DEPT ORTHOPAED SURG,GLASGOW G11 6NT,SCOTLAND; UNIV GLASGOW,DEPT IMMUNOL,GLASGOW G11 6NT,SCOTLAND; UNIV GLASGOW,DEPT CELL BIOL,GLASGOW G11 6NT,SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDREW JG, 1991, J HAND SURG-BRIT EUR, V16B, P267, DOI 10.1016/0266-7681(91)90051-O; BAIRD KS, IN PRESS J CLIN PATH; BOWER M, 1990, BRIT MED J, V300, P164, DOI 10.1136/bmj.300.6718.164; GIDDENS WE, 1985, AM J PATHOL, V119, P253; HURST LC, 1990, DUPUYTRENS DIS BIOL, P253; Jupiter JB, 1991, FLYNNS HAND SURG, P864; LING RSM, 1963, J BONE JOINT SURG BR, V45, P709, DOI 10.1302/0301-620X.45B4.709; McFarlane R.M., 1990, DUPUYTRENS DIS BIOL, P265; MILLWARDSADLER GH, 1985, LIVER BILIARY DISEAS, P844; SPENCER JD, 1984, J HAND SURG-BRIT EUR, V9B, P276, DOI 10.1016/0266-7681(84)90041-X	10	33	33	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1622	1623		10.1016/0140-6736(93)90760-E	http://dx.doi.org/10.1016/0140-6736(93)90760-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099992				2022-12-24	WOS:A1993LJ72700006
J	ERNST, E				ERNST, E			COMPLEMENTARY MEDICINE - SCRUTINIZING THE ALTERNATIVES	LANCET			English	Editorial Material											ERNST, E (corresponding author), UNIV VIENNA,SCH MED,DEPT PHYS MED & REHABIL,A-1010 VIENNA,AUSTRIA.							DELUZE C, 1992, BRIT MED J, V305, P1249, DOI 10.1136/bmj.305.6864.1249; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; ERNST E, 1990, BRIT J CLIN PHARMACO, V30, P173, DOI 10.1111/j.1365-2125.1990.tb03761.x; ERNST E, 1992, PHLEBOLOGY, V7, P154, DOI 10.1177/026835559200700407; Ernst E, 1990, PHYSIOTHERAPY, V76, P207; FULDER SJ, 1985, LANCET, V2, P542; KLEIJNEN J, 1992, LANCET, V340, P1236; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590	8	26	26	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1626	1626		10.1016/0140-6736(93)90763-7	http://dx.doi.org/10.1016/0140-6736(93)90763-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099995				2022-12-24	WOS:A1993LJ72700009
J	TAYLORROBINSON, AW; PHILLIPS, RS; SEVERN, A; MONCADA, S; LIEW, FY				TAYLORROBINSON, AW; PHILLIPS, RS; SEVERN, A; MONCADA, S; LIEW, FY			THE ROLE OF T(H)1 AND T(H)2 CELLS IN A RODENT MALARIA INFECTION	SCIENCE			English	Article							NITRIC-OXIDE; PLASMODIUM-CHABAUDI; L-ARGININE; RECRUDESCENT PARASITEMIAS; MODULATION; MICE	CD4+ T cells play a major role in protective immunity against the blood stage of malaria, but the mechanism of protection is unclear. By adoptive transfer of cloned T cell lines, direct evidence is provided that both T(H)1 and T(H)2 subsets of CD4+ T cells can protect mice against Plasmodium chabaudi chabaudi infection. T(H)1 cells protect by a nitric oxide-dependent mechanism, whereas T(H)2 cells protect by the enhancement and accelerated production of specific immunoglobulin G1 antibody.	UNIV GLASGOW,DEPT IMMUNOL,GLASGOW G11 6NT,SCOTLAND; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND	University of Glasgow; GlaxoSmithKline; Wellcome Research Laboratories	TAYLORROBINSON, AW (corresponding author), UNIV GLASGOW,WELLCOME LABS EXPTL PARASITOL,GLASGOW G61 1QH,SCOTLAND.		Taylor-Robinson, Andrew/R-2805-2019	Taylor-Robinson, Andrew/0000-0001-7342-8348	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; LANGHORNE J, 1989, PARASITOL TODAY, V5, P362, DOI 10.1016/0169-4758(89)90113-0; LEIST TP, 1984, J IMMUNOL, V138, P548; LIEW FY, 1991, EUR J IMMUNOL, V21, P2489, DOI 10.1002/eji.1830211027; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MCLEAN SA, 1982, EXP PARASITOL, V54, P296, DOI 10.1016/0014-4894(82)90038-8; MCLEAN SA, 1982, EXP PARASITOL, V54, P213, DOI 10.1016/0014-4894(82)90129-1; MELLOUK S, 1991, J IMMUNOL, V146, P3971; MONACO AP, 1966, ANN NY ACAD SCI, V129, P190, DOI 10.1111/j.1749-6632.1966.tb12851.x; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOSMANN TR, 1987, IMMUNOL TODAY, V8, P223, DOI 10.1016/0167-5699(87)90171-X; NUSSLER A, 1991, EUR J IMMUNOL, V21, P227, DOI 10.1002/eji.1830210134; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PHILLIPS RS, 1992, IMMUNOBIOLOGY, V184, P240, DOI 10.1016/S0171-2985(11)80478-X; ROCKETT KA, 1991, INFECT IMMUN, V59, P3280, DOI 10.1128/IAI.59.9.3280-3283.1991; ROCKETT KA, 1992, INFECT IMMUN, V60, P3725, DOI 10.1128/IAI.60.9.3725-3730.1992; SEPPALA I, 1981, SCAND J IMMUNOL, V14, P335, DOI 10.1111/j.1365-3083.1981.tb00573.x; STEVENSON MM, 1986, INFECT IMMUN, V54, P600, DOI 10.1128/IAI.54.2.600-602.1986; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TAYLOR DW, 1990, MALARIA HOST RESPONS, P1; TAYLORROBINSON AW, 1992, IMMUNOLOGY, V77, P99	22	348	360	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1931	1934		10.1126/science.8100366	http://dx.doi.org/10.1126/science.8100366			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8100366				2022-12-24	WOS:A1993LJ34900040
J	MUMMERT, E; GRIMM, R; SPETH, V; ECKERSKORN, C; SCHILTZ, E; GATENBY, AA; SCHAFER, E				MUMMERT, E; GRIMM, R; SPETH, V; ECKERSKORN, C; SCHILTZ, E; GATENBY, AA; SCHAFER, E			A TCP1-RELATED MOLECULAR CHAPERONE FROM PLANTS REFOLDS PHYTOCHROME TO ITS PHOTOREVERSIBLE FORM	NATURE			English	Article							RIBULOSEBISPHOSPHATE CARBOXYLASE; MITOCHONDRIAL PROTEIN; PURIFICATION; BACTERIAL; GROEL	FOLDING of the major cytoskeletal components in the cytosol of mammalian cells is mediated by interactions with t-complex polypeptide-1 (TCP1) molecular chaperones1-6, a situation analogous to the chaperonin 60-aided folding of polypeptides in bacteria7,8, chloroplasts9,10 and mitochondria11-13. We have purified a TCP1-related molecular chaperone from etiolated oat seedlings that has a unique structure. Although immunologically related to TCP1, and having amino-acid sequence similarity, its quaternary structure is different from animal TCP1 proteins5,6,14. Electron microscopy and image analysis reveals that the chaperone has two stacked rings of six subunits each, and is distinct in size and configuration. The chaperone copurifies with the soluble cytosolic photoreceptor phytochrome15, and can stimulate refolding of denatured phytochrome to a photoactive form in the presence of Mg-ATP. We propose that this protein is the cytosolic chaperone involved in phytochrome biogenesis in plant cells.	MAX PLANCK INST BIOCHEM,GENZENTRUM,W-8033 MARTINSRIED,GERMANY; INST BIOL 2,W-7800 FREIBURG,GERMANY; INST ORGAN CHEM & BIOCHEM,W-7800 FREIBURG,GERMANY; DUPONT CO INC,CENT RES & DEV,DIV MOLEC BIOL,WILMINGTON,DE 19880	Max Planck Society; DuPont								ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ELLIS RJ, 1991, REV BIOCH, V60, P321; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; Furuya M, 1989, Adv Biophys, V25, P133, DOI 10.1016/0065-227X(89)90006-3; GATENBY AA, 1990, ANNU REV CELL BIOL, V6, P125; GILMARTIN PM, 1990, PLANT CELL, V2, P369, DOI 10.1105/tpc.2.5.369; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; GRIMM R, 1993, J BIOL CHEM, V268, P5220; GRIMM R, 1986, Z NATURFORSCH C, V41, P988; Gross J, 1984, TECHNIQUES PHOTOMORP, P131; GUPTA RS, 1990, BIOCHEM INT, V20, P833; Hallberg R L, 1990, Semin Cell Biol, V1, P37; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HEMMINGSEN SM, 1986, PLANT PHYSIOL, V80, P269, DOI 10.1104/pp.80.1.269; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; JACKSON JF, 1985, MOD METHOD PLANT, V1, P301; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; KUBOTA H, 1992, GENE, V120, P207, DOI 10.1016/0378-1119(92)90095-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MARKHAM R, 1963, VIROLOGY, V20, P88, DOI 10.1016/0042-6822(63)90143-0; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MORI M, 1992, GENE, V122, P381, DOI 10.1016/0378-1119(92)90231-D; NORTH G, 1991, NATURE, V354, P434, DOI 10.1038/354434a0; PHIPPS BM, 1993, NATURE, V361, P475, DOI 10.1038/361475a0; PILWAT G, 1980, PLANTA, V147, P396, DOI 10.1007/BF00380179; RUDIGER W, 1983, P NATL ACAD SCI-BIOL, V80, P6244, DOI 10.1073/pnas.80.20.6244; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WILLISON K, 1989, CELL, V57, P631; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	33	44	44	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 17	1993	363	6430					644	648		10.1038/363644a0	http://dx.doi.org/10.1038/363644a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8099715				2022-12-24	WOS:A1993LH13900061
J	BOURGUIGNON, JP; PIERARD, GE; ERNOULD, C; HEINRICHS, C; CRAEN, M; ROCHICCIOLI, P; ARRESE, JE; FRANCHIMONT, C				BOURGUIGNON, JP; PIERARD, GE; ERNOULD, C; HEINRICHS, C; CRAEN, M; ROCHICCIOLI, P; ARRESE, JE; FRANCHIMONT, C			EFFECTS OF HUMAN GROWTH-HORMONE THERAPY ON MELANOCYTIC NEVI	LANCET			English	Note							MONOCLONAL-ANTIBODY; HMB-45; MELANOMA; RECOGNIZES; TUMORS; NEVI	Melanocytic naevi may grow more rapidly during human growth hormone (hGH) therapy. With standardised skin photographs, the growth rate of the naevi was two-fold greater in 14 hypopituitary and 5 Turner's syndrome girls treated with hGH than in untreated patients or controls. HMB-45 immunoreactivity, a marker of stimulated melanocytes, was absent in naevi from 18 of 19 individuals not treated with hGH, including 5 Turner's syndrome patients studied 2-43 months after stopping hGH. In naevi from 39 hGH-treated patients, 22 showed unusual HMB-45 reactivity in dermal naevocytes. During administration of hGH, melanocytic naevi grow faster and there is reversible stimulation of naevocytes.	STATE UNIV LIEGE,CHU SART TILMAN,DERMATOPATHOL LAB,B-4000 SART,BELGIUM; UNIV BRUSSELS,DEPT PAEDIAT,GHENT,BELGIUM	University of Liege	BOURGUIGNON, JP (corresponding author), STATE UNIV LIEGE,CHR CITADELLE,DEPT PAEDIAT,B-4000 LIEGE,BELGIUM.							COOKE KR, 1988, MELANOMA NAEVI INCID, P8; GOWN AM, 1986, AM J PATHOL, V123, P195; NIKKELS A, 1991, ANAL QUANT CYTOL, V13, P23; OAKES SR, 1992, J CLIN ENDOCR METAB, V75, P1366; PALAZZO JP, 1988, J CUTAN PATHOL, V15, P166, DOI 10.1111/j.1600-0560.1988.tb00537.x; PALMER CG, 1976, HUM GENET, V35, P35, DOI 10.1007/BF00295617; SMOLLER BR, 1989, J CUTAN PATHOL, V16, P49, DOI 10.1111/j.1600-0560.1989.tb00010.x; SMOLLER BR, 1989, AM J SURG PATHOL, V13, P680, DOI 10.1097/00000478-198908000-00006; SMOLLER BR, 1991, J CUTAN PATHOL, V18, P315, DOI 10.1111/j.1600-0560.1991.tb01542.x; WICK MR, 1988, J CUTAN PATHOL, V15, P201, DOI 10.1111/j.1600-0560.1988.tb00544.x	10	68	70	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1505	1506		10.1016/0140-6736(93)90636-U	http://dx.doi.org/10.1016/0140-6736(93)90636-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099381	Green Submitted			2022-12-24	WOS:A1993LG24200005
J	ZOLI, G; BALLINGER, A; HEALY, J; ODONNELL, LJD; CLARK, M; FARTHING, MJG				ZOLI, G; BALLINGER, A; HEALY, J; ODONNELL, LJD; CLARK, M; FARTHING, MJG			PROMOTION OF GALLBLADDER EMPTYING BY INTRAVENOUS AMINO-ACIDS	LANCET			English	Article							TOTAL PARENTERAL-NUTRITION; BILIARY SLUDGE; CHOLECYSTOKININ; CONTRACTION; HUMANS; PLASMA	Patients receiving total intravenous nutrition have inert gallbladders; gallbladder sludge and gallstones often develop, but are preventable if gallbladder emptying can be improved. We measured the effect of giving rapid intravenous infusions of aminoacid solutions in eight normal subjects. Four regimens were tested (250 mL over 30 min, 250 mL over 10 min, 125 mL over 5 min, and 50 mL over 5 min). Gallbladder emptying, as measured by ultrasound and cholecystokinin release, depended on both the amount and the rate of aminoacid infusion. Rapid infusion of 125 mL of an aminoacid mixture (Synthamin 14 without electrolytes) over 5 min (2.1 g per min) produced a 64% reduction in gallbladder volume within 30 min, whereas a 50 mL infusion over 5 min produced only a 22% reduction. Intermittent rapid infusion of small amounts of aminoacids may prevent gallstones in patients receiving intravenous nutrition.	ST BARTHOLOMEWS HOSP,DEPT GASTROENTEROL,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT RADIOL,LONDON EC1A 7BE,ENGLAND; UNIV BOLOGNA,DEPT MED PATHOL,I-40126 BOLOGNA,ITALY	University of London; Queen Mary University London; University of London; Queen Mary University London; University of Bologna				ZOLI, Giorgio/0000-0002-3244-0663				CANO N, 1986, GASTROENTEROLOGY, V91, P313, DOI 10.1016/0016-5085(86)90562-7; DODDS WJ, 1985, AM J ROENTGENOL, V145, P1009, DOI 10.2214/ajr.145.5.1009; FISHER RS, 1982, DIGEST DIS SCI, V27, P1019, DOI 10.1007/BF01391749; HOPMAN WPM, 1985, RADIOLOGY, V157, P37, DOI 10.1148/radiology.157.1.3898222; LEE SP, 1992, NEW ENGL J MED, V326, P589, DOI 10.1056/NEJM199202273260902; LEE SP, 1988, GASTROENTEROLOGY, V94, P170, DOI 10.1016/0016-5085(88)90626-9; LIDDLE RA, 1985, J CLIN INVEST, V75, P1144, DOI 10.1172/JCI111809; LILJA P, 1982, GASTROENTEROLOGY, V83, P256; MESSING B, 1983, GASTROENTEROLOGY, V84, P1012; MESSING B, 1984, GASTROENTEROLOGY, V86, P1183; MURRAY FE, 1992, GUT, V33, P1123, DOI 10.1136/gut.33.8.1123; NEALON WH, 1990, AM J PHYSIOL, V259, pG173, DOI 10.1152/ajpgi.1990.259.2.G173; POTSON GJ, 1990, GASTROENTEROLOGY, V98, P993; SITZMANN JV, 1990, SURG GYNECOL OBSTET, V170, P25	14	26	27	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1240	1241						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098392				2022-12-24	WOS:A1993LC49700004
J	GREENOUGH, A				GREENOUGH, A			NEONATOLOGY - WHERE SHOULD THE UMBILICAL CATHETER GO	LANCET			English	Editorial Material							COMPLICATIONS				GREENOUGH, A (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT CHILD HLTH,LONDON SE5 8RX,ENGLAND.							BUTT WW, 1985, PEDIATRICS, V76, P250; HARRIS MS, 1978, J PERINAT MED, V6, P15, DOI 10.1515/jpme.1978.6.1.15; HENRY M, 1991, PEDIATR RES, V29, pA257; KEMPLEY ST, 1992, ARCH DIS CHILD-FETAL, V67, P855, DOI 10.1136/adc.67.7_Spec_No.855; MOKROHISKY ST, 1978, NEW ENGL J MED, V299, P561, DOI 10.1056/NEJM197809142991101; Schick J B, 1989, J Perinatol, V9, P382; 1992, PEDIATRICS, V90, P881	7	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1186	1187		10.1016/0140-6736(93)91009-B	http://dx.doi.org/10.1016/0140-6736(93)91009-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098082				2022-12-24	WOS:A1993LB01700011
J	TSUTSUI, H; ISHIHARA, K; COOPER, G				TSUTSUI, H; ISHIHARA, K; COOPER, G			CYTOSKELETAL ROLE IN THE CONTRACTILE DYSFUNCTION OF HYPERTROPHIED MYOCARDIUM	SCIENCE			English	Article							VOLUME-OVERLOAD HYPERTROPHY; ADULT FELINE CARDIOCYTES; LOAD REGULATION; MICROTUBULE; INVITRO; TUBULIN; CAT; ENERGETICS; COLCHICINE; PRESSURE	Cardiac hypertrophy in response to systolic pressure loading frequently results in contractile dysfunction of unknown cause. In the present study, pressure loading increased the microtubule component of the cardiac muscle cell cytoskeleton, which was responsible for the cellular contractile dysfunction observed. The linked microtubule and contractile abnormalities were persistent and thus may have significance for the deterioration of initially compensatory cardiac hypertrophy into congestive heart failure.	MED UNIV S CAROLINA, DEPT MED, DIV CARDIOL, GAZES CARDIAC RES INST, CHARLESTON, SC 29401 USA; VET ADM MED CTR, CHARLESTON, SC 29403 USA; MED UNIV S CAROLINA, DEPT PHYSIOL, CHARLESTON, SC 29401 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Medical University of South Carolina			Tsutsui, Hiroyuki/A-4070-2012		NHLBI NIH HHS [HL37196] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037196] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASSETT AL, 1973, CIRC RES, V32, P15, DOI 10.1161/01.RES.32.1.15; CAVENEY S, 1969, J CELL SCI, V4, P541; COOPER G, 1973, CIRC RES, V32, P140, DOI 10.1161/01.RES.32.2.140; COOPER G, 1986, CIRC RES, V58, P692, DOI 10.1161/01.RES.58.5.692; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; COOPER G, 1973, CIRC RES, V33, P213, DOI 10.1161/01.RES.33.2.213; DENNERLL TJ, 1988, J CELL BIOL, V107, P665, DOI 10.1083/jcb.107.2.665; GOLDSTEIN MA, 1979, J CELL BIOL, V80, P183, DOI 10.1083/jcb.80.1.183; GUNDERSEN GG, 1989, J CELL BIOL, V109, P2275, DOI 10.1083/jcb.109.5.2275; HILL TL, 1982, INT REV CYTOL, V78, P1, DOI 10.1016/S0074-7696(08)60105-9; HOCKING RR, 1985, ANAL LINEAR MODELS, P69; ITOH TJ, 1984, BIOCHIM BIOPHYS ACTA, V800, P21, DOI 10.1016/0304-4165(84)90089-8; IVES CL, 1986, IN VITRO CELL DEV B, V22, P500; KENT RL, 1989, AM J PHYSIOL, V257, pH1717, DOI 10.1152/ajpheart.1989.257.5.H1717; KLEIN I, 1983, CARDIOVASC RES, V17, P459, DOI 10.1093/cvr/17.8.459; LAMPIDIS TJ, 1986, EXP CELL RES, V164, P463, DOI 10.1016/0014-4827(86)90044-3; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; MANN DL, 1991, CIRC RES, V68, P402, DOI 10.1161/01.RES.68.2.402; MARINO TA, 1985, AM J PHYSIOL, V249, pH371, DOI 10.1152/ajpheart.1985.249.2.H371; MIRANDA AF, 1973, TISSUE CELL, V5, P1, DOI 10.1016/S0040-8166(73)80002-3; NICK P, 1991, PLANT CELL PHYSIOL, V32, P873; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; OSTLUND RE, 1980, J CELL BIOL, V85, P386, DOI 10.1083/jcb.85.2.386; OSTLUND RE, 1979, ANAL BIOCHEM, V96, P155, DOI 10.1016/0003-2697(79)90568-2; RAPPAPORT L, 1988, INT REV CYTOL, V113, P101; SACK DW, 1977, BASIC RES CARDIOL, V72, P268, DOI 10.1007/BF01906372; SCHAPER J, 1991, CIRCULATION, V83, P504, DOI 10.1161/01.CIR.83.2.504; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHLIWA M, 1981, P NATL ACAD SCI-BIOL, V78, P4329, DOI 10.1073/pnas.78.7.4329; TSUTSUI H, 1992, CIRCULATION, V86, P5; TSUTSUI H, UNPUB; VIRTANEN I, 1980, EUR J CELL BIOL, V23, P80; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	33	248	248	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 30	1993	260	5108					682	687		10.1126/science.8097594	http://dx.doi.org/10.1126/science.8097594			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ641	8097594				2022-12-24	WOS:A1993KZ64100035
J	HOZAK, P; HASSAN, AB; JACKSON, DA; COOK, PR				HOZAK, P; HASSAN, AB; JACKSON, DA; COOK, PR			VISUALIZATION OF REPLICATION FACTORIES ATTACHED TO A NUCLEOSKELETON	CELL			English	Article							DNA-POLYMERASE-ALPHA; CELL NUCLEAR ANTIGEN; HELA-CELLS; RIBONUCLEOPROTEIN-PARTICLES; INTRACELLULAR-LOCALIZATION; ELECTRON-MICROSCOPY; MONOCLONAL-ANTIBODY; EUKARYOTIC CELLS; XENOPUS EGGS; MATRIX	HeLa cells in early S phase were encapsulated in agarose microbeads, permeabilized, and incubated with biotin-11-dUTP in a ''physiological'' buffer. Sites of DNA synthesis were then immunolabeled. As others have found, approximately 150 focal sites of synthesis were visible in each nucleus by light microscopy; they also contained DNA polymerase alpha and proliferating cell nuclear antigen. Electron microscopy of thick resinless sections from which approximately 90% of the chromatin had been removed revealed a similar number of dense, morphologically discrete ovoid bodies strung along a nucleoskeleton. The ovoids remained morphologically and functionally intact despite the removal of most of the chromatin. After 2.5 min of incubation with biotin-11-dUTP, the incorporated analog was associated only with ovoids; after 5 min it began to spread into the adjacent chromatin, which became extensively labeled after 1 hr. This provides visual evidence for polymerization ''factories'' fixed to a skeleton, with replication occurring as the template moves through them.	ACAD SCI PRAGUE, INST EXPTL MED, CS-12000 PRAGUE 2, CZECHOSLOVAKIA	Czech Academy of Sciences; Institute of Experimental Medicine of the Czech Academy of Sciences	HOZAK, P (corresponding author), UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, S PARKS RD, OXFORD OX1 3RE, ENGLAND.		Hozak, Pavel/J-4182-2014; Hozak, Pavel/AAB-5359-2021	Hozak, Pavel/0000-0003-1901-1394; Hozak, Pavel/0000-0003-1901-1394; Cook, Peter/0000-0002-6639-188X; Hassan, Andrew/0000-0002-2517-6681	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BENSCH KG, 1982, J BIOL CHEM, V257, P8391; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; COOK PR, 1988, J CELL SCI, V90, P1; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; FUSCONI M, 1991, CLIN EXP IMMUNOL, V83, P291; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; HURT E, 1991, EMBO J, V10, P195; HUTCHISON CJ, 1987, EMBO J, V6, P2003, DOI 10.1002/j.1460-2075.1987.tb02464.x; JACKSON DA, 1985, EMBO J, V4, P919, DOI 10.1002/j.1460-2075.1985.tb03719.x; JACKSON DA, 1986, EMBO J, V5, P1403, DOI 10.1002/j.1460-2075.1986.tb04374.x; JACKSON DA, 1988, J CELL SCI, V90, P365; JACKSON DA, 1991, BIOESSAYS, V13, P1, DOI 10.1002/bies.950130102; JACKSON DA, 1986, J MOL BIOL, V192, P77, DOI 10.1016/0022-2836(86)90465-1; JACKSON DA, 1988, EMBO J, V7, P3667, DOI 10.1002/j.1460-2075.1988.tb03248.x; JACKSON DA, 1990, EMBO J, V9, P567, DOI 10.1002/j.1460-2075.1990.tb08144.x; JACKSON DA, 1986, J MOL BIOL, V192, P65, DOI 10.1016/0022-2836(86)90464-X; JACKSON DA, 1990, NUCLEIC ACIDS RES, V18, P4385, DOI 10.1093/nar/18.15.4385; KILL IR, 1991, J CELL SCI, V100, P869; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; MARTELLI AM, 1990, EXP CELL RES, V190, P227, DOI 10.1016/0014-4827(90)90190-L; MCCREADY SJ, 1980, J CELL SCI, V46, P365; MILLS AD, 1989, J CELL SCI, V94, P471; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAMURA H, 1984, EXP CELL RES, V151, P123, DOI 10.1016/0014-4827(84)90362-8; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NELSON WG, 1986, ANNU REV BIOPHYS BIO, V15, P457, DOI 10.1146/annurev.bb.15.060186.002325; PARDOLL DM, 1980, CELL, V19, P527, DOI 10.1016/0092-8674(80)90527-9; RAO PN, 1968, SCIENCE, V160, P774, DOI 10.1126/science.160.3829.774; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; RIS H, 1985, J CELL BIOL, V100, P1474, DOI 10.1083/jcb.100.5.1474; SAUNDERS WS, 1991, J CELL BIOL, V115, P919, DOI 10.1083/jcb.115.4.919; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; TUBO RA, 1987, J BIOL CHEM, V262, P5857; VAGNERCAPODANO AM, 1982, J ULTRA MOL STRUCT R, V78, P13, DOI 10.1016/S0022-5320(82)80010-5; WANG X, 1991, J CELL SCI, V98, P107; WASEEM NH, 1990, J CELL SCI, V96, P121; XING YG, 1991, J CELL BIOL, V112, P1055, DOI 10.1083/jcb.112.6.1055	46	429	435	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 23	1993	73	2					361	373		10.1016/0092-8674(93)90235-I	http://dx.doi.org/10.1016/0092-8674(93)90235-I			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8097433				2022-12-24	WOS:A1993KY50500016
J	HORTON, R				HORTON, R			IMMUNOLOGY - NATURAL AUTOIMMUNITY	LANCET			English	Editorial Material																		BURNET FM, 1959, CLONAL SELECTION THE; COHEN IR, 1992, IMMUNOL TODAY, V13, P490, DOI 10.1016/0167-5699(92)90024-2; COHEN IR, 1992, IMMUNOL TODAY, V13, P441, DOI 10.1016/0167-5699(92)90071-E; COHEN IR, 1991, IMMUNOL TODAY, V12, P105, DOI 10.1016/0167-5699(91)90093-9; VIRELLA G, 1993, INTRO MED IMMUNOLOGY	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					932	933		10.1016/0140-6736(93)91220-G	http://dx.doi.org/10.1016/0140-6736(93)91220-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096273				2022-12-24	WOS:A1993KW98100012
J	KOMURO, H; RAKIC, P				KOMURO, H; RAKIC, P			MODULATION OF NEURONAL MIGRATION BY NMDA RECEPTORS	SCIENCE			English	Article							CEREBELLAR GRANULE CELLS; AMINO-ACIDS; L-GLUTAMATE; BRAIN; ASPARTATE; CHANNELS; CULTURES; AFFINITY; BINDING; ETHANOL	The N-methyl-D-aspartate (NMDA) subtype of the glutamate receptor is essential for neuronal differentiation and establishment or elimination of synapses in a developing brain. The activity of the NMDA receptor has now been shown to also regulate the migration of granule cells in slice preparations of the developing mouse cerebellum. First, blockade of NMDA receptors by specific antagonists resulted in the curtailment of cell migration. Second, enhancement of NMDA receptor activity by the removal of magnesium or by the application of glycine increased the rate of cell movement. Third, increase of endogenous extracellular glutamate by inhibition of its uptake accelerated the rate of cell migration. These results suggest that NMDA receptors may play an early role in the regulation of calcium-dependent cell migration before neurons reach their targets and form synaptic contacts.			KOMURO, H (corresponding author), YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510, USA.							BALCAR VJ, 1972, J NEUROCHEM, V19, P2657, DOI 10.1111/j.1471-4159.1972.tb01325.x; BLANTON MG, 1992, J NEUROPHYSIOL, V67, P1185, DOI 10.1152/jn.1992.67.5.1185; BURGOYNE RD, 1988, NEUROSCI LETT, V91, P47, DOI 10.1016/0304-3940(88)90247-9; BURNASHEV N, 1992, SCIENCE, V256, P1566, DOI 10.1126/science.1317970; CAMBRAYDEAKIN MA, 1992, DEV BRAIN RES, V66, P25, DOI 10.1016/0165-3806(92)90136-K; CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501; CHIZHMAKOV IV, 1992, J PHYSIOL-LONDON, V448, P453, DOI 10.1113/jphysiol.1992.sp019051; CHOI DW, 1991, GLUTAMATE CELL DEATH, P125; CLARREN SK, 1978, J PEDIATR-US, V92, P64, DOI 10.1016/S0022-3476(78)80072-9; CONNOR JA, 1987, J NEUROSCI, V7, P1384; CURTIS DR, 1970, EXP BRAIN RES, V10, P447; HASUO H, 1988, NEUROSCI LETT, V86, P77, DOI 10.1016/0304-3940(88)90186-3; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; HOWE JR, 1991, J PHYSIOL-LONDON, V432, P143, DOI 10.1113/jphysiol.1991.sp018381; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KOMURO H, 1992, SCIENCE, V257, P806, DOI 10.1126/science.1323145; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; LEVI G, 1991, J NEUROCHEM, V56, P199, DOI 10.1111/j.1471-4159.1991.tb02581.x; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLVERMAN HJ, 1984, NATURE, V307, P460, DOI 10.1038/307460a0; PEARCE IA, 1987, FEBS LETT, V223, P143, DOI 10.1016/0014-5793(87)80525-2; RAKIC P, 1973, J COMP NEUROL, V152, P103, DOI 10.1002/cne.901520202; RAKIC P, 1981, TRENDS NEUROSCI, V4, P184, DOI 10.1016/0166-2236(81)90060-6; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; Rakic P, 1985, CELL CONTACT ADHESIO, P67; RASHID NA, 1992, DEV BRAIN RES, V67, P301, DOI 10.1016/0165-3806(92)90231-K; SCHOUSBOE A, 1992, PROG BRAIN RES, V94, P199; ZU XZ, 1987, EUR J PHARMACOL, V141, P401	32	875	889	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					95	97		10.1126/science.8096653	http://dx.doi.org/10.1126/science.8096653			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	8096653				2022-12-24	WOS:A1993KV42300036
J	QIN, SX; COBBOLD, SP; POPE, H; ELLIOTT, J; KIOUSSIS, D; DAVIES, J; WALDMANN, H				QIN, SX; COBBOLD, SP; POPE, H; ELLIOTT, J; KIOUSSIS, D; DAVIES, J; WALDMANN, H			INFECTIOUS TRANSPLANTATION TOLERANCE	SCIENCE			English	Article							T-CELLS; INDUCTION; ANTIBODIES; ABOLITION; COMPLEX	The maintenance of transplantation tolerance induced in adult mice after short-term treatment with nonlytic monoclonal antibodies to CD4 and CD8 was investigated. CD4+ T cells from tolerant mice disabled naive lymphocytes so that they too could not reject the graft. The naive lymphocytes that had been so disabled also became tolerant and, in turn, developed the capacity to specifically disable other naive lymphocytes. This process of ''infectious'' tolerance explains why no further immunosuppression was needed to maintain long-term transplantation tolerance.	UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND; NATL INST MED RES,MOLEC IMMUNOL LAB,LONDON NW7 1AA,ENGLAND	University of Cambridge; MRC National Institute for Medical Research			waldmann, herman/W-8051-2019	Waldmann, Herman/0000-0001-7519-6720; Cobbold, Stephen/0000-0003-1206-4880				BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BILLINGHAM RE, 1956, PHILOS T R SOC B, V239, P357, DOI 10.1098/rstb.1956.0006; COBBOLD SP, 1992, IMMUNOL REV, V129, P165, DOI 10.1111/j.1600-065X.1992.tb01423.x; COBBOLD SP, 1990, EUR J IMMUNOL, V20, P2747, DOI 10.1002/eji.1830201232; GRUCHALLA RS, 1983, TRANSPLANTATION, V36, P318, DOI 10.1097/00007890-198309000-00017; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; MILLER JFA, 1990, COLD SPRING HARB SYM, V170, P87; QIN S, 1989, THESIS CAMBRIDGE U; QIN SX, 1990, EUR J IMMUNOL, V20, P2737, DOI 10.1002/eji.1830201231; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; RAMSEIER H, 1973, EUR J IMMUNOL, V3, P156, DOI 10.1002/eji.1830030310; Rieber E. P., 1989, LEUKOCYTE TYPING, VIV, P229; TIGHE HP, 1987, THESIS CAMBRIDGE U; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379	15	745	773	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					974	977		10.1126/science.8094901	http://dx.doi.org/10.1126/science.8094901			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8094901				2022-12-24	WOS:A1993KL80000044
J	BRADLEY, D; CARPENTER, R; SOMMER, H; HARTLEY, N; COEN, E				BRADLEY, D; CARPENTER, R; SOMMER, H; HARTLEY, N; COEN, E			COMPLEMENTARY FLORAL HOMEOTIC PHENOTYPES RESULT FROM OPPOSITE ORIENTATIONS OF A TRANSPOSON AT THE PLENA-LOCUS OF ANTIRRHINUM	CELL			English	Article							FLOWER DEVELOPMENT; TRANSCRIPTION FACTORS; MAJUS; EXPRESSION; ELEMENT; MORPHOGENESIS; MAIZE; GENES; TAM3	Recessive mutations at the plena (ple) locus result in a homeotic conversion of sex organs to sterile perianth organs in flowers of Antirrhinum majus. A complementary phenotype, in which sex organs replace sterile organs, is conferred by semidominant ovulata mutations. The ple locus was identified and isolated using a homologous gene, agamous from Arabidopsis, as a probe. The expression of ple is normally restricted to the inner two whorls of the flower, where sex organs develop. However, in ovulata mutants, ple is expressed ectopically in the outer two whorls of the flower and in vegetative organs. These mutants correspond to gain-of-function alleles of ple, suggesting that ple is sufficient for promoting sex organ development within the context of the flower. The plena and ovulata phenotypes result from opposite orientations of the transposon Tam3 inserted in the large intron of ple.	MAX PLANCK INST ZUCHTUNGSFORSCH,W-5000 COLOGNE 30,GERMANY	Max Planck Society	BRADLEY, D (corresponding author), AFRC,JOHN INNES RES CTR,INST PLANT SCI RES,COLNEY LANE,NORWICH NR4 7UH,ENGLAND.							BERGFELD R, 1956, Z INDUKT ABSTAMM VER, V87, P784, DOI 10.1007/BF00308511; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CARPENTER R, 1987, MOL GEN GENET, V207, P82, DOI 10.1007/BF00331494; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1988, EMBO J, V7, P877, DOI 10.1002/j.1460-2075.1988.tb02891.x; COEN ES, 1986, CELL, V47, P285, DOI 10.1016/0092-8674(86)90451-4; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; GIERL A, 1989, ANNU REV GENET, V23, P71, DOI 10.1146/annurev.ge.23.120189.000443; GOODRICH J, 1992, CELL, V68, P955, DOI 10.1016/0092-8674(92)90038-E; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAKE S, 1992, TRENDS GENET, V8, P109, DOI 10.1016/0168-9525(92)90065-C; HEHL R, 1991, PLANT MOL BIOL, V16, P369, DOI 10.1007/BF00020572; Hohn B, 1979, Methods Enzymol, V68, P299; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; LUO D, 1991, PLANT J, V1, P59, DOI 10.1111/j.1365-313X.1991.00059.x; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MANDEL MA, 1992, CELL, V71, P133, DOI 10.1016/0092-8674(92)90272-E; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; MURRAY NE, 1983, LAMBDA, V2, P395; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; SCHNEUWLY S, 1987, EMBO J, V6, P201, DOI 10.1002/j.1460-2075.1987.tb04739.x; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; STUBBE H, 1966, GENETIK ZYTOLOGIE AN; TANDA S, 1991, EMBO J, V10, P407, DOI 10.1002/j.1460-2075.1991.tb07962.x; TILNEYBASSET RAE, 1986, PLANT CHIMERAS; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	34	436	449	0	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					85	95		10.1016/0092-8674(93)90052-R	http://dx.doi.org/10.1016/0092-8674(93)90052-R			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8093684				2022-12-24	WOS:A1993KG95500012
J	LAZEBNIK, YA; KAUFMANN, SH; DESNOYERS, S; POIRIER, GG; EARNSHAW, WC				LAZEBNIK, YA; KAUFMANN, SH; DESNOYERS, S; POIRIER, GG; EARNSHAW, WC			CLEAVAGE OF POLY(ADP-RIBOSE) POLYMERASE BY A PROTEINASE WITH PROPERTIES LIKE ICE	NATURE			English	Article							DEATH GENE CED-3; ENZYME; APOPTOSIS; SYNTHETASE; INDUCTION; CDNA	RECENT studies suggest that proteases of the interleukin 1-beta-converting enzyme (ICE)/ced-3 family are involved in initiating the active phase of apoptosis(1-3). Here we identify a novel protease resembling ICE (prICE) that is active in a cell-free system that reproduces the morphological and biochemical events of apoptosis(4). prICE cleaves the nuclear enzyme poly(ADP-ribose) polymerase (PARP) at a tetrapeptide sequence identical to one of two ICE sites in pro-interleukin-1-beta. However, prICE does not cleave purified pro-interleukin-1-beta, and purified ICE does not cleave PARP, indicating that the two activities are distinct. Inhibition of prICE abolishes all manifestations of apoptosis in the extracts including morphological changes, cleavage of PARP and production of an oligonucleosomal ladder. These studies suggest that prICE might be pivotal in initiating the active phase of apoptosis in vitro and in intact cells.	JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL,BALTIMORE,MD 21205; CHU LAVAL,RES CTR,DEPT MOLEC ENDOCRINOL,POLY ADP RIBOSE METAB GRP,ST FOY G1V 4G2,PQ,CANADA; UNIV LAVAL,ST FOY G1V 4G2,PQ,CANADA	Johns Hopkins University; Johns Hopkins University; Laval University; Laval University	LAZEBNIK, YA (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,725 N WOLFE ST,BALTIMORE,MD 21205, USA.		Earnshaw, William/AAY-7438-2020	Poirier, Guy/0000-0002-4869-1424; Kaufmann, Scott/0000-0002-4900-7145; Earnshaw, William/0000-0002-7191-0621				BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; CHEMEY BW, 1987, P NATL ACAD SCI USA, V84, P8370; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; ELLIS RE, 1991, REV CELL BIOL, V7, P663; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HULETSKY A, 1989, J BIOL CHEM, V265, P8878; ITTEL ME, 1991, GENE, V102, P157, DOI 10.1016/0378-1119(91)90073-K; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; SAITO I, 1990, GENE, V90, P249, DOI 10.1016/0378-1119(90)90187-V; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; THOMBERRY NA, 1992, NATURE, V356, P768; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	22	2350	2426	2	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					346	347		10.1038/371346a0	http://dx.doi.org/10.1038/371346a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	8090205				2022-12-24	WOS:A1994PH25400056
J	TOKIWA, G; TYERS, M; VOLPE, T; FUTCHER, B				TOKIWA, G; TYERS, M; VOLPE, T; FUTCHER, B			INHIBITION OF G1 CYCLIN ACTIVITY BY THE RAS/CAMP PATHWAY IN YEAST	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; CELL-SIZE; POSITIVE FEEDBACK; GENE-EXPRESSION; BUDDING YEAST; S-CEREVISIAE; CAMP; TRANSCRIPTION; DIVISION	IN the yeast Saccharomyces cerevisiae, commitment to cell division (Start) requires growth to a critical cell size(1-3). The G1 cyclins Cln1, Cln2 and Cln3 activate the Cdc28 protein kinase and are rate-limiting activators of Start(4-6). When glucose is added to cells growing in a poor carbon source, the critical cell size required for Start is reset from a small to a large size(2,3,7). In yeast, glucose acts through Ras proteins to stimulate adenylyl cyclase, activating the three cyclic AMP-dependent protein kinases Tpk1, Tpk2 and Tpk3 (refs 8, 9). We find that stimulation of the Ras/cAMP pathway represses expression of CLN1, CLN2 and co-regulated genes, inhibiting Start. This helps explain the increase in critical size when cells are shifted from poor to rich medium. This connection between the molecules controlling growth (Ras/cAMP) and those controlling division (cyclins) helps explain how division is co-ordinated with growth.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; SUNY STONY BROOK,GRAD PROGRAM GENET,STONY BROOK,NY 11792; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ON,CANADA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Toronto			Tyers, Michael/ABE-3194-2021					BARONI MD, 1992, EXP CELL RES, V201, P299, DOI 10.1016/0014-4827(92)90277-F; BARONI MD, 1989, MOL CELL BIOL, V9, P2715, DOI 10.1128/MCB.9.6.2715; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; JAGADISH MN, 1977, NATURE, V269, P145, DOI 10.1038/269145a0; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; JOHNSTON GC, 1979, J BACTERIOL, V137, P1; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; LORINCZ A, 1979, J GEN MICROBIOL, V113, P287, DOI 10.1099/00221287-113-2-287; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; MITSUZAWA H, 1994, MOL GEN GENET, V243, P158, DOI 10.1007/BF00280312; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; RUSSELL M, 1993, MOL BIOL CELL, V4, P757, DOI 10.1091/mbc.4.7.757; THEVELEIN JM, 1987, J GEN MICROBIOL, V133, P2191; THEVELEIN JM, 1985, J GEN MICROBIOL, V131, P3199; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; WILSON RB, 1988, MOL CELL BIOL, V8, P505, DOI 10.1128/MCB.8.1.505; WILSON RB, 1993, FEBS LETT, V325, P191, DOI 10.1016/0014-5793(93)81071-7; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	30	170	171	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					342	345		10.1038/371342a0	http://dx.doi.org/10.1038/371342a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	8090204				2022-12-24	WOS:A1994PH25400055
J	TOVO, PA				TOVO, PA			CESAREAN-SECTION AND PERINATAL HIV TRANSMISSION - WHAT NEXT	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; INFECTION				TOVO, PA (corresponding author), UNIV TURIN,DEPT PAEDIAT,I-10124 TURIN,ITALY.			Tovo, Pier Angelo/0000-0002-0192-3240				BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; GABIANO C, 1992, PEDIATRICS, V90, P362; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; KIND C, 1992, EUR J PEDIATR, V151, P442, DOI 10.1007/BF01959360; LINDGREN S, 1991, AIDS, V5, P1111, DOI 10.1097/00002030-199109000-00009; NAIR P, 1993, J ACQ IMMUN DEF SYND, V6, P298; VILLARI P, 1993, ONLINE J CURR C 0708; 1992, LANCET, V339, P1007	9	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					630	630		10.1016/0140-6736(93)91753-9	http://dx.doi.org/10.1016/0140-6736(93)91753-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103140				2022-12-24	WOS:A1993LX27200004
J	ELTUMI, M; TRIVEDI, P; HOBBS, JR; PORTMANN, B; CHEESEMAN, P; DOWNIE, C; RISTELI, J; RISTELI, L; MOWAT, AP				ELTUMI, M; TRIVEDI, P; HOBBS, JR; PORTMANN, B; CHEESEMAN, P; DOWNIE, C; RISTELI, J; RISTELI, L; MOWAT, AP			MONITORING OF VENOOCCLUSIVE DISEASE AFTER BONE-MARROW TRANSPLANTATION BY SERUM AMINOPROPEPTIDE OF TYPE-III PROCOLLAGEN	LANCET			English	Article							AMINO-TERMINAL PROPEPTIDE; LIVER; CHILDREN; MARKERS	Differential diagnosis of hepatic complications after bone marrow transplantation (BMT) is often difficult. To assess whether serum concentrations of the aminopropeptide of type III procollagen (PIIINP) could facilitate diagnosis,we measured serum PIIINP, corrected for age by conversion to standard deviation scores (SDS), serially after BMT in 27 children. A preliminary study of 11 patients showed that a PNIIINP-SDS cutoff of 8.0 was an optimum for diagnosis of veno-occlusive disease (VOD). PIIINP-SDS was increased above cut-off 1-25 days before the onset of clinical signs in the 12 patients (4 from the preliminary group, the others from a group of 16 studied prospectively) who developed VOD, with subsequent changes in PIIINP-SDS mirroring the course of VOD. By contrast, PIIINP-SDS remained below cut-off in all other patients, including 7 with liver graft-versus-host disease and 3 with drug hepatotoxicity. PIIINP-SDS values greater than 8.0 predict, diagnose, and monitor VOD after BMT.	WESTMINSTER MED SCH & HOSP,BONE MARROW TRANSPLANT UNIT,LONDON,ENGLAND; UNIV LONDON KINGS COLL HOSP,INST LIVER STUDIES,LONDON SE5 8RX,ENGLAND; UNIV OULU,DEPT CLIN CHEM,SF-90100 OULU 10,FINLAND; UNIV OULU,DEPT MED BIOCHEM,SF-90100 OULU 10,FINLAND; UNIV LONDON KINGS COLL HOSP,DEPT CHILD HLTH,LONDON SE5 8RX,ENGLAND	Imperial College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of Oulu; University of Oulu; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London				Risteli, Leila/0000-0002-5532-5895				EL-TUMI M, 1990, Bone Marrow Transplantation, V5, P116; HERSHKO C, 1980, BIOL BONE MARROW TRA, P56; HOBBS JR, 1986, BONE MARROW TRANSPL, V1, P201; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MCDONALD GB, 1984, HEPATOLOGY, V4, P116, DOI 10.1002/hep.1840040121; MCDONALD GB, 1987, SEMIN LIVER DIS, V7, P210, DOI 10.1055/s-2008-1040578; PLEBANI M, 1991, CLIN BIOCHEM, V24, P219, DOI 10.1016/0009-9120(91)80013-S; RISTELI J, 1988, CLIN CHEM, V34, P715; SHULMAN HM, 1992, BONE MARROW TRANSPL, V10, P197; SMEDSROD B, 1988, COLLAGEN REL RES, V8, P375; TRIVEDI P, 1985, EUR J CLIN INVEST, V15, P69, DOI 10.1111/j.1365-2362.1985.tb00147.x; TRIVEDI P, 1987, HEPATOLOGY, V7, P1249, DOI 10.1002/hep.1840070612; TRIVEDI P, 1989, J PEDIATR-US, V114, P225, DOI 10.1016/S0022-3476(89)80787-5	13	39	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					518	521		10.1016/0140-6736(93)91646-4	http://dx.doi.org/10.1016/0140-6736(93)91646-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102667				2022-12-24	WOS:A1993LU58200009
J	OU, WJ; CAMERON, PH; THOMAS, DY; BERGERON, JJM				OU, WJ; CAMERON, PH; THOMAS, DY; BERGERON, JJM			ASSOCIATION OF FOLDING INTERMEDIATES OF GLYCOPROTEINS WITH CALNEXIN DURING PROTEIN MATURATION	NATURE			English	Article							ROUGH ENDOPLASMIC-RETICULUM; NEWLY SYNTHESIZED PROTEINS; INFLUENZA HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; LINKED OLIGOSACCHARIDES; MOLECULAR CHAPERONE; ALPHA-SUBUNIT; COMPLEX; GLYCOSYLATION; SECRETION	Calnexin, an endoplasmic reticulum transmembrane protein, represents a new type of molecular chaperone that selectively associates in a transient fashion with newly synthesized monomeric glycoproteins in HepG2 cells. Calnexin only recognizes glycoproteins when they are incompletely folded. Dissociation of glycoproteins from calnexin occurs at different rates and is related to the time taken for their folding, which may then initiate their differential transport rates from the endoplasmic reticulum.	MCGILL UNIV,DEPT BIOL,MONTREAL H3A 2B2,QUEBEC,CANADA; NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,EUKARYOT GENET GRP,MONTREAL H4P 2R2,PQ,CANADA	McGill University; National Research Council Canada	OU, WJ (corresponding author), MCGILL UNIV,DEPT ANAT & CELL BIOL,MONTREAL H3A 2B2,QUEBEC,CANADA.		Bergeron, John/AAW-1893-2021; Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; CALLEA F, 1992, LIVER, V12, P357; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; GALVIN K, 1992, P NATL ACAD SCI USA, V89, P8452, DOI 10.1073/pnas.89.18.8452; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LAW SW, 1981, NATURE, V291, P201, DOI 10.1038/291201a0; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; REDMAN CM, 1972, J CELL BIOL, V52, P231, DOI 10.1083/jcb.52.2.231; WADA I, 1991, J BIOL CHEM, V266, P19599; WEITZ G, 1992, J BIOL CHEM, V267, P10039	35	520	531	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					771	776		10.1038/364771a0	http://dx.doi.org/10.1038/364771a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8102790				2022-12-24	WOS:A1993LU58100046
J	VANMEERWIJK, JPM; GERMAIN, RN				VANMEERWIJK, JPM; GERMAIN, RN			DEVELOPMENT OF MATURE CD8+ THYMOCYTES - SELECTION RATHER THAN INSTRUCTION	SCIENCE			English	Article							T-CELL RECEPTOR; THYMIC SELECTION; SEQUENTIAL APPEARANCE; SUBLETHAL IRRADIATION; NEGATIVE SELECTION; PRECURSOR CELLS; LYMPHOCYTES-T; MOUSE THYMUS; STEM-CELLS; CD4	The role of major histocompatibility complex (MHC) molecules in T cell differentiation was investigated by comparison of thymocyte subpopulations in wild-type mice and beta2-microglobulin (beta2M) mutant mice deficient in MHC class I expression and mature CD8+ cells. On the basis of surface markers, glucocorticoid resistance, in vitro differentiation capacity, and absence in beta2M-/- mice, CD4(intermediate)CD8hi cells with high expression of alphabeta T cell receptor (TCRalphabeta) were identified as having been positively selected by MHC class I for development into mature CD8+ T cells. Activated CD4(int)CD8hi cells bearing intermediate rather than high amounts of TCR were present in both wild-type and beta2M-/- animals. These data suggest that recognition of MHC class I molecules is required for full maturation to CD8+ T cells, but not for receptor-initiated commitment to the CD8+ lineage, consistent with a stochastic (selection) model of thymocyte development.	NIAID,IMMUNOL LAB,LYMPHOCYTE BIOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Germain, Ronald N./Z-1945-2019; van Meerwijk, Joost P.M./K-1345-2014; Germain, Ronald/ABE-7090-2020	van Meerwijk, Joost P.M./0000-0001-8231-1897; 				ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; ARASE H, 1993, EUR J IMMUNOL, V23, P307, DOI 10.1002/eji.1830230151; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; CRISPE IN, 1987, NATURE, V329, P336, DOI 10.1038/329336a0; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; ECKHARDT LA, 1980, IMMUNOGENETICS, V11, P275, DOI 10.1007/BF01567794; FOWLKES BJ, 1985, J EXP MED, V162, P802, DOI 10.1084/jem.162.3.802; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; HAYAKAWA K, 1992, J EXP MED, V176, P269, DOI 10.1084/jem.176.1.269; HUGO P, 1991, INT IMMUNOL, V3, P265, DOI 10.1093/intimm/3.3.265; HUGO P, 1991, EUR J IMMUNOL, V21, P2655, DOI 10.1002/eji.1830211103; HUGO P, 1990, INT IMMUNOL, V2, P209, DOI 10.1093/intimm/2.3.209; HUISKAMP R, 1985, J IMMUNOL, V134, P2161; KADISH JL, 1975, J IMMUNOL, V114, P452; KARIV I, 1993, J EXP MED, V177, P1429, DOI 10.1084/jem.177.5.1429; KISIELOW P, 1991, IMMUNOL REV, V122, P69, DOI 10.1111/j.1600-065X.1991.tb00597.x; KISIELOW P, 1984, J IMMUNOL, V133, P1117; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; MARUSICGALESIC S, 1988, NATURE, V333, P180, DOI 10.1038/333180a0; NIKOLICZUGIC J, 1991, IMMUNOL TODAY, V12, P65, DOI 10.1016/0167-5699(91)90160-U; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; RAMSDELL F, 1991, J IMMUNOL, V147, P1779; Robey E A, 1990, Semin Immunol, V2, P25; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SCOLLAY R, 1985, J IMMUNOL, V134, P3632; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; TAKAHAMA Y, 1992, SCIENCE, V258, P653, DOI 10.1126/science.1357752; TAKAHAMA Y, 1991, J IMMUNOL, V146, P1134; TOMOOKA S, 1987, J IMMUNOL, V139, P3986; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VONBOEHMER H, 1986, IMMUNOL TODAY, V7, P333; VONBOEHMER H, 1992, IMMUNOL TODAY, V13, P454, DOI 10.1016/0167-5699(92)90075-I; YOKOYAMA WM, 1988, J IMMUNOL, V141, P369; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUNIGAPFLUCKER JC, 1990, J IMMUNOL, V144, P3736; ZUNIGAPFLUCKER JC, 1989, J EXP MED, V169, P2085, DOI 10.1084/jem.169.6.2085	47	99	99	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 13	1993	261	5123					911	915		10.1126/science.8102208	http://dx.doi.org/10.1126/science.8102208			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8102208				2022-12-24	WOS:A1993LR89700038
J	BLACK, J				BLACK, J			DEEP-VEIN THROMBOSIS AND PULMONARY-EMBOLISM	LANCET			English	Editorial Material																		BERGQVIST D, 1986, BRIT MED J, V292, P658, DOI 10.1136/bmj.292.6521.658-a; JULIAN DG, 1989, DISEASES HEART, P515; OGSTRON D, 1987, VENOUS THROMBOSIS CA, P52; SASAHARA AA, 1987, VENOUS THROMBOSIS PU, P128	4	20	20	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					352	353		10.1016/0140-6736(93)91480-A	http://dx.doi.org/10.1016/0140-6736(93)91480-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101590				2022-12-24	WOS:A1993LQ86800018
J	MONCADA, S; MARTIN, JF				MONCADA, S; MARTIN, JF			VASODILATION - EVOLUTION OF NITRIC-OXIDE	LANCET			English	Editorial Material									UNIV LONDON KINGS COLL,SCH MED,LONDON WC2R 2LS,ENGLAND	University of London; King's College London	MONCADA, S (corresponding author), WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND.							MARKWARDT F, 1991, THROMB HAEMOSTASIS, V66, P141; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RADOMSKI MW, 1991, PHILOS T ROY SOC B, V334, P129, DOI 10.1098/rstb.1991.0102; RIBEIRO JMC, 1990, BRIT J PHARMACOL, V101, P932, DOI 10.1111/j.1476-5381.1990.tb14183.x; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393	6	31	31	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1511	1511		10.1016/0140-6736(93)90641-S	http://dx.doi.org/10.1016/0140-6736(93)90641-S			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099386				2022-12-24	WOS:A1993LG24200010
J	COSTA, SH; VESSEY, MP				COSTA, SH; VESSEY, MP			MISOPROSTOL AND ILLEGAL ABORTION IN RIO-DE-JANEIRO, BRAZIL	LANCET			English	Article							TRIMESTER	We report on the determinants and consequences of induced abortion among 803 women admitted to hospital with abortion complications in Rio de Janeiro, Brazil, in 1991. 458 (57%) women reported using misoprostol to induce abortion, 74% in the first 4 months of pregnancy. Doses of 200-16 800 mug were reported, with a median of 800 mug. 65% of the women took the drug orally, 29% used a combination of oral and vaginal routes, and 6% administered it intravaginally. Vaginal bleeding and uterine cramps were the commonest reasons for seeking hospital care. Only 8% of women reported gastrointestinal side-effects. Misoprostol induced vaginal bleeding within 12 h of administration in 52% of the women, but 16% waited 10 days or more for onset of bleeding. 4% were admitted to hospital with complete abortion. The likelihood of bleeding starting within 12 h increased with duration of gestation and it was greater when the drug was used both orally and intravaginally. A significantly smaller proportion of women taking misoprostol than of those who induced abortion by catheter insertion presented signs of infection or physical injuries or required blood transfusion (<0.0005). Among 803 women interviewed at delivery as controls, 6% had taken misoprostol but abortion had not ensued. Misoprostol has an important role as an abortifacient among the women studied.	OSWALDO CRUZ FDN,NATL SCH PUBL HLTH,DEPT EPIDEMIOL & QUANTITAT METHODS,RIO JANEIRO,BRAZIL; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,OXFORD,ENGLAND	Fundacao Oswaldo Cruz; University of Oxford								ARMITAGE P, 1971, STATISTICAL METHODS; BYGDEMAN M, 1984, CLIN OBSTET GYNAECOL, V11, P573; COELHO LT, 1991, CIENCIA HOJE, V13, P60; COSTA S, 1990, INT FAMILY PLANNING, V16, P16; FONSECA W, 1991, LANCET, V338, P56, DOI 10.1016/0140-6736(91)90046-R; HILL NCW, 1989, BRIT J OBSTET GYNAEC, V96, P1424, DOI 10.1111/j.1471-0528.1989.tb06307.x; MACKENZIE IZ, 1978, LANCET, V1, P1223; MERCUCCI VL, 1991, MARKERING FERTILIDAD, P113; NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; RABE T, 1987, GEBURTSH FRAUENHEILK, V47, P324, DOI 10.1055/s-2008-1035830; Schonhofar P S, 1991, Lancet, V337, P1534, DOI 10.1016/0140-6736(91)93212-R; SONTAG SJ, 1985, DIGEST DIS SCI, V30, pS159, DOI 10.1007/BF01309403	12	132	137	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1258	1261		10.1016/0140-6736(93)91156-G	http://dx.doi.org/10.1016/0140-6736(93)91156-G			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LC497	8098402				2022-12-24	WOS:A1993LC49700014
J	SAURELCUBIZOLLES, MJ; JOBSPIRA, N; ESTRYNBEHAR, M				SAURELCUBIZOLLES, MJ; JOBSPIRA, N; ESTRYNBEHAR, M			ECTOPIC PREGNANCY AND OCCUPATIONAL EXPOSURE TO ANTINEOPLASTIC DRUGS	LANCET			English	Article							RISK-FACTORS; FETAL LOSS; NURSES	The incidence of ectopic pregnancy has risen substantially during the past two decades, but the aetiology of a third of cases remains unknown. We have used data from a survey of nurses in Paris, France, to examine the relation between ectopic pregnancy and various occupational exposures. We studied two groups of women-operating-theatre staff and nurses from other departments. The women were asked about outcomes of all pregnancies and occupational exposure to anaesthetic gases, formol, ionising radiation, and antineoplastic drugs during the first trimester of pregnancy. Of 734 pregnancies reported, 15 (2%) had been ectopic. In chi-square analysis, there were significant associations (p < 0.02) between ectopic pregnancy and exposure to antineoplastic drugs, the woman's age, and the number of previous pregnancies. Other occupational exposures and working in an operating theatre did not show significant associations. In logistic regression analysis with adjustment for gravidity, the odds ratio (by the exact method) for ectopic pregnancy associated with occupational exposure to antineoplastic drugs was 10.0 (95% Cl 2.1-56.2). Because we had only small numbers of ectopic pregnancies, the odds ratios we estimated have wide confidence intervals. Our findings should be confirmed by a larger study specifically designed to investigate the relation between antineoplastic exposure and ectopic pregnancy.	INSERM, U292, LE KREMLIN BICETRE, FRANCE; ASSISTANCE PUBL HOP PARIS, PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	SAURELCUBIZOLLES, MJ (corresponding author), INSERM, U149, 16 AVE PAUL VAILLANT COUTURIER, F-94807 VILLEJUIF, FRANCE.		Saurel-Cubizolles, Marie-Josephe/D-1571-2014	Saurel-Cubizolles, Marie-Josephe/0000-0002-2210-974X				CHOW WH, 1987, EPIDEMIOL REV, V9, P70, DOI 10.1093/oxfordjournals.epirev.a036309; COSTE J, 1991, AM J PUBLIC HEALTH, V81, P199, DOI 10.2105/AJPH.81.2.199; COSTE J, 1991, AM J EPIDEMIOL, V133, P839, DOI 10.1093/oxfordjournals.aje.a115964; ELIAS S, 1981, AM J OBSTET GYNECOL, V141, P698, DOI 10.1016/S0002-9378(15)33314-7; FALCK K, 1979, LANCET, V1, P1250; HIJRI KF, 1987, J AM STAT ASSOC, V82, P1110; JOBSPIRA N, IN PRESS CONTRACEPTI; MARCHBANKS PA, 1988, JAMA-J AM MED ASSOC, V259, P1823, DOI 10.1001/jama.259.12.1823; POLAND BJ, 1976, TERATOLOGY, V14, P315, DOI 10.1002/tera.1420140306; ROMAN E, 1984, J EPIDEMIOL COMMUN H, V38, P29, DOI 10.1136/jech.38.1.29; SAURELCUBIZOLLES MJ, 1992, BRIT J IND MED, V49, P276; SELEVAN SG, 1985, NEW ENGL J MED, V313, P1173, DOI 10.1056/NEJM198511073131901; SKOV T, 1992, BRIT J IND MED, V49, P855; STUCKER I, 1990, SCAND J WORK ENV HEA, V16, P102, DOI 10.5271/sjweh.1811; THORBURN J, 1986, EUR J OBSTET GYN R B, V23, P333, DOI 10.1016/0028-2243(86)90168-1	15	33	36	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	1993	341	8854					1169	1171		10.1016/0140-6736(93)91000-C	http://dx.doi.org/10.1016/0140-6736(93)91000-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098075				2022-12-24	WOS:A1993LB01700002
J	MADL, C; GRIMM, G; KRAMER, L; YEGANEHFAR, W; STERZ, F; SCHNEIDER, B; KRANZ, A; SCHNEEWEISS, B; LENZ, K				MADL, C; GRIMM, G; KRAMER, L; YEGANEHFAR, W; STERZ, F; SCHNEIDER, B; KRANZ, A; SCHNEEWEISS, B; LENZ, K			EARLY PREDICTION OF INDIVIDUAL OUTCOME AFTER CARDIOPULMONARY-RESUSCITATION	LANCET			English	Article							MULTIMODALITY EVOKED-POTENTIALS; HOSPITAL CARDIAC-ARREST; BRAIN-FUNCTION; COMA; IMPROVEMENT	Prediction of individual outcome after cardiopulmonary resuscitation is of major medical, ethical, and socioeconomic interest but uncertain. We studied the early predictive potency of evoked potential recording after cardiac arrest in 66 resuscitated patients who returned to spontaneous circulation but were unconscious and mechanically ventilated. Detailed long-latency and short-latency sensory evoked potentials were recorded and neurological evaluations were done 4-48 h after admission to intensive care. In all 17 patients with favourable outcome (cerebral performance categories 1 and 2) the cortical evoked potential N70 peak, a reliable measure of cortical function, was detected between 74 and 116 ms. In 49 patients with bad outcome (categories 4 and 5) the N70 peak was absent in 35 or found with a delay between 121 and 171 ms in 14 (p < 0.05 vs favourable outcome). Thus the predictive ability was 100% with cutoff of 118 ms. To confirm reproducibility and validity, repeated tracings, and linked-earlobe referenced techniques were done and gave similar results. Early recording of long-latency evoked potentials after cardiopulmonary resuscitation is highly predictive of outcome.	UNIV VIENNA, DEPT MED 4, INTENS CARE UNIT, A-1010 VIENNA, AUSTRIA; UNIV VIENNA, DEPT EMERGENCY MED, A-1010 VIENNA, AUSTRIA; UNIV VIENNA, INST MED STAT, A-1010 VIENNA, AUSTRIA	University of Vienna; University of Vienna; University of Vienna								[Anonymous], 1986, Am J Emerg Med, V4, P72; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BRUNKO E, 1987, ELECTROEN CLIN NEURO, V66, P15, DOI 10.1016/0013-4694(87)90133-7; CANT BR, 1986, EVOKED POTENTIAL, P58; CARONNA J J, 1978, Stroke, V9, P517; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; DEBEYL DZ, 1989, BRAIN FAILURE UPDATE, P206; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; GRIMM G, 1992, ELECTROEN CLIN NEURO, V82, P119, DOI 10.1016/0013-4694(92)90154-A; GRIMM G, 1988, LANCET, V2, P1392; GRIMM G, 1991, INTENS CARE MED, V17, P94, DOI 10.1007/BF01691430; GRIMM G, 1990, KIDNEY INT, V38, P480, DOI 10.1038/ki.1990.229; GRIMM G, 1990, LANCET, V336, P963, DOI 10.1016/0140-6736(90)92419-I; Grundy B.L., 1988, EVOKED POTENTIALS IN; JACOBS P, 1990, CRIT CARE MED, V18, P1282, DOI 10.1097/00003246-199011000-00020; JENNETT B, 1975, LANCET, V1, P480; LUND I, 1976, LANCET, V2, P702; Maiese K, 1988, J INTENSIVE CARE MED, V3, P153; MULLIE A, 1988, LANCET, V1, P137; NAU HE, 1987, INTENS CARE MED, V13, P249, DOI 10.1007/BF00265113; PFURTSCHELLER G, 1985, ELECTROEN CLIN NEURO, V62, P88, DOI 10.1016/0168-5597(85)90020-6; PRIOR PF, 1985, BRIT J ANAESTH, V57, P63, DOI 10.1093/bja/57.1.63; TEASDALE G, 1974, LANCET, V2, P81; VAAGENES P, 1988, J CEREBR BLOOD F MET, V8, P262, DOI 10.1038/jcbfm.1988.57; 1988, CRIT CARE MED, V8, P807	26	135	137	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	1993	341	8849					855	858		10.1016/0140-6736(93)93061-5	http://dx.doi.org/10.1016/0140-6736(93)93061-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096562				2022-12-24	WOS:A1993KV81100004
J	VERSLUYS, C				VERSLUYS, C			ETHICS OF NEONATAL CARE	LANCET			English	Letter											VERSLUYS, C (corresponding author), WILKELMINA KINDERZIEKENHUIS,UTRECHT,NETHERLANDS.								0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					794	795		10.1016/0140-6736(93)90567-Z	http://dx.doi.org/10.1016/0140-6736(93)90567-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096005				2022-12-24	WOS:A1993KU90000010
J	EMBRETSON, J; ZUPANCIC, M; RIBAS, JL; BURKE, A; RACZ, P; TENNERRACZ, K; HAASE, AT				EMBRETSON, J; ZUPANCIC, M; RIBAS, JL; BURKE, A; RACZ, P; TENNERRACZ, K; HAASE, AT			MASSIVE COVERT INFECTION OF HELPER T-LYMPHOCYTES AND MACROPHAGES BY HIV DURING THE INCUBATION PERIOD OF AIDS	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LYMPH-NODES; INSITU HYBRIDIZATION; VISNA VIRUS; LYMPHADENOPATHY; AMPLIFICATION; CELLS; DNA; PATHOGENESIS; MECHANISMS	ANIMAL and human lentiviruses elude host defences by establishing covert infections and eventually cause disease through cumulative losses of cells that die with activation of viral gene expression1-5. We used polymerase chain reaction in situ double-label methods6,7 to determine how many CD4+ lymphocytes are latently infected by human immunodeficiency virus (HIV) in patient lymph nodes and whether the pool of infected cells is large enough to account for immune depletion through continual activation of viral gene expression and attrition of cells responding to antigens. We discovered an extraordinarily large number of latently infected CD4+ lymphocytes and macrophages throughout the lymphoid system from early to late stages of infection, and confirmed8-14 the extracellular association of HIV with follicular dendritic cells. Follicular dendritic cells may transmit infection to cells as they migrate through lymphoid follicles. Latently infected lymphocytes and macrophages constitute an intracellular reservoir large enough ultimately to contribute to much of the immune depletion in AIDS, and represent a difficult problem that must be resolved in developing effective treatments and protective vaccine.	UNIV MINNESOTA,DEPT MICROBIOL,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455; HENRY M JACKSON FDN,ROCKVILLE,MD 20850; US DEPT DEF,ARMED FORCES INST PATHOL,DEPT CARDIOVASC PATHOL,WASHINGTON,DC 20306; BERNHARD NOCHT INST TROP MED,W-2000 HAMBURG 36,GERMANY	University of Minnesota System; University of Minnesota Twin Cities; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; United States Department of Defense; Bernhard Nocht Institut fur Tropenmedizin								ARMSTRONG JA, 1984, LANCET, V2, P370; BARONI CD, 1986, HISTOPATHOLOGY, V10, P5, DOI 10.1111/j.1365-2559.1986.tb02456.x; BIBERFELD P, 1986, AM J PATHOL, V125, P436; BRAHIC M, 1981, NATURE, V292, P240, DOI 10.1038/292240a0; BRAHIC M, 1989, CURR TOP MICROBIOL, V143, P9; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; EMBRETSON J, 1993, P NATL ACAD SCI USA, V90, P357, DOI 10.1073/pnas.90.1.357; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; GREENE WC, 1991, NEW ENGL J MED, V324, P308, DOI 10.1056/NEJM199101313240506; HAASE AT, 1986, NATURE, V322, P130, DOI 10.1038/322130a0; HAASE AT, 1990, P NATL ACAD SCI USA, V87, P4971, DOI 10.1073/pnas.87.13.4971; Haase AT, 1987, IN SITU HYBRIDIZATIO, P197; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; NUOVO GJ, 1991, AM J PATHOL, V139, P847; PELUSO R, 1985, VIROLOGY, V147, P231, DOI 10.1016/0042-6822(85)90246-6; RACZ P, 1986, PROG ALLERGY, V37, P81; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SPIEGEL H, 1992, AM J PATHOL, V140, P15; STASKUS KA, 1991, MICROB PATHOGENESIS, V11, P67, DOI 10.1016/0882-4010(91)90095-R; TENNERRACZ K, 1986, AM J PATHOL, V123, P9	21	1330	1357	0	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 25	1993	362	6418					359	362		10.1038/362359a0	http://dx.doi.org/10.1038/362359a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8096068				2022-12-24	WOS:A1993KU17600066
J	TELENTI, A; IMBODEN, P; MARCHESI, F; LOWRIE, D; COLE, S; COLSTON, MJ; MATTER, L; SCHOPFER, K; BODMER, T				TELENTI, A; IMBODEN, P; MARCHESI, F; LOWRIE, D; COLE, S; COLSTON, MJ; MATTER, L; SCHOPFER, K; BODMER, T			DETECTION OF RIFAMPICIN-RESISTANCE MUTATIONS IN MYCOBACTERIUM-TUBERCULOSIS	LANCET			English	Article							POLYMERASE CHAIN-REACTION; RNA-POLYMERASE; ESCHERICHIA-COLI; DNA; GENE	Control of tuberculosis is threatened by widespread emergence of drug resistance in Mycobacterium tuberculosis. Understanding the molecular basis of resistance might lead to development of novel rapid methods for diagnosing drug resistance. We set out to determine the molecular basis of resistance to rifampicin, a major component of multidrug regimens used for treating tuberculosis. Resistance to rifampicin involves alterations of RNA polymerase. The gene that encodes the RNA polymerase subunit beta (rpoB) was cloned. Sequence information from this gene was used to design primers for direct amplification and sequencing of a 411 bp rpoB fragment from 122 isolates of M tuberculosis. Mutations involving 8 conserved aminoacids were identified in 64 of 66 rifampicin-resistant isolates of diverse geographical origin, but in none of 56 sensitive isolates. All mutations were clustered within a region of 23 aminoacids. Thus, substitution of a limited number of highly conserved aminoacids encoded by the rpoB gene appears to be the molecular mechanism responsible for ''single step'' high-level resistance to rifampicin in M tuberculosis. This information was used to develop a strategy (polymerase chain reaction-single-strand conformation polymorphism) that allowed efficient detection of all known rifampicin-resistant mutants. These findings provide the basis for rapid detection of rifampicin resistance, a marker of multidrug-resistant tuberculosis.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; INST PASTEUR,BACTERIAL MOLEC GENET LAB,F-75724 PARIS 15,FRANCE	MRC National Institute for Medical Research; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	TELENTI, A (corresponding author), UNIV BERN,INST MED MICROBIOL,FRIEDBUEHLSTR 51,CH-3010 BERN,SWITZERLAND.		Trajman, Anete/C-7679-2016; Lowrie, Douglas/B-8151-2013	Trajman, Anete/0000-0002-4000-4984; Lowrie, Douglas/0000-0003-2689-9627				ALDRAINEV I, 1990, J CHEMOTHER, V2, P147; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; CULLITON BJ, 1992, NATURE, V356, P473, DOI 10.1038/356473a0; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184; FISH M, 1992, ANN INTERN MED, V117, P177; HEIL A, 1970, FEBS LETT, V11, P165, DOI 10.1016/0014-5793(70)80519-1; HONORE N, IN PRESS ANTIMICROB; HONORE NS, IN PRESS MOL MICROBI; HUI J, 1977, ANTIMICROB AGENTS CH, V11, P773, DOI 10.1128/AAC.11.5.773; HULMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937; ILAYASHI K, 1991, PCR METH APPL, V1, P34; INDERLIED C, 1991, ANTIBIOTICS LABORATO, P136; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; LAGUNA F, 1991, J INFECTION, V23, P139, DOI 10.1016/0163-4453(91)92016-X; LISITSYN NA, 1984, MOL GEN GENET, V196, P173, DOI 10.1007/BF00334112; MARTIN C, 1990, MOL BIOL MYCOBACTERI, P121; MITCHISON D, 1985, BR MED B, V40, P84; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; MONNO L, 1991, LANCET, V337, P852, DOI 10.1016/0140-6736(91)92559-K; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OVCHINNIKOV YA, 1981, EUR J BIOCHEM, V116, P621, DOI 10.1111/j.1432-1033.1981.tb05381.x; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SIDDIQI SH, 1981, J CLIN MICROBIOL, V13, P908, DOI 10.1128/JCM.13.5.908-912.1981; TELENTI A, 1993, J CLIN MICROBIOL, V31, P175, DOI 10.1128/JCM.31.2.175-178.1993; TSUKAMURA M, 1972, Tubercle, V53, P111, DOI 10.1016/0041-3879(72)90027-X; YAMADA T, 1985, ANTIMICROB AGENTS CH, V27, P921, DOI 10.1128/AAC.27.6.921; ZNANG Y, 1992, NATURE, V358, P591; 1992, MMWR, V41, P1	30	1028	1108	1	112	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					647	650		10.1016/0140-6736(93)90417-F	http://dx.doi.org/10.1016/0140-6736(93)90417-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095569				2022-12-24	WOS:A1993KR61300002
J	GARCIA, HH; GILMAN, R; MARTINEZ, M; TSANG, VCW; PILCHER, JB; HERRERA, G; DIAZ, F; ALVARADO, M; MIRANDA, E				GARCIA, HH; GILMAN, R; MARTINEZ, M; TSANG, VCW; PILCHER, JB; HERRERA, G; DIAZ, F; ALVARADO, M; MIRANDA, E			CYSTICERCOSIS AS A MAJOR CAUSE OF EPILEPSY IN PERU	LANCET			English	Article							CEREBRAL CYSTICERCOSIS; TAENIA-SOLIUM; DIAGNOSIS; ASSAY; NEUROCYSTICERCOSIS; ANTIGENS; ELISA	In countries where cysticercosis is endemic, the proportion of epilepsy due to cysticercosis is not well documented. To investigate the association between cysticercosis and epilepsy, we used the enzyme-linked immunoelectrotransfer blot (EITB) assay to detect serum antibodies to Taenia solium in 498 consecutive outpatients at a neurology clinic in Lima, Peru. Every patient was classified as epileptic (n = 189) or non-epileptic (n = 309) after neurological, and where possible electroencephalographic, examination. A substantially higher proportion of epileptic than non-epileptic patients was seropositive in the EITB (22 [12%] vs 8 [3%], p<0.001). 19% of epileptic patients born outside Lima, 20% of those with late-onset epilepsy, and 29% of patients with both these characteristics were seropositive. Thus, in Peru, cysticercosis is an important aetiological factor for epilepsy.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,PARASIT DIS BRANCH,BLDG 23,MAIL STOP F-13,ATLANTA,GA 30341; UNIV PERUANA CAYETANO HEREDIA,LIMA,PERU; INST NACL CIENCIAS NEUROL,LIMA,PERU; JOHNS HOPKINS UNIV,BALTIMORE,MD 21218	Centers for Disease Control & Prevention - USA; Universidad Peruana Cayetano Heredia; Johns Hopkins University				Evans, Carlton/0000-0002-6873-5447	Wellcome Trust [057434] Funding Source: Medline	Wellcome Trust(Wellcome Trust)		ACHA JP, 1964, AM J TROP MED HYG, V13, P48; BENDING JJ, 1983, LANCET, V1, P922; CHOPRA JS, 1981, T ROY SOC TROP MED H, V75, P4; DELBRUTTO OH, 1988, REV INFECT DIS, V10, P1075; DIAZ F, 1992, AM J EPIDEMIOL, V135, P875, DOI 10.1093/oxfordjournals.aje.a116383; DIAZ JF, 1992, AM J TROP MED HYG, V46, P610, DOI 10.4269/ajtmh.1992.46.610; DIWAN AR, 1982, AM J TROP MED HYG, V31, P364, DOI 10.4269/ajtmh.1982.31.364; Dixon HBF, 1944, Q J MED, V13, P107; GAJDUSEK DC, 1978, PAPUA NEW GUINEA MED, V21, P329; GARCIA HH, 1991, LANCET, V338, P549; GONZALEZ AE, 1990, AM J TROP MED HYG, V43, P194, DOI 10.4269/ajtmh.1990.43.194; Mahajan R.C., 1982, P39; MCCORMICK GF, 1982, ARCH NEUROL-CHICAGO, V39, P534, DOI 10.1001/archneur.1982.00510210004002; MEDINA MT, 1990, ARCH INTERN MED, V150, P325, DOI 10.1001/archinte.150.2.325; NASH TE, 1984, NEW ENGL J MED, V311, P1492, DOI 10.1056/NEJM198412063112307; PLASCENCIA M, IN PRESS NEUROEPIDEM; SARTI E, 1992, AM J TROP MED HYG, V46, P677, DOI 10.4269/ajtmh.1992.46.677; SHORVON SD, 1990, LANCET, V336, P93, DOI 10.1016/0140-6736(90)91603-8; SHORVON SD, 1991, MANAGEMENT EPILEPSY; TELLEZGIRON E, 1987, AM J TROP MED HYG, V37, P169, DOI 10.4269/ajtmh.1987.37.169; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50	21	174	180	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					197	200		10.1016/0140-6736(93)90064-N	http://dx.doi.org/10.1016/0140-6736(93)90064-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093496	Green Accepted			2022-12-24	WOS:A1993KJ21900003
J	HALLIWELL, B				HALLIWELL, B			RENAISSANCE OF PEROXISOMES	LANCET			English	Editorial Material											HALLIWELL, B (corresponding author), UNIV CALIF DAVIS,DAVIS MED CTR,DAVIS,CA 95616, USA.		Halliwell, Barry/C-8318-2009					DEDUVE C, 1966, PHYSIOL REV, V46, P322; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; MANNAERTS GP, 1992, CELL BIOCHEM FUNCT, V10, P141, DOI 10.1002/cbf.290100303; PALOSAARI PM, 1992, ANN MED, V24, P163, DOI 10.3109/07853899209147814; ROSCHER AA, 1992, CELL BIOCHEM FUNCT, V10, P201, DOI 10.1002/cbf.290100310; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315	6	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					92	92		10.1016/0140-6736(93)92566-C	http://dx.doi.org/10.1016/0140-6736(93)92566-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093412				2022-12-24	WOS:A1993KF87000013
J	SHARP, D				SHARP, D			WHEN WINE IS RED	LANCET			English	Editorial Material																		EDDY P, 1992, TELEGRAPH MAGAZ 1205, P18; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; SEIGNEUR M, 1990, J APPL CARDIOL, V5, P215; SIEMANN EH, 1992, AM J ENOL VITICULT, V43, P49	5	13	13	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					27	28		10.1016/0140-6736(93)92493-D	http://dx.doi.org/10.1016/0140-6736(93)92493-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093276				2022-12-24	WOS:A1993KF02700015
J	LEMESHOW, S; LEGALL, JR				LEMESHOW, S; LEGALL, JR			MODELING THE SEVERITY OF ILLNESS OF ICU PATIENTS - A SYSTEMS UPDATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLASSIFICATION-SYSTEM; ACUTE PHYSIOLOGY; APACHE-II; MORTALITY; CARE; PREDICTION; SEPSIS; SCORE	Objective.-To review recent revisions of systems for estimating the probability of hospital mortality of adult intensive care unit (ICU) patients. Emphasis on comparison of components of systems and potential uses. Data Sources.-Published articles in which the systems were presented. Study Selection.-Acute Physiology and Chronic Health Evaluation (APACHE III), Simplified Acute Physiology Score (SAPS II), and Mortality Probability Models (MPM II) are the major severity systems for ICU patients. Data Extraction.-Information on variables collected in the systems, characteristics of databases from which they were developed, and reported performance of models were evaluated from published articles. Data Synthesis.-APACHE III and SAPS II produce a score and probability of hospital mortality based on worst values of several variables during the first 24 hours in ICU. The MPM II system has four models, one at ICU admission and one at 24, 48, and 72 hours into the ICU stay. The SAPS II and MPM II models can be implemented from published information. The APACHE III score can be calculated from published information; weights to convert score to probability are proprietary. All reported good areas under receiver operating characteristic curve. Goodness of fit was good for SAPS II and MPM II models and was not reported for APACHE III models. Conclusions.-All models were based on rigorous research and reported performance is good. AH can be used to assist in assessing prognosis, to compare ICU performance, and to stratify patients for clinical trials. Direct comparison on a common cohort is needed.	HOP ST LOUIS,SERV REANIMAT MED,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	LEMESHOW, S (corresponding author), UNIV MASSACHUSETTS,SCH PUBL HLTH,ARNOLD HOUSE,AMHERST,MA 01003, USA.				AHRQ HHS [HS06026] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		CLEVELAND WS, 1981, AM STAT, V35, P54, DOI 10.2307/2683591; Hadorn DC., 1993, ASSESSING PERFORMANC; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KNAUS WA, 1992, CHEST, V101, P1656, DOI 10.1378/chest.101.6.1656; Le Gall J-R, 1993, REAN URG, V6, P656; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEGALL JR, 1994, HADOJAMA, V271, P1321; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LEMESHOW S, 1994, CRIT CARE MED, V22, P1351, DOI 10.1097/00003246-199409000-00003; LEMESHOW S, 1988, CRIT CARE MED, V16, P470, DOI 10.1097/00003246-198805000-00002; LOIRAT P, 1994, REANIM URG, V3, P173; MEYER AA, 1992, J TRAUMA, V32, P747, DOI 10.1097/00005373-199206000-00013; PITTET D, 1993, INTENS CARE MED, V19, P265, DOI 10.1007/BF01690546; SELKER HP, 1993, ANN INTERN MED, V118, P820, DOI 10.7326/0003-4819-118-10-199305150-00010; TERES D, 1994, CRIT CARE CLIN, V10, P93, DOI 10.1016/S0749-0704(18)30147-7; WATTS CM, 1994, CRIT CARE CLIN, V10, P111, DOI 10.1016/S0749-0704(18)30148-9	22	270	281	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					1049	1055		10.1001/jama.272.13.1049	http://dx.doi.org/10.1001/jama.272.13.1049			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089888				2022-12-24	WOS:A1994PH77500031
J	ODONOVAN, A; DAVIES, AA; MOGGS, JG; WEST, SC; WOOD, RD				ODONOVAN, A; DAVIES, AA; MOGGS, JG; WEST, SC; WOOD, RD			XPG ENDONUCLEASE MAKES THE 3' INCISION IN HUMAN DNA NUCLEOTIDE EXCISION-REPAIR	NATURE			English	Article							COMPLEMENTATION GROUP-G; PIGMENTOSUM GROUP-F; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; RAD2; PROTEINS; DEFECTS; ERCC1; GENE	HUMANS With a defect in the XPG protein suffer from xeroderma pigmentosum (XP) resulting from an inability to perform DNA nucleotide excision repair properly(1-4). Here we show that XPG makes a structure-specific endonucleolytic incision in a synthetic DNA substrate containing a duplex region and single-stranded arms. One strand of the duplex is cleaved at the border with single-stranded DNA. A cut with the same polarity is also made in a bubble structure, at the 3' side of the centrally unpaired region. Normal cell extracts introduce a nick 3' to a platinum-DNA lesion, but an XP-G cell extract is defective in making this incision. These data show that XPG has a direct role in making one of the incisions required to excise a damaged oligonucleotide, by cleaving 3' to DNA damage during nucleotide excision repair.			ODONOVAN, A (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.		Wood, Richard/M-6319-2018	Wood, Richard/0000-0002-9495-6892; West, Stephen/0000-0001-8848-9418				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ARLETT CF, 1980, CARCINOGENESIS, V1, P745, DOI 10.1093/carcin/1.9.745; BARDWELL L, IN PRESS SCIENCE; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; ICHIHASHI M, 1985, J INVEST DERMATOL, V85, P284, DOI 10.1111/1523-1747.ep12276776; KEIJZER W, 1979, MUTAT RES, V62, P183, DOI 10.1016/0027-5107(79)90231-8; LIN JJ, 1992, J BIOL CHEM, V267, P17693; MACINNES MA, 1993, MOL CELL BIOL, V13, P6393, DOI 10.1128/MCB.13.10.6393; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; NORRIS PG, 1987, BRIT J DERMATOL, V116, P861, DOI 10.1111/j.1365-2133.1987.tb04906.x; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SHIOMI T, 1994, MUTAT RES, V314, P167, DOI 10.1016/0921-8777(94)90080-9; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SUNG P, 1993, J BIOL CHEM, V268, P26391; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; VERMEULEN W, 1993, AM J HUM GENET, V53, P185	27	392	402	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 29	1994	371	6496					432	435		10.1038/371432a0	http://dx.doi.org/10.1038/371432a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	8090225				2022-12-24	WOS:A1994PJ28500047
J	BUSCHARD, K; JOSEFSEN, K; HORN, T; FREDMAN, P				BUSCHARD, K; JOSEFSEN, K; HORN, T; FREDMAN, P			SULFATIDE AND SULFATIDE ANTIBODIES IN INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Note							SULFATIDE	Insulin-dependent diabetes mellitus (IDDM) is associated with neurological disorders. Sulph I, a monoclonal antibody to sulphatide (a neural epitope), stained secretory granules in alpha and beta cells of rat islets of Langerhans, but not exocrine tissue. Sera from 88% of 57 newly diagnosed IDDM patients was anti-sulphatide positive, and 76% were positive 6 months later. All 135 healthy controls were negative. Sulphatide antibody may be an IDDM marker.	MOLNDALS SJUKHUS,DEPT CLIN NEUROSCI,PSYCHIAT & NEUROCHEM SECT,MOLNDAL,SWEDEN; HERLEV HOSP,DEPT PATHOL,DK-2730 HERLEV,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital	BUSCHARD, K (corresponding author), KOMMUNE HOSP COPENHAGEN,BARTHOLIN INST,DK-1399 COPENHAGEN K,DENMARK.			Buschard, Karsten/0000-0002-0126-7423				BUSCHARD K, 1983, DIABETOLOGIA, V24, P42; DEAN BM, 1986, DIABETOLOGIA, V29, P339, DOI 10.1007/BF00452073; FREDMAN P, 1991, J NEUROL, V238, P75, DOI 10.1007/BF00315684; FREDMAN P, 1988, BIOCHEM J, V251, P17, DOI 10.1042/bj2510017; FREDMAN P, 1993, J NEUROL, V240, P382; GLEICHMANN H, 1987, DIABETES, V36, P578, DOI 10.2337/diabetes.36.5.578; MARSHALL MO, 1992, J IMMUNOL METHODS, V149, P63, DOI 10.1016/S0022-1759(12)80049-4; RABINOWE SL, 1990, DIABETES METAB REV, V6, P169, DOI 10.1002/dmr.5610060304	8	53	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					840	840		10.1016/0140-6736(93)92697-R	http://dx.doi.org/10.1016/0140-6736(93)92697-R			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104274				2022-12-24	WOS:A1993MA02500011
J	JUDICE, JK; GAMBLE, TR; MURPHY, EC; DEVOS, AM; SCHULTZ, PG				JUDICE, JK; GAMBLE, TR; MURPHY, EC; DEVOS, AM; SCHULTZ, PG			PROBING THE MECHANISM OF STAPHYLOCOCCAL NUCLEASE WITH UNNATURAL AMINO-ACIDS - KINETIC AND STRUCTURAL STUDIES	SCIENCE			English	Article							ACTIVE-SITE; MAGNETIC-RESONANCE; CRYSTAL-STRUCTURE; DOUBLE MUTANT; SUBSTITUTIONS; RESOLUTION; CATALYSIS; PROTEINS; COMPLEX	Staphylococcal nuclease is an enzyme with enormous catalytic power, accelerating phosphodiester bond hydrolysis by a factor of 10(16) over the spontaneous rate. The mechanistic basis for this rate acceleration was investigated by substitution of the active site residues Glu43, Arg35, and Arg87 With unnatural amino acid analogs. Two Glu43 mutants, one containing the nitro analog of glutamate and the other containing homoglutamate, retained high catalytic activity at pH 9.9, but were less active than the wild-type enzyme at lower pH values. The x-ray crystal structure of the homoglutamate mutant revealed that the carboxylate side chain of this residue occupies a position and orientation similar to that of Glu43 in the wild-type enzyme. The increase in steric bulk is accommodated by a backbone shift and altered torsion angles. The nitro and the homoglutamate mutants display similar pH versus rate profiles, which differ from that of the wild-type enzyme. Taken together, these studies suggest that Glu43 may not act as a general base, as previously thought, but may play a more complex structural role during catalysis.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; UNIV CALIF SAN FRANCISCO, GRAD GRP BIOPHYS, SAN FRANCISCO, CA 94143 USA; GENENTECH INC, DEPT PROT ENGN, S SAN FRANCISCO, CA 94080 USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco; Roche Holding; Genentech					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008388, F32GM014012, R01GM049220] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM-08388, R01 GM49220, GM 14012-02S1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNETT EM, 1963, PROG PHYS ORG CHEM, V1, P223, DOI 10.1002/9780470171806.ch5; BRUNGER AT, 1992, XPLOR MANUAL; COTTON FA, 1979, P NATL ACAD SCI USA, V76, P2551, DOI 10.1073/pnas.76.6.2551; CUATRECA.P, 1967, J BIOL CHEM, V242, P1541; DUNN BM, 1973, J BIOL CHEM, V248, P4769; ELLMAN J, 1991, METHOD ENZYMOL, V202, P301; HALE SP, IN PRESS BIOCHEMISTR; HERMANN P, 1968, H-S Z PHYSIOL CHEM, V349, P390, DOI 10.1515/bchm2.1968.349.1.390; HIBLER DW, 1987, BIOCHEMISTRY-US, V26, P6278, DOI 10.1021/bi00393a048; HYNES TR, 1991, PROTEINS, V10, P92, DOI 10.1002/prot.340100203; JOESTEN MD, 1974, HYDROGEN BONDING, P309; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; LESLEY SA, UNPUB; LOLL PJ, 1990, BIOCHEMISTRY-US, V29, P6866, DOI 10.1021/bi00481a016; LOLL PJ, 1989, PROTEINS, V5, P183, DOI 10.1002/prot.340050302; MEHDI S, 1982, J AM CHEM SOC, V104, P3223, DOI 10.1021/ja00375a053; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; POURMOTABBED T, 1990, BIOCHEMISTRY-US, V29, P3677, DOI 10.1021/bi00467a013; SAMPSON NS, 1992, BIOCHEMISTRY-US, V31, P8488, DOI 10.1021/bi00151a015; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; Schowen R. L., 1977, ISOTOPE EFFECTS ENZY, P64; SERPERSU EH, 1987, BIOCHEMISTRY-US, V26, P1289, DOI 10.1021/bi00379a014; SERPERSU EH, 1986, BIOCHEMISTRY-US, V25, P68, DOI 10.1021/bi00349a011; SHORTLE D, 1983, GENE, V22, P181, DOI 10.1016/0378-1119(83)90102-6; SLATER CD, 1981, J ORG CHEM, V46, P2173, DOI 10.1021/jo00323a041; SUICH DJ, 1993, THESIS U CALIFORNIA; TAKAHARA M, 1985, J BIOL CHEM, V260, P2670; WEBER DJ, 1990, BIOCHEMISTRY-US, V29, P8632, DOI 10.1021/bi00489a020; WEBER DJ, 1991, BIOCHEMISTRY-US, V30, P6103, DOI 10.1021/bi00239a004; WEBER DJ, 1992, PROTEINS, V13, P275, DOI 10.1002/prot.340130402; WILDE JA, 1988, BIOCHEMISTRY-US, V27, P4127, DOI 10.1021/bi00411a033	31	80	81	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1993	261	5128					1578	1581		10.1126/science.8103944	http://dx.doi.org/10.1126/science.8103944			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	8103944				2022-12-24	WOS:A1993LX47400030
J	FREI, E				FREI, E			GENE DELETION - A NEW TARGET FOR CANCER-CHEMOTHERAPY	LANCET			English	Article							CELL LUNG-CANCER; RETINOBLASTOMA; 5-FLUOROURACIL; INACTIVATION; TOXICITY				FREI, E (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,44 BINNEY ST,BOSTON,MA 02115, USA.							BERTINO JR, 1993, CANC MED, P698; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRENT TP, 1985, P NATL ACAD SCI USA, V82, P2985, DOI 10.1073/pnas.82.9.2985; DIASIO RB, 1989, CLIN PHARMACOKINET, V16, P215, DOI 10.2165/00003088-198916040-00002; FREI E, 1993, CANCER MED, P631; GELEHRTER TD, 1990, PRINCIPLERS MED GENE, P255; HARRIS BE, 1991, CANCER, V68, P499, DOI 10.1002/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LEE WH, 1987, HUM GENET, V76, P33; LILENBAUM RC, 1992, P AM SOC CLIN ONCOL, V33, P11; Meyer U A, 1990, Prog Liver Dis, V9, P307; MILLER YE, 1989, J CLIN INVEST, V83, P2120, DOI 10.1172/JCI114125; OWENS TK, 1992, CANCER RES, V82, P2389; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; REMICK SC, 1990, CANCER RES, V50, P2667; SAGER R, 1984, CANCER SURV, V3, P321; TUCHMAN M, 1985, NEW ENGL J MED, V313, P245, DOI 10.1056/NEJM198507253130407; WAXMAN DJ, 1990, CANCER RES, V50, P6449; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WOLFENDEN R, 1975, BIOCHEMISTRY-US, V14, P599; 1987, CYTOGENET CELL GENET, V46, P1	23	17	18	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					662	664		10.1016/0140-6736(93)91764-D	http://dx.doi.org/10.1016/0140-6736(93)91764-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103151				2022-12-24	WOS:A1993LX27200015
J	KAMEOKA, J; TANAKA, T; NOJIMA, Y; SCHLOSSMAN, SF; MORIMOTO, C				KAMEOKA, J; TANAKA, T; NOJIMA, Y; SCHLOSSMAN, SF; MORIMOTO, C			DIRECT ASSOCIATION OF ADENOSINE-DEAMINASE WITH A T-CELL ACTIVATION ANTIGEN, CD26	SCIENCE			English	Article							DIPEPTIDYL PEPTIDASE-IV; AMINO-ACID-SEQUENCE; COMPLEXING PROTEIN; MONOCLONAL-ANTIBODIES; BINDING-PROTEIN; SURFACE; EXPRESSION; 1F7; CHROMOSOME-2; ASSIGNMENT	CD26, the T cell activation molecule dipeptidyl peptidase IV (DPPIV), associates with a 43-kilodalton protein. Amino acid sequence analysis and immunoprecipitation studies demonstrated that this 43-kilodalton protein was adenosine deaminase (ADA). ADA was coexpressed with CD26 on the Jurkat T cell lines, and an in vitro binding assay showed that the binding was through the extracellular domain of CD26. ADA deficiency causes severe combined immunodeficiency disease (SCID) in humans. Thus, ADA and CD26 (DPPIV) interact on the T cell surface, and this interaction may provide a clue to the pathophysiology of SCID caused by ADA deficiency.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NIAID NIH HHS [AI29530, AI12069] Funding Source: Medline; NIAMS NIH HHS [AR33713] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012069, R01AI012069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033713] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDY RJ, 1982, J BIOL CHEM, V257, P7922; ARAN JM, 1991, J HISTOCHEM CYTOCHEM, V39, P1001, DOI 10.1177/39.8.1856451; BARANKIEWICZ J, 1988, J BIOL CHEM, V263, P7094; BLAESE RM, 1993, PEDIATR RES, V33, pS49, DOI 10.1203/00006450-199304001-00010; BUC HA, 1990, EUR J IMMUNOL, V20, P611, DOI 10.1002/eji.1830200322; CAMM AJ, 1991, NEW ENGL J MED, V325, P1621, DOI 10.1056/NEJM199112053252306; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DADDONA PE, 1984, J BIOL CHEM, V259, P2101; DANG NH, 1991, J IMMUNOL, V147, P2825; DANG NH, 1990, J IMMUNOL, V145, P3963; DANG NH, 1990, J EXP MED, V172, P649, DOI 10.1084/jem.172.2.649; DANG NH, 1990, J IMMUNOL, V144, P4092; DARMOUL D, 1990, ANN HUM GENET, V54, P191, DOI 10.1111/j.1469-1809.1990.tb00377.x; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; DINJENS WNM, 1989, J BIOL CHEM, V264, P19215; FLEISCHER B, 1987, J IMMUNOL, V138, P1346; FOX DA, 1984, J IMMUNOL, V133, P1250; HEGEN M, 1990, J IMMUNOL, V144, P2908; HERBSCHLEBVOOGT E, 1981, HUM GENET, V59, P317, DOI 10.1007/BF00295464; HIRSCHHORN R, 1993, PEDIATR RES, V33, pS35; HIRSCHHORN R, 1990, Immunodeficiency Reviews, V2, P175; KAMEOKA J, UNPUB; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; MOORE KA, 1990, BLOOD, V75, P2085; MORIMOTO C, 1989, J IMMUNOL, V143, P3430; MORRISON ME, 1993, J EXP MED, V177, P1135, DOI 10.1084/jem.177.4.1135; SCHARENBERG JGM, 1990, INT J IMMUNOPHARMACO, V12, P113, DOI 10.1016/0192-0561(90)90074-W; SCHRADER WP, 1988, J HISTOCHEM CYTOCHEM, V36, P1481, DOI 10.1177/36.12.2461411; SCHRADER WP, 1990, J BIOL CHEM, V265, P19312; TANAKA T, 1993, P NATL ACAD SCI USA, V90, P4586, DOI 10.1073/pnas.90.10.4586; TANAKA T, 1992, J IMMUNOL, V149, P481; Tanaka T., UNPUB; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; TORIMOTO Y, 1992, MOL IMMUNOL, V29, P183, DOI 10.1016/0161-5890(92)90099-J; ULMER AJ, 1990, SCAND J IMMUNOL, V31, P429, DOI 10.1111/j.1365-3083.1990.tb02789.x	35	458	477	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					466	469		10.1126/science.8101391	http://dx.doi.org/10.1126/science.8101391			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8101391				2022-12-24	WOS:A1993LN62300034
J	WATTERSON, A				WATTERSON, A			CHEMICAL HAZARDS AND PUBLIC CONFIDENCE	LANCET			English	Editorial Material											WATTERSON, A (corresponding author), NOTTINGHAM TRENT UNIV,CTR OCCUPAT SAFETY & HLTH,NOTTINGHAM,ENGLAND.							[Anonymous], 1992, RISK ANAL PERCEPTION; Avery N., 1993, CRACKING CODEX ANAL; KRAUS N, 1992, RISK ANAL, V12, P215, DOI 10.1111/j.1539-6924.1992.tb00669.x; 1976, ENV HLTH CRITERIA, V1; 1993, DRAFT ENV HLTH CRITE; 1991, ENV HLTH CRITERIA, V126	6	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					131	132		10.1016/0140-6736(93)91341-I	http://dx.doi.org/10.1016/0140-6736(93)91341-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101252				2022-12-24	WOS:A1993LN04200007
J	VONROENN, JH; CLEELAND, CS; GONIN, R; HATFIELD, AK; PANDYA, KJ				VONROENN, JH; CLEELAND, CS; GONIN, R; HATFIELD, AK; PANDYA, KJ			PHYSICIAN ATTITUDES AND PRACTICE IN CANCER PAIN MANAGEMENT - A SURVEY FROM THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP	ANNALS OF INTERNAL MEDICINE			English	Article						PAIN; PAIN MEASUREMENT; ANALGESICS, ADDICTIVE; ONCOLOGY SERVICE, HOSPITAL; PHYSICIANS PRACTICE PATTERNS	CONTROL REGIMENS; EDUCATION; PREVALENCE; PATIENT	Objective: The Eastern Cooperative Oncology Group (ECOG) conducted a groupwide survey to determine the amount of knowledge about cancer pain and its treatment among physicians practicing in ECOG-affiliated institutions and to determine the methods of pain control being used by these physicians. Design: Survey. Setting. A questionnaire was sent to all ECOG physicians with patient care responsibilities (medical oncologists, hematologists, surgeons, and radiation therapists), practicing in university institutions, Community Clinical Oncology Program (CCOP) institutions, and Cooperative Group Outreach Programs (CGOP) institutions. Measurements: A physician cancer pain questionnaire developed by the Pain Research Group at the University of Wisconsin was used. The questionnaire was designed to assess physicians' estimates of the magnitude of pain as a specific problem for cancer patients, their perceptions of the adequacy of cancer pain management, and their report of how they manage pain in their own practice setting. Results: The study analyzed responses to 897 of 1800 surveys. In regard to the use of analgesics for cancer pain in the United States, 86% felt that the majority of patients with pain were undermedicated. Only 51% believed pain control in their own practice setting was good or very good; 31% would wait until the patient's prognosis was 6 months or less before they would start maximal analgesia. Adjuvants and prophylactic side-effect management should have been used more frequently in the treatment plan. Concerns about side-effect management and tolerance were reported as limiting analgesic prescribing. Poor pain assessment was rated by 76% of physicians as the single most important barrier to adequate pain management. Other barriers included patient reluctance to report pain and patient reluctance to take analgesics (both by 62%) as well as physician reluctance to prescribe opioids (61%). Conclusions. Professional education needs to focus on the proper assessment of pain, focus on the management of side effects, and focus on the use of adjuvant medications. A better understanding of the pharmacology of opioid analgesics is also needed. Physicians also need to educate patients to report pain and to effectively use the medications that are prescribed for pain management.			CLEELAND, CS (corresponding author), PAIN RES GRP, DEPT NEUROL, 600 HIGHLAND AVE, MADISON, WI 53792 USA.				NATIONAL CANCER INSTITUTE [R01CA026582, U10CA021115, R18CA026582, U10CA017145] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21115, CA 26582, CA 17145, R01 CA026582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Austin C, 1986, Cancer Nurs, V9, P58; AVORN J, 1988, ARCH INTERN MED, V148, P1720, DOI 10.1001/archinte.148.8.1720; Bonica J. J., 1980, PAIN, P335; BONICA JJ, 1985, ADV PAIN RES THER, V9, P589; Cleeland C., 1989, ISSUES PAIN MEASUREM; CLEELAND C, 1991, ADV PAIN RES THER, P631; CLEELAND CS, 1986, CANCER, V58, P796, DOI 10.1002/1097-0142(19860801)58:3<796::AID-CNCR2820580331>3.0.CO;2-#; CLEELAND CS, 1984, CANCER, V53, P2264; DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; DONOVAN M, 1987, PAIN, V30, P69, DOI 10.1016/0304-3959(87)90084-4; FISHMAN B, 1987, CANCER-AM CANCER SOC, V60, P1151, DOI 10.1002/1097-0142(19870901)60:5<1151::AID-CNCR2820600538>3.0.CO;2-G; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; GREENWALD HP, 1987, CANCER, V60, P2563, DOI 10.1002/1097-0142(19871115)60:10<2563::AID-CNCR2820601036>3.0.CO;2-L; GROSSMAN SA, 1991, J PAIN SYMPTOM MANAG, V6, P53, DOI 10.1016/0885-3924(91)90518-9; HODES R, 1989, ADV PAIN RES THER, P91; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JONES WL, 1984, PATIENT EDUC COUNS, V5, P159, DOI 10.1016/0738-3991(84)90175-7; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; MCGIVNEY WT, 1984, JAMA-J AM MED ASSOC, V251, P1182; MELZACK R, 1976, CAN MED ASSOC J, V115, P125; RAY WA, 1985, MED CARE, V23, P1307, DOI 10.1097/00005650-198511000-00009; RIMER B, 1987, PATIENT EDUC COUNS, V10, P267, DOI 10.1016/0738-3991(87)90128-5; SAUNDERS CM, 1981, THERAPY PAIN, P215; TROTTER JM, 1981, BMJ-BRIT MED J, V10, P122; TWYCROSS RG, 1984, CLIN ONCOLO, V3, P5; TWYCROSS RG, 1982, PAIN, V14, P303, DOI 10.1016/0304-3959(82)90137-3; Weissman D E, 1991, Wis Med J, V90, P671; Zar J.H., 2010, BIOSTAT ANAL; 1983, ANN INTERN MED, V99, P870; 1992, PHS920032 US DEP HLT; 1986, CANCER PAIN RELIEF; 1989, PRINCIPLES ANALGESIC	32	537	544	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1993	119	2					121	126		10.7326/0003-4819-119-2-199307150-00005	http://dx.doi.org/10.7326/0003-4819-119-2-199307150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU902	8099769				2022-12-24	WOS:A1993LU90200005
J	COLSTON, KW				COLSTON, KW			NEW CONCEPTS IN HORMONE-RECEPTOR ACTION	LANCET			English	Editorial Material							THYROID-HORMONE; RETINOIC ACID				COLSTON, KW (corresponding author), ST GEORGE HOSP,SCH MED,DEPT CLIN BIOCHEM,LONDON,ENGLAND.							CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	6	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					67	68		10.1016/0140-6736(93)91281-P	http://dx.doi.org/10.1016/0140-6736(93)91281-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100908				2022-12-24	WOS:A1993LL78900005
J	BODNARENKO, SR; CHALUPA, LM				BODNARENKO, SR; CHALUPA, LM			STRATIFICATION OF ON AND OFF GANGLION-CELL DENDRITES DEPENDS ON GLUTAMATE-MEDIATED AFFERENT ACTIVITY IN THE DEVELOPING RETINA	NATURE			English	Article							ACTION-POTENTIAL ACTIVITY; INNER PLEXIFORM LAYER; CAT RETINA; PHARMACOLOGICAL MODULATION; MAMMALIAN RETINA; ON-CENTER; MORPHOLOGY; BIPOLAR; BETA; ROD	A FUNDAMENTAL attribute of the vertebrate visual system is the segregation of ON and OFF pathways signalling increments and decrements of light1-4. In the mature retina, dendrites of ON- and OFF-centre retinal ganglion cells (RGCs) stratify in different sublaminae of the inner plexiform layer (IPL), and are differentially innervated by two types of bipolar cells which depolarize and hyperpolarize on exposure to light5-10. This stratification of ON and OFF RGCs is achieved by the gradual restriction of their dendrites which ramify throughout the IPL early in development11-14. The factors underlying this regressive event are unknown. Dendritic stratification occurs around the time that bipolar cells form synapses in the IPL15,16, which raises the possibility that synaptic activity is involved in this process. Here we test this hypothesis by treating the developing cat retina with the glutamate analogue 2-amino-4-phosphonobutyric acid (APB), which hyperpolarizes ON cone bipolar and rod bipolar cells, thereby preventing their release of glutamate17-19. We report that intraocular injection of APB during the period when dendritic stratification normally occurs prevents the formation of structurally segregated ON and OFF retinal pathways. These results provide evidence that glutamate-mediated afferent activity regulates the remodelling of RGC dendrites during development.	UNIV CALIF DAVIS,CTR NEUROSCI,DAVIS,CA 95616	University of California System; University of California Davis	BODNARENKO, SR (corresponding author), UNIV CALIF DAVIS,DEPT PSYCHOL,DAVIS,CA 95616, USA.							BARLOW HB, 1953, J PHYSIOL-LONDON, V119, P69, DOI 10.1113/jphysiol.1953.sp004829; BOLZ J, 1984, NEUROSCIENCE, V12, P875, DOI 10.1016/0306-4522(84)90176-3; DANN JF, 1988, J NEUROSCI, V8, P1485; DUBIN MW, 1986, J NEUROSCI, V6, P1021; FAMIGLIETTI EV, 1975, BRAIN RES, V84, P293, DOI 10.1016/0006-8993(75)90983-X; FAMIGLIETTI EV, 1976, SCIENCE, V194, P193, DOI 10.1126/science.959847; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; Hartline HK, 1938, AM J PHYSIOL, V121, P400, DOI 10.1152/ajplegacy.1938.121.2.400; KOLB H, 1974, SCIENCE, V186, P47, DOI 10.1126/science.186.4158.47; KUFFLER SW, 1953, J NEUROPHYSIOL, V16, P37, DOI 10.1152/jn.1953.16.1.37; LAU KC, 1990, J COMP NEUROL, V300, P583, DOI 10.1002/cne.903000411; LEVENTHAL AG, 1983, J NEUROSCI, V3, P332; MASLIM J, 1988, DEV BRAIN RES, V44, P87, DOI 10.1016/0165-3806(88)90120-4; MASLIM J, 1986, BRAIN RES, V373, P35, DOI 10.1016/0006-8993(86)90313-6; MASLIM J, 1986, J COMP NEUROL, V254, P382, DOI 10.1002/cne.902540310; MCGUIRE BA, 1984, J NEUROSCI, V4, P2920; MCGUIRE BA, 1986, J NEUROSCI, V6, P907; MOVSHON JA, 1981, ANNU REV PSYCHOL, V32, P477, DOI 10.1146/annurev.ps.32.020181.002401; MULLER F, 1988, J NEUROPHYSIOL, V59, P1657, DOI 10.1152/jn.1988.59.6.1657; NELSON R, 1983, VISION RES, V23, P1183, DOI 10.1016/0042-6989(83)90032-9; NELSON R, 1978, J NEUROPHYSIOL, V41, P472, DOI 10.1152/jn.1978.41.2.472; RAMOA AS, 1988, J NEUROSCI, V8, P4239; SCHILLER PH, 1992, TRENDS NEUROSCI, V15, P86, DOI 10.1016/0166-2236(92)90017-3; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHERMAN SM, 1982, PHYSIOL REV, V62, P740; SLAUGHTER MM, 1981, SCIENCE, V211, P182, DOI 10.1126/science.6255566; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; WASSLE H, 1991, VISUAL NEUROSCI, V7, P99, DOI 10.1017/S095252380001097X; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; WASSLE H, 1981, PROC R SOC SER B-BIO, V212, P177, DOI 10.1098/rspb.1981.0033; WONG ROL, 1991, J NEUROBIOL, V22, P685, DOI 10.1002/neu.480220704	32	185	187	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					144	146		10.1038/364144a0	http://dx.doi.org/10.1038/364144a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8100613				2022-12-24	WOS:A1993LL36700048
J	MILLER, JD				MILLER, JD			NEUROSURGERY - SURGICAL EXCISION FOR SINGLE CEREBRAL METASTASIS	LANCET			English	Editorial Material							BRAIN				MILLER, JD (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BLACK P, 1979, NEUROSURGERY, V5, P617, DOI 10.1227/00006123-197911000-00015; CAIRNCROSS JG, 1980, ANN NEUROL, V7, P529, DOI 10.1002/ana.410070606; PATCHELL RA, 1990, NEW ENGL J MED, V322, P494, DOI 10.1056/NEJM199002223220802; Thomas D G, 1989, Br J Neurosurg, V3, P321, DOI 10.3109/02688698909002810; TODD NV, 1987, LANCET, V1, P611; VECHT CJ, 1993, ANN NEUROL, V33, P583, DOI 10.1002/ana.410330605	6	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 19	1993	341	8860					1566	1566		10.1016/0140-6736(93)90702-I	http://dx.doi.org/10.1016/0140-6736(93)90702-I			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099645				2022-12-24	WOS:A1993LH55000009
J	TALLIS, R				TALLIS, R			GERIATRICS - HOW LONG SHOULD ELDERLY PATIENTS TAKE ANTIDEPRESSANTS	LANCET			English	Editorial Material											TALLIS, R (corresponding author), UNIV MANCHESTER,DEPT GERIATR MED,MANCHESTER M13 9PL,LANCS,ENGLAND.							Angst J., 1992, LONG TERM TREATMENT, P1; Cartwright A, 1988, ELDERLY PEOPLE THEIR; COLE MG, 1990, CAN MED ASSOC J, V143, P633; FRANK E, 1992, LONG TERM TREATMENT, P197; HOEPER EW, 1984, LANCET, V1, P33; LINDLEY CM, 1992, AGE AGEING, V21, P294, DOI 10.1093/ageing/21.4.294; MEYER RB, 1992, OXFORD TXB GERIATRIC, P105; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; WILLIAMSON J, 1980, AGE AGEING, V9, P73, DOI 10.1093/ageing/9.2.73; 1993, BRIT J PSYCHIAT, V162, P175	10	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 5	1993	341	8858					1444	1445		10.1016/0140-6736(93)90887-M	http://dx.doi.org/10.1016/0140-6736(93)90887-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099146				2022-12-24	WOS:A1993LF84100009
J	SALK, J; BRETSCHER, PA; SALK, PL; CLERICI, M; SHEARER, GM				SALK, J; BRETSCHER, PA; SALK, PL; CLERICI, M; SHEARER, GM			A STRATEGY FOR PROPHYLACTIC VACCINATION AGAINST HIV	SCIENCE			English	Editorial Material							CELL-MEDIATED-IMMUNITY; CYTOTOXIC T-CELLS; SUBSETS; HELPER; LEISHMANIASIS; RESPONSES; INFECTION; IMMUNIZATION; INDUCTION; ENVELOPE		UNIV SASKATCHEWAN, DEPT MICROBIOL, SASKATOON S7N 0X0, SK, CANADA; JONAS SALK FDN, LA JOLLA, CA 92037 USA; NCI, EXPTL IMMUNOL BRANCH, BETHESDA, MD 20892 USA	University of Saskatchewan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SALK, J (corresponding author), SALK INST BIOL STUDIES, POB 85800, SAN DIEGO, CA 92138 USA.			Clerici, Mario/0000-0001-5920-6191				ALDOVINI A, 1991, NATURE, V351, P479, DOI 10.1038/351479a0; ASHERSON GL, 1965, IMMUNOLOGY, V9, P205; BLOOM BR, 1992, IMMUNOL TODAY, V13, P131, DOI 10.1016/0167-5699(92)90110-S; BORKOWSKY W, 1990, AIDS RES HUM RETROV, V6, P673, DOI 10.1089/aid.1990.6.673; BRETSCHER PA, 1974, CELL IMMUNOL, V13, P171, DOI 10.1016/0008-8749(74)90237-8; BRETSCHER PA, 1992, IMMUNOL TODAY, V13, P342, DOI 10.1016/0167-5699(92)90168-7; BRETSCHER PA, 1991, RES IMMUNOL, V142, P45, DOI 10.1016/0923-2494(91)90011-7; BRETSCHER PA, 1981, FED PROC, V40, P1473; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; BRETSCHER PA, UNPUB; CHEYNIER R, 1992, EUR J IMMUNOL, V22, P2211, DOI 10.1002/eji.1830220905; CLERICI M, 1991, J INFECT DIS, V164, P178, DOI 10.1093/infdis/164.1.178; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; CLERICI M, 1993, IN PRESS 9 INT C AID; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; DOLAN MJ, 1993, IN PRESS 9 INT C AID; ELLNER JJ, 1990, MICROBIAL DETERMINANTS OF VIRULENCE AND HOST RESPONSE, P77; EMINI EA, 1990, J VIROL, V64, P3674, DOI 10.1128/JVI.64.8.3674-3678.1990; FITZGERALD TJ, 1992, INFECT IMMUN, V60, P3475, DOI 10.1128/IAI.60.9.3475-3479.1992; GAZZINELLI RT, 1992, J IMMUNOL, V148, P182; Gervais Francine, 1992, Immunology and Infectious Diseases (Oxford), V2, P179; HAMMOND SA, 1992, J EXP MED, V176, P1531, DOI 10.1084/jem.176.6.1531; HART MK, 1991, P NATL ACAD SCI USA, V88, P9448, DOI 10.1073/pnas.88.21.9448; HOM RC, 1991, J VIROL, V65, P220, DOI 10.1128/JVI.65.1.220-224.1991; HOWARD JG, 1986, INT REV EXP PATHOL, V28, P79; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; KELKER HC, 1992, AIDS RES HUM RETROV, V8, P1355, DOI 10.1089/aid.1992.8.1355; KOUP RA, 1993, FRONTIERS HIV PATHOG, P220; LAGRANGE PH, 1974, J EXP MED, V139, P528, DOI 10.1084/jem.139.3.528; LASARTE JJ, 1992, CELL IMMUNOL, V141, P211, DOI 10.1016/0008-8749(92)90140-K; LEVIN J, 1992, pA35; LEVY JA, 1989, JAMA-J AM MED ASSOC, V261, P2997, DOI 10.1001/jama.261.20.2997; LEVY JA, 1988, JAMA-J AM MED ASSOC, V259, P3037, DOI 10.1001/jama.259.20.3037; LOCKSLEY RM, 1991, IMMUNOPARASITOL TOD, pA58, DOI 10.1016/S0167-5699(05)80017-9; MOSMANN T, 1991, IMMUNOL TODAY, V12, P257, DOI 10.1016/0167-5699(91)90121-9; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; PEARSON RD, 1983, REV INFECT DIS, V5, P907; Plotkin SA, 1988, VACCINES-BASEL; PRINCE AM, 1991, AIDS RES HUM RETROV, V7, P971, DOI 10.1089/aid.1991.7.971; PUTKONEN P, 1991, NATURE, V352, P436, DOI 10.1038/352436a0; RAMSHAW I, 1992, IMMUNOL REV, V127, P157, DOI 10.1111/j.1600-065X.1992.tb01413.x; RAMSHAW IA, 1977, EUR J IMMUNOL, V7, P180, DOI 10.1002/eji.1830070313; RAMSHAW IA, 1976, EUR J IMMUNOL, V6, P674, DOI 10.1002/eji.1830061003; RAMSHAW IA, 1977, CELL IMMUNOL, V31, P364, DOI 10.1016/0008-8749(77)90038-7; RANKI A, 1989, AIDS, V3, P63, DOI 10.1097/00002030-198902000-00002; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SALK J, 1969, ANN NY ACAD SCI, V164, P365, DOI 10.1111/j.1749-6632.1969.tb14051.x; SASTRY KJ, 1992, VIROLOGY, V188, P502, DOI 10.1016/0042-6822(92)90504-I; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1991, IMMUNOL TODAY, V12, P346, DOI 10.1016/0167-5699(91)90063-Y; SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337; SHEARER GM, 1992, CHEM IMMUNOL, V54, P21; SHEARER GM, 1992, J CELL BIOCH E S, V16, P112; SHEARER GM, 1993, IN PRESS 9 INT C AID; SHER A, 1992, ANNU REV IMMUNOL, V127, P183; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TAKAHASHI H, 1990, NATURE, V344, P873, DOI 10.1038/344873a0; Turk J L, 1971, Adv Immunol, V13, P209, DOI 10.1016/S0065-2776(08)60185-6; TUTTOSI S, 1992, J IMMUNOL, V148, P397; VENET A, IN PRESS AIDS; WEISS SH, IN PRESS 9 INT C AID; WORTIS HH, 1968, IMMUNOLOGY, V14, P69; YASUTOMI Y, 1993, J VIROL, V67, P1707, DOI 10.1128/JVI.67.3.1707-1711.1993; YSSEL H, 1991, J EXP MED, V174, P593, DOI 10.1084/jem.174.3.593	69	193	211	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1993	260	5112					1270	1272		10.1126/science.8098553	http://dx.doi.org/10.1126/science.8098553			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8098553				2022-12-24	WOS:A1993LE02500032
J	NEWMAN, WP; MIDDAUGH, JP; PROPST, MT; ROGERS, DR				NEWMAN, WP; MIDDAUGH, JP; PROPST, MT; ROGERS, DR			ATHEROSCLEROSIS IN ALASKA NATIVES AND NON-NATIVES	LANCET			English	Note								Low mortality from coronary heart disease (CHD) among Eskimos has been attributed to less atherosclerosis in the coronary arteries because of a high dietary intake of omega-3 fatty acids. Other investigators attribute this low mortality to the fact that Eskimos have a high mortality from other causes before middle age, when CHD is common. However, most studies have been epidemiological, either by death-certificate review or risk-factor evaluation. We evaluated the extent of atherosclerotic lesions in the coronary arteries and aortas from Alaska Natives. Standardised comparisons between samples from 103 Native and 101 non-native residents show that the extent of raised lesions increases with age in both groups, but the prevalence of raised lesions in native specimens was consistently lower than in those from non-natives. This difference was statistically significant. The data suggest that the differences in CHD mortality between Alaska Natives and non-natives are, at least in part, the result of less atherosclerosis in natives.	ALASKA DIV PUBL HLTH,ANCHORAGE,AK; ALASKA MED EXAMINERS,ANCHORAGE,AK		NEWMAN, WP (corresponding author), LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT PATHOL,1901 PERDIDO ST,NEW ORLEANS,LA 70112, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042082] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42082] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANG HO, 1971, LANCET, V1, P1143, DOI 10.1016/S0140-6736(71)91658-8; Bang HO, 1980, ADV NUTR RES, P1, DOI [DOI 10.1007/978-1-4757-4448-4_1, 10.1007/978-1-4757-4448-4_1]; BJERREGAARD P, 1988, INT J EPIDEMIOL, V17, P514, DOI 10.1093/ije/17.3.514; GUZMAN MA, 1974, LAB INVEST, V31, P398; GUZMAN MA, 1968, LAB INVEST, V18, P479; MIDDAUGH JP, 1990, AM J PUBLIC HEALTH, V80, P282, DOI 10.2105/AJPH.80.3.282; STRONG JP, 1978, LAB INVEST, V39, P358; TEJADA C, 1968, LAB INVEST, V18, P509; 1990, JAMA-J AM MED ASSOC, V264, P3018	9	115	118	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1056	1057		10.1016/0140-6736(93)92413-N	http://dx.doi.org/10.1016/0140-6736(93)92413-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096960				2022-12-24	WOS:A1993KZ01800006
J	HARDING, MJ; PAUL, J; GILLIS, CR; KAYE, SB				HARDING, MJ; PAUL, J; GILLIS, CR; KAYE, SB			MANAGEMENT OF MALIGNANT TERATOMA - DOES REFERRAL TO A SPECIALIST UNIT MATTER	LANCET			English	Article							GERM-CELL TUMORS; TESTICULAR TERATOMA; CANCER; CISPLATIN; SURVIVAL; BLEOMYCIN; ETOPOSIDE; SCOTLAND	The causes of geographical differences in cancer survival among regions of the UK are unclear. Population-based audit of management of patients with non-seminomatous germ-cell tumours (NSGCT) in the west of Scotland enabled us to assess the relative contributions to outcome of recognised prognostic factors, treatment centre, and protocol treatment. Data on treatment and outcome were analysed for 440 (97%) of 454 men with NSGCT diagnosed between 1975 and 1989. All but 11 patients were treated at tertiary referral centres; 235 were treated at a single unit (unit 1) and 194 at four other units (2-5). 99 men have died, 89 (20%) from NSGCT. Independent prognostic factors for NSGCT survival were extent of tumour at diagnosis (p < 0.001), 5-year period of diagnosis (from 1975-79 to 1985-89, p < 0.001), and treatment unit (unit 1 vs units 2-5, p < 0.001). Unit 1, which had the best survival rates, treated most patients overall (53%), including the majority (70%) in the worst prognostic category (poor-prognosis metastatic disease). The proportion of men receiving nationally agreed protocol treatment was higher at unit 1 than elsewhere (97 vs 61%, p < 0.0001). However, analysis restricted to men who received protocol treatment, Adjusted for other important prognostic variables, still showed a survival advantage for this unit (relative death rate units 2-5 vs unit 1, 2.82 [95% Cl 1.53-5.19], p < 0.001). These findings suggest that centralisation of treatment for NSGCT improves outcome; the benefit seems to be additional to any advantage resulting from protocol treatment.	WESTERN INFIRM & ASSOCIATED HOSP,BEATSON ONCOL CTR,DEPT MED ONCOL,CANC RES CAMPAIGN,GLASGOW G11 6NT,SCOTLAND; RUCHILL HOSP,W SCOTLAND GREATER GLASGOW HLTH BOARD,CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,SCOTLAND	Beatson Oncology Centre				Paul, James/0000-0001-7367-5816				AASS N, 1991, J CLIN ONCOL, V9, P818, DOI 10.1200/JCO.1991.9.5.818; ARMITAGE P, 1987, STATISTICAL METHODS; BOYLE P, 1987, EUR J CANCER CLIN ON, V23, P827, DOI 10.1016/0277-5379(87)90286-0; CHARLTON JRH, 1983, LANCET, V1, P691; CHILVERS CED, 1989, BRIT J CANCER, V59, P126, DOI 10.1038/bjc.1989.25; COX DR, 1972, J R STAT SOC B, V34, P187; EINHORN LH, 1977, ANN INTERN MED, V87, P292; FREEDMAN LS, 1987, LANCET, V2, P294; GILLIS CR, 1991, LANCET, V337, P611, DOI 10.1016/0140-6736(91)91673-I; GRAHAM J, 1988, BRIT J CANCER, V57, P182, DOI 10.1038/bjc.1988.38; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARJALAINEN S, 1989, BMJ-BRIT MED J, V299, P1069, DOI 10.1136/bmj.299.6707.1069; LOEHRER PJ, 1986, J CLIN ONCOL, V4, P528, DOI 10.1200/JCO.1986.4.4.528; MCARDLE CS, 1991, BRIT MED J, V302, P1501, DOI 10.1136/bmj.302.6791.1501; MEAD GM, 1992, J CLIN ONCOL, V10, P85, DOI 10.1200/JCO.1992.10.1.85; NEWLANDS ES, 1986, BRIT J UROL, V58, P307, DOI 10.1111/j.1464-410X.1986.tb09061.x; OLIVER RTD, 1986, BRIT MED J, V292, P641, DOI 10.1136/bmj.292.6521.641; PECKHAM MJ, 1983, BRIT J CANCER, V47, P613, DOI 10.1038/bjc.1983.99; Silman A J, 1981, Community Med, V3, P291, DOI 10.1007/BF02549184; STILLER CA, 1988, ARCH DIS CHILD, V63, P23, DOI 10.1136/adc.63.1.23; THORNHILL JA, 1988, BRIT J UROL, V61, P244, DOI 10.1111/j.1464-410X.1988.tb06388.x; WILLIAMS SD, 1987, NEW ENGL J MED, V316, P1435, DOI 10.1056/NEJM198706043162302; WILSON S, 1992, J PUBLIC HEALTH MED, V14, P151; 1985, LANCET, V1, P8	24	130	130	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					999	1002		10.1016/0140-6736(93)91082-W	http://dx.doi.org/10.1016/0140-6736(93)91082-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096954				2022-12-24	WOS:A1993KY36800014
J	FALLA, TJ; DOBSON, SRM; CROOK, DWM; KRAAK, WAG; NICHOLS, WW; ANDERSON, EC; JORDENS, JZ; SLACK, MPF; MAYONWHITE, D; MOXON, ER				FALLA, TJ; DOBSON, SRM; CROOK, DWM; KRAAK, WAG; NICHOLS, WW; ANDERSON, EC; JORDENS, JZ; SLACK, MPF; MAYONWHITE, D; MOXON, ER			POPULATION-BASED STUDY OF NONTYPABLE HAEMOPHILUS-INFLUENZAE INVASIVE DISEASE IN CHILDREN AND NEONATES	LANCET			English	Article							NONTYPABLE HEMOPHILUS-INFLUENZAE; DNA PROBE; MENINGITIS; INFECTIONS; PROFILES; REGION	The extent of non-capsulate, non-serotypable Haemophilus influenzae (NST) as a cause of serious invasive disease in children has not been fully defined. We describe the epidemiology of these childhood infections from cases identified during a continuing prospective survey of invasive H influenzae disease in the Oxford region, U K. 408 strains of H influenzae were isolated from cases of invasive disease. 383 (94%) were H influenzae type b (Hib), 24 (6%) were NST strains, and 1 was a type f strain. 3 of the NST strains were non-capsulate type b mutants (b), but the remaining 21 strains were from the phylogenetically distinct and heterogeneous population of non-capsulate H influenzae (NC). 10 of the NC strains were isolated from neonates with sepsis; crude mortality rate was 40%, with an incidence of 4.6 cases per 100 000 livebirths. 11 NC strains were isolated from children after the neonatal period and under 10 years of age, 4 (36%) of which had severe, unrelated, predisposing conditions. The incidence of NC invasive diseases in these children was 0.5 per 100 000 per year. The attributable mortality for these infections was 10%. Infections due to these H influenzae strains are, after the implementation of Hib vaccines, likely to persist and represent a substantial proportion of the serious infections caused by this species.	JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND; DEPT PUBL HLTH,OXFORD,ENGLAND	University of Oxford	FALLA, TJ (corresponding author), JOHN RADCLIFFE HOSP,PUBL HLTH LAB,OXFORD OX3 9DU,ENGLAND.		Jordens, Janet Z/C-7890-2011					BARENKAMP SJ, 1981, J INFECT DIS, V143, P668, DOI 10.1093/infdis/143.5.668; BOOY R, 1992, ARCH DIS CHILD, V67, P475, DOI 10.1136/adc.67.4.475; BRUCE KD, 1991, J CLIN MICROBIOL, V29, P291, DOI 10.1128/JCM.29.2.291-296.1991; DOBSON SRM, 1992, INFECT IMMUN, V60, P618, DOI 10.1128/IAI.60.2.618-622.1992; ESKOLA J, 1992, J INFECT DIS S1, V165, P137; FADEN H, 1991, PEDIATR INFECT DIS J, V10, P254, DOI 10.1097/00006454-199103000-00020; FRIESEN CA, 1986, REV INFECT DIS, V8, P777; HOISETH SK, 1985, INFECT IMMUN, V49, P389, DOI 10.1128/IAI.49.2.389-395.1985; KILIAN M, 1976, J GEN MICROBIOL, V93, P9, DOI 10.1099/00221287-93-1-9; KROLL JS, 1991, MOL CELL PROBE, V5, P375, DOI 10.1016/S0890-8508(06)80009-5; KROLL JS, 1990, MOL MICROBIOL, V4, P1853, DOI 10.1111/j.1365-2958.1990.tb02034.x; MURPHY TF, 1987, REV INFECT DIS, V9, P1; MURPHY TF, 1983, J INFECT DIS, V147, P838, DOI 10.1093/infdis/147.5.838; MUSSER JM, 1990, REV INFECT DIS, V12, P75; PITCHER DG, 1987, FEMS MICROBIOL LETT, V48, P283, DOI 10.1016/0378-1097(87)90177-7; PITCHER DG, 1989, LETT APPL MICROBIOL, V8, P151, DOI 10.1111/j.1472-765X.1989.tb00262.x; QUENTIN R, 1990, J GEN MICROBIOL, V136, P1203, DOI 10.1099/00221287-136-7-1203; SANTOSHAM M, 1992, J INFECT DIS S1, V165, P144; SHANN F, 1984, LANCET, V2, P537; TAKALA AK, 1991, ARCH DIS CHILD-FETAL, V66, P437, DOI 10.1136/adc.66.4_Spec_No.437; TUDORWILLIAMS G, 1989, ARCH DIS CHILD, V64, P517, DOI 10.1136/adc.64.4.517; VANALPHEN L, 1983, J INFECT DIS, V148, P75, DOI 10.1093/infdis/148.1.75; VANKETEL RJ, 1990, J MED MICROBIOL, V33, P271, DOI 10.1099/00222615-33-4-271; WALLACE RJ, 1983, REV INFECT DIS, V5, P123; WEINBERG GA, 1989, J INFECT DIS, V160, P634, DOI 10.1093/infdis/160.4.634; WENGER JD, 1992, J INFECT DIS, V165, pS34, DOI 10.1093/infdis/165-Supplement_1-S34; 1988, KEY POPULATION VITAL	27	90	92	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					851	854		10.1016/0140-6736(93)93059-A	http://dx.doi.org/10.1016/0140-6736(93)93059-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096561				2022-12-24	WOS:A1993KV81100003
J	LINDSAY, R				LINDSAY, R			PREVENTION AND TREATMENT OF OSTEOPOROSIS	LANCET			English	Article							HORMONE-REPLACEMENT THERAPY; POSTMENOPAUSAL BONE LOSS; FLUORIDE TREATMENT; SODIUM-FLUORIDE; BREAST-CANCER; HIP FRACTURE; WOMEN; RISK; ESTROGEN; DENSITY		COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA	Columbia University	LINDSAY, R (corresponding author), HELEN HAYES HOSP, DEPT MED, ROUTE 9W, W HAVERSTRAW, NY 10993 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039191] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39191] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNETT TR, 1986, J BONE MINER RES, V1, pA99; Avioli Louis V., 1993, P137; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; Carter D. R., 1990, J BONE MINER RES  S1, V5, P177, DOI [DOI 10.1002/JBMR.5650051372, 10.1002/jbmr.5650051372]; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CHESNUT CH, 1983, METABOLISM, V32, P571, DOI 10.1016/0026-0495(83)90027-6; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; DELMAS PD, 1990, J BONE MINER RES  S1, V5, P143; EASTELL R, 1992, CLIN SCI, V83, P375, DOI 10.1042/cs0830375; FOGELMAN I, 1988, NUCL MED COMMUN, V9, P541, DOI 10.1097/00006231-198808000-00001; GALLAGHER JC, 1982, P NATL ACAD SCI-BIOL, V79, P3325, DOI 10.1073/pnas.79.10.3325; HEANEY RP, 1993, ANNU REV NUTR, V13, P287, DOI 10.1146/annurev.nu.13.070193.001443; HEDLUND LR, 1989, J BONE MINER RES, V4, P223; HULKA BS, 1990, CA-CANCER J CLIN, V40, P289, DOI 10.3322/canjclin.40.5.289; JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204; JOHNSTON CC, 1989, J BONE MINER RES S2, V4, P1; Kleerekoper M, 1991, Osteoporos Int, V1, P155, DOI 10.1007/BF01625446; KOMAR L, IN PRESS J AM GERIAT; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LINDSAY R, 1978, CLIN SCI MOL MED, V54, P193, DOI 10.1042/cs0540193; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LINDSAY R, 1988, OSTEOPOROSIS ETIOLOG, P333; MAMELLE N, 1988, LANCET, V2, P361, DOI 10.1016/S0140-6736(88)92834-6; MELTON LJ, 1983, OSTEOPOROTIC SYNDROM, P45; Muff R, 1991, Osteoporos Int, V1, P72, DOI 10.1007/BF01880446; OTT SM, 1989, ANN INTERN MED, V110, P267, DOI 10.7326/0003-4819-110-4-267; PARISIEN M, 1990, J CLIN ENDOCR METAB, V70, P930, DOI 10.1210/jcem-70-4-930; RAY WA, 1989, LANCET, V1, P687; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; REGINSTER JY, 1987, LANCET, V2, P1481; REID IR, 1993, NEW ENGL J MED, V328, P460, DOI 10.1056/NEJM199302183280702; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539; STEVENSON JC, 1990, LANCET, V336, P265, DOI 10.1016/0140-6736(90)91801-G; TURKEN S, 1989, J NATL CANCER I, V81, P1086, DOI 10.1093/jnci/81.14.1086; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201	38	88	89	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	1993	341	8848					801	805		10.1016/0140-6736(93)90571-W	http://dx.doi.org/10.1016/0140-6736(93)90571-W			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096009				2022-12-24	WOS:A1993KU90000014
J	JEFFCOATE, W				JEFFCOATE, W			ALCOHOL-INDUCED PSEUDO-CUSHINGS SYNDROME	LANCET			English	Editorial Material							PLASMA-CORTISOL; BLOOD-PRESSURE; ADRENOCORTICOTROPIN; HYPOGLYCEMIA; RESPONSES; DISEASE; ETHANOL				JEFFCOATE, W (corresponding author), CITY HOSP NOTTINGHAM,DEPT MED,HUCKNALL RD,NOTTINGHAM NG5 1PB,ENGLAND.							BANNAN LT, 1984, CLIN SCI, V66, P659, DOI 10.1042/cs0660659; BERMAN JD, 1990, J CLIN ENDOCR METAB, V71, P712, DOI 10.1210/jcem-71-3-712; BERTAGNA X, 1992, NEW ENGL J MED, V327, P1024, DOI 10.1056/NEJM199210013271410; CHALMERS RJ, 1978, BRIT MED J, V1, P745, DOI 10.1136/bmj.1.6115.745; CRAPO L, 1979, METABOLISM, V28, P955, DOI 10.1016/0026-0495(79)90097-0; CZAJA E, 1961, CAN J BIOCHEM PHYSIO, V39, P327; DAVE JR, 1986, ENDOCRINOLOGY, V118, P280, DOI 10.1210/endo-118-1-280; DAVIS JRE, 1983, CLIN ENDOCRINOL, V19, P461, DOI 10.1111/j.1365-2265.1983.tb00020.x; ELLIS FW, 1966, J PHARMACOL EXP THER, V153, P121; FINK RS, 1981, CLIN ENDOCRINOL, V15, P97, DOI 10.1111/j.1365-2265.1981.tb02755.x; GLASS AR, 1981, METABOLISM, V30, P89, DOI 10.1016/0026-0495(81)90224-9; HASSELBALCH H, 1982, CLIN ENDOCRINOL, V16, P73, DOI 10.1111/j.1365-2265.1982.tb03149.x; JEFFCOATE WJ, 1980, PHARMACOL BIOCHEM BE, V13, P145, DOI 10.1016/S0091-3057(80)80023-2; JENKINS JS, 1968, BRIT MED J, V2, P804, DOI 10.1136/bmj.2.5608.804; KIRKMAN S, 1988, METABOLISM, V37, P390, DOI 10.1016/0026-0495(88)90141-2; MARKS V, 1977, P ROY SOC MED, V70, P337, DOI 10.1177/003591577707000511; MENDELSON JH, 1966, PSYCHOSOM MED, V28, P616, DOI 10.1097/00006842-196607000-00037; MERRY J, 1972, LANCET, V2, P990; PAGE SR, 1990, CLIN ENDOCRINOL, V33, P761, DOI 10.1111/j.1365-2265.1990.tb03913.x; ROSMAN PM, 1982, J CLIN ENDOCR METAB, V55, P709, DOI 10.1210/jcem-55-4-709; SMALS AG, 1976, BRIT MED J, V2, P1298, DOI 10.1136/bmj.2.6047.1298; STOTT DJ, 1987, CLIN SCI, V73, P411, DOI 10.1042/cs0730411; STREETEN DH, 1969, J CLIN ENDOCR METAB, V29, P1191, DOI 10.1210/jcem-29-9-1191; UR E, 1991, BAILLIERE CLIN ENDOC, V5, P79	24	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					676	677		10.1016/0140-6736(93)90434-I	http://dx.doi.org/10.1016/0140-6736(93)90434-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095582				2022-12-24	WOS:A1993KR61300017
J	BRAHAMS, D				BRAHAMS, D			PERSISTENT VEGETATIVE STATE	LANCET			English	Editorial Material																			0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					428	428						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094184				2022-12-24	WOS:A1993KM41600020
J	BENEDIKTSSON, R; LINDSAY, RS; NOBLE, J; SECKL, JR; EDWARDS, CRW				BENEDIKTSSON, R; LINDSAY, RS; NOBLE, J; SECKL, JR; EDWARDS, CRW			GLUCOCORTICOID EXPOSURE INUTERO - NEW MODEL FOR ADULT HYPERTENSION	LANCET			English	Note							PROTEIN-TURNOVER; GROWTH; RATS; WEIGHT; FETAL	Hypertension is strongly predicted by the combination of low birthweight and a large placenta. This association could be due to increased fetal exposure to maternal glucocorticoids. Fetal protection is normally effected by placental 11beta-hydroxysteroid dehydrogenase (11beta-OHSD), which converts physiological glucocorticoids to inactive products. We found that rat placental 11beta-OHSD activity correlated positively with term fetal weight and negatively with placental weight. Offspring of rats treated during pregnancy with dexamethasone (which is not metabolised by 11beta-OHSD) had lower birthweights and higher blood pressure when adult than did offspring of control rats. Increased fetal glucocorticoid exposure secondary to attenuated placental 11beta-OHSD activity may link low birthweight and high placental weight with hypertension.	UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh			Seckl, Jonathan R/C-3555-2013; Benediktsson, Rafn/R-2457-2018	Benediktsson, Rafn/0000-0002-2954-9801; Lindsay, Robert/0000-0002-9868-5217	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALEXANDER G, 1978, ABNORMAL FETAL GROWT, P149; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BEITINS IZ, 1973, PEDIATR RES, V7, P509, DOI 10.1203/00006450-197305000-00004; CANAVAN JP, 1988, DIABETES, V37, P1671, DOI 10.2337/diabetes.37.12.1671; EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A; HELLER CL, 1988, J STEROID BIOCHEM, V31, P119, DOI 10.1016/0022-4731(88)90214-2; REINISCH JM, 1978, SCIENCE, V202, P436, DOI 10.1126/science.705336; ROBINSON J, 1988, DIABETES, V37, P1665, DOI 10.2337/diabetes.37.12.1665; TONOLO G, 1988, J HYPERTENS, V6, P25	10	724	734	0	25	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					339	341		10.1016/0140-6736(93)90138-7	http://dx.doi.org/10.1016/0140-6736(93)90138-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094115				2022-12-24	WOS:A1993KK93900006
J	HEDRICK, MH; JENNINGS, RW; MACGILLIVRAY, TE; RICE, HE; FLAKE, AW; ADZICK, NS; HARRISON, MR				HEDRICK, MH; JENNINGS, RW; MACGILLIVRAY, TE; RICE, HE; FLAKE, AW; ADZICK, NS; HARRISON, MR			CHRONIC FETAL VASCULAR ACCESS	LANCET			English	Note							DIAPHRAGMATIC-HERNIA; MANAGEMENT	Intensive management of the fetus is limited by our inability to achieve access to the fetal circulation. Using laparoscopic surgery, we can maintain long-term access to the fetal circulation by extra-amniotic catheterisation of chorionic vessels in third-trimester monkeys and early-gestation sheep. We can sample fetal blood, continuously measure blood pressure, and infuse drugs without complications. Safe vascular access will permit assessment of fetal status during fetal surgical procedures and improve postoperative monitoring.			HEDRICK, MH (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT SURG,CTR FETAL TREATMENT,ROOM 1601-HSW,BOX 0570,SAN FRANCISCO,CA 94143, USA.		Harrison, Michael/GYD-8608-2022					HARRISON MR, 1982, J PEDIATR SURG, V17, P115, DOI 10.1016/S0022-3468(82)80193-0; HARRISON MR, 1990, NEW ENGL J MED, V322, P1582, DOI 10.1056/NEJM199005313222207; HARRISON MR, 1980, SURGERY, V88, P174; HARRISON MR, 1982, J PEDIATR SURG, V17, P728, DOI 10.1016/S0022-3468(82)80437-5; HARRISON MR, 1990, LANCET, V336, P965, DOI 10.1016/0140-6736(90)92420-M; HEDRICK MH, 1993, TRANSPLANT SCI, V3, P23; HEDRICK MH, 1992, SURG FORUM, P504; JENNINGS R W, 1991, Surgical Forum (Chicago), V42, P575; RICE HE, IN PRESS SURG FORUM	9	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1086	1087		10.1016/0140-6736(93)92065-2	http://dx.doi.org/10.1016/0140-6736(93)92065-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105313				2022-12-24	WOS:A1993ME82200011
J	MEADE, TW; RUDDOCK, V; STIRLING, Y; CHAKRABARTI, R; MILLER, GJ				MEADE, TW; RUDDOCK, V; STIRLING, Y; CHAKRABARTI, R; MILLER, GJ			FIBRINOLYTIC-ACTIVITY, CLOTTING FACTORS, AND LONG-TERM INCIDENCE OF ISCHEMIC-HEART-DISEASE IN THE NORTHWICK-PARK-HEART-STUDY	LANCET			English	Article							MYOCARDIAL-INFARCTION; HEMOSTATIC FUNCTION; IMPAIRED FIBRINOLYSIS; PLASMINOGEN-ACTIVATOR; CORRELATED EXPOSURES; RISK FACTOR; PLASMA; FIBRINOGEN; DEATH	Fibrinolytic activity (FA) was measured by dilute blood clot lysis time at entry to the Northwick Park Heart Study in 1382 white men aged 40-64, of whom 179 subsequently experienced episodes of ischaemic heart disease during a mean follow-up period of 16.1 years. There was a significant interaction between age and low FA (p = 0.02) with respect to ischaemic heart disease: a difference of one standard deviation in FA was associated with a difference of about 40% in ischaemic heart disease risk (p = 0.002) in those aged 40-54 at entry. The FA association remained after adjusting for plasma fibrinogen. High fibrinogen concentrations themselves were also associated with ischaemic heart disease, as was high factor VII activity with fatal events. Low FA in younger men may exert a long-term influence by impairing the removal of fibrin deposits that contribute to atherogenesis. Low FA appears to be a leading determinant of ischaemic heart disease in younger men and methods of enhancing fibrinolytic activity, whether by life-style changes or pharmacologically, should be considered.			MEADE, TW (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,MRC,EPIDEMIOL & MED CARE UNIT,LONDON EC1M 6BQ,ENGLAND.							ASHFORD TP, 1968, AM J PATHOL, V53, P599; CHAKRABARTI R, 1968, LANCET, V1, P987; CHAKRABARTI R, 1978, THROMB HAEMOSTASIS, V39, P450; CHAKRABARTI R, 1962, J CLIN PATHOL, V15, P228, DOI 10.1136/jcp.15.3.228; FOLSOM AR, 1993, ARTERIOSCLER THROMB, V13, P162, DOI 10.1161/01.ATV.13.2.162; FRANCIS RB, 1988, AM HEART J, V115, P776, DOI 10.1016/0002-8703(88)90878-2; HAMSTEN A, 1986, BRIT HEART J, V55, P58; HAMSTEN A, 1987, LANCET, V2, P3; HEINRICH J, IN PRESS ARTERIOSCLE; HICKMAN JA, 1973, J CLIN PATHOL, V26, P189, DOI 10.1136/jcp.26.3.189; JANSSON JH, 1991, EUR HEART J, V12, P157, DOI 10.1093/oxfordjournals.eurheartj.a059862; MEADE TW, 1987, LANCET, V2, P986; MEADE TW, 1977, BRIT MED BULL, V33, P283, DOI 10.1093/oxfordjournals.bmb.a071448; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEADE TW, 1980, LANCET, V1, P1050; MILLER GJ, 1991, LANCET, V338, P1079, DOI 10.1016/0140-6736(91)91936-O; MILLER GJ, IN PRESS THROMB HAEM; MUSSONI L, 1992, ARTERIOSCLER THROMB, V12, P19, DOI 10.1161/01.ATV.12.1.19; PEDERSEN OD, 1993, EUR HEART J, V14, P785, DOI 10.1093/eurheartj/14.6.785; PHILLIPS AN, 1992, STAT MED, V11, P953, DOI 10.1002/sim.4780110712; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; PRINS MH, 1991, AM HEART J, V122, P545, DOI 10.1016/0002-8703(91)91014-E; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; SMITH EB, 1987, FIBRINOGEN, V2, P115; TORBJORN K, 1987, THROMB RES, V48, P621; WALMSLEY D, 1991, DIABETIC MED, V8, P954, DOI 10.1111/j.1464-5491.1991.tb01536.x; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; 1976, WHO5 REG OFF EUR	30	704	714	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1076	1079		10.1016/0140-6736(93)92062-X	http://dx.doi.org/10.1016/0140-6736(93)92062-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105310				2022-12-24	WOS:A1993ME82200008
J	CARPENTER, RHS				CARPENTER, RHS			BEYOND THE DARROW-YANNET DIAGRAM - AN ENHANCED PLOT FOR BODY-FLUID SPACES AND OSMOLALITY	LANCET			English	Article								The C-plot is a new method of plotting the volumes and osmolality of extracellular and intracellular body fluids, which in many circumstances is an improvement on the classical Darrow-Yannet diagram. The C-plot allows natural perturbations to be seen easily, and enables the relation between threats to fluid homoeostasis and the physiological mechanisms that counter those threats to be appreciated. The course of such events can also be shown in a single diagram.			CARPENTER, RHS (corresponding author), UNIV CAMBRIDGE,PHYSIOL LAB,CAMBRIDGE CB2 3EG,ENGLAND.			Carpenter, Roger/0000-0003-2572-1448				Darrow DC, 1935, J CLIN INVEST, V14, P266, DOI 10.1172/JCI100674; Kindig N B, 1983, Physiologist, V26, P304; SIGAARDANDERSEN O, 1971, SCAND J LAB INVEST, V27, P239	3	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					968	970		10.1016/0140-6736(93)92007-G	http://dx.doi.org/10.1016/0140-6736(93)92007-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105219				2022-12-24	WOS:A1993MC00500014
J	BENSON, JR; BAUM, M				BENSON, JR; BAUM, M			BREAST-CANCER, DESMOID TUMORS, AND FAMILIAL ADENOMATOUS POLYPOSIS - A UNIFYING HYPOTHESIS	LANCET			English	Article							GROWTH; FIBROBLASTS; FETAL; CARCINOMA; INVITRO; INVIVO; CELLS; BETA	There is widespread agreement that epithelial tumours develop as a consequence of primary events within epithelial cells. According to the monoclonal theory, a tumour is caused by genetic change within a single cell, which imparts a selective growth advantage. This simple theory fails to take into account two important concepts. First, tumour generation is likely to involve multiple genetic events, some of which initiate a tumour, and others promote its growth.1 Second, tumours are usually composed of several tissue components, although they are known by the dominant proliferative cell type. This convention has tended to obscure the importance of ''secondary'' tissue components in carcinogenesis, despite evidence for the involvement of mesenchymal elements both in the induction and maintenance of transformation. To shift emphasis from the monoclonal theory, we propose a unifying hypothesis accounting for the effect of adjuvant tamoxifen in early breast cancer and the association between gastrointestinal polyps and desmoid tumours.	ROYAL MARSDEN HOSP,LONDON SW3 1JJ,ENGLAND	Royal Marsden NHS Foundation Trust	BENSON, JR (corresponding author), INST CANC RES,ACAD SECT SURG,HARTWELL LAB,FULHAM RD,LONDON SW3 1JJ,ENGLAND.							ADAMS EF, 1988, BREAST CANCER RES TR, V11, P165, DOI 10.1007/BF01805840; BAUM M, 1991, BRIT J CANCER, V64, P205, DOI 10.1038/bjc.1991.276; BROOKS MD, 1992, EUR J CANCER, V28A, P1014, DOI 10.1016/0959-8049(92)90445-8; BULOW S, 1987, SEMIN SURG ONCOL, V3, P84, DOI 10.1002/ssu.2980030207; BUTTA A, 1992, CANCER RES, V52, P4261; COLLETTA AA, 1990, BRIT J CANCER, V62, P405, DOI 10.1038/bjc.1990.307; COOPER M, 1977, CANCER RES, V37, P2544; Cunha G R, 1987, Prog Clin Biol Res, V239, P251; CUNHA GR, 1985, CELL DIFFER DEV, V17, P137, DOI 10.1016/0045-6039(85)90481-6; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; GORSCH SM, 1992, CANCER RES, V52, P6949; GREY AM, 1989, P NATL ACAD SCI USA, V86, P2438, DOI 10.1073/pnas.86.7.2438; HAGGIE JA, 1987, LANCET, V1, P1455; HERRERA L, 1986, AM J MED GENET, V25, P269; HORGAN K, 1987, BRIT J SURG, V74, P227, DOI 10.1002/bjs.1800740326; HUYNH HT, 1993, CANCER RES, V53, P1727; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIVINGSTONE DM, 1992 WINT M BACR ABP; LONGAKER MT, 1991, PLAST RECONSTR SURG, V87, P788, DOI 10.1097/00006534-199104000-00032; MANNING AM, 1991, ONCOGENE, V6, P1471; NAYLOR EW, 1979, ARCH SURG-CHICAGO, V114, P1181; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; PFEFFER L, 1976, J CELL PHYSIOL, V89, P29, DOI 10.1002/jcp.1040890104; RICHMAN PI, 1988, J PATHOL, V156, P197, DOI 10.1002/path.1711560305; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; WILLIAMS AC, 1990, CANCER RES, V50, P4724; 1992, LANCET, V339, P11; 1992, LANCET, V339, P71	29	34	35	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					848	850		10.1016/0140-6736(93)92700-4	http://dx.doi.org/10.1016/0140-6736(93)92700-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104277				2022-12-24	WOS:A1993MA02500014
J	DEDERA, DA; WALLER, EK; LEBRUN, DP; SENMAJUMDAR, A; STEVENS, ME; BARSH, GS; CLEARY, ML				DEDERA, DA; WALLER, EK; LEBRUN, DP; SENMAJUMDAR, A; STEVENS, ME; BARSH, GS; CLEARY, ML			CHIMERIC HOMEOBOX GENE E2A-PBX1 INDUCES PROLIFERATION, APOPTOSIS, AND MALIGNANT-LYMPHOMAS IN TRANSGENIC MICE	CELL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; C-MYC EXPRESSION; PRE-B; CELL-DEATH; TRANSCRIPTION FACTORS; NEGATIVE SELECTION; ENHANCER BINDING; DNA-BINDING; N-MYC; BCL-2	Expression of the homeobox fusion gene E2A-PBX1 under control of the immunoglobulin heavy chain enhancer efficiently induced malignancies in transgenic mice. All animals died before 5 months of age with lymphomas that demonstrated phenotypes consistent with transitional intermediate thymocytes (CD4+/CD8+/CD3med). E2A-PBX1 also markedly altered lymphoid development in pretumorous animals, reducing the number of thymocytes and bone marrow B lineage progenitors to 20% of normal levels. In spite of the observed reductions in lymphoid cells, premalignant animals contained significantly increased numbers of cycling thymocytes, but a higher proportion was also undergoing apoptosis, suggesting that increased cell death resulted in the marked lymphopenias. These data indicate that the chimeric homeodomain protein E2A-PBX1 paradoxically induces both proliferation and apoptosis in lymphoid cells, suggesting an in vivo association between nuclear oncogene-induced cell cycle progression and programed cell death.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT RADIAT ONCOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	DEDERA, DA (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305, USA.		Waller, Edmund K/AAP-3055-2020		NATIONAL CANCER INSTITUTE [R01CA042971, R37CA042971] Funding Source: NIH RePORTER; NCI NIH HHS [CA42971] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ASKEW DS, 1991, ONCOGENE, V6, P1915; BINDL JM, 1986, AM J CLIN PATHOL, V85, P490, DOI 10.1093/ajcp/85.4.490; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLANKENSTEIN T, 1988, NUCLEIC ACIDS RES, V16, P10939, DOI 10.1093/nar/16.22.10939; BOROWITZ MJ, 1993, BLOOD, V82, P1086; CARROLL AJ, 1984, BLOOD, V63, P721; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FISCH P, 1992, ONCOGENE, V7, P2389; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; GROSSCHEDL R, 1984, CELL, V38, P647, DOI 10.1016/0092-8674(84)90259-9; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; Hogan B., 1986, MANIPULATING MOUSE E; HOLLANDER Z, 1988, CYTOMETRY, V9, P485, DOI 10.1002/cyto.990090513; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MELLENTIN JD, 1990, GENE CHROMOSOME CANC, V2, P239, DOI 10.1002/gcc.2870020313; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PRIVITERA E, 1992, BLOOD, V79, P1781; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SENMAJUMDAR A, 1990, J IMMUNOL, V144, P111; SENMAJUMDAR A, 1992, J EXP MED, V176, P543, DOI 10.1084/jem.176.2.543; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TILLY JL, 1992, MOL ENDOCRINOL, V6, P1942, DOI 10.1210/me.6.11.1942; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251	52	184	188	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					833	843		10.1016/0092-8674(93)90463-Z	http://dx.doi.org/10.1016/0092-8674(93)90463-Z			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8104101				2022-12-24	WOS:A1993LX29200009
J	HUSSELL, T; ISAACSON, PG; CRABTREE, JE; SPENCER, J				HUSSELL, T; ISAACSON, PG; CRABTREE, JE; SPENCER, J			THE RESPONSE OF CELLS FROM LOW-GRADE B-CELL GASTRIC LYMPHOMAS OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE TO HELICOBACTER-PYLORI	LANCET			English	Article							PROLIFERATION; ANTIGEN; MICE	An association has been shown between colonisation of gastric mucosa by Helicobacter pylori, acquisition of mucosa-associated lymphoid tissue (MALT), and occurrence of primary B-cell gastric MALT lymphoma. We investigated the immunological response of cells from 3 low-grade primary B-cell gastric MALT lymphomas to H pylori type NCTC 11637 and 12 isolates of H pylori from patients without lymphomas. After co-culture of tumour cells with bacteria, cells were examined for phenotypic evidence of activation and proliferation, and supernatant assayed to detect tumour-derived immunoglobulin and interleukin-2 (IL-2). Neoplastic B cells and non-neoplastic T cells proliferated, and IL-2-receptor expression by most cells in the cultures was increased with stimulating strains of H pylori. There were also increases in tumour immunoglobulin and IL-2 release when activation and proliferation were seen in response to stimulating bacteria. Removal of T cells from the tumour cell suspension reduced proliferation and IL-2-receptor expression. In comparison, no responses were seen in cells from high-grade gastric MALT lymphomas or low-grade B-cell MALT lymphomas of other sites. The response of low-grade B-cell gastric MALT lymphomas to stimulating strains of H pylori is dependent on H-pylori-specific T cells and their products, rather than the bacteria themselves.	UCL,SCH MED,DEPT HISTOPATHOL,UNIV ST,LONDON WC1E 6JJ,ENGLAND; ST JAMES HOSP,DEPT CLIN MED,LEEDS,ENGLAND	University of London; University College London; UCL Medical School; Saint James's University Hospital			Hussell, Tracy/O-4630-2014; Crabtree, Jean E/A-3549-2010	Hussell, Tracy/0000-0001-7186-6141; Spencer, Jo/0000-0002-7202-2431				AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P6221, DOI 10.1093/nar/20.23.6221; BEVERLEY PCL, 1981, EUR J IMMUNOL, V126, P2117; CARACCI A, 1993, P NATL ACAD SCI USA, V90, P5791; COGLIATTI SB, 1991, GASTROENTEROLOGY, V101, P1159, DOI 10.1016/0016-5085(91)90063-Q; CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; GERDES J, 1984, J IMMUNOL, V133, P1710; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HUSSELL T, 1993, AM J PATHOL, V142, P285; HUSSELL T, 1993, J PATHOL, V169, P221, DOI 10.1002/path.1711690208; ISAACSON PG, 1987, HISTOPATHOLOGY, V11, P445, DOI 10.1111/j.1365-2559.1987.tb02654.x; MASON DY, 1990, AM J PATHOL, V136, P1215; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SMITH KA, 1988, SCIENCE, V240, P1164; SPENCER J, 1990, J PATHOL, V160, P231, DOI 10.1002/path.1711600309; THOMAS JE, 1992, LANCET, V340, P1194, DOI 10.1016/0140-6736(92)92894-L; UMETSU DT, 1990, J IMMUNOL, V144, P2550; VERONESE ML, 1992, J EXP MED, V176, P1763, DOI 10.1084/jem.176.6.1763; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z	20	719	745	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					571	574		10.1016/0140-6736(93)91408-E	http://dx.doi.org/10.1016/0140-6736(93)91408-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102718				2022-12-24	WOS:A1993LV96300008
J	EDWARDSON, JA; MOORE, PB; FERRIER, IN; LILLEY, JS; NEWTON, GWA; BARKER, J; TEMPLAR, J; DAY, JP				EDWARDSON, JA; MOORE, PB; FERRIER, IN; LILLEY, JS; NEWTON, GWA; BARKER, J; TEMPLAR, J; DAY, JP			EFFECT OF SILICON ON GASTROINTESTINAL ABSORPTION OF ALUMINUM	LANCET			English	Note							ALZHEIMERS-DISEASE; CITRATE	The reported geographical association between Alzheimer's disease and levels of aluminium (Al) in water supplies may reflect the inverse relation between Al and silicon (Si) concentrations in water, and the potential for Si to reduce the bioavailability of the metal. We tested this hypothesis using isotopic Al-26 tracer administered orally to five healthy volunteers in the presence and absence of Si. Dissolved Si, at a concentration found in some water suplies (100 mumol/L), reduced the peak plasma Al-26 concentration to 15% of the value obtained in the absence of Si. The results indicate that dissolved Si is an important factor in limiting the absorption of dietary Al.	SERC, DARESBURY LAB, NUCL STRUCT FACIL, WARRINGTON WA4 4AD, CHESHIRE, ENGLAND; UNIV MANCHESTER, DEPT CHEM, MANCHESTER M13 9PL, LANCS, ENGLAND	STFC Daresbury Laboratory; University of Manchester	EDWARDSON, JA (corresponding author), NEWCASTLE GEN HOSP, MRC, NEUROCHEM PATHOL UNIT, NEWCASTLE UPON TYNE NE4 6BE, TYNE & WEAR, ENGLAND.		Barker, James/A-5103-2018	Barker, James/0000-0002-5863-9400				BARKER J, 1990, NUCL INSTRUM METH B, V52, P540, DOI 10.1016/0168-583X(90)90473-8; BIRCHALL JD, 1989, LANCET, V1, P953; Birchall JD, 1991, ALUMINIUM CHEM BIOL, P53; DAY JP, 1991, LANCET, V337, P1345, DOI 10.1016/0140-6736(91)93016-3; EDWARDSON JA, 1992, ALUMINIUM CHEM BIOL, P85; GREGER JL, 1992, CIBA F SYMP, V169, P26; Martyn C N, 1992, Ciba Found Symp, V169, P69; MOORE PB, 1992, ANN M ROYAL COLLEGE; SLANINA P, 1984, FOOD CHEM TOXICOL, V22, P391, DOI 10.1016/0278-6915(84)90369-7; TAYLOR GA, 1992, AGE AGEING, V21, P81, DOI 10.1093/ageing/21.2.81	10	134	138	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 24	1993	342	8865					211	212		10.1016/0140-6736(93)92301-9	http://dx.doi.org/10.1016/0140-6736(93)92301-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100932				2022-12-24	WOS:A1993LN62200014
J	CRAIG, EA				CRAIG, EA			CHAPERONES - HELPERS ALONG THE PATHWAYS TO PROTEIN-FOLDING	SCIENCE			English	Editorial Material							PRECURSOR PROTEINS; YEAST MITOCHONDRIA; TRANSLOCATION; MATRIX; IMPORT; HSP70				CRAIG, EA (corresponding author), UNIV WISCONSIN,DEPT BIOMOLEC CHEM,MADISON,WI 53706, USA.							BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BERTSCH U, 1992, P NATL ACAD SCI USA, V89, P8696, DOI 10.1073/pnas.89.18.8696; CHEN WJ, 1987, J BIOL CHEM, V262, P15605; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CRAIG EA, 1993, MICROBIOL REV, V57, P293; EPSTEIN CJ, 1963, COLD SPRING HARB SYM, V28, P439, DOI 10.1101/SQB.1963.028.01.060; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P316; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; NELSON R J, 1992, Current Biology, V2, P487, DOI 10.1016/0960-9822(92)90673-X; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; OSTERMANN J, 1990, FEBS LETT, V277, P281, DOI 10.1016/0014-5793(90)80865-G; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885	17	167	197	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1902	1903		10.1126/science.8100364	http://dx.doi.org/10.1126/science.8100364			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8100364				2022-12-24	WOS:A1993LJ34900030
J	POTTS, M; CARSWELL, W				POTTS, M; CARSWELL, W			INFECTION - AIDS - LOSING THE BATTLE AND THE WAR	LANCET			English	Editorial Material									UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720	University of California System; University of California Berkeley	POTTS, M (corresponding author), INT FAMILY HLTH,LONDON,ENGLAND.							SHELTON JD, 1992, LANCET, V340, P1334, DOI 10.1016/0140-6736(92)92505-A; 1992, AIDS ASSESSMENT PLAN	2	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 5	1993	341	8858					1442	1443		10.1016/0140-6736(93)90885-K	http://dx.doi.org/10.1016/0140-6736(93)90885-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099144				2022-12-24	WOS:A1993LF84100007
J	REDMAN, CWG; ROBERTS, JM				REDMAN, CWG; ROBERTS, JM			MANAGEMENT OF PREECLAMPSIA	LANCET			English	Article							ANTIHYPERTENSIVE TREATMENT; SEVERE PREECLAMPSIA; CONTROLLED TRIAL; PREGNANCY; HYPERTENSION; ATENOLOL; TOXEMIA; CALCIUM; ASPIRIN		UNIV PITTSBURGH, MAGEE WOMENS HOSP, DEPT OBSTET GYNECOL & REPROD SCI, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	REDMAN, CWG (corresponding author), JOHN RADCLIFFE HOSP, NUFFIELD DEPT OBSTET & GYNAECOL, OXFORD OX3 9DU, ENGLAND.		Roberts, James/AAI-3283-2020	Roberts, James/0000-0002-2671-3207				[Anonymous], 1993, Lancet, V341, P396; BEAUFILS M, 1985, LANCET, V1, P840, DOI 10.1016/S0140-6736(85)92207-X; BELFORT MA, 1992, AM J OBSTET GYNECOL, V167, P661, DOI 10.1016/S0002-9378(11)91567-1; BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; BLAKE S, 1991, BRIT J OBSTET GYNAEC, V98, P244, DOI 10.1111/j.1471-0528.1991.tb13387.x; BUTTERS L, 1990, BMJ-BRIT MED J, V301, P587, DOI 10.1136/bmj.301.6752.587; CHUA S, 1991, LANCET, V337, P250, DOI 10.1016/0140-6736(91)92227-S; COLLINS R, 1991, OXFORD DATABASE PERI; DEKKER GA, 1993, AM J OBSTET GYNECOL, V168, P214, DOI 10.1016/S0002-9378(12)90917-5; DOMMISSE J, 1990, BRIT J OBSTET GYNAEC, V97, P104, DOI 10.1111/j.1471-0528.1990.tb01734.x; DULEY L, 1992, OXFORD DATABASE PERI; FENAKEL K, 1991, OBSTET GYNECOL, V77, P331; GOODLIN RC, 1978, LANCET, V2, P51; HALL MH, 1980, LANCET, V2, P78; HUTTON JD, 1992, BRIT J OBSTET GYNAEC, V99, P554, DOI 10.1111/j.1471-0528.1992.tb13819.x; IMPERIALE TF, 1991, JAMA-J AM MED ASSOC, V266, P261; MCCARRON DA, 1982, NEW ENGL J MED, V307, P226, DOI 10.1056/NEJM198207223070405; OLSEN SF, 1990, BRIT J NUTR, V64, P599, DOI 10.1079/BJN19900063; PRITCHARD JA, 1984, AM J OBSTET GYNECOL, V148, P951, DOI 10.1016/0002-9378(84)90538-6; REDMAN CWG, 1976, LANCET, V2, P753; REDMAN CWG, 1978, BRIT MED J, V1, P467, DOI 10.1136/bmj.1.6111.467; REDMAN CWG, 1989, TXB OBSTETRICS, P515; ROBINSON M, 1958, LANCET, V1, P178; RUBIN PC, 1983, LANCET, V1, P431; RYAN G, 1989, AM J OBSTET GYNECOL, V161, P1297, DOI 10.1016/0002-9378(89)90687-X; SCHWARTZ ML, 1985, OBSTET GYNECOL, V66, pS19; SIBAI BM, 1981, OBSTET GYNECOL, V58, P609; TUFFNELL DJ, 1992, LANCET, V339, P224, DOI 10.1016/0140-6736(92)90017-W; WALLENBURG HCS, 1986, LANCET, V1, P1; WEINSTEIN L, 1982, AM J OBSTET GYNECOL, V142, P159, DOI 10.1016/S0002-9378(16)32330-4; 1992, LANCET, V339, P1023; 1946, J OBSTET GYN BR COMM, V53, P498; 1989, LANCET, V2, P482	33	89	91	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	1993	341	8858					1451	1454		10.1016/0140-6736(93)90890-S	http://dx.doi.org/10.1016/0140-6736(93)90890-S			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099149				2022-12-24	WOS:A1993LF84100012
J	CARO, JJ; GROOME, PA; FLEGEL, KM				CARO, JJ; GROOME, PA; FLEGEL, KM			ATRIAL-FIBRILLATION AND ANTICOAGULATION - FROM RANDOMIZED TRIALS TO PRACTICE	LANCET			English	Article							STROKE; FRAMINGHAM; WARFARIN; THERAPY; COMPLICATIONS; PREVENTION; RISK	Randomised trials confirm that anticoagulants reduce the risk of emboli in atrial fibrillation. To apply this evidence to practice, we developed an expression relating all relevant factors. Trial-based estimates of the risks of emboli and haemorrhage, and of the effects of anticoagulants on these risks were used to derive the extent to which haemorrhage has to be seen to be more detrimental than emboli to justify not using anticoagulants. Information from other studies was used to assess the risks for the types of patients not included in the trials. Haemorrhage needs to be assessed as being at least six times more detrimental than emboli to warrant withholding anticoagulants from patients like those in the trials. Only in patients with lone atrial fibrillation and in those with features suggesting a bleeding risk six times higher than the trials' average would a perception of equal detriment risk justify not giving anticoagulation.	MCGILL UNIV,ROYAL VICTORIA HOSP,DIV GEN INTERNAL MED,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,DIV CLIN EPIDEMIOL,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital				Caro, Jaime/0000-0001-5470-3754				BRAND FN, 1985, JAMA-J AM MED ASSOC, V254, P3449, DOI 10.1001/jama.254.24.3449; CHANG HJ, 1990, ARCH INTERN MED, V150, P81; CONOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; EZEKOWITZ MD, 1991, CIRCULATION S2, V84, P450; FLEGEL KM, 1991, J CLIN EPIDEMIOL, V44, P551, DOI 10.1016/0895-4356(91)90219-Y; FLEGEL KM, 1989, STROKE, V20, P1000, DOI 10.1161/01.STR.20.8.1000; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KUTNER M, 1991, ARCH INTERN MED, V151, P1950, DOI 10.1001/archinte.151.10.1950; LANCASTER TR, 1991, ARCH INTERN MED, V151, P1944, DOI 10.1001/archinte.151.10.1944; LANDEFELD CS, 1987, AM J MED, V82, P703, DOI 10.1016/0002-9343(87)90004-0; PAUKER SG, 1989, CHEST, V95, pS161; PETERSEN P, 1986, STROKE, V17, P622, DOI 10.1161/01.STR.17.4.622; PETERSEN P, 1989, LANCET, V1, P175; SELZER A, 1982, NEW ENGL J MED, V306, P1044, DOI 10.1056/NEJM198204293061709; Sox HC, 1988, MED DECISION MAKING; TSEVAT J, 1989, MED DECIS MAKING, V9, P162, DOI 10.1177/0272989X8900900303; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; 1992, ANN INTERN MED, V116, P6; 1991, CIRCULATION, V84, P527; 1990, NEW ENGL J MED, V323, P1505	23	32	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1381	1384		10.1016/0140-6736(93)90950-L	http://dx.doi.org/10.1016/0140-6736(93)90950-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098799				2022-12-24	WOS:A1993LE18000013
J	ARROLL, B; BEAGLEHOLE, R				ARROLL, B; BEAGLEHOLE, R			HYPERTENSION - EXERCISE FOR HYPERTENSION	LANCET			English	Note							PHYSICAL-ACTIVITY		UNIV AUCKLAND,DEPT GEN PRACTICE,AUCKLAND,NEW ZEALAND	University of Auckland	ARROLL, B (corresponding author), UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND.							BLAIR SN, 1992, ANNU REV PUBL HEALTH, V13, P99, DOI 10.1146/annurev.pu.13.050192.000531; Bouchard C, 1988, EXERCISE FITNESS HLT, P147; HAGBERG JM, 1989, AM J CARDIOL, V64, P348, DOI 10.1016/0002-9149(89)90533-X; HARRIS KA, 1987, MED SCI SPORT EXER, V19, P246; HURLEY BF, 1984, MED SCI SPORT EXER, V16, P483, DOI 10.1249/00005768-198410000-00011; JHURLEY BF, 1988, MED SCI SPORTS EXERC, V20, P150; MEREDITH IT, 1990, J HYPERTENS, V8, P859, DOI 10.1097/00004872-199009000-00010; NELSON L, 1986, LANCET, V2, P473, DOI 10.1016/S0140-6736(86)90354-5; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; SEALS DR, 1984, MED SCI SPORT EXER, V16, P207; SISCOVICK DS, 1984, NEW ENGL J MED, V311, P874, DOI 10.1056/NEJM198410043111402	11	14	15	2	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1248	1249		10.1016/0140-6736(93)91152-C	http://dx.doi.org/10.1016/0140-6736(93)91152-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098398				2022-12-24	WOS:A1993LC49700010
J	LERMAN, A; GIBBONS, RJ; RODEHEFFER, RJ; BAILEY, KR; MCKINLEY, LJ; HEUBLEIN, DM; BURNETT, JC				LERMAN, A; GIBBONS, RJ; RODEHEFFER, RJ; BAILEY, KR; MCKINLEY, LJ; HEUBLEIN, DM; BURNETT, JC			CIRCULATING N-TERMINAL ATRIAL-NATRIURETIC-PEPTIDE AS A MARKER FOR SYMPTOMLESS LEFT-VENTRICULAR DYSFUNCTION	LANCET			English	Article							CONGESTIVE-HEART-FAILURE; MYOCARDIAL-INFARCTION; FACTOR PROHORMONE	Early identification of patients with symptomless left-ventricular dysfunction and early pharmacologic intrervention may have an impact on the outlook of patients with heart failure. Atrial natriuretic peptide (ANP) is a cardiac hormone that is released as a C-terminal (C-ANP) and an N-terminal peptide (N-ANP).Since N-ANP has reduced clearance rates compared with C-ANP, N-ANP circulates at higher concentrations. Based on the known increased concentration of C-ANP in symptomatic congestive heart failure, our study was designed to evaluate prospectively N-ANP profile and left-ventricular function in subjects with symptomless and symptomatic heart failure, and the role of plasma N-ANP as a marker for early identification of patients with heart failure. 180 patients who were referred for rest and exercise radionuclide angiography for evaluation of left-ventricular function were studied. Blood was taken for measurement of C-ANP and N-ANP before angiography. Patients were grouped according to New York Heart Association (NYHA) heart failure classification and left-ventricular function. Mean (SD) plasma N-ANP concentration in patients with symptomless left-ventricular dysfunction (NYHA class I, n=70) was 243 (256) pmol/L (range 27-922 pmol/L), and was higher (p<0.001) than in 25 control subjects (28 [13] pmol/L). A plasma N-ANP concentration above 54 pmol/L (mean+/-1.96SD of the control group) had a sensitivity of 90% and a specificity of 92% for detection of patients-with symptomless left-ventricular dysfunction. We have shown that plasma N-ANP concentrations are significantly increased in patients with symptomless left-ventricular dysfunction and that this peptide can serve as a marker for diagnosis of such patients.			LERMAN, A (corresponding author), MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,DIV CARDIOVASC DIS,CARDIORENAL RES LAB,ROCHESTER,MN 55905, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036634] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36634, HL0711] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER BJ, 1991, AM HEART J, V122, P1395, DOI 10.1016/0002-8703(91)90583-4; BURNETT JC, 1986, SCIENCE, V231, P1145, DOI 10.1126/science.2935937; CALIFF RM, 1982, CONGESTIVE HEART FAI, P31; CALLAHAN RJ, 1982, J NUCL MED, V23, P315; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN JN, 1982, NEW ENGL J MED, V306, P1129, DOI 10.1056/NEJM198205133061902; CURRIE MG, 1983, SCIENCE, V221, P71, DOI 10.1126/science.6857267; DAVIS KM, 1992, JAMA-J AM MED ASSOC, V267, P2625, DOI 10.1001/jama.267.19.2625; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; DEHMER GJ, 1980, AM J CARDIOL, V45, P293, DOI 10.1016/0002-9149(80)90648-7; FEDERMAN J, 1978, MAYO CLIN P, V53, P623; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; GIBBONS RJ, 1987, J AM COLL CARDIOL, V10, P33, DOI 10.1016/S0735-1097(87)80156-0; GIBBONS RJ, 1991, CIRCULATION S1, V84, P93; GLEMBOTSKI CC, 1988, J BIOL CHEM, V263, P16073; HEUBLEIN D M, 1989, Journal of the American College of Cardiology, V13, p9A; MASSIE BM, 1987, CIRCULATION, V75, P11; PEVAHOUSE JB, 1989, CLIN RES, V37, P583; RAINE AEG, 1986, NEW ENGL J MED, V315, P53; SANZ G, 1982, NEW ENGL J MED, V306, P1065, DOI 10.1056/NEJM198205063061801; SCHULZE RA, 1977, AM J MED, V62, P192, DOI 10.1016/0002-9343(77)90314-X; SHARPE N, 1988, LANCET, V1, P255; SUNDSFJORD JA, 1988, J CLIN ENDOCR METAB, V66, P605, DOI 10.1210/jcem-66-3-605; SVANEGAARD J, 1992, BRIT HEART J, V68, P38; WINTERS CJ, 1989, CIRCULATION, V80, P438, DOI 10.1161/01.CIR.80.3.438; WINTERS CJ, 1988, BIOCHEM BIOPH RES CO, V150, P231, DOI 10.1016/0006-291X(88)90510-4; WINTERS CJ, 1988, CHRONOBIOL INT, V5, P301; YUSUF S, 1989, HYPERTENSION S5, V13, P174; 1991, NEW ENGL J MED, V325, P293; 1992, NEW ENGL J MED, V327, P685	30	288	300	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1105	1109		10.1016/0140-6736(93)93125-K	http://dx.doi.org/10.1016/0140-6736(93)93125-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097801				2022-12-24	WOS:A1993KZ68700001
J	GINTY, DD; KORNHAUSER, JM; THOMPSON, MA; BADING, H; MAYO, KE; TAKAHASHI, JS; GREENBERG, ME				GINTY, DD; KORNHAUSER, JM; THOMPSON, MA; BADING, H; MAYO, KE; TAKAHASHI, JS; GREENBERG, ME			REGULATION OF CREB PHOSPHORYLATION IN THE SUPRACHIASMATIC NUCLEUS BY LIGHT AND A CIRCADIAN CLOCK	SCIENCE			English	Article							C-FOS TRANSCRIPTION; GENE-EXPRESSION; RHYTHMS; PROTEIN; SYSTEM	Mammalian circadian rhythms are regulated by a pacemaker within the suprachiasmatic nuclei (SCN) of the hypothalamus. The molecular mechanisms controlling the synchronization of the circadian pacemaker are unknown; however, immediate early gene (IEG) expression in the SCN is tightly correlated with entrainment of SCN-regulated rhythms. Antibodies were isolated that recognize the activated, phosphorylated form of the transcription factor cyclic adenosine monophosphate response element binding protein (CREB). Within minutes after exposure of hamsters to light, CREB in the SCN became phosphorylated on the transcriptional regulatory site, Ser133. CREB phosphorylation was dependent on circadian time: CREB became phosphorylated only at times during the circadian cycle when light induced IEG expression and caused phase shifts of circadian rhythms. These results implicate CREB in neuronal signaling in the hypothalamus and suggest that circadian clock gating of light-regulated molecular responses in the SCN occurs upstream of phosphorylation of CREB.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; NORTHWESTERN UNIV,NSF,CTR BIOL TIMING,EVANSTON,IL 60208; NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208; NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,EVANSTON,IL 60208	Harvard University; Harvard Medical School; National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University; Northwestern University; Northwestern University			Takahashi, Joseph S/E-8482-2012; Takahashi, Joseph S./Y-2781-2019	Takahashi, Joseph S/0000-0003-0384-8878; Takahashi, Joseph S./0000-0003-0384-8878	NIMH NIH HHS [F31 MH10241] Funding Source: Medline; NINDS NIH HHS [F32 NS08764, NS 28829] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH010241] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS008764, R37NS028829, R01NS028829] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE H, 1991, NEUROSCI LETT, V127, P9, DOI 10.1016/0304-3940(91)90881-S; ABE H, 1992, BRAIN RES BULL, V28, P831, DOI 10.1016/0361-9230(92)90269-4; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; COLWELL CS, 1990, BRAIN RES, V523, P117, DOI 10.1016/0006-8993(90)91643-U; COLWELL CS, 1992, J BIOL RHYTHMS; COMB M, 1987, TRENDS NEUROSCI, V10, P473, DOI 10.1016/0166-2236(87)90103-2; EBLING FJP, 1991, J NEUROENDOCRINOL, V3, P641, DOI 10.1111/j.1365-2826.1991.tb00329.x; Ginty D D, 1992, Curr Opin Neurobiol, V2, P312, DOI 10.1016/0959-4388(92)90121-Z; GINTY DD, UNPUB; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; MEIJER JH, 1989, PHYSIOL REV, V69, P671, DOI 10.1152/physrev.1989.69.3.671; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; PITTENDRIGH CS, 1981, HDB BEHAVIORAL NEURO, V4, P95; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; TAKAHASHI JS, 1984, NATURE, V308, P186, DOI 10.1038/308186a0; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2	30	762	776	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 9	1993	260	5105					238	241		10.1126/science.8097062	http://dx.doi.org/10.1126/science.8097062			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8097062				2022-12-24	WOS:A1993KW45200046
J	PLAYFORD, RJ; WOODMAN, AC; CLARK, P; WATANAPA, P; VESEY, D; DEPREZ, PH; WILLIAMSON, RCN; CALAM, J				PLAYFORD, RJ; WOODMAN, AC; CLARK, P; WATANAPA, P; VESEY, D; DEPREZ, PH; WILLIAMSON, RCN; CALAM, J			EFFECT OF LUMINAL GROWTH-FACTOR PRESERVATION ON INTESTINAL GROWTH	LANCET			English	Article							RAT; PROLIFERATION; MUCOSA; GUT	Intestinal atrophy contributes to the clinical difficulties of patients who cannot eat normally. Atrophy is prevented by luminal food proteins but not by the equivalent amino acids. This observation is not explained by current theories of intestinal physiology. Epidermal growth factor (EGF) and transforming growth factor alpha (TGFalpha) are secreted into the gut lumen. We speculated that these are digested by pancreatic enzymes in fasting juice, but preserved when food proteins block the active sites of these enzymes. Studies based on molecular size and bioactivity confirmed that fasting human jejunal juice destroys EGF and TGFalpha. EGF, but not TGFalpha, was preserved when the milk protein casein or an enzyme inhibitor were present; elemental diets were ineffective. Diversion of pancreatic juice to the mid point of the small intestine in rats significantly increased luminal EGF-like bioactivity and all variables of growth in the proximal enzyme-free segment. Our findings support a novel mechanism of control of intestinal growth, which has important clinical implications. The addition of enzyme-inhibiting proteins such as casein to elemental diets may preserve intestinal integrity and function.	ROYAL POSTGRAD MED SCH, DEPT SURG, LONDON W12 0NN, ENGLAND; ROYAL POSTGRAD MED SCH, DEPT PHYS, LONDON W12 0NN, ENGLAND	Imperial College London; Imperial College London	PLAYFORD, RJ (corresponding author), ROYAL POSTGRAD MED SCH, DEPT MED, GASTROENTEROL UNIT, DU CANE RD, LONDON W12 0NN, ENGLAND.		Deprez, Pierre/AAC-5546-2019; Vesey, David A/C-2253-2011	Deprez, Pierre/0000-0001-8926-8967; Vesey, David A/0000-0002-2856-6650; Playford, Raymond/0000-0003-1235-8504				ALVERDY JC, 1988, SURGERY, V104, P185; BRAGG LE, 1991, NUTRITION, V7, P237; CHALLACOMBE DN, 1991, GUT, V32, P991, DOI 10.1136/gut.32.9.991; GOODLAD RA, 1987, GUT, V28, P573, DOI 10.1136/gut.28.5.573; LIDDLE RA, 1986, AM J PHYSIOL, V251, pG243, DOI 10.1152/ajpgi.1986.251.2.G243; MIURA S, 1992, GUT, V33, P484, DOI 10.1136/gut.33.4.484; MORIN CL, 1980, DIGEST DIS SCI, V25, P123, DOI 10.1007/BF01308310; NEWMAN BM, 1988, DIGESTION, V41, P172, DOI 10.1159/000199770; OLSEN PS, 1986, GASTROENTEROLOGY, V90, P911, DOI 10.1016/0016-5085(86)90867-X; POULSEN SS, 1987, SCAND J GASTROENTERO, V22, P20, DOI 10.3109/00365528709090965; ROYSTON JP, 1983, J ROY STAT SOC D-STA, V32, P297, DOI 10.2307/2987935; Schweder T., 1981, Applied Statistics, V30, P16, DOI 10.2307/2346653; SELDEN C, 1989, J HEPATOL, V9, P167, DOI 10.1016/0168-8278(89)90047-0; TERPSTRA OT, 1981, GASTROENTEROLOGY, V81, P475; ULSHEN MH, 1986, GASTROENTEROLOGY, V91, P1134, DOI 10.1016/S0016-5085(86)80008-7; VESEY DA, 1992, GUT, V33, P831, DOI 10.1136/gut.33.6.831; Winer BJ, 1971, STATISTICAL PRINCIPL, P201	17	98	101	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	1993	341	8849					843	848		10.1016/0140-6736(93)93057-8	http://dx.doi.org/10.1016/0140-6736(93)93057-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096559				2022-12-24	WOS:A1993KV81100001
J	CAMPBELL, IT; SWAN, G				CAMPBELL, IT; SWAN, G			RESUSCITATION - GUIDELINES AND TRAINING IN CARDIOPULMONARY-RESUSCITATION	LANCET			English	Editorial Material											CAMPBELL, IT (corresponding author), WITHINGTON HOSP,DEPT OBSTET & GYNAECOL,MANCHESTER M20 8LR,LANCS,ENGLAND.							HERSHEY CO, 1982, LANCET, V1, P31, DOI 10.1016/S0140-6736(82)92567-3; PEDOE HT, 1992, BRIT MED J, V304, P1347; POSWILLO D, 1990, GENERAL ANAESTHESIA; SACK JB, 1992, JAMA-J AM MED ASSOC, V267, P379; SKINNER DV, 1985, BRIT MED J, V290, P1549, DOI 10.1136/bmj.290.6481.1549; WOOG RH, 1987, ANAESTH INTENS CARE, V15, P193, DOI 10.1177/0310057X8701500213; 1992, RESUSCITATION, V24, P111; 1987, J R COLL PHYSICIANS, V21, P1; 1992, RESUSCITATION, V24, P155; 1992, JAMA-J AM MED ASSOC, V268, P2171	10	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					470	471		10.1016/0140-6736(93)90216-4	http://dx.doi.org/10.1016/0140-6736(93)90216-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094496				2022-12-24	WOS:A1993KN13700013
J	THOMSEN, OO; WULFF, HR; MARTIN, A; SINGER, PA				THOMSEN, OO; WULFF, HR; MARTIN, A; SINGER, PA			WHAT DO GASTROENTEROLOGISTS IN EUROPE TELL CANCER-PATIENTS	LANCET			English	Article								This survey concerns the variation in attitudes among European gastroenterologists to truth telling in cases of cancer. Gastroenterologists in all parts of Europe were asked to consider a case of colonic cancer and to state what they would tell the patient and the patient's spouse. 260 replied. Gastroenterologists in northern Europe would usually reveal the diagnosis to both the patient and the patient's spouse, but some would inform only the spouse with the patient's permission. They would sometimes embellish the truth if the cancer had metastasised. Gastroenterologists in southern and eastern Europe would usually conceal the diagnosis from the patient, in many cases even when the patient asked to be told the truth. Most, however, would tell the spouse the full truth about both diagnosis and prognosis. The variation probably reflects differences in both doctors' attitudes and patients' expectations.	MONOBLOCCO OSPED,CATTEDRA MALATTIE APPARATO DIGERENTE,PADUA,ITALY; UNIV TORONTO,CTR BIOETH,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University of Toronto	THOMSEN, OO (corresponding author), UNIV COPENHAGEN,HERLEV HOSP,DEPT MED C,DK-2730 HERLEV,DENMARK.							DALLAVORGIA P, 1992, J MED ETHICS, V18, P67, DOI 10.1136/jme.18.2.67; GILLON R, 1986, PHILOS MED ETHICS, P100	2	148	149	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					473	476		10.1016/0140-6736(93)90218-6	http://dx.doi.org/10.1016/0140-6736(93)90218-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094498				2022-12-24	WOS:A1993KN13700015
J	HO, DD; CAO, YZ; ZHU, TF; FARTHING, C; WANG, N; GU, GL; SCHOOLEY, RT; DAAR, ES				HO, DD; CAO, YZ; ZHU, TF; FARTHING, C; WANG, N; GU, GL; SCHOOLEY, RT; DAAR, ES			IDIOPATHIC CD4+ T-LYMPHOCYTOPENIA - IMMUNODEFICIENCY WITHOUT EVIDENCE OF HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; LYMPHOTROPIC RETROVIRUS; HOMOSEXUAL MEN; DEFICIENCY; RISK; AIDS	Background. The human immunodeficiency virus (HIV), the etiologic agent of the acquired immunodeficiency syndrome (AIDS), infects and depletes CD4+ T lymphocytes. Recently, patients have been described with profound CD4+ T-lymphocytopenia but without evident HIV infection, a condition now termed idiopathic CD4+ T-lymphocytopenia, and a national surveillance network has been set up to investigate such cases. Methods. We studied 12 patients with CD4+ T-lymphocytopenia who were referred to us from three U.S. cities. Blood samples were tested for HIV with specific antibody assays, viral cultures, and polymerase-chain-reaction (PCR) techniques. Results. The patients (10 men and 2 women) ranged in age from 30 to 69 years. Eight had risk factors for HIV infection. The clinical manifestations were heterogeneous: five patients had opportunistic infections, five had syndromes of unknown cause, and two had no symptoms. Two patients died from acute complications of their immunodeficiency. The patients' lowest CD4+ lymphocyte counts ranged from 3 to 308 per cubic millimeter (mean, 149). Three patients had complete or partial spontaneous reversal of the CD4+ T-lymphocytopenia. Concomitant CD8+ T-lymphocytopenia was noted in three patients, and abnormal immunoglobulin levels were found in five. Multiple virologic studies by serologic testing, culture, and PCR were completely negative for HIV in all patients. Conclusions. Our 12 patients with idiopathic CD4+ T-lymphocytopenia appear to be epidemiologically, clinically, and immunologically heterogeneous. It is unclear whether this syndrome is new, transmissible, or acquired. Many of the clinical and immunologic features are distinct from those found in AIDS, and our extensive virologic. studies found no evidence of HIV infection. The cause of this condition remains unknown.	UNIV COLORADO, HLTH SCI CTR, DIV INFECT DIS, DENVER, CO 80262 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR,SCH MED,DEPT MED, DIV INFECT DIS, LOS ANGELES, CA USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	HO, DD (corresponding author), NYU, SCH MED, AARON DIAMOND AIDS RES CTR, 455 1ST AVE, NEW YORK, NY 10016 USA.		Zhu, Tuofu/G-6158-2010		NIAID NIH HHS [AI28747, AI25541, AI27742] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027742, R01AI025541, R01AI028747] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P541; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; CASTRO A, 1992, LANCET, V339, P868, DOI 10.1016/0140-6736(92)90308-P; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; COHEN J, 1992, SCIENCE, V257, P1032, DOI 10.1126/science.257.5073.1032; CORTES E, 1989, NEW ENGL J MED, V320, P953, DOI 10.1056/NEJM198904133201501; COWLEY G, 1992, NEWSWEEK        0727, P41; DAAR ES, 1990, CLIN RES, V38, pA114; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; FRIEDMANKIEN AE, 1990, LANCET, V335, P168, DOI 10.1016/0140-6736(90)90041-3; GAUTIER V, 1991, CLIN EXP ALLERGY, V21, P63, DOI 10.1111/j.1365-2222.1991.tb00805.x; GUPTA S, 1992, P NATL ACAD SCI USA, V89, P7831, DOI 10.1073/pnas.89.16.7831; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JACOBS JL, 1991, NEW ENGL J MED, V324, P246, DOI 10.1056/NEJM199101243240407; KANKI PJ, 1986, SCIENCE, V232, P238, DOI 10.1126/science.3006256; KESSLER H, 1992, Morbidity and Mortality Weekly Report, V41, P578; LAURENCE J, 1992, LANCET, V340, P273, DOI 10.1016/0140-6736(92)92359-N; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; MEYER RD, 1990, J INFECT DIS, V162, P1370, DOI 10.1093/infdis/162.6.1370; MOORE JP, 1992, LANCET, V340, P475, DOI 10.1016/0140-6736(92)91784-6; SMITH DK, 1993, NEW ENGL J MED, V328, P373, DOI 10.1056/NEJM199302113280601; SPIRA TJ, 1992, J CELL BIOCH SE, V16, P56	22	133	136	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1993	328	6					380	385		10.1056/NEJM199302113280602	http://dx.doi.org/10.1056/NEJM199302113280602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL584	8093634				2022-12-24	WOS:A1993KL58400002
J	LION, T; HENN, T; GAIGER, A; KALHS, P; GADNER, H				LION, T; HENN, T; GAIGER, A; KALHS, P; GADNER, H			EARLY DETECTION OF RELAPSE AFTER BONE-MARROW TRANSPLANTATION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA	LANCET			English	Note							POLYMERASE CHAIN-REACTION; CHRONIC MYELOID-LEUKEMIA	In patients with chronic myelogenous leukaemia (CML) treated by allogeneic bone marrow transplantation (BMT), detection of residual leukaemic cells carrying the characteristic bcr/abl rearrangement by highly sensitive techniques, such as qualitative polymerase chain reaction (PCR), is of limited value in predicting disease progression. We have therefore adapted the PCR for quantitative assessment of bcr/abl rearranged cells and applied this technique to the monitoring of residual disease in 28 CML patients during up to 106 months of follow-up after BMT. In 5 patients, quantitative PCR revealed increasing amounts of the pathological bcr/abl message, indicating the presence of a proliferating neoplastic clone, and all 5 had a subsequent relapse of disease. By contrast the remaining 23 patients have been in maintenance-free complete remission for up to 106 months post-BMT. The monitoring by quantitative PCR of residual leukaemic cells during the post-transplant course of CM L patients may allow early detection of relapse and provide a rationale for the timely initiation of treatment.	UNIV VIENNA,DEPT MED 1,A-1010 VIENNA,AUSTRIA	University of Vienna	LION, T (corresponding author), ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,KINDERSPITALGASSE 6,A-1090 VIENNA,AUSTRIA.		Gaiger, Alexander/GVS-1038-2022; Lion, MD, PhD, Professor, Thomas/C-3241-2016	Gaiger, Alexander/0000-0001-6340-3446; Lion, MD, PhD, Professor, Thomas/0000-0001-9346-0994				ARTHUR CK, 1988, BLOOD, V71, P1179; DELAGE R, 1991, BLOOD, V78, P2759; GABERT J, 1989, LANCET, V2, P1125; HUGHES TP, 1991, BLOOD, V77, P874; HUGHES TP, 1990, BONE MARROW TRANSPL, V5, P3; LION T, 1992, LEUKEMIA, V6, P495; LION T, 1992, BLOOD, V79, P3325; LION T, 1991, LEUKEMIA, V5, P156; PIGNON JM, 1990, LEUKEMIA, V4, P83; THOMPSON JD, 1992, BLOOD, V79, P1629	10	121	121	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					275	276		10.1016/0140-6736(93)92619-5	http://dx.doi.org/10.1016/0140-6736(93)92619-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093920				2022-12-24	WOS:A1993KK24500007
J	KREISWIRTH, B; KORNBLUM, J; ARBEIT, RD; EISNER, W; MASLOW, JN; MCGEER, A; LOW, DE; NOVICK, RP				KREISWIRTH, B; KORNBLUM, J; ARBEIT, RD; EISNER, W; MASLOW, JN; MCGEER, A; LOW, DE; NOVICK, RP			EVIDENCE FOR A CLONAL ORIGIN OF METHICILLIN RESISTANCE IN STAPHYLOCOCCUS-AUREUS	SCIENCE			English	Article							EXPRESSION; TRANSPOSON; CLONING; STRAINS; TN554; DNA	Soon after methicillin was introduced into clinical practice in the early 1960s, resistant strains of Staphylococcus aureus (MRSA) appeared, bearing a newly acquired resistance gene, mecA, that encodes a penicillin binding protein, PBP2a. MRSA have spread throughout the world, and an investigation of the clonality of 472 isolates by DNA hybridization was performed. All 472 isolates could be divided into six temporally ordered mecA hybridization patterns, and three of these were subdivided by the chromomosomal transposon Tn554. Each Tn554 pattern occurred in association with one and only one mecA pattern, suggesting that mecA divergence preceded the acquisition of Tn554 in all cases and therefore that mecA may have been acquired just once by S. aureus.	PUBL HLTH RES INST CITY NEW YORK INC, 455 1ST AVE, NEW YORK, NY 10016 USA; NEW YORK CITY DEPT HLTH, BUR LABS, NEW YORK, NY 10016 USA; VET ADM MED CTR, MED SERV, BOSTON, MA 02130 USA; MT SINAI HOSP, DEPT MICROBIOL, TORONTO M5G 1X5, ONTARIO, CANADA; PRINCESS MARGARET HOSP, TORONTO M4X 1K9, ONTARIO, CANADA	New York City Department of Health & Mental Hygiene; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre			Low, Donald/B-1726-2012; McGeer, Allison/AAB-6885-2020; mcgeer, allison/H-7747-2014	McGeer, Allison/0000-0001-5647-6137; mcgeer, allison/0000-0001-5647-6137; Novick, richard/0000-0003-4418-7893	NIAID NIH HHS [AI22159] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022159, R01AI022159] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], COMMUNICATION; BECK WD, 1986, J BACTERIOL, V165, P373, DOI 10.1128/jb.165.2.373-378.1986; BRUMFIT W, 1989, NEW ENGL J MED, V320, P1899; DUBIN DT, 1990, MOL BIOL STAPHYLOCOC, P85; INGLIS B, 1988, J GEN MICROBIOL, V134, P1465; JEVONS MP, 1961, BRIT MED J, V1, P124, DOI 10.1136/bmj.1.5219.124-a; KREISWIRTH BN, 1986, ANN INTERN MED, V105, P704, DOI 10.7326/0003-4819-105-5-704; KREISWIRTH BN, UNPUB; KREISWIRTH BN, 1982, ANN INTERN MED, V96, P978; KREISWIRTH BN, 1990, MOL BIOL STAPHYLOCOC, P521; KROLEWSKI JJ, 1981, J MOL BIOL, V152, P19, DOI 10.1016/0022-2836(81)90093-0; LACEY RW, 1973, J MED MICROBIOL, V6, P511, DOI 10.1099/00222615-6-4-511; MULLIGAN ME, 1991, INFECT CONT HOSP EP, V12, P20, DOI 10.2307/30147085; MUSSER JM, 1992, J CLIN MICROBIOL, V30, P2058, DOI 10.1128/JCM.30.8.2058-2063.1992; NOVICK RP, 1972, J MOL BIOL, V68, P285, DOI 10.1016/0022-2836(72)90214-8; PATTEE PA, 1990, MOL BIOL STAPHYLOCOC, P41; PHILLIPS S, 1979, NATURE, V278, P476, DOI 10.1038/278476a0; SAFIGUEIREDO AM, 1991, J INFECT DIS, V164, P883; SONG M D, 1988, P352; Soolingen DV, 1991, J CLIN MICROBIOL, V29, P2578; SPEAKER MG, 1991, OPHTHALMOLOGY, V98, P639; STEWART G T, 1963, Br Med J, V1, P308; STEWART GC, 1980, J BACTERIOL, V144, P1200, DOI 10.1128/JB.144.3.1200-1202.1980; TESCH W, 1988, ANTIMICROB AGENTS CH, V32, P1494, DOI 10.1128/AAC.32.10.1494; UBUKATA K, 1989, J BACTERIOL, V171, P2882, DOI 10.1128/jb.171.5.2882-2885.1989	25	319	335	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	1993	259	5092					227	230		10.1126/science.8093647	http://dx.doi.org/10.1126/science.8093647			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	8093647				2022-12-24	WOS:A1993KF71900031
J	COX, DR; GREEN, ED; LANDER, ES; COHEN, D; MYERS, RM				COX, DR; GREEN, ED; LANDER, ES; COHEN, D; MYERS, RM			ASSESSING MAPPING PROGRESS IN THE HUMAN-GENOME-PROJECT	SCIENCE			English	Editorial Material							CHROMOSOMES; MODEL		NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	COX, DR (corresponding author), STANFORD UNIV,DEPT GENET,STANFORD,CA 94305, USA.							BRANSCOMB E, 1990, GENOMICS, V8, P315; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; GREEN ED, 1990, SCIENCE, V250, P94, DOI 10.1126/science.2218515; GYAPAY G, 1994, NAT GENET, V7, P248; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; OLSON MV, 1993, COLD SPRING HARB SYM, V58, P349, DOI 10.1101/SQB.1993.058.01.041; VANDENENGH G, 1992, SCIENCE, V257, P1410, DOI 10.1126/science.1388286	7	31	33	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2031	2032		10.1126/science.8091223	http://dx.doi.org/10.1126/science.8091223			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091223				2022-12-24	WOS:A1994PJ91200018
J	BENT, AF; KUNKEL, BN; DAHLBECK, D; BROWN, KL; SCHMIDT, R; GIRAUDAT, J; LEUNG, J; STASKAWICZ, BJ				BENT, AF; KUNKEL, BN; DAHLBECK, D; BROWN, KL; SCHMIDT, R; GIRAUDAT, J; LEUNG, J; STASKAWICZ, BJ			RPS2 OF ARABIDOPSIS-THALIANA - A LEUCINE-RICH REPEAT CLASS OF PLANT-DISEASE RESISTANCE GENES	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; AGROBACTERIUM-TUMEFACIENS; TRANSMEMBRANE PROTEIN; AVIRULENCE; TRANSDUCTION; MUTATIONS; AVRRPT2; IDENTIFICATION; TRANSFORMATION; INVOLVEMENT	Plant disease resistance genes function in highly specific pathogen recognition pathways. RPS2 is a resistance gene of Arabidopsis thaliana that confers resistance against Pseudomonas syringae bacteria that express avirulence gene avrRpt2. RPS2 was isolated by the use of a positional cloning strategy. The derived amino acid sequence of RPS2 contains leucine-rich repeat, membrane-spanning, leucine zipper, and P loop domains. The function of the RPS2 gene product in defense signal transduction is postulated to involve nucleotide triphosphate binding and protein-protein interactions and may also involve the reception of an elicitor produced by the avirulent pathogen.	UNIV CALIF BERKELEY, DEPT PLANT BIOL, BERKELEY, CA 94720 USA; JOHN INNES CTR PLANT SCI RES, CAMBRIDGE LAB, NORWICH NR4 7UJ, ENGLAND; CNRS, INST SCI VEGETALES, F-91198 GIF SUR YVETTE, FRANCE	University of California System; University of California Berkeley; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Bent, Andrew/E-5391-2016	Bent, Andrew/0000-0001-6610-9525; Schmidt, Renate/0000-0002-8037-3581				Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; ATKINSON MM, 1990, PLANT PHYSIOL, V92, P215, DOI 10.1104/pp.92.1.215; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENNETZEN JL, 1992, GENETIC ENG PRINCIPL, V14, P99; BENT AF, UNPUB; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; CHANG SS, 1994, PLANT J, V5, P551, DOI 10.1046/j.1365-313X.1994.5040551.x; CHERRY JM, 1992, PLANT MOL BIOL REP, V10, P308; DANIELS MJ, 1984, J GEN MICROBIOL, V130, P2447; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; DOKE N, 1983, PHYSIOL PLANT PATHOL, V23, P345, DOI 10.1016/0048-4059(83)90019-X; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; Gibson S. I., 1992, Methods in Arabidopsis research., P119; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; INNES RW, 1993, J BACTERIOL, V175, P4859, DOI 10.1128/JB.175.15.4859-4869.1993; JOHAL GS, 1992, SCIENCE, V258, P985, DOI 10.1126/science.1359642; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KEEN NT, 1992, GENES INVOLVED PLANT, V8, P76; KEEN NT, 1993, APPLICATION BIOTECHN, P65; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUNKEL BN, 1993, PLANT CELL, V5, P865, DOI 10.1105/tpc.5.8.865; Lacy G. H., 1982, PHYTOPATHOGENIC PROK, V2, P149; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MINDRINOS M, IN PRESS CELL; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VERAESTRELLA R, 1994, PLANT PHYSIOL, V104, P209, DOI 10.1104/pp.104.1.209; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49; WHITHAM S, IN PRESS CELL; WINANS SC, 1988, J BACTERIOL, V170, P4047, DOI 10.1128/jb.170.9.4047-4054.1988; YU GL, 1993, MOL PLANT MICROBE IN, V6, P434, DOI 10.1094/MPMI-6-434	46	747	835	6	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 23	1994	265	5180					1856	1860		10.1126/science.8091210	http://dx.doi.org/10.1126/science.8091210			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	8091210				2022-12-24	WOS:A1994PH25800030
J	PSATY, BM; SAVAGE, PJ; TELL, GS; POLAK, JF; HIRSCH, CH; GARDIN, JM; MCDONALD, RH				PSATY, BM; SAVAGE, PJ; TELL, GS; POLAK, JF; HIRSCH, CH; GARDIN, JM; MCDONALD, RH			TEMPORAL PATTERNS OF ANTIHYPERTENSIVE MEDICATION USE AMONG ELDERLY PATIENTS - THE CARDIOVASCULAR HEALTH STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; HYPERTENSION; EXPERIENCE; GLUCOSE; THERAPY; TRIAL	Objectives.-To estimate the incidence of newly treated hypertension and to describe the patterns of antihypertensive medication use among those aged 65 years and older. Design.-Medicare eligibility lists from four US communities (Forsyth County, North Carolina; Washington County, Maryland; Sacramento County, California; and Pittsburgh, Pa) were used to obtain a representative sample of 5201 community-dwelling elderly for the Cardiovascular Health Study, a prospective cohort study of risk factors for coronary heart disease and stroke. Participants were examined at baseline and again 1 year later. The two examinations included standardized questionnaires, blood pressure measurements, and the assessment of medication use by medication inventory. In this cohort analysis, we excluded 231 subjects (4.4%) who did not return for follow-up, 69 (1.3%) who had missing data for medications, and another 495 (9.5%) who were taking ''antihypertensive'' medications for an indication other than high blood pressure. Interventions.-None. Results.-Among the 4406 participants, 1613 used antihypertensive medications at both visits. Between the two visits, 144 started and 115 stopped antihypertensive therapy. Among nonusers at baseline, the annual incidence of newly treated hypertension was 5.2% in women and 5.6% in men. Due to the number of participants who stopped therapy, the overall prevalence of antihypertensive treatment increased only slightly, from 40.7% to 41.1% in women and from 37.1% to 38.2% in men, during 1 year of follow-up. After adjustment for age, systolic blood pressure, number of antihypertensive drugs, diabetes, and cardiovascular disease, the newly treated hypertensives were about half as likely as the previously treated hypertensives to receive diuretics (odds ratio [OR], 0.59; P=.008) or beta-blockers (OR, 0.52; P=.01); and they were about twice as likely to receive calcium channel blockers (OR, 1.88; P<.004) or angiotensin converting enzyme inhibitors (OR, 2.40; P<.001). A similar pattern of within-person changes over time was apparent among the continuous users. Conclusions.-Between June 1990 and June 1991, physicians were increasingly prescribing angiotensin converting enzyme inhibitors and calcium channel blockers in place of diuretics and beta-blockers for the treatment of hypertension in elderly patients, especially for those just starting therapy.	UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV PITTSBURGH, DEPT EPIDEMIOL, PITTSBURGH, PA 15260 USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98195 USA; NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, EPIDEMIOL & BIOMETRY PROGRAM, BETHESDA, MD 20892 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PUBL HLTH SCI, WINSTON SALEM, NC 27103 USA; BRIGHAM & WOMENS HOSP, DEPT RADIOL, BOSTON, MA 02115 USA; UNIV CALIF DAVIS, SACRAMENTO MED CTR, DEPT MED, SACRAMENTO, CA 95817 USA; UNIV CALIF IRVINE, DEPT MED, IRVINE, CA 92717 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Wake Forest University; Wake Forest Baptist Medical Center; Harvard University; Brigham & Women's Hospital; University of California System; University of California Davis; University of California System; University of California Irvine	PSATY, BM (corresponding author), CARDIOVASC HLTH STUDY, CTR COORDINATING, CENTURY SQ, SUITE 2025, 1501 4TH AVE, SEATTLE, WA 98101 USA.		Tell, Grethe/G-5639-2015	Tell, Grethe/0000-0003-1386-1638	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085086, N01HC085079] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043201] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43201, N01-HC-85086, N01-HC-85079] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; APPLEGATE WB, 1989, ANN INTERN MED, V110, P901, DOI 10.7326/0003-4819-110-11-901; AVANZINI F, 1989, CLIN CARDIOL, V12, P283; Cochran W.G, 1957, STAT METHODS, V6th ed; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DANNENBERG AL, 1988, AM J PUBLIC HEALTH, V78, P676, DOI 10.2105/AJPH.78.6.676; DANNENBERG AL, 1987, JAMA-J AM MED ASSOC, V257, P1477, DOI 10.1001/jama.257.11.1477; DAVIDSON RA, 1989, J AM GERIATR SOC, V37, P861, DOI 10.1111/j.1532-5415.1989.tb02267.x; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; HARRIS MI, 1985, DIABETES CARE, V8, P562, DOI 10.2337/diacare.8.6.562; MCCLOSKEY LW, 1992, ARCH INTERN MED, V152, P513, DOI 10.1001/archinte.152.3.513; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MITTELMARK MB, 1993, AM J EPIDEMIOL, V137, P311, DOI 10.1093/oxfordjournals.aje.a116678; MOSER M, 1993, ARCH INTERN MED, V153, P1843, DOI 10.1001/archinte.153.15.1843; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; PSATY BM, 1992, JAMA-J AM MED ASSOC, V268, P1287, DOI 10.1001/jama.268.10.1287; PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P683, DOI 10.1016/0895-4356(92)90143-B; PSATY BM, IN PRESS PRIMER HYPE; ROCCELLA EJ, 1985, HYPERTENSION, V7, P457; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; WEBER MA, 1993, ARCH INTERN MED, V153, P149, DOI 10.1001/archinte.153.2.149; WEISSFELD JL, 1985, J CHRON DIS, V38, P915, DOI 10.1016/0021-9681(85)90127-4; 1993, ARCH INTERN MED, V153, P1023	28	61	61	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1837	1841		10.1001/jama.270.15.1837	http://dx.doi.org/10.1001/jama.270.15.1837			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	8105112				2022-12-24	WOS:A1993MB46400027
J	ROYSTON, D				ROYSTON, D			PERIOPERATIVE BLEEDING - DRUGS FOR SURGICAL BLOOD-LOSS	LANCET			English	Editorial Material							TRANEXAMIC ACID				ROYSTON, D (corresponding author), HAREFIELD HOSP,DEPT ANAESTHESIA,HAREFIELD,MIDDX,ENGLAND.							COSGROVE DM, 1992, ANN THORAC SURG, V54, P1031, DOI 10.1016/0003-4975(92)90066-D; HERSCHLEIN H. J., 1964, MED WELT, V24, P1314; HORROW JC, 1991, CIRCULATION, V84, P2063, DOI 10.1161/01.CIR.84.5.2063; Kojima M, 1983, Bibl Haematol, P95; LORD RA, 1992, BRIT J SURG, V79, P517, DOI 10.1002/bjs.1800790614; MALLETT SV, 1990, LANCET, V336, P886, DOI 10.1016/0140-6736(90)92404-6; OVRUM E, 1993, J THORAC CARDIOV SUR, V105, P78; Royston D, 1992, J Cardiothorac Vasc Anesth, V6, P76, DOI 10.1016/1053-0770(91)90052-U; WHITTEN C W, 1992, Anesthesiology (Hagerstown), V77, pA266, DOI 10.1097/00000542-199209001-00266; WIJDICKS EFM, 1989, STROKE, V20, P1674, DOI 10.1161/01.STR.20.12.1674	10	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1629	1629		10.1016/0140-6736(93)90766-A	http://dx.doi.org/10.1016/0140-6736(93)90766-A			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099998				2022-12-24	WOS:A1993LJ72700012
J	HERNANDEZ, CA; LERCH, MM				HERNANDEZ, CA; LERCH, MM			SPHINCTER STENOSIS AND GALLSTONE MIGRATION THROUGH THE BILIARY-TRACT	LANCET			English	Note							PANCREATITIS	We have investigated whether stenosis or insufficiency at the duodenal papilla results from the passage of a gallstone through the biliary tract. In three groups of patients after cholecystectomy we studied meal-stimulated pancreatic enzyme activity in T-drain bile from the common bileduct. Group A had gallbladder stones only; group B had gallbladder stones and bileduct stones; and group C had an episode of acute gallstone-induced pancreatitis, which was taken as direct evidence for gallstone migration into the duodenum. Reflux of pancreatic juice into the common bileduct was absent in group A, was occasionally found in group B, and was strikingly increased in group C. We conclude that passage of a gallstone through the biliary tract causes functional stenosis of the sphincter of Oddi and allows for a common channel between the pancreatic duct and the common bileduct. It does not cause sphincter insufficiency as previously assumed.	UNIV ULM,DEPT MED 1,ROBERT KOCH ST 8,W-7900 ULM,GERMANY; UNIV NACL CORDOBA,CORDOBA UNIV HOSP,DEPT SURG 1,CORDOBA,ARGENTINA	Ulm University; Hospital Privado - Universitario de Cordoba; National University of Cordoba			Lerch, Markus M./E-2206-2016	Lerch, Markus M./0000-0002-9643-8263				ACOSTA JM, 1974, NEW ENGL J MED, V290, P484, DOI 10.1056/NEJM197402282900904; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; DIMAGNO EP, 1982, CANCER, V49, P361, DOI 10.1002/1097-0142(19820115)49:2<361::AID-CNCR2820490225>3.0.CO;2-O; KELLY TR, 1988, SURGERY, V104, P600; LERCH MM, 1993, GASTROENTEROLOGY, V104, P853, DOI 10.1016/0016-5085(93)91022-A; MCCUTCHEON AD, 1962, ANN SURG, V155, P523, DOI 10.1097/00000658-196204000-00007; Opie EL, 1901, B JOHNS HOPKINS HOSP, V12, P182; RINKERKNECHT H, 1978, GASTROENTEROLOGY, V75, P1083; STONE HH, 1981, ANN SURG, V194, P305, DOI 10.1097/00000658-198109000-00008	9	79	81	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1371	1373		10.1016/0140-6736(93)90942-A	http://dx.doi.org/10.1016/0140-6736(93)90942-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098791				2022-12-24	WOS:A1993LE18000005
J	AMIEL, S				AMIEL, S			METABOLISM - AMYLIN AND DIABETES	LANCET			English	Note							ISLET-AMYLOID POLYPEPTIDE; MELLITUS; RAT				AMIEL, S (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DIV MED,LONDON,ENGLAND.			Logan, Ann/0000-0003-3215-5042				BRETHERTONWATT D, 1992, J CLIN ENDOCR METAB, V74, P1032, DOI 10.1210/jc.74.5.1032; CLARK A, 1990, DIABETOLOGIA, V33, P285, DOI 10.1007/BF00403322; COOPER GJS, 1988, P NATL ACAD SCI USA, V85, P7763, DOI 10.1073/pnas.85.20.7763; EDWARDS BJA, 1992, LIFE SCI, V51, P1899, DOI 10.1016/0024-3205(92)90106-Y; FEHMANN HC, 1990, BIOCHEM BIOPH RES CO, V167, P1102, DOI 10.1016/0006-291X(90)90636-2; GHATEI MA, 1990, J ENDOCRINOL, V124, pR9, DOI 10.1677/joe.0.124R009; HARTTER E, 1990, LANCET, V335, P854, DOI 10.1016/0140-6736(90)90966-9; STRIDSBERG M, 1992, SCAND J GASTROENTERO, V27, P381, DOI 10.3109/00365529209000092; VANJAARSVELD BC, 1990, LANCET, V335, P60, DOI 10.1016/0140-6736(90)90197-D; WESTERMARK P, 1987, P NATL ACAD SCI USA, V84, P3881, DOI 10.1073/pnas.84.11.3881; YOUNG AA, 1991, J PHYSIOL-LONDON, V438, pP250	11	10	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1249	1250		10.1016/0140-6736(93)91153-D	http://dx.doi.org/10.1016/0140-6736(93)91153-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098399				2022-12-24	WOS:A1993LC49700011
J	PANCHOLI, P; MIRZA, A; BHARDWAJ, N; STEINMAN, RM				PANCHOLI, P; MIRZA, A; BHARDWAJ, N; STEINMAN, RM			SEQUESTRATION FROM IMMUNE CD4+ T-CELLS OF MYCOBACTERIA GROWING IN HUMAN MACROPHAGES	SCIENCE			English	Article							HUMAN-MONOCYTES; TUBERCULOSIS; ANTIGENS; INFECTION; MICE; ACIDIFICATION; PHAGOSOME; LINES	CD4+ helper T cells mediate resistance to tuberculosis, presumably by enhancing the antimicrobial activity of macrophages within which the Mycobacterium tuberculosis organism grows. A first step in resistance should be the presentation of mycobacterial antigens by macrophages to CD4+ T cells. However, when the antigenic stimulus is limited to organisms growing in human monocytes, the organisms become sequestered from immune CD4+ T cells. This block in presentation is selective for growing mycobacteria and not for other stimuli. Sequestration would allow replicating organisms to persist in infected individuals and may contribute to virulence.			PANCHOLI, P (corresponding author), ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021, USA.		Steinman, Ralph/F-7729-2012		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039552] Funding Source: NIH RePORTER; NCRR NIH HHS [MOI-RR00102] Funding Source: Medline; NIAID NIH HHS [AI24775] Funding Source: Medline; NIAMS NIH HHS [AR39552] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAHR GM, 1981, IMMUNOLOGY, V44, P593; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BHARDWAJ V, 1988, EUR J IMMUNOL, V18, P691, DOI 10.1002/eji.1830180506; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823, DOI 10.1128/IAI.59.5.1823-1831.1991; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DANNENBERG AM, 1984, MYCOBACTERIA SOURCEB, P721; ELLNER JJ, 1978, J IMMUNOL, V121, P2573; ELLNER JJ, 1989, REV INFECT DIS, V11, pS455; FUJIWARA H, 1991, IMMUNOLOGY, V72, P194; HORWITZ MA, 1984, J CELL BIOL, V99, P1936, DOI 10.1083/jcb.99.6.1936; IZZO AA, 1992, J EXP MED, V176, P581, DOI 10.1084/jem.176.2.581; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; LAGRANGE PH, 1988, MYCOBACTERIUM TUBERC, P171; LAMB JR, 1989, REV INFECT DIS, V11, pS443; LEVETON C, 1989, INFECT IMMUN, V57, P390, DOI 10.1128/IAI.57.2.390-395.1989; NAKAMURA RM, 1988, MYCOBACTERIUM TUBERC, P227; PANCHOLI P, 1992, IMMUNOLOGY, V76, P217; PANCHOLI P, 1991, CLIN EXP IMMUNOL, V85, P349; PANCHOLI P, UNPUB; PEDRAZZINI T, 1987, J IMMUNOL, V139, P2032; ROOK GAW, 1986, CLIN EXP IMMUNOL, V63, P105; SIBLEY LD, 1985, NATURE, V315, P416, DOI 10.1038/315416a0; TURCOTTE R, 1981, INFECT IMMUN, V34, P315, DOI 10.1128/IAI.34.2.315-322.1981	24	169	171	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 14	1993	260	5110					984	986		10.1126/science.8098550	http://dx.doi.org/10.1126/science.8098550			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8098550				2022-12-24	WOS:A1993LB79100043
J	DELAROCHEFORDIERE, A; ASSELAIN, B; CAMPANA, F; SCHOLL, SM; FENTON, J; VILCOQ, JR; DURAND, JC; POUILLART, P; MAGDELENAT, H; FOURQUET, A				DELAROCHEFORDIERE, A; ASSELAIN, B; CAMPANA, F; SCHOLL, SM; FENTON, J; VILCOQ, JR; DURAND, JC; POUILLART, P; MAGDELENAT, H; FOURQUET, A			AGE AS PROGNOSTIC FACTOR IN PREMENOPAUSAL BREAST-CARCINOMA	LANCET			English	Article							CONSERVING THERAPY; TUMOR RECURRENCE; CANCER REGISTRY; SURVIVAL; WOMEN; RADIOTHERAPY; MANAGEMENT; DIAGNOSIS; YOUNGER	Whether or not young age at diagnosis is an adverse prognostic factor in breast cancer has long been controversial, in part because much previous work has not taken due account of menopausal status and confounding factors. We have analysed the influence of age on prognosis in a consecutive series of 1703 patients with stage I-III breast cancer. All were premenopausal and all were treated in one centre (Institut Curie, Paris) between 1981 and 1985. Mean age was 44 years (range 23-55) and median follow-up was 82 months. Younger patients had significantly lower survival rates and higher local and distant relapse rates than older patients. The hazard rate of relapse decreased over time in the youngest age group (less-than-or-equal-to 33) to reach that of older patients after 5 years. The relation between the hazard of recurrence and age was a continuous one, best fitted by a log-linear function and indicating a 4% decrease in recurrence for every year of age. Multivariate analysis of both survival and disease-free interval demonstrated that the worse prognosis of young age was independent of other factors such as clinical tumour size, clinical node status, histological grade, hormone receptor status, locoregional treatment procedure, and adjuvant systemic therapy. This difference in outlook has yet to be explained biologically but it does suggest the need for a closer look at the natural history of breast cancer in young women.	INST CURIE,DEPT BIOSTAT,F-75231 PARIS 05,FRANCE; INST CURIE,DEPT MED ONCOL,F-75231 PARIS 05,FRANCE; INST CURIE,DEPT SURG,F-75231 PARIS 05,FRANCE; INST CURIE,DEPT PATHOL,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	DELAROCHEFORDIERE, A (corresponding author), INST CURIE,DEPT RADIOTHERAPY,26 RUE ULM,F-75231 PARIS 005,FRANCE.							ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; BARTELINK H, 1988, RADIOTHER ONCOL, V11, P297, DOI 10.1016/0167-8140(88)90200-9; BLOOM HJS, 1957, BRIT J CANCER, V11, P339; CABANES PA, 1992, LANCET, V339, P1245, DOI 10.1016/0140-6736(92)91591-U; CLAUS EB, 1991, AM J HUM GENET, V48, P232; COX DR, 1972, J R STAT SOC B, V34, P187; FISHER B, 1991, LANCET, V338, P327, DOI 10.1016/0140-6736(91)90475-5; FOURQUET A, 1989, INT J RADIAT ONCOL, V17, P719, DOI 10.1016/0360-3016(89)90057-6; HOST H, 1986, CANCER-AM CANCER SOC, V57, P2217, DOI 10.1002/1097-0142(19860601)57:11<2217::AID-CNCR2820571124>3.0.CO;2-T; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KURTZ JM, 1990, J CLIN ONCOL, V8, P591, DOI 10.1200/JCO.1990.8.4.591; LANGLANDS AO, 1979, CLIN ONCOL, V5, P123; LEE CG, 1992, INT J RADIAT ONCOL, V23, P969, DOI 10.1016/0360-3016(92)90901-S; LEES AW, 1989, BREAST CANCER RES TR, V13, P143, DOI 10.1007/BF01806526; MAGDELENAT H, 1987, EUR J CANCER CLIN ON, V23, P425, DOI 10.1016/0277-5379(87)90381-6; MUELLER CB, 1978, SURGERY, V83, P123; NEMOTO T, 1980, CANCER, V45, P2917, DOI 10.1002/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M; NOYES RD, 1982, CANCER, V49, P1302, DOI 10.1002/1097-0142(19820315)49:6<1302::AID-CNCR2820490638>3.0.CO;2-0; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PILLERS EMK, 1992, LANCET, V339, P1483, DOI 10.1016/0140-6736(92)92079-U; RECHT A, 1988, INT J RADIAT ONCOL, V14, P3, DOI 10.1016/0360-3016(88)90043-0; RIBEIRO GG, 1981, CLIN RADIOL, V32, P231, DOI 10.1016/S0009-9260(81)80168-7; RIES LG, 1983, JNCI-J NATL CANCER I, V70, P693; ROSEN PP, 1984, ANN SURG, V199, P133, DOI 10.1097/00000658-198402000-00001; RUTQVIST LE, 1984, CANCER, V53, P1793, DOI 10.1002/1097-0142(19840415)53:8<1793::AID-CNCR2820530832>3.0.CO;2-Y; SANT M, 1991, EUR J CANCER, V27, P981, DOI 10.1016/0277-5379(91)90263-D; SOLIN LJ, 1989, INT J RADIAT ONCOL, V16, P373, DOI 10.1016/0360-3016(89)90333-7; STABLEIN DM, 1981, CONTROL CLIN TRIALS, V2, P149, DOI 10.1016/0197-2456(81)90005-2; VILCOQ JR, 1981, INT J RADIAT ONCOL, V7, P1327, DOI 10.1016/0360-3016(81)90027-4; VILCOQ JR, 1983, CONSERVATIVE MANAGEM, P213	30	350	351	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1039	1043		10.1016/0140-6736(93)92407-K	http://dx.doi.org/10.1016/0140-6736(93)92407-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096955				2022-12-24	WOS:A1993KZ01800001
J	RAMIREZSOLIS, R; ZHENG, H; WHITING, J; KRUMLAUF, R; BRADLEY, A				RAMIREZSOLIS, R; ZHENG, H; WHITING, J; KRUMLAUF, R; BRADLEY, A			HOXB-4 (HOX-2.6) MUTANT MICE SHOW HOMEOTIC TRANSFORMATION OF A CERVICAL VERTEBRA AND DEFECTS IN THE CLOSURE OF THE STERNAL RUDIMENTS	CELL			English	Article							DNA-BINDING SPECIFICITY; HOMEOBOX GENE; TRANSGENIC MICE; TARGETED DISRUPTION; XENOPUS EMBRYOS; RETINOIC ACID; MOUSE EMBRYOS; EXPRESSION; DROSOPHILA; HOMEODOMAIN	Two Hoxb-4 (Hox-2.6) mutations were introduced into the mouse germline. The overt phenotype caused by one of the mutations was assayed on two different genetic backgrounds, an inbred 129SvEv and a hybrid 129SvEv-C57BL/6J. The allele hoxb-4r is a disruption of the first exon and causes two obvious skeletal changes: a partial homeotic transformation of the second cervical vertebra from axis to atlas and a defective morphogenesis of the sternum. Both phenotypes have incomplete penetrance and variable expressivity when assayed in the hybrid genetic background, but the sternum defect is completely penetrant in the inbred background. The mutant allele hoxb-4s has a premature stop codon, introduced by the ''hit and run'' method in the second exon, that disrupts the third helix of the homeodomain. This allele also causes the partial homeotic transformation of axis to atlas, but it does not affect the sternum.	BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA; NATL INST MED RES, EUKARYOT MOLEC GENET LAB, LONDON NW7 1AA, ENGLAND	Baylor College of Medicine; Howard Hughes Medical Institute; MRC National Institute for Medical Research	RAMIREZSOLIS, R (corresponding author), BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA.		Krumlauf, Robb/AAH-5012-2019	Krumlauf, Robb/0000-0001-9102-7927; Bradley, Allan/0000-0002-2349-8839				AWGULEWITSCH A, 1992, NATURE, V358, P341, DOI 10.1038/358341a0; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BONCINELLI E, 1988, HUM REPROD, V3, P880, DOI 10.1093/oxfordjournals.humrep.a136802; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; BRADLEY A, 1992, NATURE, V360, P313; BRAUN RE, 1990, BIOL REPROD, V43, P684, DOI 10.1095/biolreprod43.4.684; BRYSON V, 1945, ANAT REC, V91, P119, DOI 10.1002/ar.1090910204; CHEN JM, 1953, J ANAT, V87, P130; CHEN JM, 1952, J ANAT, V86, P373; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; DAVIS AC, 1992, MOL CELL BIOL, V12, P2769, DOI 10.1128/MCB.12.6.2769; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; GALLIOT B, 1989, DEVELOPMENT, V107, P343; GAUNT SJ, 1991, BIOESSAYS, V13, P505, DOI 10.1002/bies.950131004; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GEADA AMC, 1992, DEVELOPMENT, V116, P497; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GRAHAM A, 1988, GENE DEV, V2, P1424, DOI 10.1101/gad.2.11.1424; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GRUNEBERG H, 1950, J GENET, V50, P112, DOI 10.1007/BF02986799; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARVEY RP, 1988, CELL, V53, P687, DOI 10.1016/0092-8674(88)90087-6; HARVEY RP, 1986, EMBO J, V5, P1237, DOI 10.1002/j.1460-2075.1986.tb04352.x; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HOGAN B, 1985, TRENDS GENET, V1, P67, DOI 10.1016/0168-9525(85)90029-0; HOLLAND PWH, 1986, NATURE, V321, P251, DOI 10.1038/321251a0; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cb.08.110192.001303; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNT P, 1991, DEVELOPMENT, V112, P43; JACOBSON AG, 1988, DEVELOPMENT, V104, P209; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; KAUFMAN TC, 1990, ADV GENET, V27, P9; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI DOI 10.1083/JCB.108.2.229; KRUMLAUF R, 1992, BIOESSAYS, V14, P245, DOI 10.1002/bies.950140408; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; McLAREN A., 1956, Journal of Genetics, V54, P440, DOI 10.1007/BF02982959; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; OLIVER G, 1988, EMBO J, V7, P3199, DOI 10.1002/j.1460-2075.1988.tb03187.x; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; OUDEJANS CBM, 1990, DEVELOPMENT, V108, P471; POLLOCK RA, 1992, CELL, V71, P911, DOI 10.1016/0092-8674(92)90388-S; PUSCHEL AW, 1990, DEVELOPMENT, V108, P435; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RUSSELL LB, 1979, TERATOLOGY, V20, P115, DOI 10.1002/tera.1420200115; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; SIMEONE A, 1988, NUCLEIC ACIDS RES, V16, P5379, DOI 10.1093/nar/16.12.5379; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Stern C.D., 1990, Seminars in Developmental Biology, V1, P109; THEILER K, 1988, ADV ANAT EMBRYOL CEL, V112, P1; TREISMAN J, 1989, CELL, V59, P553; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WOLGEMUTH DJ, 1989, NATURE, V337, P464, DOI 10.1038/337464a0; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; ZIMMER A, 1989, NATURE, V338, P150, DOI 10.1038/338150a0	79	286	290	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 23	1993	73	2					279	294						16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8097432				2022-12-24	WOS:A1993KY50500010
J	MARKUS, H; LOH, A; ISRAEL, D; BUCKENHAM, T; CLIFTON, A; BROWN, MM				MARKUS, H; LOH, A; ISRAEL, D; BUCKENHAM, T; CLIFTON, A; BROWN, MM			MICROSCOPIC AIR-EMBOLISM DURING CEREBRAL-ANGIOGRAPHY AND STRATEGIES FOR ITS AVOIDANCE	LANCET			English	Article							CARDIAC-SURGERY; MICROEMBOLI; ARTERY; BYPASS; BRAIN	Cerebral angiography is associated with a risk of neurological complications and air embolism may contribute towards this risk. To test this hypothesis, transcranial doppler ultrasonography was used to monitor the presence of air emboli in the middle cerebral arteries of 7 patients undergoing cerebral angiography. Doppler signals consistent with numerous air emboli were noted during each injection of radiographic contrast. This phenomenon was studied further in sheep. Radiographic contrast medium was injected into the carotid artery while a major carotid branch was insonated transorbitally. Embolic signals similar to those seen in patients were noted. Air was introduced at two points. First, at the time of drawing up the contrast into the syringe, especially with more viscous media. Standing the media before injection resulted in a highly significant reduction of air embolism, reducing the total mean duration of emboli from 1.32 (SD 0.60) s after immediate injection to 0.04 (0.05) s after ten minutes standing for iohexol 340 mg/mL (p < 0.001 ). Second, air was introduced at the time of injection, possibly by the formation of cavitation bubbles under pressure. This occurred most prominently with the less viscous contrast media and with saline, and was significantly reduced by slow injection (mean duration of emboli for saline 2.85 [2.43] s with fast injection compared with 0.32 [0.37] s with slow injection, p = 0.004). Air embolism may contribute towards neurological dysfunction after angiography. Measures should be taken to reduce this by allowing contrast media to stand prior to injection, and by flushing catheters with saline injected slowly.	ATKINSON MORLEYS HOSP,DEPT NEURORADIOL,LONDON SW20,ENGLAND; ST GEORGE HOSP,DEPT SURG,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,DEPT RADIOL,LONDON SW17 0RE,ENGLAND	St Georges University London; St Georges University London	MARKUS, H (corresponding author), ST GEORGE HOSP,SCH MED,DIV CLIN NEUROSCI,LONDON SW17 0RE,ENGLAND.			Brown, Martin M/0000-0002-3273-1356				AUSTEN WG, 1965, J SURG RES, V5, P283; COFFEY CE, 1983, NEUROLOGY, V33, P1416, DOI 10.1212/WNL.33.11.1416; DION JE, 1987, STROKE, V18, P997, DOI 10.1161/01.STR.18.6.997; FIESCHI C, 1989, J NEUROL SCI, V91, P311, DOI 10.1016/0022-510X(89)90060-9; FRITZ H, 1979, STROKE, V10, P581, DOI 10.1161/01.STR.10.5.581; GABRIEL KR, 1964, BIOMETRICS, V20, P459, DOI 10.2307/2528488; HANKEY GJ, 1990, STROKE, V21, P209, DOI 10.1161/01.STR.21.2.209; MARKUS HS, 1993, STROKE, V24, P1; MELDRUM BS, 1971, BRAIN RES, V25, P301, DOI 10.1016/0006-8993(71)90440-9; MENKIN M, 1977, ARCH NEUROL-CHICAGO, V34, P168, DOI 10.1001/archneur.1977.00500150054010; MOODY DM, 1990, ANN NEUROL, V28, P477, DOI 10.1002/ana.410280403; NEWMAN S, 1992, 1ST INT CONS C EMB D; PADAYACHEE TS, 1987, ANN THORAC SURG, V44, P298, DOI 10.1016/S0003-4975(10)62077-2; PFEIFFER FE, 1984, ARCH NEUROL-CHICAGO, V41, P1175, DOI 10.1001/archneur.1984.04050220073017; PFEIFFER FE, 1987, MAYO CLIN PROC, V62, P351, DOI 10.1016/S0025-6196(12)65438-X; PUGSLEY W, 1990, VASCULAR SURG, V24, P34, DOI 10.1177/153857449002400107; SHAW PJ, 1986, Q J MED, V58, P59; Spencer M P, 1969, Ann Thorac Surg, V8, P489; SPENCER MP, 1969, JOM-J OCCUP MED, V11, P238; SPENCER MP, 1990, STROKE, V21, P415, DOI 10.1161/01.STR.21.3.415; STUMP D, 1992, 1ST INT CONS C EMB D	21	113	121	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					784	787		10.1016/0140-6736(93)90561-T	http://dx.doi.org/10.1016/0140-6736(93)90561-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096000				2022-12-24	WOS:A1993KU90000004
J	SHANN, F				SHANN, F			NUTRITION - NUTRITIONAL INDEXES - Z, CENTILE, OR PERCENT	LANCET			English	Editorial Material											SHANN, F (corresponding author), ROYAL CHILDRENS HOSP,PARKVILLE,VIC 3052,AUSTRALIA.		Shann, Frank/C-9510-2011					DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; SACHDEV HPS, 1992, INT J EPIDEMIOL, V21, P916, DOI 10.1093/ije/21.5.916; SULLIVAN K M, 1990, Food and Nutrition Bulletin, V12, P116; 1986, B WORLD HEALTH ORGAN, V64, P929	4	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					526	527		10.1016/0140-6736(93)90283-M	http://dx.doi.org/10.1016/0140-6736(93)90283-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094776				2022-12-24	WOS:A1993KP08300009
J	TENWOLDE, S; BREEDVELD, FC; DEVRIES, RRP; DAMARO, J; RUBENSTEIN, P; SCHREUDER, GMT; CLAAS, FHJ; VANROOD, JJ				TENWOLDE, S; BREEDVELD, FC; DEVRIES, RRP; DAMARO, J; RUBENSTEIN, P; SCHREUDER, GMT; CLAAS, FHJ; VANROOD, JJ			INFLUENCE OF NONINHERITED MATERNAL HLA ANTIGENS ON OCCURRENCE OF RHEUMATOID-ARTHRITIS	LANCET			English	Article							T-CELL REPERTOIRE; SELF-ANTIGENS; TOLERANCE	Many HLA-associated diseases occur in patients not carrying the putative predisposing antigen. The suggestion that this might be due to disease heterogeneity is not sufficiently supported by available data. We hypothesise that HLA-DR4-associated genetic susceptibility to rheumatoid arthritis is due to an effect of DR4 on T-cell receptor repertoire expression and that the presence of antigen in the mother is capable of producing this effect in her children, even when DR4 is not inherited by them. To investigate this possibility we HLA typed 94 rheumatoid arthritis patients and their parents and 86 control families. An increased frequency, compared with controls, of non-inherited maternal HLA-DR4 was found predominantly in the mothers of DR4-negative patients. Unexpectedly, we also found an increased frequency of non-inherited maternal HLA-DR4 and a decreased frequency of non-inherited maternal HLA-DR3 in the mothers of DR4-positive patients. The results of our analyses are consistent with our hypothesis.	UNIV HOSP LEIDEN,DEPT IMMUNOHAEMATOL,POB 9600,2300 RC LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,BLOOD BANK,2333 AA LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT RHEUMATOL,2333 AA LEIDEN,NETHERLANDS; NEW YORK BLOOD CTR,NEW YORK,NY 10021	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); New York Blood Center								BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; CLAAS FHJ, 1988, SCIENCE, V241, P1815, DOI 10.1126/science.3051377; FISHER RA, 1958, STATISTICAL METHODS; MULLBACHER A, 1983, J EXP MED, V157, P1324, DOI 10.1084/jem.157.4.1324; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; ROBES MW, 1958, B RHEUM DIS, V9, P175; RUBINSTEIN P, 1990, 3RD INT C JEW GEN DI; TIWARI JL, 1985, HLA DISEASE ASS; VANROOD JJ, 1976, NATURE, V262, P795, DOI 10.1038/262795a0; ZHANG L, 1991, RES IMMUNOL, V142, P441, DOI 10.1016/0923-2494(91)90044-J	10	48	49	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					200	202						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093497				2022-12-24	WOS:A1993KJ21900004
J	MILNER, SM; HODGETTS, TJ; RYLAH, LTA				MILNER, SM; HODGETTS, TJ; RYLAH, LTA			THE BURNS-CALCULATOR - A SIMPLE PROPOSED GUIDE FOR FLUID RESUSCITATION	LANCET			English	Article							CHILDREN	Most burn casualties will receive their primary care in an emergency department. These departments are staffed by doctors with a varying degree of supervision, and their experience of the treatment of burns is often very modest. Evidently there is a need for a simple method to calculate the fluid requirements of these patients. The Burns Calculator is designed for use during the first eight hours post-injury and is based upon the Parkland resuscitation formula, using only Hartmann's solution BP. It is expected that the patient will have received expert aid by the end of this time. Values for children have been predetermined using body surface area nomograms. The calculator will assist the non-specialist to determine the correct amount of fluid needed to resuscitate a burned patient, and perhaps decrease morbidity and mortality associated with this injury.	ST ANDREWS HOSP,REG BURNS UNIT,BILLERICAY,ESSEX,ENGLAND; ROYAL ARMY MED COLL,LONDON SW1P 4RJ,ENGLAND		MILNER, SM (corresponding author), CHEM & BIOL DEF ESTAB,SALISBURY,WILTS,ENGLAND.							Baxter C R, 1974, Clin Plast Surg, V1, P693; BAXTER CR, 1981, J TRAUMA, V21, P687, DOI 10.1097/00005373-198108001-00016; GRAVES TA, 1988, J TRAUMA, V28, P1656, DOI 10.1097/00005373-198812000-00007; HAMMOND JS, 1987, J TRAUMA, V27, P1161, DOI 10.1097/00005373-198710000-00011; HERNDON DN, 1985, PEDIATR CLIN N AM, V32, P1311; HERNDON DN, 1987, CURR PROB SURG, P347; Lund CC., SURG GYNECOL OBSTET, V79, P352; MILNER SM, 1993, BRIT J HOSP MED, V50, P163; MONAFO WW, 1993, CRITICAL CARE BURNED; Muir IFK, 1987, BURNS THEIR TREATMEN; OAKLEY P, 1993, BRIT MED J, V306, P1613, DOI 10.1136/bmj.306.6892.1613; PRUITT BA, 1987, CLIN SURG, P2823; RYLAH LTA, 1991, ANESTHESIOLOGY, V5, P35; 1988, ADV TRAUMA LIFE SUPP, P206; 1993, ADV PAEDIATRIC LIFE	15	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1089	1091		10.1016/0140-6736(93)92067-4	http://dx.doi.org/10.1016/0140-6736(93)92067-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105315				2022-12-24	WOS:A1993ME82200013
J	SCHEPERHUGHES, N				SCHEPERHUGHES, N			AIDS, PUBLIC-HEALTH, AND HUMAN-RIGHTS IN CUBA	LANCET			English	Article									UNIV CALIF BERKELEY,DEPT ANTHROPOL,BERKELEY,CA 94720	University of California System; University of California Berkeley									0	36	38	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					965	967		10.1016/0140-6736(93)92006-F	http://dx.doi.org/10.1016/0140-6736(93)92006-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MC005	8105218				2022-12-24	WOS:A1993MC00500013
J	STEEL, M				STEEL, M			CANCER GENES - COMPLEXES AND COMPLEXITIES	LANCET			English	Editorial Material							NM23 GENE				STEEL, M (corresponding author), WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.							BASERGA R, 1993, CANCER SURV, V16, P201; BLACK DM, 1993, AM J HUM GENET, V52, P702; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; LEONE A, 1993, ONCOGENE, V8, P2325; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEL CM, 1989, J R COLL PHYSICIANS, V19, P413; ZHOU M, 1993, BRIT J CANCER, V68, P385, DOI 10.1038/bjc.1993.345	11	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	1993	342	8874					754	755		10.1016/0140-6736(93)91533-R	http://dx.doi.org/10.1016/0140-6736(93)91533-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103869				2022-12-24	WOS:A1993LY86800002
J	SAUNDERS, AM; SCHMADER, K; BREITNER, JCS; BENSON, MD; BROWN, WT; GOLDFARB, L; GOLDGABER, D; MANWARING, MG; SZYMANSKI, MH; MCCOWN, N; DOLE, KC; SCHMECHEL, DE; STRITTMATTER, WJ; PERICAKVANCE, MA; ROSES, AD				SAUNDERS, AM; SCHMADER, K; BREITNER, JCS; BENSON, MD; BROWN, WT; GOLDFARB, L; GOLDGABER, D; MANWARING, MG; SZYMANSKI, MH; MCCOWN, N; DOLE, KC; SCHMECHEL, DE; STRITTMATTER, WJ; PERICAKVANCE, MA; ROSES, AD			APOLIPOPROTEIN-E-EPSILON-4 ALLELE DISTRIBUTIONS IN LATE-ONSET ALZHEIMERS-DISEASE AND IN OTHER AMYLOID-FORMING DISEASES	LANCET			English	Note								The frequency of the allele for apolipoprotein E type 4 (epsilon4) is increased in late-onset familial and sporadic Alzheimer's disease (AD). We have examined epsilon4 frequencies in. four distinct, normal, elderly control groups and, most importantly, in patients with amyloid-forming diseases whose epsilon4 distributions were not previously known (Creutzfeldt-Jakob disease, familial amyloidotic polyneuropathy, Down's syndrome). There were no differences between any of these controls and published control series, cementing the relevance of epsilon4 for late-onset AD. The increase in late-onset AD was confirmed in two new series.	DUKE UNIV,MED CTR,BRYAN ALZHEIMERS DIS RES CTR,DIV NEUROL,DURHAM,NC 27710; SUNY,DEPT PSYCHIAT,STONY BROOK,NY 11794; INDIANA UNIV,SCH MED,INDIANAPOLIS,IN 46202; NIH,BETHESDA,MD 20892; NEW YORK STATE INST BASIC RES DEV DISABIL,STATEN ISL,NY 10314	Duke University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; Indiana University System; Indiana University-Purdue University Indianapolis; National Institutes of Health (NIH) - USA; Institute for Basic Research in Developmental Disabilities			Brown, William/GXN-2777-2022		NCRR NIH HHS [M01-RR-30] Funding Source: Medline; NIA NIH HHS [AG05128, U24 AG021886, AGO7922] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R35AG007922, U24AG021886] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		LIDDELL M, IN PRESS J MED GENET; MAYEAX R, IN PRESS ANN NEUROL; Robinette C. D., 1990, Dementia and Geriatric Cognitive Disorders,, V1, P297, DOI [10.1159/000107157, DOI 10.1159/000107157]; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C	6	481	492	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					710	711		10.1016/0140-6736(93)91709-U	http://dx.doi.org/10.1016/0140-6736(93)91709-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103823				2022-12-24	WOS:A1993LX46900010
J	HORNER, PJ; GILROY, CB; THOMAS, BJ; NAIDOO, ROM; TAYLORROBINSON, D				HORNER, PJ; GILROY, CB; THOMAS, BJ; NAIDOO, ROM; TAYLORROBINSON, D			ASSOCIATION OF MYCOPLASMA-GENITALIUM WITH ACUTE NONGONOCOCCAL URETHRITIS	LANCET			English	Article							POLYMERASE CHAIN-REACTION; HUMAN UROGENITAL TRACT; DISCOVERED MYCOPLASMA; CHLAMYDIA-TRACHOMATIS; DNA PROBES; PNEUMONIAE; SPECIMENS; INFECTION	Chlamydia trachomatis is known to be a cause of acute non-gonococcal urethritis (NGU), though the aetiology of this disorder is not fully understood. Mycoplasma genitalium has been isolated from a few men with NGU, but culture has remained difficult and reliable detection became possible only with a specific polymerase chain reaction (PCR). We have used the PCR to examine the role of M genitalium in NGU. M genitalium was detected in urethral samples from 24 (23%) of 103 men with symptoms, signs, or both, of acute NGU, but from only 3 (6%) of 53 men without NGU (p < 0.006). This association was independent of the presence of C trachomatis and could not be explained by differences in age, ethnic origin, lifetime number of sexual partners or a change in sexual partner during the previous 3 months. The clinical response of the mycoplasma-positive men to doxycycline treatment was at least as satisfactory as that of the chlamydia-positive men. These findings suggest that the association of M genitalium with NGU is likely to be causal, a notion consistent with the known virulence characteristics of this microorganism and its ability to cause urethritis in male sub-human primates.	CLIN RES CTR,DIV SEXUALLY TRANSMITTED DIS,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND; ST MARYS HOSP,LONDON,ENGLAND	Imperial College London				Horner, Paddy/0000-0003-0411-8332				BOWIE WR, 1981, ANN INTERN MED, V95, P306, DOI 10.7326/0003-4819-95-3-306; DALLO SF, 1989, INFECT IMMUN, V57, P1059, DOI 10.1128/IAI.57.4.1059-1065.1989; HAWKINS DA, 1986, MICROBIAL DISEASES N, P47; HAY PE, 1992, INT J STD AIDS, V3, P191, DOI 10.1177/095646249200300307; HOOTON TM, 1988, LANCET, V1, P266; HYMAN HC, 1987, J CLIN MICROBIOL, V25, P726, DOI 10.1128/JCM.25.4.726-728.1987; JENSEN JS, 1991, J CLIN MICROBIOL, V29, P46, DOI 10.1128/JCM.29.1.46-50.1991; KIRCHHOFF H, 1984, ISRAEL J MED SCI, V20, P848; MUNDAY PE, 1985, CLIN PROBLEMS SEXUAL, P15; Palmer H M, 1991, Int J STD AIDS, V2, P261; PALMER HM, 1991, FEMS MICROBIOL LETT, V77, P199, DOI 10.1016/0378-1097(91)90551-K; ROBERTS MC, 1987, ISRAEL J MED SCI, V23, P618; SAMRA Z, 1988, EUR J CLIN MICROBIOL, V7, P49, DOI 10.1007/BF01962172; TAYLORROBINSON D, 1987, ISRAEL J MED SCI, V23, P561; TAYLORROBINSON D, 1980, J CLIN PATHOL, V33, P205, DOI 10.1136/jcp.33.3.205; TAYLORROBINSON D, 1981, ISRAEL J MED SCI, V17, P524; TAYLORROBINSON D, 1985, GENITOURIN MED, V61, P319; TAYLORROBINSON D, 1993, CLIN INFECT DIS   S1, V17, P66; THOMAS BJ, 1984, J CLIN PATHOL, V37, P812, DOI 10.1136/jcp.37.7.812; TULLY JG, 1981, LANCET, V1, P1288; TULLY JG, 1983, INT J SYST BACTERIOL, V33, P387, DOI 10.1099/00207713-33-2-387; TULLY JG, 1986, J INFECT DIS, V153, P1046, DOI 10.1093/infdis/153.6.1046; WILSON K, 1987, CUURRENT PROTOCOLS M, V1	23	173	182	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					582	585		10.1016/0140-6736(93)91411-E	http://dx.doi.org/10.1016/0140-6736(93)91411-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102721				2022-12-24	WOS:A1993LV96300011
J	LEUNG, WH; LAU, CP; WONG, CK				LEUNG, WH; LAU, CP; WONG, CK			BENEFICIAL EFFECT OF CHOLESTEROL-LOWERING THERAPY ON CORONARY ENDOTHELIUM-DEPENDENT RELAXATION IN HYPERCHOLESTEROLEMIC PATIENTS	LANCET			English	Article							LOW-DENSITY LIPOPROTEINS; ARTERY DISEASE; EXPERIMENTAL ATHEROSCLEROSIS; RABBIT AORTA; L-ARGININE; ACETYLCHOLINE; DYSFUNCTION; RESPONSES; VASOCONSTRICTION; REGRESSION	Since hypercholesterolaemia is associated with impaired endothelium-dependent vasodilation, a study was conducted to find out whether cholesterol reduction will improve endothelial function in patients with hypercholesterolaemia and normal coronary arteries. 25 men (mean age 51 [SD 8] years) with total serum cholesterol >6.2 mmol/L) and angiographically normal coronary arteries had their coronary vasomotor responses to intracoronary acetylcholine and nitroglycerin assessed by computer-assisted quantitative angiography at baseline and after 6 months of cholesterol-reducing diet and cholestyramine. Between baseline and follow-up mean total serum cholesterol level fell by 28.7 (SD 5.6)% (p <0.001); mean low-density lipoprotein (LDL) cholesterol level by 35.6 (8.7)% (p <0.001); and mean total cholesterol to high-density lipoprotein (HDL) cholesterol ratio by 29.4 (10.6)% (p <0.001). Acetylcholine significantly reduced the mean segment diameter at baseline, by 21.7 (14.0)% (p <0.01), but it increased the diameter at follow-up, by 6.16 (13.3)% (p < 0.01), the difference between the two occasions being significant (p < 0.001). Nitroglycerin significantly increased the mean segment diameter, both at baseline, by 18.7 (11.5)% (p < 0.01), and at follow-up, by 19.3 (12.1)% (p < 0.01), the difference between the two responses being not significant. At baseline total cholesterol and LDL cholesterol did not correlate with acetylcholine response, but they did at follow-up (total cholesterol, r = 0.67, p < 0.01; LDL cholesterol, r = 0.64, p < 0.01). Impairment of endothelium-dependent (acetylcholine-induced) dilation of the epicardial coronary arteries in hypercholesterolaemic patients with angiographically normal coronary arteries is thus reversible by reducing serum cholesterol. In addition, the degree of impairment of acetylcholine-induced vasomotor response is related to the cholesterol concentrations after therapy.			LEUNG, WH (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT MED,DIV CARDIOL,HONG KONG,HONG KONG.							ANDREWS HE, 1987, NATURE, V327, P237, DOI 10.1038/327237a0; ARNETT EN, 1979, ANN INTERN MED, V91, P350, DOI 10.7326/0003-4819-91-3-350; BASSENGE E, 1988, PROG CARDIOVASC DIS, V30, P249; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CHAPPELL SP, 1987, CARDIOVASC RES, V21, P34, DOI 10.1093/cvr/21.1.34; COCKS TM, 1983, NATURE, V305, P627, DOI 10.1038/305627a0; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; DREXLER H, 1991, HYPERTENSION, V18, P1190; Farmer JA, 1988, HEART DISEASE TXB CA, P1153; FISH RD, 1988, J CLIN INVEST, V81, P21, DOI 10.1172/JCI113297; FREIMAN PC, 1986, CIRC RES, V58, P783, DOI 10.1161/01.RES.58.6.783; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; GALLE J, 1991, ARTERIOSCLER THROMB, V11, P198, DOI 10.1161/01.ATV.11.1.198; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; HENDERSON AH, 1991, BRIT HEART J, V65, P116; HODGSON JM, 1989, CIRCULATION, V79, P1043, DOI 10.1161/01.CIR.79.5.1043; HOLTZ J, 1984, J CARDIOVASC PHARM, V6, P1161; JAYAKODY L, 1987, CIRC RES, V60, P251, DOI 10.1161/01.RES.60.2.251; LEUNG W-H, 1991, Journal of the American College of Cardiology, V17, p230A; LEUNG WH, 1991, CATHETER CARDIO DIAG, V24, P121, DOI 10.1002/ccd.1810240211; LEUNG WH, 1990, CATHETER CARDIO DIAG, V21, P148, DOI 10.1002/ccd.1810210305; LEUNG WH, 1992, J AM COLL CARDIOL, V20, P307, DOI 10.1016/0735-1097(92)90095-5; LEUNG WH, 1991, CIRCULATION, V84, P2294, DOI 10.1161/01.CIR.84.6.2294; LEUNG WH, 1991, AM J CARDIOL, V67, P1061, DOI 10.1016/0002-9149(91)90866-J; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MCPHERSON DD, 1987, NEW ENGL J MED, V316, P304, DOI 10.1056/NEJM198702053160604; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; RUBANYI GM, 1991, CIRCULATION, V83, P1118, DOI 10.1161/01.CIR.83.3.1118; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; SREEHARAN N, 1986, CAN J PHYSIOL PHARM, V64, P1451, DOI 10.1139/y86-246; VANHOUTTE PM, 1988, NEW ENGL J MED, V319, P349; VERHEUREN TJ, 1986, CIRC RES, V58, P783; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; WATERS D, 1991, AM J MED, V91, pS10, DOI 10.1016/0002-9343(91)90051-X; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WERNS SW, 1989, CIRCULATION, V79, P287, DOI 10.1161/01.CIR.79.2.287; YASUE H, 1990, CIRCULATION, V81, P482, DOI 10.1161/01.CIR.81.2.482; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391	38	447	449	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1496	1500		10.1016/0140-6736(93)90634-S	http://dx.doi.org/10.1016/0140-6736(93)90634-S			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099379				2022-12-24	WOS:A1993LG24200003
J	CAMPBELL, RWF				CAMPBELL, RWF			VENTRICULAR ECTOPIC BEATS AND NONSUSTAINED VENTRICULAR-TACHYCARDIA	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; SEVERE HEART-FAILURE; CONTROLLED TRIAL; HEALTHY-SUBJECTS; DOUBLE-BLIND; ARRHYTHMIAS; FREQUENT; PREVENTION; MORTALITY; THERAPY				CAMPBELL, RWF (corresponding author), UNIV NEWCASTLE UPON TYNE, NEW MED SCH, FRAMLINGTON PL, NEWCASTLE UPON TYNE NE2 4HH, ENGLAND.							[Anonymous], 1989, NEW ENGL J MED, V321, P406; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BRODSKY M, 1977, AM J CARDIOL, V39, P390, DOI 10.1016/S0002-9149(77)80094-5; BUXTON AE, 1984, AM J CARDIOL, V53, P1275, DOI 10.1016/0002-9149(84)90078-X; CAMPBELL RWF, 1981, BRIT HEART J, V46, P351; CHAKKO CS, 1985, AM HEART J, V109, P497, DOI 10.1016/0002-8703(85)90554-X; CLELAND JGF, 1984, BRIT HEART J, V52, P530; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; CULLEN K, 1982, BRIT HEART J, V47, P209; HUGENHOLTZ PG, 1978, MANAGEMENT VENTRICUL, P572; KENNEDY HL, 1985, NEW ENGL J MED, V312, P193, DOI 10.1056/NEJM198501243120401; KENNEDY HL, 1980, ANN INTERN MED, V92, P179, DOI 10.7326/0003-4819-92-2-179; KOSTER RW, 1985, NEW ENGL J MED, V313, P1105, DOI 10.1056/NEJM198510313131801; LOWN B, 1967, J AMER MED ASSOC, V199, P188, DOI 10.1001/jama.199.3.188; MAY GS, 1982, PROG CARDIOVASC DIS, V24, P331, DOI 10.1016/0033-0620(82)90010-X; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; STEWART RA, 1989, BRIT HEART J, V61, P459; SULPIZI AM, 1987, AM J CARDIOL, V59, P841, DOI 10.1016/0002-9149(87)91103-9; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; WILBER DJ, 1990, CIRCULATION, V82, P350, DOI 10.1161/01.CIR.82.2.350; WREN C, 1987, EUR HEART J, V8, P647, DOI 10.1093/oxfordjournals.eurheartj.a062336; WYMAN MG, 1968, DIS CHEST, V53, P584	22	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	1993	341	8858					1454	1458		10.1016/0140-6736(93)90891-J	http://dx.doi.org/10.1016/0140-6736(93)90891-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099150				2022-12-24	WOS:A1993LF84100013
J	RUTGEERTS, P; GEBOES, K				RUTGEERTS, P; GEBOES, K			INFLAMMATORY BOWEL-DISEASE - CROHNS-DISEASE AND PRE-APHTHOID LESIONS	LANCET			English	Editorial Material							CELLS				RUTGEERTS, P (corresponding author), UNIV HOSP LEUVEN,DEPT GASTROENTEROL,LOUVAIN,BELGIUM.							GEBOES K, 1992, GASTROENTEROLOGY, V103, P439, DOI 10.1016/0016-5085(92)90832-J; KATZ KD, 1989, GASTROENTEROLOGY, V97, P927, DOI 10.1016/0016-5085(89)91499-6; MASUYAMA J, 1986, J CLIN INVEST, V77, P1596, DOI 10.1172/JCI112475; MAYER L, 1990, J CLIN INVEST, V86, P1255, DOI 10.1172/JCI114832; RIDDELL RM, 1991, EFFECTS IMMUNE CELLS, P11; RUTGEERTS P, 1990, GASTROENTEROLOGY, V99, P956, DOI 10.1016/0016-5085(90)90613-6; RUTGEERTS P, 1991, LANCET, V338, P771, DOI 10.1016/0140-6736(91)90663-A; SANKEY EA, 1993, GUT, V34, P375, DOI 10.1136/gut.34.3.375; WAKEFIELD AJ, 1989, LANCET, V2, P1057	9	9	10	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 5	1993	341	8858					1443	1444		10.1016/0140-6736(93)90886-L	http://dx.doi.org/10.1016/0140-6736(93)90886-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099145				2022-12-24	WOS:A1993LF84100008
J	JICK, SS; TERRIS, BZ; JICK, H				JICK, SS; TERRIS, BZ; JICK, H			1ST TRIMESTER TOPICAL TRETINOIN AND CONGENITAL DISORDERS	LANCET			English	Article							1ST-TRIMESTER DRUG-USE; PHOTODAMAGED SKIN	We used information from the Group Health Cooperative of Puget Sound, Washington, USA, to evaluate the risk of birth defects in mothers exposed to topical tretinoin-a retinoid preparation used to treat acne-in the first trimester of pregnancy. We identified 215 women who delivered live or stillborn infants at Group Health Cooperative hospitals and who were exposed to topical tretinoin early in pregnancy, and 430 age-matched nonexposed women who delivered live or stillborn infants at the same hospitals. The prevalence of major anomalies among babies born to the exposed women was 1.9% and among babies born to the nonexposed women was 2.6%. The relative risk estimate for having a baby with a major congenital anomaly for exposed versus nonexposed women was 0.7 (95% Cl 0.2-2.3). We conclude that topical tretinoin is not associated with an increased risk for major congenital disorders.			JICK, SS (corresponding author), BOSTON UNIV,MED CTR,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,11 MUZZEY ST,LEXINGTON,MA 02173, USA.			Jick, Hershel/0000-0003-4270-5992; Jick, Susan/0000-0002-2215-1067				ASELTON P, 1985, OBSTET GYNECOL, V65, P451; BHAWAN J, 1991, ARCH DERMATOL, V127, P666, DOI 10.1001/archderm.127.5.666; CAMERA G, 1992, LANCET, V339, P687, DOI 10.1016/0140-6736(92)90854-V; De Wals P, 1991, Paediatr Perinat Epidemiol, V5, P445; JICK H, 1979, NEW ENGL J MED, V300, P218, DOI 10.1056/NEJM197902013000502; JICK H, 1981, JAMA-J AM MED ASSOC, V246, P343, DOI 10.1001/jama.246.4.343; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; RAFAL ES, 1992, NEW ENGL J MED, V326, P368, DOI 10.1056/NEJM199202063260603; STERN RS, 1989, NEW ENGL J MED, V320, P1007, DOI 10.1056/NEJM198904133201510; WEINSTEIN GD, 1991, ARCH DERMATOL, V127, P659, DOI 10.1001/archderm.127.5.659	10	107	108	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1181	1182		10.1016/0140-6736(93)91004-6	http://dx.doi.org/10.1016/0140-6736(93)91004-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098078				2022-12-24	WOS:A1993LB01700006
J	GARATTINI, S				GARATTINI, S			PAIN RELIEF - NARCOTIC DRUG-USE FOR SEVERE PAIN	LANCET			English	Editorial Material											GARATTINI, S (corresponding author), MARIO NEGRI INST PHARMACOL RES,I-20157 MILAN,ITALY.		Garattini, Silvio/AAA-6390-2020	Garattini, Silvio/0000-0003-0647-9297				1990, GAZZETTA OFFICI 1030, P14	1	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1061	1062		10.1016/0140-6736(93)92418-S	http://dx.doi.org/10.1016/0140-6736(93)92418-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096965				2022-12-24	WOS:A1993KZ01800011
J	DAVIS, CB; KILLEEN, N; CROOKS, MEC; RAULET, D; LITTMAN, DR				DAVIS, CB; KILLEEN, N; CROOKS, MEC; RAULET, D; LITTMAN, DR			EVIDENCE FOR A STOCHASTIC MECHANISM IN THE DIFFERENTIATION OF MATURE SUBSETS OF T-LYMPHOCYTES	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CELL RECEPTOR; POSITIVE SELECTION; TRANSGENIC MICE; ANTIGEN RECEPTOR; ALPHA-3 DOMAIN; THYMIC SELECTION; CYTOPLASMIC TAIL; CD8 LINEAGE; MHC	Thymocytes that coexpress the CD4 and CD8 glycoproteins differentiate into mature CD4+ helper or CD8+ cytotoxic cells depending on whether their antigen receptors are specific for MHC class II or class I molecules, respectively. The mechanism of this decision process was investigated in mice whose T cell development was biased toward the class II-specific lineage. We found that constitutive expression of CD4 allows a developmentally arrested population of thymocytes that have mismatched class II-specific TCRs and the CD8 coreceptor to be rescued and to acquire a cytotoxic phenotype. This result is consistent with a two-step process of thymocyte maturation, in which there is stochastic down-regulation of either CD4 or CD8 and subsequent selection based on the ability of the TCR and remaining coreceptor to engage the same MHC molecule.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California Berkeley	DAVIS, CB (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.			Raulet, David/0000-0002-1257-8649				ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; BENDELAC A, 1991, NATURE, V353, P68, DOI 10.1038/353068a0; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BILL J, 1989, NATURE, V341, P649, DOI 10.1038/341649a0; BLACKMAN MA, 1989, SCIENCE, V244, P214, DOI 10.1126/science.2784868; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COHEN JJ, 1984, J IMMUNOL, V132, P38; COLLINS TL, 1992, J IMMUNOL, V148, P2159; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; CRISPE IN, 1987, J IMMUNOL, V138, P2012; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GUYGRAND D, 1991, J EXP MED, V173, P471, DOI 10.1084/jem.173.2.471; Hogan B, 1986, MANIPULATING MOUSE E, P89; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; JAMESON SC, 1991, J IMMUNOL, V147, P3185; JAMESON SC, 1990, J IMMUNOL, V145, P1324; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KILLEEN N, 1992, J EXP MED, V176, P89, DOI 10.1084/jem.176.1.89; KILLEEN N, 1993, IN PRESS EMBO J; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; MARRACK P, 1988, IMMUNOL TODAY, V9, P308, DOI 10.1016/0167-5699(88)91324-2; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; MISHELL BB, 1980, SELECTED METHODS CEL, P3; NIKOLICZUGIC J, 1991, IMMUNOL TODAY, V12, P65, DOI 10.1016/0167-5699(91)90160-U; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; RAMSDELL F, 1991, J IMMUNOL, V147, P1779; RAULET DH, 1980, J IMMUNOL, V125, P1136; ROBEY E, 1991, P NATL ACAD SCI USA, V88, P608, DOI 10.1073/pnas.88.2.608; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; ROCHA B, 1991, J EXP MED, V173, P483, DOI 10.1084/jem.173.2.483; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SWAT W, 1992, EUR J IMMUNOL, V22, P2367, DOI 10.1002/eji.1830220928; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TORRESNAGEL N, 1992, EUR J IMMUNOL, V22, P2841, DOI 10.1002/eji.1830221113; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANOERS NSC, 1992, EUR J IMMUNOL, V22, P735, DOI 10.1002/eji.1830220317; VONBOEHMER H, 1992, IMMUNOL TODAY, V13, P454, DOI 10.1016/0167-5699(92)90075-I; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WILSON A, 1988, CELL IMMUNOL, V117, P312, DOI 10.1016/0008-8749(88)90121-9; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	62	217	218	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 23	1993	73	2					237	247		10.1016/0092-8674(93)90226-G	http://dx.doi.org/10.1016/0092-8674(93)90226-G			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8097431				2022-12-24	WOS:A1993KY50500007
J	CURRAN, ME; ATKINSON, DL; EWART, AK; MORRIS, CA; LEPPERT, MF; KEATING, MT				CURRAN, ME; ATKINSON, DL; EWART, AK; MORRIS, CA; LEPPERT, MF; KEATING, MT			THE ELASTIN GENE IS DISRUPTED BY A TRANSLOCATION ASSOCIATED WITH SUPRAVALVULAR AORTIC-STENOSIS	CELL			English	Article							GEL-ELECTROPHORESIS; MESSENGER-RNA; 3' REGION; DNA; SEQUENCES; CLONING; FIBRILLIN	To identify genes involved in vascular disease, we investigated patients with supravalvular aortic stenosis (SVAS), an inherited vascular disorder that causes hemodynamically significant narrowing of large elastic arteries. Pulsed-field gel and Southern analyses showed that a translocation near the elastin gene cosegregated with SVAS in one family. DNA sequence analyses demonstrated that the translocation disrupted the elastin gene and localized the breakpoint to exon 28. Taken together with our previous study linking SVAS to the elastin gene in two additional families and existing knowledge of vascular biology, these data suggest that mutations in the elastin gene can cause SVAS.	UNIV UTAH,DIV CARDIOL,SALT LAKE CITY,UT 84112; UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; UNIV UTAH,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV NEVADA,SCH MED,DEPT PEDIAT,LAS VEGAS,NV 89102	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas	CURRAN, ME (corresponding author), UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.		Toland, Amanda Ewart/E-4202-2011		NCRR NIH HHS [MO1-RR00064] Funding Source: Medline; NHLBI NIH HHS [R01HL4807] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BEUREN A J, 1972, Birth Defects Original Article Series, V8, P45; BLACK JA, 1963, LANCET, V2, P745; BRESSAN GM, 1987, BIOCHEMISTRY-US, V26, P1497, DOI 10.1021/bi00380a001; BURRY AF, 1958, BRIT HEART J, V20, P143; CHEN SJ, 1989, ONCOGENE, V4, P195; CHEVERS N, 1842, GUYS HOSP REP, V7, P387; Davidson J, 1987, CONNECTIVE TISSUE DI, P29; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; EISENBERG R, 1964, AM J DIS CHILD, V108, P341, DOI 10.1001/archpedi.1964.02090010343002; EWART AK, 1993, IN PRESS P NATL ACAD, V90; FAZIO MJ, 1988, J INVEST DERMATOL, V91, P458, DOI 10.1111/1523-1747.ep12476591; FAZIO MJ, 1991, AM J HUM GENET, V48, P696; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GIACALONE JP, 1992, AM J HUM GENET, V50, P725; GRIMM T, 1980, Z KARDIOL, V69, P168; INDIK Z, 1987, CONNECT TISSUE RES, V16, P197, DOI 10.3109/03008208709006976; INDIK Z, 1987, P NATL ACAD SCI USA, V84, P809; JONES KL, 1975, J PEDIATR-US, V86, P718, DOI 10.1016/S0022-3476(75)80356-8; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; Maniatis T., 1982, MOL CLONING; MILEWICZ DM, 1992, J CLIN INVEST, V89, P79, DOI 10.1172/JCI115589; MORRIS CA, 1988, J PEDIATR-US, V113, P318, DOI 10.1016/S0022-3476(88)80272-5; MORRIS CA, 1991, P GREENWOOD GENET CT, V10, P81; OCONNOR WN, 1985, ARCH PATHOL LAB MED, V109, P179; PEROU M, 1961, ARCH PATHOL, V71, P113; PIERCE RA, 1990, BIOCHEMISTRY-US, V29, P9677, DOI 10.1021/bi00493a024; ROSENBLOOM J, 1991, EUK GENE EXPR, V1, P145; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SANDBERG LB, 1981, NEW ENGL J MED, V304, P566, DOI 10.1056/NEJM198103053041004; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TROMP G, 1991, NUCLEIC ACIDS RES, V19, P4314, DOI 10.1093/nar/19.15.4314-a; UITTO J, 1991, BIOCHEM SOC T, V19, P824, DOI 10.1042/bst0190824; YEH H, 1987, COLLAGEN REL RES, V7, P235; YOON K, 1985, ARCH BIOCHEM BIOPHYS, V241, P684, DOI 10.1016/0003-9861(85)90595-8	40	329	338	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					159	168		10.1016/0092-8674(93)90168-P	http://dx.doi.org/10.1016/0092-8674(93)90168-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8096434				2022-12-24	WOS:A1993KW75300016
J	DONNELLY, SC; STRIETER, RM; KUNKEL, SL; WALZ, A; ROBERTSON, CR; CARTER, DC; GRANT, IS; POLLOK, AJ; HASLETT, C				DONNELLY, SC; STRIETER, RM; KUNKEL, SL; WALZ, A; ROBERTSON, CR; CARTER, DC; GRANT, IS; POLLOK, AJ; HASLETT, C			INTERLEUKIN-8 AND DEVELOPMENT OF ADULT RESPIRATORY-DISTRESS SYNDROME IN AT-RISK PATIENT GROUPS	LANCET			English	Article							NEUTROPHIL CHEMOTACTIC FACTOR; GENE-EXPRESSION; LUNG; IL-8; MEDIATORS; LPS	Neutrophils have been implicated in the pathogenesis of the adult respiratory distress syndrome (ARDS). We have measured concentrations of the neutrophil attractant interleukin-8 in blood and bronchoalveolar lavage fluid (BAL) from patients at risk of ARDS. We studied 29 patients from three groups at risk of developing ARDS: multiple trauma (n=16), perforated bowel (n=6), and pancreatitis (n=7). ARDS developed in 7 of these patients. Interleukin-8 in BAL and blood samples taken on initial hospital presentation was measured by a sandwich enzyme-linked immunosorbent assay. The mean BAL interleukin-8 concentration was significantly higher for the patients who subsequently progressed to ARDS than for the non-ARDS group (3.06 [SE 2.64] vs 0.053 [0.010] ng/mL, p=0.0006). There was no difference between the groups in plasma interleukin-8 (6.23 [2.60] vs 5.12 [2.22] ng/mL, p=0.31 ). Immunocytochemistry suggested that the alveolar macrophage is an important source of interleukin-8 at this early stage in ARDS development. This study provides evidence of a relation between the presence of interleukin-8 in early BAL samples and the development of ARDS. The early appearance of interleukin-8 in BAL of patients at risk of ARDS may be an important prognostic indicator for the development of the disorder and reinforces the likely importance of neutrophils and the effects of their accumulation and activation in the pathogenesis of many cases of ARDS.	UNIV EDINBURGH,CITY HOSP,RESP MED UNIT,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; UNIV MICHIGAN,DEPT PATHOL & MED,DIV PULM & CRIT CARE MED,ANN ARBOR,MI 48109; UNIV BERN,THEODOR KOCHER INST,CH-3001 BERN,SWITZERLAND; ROYAL EDINBURGH & ASSOCIATED HOSP,DEPT ACCID & EMERGENCY,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND; ROYAL EDINBURGH & ASSOCIATED HOSP,DEPT SURG,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND; ROYAL EDINBURGH & ASSOCIATED HOSP,DEPT ANAESTHET,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,INTENS THERAPY UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Michigan System; University of Michigan; University of Bern; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh				Donnelly, Seamas/0000-0001-7145-1843				BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHRISTNER P, 1985, AM REV RESPIR DIS, V131, P690; GREGORY H, 1988, BIOCHEM BIOPH RES CO, V151, P883, DOI 10.1016/S0006-291X(88)80364-4; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; KOCH AE, 1991, J IMMUNOL, V147, P2187; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; LARSEN GL, 1983, ANNU REV IMMUNOL, V1, P335, DOI 10.1146/annurev.iy.01.040183.002003; LYNCH JP, 1992, AM REV RESPIR DIS, V145, P1433, DOI 10.1164/ajrccm/145.6.1433; MCNAUGHTON PD, 1992, LANCET, V339, P469; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; OSBORNE DH, 1981, BRIT J SURG, V68, P758, DOI 10.1002/bjs.1800681103; PARSONS PE, 1992, AM REV RESPIR DIS, V146, P694, DOI 10.1164/ajrccm/146.3.694; PARSONS PE, 1989, AM REV RESPIR DIS, V140, P294, DOI 10.1164/ajrccm/140.2.294; PETTY TL, 1983, RECENT ADV RESPIRATO, P103; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; REPINE JE, 1991, AM REV RESPIR DIS, V144, P251, DOI 10.1164/ajrccm/144.2.251; RINALDO JE, 1990, CLIN CHEST MED, V11, P621; RINALDO JE, 1982, NEW ENGL J MED, V306, P900, DOI 10.1056/NEJM198204153061504; ROCKER GM, 1989, LANCET, V1, P120; SCHRODER JM, 1989, J IMMUNOL, V142, P244; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; STANDIFORD TJ, 1992, AM J RESPIR CELL MOL, V6, P675; STRIETER RM, 1990, BIOCHEM BIOPH RES CO, V173, P725, DOI 10.1016/S0006-291X(05)80095-6; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; The BAL Cooperative Group Steering Committee, 1990, AM REV RESPIR DIS, V141, pS169; WARSHAWSKI FJ, 1986, AM REV RESPIR DIS, V133, P797; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218; WILLEMS J, 1989, IMMUNOLOGY, V67, P540	29	577	607	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					643	647		10.1016/0140-6736(93)90416-E	http://dx.doi.org/10.1016/0140-6736(93)90416-E			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095568	Green Submitted			2022-12-24	WOS:A1993KR61300001
J	WU, TC; TRUJILLO, JM; KASHIMA, HK; MOUNTS, P				WU, TC; TRUJILLO, JM; KASHIMA, HK; MOUNTS, P			ASSOCIATION OF HUMAN PAPILLOMAVIRUS WITH NASAL NEOPLASIA	LANCET			English	Note							CARCINOMA; CAVITIES; SINUSES; DNA	Since HPV-57b has been identified by two different techniques in benign, premalignant, and malignant lesions of the nasal cavity, but not in cases of chronic sinusitis, HPV-57 should be recognised as at least a co-factor in the aetiology of nasal neoplasia. Paraffin sections of 22 histologically confirmed nasal tumours were screened by in-situ hybridisation with riboprobes specific for HPV-57b. Virus was demonstrated in 6 of 7 fungiform papillomas, 6 of 8 inverted papillomas, 1 of 3 inverted papillomas with dysplasia, and 2 of 4 inverted papillomas with carcinoma. The presence of HPV-57b was confirmed with the polymerase chain reaction, which identified an additional 4 positive samples, bringing the total to 86% positive specimens. The results underscore the importance of HPVs in the aetiology of cancers at extragenital sites.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT IMMUNOL & INFECT DIS, 615 N WOLFE ST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV HOSP, DEPT OTOLARYNGOL HEAD & NECK SURG, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine								DEVILLIERS EM, 1989, VIROLOGY, V171, P248, DOI 10.1016/0042-6822(89)90532-1; FURUTA Y, 1991, LARYNGOSCOPE, V101, P79; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HYAMS VJ, 1971, ANN OTO RHINOL LARYN, V80, P192, DOI 10.1177/000348947108000205; Kashima HK, 1987, PAPILLOMAVIRUSES HUM, P138; MILLS SE, 1989, DIAGNOTIC SURGICAL P, P664; RESPLER DS, 1987, ANN OTO RHINOL LARYN, V96, P170, DOI 10.1177/000348948709600206; SYRJANEN S, 1987, ACTA OTO-LARYNGOL, V104, P334, DOI 10.3109/00016488709107337; WEBER RS, 1988, ARCH OTOLARYNGOL, V114, P23; WU TC, 1991, AM J PATHOL, V138, P1461	10	55	58	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 27	1993	341	8844					522	524		10.1016/0140-6736(93)90280-T	http://dx.doi.org/10.1016/0140-6736(93)90280-T			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094773				2022-12-24	WOS:A1993KP08300006
J	FRANKEL, EN; KANNER, J; GERMAN, JB; PARKS, E; KINSELLA, JE				FRANKEL, EN; KANNER, J; GERMAN, JB; PARKS, E; KINSELLA, JE			INHIBITION OF OXIDATION OF HUMAN LOW-DENSITY-LIPOPROTEIN BY PHENOLIC SUBSTANCES IN RED WINE	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; ALCOHOL-CONSUMPTION; LIPID-PEROXIDATION; FLAVONOIDS; CHOLESTEROL; MECHANISMS; QUERCETIN; RISK	The ''French paradox'' (apparent compatibility of a high fat diet with a low incidence of coronary atherosclerosis) has been attributed to the regular drinking of red wine. However, the alcohol content of wine may not be the sole explanation for this protection. Red wine also contains phenolic compounds, and the antioxidant properties of these may have an important role. In in-vitro studies with phenolic substances in red wine and normal human low-density lipoprotein (LDL) we found that red wine inhibits the copper-catalysed oxidation of LDL. Wine diluted 1000-fold containing 10 mumol/L total phenolics inhibited LDL oxidation significantly more than alpha-tocopherol. Our findings show that the non-alcoholic components of red wine have potent antioxidant properties toward oxidation of human LDL.	UNIV CALIF DAVIS,DEPT NUTR,DAVIS,CA 95616; VOLCANI CTR,BET DAGAN,ISRAEL	University of California System; University of California Davis; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	FRANKEL, EN (corresponding author), UNIV CALIF DAVIS,LIPID RES GRP,MRAK HALL,DAVIS,CA 95616, USA.		Frankel, Edwin N/G-1200-2011					AFANASEV IB, 1989, BIOCHEM PHARMACOL, V38, P1763, DOI 10.1016/0006-2952(89)90410-3; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; DAS NP, 1971, BIOCHEM PHARMACOL, V20, P3435, DOI 10.1016/0006-2952(71)90449-7; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FRANKEL EN, 1992, LIPIDS, V27, P1047, DOI 10.1007/BF02535586; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; GEY KF, 1987, AM J CLIN NUTR, V45, P1368, DOI 10.1093/ajcn/45.5.1368; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2849, DOI 10.1001/jama.256.20.2849; GUGLER R, 1975, EUR J CLIN PHARMACOL, V9, P229, DOI 10.1007/BF00614022; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; HUSAIN SR, 1987, PHYTOCHEMISTRY, V26, P2489, DOI 10.1016/s0031-9422(00)83860-1; JIALAL I, 1990, ATHEROSCLEROSIS, V82, P185, DOI 10.1016/0021-9150(90)90039-L; KANNER J, 1985, ARCH BIOCHEM BIOPHYS, V237, P314, DOI 10.1016/0003-9861(85)90282-6; KANNER J, 1977, J FOOD SCI, V42, P60, DOI 10.1111/j.1365-2621.1977.tb01218.x; KINSELLA JE, 1990, AM J CLIN NUTR, V52, P1; LAZARUS NB, 1991, BRIT MED J, V303, P553, DOI 10.1136/bmj.303.6802.553; MANGIAPANE H, 1992, BIOCHEM PHARMACOL, V43, P445, DOI 10.1016/0006-2952(92)90562-W; MORONEY MA, 1988, J PHARM PHARMACOL, V40, P787, DOI 10.1111/j.2042-7158.1988.tb05173.x; NEGRESALVAYRE A, 1992, FREE RADICAL BIO MED, V12, P101, DOI 10.1016/0891-5849(92)90002-X; ORR JR, 1991, ANAL FATS OILS LIPOP, P524; PARTHASARATHY S, 1986, J CLIN INVEST, V77, P641, DOI 10.1172/JCI112349; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; SIGNLETON VL, 1982, P U CALIFORNIA DAVIS, P215; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TOREL J, 1986, PHYTOCHEMISTRY, V25, P383, DOI 10.1016/S0031-9422(00)85485-0; 1988, CIRCULATION, V77, pA721	30	1449	1513	0	114	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					454	457		10.1016/0140-6736(93)90206-V	http://dx.doi.org/10.1016/0140-6736(93)90206-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094487				2022-12-24	WOS:A1993KN13700003
J	DONNELLY, R; HILLIS, WS				DONNELLY, R; HILLIS, WS			MYOCARDIAL INJURY - CARDIAC TROPONIN-T	LANCET			English	Editorial Material							INFARCTION; HEART		WESTERN INFIRM & ASSOCIATED HOSP,DEPT CARDIOL,GLASGOW G11 6NT,SCOTLAND		DONNELLY, R (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305, USA.							ANDERSON PAW, 1992, BASIC RES CARDIOL, V87, P117; ANDERSON PAW, 1991, CIRC RES, V69, P1226, DOI 10.1161/01.RES.69.5.1226; GERHARDT W, 1992, CLIN CHEM, V38, P1194; GERHARDT W, 1991, CLIN CHEM, V37, P1405; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; KATUS HA, 1992, CLIN CHEM, V38, P386; KATUS HA, 1991, AM J CARDIOL, V67, P1360, DOI 10.1016/0002-9149(91)90466-X; KOBAYASHI S, 1992, LANCET, V340, P726, DOI 10.1016/0140-6736(92)92262-E; MAIR J, 1991, LANCET, V337, P434, DOI 10.1016/0140-6736(91)91218-J; MAIR J, 1992, LANCET, V340, P1048, DOI 10.1016/0140-6736(92)93072-U; MAIR P, 1991, LANCET, V338, P693, DOI 10.1016/0140-6736(91)91266-W; TALASZ H, 1992, LANCET, V339, P1380, DOI 10.1016/0140-6736(92)91198-H	13	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					410	411		10.1016/0140-6736(93)92996-7	http://dx.doi.org/10.1016/0140-6736(93)92996-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094176				2022-12-24	WOS:A1993KM41600011
J	MCCARTHY, M				MCCARTHY, M			AIDS IMPACT SEEN AS SMALL IN THE UNITED-STATES	LANCET			English	Editorial Material																		1983, SOCIAL IMPACT AIDS U	1	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					429	430		10.1016/0140-6736(93)93016-T	http://dx.doi.org/10.1016/0140-6736(93)93016-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094185				2022-12-24	WOS:A1993KM41600023
J	OLD, R				OLD, R			HETEROZYGOTE ADVANTAGE - WHY ARE SOME DELETERIOUS GENES SO COMMON	LANCET			English	Editorial Material											OLD, R (corresponding author), UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND.							PRITCHARD DJ, 1991, HUM GENET, V87, P671; VULLIAMY T, 1992, TRENDS GENET, V8, P138, DOI 10.1016/0168-9525(92)90372-B	2	1	1	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					214	214		10.1016/0140-6736(93)90076-S	http://dx.doi.org/10.1016/0140-6736(93)90076-S			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093507				2022-12-24	WOS:A1993KJ21900014
J	THEURKAUF, WE				THEURKAUF, WE			PREMATURE MICROTUBULE-DEPENDENT CYTOPLASMIC STREAMING IN CAPPUCCINO AND SPIRE MUTANT OOCYTES	SCIENCE			English	Article							DROSOPHILA OOGENESIS; BICOID RNA; LOCALIZATION; ANTEROPOSTERIOR; PROTEIN; EMBRYO; VASA; POLE	Embryonic axis specification in Drosophila melanogaster is achieved through the asymmetric subcellular localization of morphogenetic molecules within the oocyte. The cappuccino and spire loci are required for both posterior and dorsoventral patterning. Time-lapse confocal microscopic analyses of living egg chambers demonstrated that these mutations induce microtubule reorganization and the premature initiation of microtubule-dependent ooplasmic streaming. As a result, microtubule organization is altered and bulk ooplasm rapidly streams during the developmental stages in which morphogens are normally localized. These changes in oocyte cytoarchitecture and dynamics appear to disrupt axial patterning of the embryo.			THEURKAUF, WE (corresponding author), SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA.			Theurkauf, William/0000-0001-7342-1912				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; Driever Wolfgang, 1993, P301; GUTZEIT HO, 1982, J EMBRYOL EXP MORPH, V67, P101; HAY B, 1990, DEVELOPMENT, V109, P425; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KOCH EA, 1983, CELL TISSUE RES, V228, P21; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; NUSSLEINVOLHARD C, 1989, CIBA F SYMP, V144, P37; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; SCHUPBACH T, 1991, GENETICS, V129, P1119; Spradling Allan C., 1993, P1; St Johnston Daniel, 1993, P325; STJOHNSTON D, 1992, CELL, V68, P201; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; THEURKAUF WE, UNPUB	18	130	129	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	1994	265	5181					2093	2096		10.1126/science.8091233	http://dx.doi.org/10.1126/science.8091233			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091233				2022-12-24	WOS:A1994PJ91200030
J	NITTI, VW				NITTI, VW			ICE-WATER TEST IN URODYNAMIC ASSESSMENT	LANCET			English	Editorial Material							BLADDER				NITTI, VW (corresponding author), SUNY HLTH SCI CTR,DEPT UROL,BROOKLYN,NY 11203, USA.			Nitti, Victor/0000-0002-1390-7053				BALMASEDA MT, 1988, AM J PHYS MED REHAB, V67, P225, DOI 10.1097/00002060-198810000-00008; BORS EH, 1957, ARCH NEURO PSYCHIATR, V78, P339, DOI 10.1001/archneurpsyc.1957.02330400013002; FALL M, 1989, BRIT J UROL, V64, P368, DOI 10.1111/j.1464-410X.1989.tb06045.x; GEIRSSON G, 1993, BRIT J UROL, V71, P681, DOI 10.1111/j.1464-410X.1993.tb16065.x; GEIRSSON G, 1993, J UROLOGY, V150, P427, DOI 10.1016/S0022-5347(17)35501-5; HELLSTROM PA, 1991, BRIT J UROL, V67, P275, DOI 10.1111/j.1464-410X.1991.tb15134.x; LINDSTROM S, 1990, NEUROUROL URODYNAM, V9, P365; RAZ S, 1973, J UROLOGY, V109, P603, DOI 10.1016/S0022-5347(17)60491-9; SUSSET JG, 1985, NEUROUROL URODYNAM, V4, P157, DOI 10.1002/nau.1930040303	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1066	1067		10.1016/0140-6736(93)92057-Z	http://dx.doi.org/10.1016/0140-6736(93)92057-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105305				2022-12-24	WOS:A1993ME82200003
J	SMITH, GCM; KENNA, JG; HARRISON, DJ; TEW, D; WOLF, CR				SMITH, GCM; KENNA, JG; HARRISON, DJ; TEW, D; WOLF, CR			AUTOANTIBODIES TO HEPATIC-MICROSOMAL CARBOXYLESTERASE IN HALOTHANE HEPATITIS	LANCET			English	Note							ANTIBODIES; LIVER; SERA; NEOANTIGENS	Halothane hepatitis can be life-threatening, and this severe adverse reaction may arise via an immune process. We have detected autoantibodies to purified human liver microsomal carboxylesterase in sera of 17 out of 20 patients with halothane hepatitis (85%) but not in 9 halothane-exposed controls and in only 2 (at low levels) of 33 patients with liver disease due to other causes. Immunohistochemical studies localised the carboxylesterase predominantly to the centrilobular region of liver sections, which is consistent with the area affected by halothane hepatitis. Human hepatic microsomal carboxylesterase is a target antigen in halothane hepatitis, and an immune response to this protein may be involved in the liver damage observed.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,BIOMED RES CTR,IMPERIAL CANC RES UNIT,MOLEC PHARMACOL UNIT,DUNDEE DD1 9SY,SCOTLAND; IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT PHARMACOL & TOXICOL,LONDON W2,ENGLAND; UNIV EDINBURGH,SCH MED,DEPT PATHOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; SMITHKLINE BEECHAM RES,WELWYN GARDEN CIT,ENGLAND	University of Dundee; Imperial College London; University of Edinburgh; GlaxoSmithKline			Kenna, J Gerry/H-9929-2012	Wolf, Charles Roland/0000-0002-6969-0113; Smith, Gillian/0000-0001-9288-7566				CHRIST DD, 1988, ANESTHESIOLOGY, V69, P833, DOI 10.1097/00000542-198812000-00006; HARRISON DJ, 1989, J CLIN PATHOL, V42, P624, DOI 10.1136/jcp.42.6.624; KENNA JG, 1988, J PHARMACOL EXP THER, V245, P1103; KENNA JG, 1988, HEPATOLOGY, V8, P1635, DOI 10.1002/hep.1840080627; KENNA JG, 1993, ANN NY ACAD SCI, V685, P646, DOI 10.1111/j.1749-6632.1993.tb35930.x; KENNA JG, 1984, J IMMUNOL METHODS, V75, P3, DOI 10.1016/0022-1759(84)90219-9; RAY DC, 1991, BRIT J ANAESTH, V67, P84, DOI 10.1093/bja/67.1.84; SATOH H, 1985, J PHARMACOL EXP THER, V233, P857; SATOH H, 1989, P NATL ACAD SCI USA, V86, P322, DOI 10.1073/pnas.86.1.322	9	41	41	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					963	964		10.1016/0140-6736(93)92005-E	http://dx.doi.org/10.1016/0140-6736(93)92005-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105217				2022-12-24	WOS:A1993MC00500012
J	LITTLETON, JT; STERN, M; SCHULZE, K; PERIN, M; BELLEN, HJ				LITTLETON, JT; STERN, M; SCHULZE, K; PERIN, M; BELLEN, HJ			MUTATIONAL ANALYSIS OF DROSOPHILA SYNAPTOTAGMIN DEMONSTRATES ITS ESSENTIAL ROLE IN CA(2+)-ACTIVATED NEUROTRANSMITTER RELEASE	CELL			English	Article							SYNAPTIC TRANSMITTER RELEASE; ALPHA-LATROTOXIN RECEPTOR; PROTEIN KINASE-C; NEUROMUSCULAR-JUNCTION; VESICLE EXOCYTOSIS; NERVE TERMINALS; ACTIVE ZONES; CALCIUM-IONS; BINDING; MELANOGASTER	Synaptotagmin (syt), a synaptic vesicle-specific protein known to bind Call in the presence of phospholipids, has been proposed to mediate Ca2+-dependent neurotransmitter release. We have addressed the role of syt in neurotransmitter release in vivo by generating mutations in synaptotagmin (syt) in the fruitfly and assaying the subsequent effects on neurotransmission. Most embryos that lack syt fall to hatch and exhibit very reduced, uncoordinated muscle contractions. Larvae with partial lack-of-function mutations show almost no evoked excitatory junctional potentials (EJPs) in 0.4 mM Ca2+ and a 15-fold reduction in EJP amplitude in 1.0 mM Ca2+ when compared with heterozygous controls. In contrast, we observe an increase in the frequency of spontaneous miniature EJPs in the mutants. These results provide in vivo evidence that syt plays a key role in Ca2+ activation of neurotransmitter release and indicate the existence of separate pathways for evoked and spontaneous neurotransmitter release.	BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA; RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Rice University	LITTLETON, JT (corresponding author), BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA.			Littleton, J. Troy/0000-0001-5576-2887; Bellen, Hugo/0000-0001-5992-5989				AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BELLEN HJ, 1992, GENE DEV, V6, P2125, DOI 10.1101/gad.6.11.2125; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROADIE KS, 1993, J NEUROSCI, V13, P144; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CECCARELLI B, 1980, PHYSIOL REV, V60, P396, DOI 10.1152/physrev.1980.60.2.396; COHEN MW, 1991, J NEUROSCI, V11, P1032; COPE TC, 1982, J NEUROPHYSIOL, V47, P469, DOI 10.1152/jn.1982.47.3.469; DELCASTILLO J, 1956, PROG BIOPHYS MOL BIO, V6, P122, DOI 10.1016/S0096-4174(18)30106-9; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; GANETZKY B, 1982, J NEUROPHYSIOL, V47, P501, DOI 10.1152/jn.1982.47.3.501; HEUSER JE, 1979, J CELL BIOL, V81, P275, DOI 10.1083/jcb.81.2.275; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; JAN YN, 1978, P NATL ACAD SCI USA, V75, P515, DOI 10.1073/pnas.75.1.515; KAISER K, 1990, P NATL ACAD SCI USA, V87, P1686, DOI 10.1073/pnas.87.5.1686; KATZ B, 1967, PROC R SOC SER B-BIO, V167, P23, DOI 10.1098/rspb.1967.0011; KUFFLER SW, 1984, NEURON BRAIN; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; LLINAS R, 1981, BIOPHYS J, V33, P289, DOI 10.1016/S0006-3495(81)84898-9; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MATTEOLI M, 1988, P NATL ACAD SCI USA, V85, P7366, DOI 10.1073/pnas.85.19.7366; MILEDI R, 1973, PROC R SOC SER B-BIO, V183, P421, DOI 10.1098/rspb.1973.0026; MULKEY RM, 1991, NATURE, V350, P153, DOI 10.1038/350153a0; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; POPOV SV, 1993, CELL, V73, P1247, DOI 10.1016/0092-8674(93)90352-Q; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STERN M, 1989, J NEUROGENET, V5, P215, DOI 10.3109/01677068909066209; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOWER J, 1993, GENETICS, V133, P347; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; Walch-Solimena C, 1993, Curr Opin Neurobiol, V3, P329, DOI 10.1016/0959-4388(93)90125-I; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0	52	384	390	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 24	1993	74	6					1125	1134		10.1016/0092-8674(93)90733-7	http://dx.doi.org/10.1016/0092-8674(93)90733-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8104705				2022-12-24	WOS:A1993LY49300018
J	FELDMAN, RD; BIERBRIER, GS				FELDMAN, RD; BIERBRIER, GS			INSULIN-MEDIATED VASODILATION - IMPAIRMENT WITH INCREASED BLOOD-PRESSURE AND BODY-MASS	LANCET			English	Article							LOW-SODIUM DIET; BETA-ADRENERGIC RESPONSE; ESSENTIAL-HYPERTENSION; SKELETAL-MUSCLE; RESISTANCE; CORRECTS; RESPONSIVENESS; PATHOGENESIS; DISORDERS; HUMANS	Insulin resistance is associated with hypertension although it is not known if this relationship is casual. Studies have shown that insulin increases skeletal-muscle blood flow despite also increasing sympathetic activity. To determine whether insulin may act as a direct vasodilator and whether insulin-mediated vascular effects are altered in hypertension, we studied insulin-mediated alterations in dorsal-hand-vein compliance in normotensive and mild and borderline hypertensive subjects. In phenylephrine pre-constricted vessels, insulin caused a dose-dependent increase in venous distensibility. Insulin-mediated venodilation was significantly impaired in hypertensive subjects. The vasodilator potency of insulin was significantly correlated with both blood pressure and body mass index. Insulin may be an endogenous vasodilator. Further, in hypertensive and obese subjects, impairment of insulin-mediated vasodilation may contribute to the increase in peripheral resistance characteristic of hypertension.	UNIV WESTERN ONTARIO,DEPT MED,LONDON N6A 3K7,ONTARIO,CANADA; UNIV WESTERN ONTARIO,DEPT PHARMACOL & TOXICOL,LONDON N6A 3K7,ONTARIO,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario)			Feldman, Ross/G-3293-2011					AELLIG WH, 1981, BRIT J CLIN PHARMACO, V11, P237, DOI 10.1111/j.1365-2125.1981.tb00527.x; ANDERSON EA, 1993, HYPERTENSION, V21, P136, DOI 10.1161/01.HYP.21.2.136; ANDERSON EA, 1992, HYPERTENSION, V19, P621, DOI 10.1161/01.HYP.19.6.621; ANDERSON EA, 1991, J CLIN INVEST, V87, P2246, DOI 10.1172/JCI115260; CAPALDO B, 1991, METABOLISM, V40, P1320, DOI 10.1016/0026-0495(91)90036-V; CREAGER MA, 1985, J PHARMACOL EXP THER, V235, P709; FELDMAN RD, 1992, CIRCULATION, V85, P612, DOI 10.1161/01.CIR.85.2.612; FELDMAN RD, 1987, J CLIN INVEST, V79, P290, DOI 10.1172/JCI112797; FELDMAN RD, 1990, J CLIN INVEST, V85, P647, DOI 10.1172/JCI114487; FERRANNINI E, 1991, AM HEART J, V121, P1274, DOI 10.1016/0002-8703(91)90433-I; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; KORNER PI, 1984, CLIN EXP HYPERTENS A, V6, P565, DOI 10.3109/10641968409062584; KUZYA H, 1977, DIABETES, V26, P22; LAAKSO M, 1990, J CLIN INVEST, V85, P1844, DOI 10.1172/JCI114644; LEE A, 1992, DIABETES, V41, P759; NASLUND T, 1990, CLIN PHARMACOL THER, V48, P87, DOI 10.1038/clpt.1990.121; NATALI A, 1991, HYPERTENSION, V17, P170, DOI 10.1161/01.HYP.17.2.170; PAN HYM, 1986, J PHARMACOL EXP THER, V239, P802; STROZZI C, 1979, GERONTOLOGY, V25, P24, DOI 10.1159/000212317; THORBURN AW, 1986, BRIT MED J, V292, P1697, DOI 10.1136/bmj.292.6537.1697; VANBRUMMELEN P, 1981, CLIN SCI, V60, P571, DOI 10.1042/cs0600571; WEBB RC, 1981, AM HEART J, V102, P251	22	133	133	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					707	709		10.1016/0140-6736(93)91708-T	http://dx.doi.org/10.1016/0140-6736(93)91708-T			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103822				2022-12-24	WOS:A1993LX46900009
J	SCHLAGGAR, BL; FOX, K; OLEARY, DDM				SCHLAGGAR, BL; FOX, K; OLEARY, DDM			POSTSYNAPTIC CONTROL OF PLASTICITY IN DEVELOPING SOMATOSENSORY CORTEX	NATURE			English	Article							RECEPTOR ANTAGONISTS DISRUPT; STRIATE CORTEX; BLOCKADE PREVENTS; CORTICAL ACTIVITY; NMDA RECEPTORS; VISUAL-CORTEX; RAT; ACETYLCHOLINESTERASE; PERIOD; AXONS	THE rearrangement of synaptic connections during normal and deprived development is thought to be controlled by correlations in afferent impulse activity1. A favoured model is based on postsynaptic detection of synchronously active afferents; synapses are stabilized when pre- and postsynaptic activity is correlated and weakened or eliminated when their activity is uncorrelated2,3. Most evidence for this model comes from demonstrations that correlated afferent input is necessary for the segregation of eye-dominant inputs in the developing vertebrate visual system1,4,5 and that critical period plasticity of ocular dominance columns in cat visual cortex is disrupted by blockade of postsynaptic transmission6-8. We tested whether the developmental plasticity of somatosensory columns, known as 'barrels', in rodent primary somatosensory cortex (S1)9-13 is similar to that of ocular dominance columns. We report here that the selective disruption of postsynaptic activation in rat S1 by application of a glutamate receptor antagonist inhibits rearrangements in the somatotopic patterning of thalamocortical afferents induced by manipulations of the sensory periphery during the critical period. These findings show that postsynaptic activation has a prominent role in critical period plasticity in S1 cortex.	SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037; UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455	Salk Institute; University of Minnesota System; University of Minnesota Twin Cities			Schlaggar, Bradley/AAZ-4153-2020; Fox, Kevin/E-8836-2010	Fox, Kevin/0000-0002-2563-112X				AGMON A, 1992, J NEUROPHYSIOL, V68, P345, DOI 10.1152/jn.1992.68.1.345; BEAR MF, 1985, J COMP NEUROL, V234, P411, DOI 10.1002/cne.902340402; BEAR MF, 1990, J NEUROSCI, V10, P909; BELFORD GR, 1980, J COMP NEUROL, V193, P335, DOI 10.1002/cne.901930203; CHIAIA NL, 1992, DEV BRAIN RES, V66, P244, DOI 10.1016/0165-3806(92)90086-C; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; CONSTAINTINEPAT.M, 1991, A REV NEUROSCI, V13, P129; ERZURUMLU RS, 1990, DEV BRAIN RES, V56, P229; FOX K, 1992, J NEUROSCI, V12, P1826; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; HEBB DO, 1949, ORG BEHAVIOR; HENDERSON TA, 1992, DEV BRAIN RES, V66, P146, DOI 10.1016/0165-3806(92)90152-M; HONORE T, 1988, SCIENCE, V214, P1701; KILLACKEY HP, 1975, BRAIN RES, V86, P469, DOI 10.1016/0006-8993(75)90897-5; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; LEVAY S, 1980, J COMP NEUROL, V91, P1; MCCASLAND JS, 1992, P NATL ACAD SCI USA, V89, P1832, DOI 10.1073/pnas.89.5.1832; REITER HO, 1986, EXP BRAIN RES, V65, P182; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; ROBERTSON RT, 1987, NEUROSCI LETT, V75, P259, DOI 10.1016/0304-3940(87)90531-3; Schlaggar B L, 1993, Perspect Dev Neurobiol, V1, P81; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; STRYKER MP, 1986, J NEUROSCI, V6, P2117; VANDERLO.H, 1973, SCIENCE, V179, P395, DOI 10.1126/science.179.4071.395; WIESEL TN, 1965, J NEUROPHYSIOL, V28, P1029, DOI 10.1152/jn.1965.28.6.1029; WOOLSEY TA, 1976, J COMP NEUROL, V170, P53, DOI 10.1002/cne.901700105; WOOLSEY TA, 1970, BRAIN RES, V1, P205	30	279	280	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					623	626		10.1038/364623a0	http://dx.doi.org/10.1038/364623a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	8102476				2022-12-24	WOS:A1993LR77100052
J	HOCKLEY, AD				HOCKLEY, AD			CRANIOSYNOSTOSIS	LANCET			English	Editorial Material											HOCKLEY, AD (corresponding author), QUEEN ELIZABETH HOSP,DEPT NEUROSURG,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							CHAR F, 1978, JUN BIRTH DEF ANN M; Cohen, 1986, CRANIOSYNOSTOSIS DIA; GOLDIN H, 1986, BR J HOSP MED, V37, P368; HUNT L, 1993, INDEPENDENT     0707, P2; KIRBY PJG, 1993, LANCET, V341, P1412, DOI 10.1016/0140-6736(93)90979-Q; MUNRO IR, 1975, PLAST RECONSTR SURG, V55, P170, DOI 10.1097/00006534-197502000-00006; RENIER D, 1982, J NEUROSURG, V57, P370, DOI 10.3171/jns.1982.57.3.0370; TESSIER P, 1971, 5TH T INT C PLAST RE, P903; VINKEN PJ, 1977, HDB CLIN NEUROLOGY 1, V30, P1	9	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					189	190		10.1016/0140-6736(93)92291-Z	http://dx.doi.org/10.1016/0140-6736(93)92291-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100923				2022-12-24	WOS:A1993LN62200004
J	BRAHAMS, D				BRAHAMS, D			COURT AWARD FOR PERTUSSIS-VACCINE DAMAGE	LANCET			English	Editorial Material																			0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 22	1993	341	8856					1338	1339		10.1016/0140-6736(93)90837-7	http://dx.doi.org/10.1016/0140-6736(93)90837-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098462				2022-12-24	WOS:A1993LD25300017
J	PARMET, JL; BERMAN, AT; HORROW, JC; HARDING, S; ROSENBERG, H				PARMET, JL; BERMAN, AT; HORROW, JC; HARDING, S; ROSENBERG, H			THROMBOEMBOLISM COINCIDENT WITH TOURNIQUET DEFLATION DURING TOTAL KNEE ARTHROPLASTY	LANCET			English	Note							EMBOLISM	Despite prophylactic therapy, pulmonary embolism remains the leading cause of perioperative mortality in patients undergoing total knee arthroplasty (TKA). We used transoesophageal echocardiography to monitor 29 consecutive patients during TKA. Showers of substantial amounts of echogenic material, lasting for 3-15 min, were visible in the right atrium and ventricle within 10-15 s of tourniquet deflation in all patients. A 3 x 6 mm fresh thrombus was aspirated from the central circulation of one patient. Another patient, who had had a Greenfield filter placed for previous thromboembolism, showed very little echogenic material after tourniquet deflation. The composition and importance of these echogenic emboli remain uncertain.	HAHNEMANN UNIV,DEPT ORTHOPED,PHILADELPHIA,PA 19102	Drexel University	PARMET, JL (corresponding author), HAHNEMANN UNIV,DEPT ANESTHESIOL,BROAD & VINC,PHILADELPHIA,PA 19102, USA.							ERETH MH, 1992, MAYO CLIN PROC, V67, P1066, DOI 10.1016/S0025-6196(12)61121-5; Heinrich H, 1988, Acta Orthop Belg, V54, P12; MCGRATH BG, 1992, ANESTHESIOLOGY S, V77, pA1080; MCGRATH BJ, 1991, ANESTHESIOLOGY, V74, P618, DOI 10.1097/00000542-199103000-00034; MESSAHEL F M, 1991, Middle East Journal of Anesthesiology, V11, P187; ORSINI EC, 1986, CAN J SURG, V29, P385; Schlag G, 1988, Acta Orthop Belg, V54, P6; WEDEL DJ, 1993, ORTHOPEDIC ANESTHESI, P355; 1990, NATIONAL CTR HLTH 13, V113	9	84	85	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1057	1058		10.1016/0140-6736(93)92414-O	http://dx.doi.org/10.1016/0140-6736(93)92414-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096961				2022-12-24	WOS:A1993KZ01800007
J	THOMAS, DJ; PENNOCK, JM; HAJNAL, JV; YOUNG, IR; BYDDER, GM; STEINER, RE				THOMAS, DJ; PENNOCK, JM; HAJNAL, JV; YOUNG, IR; BYDDER, GM; STEINER, RE			MAGNETIC-RESONANCE-IMAGING OF SPINAL-CORD IN MULTIPLE-SCLEROSIS BY FLUID-ATTENUATED INVERSION RECOVERY	LANCET			English	Note								Magnetic resonance imaging examination of the upper spinal cord was done in sixteen adult patients with clinically definite multiple sclerosis (MS) by T2 weighted fluid attenuated inversion recovery (FLAIR) scanning in which the signal from cerebrospinal fluid was suppressed. These scans were compared with matched images obtained with conventional T1 and T2 weighted pulse sequences (including contrast enhancement). 6 lesions (five patients) were seen with the conventional scans and 37 lesions (fourteen patients) were seen with the FLAIR scans. The FLAIR sequence considerably improves the ability of MRI to demonstrate spinal involvement in MS.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,ROBERT STEINER MAGNET RESONANCE UNIT,LONDON W12 0HS,ENGLAND; ST MARYS HOSP,DEPT NEUROL,LONDON,ENGLAND; NATL HOSP,LONDON WC1N 3BG,ENGLAND; PICKER INTL,WEMBLEY,MIDDX,ENGLAND	Imperial College London; Imperial College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust			Hajnal, Joseph/P-6251-2018	Hajnal, Joseph/0000-0002-2690-5495				FOG T, 1950, ARCH NEURO PSYCHIATR, V63, P382, DOI 10.1001/archneurpsyc.1950.02310210028003; HAJNAL JV, 1992, 11TH ANN M SOC MAGN, P1528; HONIG LS, 1989, J NEUROL NEUROSUR PS, V52, P459, DOI 10.1136/jnnp.52.4.459; KURTZKE JF, 1970, HDB CLIN NEUROLOGY, V7, P206; MARAVILLA KR, 1985, AM J ROENTGENOL, V144, P381, DOI 10.2214/ajr.144.2.381; MCDONALD WI, 1989, BRIT MED J, V299, P635, DOI 10.1136/bmj.299.6700.635; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; THORPE JW, 1992, 11TH ANN M SOC MAGN, P419; WALLACE CJ, 1992, AM J ROENTGENOL, V158, P849, DOI 10.2214/ajr.158.4.1546605; WHITE SJ, 1992, MAGNET RESON MED, V28, P153, DOI 10.1002/mrm.1910280116	10	67	68	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					593	594		10.1016/0140-6736(93)90353-I	http://dx.doi.org/10.1016/0140-6736(93)90353-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094830				2022-12-24	WOS:A1993KQ23400005
J	MATSUMURA, K; NONAKA, I; CAMPBELL, KP				MATSUMURA, K; NONAKA, I; CAMPBELL, KP			ABNORMAL EXPRESSION OF DYSTROPHIN-ASSOCIATED PROTEINS IN FUKUYAMA-TYPE CONGENITAL MUSCULAR-DYSTROPHY	LANCET			English	Note								The absence of dystrophin causes Duchenne muscular dystrophy. Dystrophin is associated with a large complex of sarcolemmal glycoproteins which provides a linkage to the extracellular matrix component laminin, and when dystrophin is absent all the dystrophin-associated proteins are much reduced. We report here that dystrophin-associated proteins have abnormally low expression in Fukuyama-type congenital muscular dystrophy (FCMD), despite near-normal expression of dystrophin. An abnormality of dystrophin-associated proteins in the sarcolemma seems to be a common denominator in the pathological processes leading to muscle cell necrosis in three forms of severe muscular dystrophy (Duchenne, Japanese Fukuyama-type, and north African Duchenne-like autosomal recessive).	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,TOKYO,JAPAN	Howard Hughes Medical Institute; University of Iowa; University of Iowa; National Center for Neurology & Psychiatry - Japan				Campbell, Kevin/0000-0003-2066-5889				ARAHATA K, 1989, P NATL ACAD SCI USA, V86, P7154, DOI 10.1073/pnas.86.18.7154; ARIKAWA E, 1991, J NEUROL SCI, V105, P79, DOI 10.1016/0022-510X(91)90122-N; BEGGS AH, 1992, P NATL ACAD SCI USA, V89, P623, DOI 10.1073/pnas.89.2.623; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; NONAKA I, 1979, HDB CLIN NEUROLOGY, V41, P27; OHLENDIECK K, IN PRESS NEUROLOGY	8	77	81	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					521	522		10.1016/0140-6736(93)90279-P	http://dx.doi.org/10.1016/0140-6736(93)90279-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094772				2022-12-24	WOS:A1993KP08300005
J	WILCKEN, B; LEUNG, KC; HAMMOND, J; KAMATH, R; LEONARD, JV				WILCKEN, B; LEUNG, KC; HAMMOND, J; KAMATH, R; LEONARD, JV			PREGNANCY AND FETAL LONG-CHAIN 3-HYDROXYACYL COENZYME-A DEHYDROGENASE-DEFICIENCY	LANCET			English	Note							ACID OXIDATION DEFECT	We report on eleven pregnancies in 5 mothers. 6 of the babies had long-chain 3-hydroxyacyl coenzyme A dehydrogenase (LCHAD) deficiency, and each of the pregnancies was complicated by features such as fatty liver and HELLP (haemolysis, elevated liver enzymes, low platelets) syndrome. By contrast, 3 of the mothers also gave birth to unaffected babies, and these pregnancies were largely uncomplicated. We conclude that there may be adverse effects on maternal liver function from a fetus with LCHAD deficiency. Heterozygosity in the, mother cannot alone account for the adverse effects because of the segregation of these effects with fetal LCHAD status.	CHILDRENS HOSP,SYDNEY,AUSTRALIA; INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND	University of Sydney; University of London; University College London	WILCKEN, B (corresponding author), NEW S WALES HLTH DEPT,OLIVER LATHAM LAB,POB 53,SYDNEY,NSW 2113,AUSTRALIA.							HAGENFELDT L, 1990, J PEDIATR-US, V116, P387, DOI 10.1016/S0022-3476(05)82826-4; HALE DE, 1990, FATTY ACID OXIDATION, P503; JACKSON S, 1991, PEDIATR RES, V29, P406, DOI 10.1203/00006450-199104000-00016; SCHOEMAN MN, 1991, GASTROENTEROLOGY, V100, P544, DOI 10.1016/0016-5085(91)90228-D; STANLEY CA, 1990, INBORN METABOLIC DIS, P395; WEINSTEIN L, 1982, AM J OBSTET GYNECOL, V142, P159, DOI 10.1016/S0002-9378(16)32330-4	6	164	168	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					407	408		10.1016/0140-6736(93)92993-4	http://dx.doi.org/10.1016/0140-6736(93)92993-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094173				2022-12-24	WOS:A1993KM41600008
J	MURPHY, GS; BASRI, H; PURNOMO; ANDERSEN, EM; BANGS, MJ; MOUNT, DL; GORDEN, J; LAL, AA; PURWOKUSUMO, AR; HARJOSUWARNO, S; SORENSEN, K; HOFFMAN, SL				MURPHY, GS; BASRI, H; PURNOMO; ANDERSEN, EM; BANGS, MJ; MOUNT, DL; GORDEN, J; LAL, AA; PURWOKUSUMO, AR; HARJOSUWARNO, S; SORENSEN, K; HOFFMAN, SL			VIVAX MALARIA RESISTANT TO TREATMENT AND PROPHYLAXIS WITH CHLOROQUINE	LANCET			English	Article							FINGER-STICK BLOOD; PLASMODIUM-VIVAX; WHOLE-BLOOD; DESETHYLCHLOROQUINE; PYRIMETHAMINE; FALCIPARUM; INDONESIA; SAMPLES; PLASMA; SERUM	Chloroquine has been the treatment of choice for vivax malaria for more than 40 years. Lately, several case-reports have suggested the emergence of resistance to chloroquine in Plasmodium vivax in Papua New Guinea and Indonesia. We undertook prospective treatment and prophylaxis trials of chloroquine in children and adults with vivax malaria living in Irian Jaya (Indonesian New Guinea). 46 villagers with P vivax parasitaemia were treated with chloroquine by mouth (25 mg base/kg body weight divided over 3 days) and followed up for 14 days. Parasitaemia cleared initially but recurred within 14 days in 10 (22%) subjects. All recurrences were in children younger than 11 years, 7 of whom were younger than 4 years; the failure rate among children under 4 was 70%. 7 of the patients with recurrences were given a second course of chloroquine. In all, the infections initially cleared but recurrent parasitaemia developed in 5 (71%) within 14 days. Whole-blood chloroquine concentrations were consistently above those previously shown to cure P vivax blood infections (90 mug/L whole blood). Subjects whose initial infections cleared and who had no parasitaemia on day 14 received weekly prophylaxis with chloroquine. Despite the presence of expected blood chloroquine concentrations, P vivax parasitaemia developed in 9 of 17 subjects receiving prophylaxis during 8 weeks of follow-up (median time to parasitaemia 5.3 weeks). Chloroquine can no longer be relied upon for effective treatment or chemoprophylaxis of P vivax blood infections acquired in this part of New Guinea.	USN, MED RES UNIT 2, JAKARTA, INDONESIA; MINIST HLTH REPUBL INDONESIA, JAKARTA, INDONESIA; CTR DIS CONTROL, MALARIA BRANCH, ATLANTA, GA 30333 USA; USN, MED RES INST, BETHESDA, MD 20814 USA	University of 19 November Kolaka; Ministry of Health - Indonesia; Centers for Disease Control & Prevention - USA; Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy				Gorden, Jed/0000-0003-0683-9547				ARIAS AE, 1989, TROP MED PARASITOL, V40, P21; BAIRD JK, 1991, AM J TROP MED HYG, V44, P547, DOI 10.4269/ajtmh.1991.44.547; BERGQVIST Y, 1983, J CHROMATOGR, V272, P137, DOI 10.1016/S0378-4347(00)86110-1; BERLINER RW, 1948, J CLIN INVEST, V27, P98, DOI 10.1172/JCI101980; BROCKELMAN C R, 1989, Southeast Asian Journal of Tropical Medicine and Public Health, V20, P41; Bruce-Chwatt LJ, 1981, CHEMOTHERAPY MALARIA; COLLIGNON P, 1991, J INFECT DIS, V164, P222, DOI 10.1093/infdis/164.1.222; DEAN AG, 1990, EPI INFO VERSION 5; DOBERSTYN EB, 1979, T ROY SOC TROP MED H, V73, P15, DOI 10.1016/0035-9203(79)90121-4; GORDON HH, 1947, ARCH INTERN MED, V79, P365, DOI 10.1001/archinte.1947.00220100015001; GORNHAM PCC, 1988, MALARIA PRINCIPLES P, V1, P61; GUSTAFSSON LL, 1983, LANCET, V1, P126; GUSTAFSSON LL, 1983, BRIT J CLIN PHARMACO, V15, P471, DOI 10.1111/j.1365-2125.1983.tb01532.x; MILLER KD, 1986, AM J TROP MED HYG, V35, P451, DOI 10.4269/ajtmh.1986.35.451; MOST H, 1946, JAMA-J AM MED ASSOC, V131, P963, DOI 10.1001/jama.1946.02870290013005; MOUNT DL, 1988, J CHROMATOGR-BIOMED, V428, P196, DOI 10.1016/S0378-4347(00)83908-0; PATCHEN LC, 1983, J CHROMATOGR, V278, P81, DOI 10.1016/S0378-4347(00)84758-1; Peters W, 1970, CHEMOTHERAPY DRUG RE; QARI SH, 1991, J BIOL CHEM, V266, P16297; RIECKMANN KH, 1989, LANCET, V2, P1183, DOI 10.1016/S0140-6736(89)91792-3; ROMBO L, 1987, TROP MED PARASITOL, V38, P49; ROMBO L, 1985, THER DRUG MONIT, V7, P211, DOI 10.1097/00007691-198506000-00013; ROMBO L, 1986, T ROY SOC TROP MED H, V80, P763, DOI 10.1016/0035-9203(86)90380-9; ROMBO L, 1987, B WORLD HEALTH ORGAN, V65, P879; SCHMIDT LH, 1978, AM J TROP MED HYG, V27, P703, DOI 10.4269/ajtmh.1978.27.703; SCHUURKAMP GJ, 1992, T ROY SOC TROP MED H, V86, P121, DOI 10.1016/0035-9203(92)90531-G; SCHUURKAMP GJ, 1989, T ROY SOC TROP MED H, V83, P607, DOI 10.1016/0035-9203(89)90370-2; SCHWARTZ IK, 1991, NEW ENGL J MED, V324, P927; WHITBY M, 1989, LANCET, V2, P1395, DOI 10.1016/S0140-6736(89)92002-3	29	166	169	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 9	1993	341	8837					96	100		10.1016/0140-6736(93)92568-E	http://dx.doi.org/10.1016/0140-6736(93)92568-E			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093414				2022-12-24	WOS:A1993KF87000015
J	SKRABANEK, P				SKRABANEK, P			ASYMMETRICAL AUTOIMMUNITY	LANCET			English	Editorial Material							HANDEDNESS											CHENGAPPA KNR, 1991, LANCET, V338, P694, DOI 10.1016/0140-6736(91)91268-Y; CHENGAPPA KNR, 1992, LIFE SCI, V51, P1843, DOI 10.1016/0024-3205(92)90035-N; CHYATTE C, 1980, J IRISH MED ASSOC, V73, P247; Coren S., 1992, LEFT HANDER SYNDROME; GESCHWIND N, 1982, P NATL ACAD SCI-BIOL, V79, P5097, DOI 10.1073/pnas.79.16.5097; SKRABANEK P, 1992, PERSPECT BIOL MED, V35, P182	6	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					26	27		10.1016/0140-6736(93)92491-B	http://dx.doi.org/10.1016/0140-6736(93)92491-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093274				2022-12-24	WOS:A1993KF02700013
J	LYNCH, A; MARLAR, R; MURPHY, J; DAVILA, G; SANTOS, M; RUTLEDGE, J; EMLEN, W				LYNCH, A; MARLAR, R; MURPHY, J; DAVILA, G; SANTOS, M; RUTLEDGE, J; EMLEN, W			ANTIPHOSPHOLIPID ANTIBODIES IN PREDICTING ADVERSE PREGNANCY OUTCOME - A PROSPECTIVE-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						ANTIBODIES, ANTIPHOSPHOLIPID; PREGNANCY COMPLICATION; BIRTH WEIGHT; APGAR SCORE; FETAL DEATH	SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTICARDIOLIPIN ANTIBODIES; FETAL LOSS; CLINICAL-SIGNIFICANCE; ANTI-CARDIOLIPIN; IMMUNOGLOBULIN-G; ANTICOAGULANT; PREVALENCE; ASSOCIATION; THROMBOSIS	Objective: To determine if the presence of antiphospholipid antibody (aPL) in healthy pregnant women is associated with adverse pregnancy outcome, including 1) intrauterine fetal loss, 2) maternal pregnancy complications, 3) low birth weight, and 4) low 5-minute Apgar scores. Design: Prospective cohort study in women with normal pregnancies. Setting: Obstetrics clinic at the University of Colorado Health Sciences Center. Patients: Eligible patients included 451 low-risk, nulliparous pregnant women who came to the obstetrics clinic before 25 weeks gestation; 408 were enrolled and 389 had blood drawn at the first prenatal visit and completed clinical follow-up. Measurements: Blood for six aPL measures was drawn at the first prenatal visit and for 239 patients at delivery. Results: Ninety-five patients (24.4%) had elevated aPL levels by one or more measures at the first prenatal visit: 15.8% of the aPL-positive and 6.5% of the aPL-negative patients experienced fetal loss (relative risk, 2.44; 95% CI, 1.29 to 4.62). However, an elevated IgG anticardiolipin antibody level at the first prenatal visit was the only aPL measurement that was significantly associated with fetal loss (relative risk, 3.5; CI, 1.56 to 8.07). Adjustment for confounding variables decreased the relative risk of aPL for fetal loss slightly, but the difference remained statistically significant. Neither a positive aPL result at the initial visit nor a positive result at delivery was associated with maternal complications of pregnancy, low birth weight, or low Apgar scores. Conclusions: Patients with elevated aPL levels at their initial prenatal visit had an increase in fetal loss but no increase in maternal pregnancy complications, low birth weight, or low Apgar scores. Immunoglobulin G anticardiolipin antibody was the only single test of aPL significantly associated with fetal loss.	REAADS MED PROD, WESTMINSTER, CO 80234 USA		LYNCH, A (corresponding author), UNIV COLORADO, HLTH SCI CTR, DIV RHEUMATOL, BOX B115, 4200 E 9TH AVE, DENVER, CO 80262 USA.							ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P482; BONNAR J, 1977, RECENT ADV BLOOD COA, P363; BRANCH DW, 1989, OBSTET GYNECOL, V73, P541; BRANCH DW, 1990, AM J OBSTET GYNECOL, V163, P210, DOI 10.1016/S0002-9378(11)90700-5; BROWN HL, 1990, 10TH SOC PER OBST AN; FEINSTEIN DI, 1992, BLOOD, V80, P859; FORT JG, 1987, ARTHRITIS RHEUM, V30, P752, DOI 10.1002/art.1780300705; GABBE SG, 1986, OBSTETRICS NORMAL PR; GALLI M, 1990, LANCET, V335, P1544, DOI 10.1016/0140-6736(90)91374-J; HARRIS EN, 1991, AM J OBSTET GYNECOL, V165, P1272; HARRIS EN, 1983, LANCET, V2, P1211; HARRIS EN, 1986, ARCH INTERN MED, V146, P2153, DOI 10.1001/archinte.146.11.2153; HULL RG, 1984, ANN RHEUM DIS, V43, P746, DOI 10.1136/ard.43.5.746; INFANTERIVARD C, 1991, NEW ENGL J MED, V325, P1063, DOI 10.1056/NEJM199110103251503; KEANE A, 1987, BRIT J RHEUMATOL, V26, P346; LASKIN CA, 1988, J RHEUMATOL, V15, P7; LEVINE SR, 1987, ARCH NEUROL-CHICAGO, V44, P876, DOI 10.1001/archneur.1987.00520200078024; LOCKSHIN MD, 1985, NEW ENGL J MED, V313, P152, DOI 10.1056/NEJM198507183130304; LOCKSHIN MD, 1987, J RHEUMATOL, V14, P259; LOCKSHIN MD, 1992, ARTHRITIS RHEUM, V35, P1234, DOI 10.1002/art.1780351017; LOCKWOOD CJ, 1989, AM J OBSTET GYNECOL, V161, P369, DOI 10.1016/0002-9378(89)90522-X; LOPEZ LR, 1992, AM J CLIN PATHOL, V98, P449, DOI 10.1093/ajcp/98.4.449; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; MANOUSSAKIS MN, 1987, CLIN EXP IMMUNOL, V69, P557; MCNEIL HP, 1991, ADV IMMUNOL, V49, P193; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; MULHALL BP, 1989, J CLIN IMMUNOL, V9, P208, DOI 10.1007/BF00916816; ONT HJ, 1992, AM J OBSTET GYNECOL, V167, P26; PARKE AL, 1991, ARTHRITIS RHEUM, V34, P1231, DOI 10.1002/art.1780341005; PETRI M, 1987, ANN INTERN MED, V106, P524, DOI 10.7326/0003-4819-106-4-524; POLZIN WJ, 1991, OBSTET GYNECOL, V78, P1108; RAUCH J, 1989, THROMB HAEMOSTASIS, V62, P892; ROBINSON RD, 1992, 5TH INT S ANT ANT SA; ROTE NS, 1992, AM J REPROD IMMUNOL, V28, P31, DOI 10.1111/j.1600-0897.1992.tb00753.x; SHI W, 1990, AUST NZ J MED, V20, P231, DOI 10.1111/j.1445-5994.1990.tb01025.x; TATE G, 1984, LANCET, V2, P587; TRIPLETT DA, 1989, AM J REPROD IMMUNOL, V20, P52, DOI 10.1111/j.1600-0897.1989.tb00639.x; ZARRABI MH, 1979, ANN INTERN MED, V91, P194, DOI 10.7326/0003-4819-91-2-194	38	172	177	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1994	120	6					470	475		10.7326/0003-4819-120-6-199403150-00004	http://dx.doi.org/10.7326/0003-4819-120-6-199403150-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB625	8093135				2022-12-24	WOS:A1994NB62500004
J	KASS, DA; WOLFF, MR; TING, CT; LIU, CP; CHANG, MS; LAWRENCE, W; MAUGHAN, WL				KASS, DA; WOLFF, MR; TING, CT; LIU, CP; CHANG, MS; LAWRENCE, W; MAUGHAN, WL			DIASTOLIC COMPLIANCE OF HYPERTROPHIED VENTRICLE IS NOT ACUTELY ALTERED BY PHARMACOLOGICAL AGENTS INFLUENCING ACTIVE PROCESSES	ANNALS OF INTERNAL MEDICINE			English	Article						VENTRICULAR FUNCTION, LEFT; HYPERTROPHY, LEFT VENTRICULAR; VERAPAMIL; ESMOLOL; COMPLIANCE	PRESSURE-VOLUME RELATIONS; CONDUCTANCE CATHETER; HEART-FAILURE; SHORT-TERM; CARDIOMYOPATHY; VERAPAMIL; RELAXATION; DYSFUNCTION; NIFEDIPINE; DETERMINANTS	Objective: To test, by studying the acute effects of drugs that influence active processes, the hypothesis that in humans with marked ventricular hypertrophy, reduced chamber compliance is primarily caused by passive structural changes. Design: An uncontrolled (before-after) study. Setting: University Medical Center. Patients: Fourteen patients with ventricular hypertrophy (19 +/- 4.5-mm diastolic-wall thickness) and normal resting systolic function were studied while they had invasive cardiac catheterization. Intervention: Intravenous beta-blocker (esmolol) or calcium channel blocker (verapamil) or both. Measurements: Left ventricular function was determined by pressure-volume relations. Volume was measured using conductance catheter, providing a continuous voltage signal proportional to chamber volume. Pressure was measured by micromanometer. Cardiac-specific assessment of change in chamber contractility and diastolic compliance due to each drug was determined. Results: Both drugs lowered contractility by approximately 30% (P < 0.01). Esmolol slowed relaxation and reduced early peak filling rate, whereas verapamil delayed the time to peak filling (all P < 0.05). In contrast to the effects of both drugs on active contraction and early diastole, late-diastolic compliance was unaltered, and end-diastolic pressure-volume relations were almost identical. Conclusion: Neither beta-receptor nor calcium channel blockade acutely alters left ventricular compliance despite substantial active effects manifest in systole and early diastole. This supports the notion that chamber compliance is principally determined by passive structural elements in the heart rather than by active processes.	JOHNS HOPKINS MED INST, BALTIMORE, MD 21205 USA; VET GEN HOSP, TAIPEI, TAIWAN	Johns Hopkins University; Johns Hopkins Medicine					NHLBI NIH HHS [HL-33243, HL-01610, HL-01820] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033243, K11HL001820] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPLEGATE RJ, 1990, CIRCULATION, V81, P638, DOI 10.1161/01.CIR.81.2.638; BAAN J, 1984, CIRCULATION, V70, P812, DOI 10.1161/01.CIR.70.5.812; BETOCCHI S, 1986, J AM COLL CARDIOL, V7, P74, DOI 10.1016/S0735-1097(86)80262-5; BONOW RO, 1985, CIRCULATION, V72, P853, DOI 10.1161/01.CIR.72.4.853; BONOW RO, 1983, CIRCULATION, V68, P1062, DOI 10.1161/01.CIR.68.5.1062; BONOW RO, 1981, CIRCULATION, V64, P787, DOI 10.1161/01.CIR.64.4.787; BURKHOFF D, 1985, CIRCULATION, V72, P440, DOI 10.1161/01.CIR.72.2.440; COHEN LS, 1967, CIRCULATION, V35, P847, DOI 10.1161/01.CIR.35.5.847; EPSTEIN SE, 1965, J CLIN INVEST, V44, P1745, DOI 10.1172/JCI105282; GILBERT JC, 1989, CIRC RES, V64, P827, DOI 10.1161/01.RES.64.5.827; Glantz SA, 1990, PRIMER APPL REGRESSI, P381; GROSSMAN W, 1991, NEW ENGL J MED, V325, P1557; GWATHMEY JK, 1991, J CLIN INVEST, V87, P1023, DOI 10.1172/JCI115061; HESS OM, 1986, CIRCULATION, V74, P530, DOI 10.1161/01.CIR.74.3.530; KASS DA, 1988, CIRCULATION, V77, P1203, DOI 10.1161/01.CIR.77.6.1203; KASS DA, 1988, CATHETER CARDIO DIAG, V15, P192, DOI 10.1002/ccd.1810150314; KASS DA, 1990, CIRCULATION, V81, P447, DOI 10.1161/01.CIR.81.2.447; LIU CP, 1992, CIRCULATION, V85, P1447, DOI 10.1161/01.CIR.85.4.1447; LORELL BH, 1987, J AM COLL CARDIOL, V9, P1189, DOI 10.1016/S0735-1097(87)80326-1; LORELL BH, 1980, NEW ENGL J MED, V303, P801, DOI 10.1056/NEJM198010023031407; LORELL BH, 1982, CIRCULATION, V65, P499, DOI 10.1161/01.CIR.65.3.499; LUDBROOK PA, 1977, CIRCULATION, V56, P937, DOI 10.1161/01.CIR.56.6.937; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MORGAN JP, 1990, CIRCULATION, V81, P21; PAULUS WJ, 1983, J AM COLL CARDIOL, V2, P879, DOI 10.1016/S0735-1097(83)80235-6; REFSUM H, 1981, CIRCULATION, V64, P997, DOI 10.1161/01.CIR.64.5.997; SCHULMAN SP, 1990, NEW ENGL J MED, V322, P1350, DOI 10.1056/NEJM199005103221904; Speiser K W, 1981, Eur Heart J, V2, P21; STEWART S, 1968, CIRCULATION, V37, P8, DOI 10.1161/01.CIR.37.1.8; SUGA H, 1974, CIRC RES, V35, P117, DOI 10.1161/01.RES.35.1.117; SWANTON RH, 1977, EUR J CARDIOL, V5, P327; TENCATE FJ, 1983, CIRCULATION, V68, P1274, DOI 10.1161/01.CIR.68.6.1274; WEBER KT, 1987, CIRCULATION, V75, P40; WEBER KT, 1989, AM J HYPERTENS, V2, P931, DOI 10.1093/ajh/2.12.931; WEISS JL, 1976, J CLIN INVEST, V58, P751, DOI 10.1172/JCI108522	35	58	60	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					466	473		10.7326/0003-4819-119-6-199309150-00004	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8102838				2022-12-24	WOS:A1993LZ27500004
J	BU, XD; ROTTER, JI				BU, XD; ROTTER, JI			WOLFRAM-SYNDROME - A MITOCHONDRIAL-MEDIATED DISORDER	LANCET			English	Article							PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; HEREDITARY OPTIC NEUROPATHY; KEARNS-SAYRE SYNDROME; DIABETES-MELLITUS; DNA MUTATION; DELETIONS; DEAFNESS; PEDIGREE; GENES	Mitochondrial DNA mutations cause several human diseases, (eg, Leber's hereditary optic neuropathy). Wolfram syndrome (characterised by diabetes insipidus, diabetes mellitus, optic atrophy, and deafness) also has, in some cases, a mitochondrial origin. The disease, often familial, has been well documented as an autosomal recessive disorder, and most of the clinical phenotypes are consistent with an ATP supply defect that is often seen in mitochondrial-mediated disorders. We propose a dual genome defect model for Wolfram syndrome in which nuclear genetic defects or mitochondrial genetic defects can independently lead to the disease. This model suggests that besides a mitochondrial gene defect alone, a nuclear gene defect, which interferes with the normal function of mitochondria (probably with a normal mitochondrial genome), can also be the underlying explanation for the pleiotropic features of Wolfram syndrome. This hypothesis explains how an autosomal recessive disorder can result in mitochondrial dysfunction, and has a general application in the identification of candidate genes for the various important phenotypes (eg, deafness and diabetes mellitus) seen in mitochondrial disorders.	CEDARS SINAI MED CTR, DEPT PEDIAT, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	BU, XD (corresponding author), CEDARS SINAI MED CTR, DEPT MED, DIV MED GENET, SSB-3, 8700 W BEVERLY BLVD, LOS ANGELES, CA 90048 USA.				NHLBI NIH HHS [HL28481] Funding Source: Medline; NIDCD NIH HHS [DCO1402] Funding Source: Medline; NIDDK NIH HHS [DK07426] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001402] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALCOLADO JC, 1991, BRIT MED J, V302, P1178, DOI 10.1136/bmj.302.6786.1178; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BELCOUR L, 1991, P NATL ACAD SCI USA, V88, P3579, DOI 10.1073/pnas.88.9.3579; BU XD, 1993, GENET EPIDEMIOL, V10, P3, DOI 10.1002/gepi.1370100102; BU XD, 1991, P NATL ACAD SCI USA, V88, P8198, DOI 10.1073/pnas.88.18.8198; BU XD, 1992, GENET EPIDEMIOL, V9, P27, DOI 10.1002/gepi.1370090105; BUNDEY S, 1992, J INHERIT METAB DIS, V15, P315, DOI 10.1007/BF02435965; CAVELIER L, 1993, CLIN GENET, V43, P69, DOI 10.1111/j.1399-0004.1993.tb04429.x; CORMIER V, 1991, AM J HUM GENET, V48, P643; GERBITZ KD, 1992, DIABETOLOGIA, V35, P1181, DOI 10.1007/BF00401375; JABER L, 1992, J MED GENET, V29, P86, DOI 10.1136/jmg.29.2.86; MCKUSICK VA, 1992, MENDELIAN INHERITANC, P1333; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; PREZANT TR, 1992, AM J MED GENET, V44, P465, DOI 10.1002/ajmg.1320440416; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3; ROTIG A, 1993, J CLIN INVEST, V91, P1095, DOI 10.1172/JCI116267; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SINGH G, 1989, NEW ENGL J MED, V320, P1300, DOI 10.1056/NEJM198905183202002; SWIFT RG, 1990, LANCET, V336, P667, DOI 10.1016/0140-6736(90)92157-D; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VANDENOUWELAND JMW, 1992, NUCLEIC ACIDS RES, V20, P679, DOI 10.1093/nar/20.4.679; VILKKI J, 1991, American Journal of Human Genetics, V48, P486; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; ZEVIANI M, 1988, NEUROLOGY, V38, P1339; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0	27	55	56	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					598	600		10.1016/0140-6736(93)91416-J	http://dx.doi.org/10.1016/0140-6736(93)91416-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102726				2022-12-24	WOS:A1993LV96300016
J	DURING, MJ; SPENCER, DD				DURING, MJ; SPENCER, DD			EXTRACELLULAR HIPPOCAMPAL GLUTAMATE AND SPONTANEOUS SEIZURE IN THE CONSCIOUS HUMAN BRAIN	LANCET			English	Article							GAMMA-AMINOBUTYRIC ACID; EXCITATORY AMINO-ACIDS; PRIMARY CULTURE; NEURONS; INVIVO; ANTAGONISTS; INJECTION; AMYGDALA; EPILEPSY; DIALYSIS	An alteration in excitatory and inhibitory influences may underlie epilepsy. We used bilateral intrahippocampal microdialysis to test the hypothesis that an increase in extracellular glutamate may trigger spontaneous seizures. The concentrations of glutamate and gamma-aminobutyric acid (GABA), the brain's major inhibitory neutrotransmitter, were measured in microdialysates before and during seizures in 6 patients with complex partial epilepsy investigated before surgery. Before seizures, concentrations of glutamate were higher in the epileptogenic hippocampus, whereas GABA concentrations were lower. During seizures, there was a sustained increase in extracellular glutamate to potentially neurotoxic concentrations in the epileptogenic hippocampus. Moreover, the increase preceded seizure. GABA concentrations were unchanged before seizures, but increased during them, with a greater rise in the non-epileptogenic hippocampus, suggesting that a rise in extracellular glutamate may precipitate seizures and that the concentrations reached may cause cell death.	YALE UNIV, SCH MED, DEPT INTERNAL MED, NEUROENDOCRINE PROGRAM, NEW HAVEN, CT 06510 USA	Yale University	DURING, MJ (corresponding author), YALE UNIV, SCH MED,DEPT SURG,NEUROL SURG SECT,NEUROCHEM LAB, 333 CEDAR ST, NEW HAVEN, CT 06510 USA.		During, Matthew/AAC-1388-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS006208, R29NS028227] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 28227, NS06208] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMBERG G, 1989, J PHARMACOL METHOD, V22, P157, DOI 10.1016/0160-5402(89)90012-0; BISCOE TJ, 1966, J PHYSIOL-LONDON, V183, P341, DOI 10.1113/jphysiol.1966.sp007869; CARLSON H, 1992, NEUROSCI LETT, V140, P30, DOI 10.1016/0304-3940(92)90674-V; CHAMBERLIN NL, 1990, J NEUROPHYSIOL, V64, P1000, DOI 10.1152/jn.1990.64.3.1000; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CORNELLBELL A, 1992, EXCITATORY AMINO ACI, V9, P273; CROUCHER MJ, 1982, SCIENCE, V216, P899, DOI 10.1126/science.7079744; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; DO KQ, 1991, FID RES FDN, V5, P677; DODD PR, 1980, BRAIN RES, V193, P505, DOI 10.1016/0006-8993(80)90180-8; DURING M J, 1989, Society for Neuroscience Abstracts, V15, P340; FRANDSEN A, 1987, NEUROCHEM INT, V10, P583, DOI 10.1016/0197-0186(87)90088-X; IVES AE, 1990, NEUROSCI LETT, V112, P239, DOI 10.1016/0304-3940(90)90210-Z; LEHMANN A, 1987, NEUROSCIENCE, V22, P573, DOI 10.1016/0306-4522(87)90354-X; LEHMANN A, 1985, BRAIN RES, V359, P147, DOI 10.1016/0006-8993(85)91422-2; LENCZ T, 1992, ANN NEUROL, V31, P629, DOI 10.1002/ana.410310610; MCCARTHY G, 1991, SURGERY EPILEPSY, P385; Meldrum B S, 1983, Adv Neurol, V34, P261; MILLAN MH, 1991, EPILEPSY RES, V9, P86, DOI 10.1016/0920-1211(91)90017-A; PETERSON DW, 1983, BRAIN RES, V275, P169, DOI 10.1016/0006-8993(83)90431-6; PIN JP, 1989, J NEUROSCI, V9, P648; SAJI M, 1987, SCIENCE, V235, P66, DOI 10.1126/science.3798095; SHEA PA, 1989, CURR SEP, V9, P53; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; SPENCER SS, 1990, SEMIN NEUROL, V10, P422, DOI 10.1055/s-2008-1063987; STERNAU LL, 1989, STROKE, V20, P281, DOI 10.1161/01.STR.20.2.281; STORMMATHISEN J, 1977, BRAIN RES, V120, P379, DOI 10.1016/0006-8993(77)90918-0; VEZZANI A, 1985, J NEUROCHEM, V45, P335, DOI 10.1111/j.1471-4159.1985.tb03993.x; WADE JV, 1987, J NEUROCHEM, V49, P645, DOI 10.1111/j.1471-4159.1987.tb02912.x	29	725	766	0	28	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	1993	341	8861					1607	1610						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099987				2022-12-24	WOS:A1993LJ72700001
J	COLEMAN, R; TREMBATH, RC; HARPER, JI				COLEMAN, R; TREMBATH, RC; HARPER, JI			CHROMOSOME 11Q13 AND ATOPY UNDERLYING ATOPIC ECZEMA	LANCET			English	Note								Genetic linkage has been reported between atopic respiratory disease and chromosome site 11q13. We recruited 95 multiplex families through probands with active atopic eczema. Linkage analyses between atopy and markers on 11q13 excluded a major susceptibility locus for atopy in this region. Nor was there significant deviation from the expected proportions of alleles shared by affected sib-pairs. When we analysed families according to parental atopic phenotype, we observed a positive lod score (0.8) in 19 families with unaffected fathers, in contrast to markedly negative scores for other combinations of affected parental phenotype. The possibility of a maternal influence on the inheritance of atopy cannot, therefore, be excluded.	HOSP SICK CHILDREN, DEPT DERMATOL, GREAT ORMOND ST, LONDON WC1N 3JH, ENGLAND; INST CHILD HLTH, MOTHERCARE UNIT CLIN GENET & FETAL MED, LONDON WC1N 1EH, ENGLAND; UNIV LEICESTER, DEPT MED, LEICESTER LE1 7RH, ENGLAND; UNIV LEICESTER, DEPT GENET, LEICESTER LE1 7RH, ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; University of Leicester; University of Leicester				Trembath, Richard/0000-0003-0550-3400				BRAY GEORGE W., 1931, JOUR ALLERGY, V2, P205, DOI 10.1016/S0021-8707(31)90069-5; COOKSON WOCM, 1988, LANCET, V1, P86; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; ITO K, 1992, JAP J ALLERGOL, V4, P444; IWASAKI H, 1992, GENOMICS, V13, P7, DOI 10.1016/0888-7543(92)90194-W; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; UEHARA M, 1989, ACTA DERM-VENEREOL, P78; VICKERS CFH, 1980, ACTA DERM-VENEREOL, V92, P113	10	66	67	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 1	1993	341	8853					1121	1122		10.1016/0140-6736(93)93130-S	http://dx.doi.org/10.1016/0140-6736(93)93130-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097806				2022-12-24	WOS:A1993KZ68700006
J	PHILLIPS, DIW				PHILLIPS, DIW			TWIN STUDIES IN MEDICAL-RESEARCH - CAN THEY TELL US WHETHER DISEASES ARE GENETICALLY-DETERMINED	LANCET			English	Editorial Material							BIRTH-WEIGHT				PHILLIPS, DIW (corresponding author), SOUTHAMPTON GEN HOSP,METAB PROGRAMMING GRP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							Barker DJP, 1992, FETAL INFANT ORIGINS; BLEKER OP, 1979, BRIT J OBSTET GYNAEC, V86, P111, DOI 10.1111/j.1471-0528.1979.tb10577.x; Bulmer M. G., 1970, BIOL TWINNING MAN; COREY LA, 1979, ACTA GENET MED GEMEL, V28, P41, DOI 10.1017/S0001566000009326; GRUENWALD P, 1970, BIOL NEONATE, V15, P79; NAEYE RL, 1966, PEDIATRICS, V37, P409; PHILLIPS DIW, IN PRESS Q J MED; PRICE B, 1950, AM J HUM GENET, V2, P293; PROPPING P, 1976, ACTA GENET MED GEMEL, V25, P249, DOI 10.1017/S0001566000014215; RAMOSARROYO MA, 1988, ACTA GENET MED GEMEL, V37, P229, DOI 10.1017/S0001566000003834; SEIDMAN DS, 1991, ARCH DIS CHILD, V66, P584, DOI 10.1136/adc.66.5.584	11	181	181	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					1008	1009		10.1016/0140-6736(93)91086-2	http://dx.doi.org/10.1016/0140-6736(93)91086-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096890				2022-12-24	WOS:A1993KY36800017
J	SLACK, JMW; HOLLAND, PWH; GRAHAM, CF				SLACK, JMW; HOLLAND, PWH; GRAHAM, CF			THE ZOOTYPE AND THE PHYLOTYPIC STAGE	NATURE			English	Editorial Material							DROSOPHILA HOMEOTIC GENES; PATTERN-FORMATION; HOMEOBOX; ORGANIZATION; HOMEODOMAIN; VERTEBRATES; EXPRESSION; MURINE		UNIV OXFORD,DEPT ZOOL,OXFORD OX1 3PS,ENGLAND	University of Oxford				Holland, Peter/0000-0003-1533-9376				BALLARD WW, 1981, AM ZOOL, V21, P391; Brusca R.C., 1990, INVERTEBRATES; CARRASCO AE, 1984, CELL, V37, P409, DOI 10.1016/0092-8674(84)90371-4; COSTA M, 1988, CELL, V55, P747, DOI 10.1016/0092-8674(88)90131-6; COWING DW, 1992, DEVELOPMENT, V116, P481; DEROBERTIS EM, 1991, DEVELOPMENT, V112, P669; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Hall B.K., 1999, EVOLUTIONARY DEV BIO; HAMILTON WJ, 1976, HUMAN EMBRYOLOGY; HOLLAND PWH, 1992, DEVELOPMENT, V116, P653; KESSEL M, 1992, DEVELOPMENT, V115, P487; KRUMLAUF R, 1992, BIOESSAYS, V14, P245, DOI 10.1002/bies.950140408; Lawrence P., 1992, MAKING FLY GENETICS; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Margulis L., 1988, 5 KINGDOMS ILLUSTRAT; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; NARDELLHAEFLIGER D, 1992, DEVELOPMENT, V116, P697; PATEL NH, 1992, NATURE, V357, P339, DOI 10.1038/357339a0; RAFF RA, 1987, DEV BIOL, V119, P6, DOI 10.1016/0012-1606(87)90201-6; Sander K., 1976, Advances in insect physiology. Volume 12., P125, DOI 10.1016/S0065-2806(08)60255-6; Sander K., 1983, DEV EVOLUTION, P137; SCHUMMER M, 1992, EMBO J, V11, P1815, DOI 10.1002/j.1460-2075.1992.tb05233.x; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; Seidel F., 1960, ZOOL ANZ, V164, P245; SHASHIKANT C S, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P207; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; SLACK J, 1984, NATURE, V310, P364, DOI 10.1038/310364a0; SLACK JMW, 1980, J THEOR BIOL, V82, P105, DOI 10.1016/0022-5193(80)90092-2; WEBSTER PJ, 1992, MECH DEVELOP, V38, P25, DOI 10.1016/0925-4773(92)90035-I; Willmer P, 1990, INVERTEBRATE RELATIO; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; WYSOCKADILLER JW, 1989, NATURE, V341, P760, DOI 10.1038/341760a0	37	497	506	2	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					490	492		10.1038/361490a0	http://dx.doi.org/10.1038/361490a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8094230				2022-12-24	WOS:A1993KL71400028
J	SANDFORD, AJ; SHIRAKAWA, T; MOFFATT, MF; DANIELS, SE; RA, C; FAUX, JA; YOUNG, RP; NAKAMURA, Y; LATHROP, GM; COOKSON, WOCM; HOPKIN, JM				SANDFORD, AJ; SHIRAKAWA, T; MOFFATT, MF; DANIELS, SE; RA, C; FAUX, JA; YOUNG, RP; NAKAMURA, Y; LATHROP, GM; COOKSON, WOCM; HOPKIN, JM			LOCALIZATION OF ATOPY AND BETA-SUBUNIT OF HIGH-AFFINITY IGE RECEPTOR (FC-EPSILON-RI) ON CHROMOSOME-11Q	LANCET			English	Article							IMMUNOGLOBULIN-E; SERUM IGE; LYMPHOKINES; LINKAGE; ASTHMA	Atopy, a common familial syndrome underlying allergic asthma and rhinitis, is characterised by sustained immunoglobulin E (IgE) responses to common allergens. We have previously shown genetic linkage of atopy to the chromosome 11q13 marker D11S97 (pms51) through maternally derived alleles, but no likely candidate genes were known to lie near this marker. We have analysed maternally derived alleles from 155 sibling-pairs affected by atopy to seek evidence of linkage between the gene predisposing to atopy and other markers on chromosome 11q13. We found that the beta subunit of the high-affinity receptor for IgE (FcepsilonRI-beta) also lies on chromosome 11q13, and that it is in close genetic linkage with the gene for atopy. The known roles of FcepsilonRI in antigen-induced mast-cell degranulation and in the release of cytokines that enhance IgE production make the gene for its beta subunit a candidate for the chromosome 11 atopy locus.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT MED,OXFORD OX3 9DU,ENGLAND; JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,TOKYO 113,JAPAN; JAPANESE FDN CANC RES,INST CANC,DIV BIOCHEM,TOKYO 170,JAPAN; CTR ETUD POLYMORPHISME HUMAINE,PARIS,FRANCE; CHURCHILL HOSP,OSLER CHEST UNIT,OXFORD OX3 7LJ,ENGLAND	University of Oxford; Juntendo University; Japanese Foundation for Cancer Research; University of Oxford			Cookson, William/HHC-1790-2022		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; BENSASSON SZ, 1990, P NATL ACAD SCI USA, V87, P1421, DOI 10.1073/pnas.87.4.1421; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; HUPP K, 1989, J IMMUNOL, V143, P3787; JULIER C, 1990, GENOMICS, V7, P335, DOI 10.1016/0888-7543(90)90167-S; KINET JP, 1988, P NATL ACAD SCI USA, V85, P6483, DOI 10.1073/pnas.85.17.6483; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; KUSTER H, 1992, J BIOL CHEM, V267, P12782; LEE DA, 1983, BRIT MED J, V286, P1256, DOI 10.1136/bmj.286.6373.1256; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RUIZ RGG, 1992, CLIN EXP ALLERGY, V22, P762, DOI 10.1111/j.1365-2222.1992.tb02816.x; SHIRAKAWA T, 1991, CYTOGENET CELL GENET, V58, P1970; TANIGAMI A, 1992, AM J HUM GENET, V50, P56; TOKINO T, 1991, AM J HUM GENET, V48, P258; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WAYE JS, 1987, HUM GENET, V77, P151, DOI 10.1007/BF00272383; WILLIAMSON R, 1991, CYTOGENET CELL GENET, V58, P1190, DOI 10.1159/000133727; YOUNG RP, 1992, J MED GENET, V29, P236, DOI 10.1136/jmg.29.4.236	25	259	273	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					332	334		10.1016/0140-6736(93)90136-5	http://dx.doi.org/10.1016/0140-6736(93)90136-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094113				2022-12-24	WOS:A1993KK93900004
J	KLEUSS, C; SCHERUBL, H; HESCHELER, J; SCHULTZ, G; WITTIG, B				KLEUSS, C; SCHERUBL, H; HESCHELER, J; SCHULTZ, G; WITTIG, B			SELECTIVITY IN SIGNAL TRANSDUCTION DETERMINED BY GAMMA-SUBUNITS OF HETEROTRIMERIC G-PROTEINS	SCIENCE			English	Article							ROD OUTER SEGMENTS; K+-CHANNEL; BETA; DIVERSITY; PHOSPHOLIPASE-A2; INHIBITION; CURRENTS	Various heterotrimeric guanine nucleotide-binding proteins have been identified on the basis of the individual subtypes of their alpha subunits. The betagamma complexes, composed of beta and gamma subunits, remain tightly associated under physiological conditions and have been assumed to constitute a common pool shared among various guanosine triphosphate (GTP)-binding (G) protein heterotrimers. Particular alpha and beta subunit subtypes participate in the signal transduction processes between somatostatin or muscarinic receptors and the voltage-sensitive L-type calcium channel in rat pituitary GH3 cells. Among gamma subunits the gamma3 subtype was found to be required for coupling of the somatostatin receptor to voltage-sensitive calcium channels, whereas the gamma4 subtype was found to be required for coupling of the muscarinic receptor to those channels.	FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,ARNIMALLEE 22,W-1000 BERLIN 33,GERMANY; FREE UNIV BERLIN,INST PHARMAKOL,W-1000 BERLIN 33,GERMANY	Free University of Berlin; Free University of Berlin								[Anonymous], [No title captured]; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HILDEBRANDT JD, 1985, J BIOL CHEM, V260, P4867; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; ROSENTHAL W, 1988, EMBO J, V7, P1627, DOI 10.1002/j.1460-2075.1988.tb02989.x; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018	22	368	376	3	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 5	1993	259	5096					832	834		10.1126/science.8094261	http://dx.doi.org/10.1126/science.8094261			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8094261				2022-12-24	WOS:A1993KL11000039
J	VELDMAN, PHJM; REYNEN, HM; ARNTZ, IE; GORIS, RJA				VELDMAN, PHJM; REYNEN, HM; ARNTZ, IE; GORIS, RJA			SIGNS AND SYMPTOMS OF REFLEX SYMPATHETIC DYSTROPHY - PROSPECTIVE-STUDY OF 829 PATIENTS	LANCET			English	Article							CORTICOSTEROIDS; CAUSALGIA; TRIAL	The pathogenesis of reflex sympathetic dystrophy-variously known as Sudeck's atrophy, causalgia, algodystrophy, and peripheral trophoneurosis-is not yet understood, and diagnosing and treating patients is difficult. We have prospectively studied 829 patients, paying particular attention to early signs and symptoms. In its early phase, reflex sympathetic dystrophy is characterised by regional inflammation, which increases after muscular exercise. Pain was present in 93% of patients, and hypoaesthesia and hyperpathy were present in 69% and 75% respectively. With time, tissue atrophy may occur as well as involuntary movements, muscle spasms, or pseudoparalysis. Tremor was found in 49% and muscular incoordination in 54% of patients. Sympathetic signs such as hyperhidrosis are infrequent and therefore have no diagnostic value. We found no evidence consistent with the presence of three consecutive phases of the disease. Early symptoms are those of an inflammatory reaction and not of a disturbance of the sympathetic nervous system. These data support the concept of an exaggerated regional inflammatory response to injury or operation in reflex sympathetic dystrophy.			VELDMAN, PHJM (corresponding author), UNIV HOSP NIJMEGEN,DEPT SURG,6500 HB NIJMEGEN,NETHERLANDS.							ACQUAVIVA P, 1982, REV RHUM, V49, P761; ADLER E., 1959, PSYCHIAT ET NEUROL, V138, P256; ATKINS RM, 1990, J BONE JOINT SURG BR, V72, P105, DOI 10.1302/0301-620X.72B1.2298766; BABINSKY J, 1917, HYSTERIE PITHIATISME; Bohm E., 1985, HEFTE UNFALLHEILKD, V174, P241; BONNET J, 1953, THESIS LEIDEN; CHRISTENSEN K, 1982, ACTA CHIR SCAND, V148, P653; EVANS JA, 1947, ANN INTERN MED, V26, P417, DOI 10.7326/0003-4819-26-3-417; GORIS RJA, 1990, LETSELS ENKEL VOET E, P435; Goris RJA, 1991, TISSUE OXYGEN UTILIZ, P350; HADDOX JD, 1990, PAIN SYMPATHETIC NER, P207; HANNA MH, 1989, PAIN, V38, P145, DOI 10.1016/0304-3959(89)90232-7; HEERSCHAP A, 1993, MUSCLE NERVE, V16, P367, DOI 10.1002/mus.880160405; HOLDER LE, 1984, RADIOLOGY, V152, P517, DOI 10.1148/radiology.152.2.6739825; Johnson AC, 1943, ANN INTERN MED, V19, P433, DOI 10.7326/0003-4819-19-3-433; Kleinert H E, 1973, Orthop Clin North Am, V4, P917; KOZIN F, 1976, AM J MED, V60, P321, DOI 10.1016/0002-9343(76)90747-6; KOZIN F, 1981, RADIOLOGY, V138, P437, DOI 10.1148/radiology.138.2.7455127; MARSDEN CD, 1984, BRIT MED J, V288, P173, DOI 10.1136/bmj.288.6412.173; MAURER G, 1940, ERG CHIR, V33, P476; MILLER DS, 1942, SURG GYNECOL OBSTET, V75, P558; Mitchell SW., 1864, GUNSHOT WOUNDS OTHER; MOESKER A, 1985, PAIN CLINIC, V1, P171; Omer G, 1971, Tex Med, V67, P93; OYEN WJG, 1993, IN PRESS PAIN; Pak T J, 1970, Minn Med, V53, P507; PLEWES LW, 1956, J BONE JOINT SURG BR, V38, P195, DOI 10.1302/0301-620X.38B1.195; PROUGH DS, 1985, ANESTHESIOLOGY, V62, P796, DOI 10.1097/00000542-198506000-00017; ROSEN P S, 1957, Can Med Assoc J, V77, P86; ROUMEN RMH, 1991, J BONE JOINT SURG BR, V73, P307, DOI 10.1302/0301-620X.73B2.2005162; SAUNDERS PR, 1988, BRIT MED J, V297, P1635, DOI 10.1136/bmj.297.6664.1635-b; SCHUTZER SF, 1984, J BONE JOINT SURG AM, V66A, P625, DOI 10.2106/00004623-198466040-00025; SHAW RS, 1964, NEW ENGL J MED, V271, P22, DOI 10.1056/NEJM196407022710104; SHUMACKER HB, 1948, SURG GYNECOL OBSTET, V86, P452; STEINBROCKER O, 1947, AM J MED, V3, P402, DOI 10.1016/0002-9343(47)90170-8; Subarrao J, 1981, ARCH PHYS MED REHAB, V62, P549; Sudeck P, 1942, CHIRURG, V15, P449; SUDECK P, 1900, ARCH KLIN CHIR, V62, P147; TAHMOUSH AJ, 1983, NEUROLOGY, V33, P1483, DOI 10.1212/WNL.33.11.1483; TILMAN P B J, 1990, Micron and Microscopica Acta, V21, P271, DOI 10.1016/0739-6260(90)90143-4; WILDER RT, 1992, J BONE JOINT SURG AM, V74A, P910, DOI 10.2106/00004623-199274060-00013	41	801	819	0	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1012	1016		10.1016/0140-6736(93)92877-V	http://dx.doi.org/10.1016/0140-6736(93)92877-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105263				2022-12-24	WOS:A1993MD06600008
J	BLAU, JN				BLAU, JN			BEHAVIOR DURING A CLUSTER HEADACHE	LANCET			English	Article								Because cluster headache is short-lasting and tends to occur during the early morning hours, physicians rarely witness an attack. Accurate diagnosis is important because effective treatments are available. The diagnosis is made from the history of temporal pattern, reddening and tearing of the affected eye, and ipsilateral nasal congestion. An additional diagnostic aid is to invite patients to demonstrate how they respond to attacks. The pain, one of the worst known, causes extreme restlessness. 50 patients showed how they walk around, sit (or kneel) and rock, and clutch the affected side of the head. Diagnostic value apart, the patient will often be relieved to learn that bizarre behavioural responses are not a mark of insanity.			BLAU, JN (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							EKBOM K, 1970, ACTA NEUROL SCAND, V46, P1; EKBOM K, 1968, BRAIN MIND PROBLEMS, P482; HORTON BT, 1956, JAMA-J AM MED ASSOC, V160, P468, DOI 10.1001/jama.1956.02960410044011; KUDROW L, 1980, CLUSTER HEADACHE, P35; LANCE JW, NEUROL SCI, V13, P401; LEVI P, 1986, MOMENTS REPRIEVE, P100; MCKINNEY AS, 1983, HEADACHE, V23, P305, DOI 10.1111/j.1526-4610.1983.hed2306305.x; NAPPI G, 1992, CEPHALALGIA, V12, P165, DOI 10.1046/j.1468-2982.1992.1203165.x; SAKAI F, 1990, HEADACHE Q-CURR TREA, V1, P71; SJAASTAD O, 1992, CLUSTER HEADACHE SYN, P206; SOLZHENITSYN A, 1969, CANCER WARD, P454	11	31	34	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					723	725		10.1016/0140-6736(93)91713-V	http://dx.doi.org/10.1016/0140-6736(93)91713-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103827				2022-12-24	WOS:A1993LX46900014
J	FRIEDEN, TR; MUNSIFF, SS; LOW, DE; WILLEY, BM; WILLIAMS, G; FAUR, Y; EISNER, W; WARREN, S; KREISWIRTH, B				FRIEDEN, TR; MUNSIFF, SS; LOW, DE; WILLEY, BM; WILLIAMS, G; FAUR, Y; EISNER, W; WARREN, S; KREISWIRTH, B			EMERGENCE OF VANCOMYCIN-RESISTANT ENTEROCOCCI IN NEW-YORK-CITY	LANCET			English	Article							GENTAMICIN; SUSCEPTIBILITY; EPIDEMIOLOGY; TEICOPLANIN; INFECTION; FAECIUM	Enterococci, a common cause of nosocomial infection, are intrinsically resistant to most antimicrobials and readily acquire additional resistance. Vancomycin-resistant enterococci (VRE) have caused clusters of nosocomial infections since 1988. In April, 1991, the New York City Department of Health asked all city laboratories to submit suspected VRE isolates for confirmation. Clinical and epidemiological characteristics of the first 100 patients with VRE were identified, and antimicrobial susceptibilty testing, restriction enzyme analysis, and DNA-DNA hybridisation with the vanA gene probe were done. From September, 1989, to October, 1991, 361 patients with VRE were identified at 38 hospitals. The number of hospitals reporting VRE increased from 1 in 1989 to 38 by October, 1991. 98% of 100 VRE infections were nosocomially acquired and 83% patients had received vancomycin and/or a cephalosporin in the 30 days before isolation of VRE. Of 23 isolates from 21 of the first 100 patients, 19 (83%) were resistant to all available antimicrobials. Four vanA probing patterns were noted, and restriction enzyme analysis of the 23 isolates revealed 14 strains. VRE have emerged rapidly in New York City. Molecular analyses suggest that a highly mobile genetic element-eg, a transposon-is responsible for the rapid spread of vancomycin resistance.	PRINCESS MARGARET HOSP, DEPT MICROBIOL, TORONTO M4X 1K9, ONTARIO, CANADA; MT SINAI HOSP, DEPT MICROBIOL, TORONTO M5G 1X5, ONTARIO, CANADA; CTR DIS CONTROL, EPIDEMIOL PROGRAM OFF, DIV FIELD EPIDEMIOL, ATLANTA, GA 30333 USA; COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA; PUBL HLTH RES INST CITY NEW YORK INC, NEW YORK, NY 10016 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Centers for Disease Control & Prevention - USA; Columbia University	FRIEDEN, TR (corresponding author), NEW YORK CITY DEPT HLTH, DIV DIS INTERVENT, 125 WORTH ST, NEW YORK, NY 10013 USA.		Low, Donald/B-1726-2012					AXELROD P, 1989, ARCH INTERN MED, V149, P1397, DOI 10.1001/archinte.149.6.1397; DUTKAMALEN S, 1990, MOL GEN GENET, V224, P364, DOI 10.1007/BF00262430; ELIOPOULOS GM, 1988, ANTIMICROB AGENTS CH, V32, P1528, DOI 10.1128/AAC.32.10.1528; GEORGE RC, 1989, EPIDEMIOL INFECT, V103, P403, DOI 10.1017/S0950268800030806; LECLERCQ R, 1992, CLIN INFECT DIS, V15, P495, DOI 10.1093/clind/15.3.495; LECLERCQ R, 1989, ANTIMICROB AGENTS CH, V33, P10, DOI 10.1128/AAC.33.1.10; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; MEDERSKISAMORAJ BD, 1983, J INFECT DIS, V147, P751, DOI 10.1093/infdis/147.4.751; MOELLERING RC, 1982, T AM CLIN CLIMAT ASS, V94, P55; MURRAY BE, 1991, J INFECT DIS, V163, P1185, DOI 10.1093/infdis/163.6.1185; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; PATTERSON JE, 1990, REV INFECT DIS, V12, P644; SCHABERG DR, 1991, AM J MED, V91, pS72, DOI 10.1016/0002-9343(91)90346-Y; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SZETO S, 1991, J CLIN MICROBIOL, V29, P1258, DOI 10.1128/JCM.29.6.1258-1259.1991; TERPENNING MS, 1988, INFECT CONT HOSP EP, V9, P457, DOI 10.1086/645743; TOALA P, 1969, AM J MED SCI, V258, P416, DOI 10.1097/00000441-196912000-00006; 1991, M7A2 NAT COMM CLIN L	19	262	265	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	1993	342	8863					76	79		10.1016/0140-6736(93)91285-T	http://dx.doi.org/10.1016/0140-6736(93)91285-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100912				2022-12-24	WOS:A1993LL78900009
J	BRANCATI, FL; CHOW, JW; WAGENER, MM; VACARELLO, SJ; YU, VL				BRANCATI, FL; CHOW, JW; WAGENER, MM; VACARELLO, SJ; YU, VL			IS PNEUMONIA REALLY THE OLD MANS FRIEND - 2-YEAR PROGNOSIS AFTER COMMUNITY-ACQUIRED PNEUMONIA	LANCET			English	Article							ETIOLOGY; MORTALITY; FEATURES; AGE	Is pneumonia ''the old man's friend''-a terminal event for patients who will otherwise die soon of underlying chronic disease? If so, chronological age might influence treatment policy. We investigated the predictors of 2-year mortality after patients' admission to hospital for community-acquired pneumonia, and focused on the predictive value of age. In a prospective cohort study 141 consecutive patients were admitted to hospital with community-acquired pneumonia. Clinical, laboratory, and sociodemographic data were collected on admission. Comorbidity was categorised as mild, moderate, or severe by a physician based on the patient's medical history. Survival was assessed at 24 months after discharge. 22 (16%) patients died in hospital. Of the remaining 119, 38 (32%) died over the next 24 months. In a Cox model, 2-year mortality was independently related to severe comorbidity (relative risk [RR] = 9.4) or moderate comorbidity (RR = 3.1), and to haematocrit less than 35% (RR = 2.9) (all p less-than-or-equal-to 0.005). However, compared with patients aged 18-44 years, patients aged 45-64 (RR = 0.84), 65-74 (RR = 1.28), and 75-92 (RR = 1.99) were not significantly more likely to die during the 24 months after discharge (all p greater-than-or-equal-to 0.2). Old age should not be a sole criterion for withholding aggressive treatment of community-acquired pneumonia.	JOHNS HOPKINS MED INST,WELCH CTR PREVENT EPIDEMIOL & CLIN RES,BALTIMORE,MD 21205; WAYNE STATE UNIV,SCH MED,DIV INFECT DIS,DETROIT,MI 48201; UNIV PITTSBURGH,SCH MED,DIV INFECT DIS,PITTSBURGH,PA 15261	Johns Hopkins University; Johns Hopkins Medicine; Wayne State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Chow, Joseph W/W-4164-2017	Chow, Joseph W/0000-0002-5934-5877	NHLBI NIH HHS [HL07180, HL07024] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURNS MW, 1976, MED J AUSTRALIA, V2, P787, DOI 10.5694/j.1326-5377.1976.tb115356.x; COX DR, 1972, J R STAT SOC B, V34, P187; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; DORFF GJ, 1973, AM J MED SCI, V266, P349, DOI 10.1097/00000441-197311000-00002; EBRIGHT JR, 1980, J AM GERIATR SOC, V28, P220, DOI 10.1111/j.1532-5415.1980.tb00523.x; FALK RH, 1987, AM J MED, V83, P1134, DOI 10.1016/0002-9343(87)90954-5; FARR BM, 1991, ANN INTERN MED, V115, P428, DOI 10.7326/0003-4819-115-6-428; FEDULLO AJ, 1985, J GERONTOL, V40, P29, DOI 10.1093/geronj/40.1.29; FILICE GA, 1980, AM J EPIDEMIOL, V112, P828, DOI 10.1093/oxfordjournals.aje.a113055; FINE MJ, 1990, AM J MED, V88, pN1; GOLDBERG AI, 1988, CHEST, V94, P1277, DOI 10.1378/chest.94.6.1277; HASLEY PB, IN PRESS MED CARE; JECKER NS, 1991, JAMA-J AM MED ASSOC, V266, P3012, DOI 10.1001/jama.266.21.3012; KILNER JF, 1989, ARCH INTERN MED, V149, P2342; MACFARLANE JT, 1982, LANCET, V2, P255; MANOLIO TA, 1992, AM J MED, V92, P1, DOI 10.1016/0002-9343(92)90007-X; MCNABB WR, 1984, J ROY SOC MED, V77, P550, DOI 10.1177/014107688407700705; MOORE MA, 1977, JOHNS HOPKINS MED J, V140, P9; ORTQVIST A, 1985, SCAND J INFECT DIS, V17, P377; Osler W, 1998, PRINCIPLES PRACTICE, P109; PACHON J, 1990, AM REV RESPIR DIS, V142, P369, DOI 10.1164/ajrccm/142.2.369; SULLIVAN P, 1989, CAN MED ASSOC J, V141, P720; SULLIVAN RJ, 1972, ARCH INTERN MED, V129, P935, DOI 10.1001/archinte.129.6.935; TORRES A, 1991, AM REV RESPIR DIS, V144, P312, DOI 10.1164/ajrccm/144.2.312; VENKATASEN P, 1990, THORAX, V43, P234; WOODHEAD MA, 1987, LANCET, V1, P671; WOODHEAD MA, 1985, J INFECTION, V10, P204, DOI 10.1016/S0163-4453(85)92463-6; ZWEIG S, 1990, J FAM PRACTICE, V30, P153; 1991, HEALTH; 1987, Q J MED, V239, P195	30	119	123	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					30	33		10.1016/0140-6736(93)91887-R	http://dx.doi.org/10.1016/0140-6736(93)91887-R			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100295				2022-12-24	WOS:A1993LK98500016
J	CAINE, SB; KOOB, GF				CAINE, SB; KOOB, GF			MODULATION OF COCAINE SELF-ADMINISTRATION IN THE RAT THROUGH D-3 DOPAMINE-RECEPTORS	SCIENCE			English	Article							MOLECULAR-CLONING; NUCLEUS ACCUMBENS; RHESUS-MONKEYS; D1; EXPRESSION; GENE; AMPHETAMINE; ANTAGONISTS; MECHANISMS; LESIONS	The reinforcing properties of cocaine are probably mediated by the mesocorticolimbic dopamine pathways in the central nervous system, but not all of the dopamine receptor subtypes involved in cocaine's reinforcing actions have been clearly identified. Recently, the D-3 receptor has been cloned, and its distribution in the brain has been found to be relatively restricted to limbic projections of the midbrain dopamine system. The D-3-selective compounds 7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OHDPAT) and quinpirole potently decreased cocaine self-administration in the rat at doses that were not by themselves reinforcing. Moreover, three dopamine receptor agonists had affinities for binding to the D-3 receptor that correlated highly with their relative potencies in decreasing cocaine self-administration. The D-3 receptor may be involved in the reinforcing effects of cocaine and may be a useful target for the development of new pharmacotherapies for cocaine abuse.			CAINE, SB (corresponding author), SCRIPPS RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [F31DA005478, R01DA004398] Funding Source: NIH RePORTER; NIDA NIH HHS [NIDA DA04398, NIDA DA05478] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Bergman J., 1990, Behav Pharmacol, V1, P355; BERGMAN J, 1988, FASEB J, V2, pA1137; BRITTON DR, 1991, PHARMACOL BIOCHEM BE, V39, P911, DOI 10.1016/0091-3057(91)90052-4; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CAINE SB, UNPUB; CAINE SB, IN PRESS BEHAVIORAL; CALLAHAN PM, 1992, PSYCHOPHARMACOLOGY, V107, P73, DOI 10.1007/BF02244968; CEDARBAUM JM, 1990, PHARMACOL BASIS THER, P470; CREESE I, 1975, BRAIN RES, V83, P419, DOI 10.1016/0006-8993(75)90834-3; DAVIS WM, 1977, LIFE SCI, V20, P483; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738; GILL CA, 1978, 10TH P C COLL INT NE, P1477; HERLING S, 1979, PSYCHOPHARMACOLOGY, V64, P261, DOI 10.1007/BF00427508; HUBNER CB, 1991, PSYCHOPHARMACOLOGY, V105, P151, DOI 10.1007/BF02244301; HUBNER CB, 1990, NEUROPSYCHOPHARMACOL, V3, P101; KELLY PH, 1975, BRAIN RES, V94, P507, DOI 10.1016/0006-8993(75)90233-4; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; KOOB GF, 1987, NEUROSCI LETT, V79, P315, DOI 10.1016/0304-3940(87)90451-4; KOOB GF, 1987, BRAIN REWARD SYSTEMS, P35; LEVESQUE D, 1992, P NATL ACAD SCI USA, V89, P8155, DOI 10.1073/pnas.89.17.8155; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROBERTS DCS, 1977, PHARMACOL BIOCHEM BE, V6, P615, DOI 10.1016/0091-3057(77)90084-3; ROBERTS DCS, 1980, PHARMACOL BIOCHEM BE, V12, P781, DOI 10.1016/0091-3057(80)90166-5; Schwartz J-C, 1992, SEMIN NEUROSCI, V4, P99, DOI 10.1016/1044-5765(92)90008-P; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; SVENSSON K, 1986, N-S ARCH PHARMACOL, V334, P234, DOI 10.1007/BF00508777; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA, P35; TIBERI M, 1991, P NATL ACAD SCI USA, V88, P7491, DOI 10.1073/pnas.88.17.7491; WOLF ME, 1987, DOPAMINE RECEPTORS, V8, P45; WOOLVERTON WL, 1984, J PHARMACOL EXP THER, V230, P678	34	431	441	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	1993	260	5115					1814	1816		10.1126/science.8099761	http://dx.doi.org/10.1126/science.8099761			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8099761				2022-12-24	WOS:A1993LH20500053
J	BONITA, R; BEAGLEHOLE, R				BONITA, R; BEAGLEHOLE, R			CEREBROVASCULAR-DISEASE - EXPLAINING STROKE MORTALITY TRENDS	LANCET			English	Editorial Material									UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND	University of Auckland	BONITA, R (corresponding author), UNIV AUCKLAND,DEPT MED,AUCKLAND,NEW ZEALAND.							ANDERSON CS, 1993, MED J AUSTRALIA, V158, P80, DOI 10.5694/j.1326-5377.1993.tb137528.x; BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989; Bonita R, 1989, HYPERTENSION S1, V3; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; HARMSEN P, 1992, STROKE, V23, P1410, DOI 10.1161/01.STR.23.10.1410; JACOBS DR, 1992, AM J PUBLIC HEALTH, V82, P1596, DOI 10.2105/AJPH.82.12.1596; JORGENSEN HS, 1992, STROKE, V23, P1701, DOI 10.1161/01.STR.23.12.1701; LINDENSTROM E, 1992, STROKE, V23, P28, DOI 10.1161/01.STR.23.1.28; WOLF PA, 1992, STROKE, V23, P1551, DOI 10.1161/01.STR.23.11.1551	9	30	30	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1510	1511		10.1016/0140-6736(93)90640-3	http://dx.doi.org/10.1016/0140-6736(93)90640-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099385				2022-12-24	WOS:A1993LG24200009
J	ADAMI, HO; BERGSTROM, R; SPAREN, P; BARON, J				ADAMI, HO; BERGSTROM, R; SPAREN, P; BARON, J			INCREASING CANCER RISK IN YOUNGER BIRTH COHORTS IN SWEDEN	LANCET			English	Article							EPIDEMIOLOGIC ASSESSMENT; TEMPORAL VARIATION; MEMORIAL LECTURE; AGE PERIOD; TRENDS; RATES; MORTALITY; PROGRESS; MODELS; DEATH	There is controversy about cancer mortality trends; some analyses show increasing mortality, but others suggest that rates are falling in the youngest age groups. We have investigated trends in cancer incidence in the whole of Sweden for the period 1958 to 1987. 837 085 cancer cases were registered during the period studied. Incidence rate patterns were studied by age-period-cohort modelling. The risk of cancer was higher for people born during the 1950s than for those born in 1873-82; for women the risk was doubled and for men it was trebled. Although the rate of increase slowed, it showed no sign of levelling off in the youngest birth cohorts. The frequency of smoking-related cancers increased greatly in both sexes, but such tumours could explain only part of the rise in total cancer. These trends predict a continuing rise in the incidence rate of cancer, and suggest a worrying pattern of increasing population exposure to carcinogenic influences.	UNIV UPPSALA, DEPT STAT, S-75105 UPPSALA, SWEDEN	Uppsala University	ADAMI, HO (corresponding author), UNIV HOSP UPPSALA, CANC EPIDEMIOL UNIT, S-75185 UPPSALA, SWEDEN.			Sparen, Par/0000-0002-5184-8971				ADAMI HO, 1992, ACTA ONCOL, V31, P1; ADAMI HO, 1990, AM J EPIDEMIOL, V132, P446, DOI 10.1093/oxfordjournals.aje.a115679; ADAMI HO, 1989, JNCI-J NATL CANCER I, V81, P1640, DOI 10.1093/jnci/81.21.1640; BAILAR JC, 1986, NEW ENGL J MED, V315, P968; BAILAR JC, 1990, ANN NY ACAD SCI, V609, P49, DOI 10.1111/j.1749-6632.1990.tb32056.x; BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; BRESLOW NE, 1984, APPL STAT-J ROY ST C, V33, P38; CLAYTON D, 1987, STAT MED, V6, P449, DOI 10.1002/sim.4780060405; CLAYTON D, 1987, STAT MED, V6, P469, DOI 10.1002/sim.4780060406; DAVIS DL, 1990, LANCET, V336, P474, DOI 10.1016/0140-6736(90)92020-I; DAVIS DL, 1992, LANCET, V340, P666, DOI 10.1016/0140-6736(92)92196-M; Day NE, 1982, TRENDS CANCER INCIDE, P51; DEVITA VT, 1986, NEW ENGL J MED, V315, P964; DOLL R, 1991, AM J EPIDEMIOL, V134, P675, DOI 10.1093/oxfordjournals.aje.a116143; DOLL R, 1990, EUR J CANCER, V26, P500; DOLL R, 1989, ACTA ONCOL, V28, P611; ENSTROM JE, 1977, SCIENCE, V195, P847, DOI 10.1126/science.841309; GREENSPAN EM, 1986, NEW ENGL J MED, V315, P963; HANSSON LE, 1991, INT J CANCER, V47, P499, DOI 10.1002/ijc.2910470405; HOLFORD TR, 1991, ANNU REV PUBL HEALTH, V12, P425, DOI 10.1146/annurev.pu.12.050191.002233; MARSHALL E, 1990, SCIENCE, V250, P900, DOI 10.1126/science.2237436; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; MYERS MH, 1982, TRENDS CANCER INCIDE, P79; RATKIN GA, 1986, NEW ENGL J MED, V315, P964; RUTQVIST LE, 1989, ACTA ONCOL, V28, P771, DOI 10.3109/02841868909092306; SONDIK EJ, 1990, J NATL CANCER I, V82, P825; THORN M, 1990, AM J EPIDEMIOL, V132, P1066; 1990, CANCER INCIDENCE SWE	28	33	33	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	1993	341	8848					773	777		10.1016/0140-6736(93)90557-W	http://dx.doi.org/10.1016/0140-6736(93)90557-W			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8095997				2022-12-24	WOS:A1993KU90000001
J	BROOME, IJ				BROOME, IJ			ANESTHESIA - HEARING-LOSS AND DURAL PUNCTURE	LANCET			English	Editorial Material							SPINAL-ANESTHESIA				BROOME, IJ (corresponding author), FALKIRK & DIST ROYAL INFIRM, DEPT ANAESTHESIA, FALKIRK, SCOTLAND.							FOG J, 1990, ANESTH ANALG, V70, P517; LEE CM, 1986, ANESTH ANALG, V65, P312, DOI 10.1213/00000539-198603000-00016; MICHEL O, 1992, ANN OTO RHINOL LARYN, V101, P390, DOI 10.1177/000348949210100503; SUNDBERG A, 1992, ANAESTHESIA, V47, P981, DOI 10.1111/j.1365-2044.1992.tb03205.x; VANDAM LD, 1956, JAMA-J AM MED ASSOC, V161, P586, DOI 10.1001/jama.1956.02970070018005	5	7	7	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	1993	341	8846					667	668		10.1016/0140-6736(93)90429-K	http://dx.doi.org/10.1016/0140-6736(93)90429-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095578				2022-12-24	WOS:A1993KR61300013
J	FORGACS, I				FORGACS, I			INFLAMMATORY BOWEL-DISEASE - AUTOIMMUNITY IN ULCERATIVE-COLITIS	LANCET			English	Editorial Material							MONOCLONAL-ANTIBODY; IMMUNOGLOBULIN-G; EPITHELIUM; ANTIGEN; SERUM; COLON				FORGACS, I (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT GASTROENTEROL,LONDON SE5 8RX,ENGLAND.			Burns, Alistair/0000-0002-9837-0645				DAS KM, 1987, J IMMUNOL, V139, P77; DAS KM, 1990, GASTROENTEROLOGY, V98, P464, DOI 10.1016/0016-5085(90)90839-S; DAS KM, 1992, J CLIN GASTROENTEROL, V15, P311, DOI 10.1097/00004836-199212000-00009; HIBI T, 1990, GUT, V31, P1371, DOI 10.1136/gut.31.12.1371; MACDERMOTT RP, 1989, GASTROENTEROLOGY, V96, P764; SNOOK JA, 1991, GUT, V32, P163, DOI 10.1136/gut.32.2.163; SNOOK JA, 1989, Q J MED, V72, P835; TAKAHASHI F, 1985, J CLIN INVEST, V76, P311, DOI 10.1172/JCI111963; TAKAHASI F, 1990, GUT, V31, P1016, DOI 10.1136/gut.31.9.1016	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					602	602		10.1016/0140-6736(93)90361-J	http://dx.doi.org/10.1016/0140-6736(93)90361-J			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094837				2022-12-24	WOS:A1993KQ23400013
J	HEIN, HO; SORENSEN, H; SUADICANI, P; GYNTELBERG, F				HEIN, HO; SORENSEN, H; SUADICANI, P; GYNTELBERG, F			ALCOHOL-CONSUMPTION, LEWIS PHENOTYPES, AND RISK OF ISCHEMIC-HEART-DISEASE	LANCET			English	Article							U-SHAPED CURVE; INSULIN RESISTANCE; LIPOPROTEINS; MORTALITY; GENETICS	We have previously found an increased risk of ischaemic heart disease (IHD) in men with the Lewis phenotype Le(a-b-) and suggested that the Lewis blood group has a close genetic relation with insulin resistance. We have investigated whether any conventional risk factors explain the increased risk in Le(a-b-) men. 3383 men aged 53-75 years were examined in 1985-86, and morbidity and mortality during the next 4 years were recorded. At baseline, we excluded 343 men with a history of myocardial infarction, angina pectoris, intermittent claudication, or stroke. The potential risk factors examined were alcohol consumption, physical activity, tobacco smoking, serum cotinine, serum lipids, body-mass index, blood pressure, prevalence of hypertension and non-insulin-dependent diabetes mellitus, and social class. In 280 (9.6%) men with Le(a-b-), alcohol was the only risk factor significantly associated with risk of IHD. There was a significant inverse dose-effect relation between alcohol consumption and risk; trend tests, with adjustment for age, were significant for fatal IHD (p=0.02), all IHD (p=0.03), and all causes of death (p=0.02). In 2649 (90.4%) men with other phenotypes, there was a limited negative association with alcohol consumption. In Le(a-b-) men, a group genetically at high risk of IHD, alcohol consumption seems to be especially protective. We suggest that alcohol consumption may modify insulin resistance in Le(a-b-) men.	STATE UNIV HOSP COPENHAGEN,RIGSHOSP,DEPT CLIN IMMUNOL,COPENHAGEN,DENMARK; UNIV COPENHAGEN,GLUSTROP HOSP,DEPT INTERNAL MED C,GLOSTRUP POPULAT STUDIES,DK-1168 COPENHAGEN,DENMARK	Rigshospitalet; University of Copenhagen; University of Copenhagen	HEIN, HO (corresponding author), STATE UNIV HOSP COPENHAGEN,RIGSHOSP,EPIDEMIOL RES UNIT,COPENHAGEN MALE STUDY,7122,DK-2200 COPENHAGEN N,DENMARK.							BURSTEIN M, 1970, J LIPID RES, V11, P583; Dean A. G., 1990, EPI INFO VERSION 5 W; EIBERG H, 1983, CLIN GENET, V24, P159; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GYNTELBERG F, 1974, ACTA MED SCAND, V195, P375; GYNTELBERG F, 1973, DAN MED BULL, V20, P1; HEIN HO, 1992, J INTERN MED, V231, P477, DOI 10.1111/j.1365-2796.1992.tb00963.x; HEIN HO, 1992, J INTERN MED, V232, P471, DOI 10.1111/j.1365-2796.1992.tb00619.x; HHEIN HO, 1992, J INTERN MED, V232, P481; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P407; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; MOURANT AE, 1976, DAMANIEWSKASOBCZAK D; NORUSIS M, 1988, SPS PC PLUS BASE MAN; NORUSIS MJ, 1988, SPSS PC PLUS ADV STA; ORIOL R, 1986, VOX SANG, V51, P161, DOI 10.1111/j.1423-0410.1986.tb01946.x; RAZAY G, 1992, BRIT MED J, V304, P80, DOI 10.1136/bmj.304.6819.80; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSE GA, 1964, LANCET, V1, P296; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; RUSSELL JC, 1989, ARTERIOSCLEROSIS, V9, P122, DOI 10.1161/01.ATV.9.1.122; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SEIDEL J, 1981, J CLIN CHEM, V19, P838; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, LANCET, V2, P1267; Stahler F, 1977, Med Lab (Stuttg), V30, P29; SUADICANI P, 1992, ATHEROSCLEROSIS, V96, P33, DOI 10.1016/0021-9150(92)90035-F; Svalastoga Kaare, 1959, PRESTIGE CLASS MOBIL	30	68	70	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					392	396		10.1016/0140-6736(93)92987-5	http://dx.doi.org/10.1016/0140-6736(93)92987-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094167				2022-12-24	WOS:A1993KM41600002
J	YAU, SC; ROBERTS, RG; BOBROW, M; MATHEW, CG				YAU, SC; ROBERTS, RG; BOBROW, M; MATHEW, CG			DIRECT DIAGNOSIS OF CARRIERS OF POINT MUTATIONS IN DUCHENNE MUSCULAR-DYSTROPHY	LANCET			English	Note							GENE	In about one-third of patients with Duchenne/Becker muscular dystrophy, the causative mutation does not involve gross alterations in the structure of the dystrophin gene. Prenatal diagnosis and carrier detection for such families is therefore dependent on the indirect method of linkage analysis with polymorphic DNA markers, a method that is subject to error. The identification of point mutations in the dystrophin gene in six affected males enabled us to develop direct assays, based on the polymerase chain reaction, that are specific for each of the mutations. In all six cases, the assays allowed us to offer families accurate carrier testing and prenatal diagnosis.			YAU, SC (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV MED & MOLEC GENET,PAEDIAT RES UNIT,LONDON SE1 9RT,ENGLAND.		Mathew, Christopher G/G-3434-2015; Roberts, Roland G/C-3596-2009	Mathew, Christopher G/0000-0003-4178-1838; Roberts, Roland/0000-0001-6636-1579				ABBS S, 1990, GENOMICS, V7, P602, DOI 10.1016/0888-7543(90)90205-9; ABBS S, 1992, J MED GENET, V29, P191, DOI 10.1136/jmg.29.3.191; CLEMENS PR, 1991, AM J HUM GENET, V49, P951; DENDUNNEN JT, 1989, AM J HUM GENET, V45, P835; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P3606, DOI 10.1093/nar/17.9.3606; ROBERTS RG, 1992, P NATL ACAD SCI USA, V89, P2331, DOI 10.1073/pnas.89.6.2331; ROBERTS RG, 1990, LANCET, V336, P1523, DOI 10.1016/0140-6736(90)93305-9; VANESSEN AJ, 1992, HUM GENET, V88, P249, DOI 10.1007/BF00197255	8	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					273	275		10.1016/0140-6736(93)92618-4	http://dx.doi.org/10.1016/0140-6736(93)92618-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093919				2022-12-24	WOS:A1993KK24500006
J	JOUNG, JK; KOEPP, DM; HOCHSCHILD, A				JOUNG, JK; KOEPP, DM; HOCHSCHILD, A			SYNERGISTIC ACTIVATION OF TRANSCRIPTION BY BACTERIOPHAGE-LAMBDA CI-PROTEIN AND ESCHERICHIA-COLI CAMP RECEPTOR PROTEIN	SCIENCE			English	Article							INTEGRATION HOST FACTOR; POLYMERASE-ALPHA SUBUNIT; ESCHERICHIA-COLI; RNA-POLYMERASE; POSITIVE CONTROL; CYCLIC-AMP; CRYSTAL-STRUCTURE; PHAGE REPRESSOR; GENE; DNA	Two heterologous prokaryotic activators, the bacteriophage lambda cI protein (lambda cI) and the Escherichia coli cyclic AMP receptor protein (CRP), were shown to activate transcription synergistically from an artificial promoter bearing binding sites for both proteins. The synergy depends on a functional activation (positive control) surface on each activator. These results imply that both proteins interact directly with RNA polymerase and thus suggest a precise mechanism for transcriptional synergy: the interaction of two activators with two distinct surfaces of RNA polymerase.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School					OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD006862] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44025] Funding Source: Medline; NIH HHS [DP1 OD006862] Funding Source: Medline	OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; BEAMER LJ, 1992, J MOL BIOL, V227, P177, DOI 10.1016/0022-2836(92)90690-L; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BUSBY S, 1994, J MOL BIOL, V241, P341, DOI 10.1006/jmbi.1994.1511; BUSHMAN FD, 1989, CELL, V58, P1163, DOI 10.1016/0092-8674(89)90514-X; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; COSSART P, 1982, NUCLEIC ACIDS RES, V10, P1363, DOI 10.1093/nar/10.4.1363; DONG XR, 1992, J BIOL CHEM, V267, P14122; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P2236, DOI 10.1073/pnas.79.7.2236; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; HOCHSCHILD A, 1988, NATURE, V336, P353, DOI 10.1038/336353a0; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1992, MOL MICROBIOL, V6, P3283, DOI 10.1111/j.1365-2958.1992.tb02196.x; JENNINGS MP, 1993, MOL MICROBIOL, V9, P155, DOI 10.1111/j.1365-2958.1993.tb01677.x; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; JOUNG JK, 1993, P NATL ACAD SCI USA, V90, P3083, DOI 10.1073/pnas.90.7.3083; JOUNG JK, UNPUB; KINGSTON RE, 1994, CURR BIOL, V4, P325, DOI 10.1016/S0960-9822(00)00071-3; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KULDELL N, 1994, J BACTERIOL, V176, P2991, DOI 10.1128/JB.176.10.2991-2998.1994; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LODGE J, 1992, FEMS MICROBIOL LETT, V95, P271; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; MCKAY DB, 1982, J BIOL CHEM, V257, P9518; MEYER BJ, 1980, J MOL BIOL, V139, P195, DOI 10.1016/0022-2836(80)90304-6; Miller J.H., 1972, EXPT MOL GENETICS; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PTASHNE M, 1992, GENETIC SWITCH GENE; RICHET E, 1991, CELL, V66, P1185, DOI 10.1016/0092-8674(91)90041-V; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; SCHRODER I, 1993, J BIOL CHEM, V268, P771; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; STEWART V, 1993, MOL MICROBIOL, V9, P425, DOI 10.1111/j.1365-2958.1993.tb01704.x; USHIDA C, 1990, NUCLEIC ACIDS RES, V18, P6325, DOI 10.1093/nar/18.21.6325; WALKER MS, 1992, J BACTERIOL, V174, P1119, DOI 10.1128/jb.174.4.1119-1123.1992; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WHIPPLE FW, 1994, GENE DEV, V8, P1212, DOI 10.1101/gad.8.10.1212; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x	52	64	64	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1994	265	5180					1863	1866		10.1126/science.8091212	http://dx.doi.org/10.1126/science.8091212			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	8091212				2022-12-24	WOS:A1994PH25800032
J	THOROGOOD, M				THOROGOOD, M			LOSING HEART	LANCET			English	Editorial Material											THOROGOOD, M (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,HLTH PROMOT SCI UNIT,LONDON WC1E 7HT,ENGLAND.							ANDA R, 1993, EPIDEMIOLOGY, V4, P285, DOI 10.1097/00001648-199307000-00003	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					570	570		10.1016/0140-6736(93)91407-D	http://dx.doi.org/10.1016/0140-6736(93)91407-D			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102717				2022-12-24	WOS:A1993LV96300007
J	BRINDLE, P; LINKE, S; MONTMINY, M				BRINDLE, P; LINKE, S; MONTMINY, M			PROTEIN-KINASE-A-DEPENDENT ACTIVATOR IN TRANSCRIPTION FACTOR CREB REVEALS NEW ROLE FOR CREM REPRESSORS	NATURE			English	Article							MAMMALIAN-CELLS; GENE; CAMP; PHOSPHORYLATION; EXPRESSION; PROMOTER	HORMONALLY induced increases in cyclic AMP levels induce phosphorylation of the transcription factor CREB at a serine residue at position 133 by protein kinase A (ref. 1), enhancing its ability to activate transcription without affecting its intracellular location or DNA-binding activity. This effect is dependent on a 60-amino-acid region of CREB that contains Ser 133 and is termed the kinase-inducible domain (KID)2, which also occurs in the CREB-related CREM-alpha and -beta proteins, although these are transcriptional repressors3 . Here we show that the KID domain confers a cAMP-inducible increase on the activity of the Q2 activation domain from CREB and the acidic activation domains from the yeast proteins GAL4 and GCN4. Remarkably, it retains this ability even when attached to a separate polypeptide bound to an adjacent site in the promoter. KID may therefore be the first of a new class of conditional activators that work through other promoter-bound factors to stimulate gene expression in response to hormonal stimuli.			BRINDLE, P (corresponding author), SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037, USA.			Brindle, Paul/0000-0001-7172-8478; Linke, Steven/0000-0001-8584-4947				CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OHLSSON M, 1993, MOL CELL BIOL, V13, P266, DOI 10.1128/MCB.13.1.266; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597	16	151	153	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					821	824		10.1038/364821a0	http://dx.doi.org/10.1038/364821a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8102791				2022-12-24	WOS:A1993LU58100061
J	POWELLTUCK, J				POWELLTUCK, J			GLUTAMINE, PARENTERAL-FEEDING, AND INTESTINAL NUTRITION	LANCET			English	Editorial Material							METABOLISM; MUSCLE				POWELLTUCK, J (corresponding author), ROYAL LONDON HOSP,DEPT MED,LONDON,ENGLAND.							ADIBI SA, 1987, DIPEPTIDES NEW SUBST; DEUTZ NEP, 1992, CLIN SCI, V83, P607, DOI 10.1042/cs0830607; HAUSSINGER D, 1993, LANCET, V341, P1330, DOI 10.1016/0140-6736(93)90828-5; HAUSSINGER D, 1989, METABOLISM, V38, P14, DOI 10.1016/0026-0495(89)90133-9; RENNIE MJ, 1986, LANCET, V2, P1008; SOUBA WW, 1985, JPEN-PARENTER ENTER, V9, P608, DOI 10.1177/0148607185009005608; TAMARAPPOO BK, 1990, MINER ELECTROL METAB, V16, P322; VANDERHULST RRWJ, 1993, LANCET, V341, P1363, DOI 10.1016/0140-6736(93)90939-E; WINDMUELLER HG, 1980, J BIOL CHEM, V255, P107	9	6	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					451	452		10.1016/0140-6736(93)91589-E	http://dx.doi.org/10.1016/0140-6736(93)91589-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102425				2022-12-24	WOS:A1993LU07500006
J	NICOLAOU, KC; RIEMER, C; KERR, MA; RIDEOUT, D; WRASIDLO, W				NICOLAOU, KC; RIEMER, C; KERR, MA; RIDEOUT, D; WRASIDLO, W			DESIGN, SYNTHESIS AND BIOLOGICAL-ACTIVITY OF PROTAXOLS	NATURE			English	Article							WATER-SOLUBLE PRODRUGS; ANTITUMOR-ACTIVITY; TAXOL; CELLS; MICROTUBULES; AGENTS; ASSAY	TAXOL1-6 is a product isolated from the Pacific yew tree (Taxus brevifolia) and is a potent microtubule-stabilizing agent which has recently been approved for treatment of otherwise intractable ovarian cancer. Despite taxol's therapeutic promise, its aqueous insolubility (<0.004 mg ml-1) hampers its clinical application. Here we report the design, synthesis and biological activity of a series of taxol-releasing compounds (protaxols) with improved pharmacological properties. These prodrugs were designed to increase their aqueous solubility and allow for taxol release under basic or physiological conditions. We demonstrate the stability of these prodrugs at pH less-than-or-equal-to 7 and their ability to release taxol in a basic medium. Taxol-like microtubule-stabilizing activity7-9 appears after the release of taxol. In vitro these prodrugs have cytotoxic properties against tumour cell lines comparable to those of taxol; moreover, human plasma catalyses the release of active taxol. These protaxols have greater potential as anticancer agents than the parent compounds taxol and taxotere (Fig. 1a).	UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DRUG DISCOVERY UNIT, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; Scripps Research Institute; Scripps Research Institute	NICOLAOU, KC (corresponding author), SCRIPPS RES INST, DEPT CHEM, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							DEBRABANDER M, 1981, P NATL ACAD SCI-BIOL, V78, P5608; DEUTSCH HM, 1989, J MED CHEM, V32, P788, DOI 10.1021/jm00124a011; KEIZER HG, 1989, J NATL CANCER I, V81, P706, DOI 10.1093/jnci/81.9.706; KINGSTON DGI, 1991, PHARMACOL THERAPEUT, V52, P1, DOI 10.1016/0163-7258(91)90085-Z; LONGNECKER SM, 1987, CANCER TREAT REP, V71, P53; MATHEW AE, 1992, J MED CHEM, V35, P145, DOI 10.1021/jm00079a019; MERLOCK R, IN PRESS ANAL BIOCH; NICOLAOU KC, IN PRESS ANGEW CHEM; POITIER P, 1992, CHEM SOC REV, V21, P113; ROWINSKY EK, 1991, PHARMACOL THERAPEUT, V52, P35, DOI 10.1016/0163-7258(91)90086-2; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SWINDELL CS, 1991, ORG PREP PROCED INT, V23, P465, DOI 10.1080/00304949109458240; SWINDELL CS, 1991, J MED CHEM, V34, P1176, DOI 10.1021/jm00107a042; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; ZHAO ZY, 1991, J NAT PROD, V54, P1607, DOI 10.1021/np50078a018	17	118	157	3	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 29	1993	364	6436					464	466		10.1038/364464a0	http://dx.doi.org/10.1038/364464a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	LP640	8101355				2022-12-24	WOS:A1993LP64000061
J	MULLIGAN, LM; KWOK, JBJ; HEALEY, CS; ELSDON, MJ; ENG, C; GARDNER, E; LOVE, DR; MOLE, SE; MOORE, JK; PAPI, L; PONDER, MA; TELENIUS, H; TUNNACLIFFE, A; PONDER, BAJ				MULLIGAN, LM; KWOK, JBJ; HEALEY, CS; ELSDON, MJ; ENG, C; GARDNER, E; LOVE, DR; MOLE, SE; MOORE, JK; PAPI, L; PONDER, MA; TELENIUS, H; TUNNACLIFFE, A; PONDER, BAJ			GERM-LINE MUTATIONS OF THE RET PROTOONCOGENE IN MULTIPLE ENDOCRINE NEOPLASIA TYPE-2A	NATURE			English	Article							POINT MUTATION; TYROSINE KINASE; PROTOONCOGENE; DOMAIN; CHROMOSOME-10; CARCINOMAS	MULTIPLE endocrine neoplasia type 2A (MEN 2A) is a dominantly inherited cancer syndrome that affects tissues derived from neural ectoderm. It is characterized by medullary thyroid carcinoma (MTC) and phaeochromocytoma1. The MEN2A gene has recently been localized by a combination of genetic and physical mapping techniques to a 480-kilobase region in chromosome 10q11.2 (refs 2,3). The DNA segment encompasses the RET proto-oncogene, a receptor tyrosine kinase gene expressed in MTC and phaeochromocytoma and at lower levels in normal human thyroid4. This suggested RET as a candidate for the MEN2A gene. We have identified missense mutations of the RET proto-oncogene in 20 of 23 apparently distinct MEN 2A families, but not in 23 normal controls. Further, 19 of these 20 mutations affect the same conserved cysteine residue at the boundary of the RET extracellular and transmembrane domains.	UNIV CAMBRIDGE,DEPT PATHOL,CANC RES CAMPAIGN,HUMAN CANC GENET GRP,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND	CRUK Cambridge Institute; University of Cambridge			Mole, Sara/C-2024-2008	Mole, Sara/0000-0003-4385-4957; Papi, Laura/0000-0003-4552-9517; Love, Donald/0000-0003-4669-8769; Kwok, John/0000-0001-9574-6195; Eng, Charis/0000-0002-3693-5145; Tunnacliffe, Alan/0000-0001-8570-125X				BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GARDNER E, 1993, HUM MOL GENET, V2, P241, DOI 10.1093/hmg/2.3.241; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; IWAMOTO T, 1993, ONCOGENE, V8, P1087; LANDSVATER RM, 1989, GENOMICS, V4, P246, DOI 10.1016/0888-7543(89)90327-3; MOLE SE, 1993, HUM MOL GENET, V2, P247, DOI 10.1093/hmg/2.3.247; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; MULLIGAN LM, 1991, NUCLEIC ACIDS RES, V19, P5795, DOI 10.1093/nar/19.20.5795; NELKIN BD, 1989, CANCER RES, V49, P4114; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; TAHIRA T, 1991, NUCLEIC ACIDS RES, V18, P7472; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; YAMAMOTO M, 1991, JPN J CLIN ONCOL, V21, P149	20	1612	1652	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					458	460		10.1038/363458a0	http://dx.doi.org/10.1038/363458a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8099202				2022-12-24	WOS:A1993LE93800061
J	OU, CY; TAKEBE, Y; WENIGER, BG; LUO, CC; KALISH, ML; AUWANIT, W; YAMAZAKI, S; GAYLE, HD; YOUNG, NL; SCHOCHETMAN, G				OU, CY; TAKEBE, Y; WENIGER, BG; LUO, CC; KALISH, ML; AUWANIT, W; YAMAZAKI, S; GAYLE, HD; YOUNG, NL; SCHOCHETMAN, G			INDEPENDENT INTRODUCTION OF 2 MAJOR HIV-1 GENOTYPES INTO DISTINCT HIGH-RISK POPULATIONS IN THAILAND	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PRINCIPAL NEUTRALIZING DETERMINANT; SEQUENCE-ANALYSIS; TYPE-1; AIDS; SUBSTITUTIONS; EVOLUTION; REGIONS	To investigate the genetic heterogeneity and epidemiological distribution of human immunodeficiency virus type 1 (HIV-1) in Thailand, we determined proviral sequences for 63 HIV-1-infected patients in various risk groups from all over the country between April and July, 1991. Two distinct genotypes of HIV-1, A and B, were found to segregate by mode of transmission. Of 29 sexually infected patients, 25 (86%) had HIV-1 of genotype A and 4 (14%) had genotype B. Among 29 injecting drug users, probably parenterally infected, only 7 (24%) had genotype A and 22 (76%) had genotype B. This segregation is unlikely to have arisen by chance (p < 0.001). No patient was found to have dual infection. Nucleotide divergence averaged 3.4% among genotype-A-infected patients and 3.5% among genotype-B-infected patients, but 22.0% between the genotypes. 37 of 40 isolates (both genotypes) had the GPGQ tetrapeptide at the tip of the V3 loop, which is common in African HIV-1 strains but rare in North American and European strains, where the GPGR motif predominates. These findings suggest that the waves of HIV-1 infection in injecting drug users and in sexually infected patients in Thailand may not be epidemiologically linked. The nucleotide divergence data point to the separate introductions of the two genotypes into Thailand. Further studies in Thailand and neighbouring countries will be useful in the design and selection of candidate HIV vaccines.	NATL INST HLTH,TOKYO 141,JAPAN; NATL INST HLTH,BANGKOK,THAILAND; HIV AIDS COLLABORAT,BANGKOK,THAILAND	National Institute of Health Sciences - Japan; Ministry of Public Health - Thailand				Weniger, Bruce/0000-0002-5450-5464				ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; DELASSUS S, 1991, J VIROL, V65, P225, DOI 10.1128/JVI.65.1.225-231.1991; GOLDSMITH MF, 1991, JAMA-J AM MED ASSOC, V266, P1048, DOI 10.1001/jama.266.8.1048; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; HATTORI T, 1991, AIDS RES HUM RETROV, V7, P825, DOI 10.1089/aid.1991.7.825; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MELOEN RH, 1989, J GEN VIROL, V70, P1505, DOI 10.1099/0022-1317-70-6-1505; MYERHANS A, 1989, CELL, V58, P901; Myers G, 1992, COMPILATION ANAL NUC; ORAM JD, 1991, AIDS RES HUM RETROV, V7, P605, DOI 10.1089/aid.1991.7.605; OU CY, 1992, AIDS RES HUM RETROV, V8, P1471, DOI 10.1089/aid.1992.8.1471; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; OU CY, 1992, 8 INT C AIDS AMST; PAU CP, 1993, AIDS, V7, P337, DOI 10.1097/00002030-199303000-00005; Phongpaichit Pasuk, 1982, PEASANT GIRLS BANGKO, P71; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; SIRIPRAPASRI T, 1991, AIDS, V5, P579; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; Traisupa A., 1990, Thai AIDS Journal, V2, P57; TRAISUPA A, 1987, GENITOURIN MED, V63, P106; Ungchusak K., 1989, Thai AIDS Journal, V1, P57; VANICHSENI S, 1990, THAI AIDS J, V1, P75; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; WANGROONGSARB Y, 1985, Southeast Asian Journal of Tropical Medicine and Public Health, V16, P517; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011; 1984, WKLY EPIDEMIOL SURVE, V15, P509; 1989, 1989 ANN STAT REP TO, P1	29	294	306	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1171	1174		10.1016/0140-6736(93)91001-3	http://dx.doi.org/10.1016/0140-6736(93)91001-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098076				2022-12-24	WOS:A1993LB01700003
J	TEVELDE, ER				TEVELDE, ER			REPRODUCTIVE MEDICINE - DISAPPEARING OVARIAN FOLLICLES AND REPRODUCTIVE AGING	LANCET			English	Editorial Material							CHILDBEARING; FECUNDITY				TEVELDE, ER (corresponding author), UNIV UTRECHT HOSP,DEPT OBSTET & GYNAECOL,3511 GV UTRECHT,NETHERLANDS.							BONGAARTS J, 1982, 89 CTR POL STUD POP, P1; FADDY MJ, 1992, HUM REPROD, V7, P1342, DOI 10.1093/oxfordjournals.humrep.a137570; HENDERSON SA, 1968, NATURE, V218, P22, DOI 10.1038/218022a0; LERIDON H, 1977, P202; MOSHER WD, 1991, FERTIL STERIL, V56, P192; SAUER MV, 1993, LANCET, V341, P321, DOI 10.1016/0140-6736(93)90132-Z; SPEROFF L, 1989, CLIN GYNECOLOGIC END, P124; STEIN ZA, 1985, AM J EPIDEMIOL, V121, P327, DOI 10.1093/oxfordjournals.aje.a114004; Treloar AE, 1981, MATURITAS, V19, P49; VANNOORDZAADSTRA BM, 1991, BMJ-BRIT MED J, V302, P1361, DOI 10.1136/bmj.302.6789.1361	10	17	17	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1125	1126		10.1016/0140-6736(93)93133-L	http://dx.doi.org/10.1016/0140-6736(93)93133-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097809				2022-12-24	WOS:A1993KZ68700009
J	HSIEH, CS; MACATONIA, SE; TRIPP, CS; WOLF, SF; OGARRA, A; MURPHY, KM				HSIEH, CS; MACATONIA, SE; TRIPP, CS; WOLF, SF; OGARRA, A; MURPHY, KM			DEVELOPMENT OF TH1 CD4+ T-CELLS THROUGH IL-12 PRODUCED BY LISTERIA-INDUCED MACROPHAGES	SCIENCE			English	Article							INHIBITS CYTOKINE PRODUCTION; TUMOR-NECROSIS-FACTOR; LYMPHOCYTES-T; IFN-GAMMA; CUTANEOUS LEISHMANIASIS; LYMPHOKINE PRODUCTION; STIMULATORY FACTOR; INTERFERON-GAMMA; HELPER CELL; SCID MICE	Development of the appropriate CD4+ T helper (T(H)) subset during an immune response is important for disease resolution. With the use of naive, ovalbumin-specific alphabeta T cell receptor transgenic T cells, it was found that heat-killed Listeria monocytogenes induced T(H)1 development in vitro through macrophage production of interleukin-12 (IL-12). Moreover, inhibition of macrophage production of IL-12 may explain the ability of IL-10 to suppress T(H)1 development. Murine immune responses to L. monocytogenes in vivo are of the appropriate T(H)1 phenotype. Therefore, this regulatory pathway may have evolved to enable innate immune cells, through interactions with microbial pathogens, to direct development of specific immunity toward the appropriate T(H) phenotype.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; GENET INST,CAMBRIDGE,MA 02140	Washington University (WUSTL); Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Yang, Chen/G-1379-2010	O'Garra, Anne/0000-0001-9845-6134	NIGMS NIH HHS [5 T32 GM07200-17] Funding Source: Medline; PHS HHS [1 PO1 A131238-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANCROFT GJ, 1989, J IMMUNOL, V143, P127; BOTTOMLY K, 1988, IMMUNOL TODAY, V9, P268, DOI 10.1016/0167-5699(88)91308-4; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; CROFT M, 1992, J EXP MED, V176, P1431, DOI 10.1084/jem.176.5.1431; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DAYNES RA, 1990, J EXP MED, V171, P979, DOI 10.1084/jem.171.4.979; de Waal Malefyt R., 1991, J EXP MED, V174, P1209, DOI DOI 10.1084/JEM.174.5.1209; FINKELMAN FD, 1991, J EXP MED, V174, P1179, DOI 10.1084/jem.174.5.1179; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HSIEH CC, UNPUB; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; HSIEH CS, IN PRESS INT IMMUNOL; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; KULLBERG MC, 1992, J IMMUNOL, V148, P3264; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LI TK, 1993, J IMMUNOL, V150, P1680; MACATONIA SE, UNPUB; MAGEE DM, 1988, J IMMUNOL, V141, P3203; MAGGI E, 1992, J IMMUNOL, V148, P2142; MIELKE MEA, 1988, INFECT IMMUN, V56, P1920, DOI 10.1128/IAI.56.8.1920-1925.1988; MOORE KE, IN PRESS; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAUME B, 1992, J IMMUNOL, V148, P2429; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1991, IMMUNOL TODAY, V12, P346, DOI 10.1016/0167-5699(91)90063-Y; SCOTT P, 1991, J IMMUNOL, V147, P3149; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHER A, 1991, J IMMUNOL, V147, P2713; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; SILVA JS, 1992, J EXP MED, V175, P169, DOI 10.1084/jem.175.1.169; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; SWAIN SL, 1991, J IMMUNOL, V147, P2991; SWAIN SL, 1990, J IMMUNOL, V145, P3796; TRIPP CS, IN PRESS P NATL ACAD; URBAN JF, 1992, IMMUNOL REV, V127, P205, DOI 10.1111/j.1600-065X.1992.tb01415.x; WHERRY JC, 1991, INFECT IMMUN, V59, P1709, DOI 10.1128/IAI.59.5.1709-1715.1991	43	2900	2979	3	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 23	1993	260	5107					547	549		10.1126/science.8097338	http://dx.doi.org/10.1126/science.8097338			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY504	8097338				2022-12-24	WOS:A1993KY50400036
J	GREIG, S; AKAM, M				GREIG, S; AKAM, M			HOMEOTIC GENES AUTONOMOUSLY SPECIFY ONE ASPECT OF PATTERN IN THE DROSOPHILA MESODERM	NATURE			English	Article							EMBRYOS; EXPRESSION; TWIST; GRADIENT; PROTEIN	TRANSPLANTATION and ablation experiments have led to the generalization that in insects the mesoderm is naive, and that pattern is imposed upon it by the ectoderm1-6. This has been demonstrated directly by mosaic analysis for the case of one muscle in Drosophila. The unique character of this muscle depends on the activity of sex-determining and homeotic genes, not in the muscle itself, but in the nerve that innervates it7. Indirect evidence suggests, however, that homeotic genes specify some aspects of mesoderm patterning autonomously. Homeotic genes are expressed in the mesoderm, and are regulated in a segment-specific pattern analogous to, but different from, that seen in the ectoderm6,8. Moreover, the effects of homeotic mutations on the muscles do not always mirror transformations seen in the epidermis9,10. Here we examine this problem directly, by expressing homeotic genes ectopically in the mesoderm without altering their expression in the overlying ectoderm. We find that the pattern of adult muscle precursor cells characteristic of the thorax can be converted to that seen in the abdomen by expressing the homeotic gene abdominal-A specifically in the mesoderm.	DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND		GREIG, S (corresponding author), WELLCOME CRC INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKAM ME, 1985, EMBO J, V4, P1689, DOI 10.1002/j.1460-2075.1985.tb03838.x; BATE MA, 1991, DEVELOPMENT, V113, P7; BEER J, 1987, ROUX ARCH DEV BIOL, V196, P222, DOI 10.1007/BF00376346; Bock E, 1942, ROUX ARCH, V141, P159; BRAND A, IN PRESS DEVELOPMENT; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; Cohen SM., 1993, DEV DROSOPHILA MELAN; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; Haget A., 1953, Bulletin Biol Paris, V87, P123; HOOPER JE, 1986, EMBO J, V5, P2321, DOI 10.1002/j.1460-2075.1986.tb04500.x; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JIANG J, 1991, GENE DEV, V5, P265, DOI 10.1101/gad.5.2.265; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; LAWRENCE PA, 1986, CELL, V45, P505, DOI 10.1016/0092-8674(86)90282-5; LAWRENCE PA, 1983, GENETICS NEW FRONTIE; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; MACIAS A, 1990, DEVELOPMENT, V110, P1197; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; SAHOTA TS, 1967, CAN J ZOOLOG, V45, P421, DOI 10.1139/z67-053; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; WILLIAMS GJA, 1980, J EMBRYOL EXP MORPH, V58, P13	23	143	147	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 15	1993	362	6421					630	632		10.1038/362630a0	http://dx.doi.org/10.1038/362630a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX438	8096627				2022-12-24	WOS:A1993KX43800047
J	INGLIS, TJJ; SHERRATT, MJ; SPROAT, LJ; GIBSON, JS; HAWKEY, PM				INGLIS, TJJ; SHERRATT, MJ; SPROAT, LJ; GIBSON, JS; HAWKEY, PM			GASTRODUODENAL DYSFUNCTION AND BACTERIAL-COLONIZATION OF THE VENTILATED LUNG	LANCET			English	Article							MULTIPLE TRAUMA PATIENTS; RESPIRATORY-TRACT; NOSOCOMIAL PNEUMONIA; COLONIZATION; DECONTAMINATION; CIMETIDINE; INFECTIONS; FLORA	The source of ventilator-associated pneumonia (gastric or oropharyngeal flora) remains controversial. We investigated the source of bacterial colonisation of the ventilated lung in 100 consecutive intensive-care patients. Gram-negative bacilli were isolated from the lower respiratory tract in 19 patients. Bacteria isolated from the stomach contents either previously or at the same time were identical to lower respiratory isolates in 11 patients. No gram-negative oropharyngeal isolate was identical to a lower respiratory tract isolate. Gastric bacterial overgrowth with gram-negative bacilli was associated with the presence of bilirubin in the stomach contents. Detectable bilirubin was also associated with subsequent acquisition of gram-negative bacilli in the lower respiratory tract. Only 5 gastric aspirate specimens with pH <3.5 contained gram-negative bacilli. These results establish a relation between duodenal reflux and subsequent bacterial colonisation of the lower respiratory tract. Restoration of normal gastroduodenal motility might help prevent pneumonia in intensive-care patients.	UNIV LEEDS,DEPT MICROBIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; GEN INFIRM,INTENS CARE UNIT,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	University of Leeds; Leeds General Infirmary			Sherratt, Michael J/A-1175-2015	Sherratt, Michael J/0000-0003-4759-6617				ATHERTON ST, 1978, LANCET, V2, P968; CRAIG CP, 1984, AM J INFECT CONTROL, V12, P233, DOI 10.1016/0196-6553(84)90114-7; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DONOWITZ LG, 1986, INFECT CONT HOSP EP, V7, P23, DOI 10.1017/S0195941700063748; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; DUMOULIN GC, 1982, LANCET, V1, P242; GRAY JDA, 1967, GUT, V8, P574, DOI 10.1136/gut.8.6.574; GRAYCEY M, 1983, HUMAN INTESTINAL MIC, P495; HAMMOND JMJ, 1992, LANCET, V340, P5, DOI 10.1016/0140-6736(92)92422-C; Hawkey PM, 1989, MED BACTERIOLOGY PRA; HAWKEY PM, 1989, MED BACTERIOLOGY PRA, P247; INGLIS T, 1991, BR J ANAESTHESIOL, V68, P499; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; Malloy HT, 1937, J BIOL CHEM, V119, P481; POWER I, 1989, ANAESTHESIA, V44, P563, DOI 10.1111/j.1365-2044.1989.tb11442.x; RUDDELL WSJ, 1980, LANCET, V1, P672; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; STOUTENBEEK CP, 1987, J TRAUMA, V27, P357, DOI 10.1097/00005373-198704000-00003; WOODS CR, 1992, J CLIN MICROBIOL, V30, P2921, DOI 10.1128/JCM.30.11.2921-2929.1992	19	133	135	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					911	913		10.1016/0140-6736(93)91208-4	http://dx.doi.org/10.1016/0140-6736(93)91208-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096263				2022-12-24	WOS:A1993KW98100002
J	ZAAIJER, HL; CUYPERS, HTM; REESINK, HW; WINKEL, IN; GERKEN, G; LELIE, PN				ZAAIJER, HL; CUYPERS, HTM; REESINK, HW; WINKEL, IN; GERKEN, G; LELIE, PN			RELIABILITY OF POLYMERASE CHAIN-REACTION FOR DETECTION OF HEPATITIS-C VIRUS	LANCET			English	Note								The polymerase chain reaction (PCR) is used to detect hepatitis C virus (HCV) RNA, and the results of this assay may have a bearing on management of patients. We tested 31 laboratories for performance of HCV PCR with a coded panel that comprised 4 HCV-positive plasma samples, 6 HCV-negative samples, and two dilution series of HCV-positive plasma. 15 (48%) laboratories had faultless results with both dilution series, and 16 (52%) laboratories reported erroneous results with one or both series. 10 (32%) laboratories had faultless results when testing undiluted plasma samples, 11 (35%) produced a false-negative result with a weak-positive sample, and 10 (32%) produced false negative and/or false positive results. Only 5 (16%) laboratories performed faultlessly with the entire panel of samples. Reports of presence of HCV should be interpreted with care until reliable HCV-RNA detection becomes widely available.	UNIV MAINZ,MED KLIN & POLIKLIN,W-6500 MAINZ,GERMANY	Johannes Gutenberg University of Mainz	LELIE, PN (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,EUROHEP CONCERTED ACT VIRAL HEPATITIS,1066 CX AMSTERDAM,NETHERLANDS.							BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GARSON JA, 1991, LANCET, V338, P1466, DOI 10.1016/0140-6736(91)92775-W; KIEVITS T, 1991, J VIROL METHODS, V35, P273, DOI 10.1016/0166-0934(91)90069-C; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; SUGITANI M, 1992, LANCET, V339, P1018, DOI 10.1016/0140-6736(92)90538-E; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B	7	394	401	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					722	724		10.1016/0140-6736(93)90488-3	http://dx.doi.org/10.1016/0140-6736(93)90488-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095626				2022-12-24	WOS:A1993KT36200005
J	GOUREVITCH, MN; SELWYN, PA; DAVENNY, K; BUONO, D; SCHOENBAUM, EE; KLEIN, RS; FRIEDLAND, GH				GOUREVITCH, MN; SELWYN, PA; DAVENNY, K; BUONO, D; SCHOENBAUM, EE; KLEIN, RS; FRIEDLAND, GH			EFFECTS OF HIV-INFECTION ON THE SEROLOGIC MANIFESTATIONS AND RESPONSE TO TREATMENT OF SYPHILIS IN INTRAVENOUS-DRUG-USERS	ANNALS OF INTERNAL MEDICINE			English	Article						SYPHILIS; SUBSTANCE ABUSE, INTRAVENOUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS SEROPOSITIVITY; HUMAN IMMUNODEFICIENCY SEROPREVALENCE	IMMUNODEFICIENCY-VIRUS-INFECTION; SEXUALLY-TRANSMITTED DISEASE; SECONDARY SYPHILIS; TREPONEMA-PALLIDUM; PRIMARY CARE; RISK-FACTORS; COCAINE USE; PATIENT; CLINICS; TESTS	Objective: To describe the effects of human immunodeficiency virus (HIV) infection on the serologic manifestations and response to treatment of syphilis in intravenous drug users. Design: Cohort study of intravenous drug users. Setting: Medical clinic in a hospital-based methadone maintenance treatment program in New York City. Patients: Fifty patients with syphilis, of whom 31 were HIV seropositive and 19 HIV seronegative. Measurements: Serologic tests for syphilis and clinical manifestations. Results: Stage of syphilis at presentation was not associated with HIV serologic status. No unusual or fulminant manifestations of early syphilis or neurosyphilis were noted among HIV-seropositive cases. Maximum nontreponemal titers were higher among HIV-seropositive (median, 1:128) than among HIV-seronegative (median, 1:32) patients with syphilis (P = 0.05); this difference was present only among patients with first-episode syphilis. All 26 evaluable, HIV-seropositive patients treated for syphilis responded appropriately, including 13 patients given standard or less-than-standard doses of penicillin. Seven of 43 patients (16%) showed reversion to negative treponemal antibody assay results after treatment for syphilis; this finding was not associated with HIV infection, CD4 count, or stage of syphilis. Low nontreponemal titer was weakly associated with treponemal test reversion. Conclusions: Infection with HIV did not alter the stage at presentation, clinical course, serologic manifestations, or response to treatment of syphilis in this cohort of intravenous drug users.			GOUREVITCH, MN (corresponding author), MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, DEPT EPIDEMIOL & SOCIAL MED, BRONX, NY 10467 USA.			Schoenbaum, Ellie/0000-0002-0878-284X; Gourevitch, Marc/0000-0001-6865-2126	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004347] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA04347-05] Funding Source: Medline; PHS HHS [U64/CCU200714] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERRY CD, 1987, NEW ENGL J MED, V316, P1587, DOI 10.1056/NEJM198706183162507; CHERUBIN CE, 1968, ANN INTERN MED, V69, P739, DOI 10.7326/0003-4819-69-4-739; CHIASSON MA, 1991, AIDS, V5, P1121, DOI 10.1097/00002030-199109000-00011; DRUSIN LM, 1974, AM J MED, V56, P429, DOI 10.1016/0002-9343(74)90626-3; DRUSIN LM, 1984, UROL CLIN N AM, V11, P121; FARLEY TA, 1990, SEX TRANSM DIS, V17, P163, DOI 10.1097/00007435-199010000-00003; FIUMARA N, 1989, J AM ACAD DERMATOL, V21, P141, DOI 10.1016/S0190-9622(89)80357-3; FULLILOVE RE, 1990, JAMA-J AM MED ASSOC, V263, P851, DOI 10.1001/jama.263.6.851; GILES AJH, 1979, BRIT J VENER DIS, V55, P62; GREGORY N, 1990, J AM ACAD DERMATOL, V22, P1061, DOI 10.1016/0190-9622(90)70153-9; HAAS JS, 1990, J INFECT DIS, V162, P862, DOI 10.1093/infdis/162.4.862; HARRIS WDM, 1967, NEW YORK STATE J MED, V67, P2967; HICKS CB, 1987, ANN INTERN MED, V107, P492, DOI 10.7326/0003-4819-107-4-492; HOOK EW, 1989, J INFECT DIS, V160, P530, DOI 10.1093/infdis/160.3.530; HUTCHINSON CM, 1991, ARCH INTERN MED, V151, P511, DOI 10.1001/archinte.151.3.511; HUTCHINSON CM, 1992, 8 INT C AIDS 3 STD W; JOHNS DR, 1987, NEW ENGL J MED, V316, P1569, DOI 10.1056/NEJM198706183162503; JOHNSON PDR, 1991, AIDS, V5, P419, DOI 10.1097/00002030-199104000-00010; KATZ DA, 1989, ARCH NEUROL-CHICAGO, V46, P895, DOI 10.1001/archneur.1989.00520440085024; LANSKA MJ, 1988, NEUROLOGY, V38, P1297, DOI 10.1212/WNL.38.8.1297; LARSEN SA, 1990, MANUAL TESTS SYPHILI, P19; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; MINKOFF HL, 1990, AM J OBSTET GYNECOL, V163, P521, DOI 10.1016/0002-9378(90)91188-I; MUSHER DM, 1990, ANN INTERN MED, V113, P872, DOI 10.7326/0003-4819-113-11-872; QUINN TC, 1990, ARCH INTERN MED, V150, P1297, DOI 10.1001/archinte.150.6.1297; RADOLF JD, 1988, J AM ACAD DERMATOL, V18, P423, DOI 10.1016/S0190-9622(88)70062-6; ROLFS RT, 1990, AM J PUBLIC HEALTH, V80, P853, DOI 10.2105/AJPH.80.7.853; ROLFS RT, 1990, JAMA-J AM MED ASSOC, V264, P1432, DOI 10.1001/jama.264.11.1432; ROMANOWSKI B, 1991, ANN INTERN MED, V114, P1005, DOI 10.7326/0003-4819-114-12-1005; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SCHOENBAUM EE, 1990, SEX TRANSM DIS, V17, P190, DOI 10.1097/00007435-199010000-00008; SCHROETER AL, 1972, J AMER MED ASSOC, V221, P471, DOI 10.1001/jama.221.5.471; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, ANN INTERN MED, V111, P761, DOI 10.7326/0003-4819-111-9-761; SHULKIN D, 1988, AM J MED, V85, P425, DOI 10.1016/0002-9343(88)90600-6; TELZAK EE, 1991, AIDS, V5, P591, DOI 10.1097/00002030-199105000-00020; WHARTON M, 1990, MMWR-MORBID MORTAL W, V39, P34; WUEPPER KD, 1966, J AMER MED ASSOC, V195, P868, DOI 10.1001/jama.1966.03100100120044; 1989, MMWR S8, V38, P5	40	69	71	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1993	118	5					350	355		10.7326/0003-4819-118-5-199303010-00005	http://dx.doi.org/10.7326/0003-4819-118-5-199303010-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN688	8094280				2022-12-24	WOS:A1993KN68800005
J	GANDEVIA, SC				GANDEVIA, SC			MUSCLE FATIGUE - DOES THE DIAPHRAGM FATIGUE DURING PARTURITION	LANCET			English	Editorial Material											GANDEVIA, SC (corresponding author), PRINCE WALES MED RES INST, RANDWICK, AUSTRALIA.		Gandevia, Simon C/D-5009-2011	Gandevia, Simon C/0000-0002-1345-3821				BELLEMARE F, 1987, J APPL PHYSIOL, V62, P1307, DOI 10.1152/jappl.1987.62.3.1307; BELLEMARE F, 1982, J APPL PHYSIOL, V53, P1190, DOI 10.1152/jappl.1982.53.5.1190; GANDEVIA SC, 1990, J PHYSIOL-LONDON, V428, P387, DOI 10.1113/jphysiol.1990.sp018218; MCKENZIE DK, 1992, J PHYSIOL-LONDON, V454, P643, DOI 10.1113/jphysiol.1992.sp019284; NAVA S, 1992, AM REV RESPIR DIS, V146, P1226, DOI 10.1164/ajrccm/146.5_Pt_1.1226	5	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 6	1993	341	8841					347	348		10.1016/0140-6736(93)90144-6	http://dx.doi.org/10.1016/0140-6736(93)90144-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094121				2022-12-24	WOS:A1993KK93900012
J	GALE, RE; WHEADON, H; GOLDSTONE, AH; BURNETT, AK; LINCH, DC				GALE, RE; WHEADON, H; GOLDSTONE, AH; BURNETT, AK; LINCH, DC			FREQUENCY OF CLONAL REMISSION IN ACUTE MYELOID-LEUKEMIA	LANCET			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; X-CHROMOSOME INACTIVATION; DNA; DIFFERENTIATION; POLYMORPHISMS; DIAGNOSIS; DISORDERS; TUMORS; CELLS; GENE	Analysis of X-chromosome inactivation patterns in females has been used to assess clonality of various tumours and for prenatal diagnosis of X-linked disorders. Studies with these methods in acute myeloid leukaemia suggest that a significant proportion of cases have clonal remissions (ie, persistence of the malignant clone), which may represent return to a preleukaemic state. We therefore analysed X-chromosome inactivation patterns with differential methylation patterns of heterozygotes for three DNA probes, HPRT, PGK, and M27beta, in leukaemic patients and normal controls. As expected, blast cells from 67 of 68 analysable samples (99%) were monoclonal or had a skewed X-inactivation pattern. A skewed pattern in remission was also found in 26 of 77 patients (34%), proportion only slightly greater than control (16/75, 21%). In 7 of 10 patients with a skewed pattern in myeloid cells there was similar skewing in the T cells, which is compatible with the concept of a constitutively skewed X-chromosome inactivation pattern of haemopoietic cells in these patients. Our study illustrates the difficulty of interpreting clonality in individual tumour samples and emphasises the importance of comparisons with non-malignant tissue of the same cell type from that individual and from normal control populations.	UNIV HOSP WALES, DEPT HAEMATOL, CARDIFF, WALES	Cardiff University	GALE, RE (corresponding author), UCL, SCH MED, DEPT HAEMATOL, LONDON WC1E 6HX, ENGLAND.		SHAKOORI, ABDUL RAUF/Q-9373-2019	Wheadon, Helen/0000-0001-9902-3170				ABKOWITZ JL, 1988, BLOOD, V71, P1687; BARTRAM CR, 1989, LEUKEMIA, V3, P247; BURNETT AK, 1991, HEMATOL ONCOL, V1, P111; CHANARIN I, 1989, LABORATORY HAEMATOLO; CHESON BD, 1990, J CLIN ONCOL, V8, P813, DOI 10.1200/JCO.1990.8.5.813; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEY MF, 1987, BRIT J HAEMATOL, V67, P489, DOI 10.1111/j.1365-2141.1987.tb06174.x; FEY MF, 1992, J CLIN INVEST, V89, P1438, DOI 10.1172/JCI115733; Fialkow P J, 1972, Adv Cancer Res, V15, P191, DOI 10.1016/S0065-230X(08)60375-9; FIALKOW PJ, 1981, BLOOD, V57, P1068; FIALKOW PJ, 1991, BLOOD, V77, P1415; FIALKOW PJ, 1987, NEW ENGL J MED, V317, P468, DOI 10.1056/NEJM198708203170802; FRASER NJ, 1989, GENOMICS, V5, P144, DOI 10.1016/0888-7543(89)90099-2; GALE RE, 1992, LEUKEMIA, V6, P649; GALE RE, 1991, BRIT J HAEMATOL, V79, P193, DOI 10.1111/j.1365-2141.1991.tb04521.x; HODGES E, 1991, BRIT J HAEMATOL, V77, P315, DOI 10.1111/j.1365-2141.1991.tb08577.x; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KERE J, 1987, BLOOD, V70, P1349; KIBBELAAR RE, 1992, BLOOD, V79, P1823; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Maniatis T., 1982, MOL CLONING; POWLES RL, 1979, LANCET, V2, P674; PUCK JM, 1990, NEW ENGL J MED, V322, P1063, DOI 10.1056/NEJM199004123221508; SINGER JW, 1991, SEMIN HEMATOL, V28, P1; TILLY H, 1986, NEW ENGL J MED, V314, P246; TURHAN AG, 1989, NEW ENGL J MED, V320, P1655, DOI 10.1056/NEJM198906223202504; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WAINSCOAT JS, 1990, CANCER RES, V50, P1355	29	62	62	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					138	142		10.1016/0140-6736(93)90004-Z	http://dx.doi.org/10.1016/0140-6736(93)90004-Z			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093744				2022-12-24	WOS:A1993KG62700004
J	VALORI, R				VALORI, R			LINES WRITTEN ON READING ANOTHER REVIEW ARTICLE ABOUT THE IRRITABLE-BOWEL-SYNDROME	LANCET			English	Editorial Material											VALORI, R (corresponding author), MIDDLESEX HOSP,LONDON W1N 8AA,ENGLAND.								0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					36	37		10.1016/0140-6736(93)92498-I	http://dx.doi.org/10.1016/0140-6736(93)92498-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093280				2022-12-24	WOS:A1993KF02700019
J	ZURLO, JJ; ONEILL, D; POLIS, MA; MANISCHEWITZ, J; YARCHOAN, R; BASELER, M; LANE, HC; MASUR, H				ZURLO, JJ; ONEILL, D; POLIS, MA; MANISCHEWITZ, J; YARCHOAN, R; BASELER, M; LANE, HC; MASUR, H			LACK OF CLINICAL UTILITY OF CYTOMEGALOVIRUS BLOOD AND URINE CULTURES IN PATIENTS WITH HIV-INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						CYTOMEGALOVIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; VIRUS CULTIVATION; VIREMIA; VIRURIA; ACQUIRED IMMUNODEFICIENCY SYNDROME	IMMUNE-DEFICIENCY SYNDROME; ACQUIRED IMMUNODEFICIENCY SYNDROME; HOMOSEXUAL MEN; VIRUS INFECTION; SYNDROME AIDS; RETINITIS; MANIFESTATION; DISEASE; GUANINE	Objective: To determine the clinical significance of cytomegalovirus (CMV) blood and urine cultures in patients with human immunodeficiency virus (HIV) infection. Design: Inception cohort of patients with HIV infection and CMV culture data. Setting: Government referral-based research hospital. Patients: A total of 322 HIV-infected patients who had a CMV blood culture and 293 HIV-infected patients who had a CMV urine culture within 7 days of a CD4 determination. Measurements: Cytomegalovirus blood and urine culture results; circulating CD4 lymphocyte counts; pathologic or retinopathic findings of CMV disease. Results: Nine of 26 patients (34.6%) with CMV viremia subsequently developed CMV end-organ disease compared with 11 of 74 (14.9%) patients without viremia, (difference, 19.7%; 95% CI, -0.3% to 39.7%). Fifteen of 47 patients (31.9%) with CMV viruria developed end-organ disease compared with 4 of 43 (9.3%) patients without viruria, (difference, 22.6%; CI, 6.7% to 38.5%). Cytomegalovirus culture positivity had poor predictive value for the subsequent development of end-organ disease (35% for viremia and 28% for viruria). Further, patients with proven end-organ disease were often not viremic (45%), but most were viruric (88%). Cytomegalovirus viremia did not correlate with the presence of either fever or weight loss in this patient group. Both blood culture positivity and urine culture positivity varied inversely with the CD4 count (P = 0.0001 for both associations). Conclusions: The likelihood that a blood or urine culture will be positive in a patient with HIV infection correlates better with immunologic status than with current or future clinical status. Although the absence of CMV viruria may suggest that CMV disease is not present, CMV blood and urine cultures have poor diagnostic and predictive value and therefore should be used primarily for research purposes or drug susceptibility testing and not for making clinical decisions.	NIH, WARREN GRANT MAGNUSON CLIN CTR, BETHESDA, MD 20892 USA; US FDA, CTR BIOL EVALUAT & RES, BETHESDA, MD 20892 USA; NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, FREDERICK, MD 21702 USA; NIAID, BETHESDA, MD 20892 USA; NCI, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Polis, Michael/0000-0002-9151-2268	OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALTHAZAR EJ, 1985, AM J ROENTGENOL, V144, P1201, DOI 10.2214/ajr.144.6.1201; DREW WL, 1981, J INFECT DIS, V143, P188, DOI 10.1093/infdis/143.2.188; DREW WL, 1985, ANN INTERN MED, V103, P61, DOI 10.7326/0003-4819-103-1-61; FRANK D, 1984, AM J GASTROENTEROL, V79, P201; FRIEDMAN AH, 1983, BRIT J OPHTHALMOL, V67, P372, DOI 10.1136/bjo.67.6.372; HENDERLY DE, 1987, AM J OPHTHALMOL, V103, P316; JACOBSON MA, 1988, ANN INTERN MED, V108, P585, DOI 10.7326/0003-4819-108-4-585; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; MASUR H, 1986, ANN INTERN MED, V104, P41, DOI 10.7326/0003-4819-104-1-41; MCKENZIE R, 1991, MEDICINE, V70, P326, DOI 10.1097/00005792-199109000-00004; MINTZ L, 1983, ANN INTERN MED, V99, P326, DOI 10.7326/0003-4819-99-3-326; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; PALESTINE AG, 1984, OPHTHALMOLOGY, V91, P1092; PALESTINE AG, 1986, AM J OPHTHALMOL, V101, P95, DOI 10.1016/0002-9394(86)90470-8; QUINNAN GV, 1984, JAMA-J AM MED ASSOC, V252, P72, DOI 10.1001/jama.252.1.72	16	81	84	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1993	118	1					12	17		10.7326/0003-4819-118-1-199301010-00003	http://dx.doi.org/10.7326/0003-4819-118-1-199301010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE605	8093214				2022-12-24	WOS:A1993KE60500003
J	ROBINSON, SR; HAMPSON, ECGM; MUNRO, MN; VANEY, DI				ROBINSON, SR; HAMPSON, ECGM; MUNRO, MN; VANEY, DI			UNIDIRECTIONAL COUPLING OF GAP-JUNCTIONS BETWEEN NEUROGLIA	SCIENCE			English	Article							RAT OPTIC-NERVE; ADULT-RABBIT; MEMBRANE CHANNELS; CELL JUNCTION; ASTROCYTES; OLIGODENDROCYTES; EXPRESSION; RETINA; IMMUNOHISTOCHEMISTRY; INJECTION	Gap junctions permit the passage of ions and small molecules between cells, thereby providing a basis for direct intercellular communication. In the rabbit retina, the low molecular weight dyes Lucifer yellow and biocytin passed readily from astrocytes into adjacent astrocytes, oligodendrocytes, and Muller cells. However, the dyes rarely passed from either oligodendrocytes or Muller cells into astrocytes. Unidirectional passage of dye suggests the presence of an asymmetric barrier to the movement of molecules through heterologous gap junctions and indicates the potential for a hierarchy of command between interconnected cells.			ROBINSON, SR (corresponding author), UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,VIS TOUCH & HEARING RES CTR,BRISBANE 4072,AUSTRALIA.		Robinson, Stephen R./AAU-3219-2021; Hampson, Edith/G-2692-2011; Robinson, Stephen R/B-7155-2013	Robinson, Stephen R./0000-0002-0987-0075; 				BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BUTT AM, 1989, GLIA, V2, P470, DOI 10.1002/glia.440020609; DERMIETZEL R, 1990, ANAT EMBRYOL, V182, P517; DERMIETZEL R, 1989, P NATL ACAD SCI USA, V86, P10148, DOI 10.1073/pnas.86.24.10148; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; FLAGGNEWTON J, 1979, SCIENCE, V205, P404, DOI 10.1126/science.377490; FLAGGNEWTON JL, 1980, SCIENCE, V207, P771, DOI 10.1126/science.7352287; GIAUME C, 1991, NEURON, V6, P133, DOI 10.1016/0896-6273(91)90128-M; HORIKAWA K, 1988, J NEUROSCI METH, V25, P1, DOI 10.1016/0165-0270(88)90114-8; KETTENMANN H, 1988, GLIA, V1, P64, DOI 10.1002/glia.440010108; KETTENMANN H, 1983, J NEUROSCI, V3, P506; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; NAUS CCG, 1991, NEUROSCI LETT, V126, P33, DOI 10.1016/0304-3940(91)90364-Y; RANSOM BR, 1990, GLIA, V3, P258, DOI 10.1002/glia.440030405; RANSOM BR, 1991, GLIA, V4, P37, DOI 10.1002/glia.440040105; REICHENBACH A, 1988, J HIRNFORSCH, V29, P481; ROBAIN O, 1970, J NEUROL SCI, V11, P445, DOI 10.1016/0022-510X(70)90003-1; ROBINSON SR, 1990, J COMP NEUROL, V292, P178, DOI 10.1002/cne.902920203; ROBINSON SR, 1989, NEUROSCI LETT, V106, P261, DOI 10.1016/0304-3940(89)90174-2; SCHERER J, 1991, J COMP NEUROL, V312, P175, DOI 10.1002/cne.903120202; SCHNITZER J, 1986, CELL TISSUE RES, V246, P91; SHERIDAN JD, 1985, ANNU REV PHYSIOL, V47, P337; SONTHEIMER H, 1990, P NATL ACAD SCI USA, V87, P9833, DOI 10.1073/pnas.87.24.9833; SPIEGEL K, 1988, Society for Neuroscience Abstracts, V14, P578; STEWART WW, 1978, CELL, V14, P741, DOI 10.1016/0092-8674(78)90256-8; VANEY DI, 1992, J NEUROSCI METH, V44, P217, DOI 10.1016/0165-0270(92)90013-4; VANEY DI, 1991, NEUROSCI LETT, V125, P187, DOI 10.1016/0304-3940(91)90024-N; VONBLANKENFELD G, 1993, GLIA, V7, P322, DOI 10.1002/glia.440070407; YAMAMOTO T, 1990, J COMP NEUROL, V302, P853, DOI 10.1002/cne.903020414	29	172	176	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1072	1074						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8093125				2022-12-24	WOS:A1993MG18700041
J	YIP, J; MATTOCK, MB; MOROCUTTI, A; SETHI, M; TREVISAN, R; VIBERTI, GC				YIP, J; MATTOCK, MB; MOROCUTTI, A; SETHI, M; TREVISAN, R; VIBERTI, GC			INSULIN-RESISTANCE IN INSULIN-DEPENDENT DIABETIC-PATIENTS WITH MICROALBUMINURIA	LANCET			English	Article							SODIUM-LITHIUM COUNTERTRANSPORT; AMBULATORY BLOOD-PRESSURE; ESCAPE RATE; MELLITUS; DISEASE; HYPERINSULINEMIA; HYPERTENSION; SENSITIVITY; MORTALITY; ALBUMIN	In insulin-dependent diabetes, microalbuminuria increases the risk of cardiovascular and renal disease. By means of a euglycaemic hyperinsulinaemic clamp method, we measured total-body glucose utilisation rate and studied the interaction of this measure of insulin sensitivity with known risk factors for cardiovascular disease in 14 diabetic patients with microalbuminuria and 14 with normal albumin excretion (median albumin excretion rate [AER] 56.2 [range 39.2-80.6] vs 8.8 [7.4-10.7] mug per min). The two groups were of similar age, duration of diabetes, and body-mass index. Total-body glucose disposal rate was significantly lower in the patients with microalbuminuria than in those without (mean 7.86 [SD 1.40] vs 9.04 [0.90] mg/kg per min; p<0.05). There were also significant differences between the groups in the daily insulin dose needed for equivalent glucose control (0.76 [0.20] vs 0.65 [0.10] U/kg, p<0.05), mean systolic blood pressure over 24 h ambulatory monitoring (134 [7] vs 127 [7] mm Hg; p<0.05), and various plasma lipid concentrations, contributing to a more atherogenic profile in the microalbuminuric group. Total-body glucose disposal rate was inversely correlated with body-mass index and log10 AER. The insulin sensitivity of the microalbuminuric group remained impaired after adjustment for blood pressure and body-mass index. Impaired insulin sensitivity is a feature of insulin-dependent diabetic patients with microalbuminuria, which adds, with other factors, to the increased risks of renal and cardiovascular disease in these patients.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,METAB MED UNIT,LONDON,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			TREVISAN, ROBERTO/Q-8706-2016	TREVISAN, ROBERTO/0000-0003-0420-4468				COLLINS ACG, 1985, DIABETIC MED, V2, P456, DOI 10.1111/j.1464-5491.1985.tb00682.x; DEFARIA JBL, 1992, DIABETES, V41, P610, DOI 10.2337/diab.41.5.610; DEFRONZO RA, 1982, DIABETES, V31, P795, DOI 10.2337/diab.31.9.795; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DUCIMETIERE P, 1980, DIABETOLOGIA, V19, P205, DOI 10.1007/BF00275270; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FELDTRASMUSSEN B, 1986, DIABETOLOGIA, V29, P282, DOI 10.1007/BF00452063; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FERRARI P, 1991, AM J MED, V91, P589, DOI 10.1016/0002-9343(91)90211-F; HAFFNER SM, 1993, J CLIN ENDOCR METAB, V76, P541, DOI 10.1210/jc.76.3.541; HANSEN KW, 1992, KIDNEY INT, V41, P847, DOI 10.1038/ki.1992.130; JONES SL, 1989, BRIT MED J, V298, P487, DOI 10.1136/bmj.298.6672.487; LAGER I, 1983, BRIT MED J, V287, P1661, DOI 10.1136/bmj.287.6406.1661; MARTIN FIR, 1987, DIABETOLOGIA, V30, P149, DOI 10.1007/BF00274219; MESSENT JWC, 1992, KIDNEY INT, V41, P836, DOI 10.1038/ki.1992.128; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; MONTINI G, 1989, PAEDIATR NEPHROL, V3, pA2010; MOORE WV, 1992, DIABETES, V41, P1035, DOI 10.2337/diabetes.41.9.1035; NESTLER JE, 1990, DIABETES, V39, P1212, DOI 10.2337/diabetes.39.10.1212; PYORALA K, 1985, ACTA MED SCAND S, V701, P38; REAVEN GM, 1967, J CLIN INVEST, V46, P1756, DOI 10.1172/JCI105666; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; TREVISAN R, 1992, KIDNEY INT, V41, P855, DOI 10.1038/ki.1992.131; VIBERTI GC, 1982, LANCET, V1, P32; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; WHITE WB, 1989, AM HEART J, V118, P782, DOI 10.1016/0002-8703(89)90593-0; WHITE WB, 1992, J HYPERTENS, V10, pS35, DOI 10.1097/00004872-199204001-00008; WISEMAN MJ, 1984, DIABETOLOGIA, V2, P401; YIP J, 1993, LANCET, V341, P369, DOI 10.1016/0140-6736(93)90167-F; 1993, BMJ, V306, P1235	30	226	228	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 9	1993	342	8876					883	887		10.1016/0140-6736(93)91943-G	http://dx.doi.org/10.1016/0140-6736(93)91943-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105164				2022-12-24	WOS:A1993MA96300007
J	MCGUIRE, PK; SHAH, GMS; MURRAY, RM				MCGUIRE, PK; SHAH, GMS; MURRAY, RM			INCREASED BLOOD-FLOW IN BROCA AREA DURING AUDITORY HALLUCINATIONS IN SCHIZOPHRENIA	LANCET			English	Article							TEMPORAL-LOBE EPILEPSY; PSYCHOSIS	Verbal auditory hallucinations are common in schizophrenia but little is known about how they arise. We have used single photon emission tomography (SPET) to measure regional cerebral blood flow with the aim of identifying brain areas that are especially active during auditory hallucinations. We scanned twelve men with schizophrenia while they were experiencing hallucinations. The subjects were rescanned under identical conditions when their hallucinations had resolved (mean 19 weeks later). Blood flow was significantly greater during hallucinations than in the non-hallucinating state in Broca's area (mean count density on SPET 1.18 [SD 0.04] vs 1.13 [0.06]; p<0.001); flow was also higher during hallucinations in the left anterior cingulate cortex and regions in the left temporal lobe, but these differences did not achieve significance. The increased flow in Broca's area was not accounted for by changes in other clinical variables nor by changes in the dose of neuroleptic drugs. These findings suggest that the production of auditory hallucinations in schizophrenia is associated with increased activity in a network of cortical areas specialised for language.	INST PSYCHIAT, DEPT PSYCHOL MED, GENET SECT, LONDON SE5 8AF, ENGLAND	University of London; King's College London	MCGUIRE, PK (corresponding author), KINGS COLL HOSP, DEPT NUCL MED, DE CRESPIGNY PK, LONDON SE5 8AF, ENGLAND.		Murray, Robin M/F-8658-2012	Murray, Robin M/0000-0003-0829-0519; McGuire, Philip/0000-0003-4381-0532	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANNETT M, 1970, BRIT J PSYCHOL, V61, P303, DOI 10.1111/j.2044-8295.1970.tb01248.x; BARTA PE, 1990, AM J PSYCHIAT, V39, P784; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BOGERTS B, 1985, ARCH GEN PSYCHIAT, V43, P36; CLEGHORN JM, 1992, AM J PSYCHIAT, V149, P1062; COSTA DC, 1986, NUCL MED COMMUN, V7, P647; DAVID AS, 1993, NEUROPSYCHOLOGY SCHI, P269; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; FALKAI P, 1986, EUR ARCH PSY CLIN N, V236, P154, DOI 10.1007/BF00380943; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; FRITH CD, 1988, BRIT J PSYCHIAT, V153, P437, DOI 10.1192/bjp.153.4.437; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; GROSSMAN M, 1993, J CEREB BLOOD FLO S1, V13, pS525; HOWARD D, 1992, BRAIN, V115, P1769, DOI 10.1093/brain/115.6.1769; LAGER AC, 1985, PSYCHIAT RES, V16, P27, DOI 10.1016/0165-1781(85)90025-3; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; MUSALEK M, 1989, COMPR PSYCHIAT, V30, P99, DOI 10.1016/0010-440X(89)90123-5; NIE NH, 1975, STATISTICAL PACKAGE; PANDYA DN, CEREBRAL CORTEX, V4; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; PENFIELD W, 1963, BRAIN, V86, P595, DOI 10.1093/brain/86.4.595; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PRICE C, 1993, J CEREB BLOOD FLO S1, V13, pS501; ROBERTS GW, 1990, BIOL PSYCHIAT, V28, P127, DOI 10.1016/0006-3223(90)90630-K; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; TALAIRACH J, 1988, COPLANOR STEREOTAXIC; TAYLOR DC, 1975, PSYCHOL MED, V5, P249, DOI 10.1017/S0033291700056609; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; [No title captured]	29	330	336	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1993	342	8873					703	706		10.1016/0140-6736(93)91707-S	http://dx.doi.org/10.1016/0140-6736(93)91707-S			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103821				2022-12-24	WOS:A1993LX46900008
J	JAMES, A				JAMES, A			PAINLESS HUMAN RIGHT	LANCET			English	Editorial Material																		BONICA JJ, 1985, ADV PAIN RES THER, V9, P589; STJERNSWARD J, 1993, J PAIN SYMPTOM MANAG, V8, P340, DOI 10.1016/0885-3924(93)90050-6; ZENZ M, 1993, LANCET, V341, P1075, DOI 10.1016/0140-6736(93)92425-S; 1990, CANCER PAIN RELIEF P; 1986, CANCER PAIN RELIEF	5	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					567	568		10.1016/0140-6736(93)91403-9	http://dx.doi.org/10.1016/0140-6736(93)91403-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102713				2022-12-24	WOS:A1993LV96300003
J	PELTOLA, H				PELTOLA, H			EARLY MENINGOCOCCAL DISEASE - ADVISING THE PUBLIC AND THE PROFESSION	LANCET			English	Editorial Material							TUMOR NECROSIS FACTOR; MENINGITIS				PELTOLA, H (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,SF-00100 HELSINKI 10,FINLAND.							BEGG N, 1992, BRIT MED J, V305, P133, DOI 10.1136/bmj.305.6846.133; CARTWRIGHT K, 1992, BRIT MED J, V305, P774, DOI 10.1136/bmj.305.6856.774; FRIEDLAND J, 1990, LANCET, V335, P300, DOI 10.1016/0140-6736(90)90128-R; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; MCGOWAN JE, 1992, J INFECT DIS, V165, P1, DOI 10.1093/infdis/165.1.1; PELTOLA H, 1983, REV INFECT DIS, V5, P71; SORENSEN HT, 1992, BRIT MED J, V305, P774, DOI 10.1136/bmj.305.6856.774-a; TARLOW MJ, 1992, LANCET, V340, P1481, DOI 10.1016/0140-6736(92)92678-9; THOMSON AP, 1993, ARCH DIS CHILD, V69, P166, DOI 10.1136/adc.69.1.166; WAAGE A, 1987, LANCET, V1, P355; 1985, LANCET, V2, P594	11	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					509	510		10.1016/0140-6736(93)91642-Y	http://dx.doi.org/10.1016/0140-6736(93)91642-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102663				2022-12-24	WOS:A1993LU58200005
J	WALSH, D				WALSH, D			DYSPNEA IN ADVANCED CANCER	LANCET			English	Editorial Material											WALSH, D (corresponding author), CLEVELAND CLIN EDUC FDN,PALLAT CARE PROGRAM,CLEVELAND,OH 44106, USA.			Walsh, (Thomas) Declan/0000-0002-9310-1729				Bruera E, 1990, J Pain Symptom Manage, V5, P341, DOI 10.1016/0885-3924(90)90027-H; BRUERA E, 1993, LANCET, V342, P13, DOI 10.1016/0140-6736(93)91880-U; COOKE N, 1988, SYMPTOM CONTROL, P157; Curtis E B, 1991, J Palliat Care, V7, P25; KRECH RL, 1991, J PAIN SYMPTOM MANAG, V6, P360, DOI 10.1016/0885-3924(91)90027-2; NELSON K, 1991, CANCER B, V4, P423; RESTRICK LJ, 1992, LANCET, V339, P850; REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234; VENTAFRIDDA V, 1990, CHEST, V6, P1544; WALSH TD, 1984, RECENT RESULTS CANC, V89, P115	10	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					450	451		10.1016/0140-6736(93)91588-D	http://dx.doi.org/10.1016/0140-6736(93)91588-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102424				2022-12-24	WOS:A1993LU07500005
J	GOLDACRE, M; SEAGROATT, V; HAWTON, K				GOLDACRE, M; SEAGROATT, V; HAWTON, K			SUICIDE AFTER-DISCHARGE FROM PSYCHIATRIC INPATIENT CARE	LANCET			English	Article							IOWA RECORD-LINKAGE; MORTALITY	People with a history of psychiatric disorder are at higher risk of suicide than people without such a history. The policy of reducing inpatient care in psychiatry has probably meant that some of the risk of suicide has shifted from the hospital to the community setting. We have quantified the risk of suicide within a year of psychiatric discharge in a population-based study in the Oxford health region, UK. We calculated suicide rates per 1000 person-years at risk (time from discharge to death, subsequent readmission, or the end of the study) and the standardised mortality ratio (SMR) for suicide, taking the value among the general population as 1. Among male patients the SMR for suicide (defined by coroner's verdict of suicide) in the first 28 days after discharge from inpatient care was 213 (95% CI 137-317); the equivalent SMR for female patients was 134 (67-240). The result was similar when we defined suicide more broadly as a suicide, open, or misadventure verdict. The suicide rate in the first 28 days after discharge was 7.1 (4.1-12) times higher for male patients and 3.0 (1.5-6.0) times higher for female patients than the rate during the remaining 48 weeks of the first year after discharge. Most of the patients studied (both those who committed suicide and those who did not) had been psychiatric inpatients for only a short time. The findings confirm that there is significant clustering of suicide soon after discharge from psychiatric care. Skilled support after discharge for high-risk patients in the community is essential. Audit of suicides that occur soon after discharge may help identify the patients at highest risk and thereby reduce the number of avoidable deaths.	UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7J,ENGLAND	University of Oxford	GOLDACRE, M (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE EPIDEMIOL UNIT,OLD RD,OXFORD OX3 7LF,ENGLAND.							Acheson E.D., 1967, MED RECORD LINKAGE; BAKER RJ, 1978, GLIM SYSTEM; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BLACK DW, 1985, JAMA-J AM MED ASSOC, V253, P58, DOI 10.1001/jama.253.1.58; BLACK DW, 1989, SUICIDE LIFE-THREAT, V19, P78; Charlton J., 1992, Population Trends, P10; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; GILL LE, 1987, TXB MED RECORD LINKA, P39; HAWTON K, 1992, BMJ-BRIT MED J, V304, P1000, DOI 10.1136/bmj.304.6833.1000; HAWTON K, 1987, BRIT J PSYCHIAT, V150, P145, DOI 10.1192/bjp.150.2.145; HENDERSON J, 1992, J EPIDEMIOL COMMUN H, V46, P297, DOI 10.1136/jech.46.3.297; HOFFMANN H, 1987, SOC PSYCH PSYCH EPID, V22, P93, DOI 10.1007/BF00584011; MILES CP, 1977, J NERV MENT DIS, V164, P231, DOI 10.1097/00005053-197704000-00002; MONK M, 1987, EPIDEMIOL REV, V9, P51, DOI 10.1093/oxfordjournals.epirev.a036308; ODEGARD O, 1952, ACTA PSYCH NEUROL, V27, P353, DOI 10.1111/j.1600-0447.1952.tb04667.x; PIERCE J, 1964, ARCH GEN PSYCHIAT, V10, P43; POUNDER DJ, 1992, BRIT MED J, V305, P472, DOI 10.1136/bmj.305.6851.472; ROY A, 1983, COMPR PSYCHIAT, V24, P487, DOI 10.1016/0010-440X(83)90040-8; ROY A, 1984, CAN J PSYCHIAT, V29, P319, DOI 10.1177/070674378402900408; SCHNEIDMAN ES, 1981, SUICIDE LIFE-THREAT, V11, P325; SEAGROATT V, 1991, BRIT MED J, V303, P1431, DOI 10.1136/bmj.303.6815.1431; SURTEES J, 1992, BRIT MED J, V305, P716, DOI 10.1136/bmj.305.6855.716-a; 1992, LANCET, V340, P700; 1992, HLTH NATION STRATEGY; 1982, STEERING GROUP HLTH	25	297	300	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					283	286		10.1016/0140-6736(93)91822-4	http://dx.doi.org/10.1016/0140-6736(93)91822-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101307				2022-12-24	WOS:A1993LQ16300015
J	ELDER, GH; HUNTER, PR; CODD, GA				ELDER, GH; HUNTER, PR; CODD, GA			HAZARDOUS FRESH-WATER CYANOBACTERIA (BLUE-GREEN-ALGAE)	LANCET			English	Article							DIARRHEA		COUNTESS CHESTER HOSP,PUBL HLTH LAB SERV LAB,CHESTER,ENGLAND; UNIV DUNDEE,DEPT BIOL SCI,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	ELDER, GH (corresponding author), UNIV WALES COLL MED,DEPT MED BIOCHEM,CARDIFF CF4 4XN,S GLAM,WALES.		Hunter, Paul/N-9021-2019; Hunter, Paul/A-7172-2008	Hunter, Paul/0000-0002-5608-6144; Hunter, Paul/0000-0002-5608-6144				BEASLEY VR, 1989, VET CLIN N AM-FOOD A, V5, P345, DOI 10.1016/S0749-0720(15)30980-4; BENDALL RP, 1993, LANCET, V341, P590, DOI 10.1016/0140-6736(93)90352-H; CODD GA, 1992, NATURE, V359, P110, DOI 10.1038/359110b0; CODD GA, 1991, PHLS MICROBIOL, V8, P79; EDWARDS C, 1992, TOXICON, V30, P1165, DOI 10.1016/0041-0101(92)90432-5; FALCONER IR, 1991, ENVIRON TOXIC WATER, V6, P177, DOI 10.1002/tox.2530060207; GUNN GJ, 1992, VET REC, V130, P301, DOI 10.1136/vr.130.14.301; HUNTER PR, 1992, J MED MICROBIOL, V36, P301, DOI 10.1099/00222615-36-5-301; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MATSUSHIMA R, 1990, BIOCHEM BIOPH RES CO, V171, P867, DOI 10.1016/0006-291X(90)91226-I; NISHIWAKIMATSUSHIMA R, 1992, J CANCER RES CLIN, V118, P420, DOI 10.1007/BF01629424; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; SOONG FS, 1992, MED J AUSTRALIA, V156, P67; TURNER PC, 1990, BRIT MED J, V300, P1440, DOI 10.1136/bmj.300.6737.1440; 1990, WATER QUALITY SERIES, V2	16	27	27	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1519	1520		10.1016/0140-6736(93)90643-U	http://dx.doi.org/10.1016/0140-6736(93)90643-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099388				2022-12-24	WOS:A1993LG24200012
J	SCOTT, M; GROTH, D; FOSTER, D; TORCHIA, M; YANG, SL; DEARMOND, SJ; PRUSINER, SB				SCOTT, M; GROTH, D; FOSTER, D; TORCHIA, M; YANG, SL; DEARMOND, SJ; PRUSINER, SB			PROPAGATION OF PRIONS WITH ARTIFICIAL PROPERTIES IN TRANSGENIC MICE EXPRESSING CHIMERIC PRP GENES	CELL			English	Article							SCRAPIE AGENT; SECONDARY STRUCTURE; MOUSE SCRAPIE; PROTEINS; HAMSTERS; TRANSMISSION; PURIFICATION; INFECTIVITY; STRAINS; ASSAY	Transgenic mice expressing chimeric prion protein (PrP) genes derived from Syrian hamster (SHa) and mouse (Mo) PrP genes were constructed. One SHa/MoPrP gene, designated MH2M PrP, contains five amino acid substitutions encoded by SHaPrP, while another construct, designated MHM2 PrP, has two substitutions. Transgenic (Tg) (MH2M PrP) mice were susceptible to both Syrian hamster and mouse prions, whereas three lines expressing MHM2 PrP were resistant to Syrian hamster prions. The brains of Tg(MH2M PrP) mice dying of scrapie contained chimeric PrP(Sc) and prions with an artificial host range favoring propagation in mice that express the corresponding chimeric PrP and were also transmissible, at reduced efficiency, to nontransgenic mice and hamsters. Our findings provide genetic evidence for homophilic interactions between PrP(Sc) in the inoculum and PrP(c) synthesized by the host.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	SCOTT, M (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143, USA.				NIA NIH HHS [AG08967, AG02132] Funding Source: Medline; NINDS NIH HHS [NS14069] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS014069, P01NS014069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG008967, P01AG002132] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRY RA, 1986, J INFECT DIS, V154, P518, DOI 10.1093/infdis/154.3.518; BAZAN JF, 1987, PROTEIN ENG, V1, P125, DOI 10.1093/protein/1.2.125; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHANDLER RL, 1961, LANCET, V1, P1378; Dickinson A. G., 1976, Slow virus diseases of animals and man,, P209; Dickinson A. G., 1979, Slow transmissible diseases of the nervous system. Volume 1., P367; DICKINSON AG, 1988, CIBA F SYMP, V135, P63; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GABIZON R, 1987, P NATL ACAD SCI USA, V84, P4017, DOI 10.1073/pnas.84.12.4017; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KIMBERLIN RH, 1978, J GEN VIROL, V39, P487, DOI 10.1099/0022-1317-39-3-487; KIMBERLIN RH, 1987, J GEN VIROL, V68, P1875, DOI 10.1099/0022-1317-68-7-1875; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; LOWENSTEIN DH, 1990, MOL CELL BIOL, V10, P1153, DOI 10.1128/MCB.10.3.1153; MARSH RF, 1975, J INFECT DIS, V131, P104, DOI 10.1093/infdis/131.2.104; MARSH RF, 1977, FED PROC, V37, P2076; PATTISON IH, 1968, RES VET SCI, V9, P408; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1980, BIOCHEMISTRY-US, V19, P4883, DOI 10.1021/bi00562a028; ROGERS M, 1991, J IMMUNOL, V147, P3568; Sambrook J., 1989, MOL CLONING LAB MANU, P17; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	38	285	301	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					979	988		10.1016/0092-8674(93)90275-U	http://dx.doi.org/10.1016/0092-8674(93)90275-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8098995	Bronze			2022-12-24	WOS:A1993LF06100013
J	WAGNER, JJ; TERMAN, GW; CHAVKIN, C				WAGNER, JJ; TERMAN, GW; CHAVKIN, C			ENDOGENOUS DYNORPHINS INHIBIT EXCITATORY NEUROTRANSMISSION AND BLOCK LTP INDUCTION IN THE HIPPOCAMPUS	NATURE			English	Article							GUINEA-PIG; RAT HIPPOCAMPUS; PERFORANT PATH; MOSSY FIBERS; AGED RATS; RECEPTOR; PEPTIDES; MEMORY; IMMUNOREACTIVITY; TRANSMISSION	ALTHOUGH anatomical and neurochemical studies suggest that endogenous opioids act as neurotransmitters1-7, their roles in normal and pathophysiological regulation of synaptic transmission are not defined. Here we examine the actions of prodynorphin-derived opioid peptides in the guinea-pig hippocampus and show that physiological stimulation of the dynorphin-containing dentate granule cells can release endogenous dynorphins, which then activate kappa1 opioid receptors present in the molecular layer of the dentate gyrus. Activation of kappa1 receptors by either pharmacologically applied agonist or endogenously released peptide reduces excitatory transmission in the dentate gyrus, as shown by a reduction in the excitatory postsynaptic currents evoked by stimulation of the perforant path, a principal excitatory afferent. In addition, released dynorphin peptides were found to block the induction of long-term potentiation (LTP) at the granule cell-perforant path synapse. The results indicate that endogenous dynorphins function in this hippocampal circuit, as retrograde, inhibitory neurotransmitters.	UNIV WASHINGTON,DEPT PHARMACOL,SJ-30,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT ANESTHESIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Wagner, John J/U-9056-2018; Chavkin, Charles/G-2797-2010	Wagner, John J/0000-0002-2552-3727; 	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004123] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA004123-13, R01 DA004123-11A1, R01 DA004123-15, R01 DA004123-14, R01 DA004123, R01 DA004123-12] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BRAMHAM CR, 1991, BRAIN RES, V567, P42, DOI 10.1016/0006-8993(91)91433-2; CHAVKIN C, 1983, P NATL ACAD SCI-BIOL, V80, P7669, DOI 10.1073/pnas.80.24.7669; CHAVKIN C, 1985, J NEUROSCI, V5, P808; COLLIER TJ, 1984, BRAIN RES, V310, P384, DOI 10.1016/0006-8993(84)90166-5; CRONIN J, 1992, BRAIN RES, V573, P305, DOI 10.1016/0006-8993(92)90777-7; DECKER MW, 1991, SYNAPSE, V7, P151, DOI 10.1002/syn.890070209; EVANS CJ, 1985, J NEUROSCI, V5, P3423; GALL C, 1981, J COMP NEUROL, V198, P335, DOI 10.1002/cne.901980211; GALLAGHER M, 1985, BEHAV NEURAL BIOL, V44, P374, DOI 10.1016/S0163-1047(85)90688-0; HOUSER CR, 1990, J NEUROSCI, V10, P267; JAN LY, 1982, J PHYSIOL-LONDON, V327, P219, DOI 10.1113/jphysiol.1982.sp014228; JIANG HK, 1989, P NATL ACAD SCI USA, V86, P2948, DOI 10.1073/pnas.86.8.2948; JONES LS, 1991, BRAIN RES, V564, P336, DOI 10.1016/0006-8993(91)91473-E; LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5; LUNDBERG JM, 1986, NEUROSCI LETT, V63, P96, DOI 10.1016/0304-3940(86)90020-0; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MADISON DV, 1991, REV NEUROSCI, V14, P379; MARTINEZ JL, 1990, NIDA RES MG, V97, P48; MCGINTY JF, 1983, P NATL ACAD SCI-BIOL, V80, P589, DOI 10.1073/pnas.80.2.589; MCLEAN S, 1987, J COMP NEUROL, V255, P497, DOI 10.1002/cne.902550403; NOCK B, 1990, J PHARMACOL EXP THER, V254, P412; PORTOGHESE PS, 1987, LIFE SCI, V40, P1287, DOI 10.1016/0024-3205(87)90585-6; SINGH L, 1990, EUR J PHARMACOL, V191, P477, DOI 10.1016/0014-2999(90)94183-X; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; TORTELLA FC, 1988, TRENDS PHARMACOL SCI, V9, P366, DOI 10.1016/0165-6147(88)90256-8; WAGNER JJ, 1991, J NEUROCHEM, V57, P333, DOI 10.1111/j.1471-4159.1991.tb02132.x; WAGNER JJ, 1992, J NEUROSCI, V12, P132; WEISSKOPF MG, 1993, NATURE, V362, P423, DOI 10.1038/362423a0; XIE CW, 1991, J PHARMACOL EXP THER, V256, P289; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	31	235	237	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					451	454		10.1038/363451a0	http://dx.doi.org/10.1038/363451a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8099201	Green Accepted			2022-12-24	WOS:A1993LE93800059
J	JORGENSEN, JOL; CHRISTIANSEN, JS				JORGENSEN, JOL; CHRISTIANSEN, JS			GROWTH-HORMONE THERAPY - BRAVE NEW SENESCENCE - GH IN ADULTS	LANCET			English	Note											JORGENSEN, JOL (corresponding author), AARHUS KOMMUNE HOSP,DEPT MED M ENDOCRINOL & DIABET,DK-8000 AARHUS,DENMARK.		Jorgensen, Jens Otto Lunde/O-8003-2019					BOWERS CY, 1992, J CLIN ENDOCR METAB, V74, P292, DOI 10.1210/jc.74.2.292; CORPAS E, 1993, J CLIN ENDOCR METAB, V76, P134, DOI 10.1210/jc.76.1.134; CUNEO RC, 1992, CLIN ENDOCRINOL, V37, P387, DOI 10.1111/j.1365-2265.1992.tb02347.x; JORGENSEN JOL, 1989, LANCET, V1, P1221; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; RUDMAN D, 1985, J AM GERIATR SOC, V33, P800, DOI 10.1111/j.1532-5415.1985.tb04195.x; ZIEGLER TR, 1992, J CLIN ENDOCR METAB, V74, P865, DOI 10.1210/jc.74.4.865	7	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1247	1248						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098396				2022-12-24	WOS:A1993LC49700008
J	BOMMERT, K; CHARLTON, MP; DEBELLO, WM; CHIN, GJ; BETZ, H; AUGUSTINE, GJ				BOMMERT, K; CHARLTON, MP; DEBELLO, WM; CHIN, GJ; BETZ, H; AUGUSTINE, GJ			INHIBITION OF NEUROTRANSMITTER RELEASE BY C2-DOMAIN PEPTIDES IMPLICATES SYNAPTOTAGMIN IN EXOCYTOSIS	NATURE			English	Article							SQUID GIANT SYNAPSE; PROTEIN KINASE-C; TRANSMITTER RELEASE; BINDING; FAMILY; P65; DNA	NEUROTRANSMITTER release is triggered by Ca2+ ions binding to an unknown Ca2+ receptor within presynaptic terminals1,2. Synaptotagmin, a Ca2+-binding protein of synaptic and other secretory vesicles3, has been proposed to mediate vesicle-plasma membrane interactions during neurotransmitter release4-9. Here we test this hypothesis using the giant synapse of the squid Loligo pealei, which because of its unusually large size and well established physiology is uniquely suited for dissecting presynaptic events10. We find that injection of peptides from the C2 domains of synaptotagmin into squid giant presynaptic terminals rapidly and reversibly inhibits neurotransmitter release. Our data are consistent with these peptides competitively blocking release after synaptic vesicle docking and indicate that Ca2+ probably initiates neurotransmitter release by regulating the interaction of synaptotagmin with an acceptor protein.	MAX PLANCK INST BRAIN RES,DEPT NEUROCHEM,W-6000 FRANKFURT 71,GERMANY; UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 1A8,ONTARIO,CANADA; DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710; NIH,DEV NEUROBIOL LAB,BETHESDA,MD 20892	Max Planck Society; University of Toronto; Duke University; National Institutes of Health (NIH) - USA	BOMMERT, K (corresponding author), MARINE BIOL LAB,WOODS HOLE,MA 02543, USA.		Bommert, Kurt/G-9247-2011; Augustine, George James/J-9228-2013					ADLER EM, 1991, J NEUROSCI, V11, P1496; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; GREENINGLOH G, 1987, NATURE, V328, P215; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; Katz B., 1969, RELEASE NEURAL TRANS; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; LLINAS RR, 1984, CURR TOP MEMBR TRANS, V22, P519; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; OSSES LR, 1989, BIOL BULL, V177, P146, DOI 10.2307/1541842; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; PUMPLIN DW, 1978, NEUROSCIENCE, V3, P685, DOI 10.1016/0306-4522(78)90065-9; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRA R, 1987, NATURE, V325, P58, DOI 10.1038/325058a0; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SMITH SJ, 1988, CALCIUM ION CHANNEL, P147; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; TRIMBLE WS, 1991, REV NEUROSCI, V14, P93; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V	31	282	284	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 13	1993	363	6425					163	165		10.1038/363163a0	http://dx.doi.org/10.1038/363163a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB801	8097867				2022-12-24	WOS:A1993LB80100048
J	PIJNENBORG, L; van der Maas, PJ; VANDELDEN, JJM; LOOMAN, CWN				PIJNENBORG, L; van der Maas, PJ; VANDELDEN, JJM; LOOMAN, CWN			LIFE-TERMINATING ACTS WITHOUT EXPLICIT REQUEST OF PATIENT	LANCET			English	Article								In the Dutch nationwide study on medical decisions concerning the end of life (MDEL) life-terminating acts without the explicit request of the patient (LAWER) were noted in 0.8% of all deaths. We present here quantitative information and a discussion of the main issues raised by LAWER. In 59% of LAWER the physician had some information about the patient's wish; in 41% discussion on the decision would no longer have been possible. In LAWER patients tend to be younger and more likely to be male and to have cancer than in non-acute deaths generally. The physician (specialist or general practitioner) knew the patient on average 2.4 years and 7.2 years, respectively. Life was shortened by between some hours and a week at most in 86%. ln 83% the decision has been discussed with relatives and in 70% with a colleague. In nearly all cases, according to the physician, the patient was suffering unbearably, there was no chance of improvement, and palliative possibilities were exhausted. MDEL probably will increase in number in future but interviews with Dutch physicians suggest a possible fall in LAWER, even though there will always be some situations in which a well-considered LAWER decision may have to be made.	UNIV UTRECHT, CTR BIOETH & HLTH LAW, UTRECHT, NETHERLANDS	Utrecht University	PIJNENBORG, L (corresponding author), ERASMUS UNIV, DEPT PUBL HLTH, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Lindtjorn, Bernt/K-9465-2018	Lindtjorn, Bernt/0000-0002-6267-6984				KUHSE H, 1992, BIOETHICS NEWS, V11, P1; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1992, HEALTH POLICY, V22, P1; VANDELDEN JJM, IN PRESS BIOETHICS; VANDERWAL G, 1991, HUISARTS WET, V34, P523; 1992, LANCET, V340, P757; 1988, JAMA-J AM MED ASSOC, V259, P272; 1992, END LIFE MED PRACTIC	8	87	87	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1196	1199		10.1016/0140-6736(93)91014-D	http://dx.doi.org/10.1016/0140-6736(93)91014-D			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098087				2022-12-24	WOS:A1993LB01700016
J	TIRET, L; KEE, F; POIRIER, O; NICAUD, V; LECERF, L; EVANS, A; CAMBOU, JP; ARVEILER, D; LUC, G; AMOUYEL, P; CAMBIEN, F				TIRET, L; KEE, F; POIRIER, O; NICAUD, V; LECERF, L; EVANS, A; CAMBOU, JP; ARVEILER, D; LUC, G; AMOUYEL, P; CAMBIEN, F			DELETION POLYMORPHISM IN ANGIOTENSIN-CONVERTING ENZYME GENE ASSOCIATED WITH PARENTAL HISTORY OF MYOCARDIAL-INFARCTION	LANCET			English	Note								In a European study an insertion (I)/deletion (D) polymorphism in the angiotensin converting enzyme (ACE) gene has been shown to be associated with the risk of myocardial infarction (MI). In the same study, we investigated the association of the polymorphism with a parental history of fatal MI. There was an excess of both DD (odds ratio 2.6, p = 0.02) and ID (odds ratio = 1.9, p = 0.08) genotypes among those having a parental history of MI, confirming that genetic variation in the ACE locus could be involved in the risk of MI.	INSERM,SC7,17 RUE FER A MOULIN,F-75005 PARIS,FRANCE; INSERM,U258,F-75005 PARIS,FRANCE; MONICA PROJECT BELFAST,BELFAST,NORTH IRELAND	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Cambien, Francois/AAP-9751-2020	Amouyel, Philippe/0000-0001-9088-234X; LECERF, LAURE/0000-0001-8342-5298				CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CAMBIEN F, 1988, AM J HUM GENET, V43, P774; HUBERT C, 1991, J BIOL CHEM, V266, P15377; PARRA HJ, 1992, ARTERIOSCLER THROMB, V12, P701, DOI 10.1161/01.ATV.12.6.701; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; TIRET L, 1992, AM J HUM GENET, V51, P197	6	253	257	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					991	992		10.1016/0140-6736(93)91075-W	http://dx.doi.org/10.1016/0140-6736(93)91075-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096947				2022-12-24	WOS:A1993KY36800007
J	VANDEPERRE, P; SIMONON, A; HITIMANA, DG; DABIS, F; MSELLATI, P; MUKAMABANO, B; BUTERA, JB; VANGOETHEM, C; KARITA, E; LEPAGE, P				VANDEPERRE, P; SIMONON, A; HITIMANA, DG; DABIS, F; MSELLATI, P; MUKAMABANO, B; BUTERA, JB; VANGOETHEM, C; KARITA, E; LEPAGE, P			INFECTIVE AND ANTIINFECTIVE PROPERTIES OF BREAST-MILK FROM HIV-1-INFECTED WOMEN	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MILK; ANTIBODIES; IGG; TRANSMISSION; SUBCLASSES; KIGALI; RWANDA; SYSTEM; HIV-1	Human immunodeficiency virus type 1 (HIV-1) is transmitted mainly by cell-to-cell contact. We postulated that transmission of HIV-1 through breastmilk could be favoured by the presence of infected cells, by deficiency of anti-infective substances in breastmilk, or both factors. 215 HIV-1-infected women were enrolled at delivery in Kigali, Rwanda; milk samples were collected 15 days, 6 months, and 18 months post partum. HIV-1 IgG, secretory IgA, and IgM were assayed by western blot, for the latter two after removal of IgG with protein G. In the 15-day and 6-month samples, we sought viral genome in milk cells by a double polymerase chain reaction with three sets of primers (gag, pol, and env). HIV-1 infection in the offspring was defined according to serological and clinical criteria. At 15 days, 6 months, and 18 months postpartum, HIV-1 specific IgG was detected in 95%, 98%, and 97% of breastmilk samples, IgA in 23%, 28%, and 41%, and IgM in 66%, 78%, and 41%. In children who survived longer than 18 months, the probability of infection was associated with lack of persistence of IgM and IgA in their mothers' milk (adjusted chi2 for trend, p = 0.01 for IgM and p = 0.05 for IgA). The presence of HIV-1-infected cells in the milk 15 days post partum was strongly predictive of HIV-1 infection in the child, by both univariate (p < 0.05) and multivariate analysis (p = 0.01). The combination of HIV-1-infected cells in breastmilk and a defective IgM response was the strongest predictor of infection. HIV-1 infection in breastfed children born to infected mothers is associated with the presence of integrated viral DNA in the mothers' milk cells. IgM and IgA anti-HIV-1 in breastmilk may protect against postnatal transmission of the virus.	CTR HOSP KIGALI,DEPT PAEDIAT,KIGALI,RWANDA; UNIV BORDEAUX 2,INSERM,U330,F-33076 BORDEAUX,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	VANDEPERRE, P (corresponding author), NATL AIDS CONTROL PROGRAMME,AIDS REFERENCE LAB,BP 780,KIGALI,RWANDA.		DABIS, FRANCOIS/S-9298-2019; Van de Perre, Philippe/B-9692-2008	DABIS, FRANCOIS/0000-0002-1614-8857; Van de Perre, Philippe/0000-0002-3912-0427				BELEC L, 1990, PEDIATRICS, V85, P1022; BRANDTZAEG P, 1975, IMMUNOLOGY, V29, P559; BRANDTZAEG P, 1979, IMMUNOLOGY BREAST MI, P91; BULTERYS M, 1992, 8TH INT C AIDS 3RD S, V1; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; FLEISS JL, 1973, STATISTICAL METHODS, P99; GOLDMAN AS, 1982, J PEDIATR-US, V100, P563, DOI 10.1016/S0022-3476(82)80753-1; HANSON LA, 1985, PEDIATRICS, V75, P172; LAMON EW, 1975, J IMMUNOL, V114, P1171; LEPAGE P, 1991, AIDS, V5, P295, DOI 10.1097/00002030-199103000-00008; MAASINDERWIESEN F, 1978, DEUT TIERARZTL WOCH, V85, P309; MULLER F, 1991, CLIN EXP IMMUNOL, V83, P203, DOI 10.1111/j.1365-2249.1991.tb05615.x; NARA PL, 1987, J VIROL, V61, P3173, DOI 10.1128/JVI.61.10.3173-3180.1987; RUFF A, 1992, 8TH INT C AIDDS 3RD, V1; SATO H, 1992, VIROLOGY, V186, P712, DOI 10.1016/0042-6822(92)90038-Q; SCHUPBACH J, 1989, AIDS, V3, P583, DOI 10.1097/00002030-198909000-00005; VANDEPERRE P, 1992, CLIN INFECT DIS, V15, P502, DOI 10.1093/clind/15.3.502; VANDEPERRE P, 1992, AIDS RES HUM RETROV, V8, P435, DOI 10.1089/aid.1992.8.435; VANDEPERRE P, 1988, J PEDIATR-US, V113, P1039, DOI 10.1016/S0022-3476(88)80578-X; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; WELSH JK, 1979, J PEDIATR-US, V94, P1, DOI 10.1016/S0022-3476(79)80340-6; WOLFF H, 1992, J ACQ IMMUN DEF SYND, V5, P65; ZOLLAPAZNER S, 1992, 7TH CENT GARD M MARN, P62; 1986, WKLY EPIDEMIOL REC, V61, P69; 1992, FEB M TECHN WORK GRO; 1992, GLOBAL PROGRAM AIDS; 1992, LANCET, V339, P1007	28	193	197	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					914	918		10.1016/0140-6736(93)91210-D	http://dx.doi.org/10.1016/0140-6736(93)91210-D			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096264				2022-12-24	WOS:A1993KW98100003
J	WEISSKOPF, MG; ZALUTSKY, RA; NICOLL, RA				WEISSKOPF, MG; ZALUTSKY, RA; NICOLL, RA			THE OPIOID PEPTIDE DYNORPHIN MEDIATES HETEROSYNAPTIC DEPRESSION OF HIPPOCAMPAL MOSSY FIBER SYNAPSES AND MODULATES LONG-TERM POTENTIATION	NATURE			English	Article							CA3 PYRAMIDAL CELLS; GUINEA-PIG; RAT HIPPOCAMPUS; N-TYPE; CALCIUM CHANNELS; DENTATE GYRUS; BINDING-SITES; PAIRED-PULSE; RECEPTOR; NEURONS	The mossy fibre pathway in the hippocampus uses glutamate as a neurotransmitter, but also contains the opioid peptide dynorphin. Synaptic release of dynorphin causes a presynaptic inhibition of neighbouring mossy fibres and inhibits the induction and expression of mossy fibre long-term potentiation. These findings demonstrate a physiological role for a neuropeptide in the central nervous system, provide a functional basis for the coexistence of a neuropeptide with classic neurotransmitters and demonstrate the very different roles played by these two classes of signalling molecules.	UNIV CALIF SAN FRANCISCO, GRAD PROGRAM NEUROSCI, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ADAMSON P, 1989, EUR J PHARMACOL, V174, P63, DOI 10.1016/0014-2999(89)90874-1; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BRADLER JE, 1990, NEUROSCIENCE, V35, P265, DOI 10.1016/0306-4522(90)90080-N; CAUDLE RM, 1990, J PHARMACOL EXP THER, V252, P1361; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; COLLIER TJ, 1984, BRAIN RES, V310, P384, DOI 10.1016/0006-8993(84)90166-5; CRAWFORD IL, 1973, NATURE, V244, P442, DOI 10.1038/244442a0; CREAGER R, 1980, J PHYSIOL-LONDON, V299, P409, DOI 10.1113/jphysiol.1980.sp013133; DECKER MW, 1991, SYNAPSE, V7, P151, DOI 10.1002/syn.890070209; GALL C, 1981, J COMP NEUROL, V198, P335, DOI 10.1002/cne.901980211; GALLAGHER M, 1988, OPIOIDS HIPPOCAMPUS, P118; GANNON RL, 1991, BRAIN RES, V548, P242, DOI 10.1016/0006-8993(91)91127-M; GAUCHY C, 1991, NEUROSCIENCE, V41, P449, DOI 10.1016/0306-4522(91)90340-T; GILLAN MGC, 1982, BRIT J PHARMACOL, V77, P461, DOI 10.1111/j.1476-5381.1982.tb09319.x; GOLDSTEIN A, 1987, TRENDS PHARMACOL SCI, V8, P456, DOI 10.1016/0165-6147(87)90038-1; GROSS RA, 1987, P NATL ACAD SCI USA, V84, P5469, DOI 10.1073/pnas.84.15.5469; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; IWAMA T, 1986, NEUROSCI LETT, V63, P190, DOI 10.1016/0304-3940(86)90060-1; JAN LY, 1982, J PHYSIOL-LONDON, V327, P219, DOI 10.1113/jphysiol.1982.sp014228; JAN YN, 1983, TRENDS NEUROSCI, V6, P320, DOI 10.1016/0166-2236(83)90148-0; KAMIYA H, 1988, NEUROSCI LETT, V91, P84, DOI 10.1016/0304-3940(88)90253-4; KATO M, 1992, BRAIN RES, V574, P138, DOI 10.1016/0006-8993(92)90810-V; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; LUNDBERG JM, 1983, TRENDS NEUROSCI, V6, P325, DOI 10.1016/0166-2236(83)90149-2; LUPICA CR, 1991, SYNAPSE, V8, P237, DOI 10.1002/syn.890080402; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MARTIN MR, 1983, NEUROPEPTIDES, V4, P45, DOI 10.1016/0143-4179(83)90007-0; MCFADZEAN I, 1987, NEUROSCIENCE, V20, P231, DOI 10.1016/0306-4522(87)90015-7; MCGINTY JF, 1983, P NATL ACAD SCI-BIOL, V80, P589, DOI 10.1073/pnas.80.2.589; MCLEAN S, 1987, J COMP NEUROL, V255, P497, DOI 10.1002/cne.902550403; MOSBERG HI, 1983, P NATL ACAD SCI-BIOL, V80, P5871, DOI 10.1073/pnas.80.19.5871; NEUMAIER JF, 1988, J PHARMACOL EXP THER, V244, P564; NICOLL RA, 1977, P NATL ACAD SCI USA, V74, P2584, DOI 10.1073/pnas.74.6.2584; NOCK B, 1990, J PHARMACOL EXP THER, V254, P412; PINNOCK RD, 1992, BRAIN RES, V583, P237, DOI 10.1016/S0006-8993(10)80029-0; ROLLS ET, 1990, COLD SPRING HARB SYM, V55, P995; STAUBLI U, 1990, SYNAPSE, V5, P333, DOI 10.1002/syn.890050410; STORMMATHISEN J, 1983, NATURE, V301, P517, DOI 10.1038/301517a0; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; TERRIAN DM, 1988, BRAIN RES BULL, V21, P343, DOI 10.1016/0361-9230(88)90146-3; WAGNER JJ, 1991, J NEUROCHEM, V57, P333, DOI 10.1111/j.1471-4159.1991.tb02132.x; WAGNER JJ, 1992, J NEUROSCI, V12, P132; XIANG JZ, 1990, NEUROPHARMACOLOGY, V29, P439, DOI 10.1016/0028-3908(90)90165-N; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZALUTSKY RA, 1992, NEUROSCI LETT, V138, P193, DOI 10.1016/0304-3940(92)90503-Y; ZALUTSKY RA, 1991, TRANSMITTER AMINO AC, V6, P415; ZIEGLGANSBERGER W, 1979, SCIENCE, V205, P415, DOI 10.1126/science.451610; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	49	252	259	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	1993	362	6419					423	427		10.1038/362423a0	http://dx.doi.org/10.1038/362423a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8096624				2022-12-24	WOS:A1993KV42400074
J	SUN, SC; GANCHI, PA; BALLARD, DW; GREENE, WC				SUN, SC; GANCHI, PA; BALLARD, DW; GREENE, WC			NF-KAPPA-B CONTROLS EXPRESSION OF INHIBITOR I-KAPPA-B-ALPHA - EVIDENCE FOR AN INDUCIBLE AUTOREGULATORY PATHWAY	SCIENCE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; TRANS-ACTIVATOR PROTEIN; NECROSIS FACTOR-ALPHA; DNA-BINDING SUBUNIT; TRANSCRIPTION FACTOR; 65-KD SUBUNIT; GENE-EXPRESSION; T-CELLS; ENHANCER; REL	The eukaryotic transcription factor nuclear factor-kappa B (NF-kappaB) participates in many parts of the genetic program mediating T lymphocyte activation and growth. Nuclear expression of NF-kappaB occurs after its induced dissociation from its cytoplasmic inhibitor IkappaBalpha. Phorbol ester and tumor necrosis factor-alpha induction of nuclear NF-kappaB is associated with both the degradation of preformed IkappaBalpha and the activation of IkappaBalpha gene expression. Transfection studies indicate that the IkappaBalpha gene is specifically induced by the 65-kilodalton transactivating subunit of NF-kappaB. Association of the newly synthesized IkappaBalpha with p65 restores intracellular inhibition of NF-kappaB DNA binding activity and prolongs the survival of this labile inhibitor. Together, these results show that NF-kappaB controls the expression of IkappaBalpha by means of an inducible autoregulatory pathway.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST VIROL & IMMUNOL,POB 419100,SAN FRANCISCO,CA 94141; SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94141; VANDERBILT UNIV,HOWARD HUGHES MED INST,NASHVILLE,TN 37232	University of California System; University of California San Francisco; The J David Gladstone Institutes; San Francisco General Hospital Medical Center; Howard Hughes Medical Institute; Vanderbilt University					NATIONAL CANCER INSTITUTE [T32CA009111] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIMA N, 1992, J IMMUNOL, V149, P83; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P789, DOI 10.1101/SQB.1988.053.01.089; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1990, MOL ASPECTS CELLULAR, P409; BALLARD D W, 1989, New Biologist, V1, P83; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; CHMITZ ML, 1991, EMBO J, V10, P3805; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMAN M, 1987, CURRENT PROTOCOLS MO; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MEYER M, 1992, EMBO J, V11, P2991, DOI 10.1002/j.1460-2075.1992.tb05369.x; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SUN SY, UNPUB; THORNELL A, 1988, MOL CELL BIOL, V8, P1625, DOI 10.1128/MCB.8.4.1625; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0	45	1028	1052	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 26	1993	259	5103					1912	1915		10.1126/science.8096091	http://dx.doi.org/10.1126/science.8096091			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8096091				2022-12-24	WOS:A1993KU17200036
J	VICTORA, CG; TOMASI, E; OLINTO, MTA; BARROS, FC				VICTORA, CG; TOMASI, E; OLINTO, MTA; BARROS, FC			USE OF PACIFIERS AND BREAST-FEEDING DURATION	LANCET			English	Note								Pacifiers are widely used in many developing countries. Although their use is not recommended for breastfeeding infants, there have been no published reports on the association between pacifier use and risk of early weaning. In a study of 354 infants in Brazil, mothers were asked about pacifier use at age 1 month, duration of breastfeeding, and introduction of other foods. Among 249 children still breastfed at 1 month, the risk that a child would be weaned at any age between 1 and 24 months was higher in pacifier users than in non-users (hazard ratio 3.0, 95% CI 2.0-4.6). The association remained even after adjustment for the child's age, sex, birthweight, socioeconomic status, and age at introduction of bottle-feeding.			VICTORA, CG (corresponding author), UNIV FED PELOTAS,CP 464,BR-96100 PELOTAS,RS,BRAZIL.		Victora, Cesar Gomes/Y-2455-2019; Barros, Fernando C/D-4857-2013; Tomasi, Elaine/AAH-2226-2021; Victora, Cesar G/D-4476-2013; Olinto, Maria Teresa Anselmo/AAH-5897-2021	Victora, Cesar Gomes/0000-0002-2465-2180; Victora, Cesar G/0000-0002-2465-2180; Olinto, Maria Teresa Anselmo/0000-0002-3950-4594				HELSING E, 1982, BREASTFEEDING PRACTI; KING FS, 1985, HELPING MOTHERS BREA; MATHUR G P, 1990, Indian Pediatrics, V27, P1187; MURAHOVSCHI J, 1982, CARTILHA AMAMENTACAO; RIORDAN J, 1991, PRACTICAL GUIDE BREA, P47; SEHGAL S K, 1990, Indian Pediatrics, V27, P263; VICTORA C, IN PRESS P C NURITIO; VICTORA CG, 1987, LANCET, V2, P319; 1989, PROTECTING PROMOTING	9	76	92	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					404	406		10.1016/0140-6736(93)92991-2	http://dx.doi.org/10.1016/0140-6736(93)92991-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094171				2022-12-24	WOS:A1993KM41600006
J	CHAN, P; PATEL, M; BETTERIDGE, L; MUNRO, E; SCHACHTER, M; WOLFE, J; SEVER, P				CHAN, P; PATEL, M; BETTERIDGE, L; MUNRO, E; SCHACHTER, M; WOLFE, J; SEVER, P			ABNORMAL GROWTH-REGULATION OF VASCULAR SMOOTH-MUSCLE CELLS BY HEPARIN IN PATIENTS WITH RESTENOSIS	LANCET			English	Note								Proliferation of vascular smooth muscle cells (VSMC) underlies myointimal hyperplasia, which can lead to restenosis after angioplasty and vascular surgery. We propose that some individuals have an intrinsic capacity for this exaggerated response to vascular injury, partly through decreased sensitivity to the physiological growth inhibitor heparin. We investigated the effect of heparin on VSMC from restenotic lesions and from apparently normal vessels of the same patients, and VSMC from control patients undergoing primary bypass procedures. Cells from patients with restenosis (both restenotic lesion and undiseased vein) showed much lower sensitivity to growth inhibition by heparin than the controls (median inhibition 8 [95% CI - 2 to 25] vs 22 [15-44]%, p<0.001); this finding suggests aberrant growth regulation in these cells.	ST MARYS HOSP,DEPT VASC SURG,LONDON,ENGLAND	Imperial College London	CHAN, P (corresponding author), IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT CLIN PHARMACOL,LONDON W2 1NY,ENGLAND.							AU YPT, 1992, J BIOL CHEM, V267, P3438; CHAN P, IN PRESS EUR J VASC; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; DARTSCH PC, 1990, ARTERIOSCLEROSIS, V10, P62, DOI 10.1161/01.ATV.10.1.62; LEHMANN K G, 1991, Journal of the American College of Cardiology, V17, p181A; PUKAC LA, 1992, J BIOL CHEM, V267, P3707; RESINK TJ, 1989, J CELL PHYSIOL, V138, P137, DOI 10.1002/jcp.1041380119; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SNOW AD, 1990, AM J PATHOL, V137, P313; YLAHERTTUALA S, 1986, LAB INVEST, V54, P402	10	58	59	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					341	342		10.1016/0140-6736(93)90139-8	http://dx.doi.org/10.1016/0140-6736(93)90139-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094116				2022-12-24	WOS:A1993KK93900007
J	BLATT, SP; LUCEY, CR; BUTZIN, CA; HENDRIX, CW; LUCEY, DR				BLATT, SP; LUCEY, CR; BUTZIN, CA; HENDRIX, CW; LUCEY, DR			TOTAL LYMPHOCYTE COUNT AS A PREDICTOR OF ABSOLUTE CD4+ COUNT AND CD4+ PERCENTAGE IN HIV-INFECTED PERSONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HOMOSEXUAL MEN; RISK; COHORT; AIDS; PNEUMONIA; DECLINE; TYPE-1	Objective.-To determine whether the total lymphocyte count (TLC) accurately predicts a low absolute CD4+ T-cell count and CD4+ percentage in persons infected with human immunodeficiency virus (HIV). Design.-Retrospective analysis of data collected in the US Air Force HIV Natural History Study. Setting.-Military medical center that performs annual medical evaluation of all HIV-infected US Air Force personnel. Patients.-A total of 828 consecutive patients with no prior history of zidovudine use, evaluated from January 1985 through July 1991. For patients with multiple observations over time, a single data point within each 6-month interval was included in the analysis (N=2866). Measurements and Main Results.-The sensitivity, specificity, and likelihood ratio (LR) of the TLC, in the range of 1.00x10(9)/L to 2.00x10(9)/L, in predicting an absolute CD4+ T-cell count less than 0.20x10(9)/L or a CD4+ percentage less than 20% were calculated. In addition, the LR and pretest probability of significant immunosuppression were used to calculate posttest probabilities of a low CD4+ count for a given TLC value. The LR of the TLC in predicting an absolute CD4+ count <0.20x10(9)/L increased from 2.4 (95% confidence interval, 2.2 to 2.5) for all TLCs less than 2.00x10(9)/L, to 33.2 (95% confidence interval, 24.1 to 45.7) for all TLCs less than 1.00x10(9)/L. The specificity for this prediction increased from 57% to 97% over this range. The LR also increased from 1.4 (95% confidence interval, 1.3 to 1.6) for all TLCs less than 2.00x10(9)/L to 9.7 (95% confidence interval, 7.1 to 13.1) for all TLCs less than 1.00x10(9)/L in predicting a CD4+ percentage less than 20%. Conclusions.-The TLC, between 1.00x10(9)/L and 2.00x10(9)/L, appears to be a useful predictor of significant immunosuppression as measured by a CD4+ T-cell count less than 0.20x10(9)/L in HIV-infected persons. The LR fora given TLC value and the pretest probability of immunosuppression can be used to determine the posttest probability of significant immunosuppression in individual patients. For example, in a patient with a TLC less than 1.50x10(9)/L and a pretest probability of 16%, the posttest probability of a low CD4+ T-cell count increases to 53%. In contrast, a TLC greater than 2.00x10(9)/L in an individual with a pretest probability of 30% will decrease the posttest probability of a low CD4+ T-cell count to less than 4%. Physicians should find these data useful to help predict the risk for opportunistic infection among HIV-infected persons who present with syndromes that are potentially compatible with opportunistic infection but who have not had recent or prior CD4+ T-cell analysis.	WILFORD HALL USAF MED CTR,CLIN INVEST DIRECTORATE,LACKLAND AFB,TX 78236; SW FDN BIOMED RES,CTR AIDS RES,SAN ANTONIO,TX 78284; MIL MED CONSORTIUM APPL RETROVIRAL RES,SAN ANTONIO,TX; WALTER REED ARMY MED CTR,GEN MED SERV,WASHINGTON,DC 20307	United States Department of Defense; United States Air Force; Texas Biomedical Research Institute; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	BLATT, SP (corresponding author), WILFORD HALL USAF MED CTR,DEPT MED,INFECT DIS SERV,HIV PROGRAM,SGHMMI HIV,2200 BERGQUIST DR,LACKLAND AFB,TX 78236, USA.		Hendrix, Craig W/G-4182-2014	Hendrix, Craig W/0000-0002-5696-8665				[Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; BURCHAM J, 1991, AIDS, V5, P365, DOI 10.1097/00002030-199104000-00002; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; DETELS R, 1987, INT J EPIDEMIOL, V16, P271, DOI 10.1093/ije/16.2.271; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GOEDERT JJ, 1986, SCIENCE, V231, P992, DOI 10.1126/science.3003917; HECKERLING PS, 1988, J GEN INTERN MED, V3, P604, DOI 10.1007/BF02596109; KATZ MH, 1991, ARCH INTERN MED, V151, P105, DOI 10.1001/archinte.151.1.105; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P298; KOVACS JA, 1992, CLIN INFECT DIS, V14, P1005, DOI 10.1093/clinids/14.5.1005; LUCEY DR, 1991, J ACQ IMMUN DEF SYND, V4, P24; LUCEY DR, 1991, J INFECT DIS, V164, P631, DOI 10.1093/infdis/164.4.631; MALONE JL, 1990, J ACQ IMMUN DEF SYND, V3, P144; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MELBYE M, 1986, ANN INTERN MED, V104, P496, DOI 10.7326/0003-4819-104-4-496; MUNOZ A, 1988, J ACQ IMMUN DEF SYND, V1, P396; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P108; SLOAN P, 1991, 7 INT C AIDS FLOR; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; 1992, MMWR, V41, P608; 1992, MMWR, V41, P1; 1988, J ACQ IMMUN DEF SYND, V1, P390	24	63	67	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					622	626		10.1001/jama.269.5.622	http://dx.doi.org/10.1001/jama.269.5.622			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8093628				2022-12-24	WOS:A1993KJ44400030
J	JOHNELL, O; COOPER, C; MELTON, LJ				JOHNELL, O; COOPER, C; MELTON, LJ			HOW DO WE PREVENT HIP-FRACTURES	LANCET			English	Editorial Material									MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON,ENGLAND; MAYO CLIN & MAYO FDN,CLIN EPIDEMIOL SECT,ROCHESTER,MN 55905	University of Southampton; Mayo Clinic	JOHNELL, O (corresponding author), MALMO GEN HOSP,DEPT ORTHOPAED,S-21401 MALMO,SWEDEN.							[Anonymous], 1989, GUIDE CLIN PREVENTIV; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; Melton LJ, 1991, J BONE MINER RES  S1, V6, pS136; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; 1991, PRIORITIZATION HLTH	6	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					89	89		10.1016/0140-6736(93)92562-8	http://dx.doi.org/10.1016/0140-6736(93)92562-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093409				2022-12-24	WOS:A1993KF87000009
J	KETLEY, D; WOODS, KL				KETLEY, D; WOODS, KL			IMPACT OF CLINICAL-TRIALS ON CLINICAL-PRACTICE - EXAMPLE OF THROMBOLYSIS FOR ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Article							INFLUENCE MEDICAL-PRACTICE; THERAPY	Little is known about incorporation of new knowledge from randomised clinical trials into clinical practice. Thrombolytic therapy was shown to reduce the mortality of acute myocardial infarction in several large trials published during 1986-88. To examine the effect of these data on clinical practice, we analysed the supply of thrombolytic drugs in a representative English region (population 4.7 million) in 1987-92. During the study period there were over 10 000 hospital admissions per year in the region for acute myocardial infarction. From a very low initial level, thrombolytic drug use rose slowly for several years after publication of the trial results and reached a plateau in 1991-92. Rates of use per 1000 patients admitted with myocardial infarction varied almost six-fold between districts in 1989-90 and over two-fold in 1991-92. Level of use attained by districts in the latter period was strongly associated with the extent of their previous participation in multicentre trials of thrombolysis (p = 0.003); we estimate that 35-50% of patients admitted with acute myocardial infarction were receiving thrombolytics. The full potential of thrombolytic treatment has still not been achieved in routine care and the limiting factors need to be defined.	LEICESTER ROYAL INFIRM, DEPT PHARMACOL & THERAPEUT, CLIN SCI BLDG, LEICESTER LE2 7LX, ENGLAND; LEICESTER ROYAL INFIRM, DEPT PHARM, LEICESTER LE2 7LX, ENGLAND	University of Leicester; University of Leicester								[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; BOISSEL JP, 1989, CONTROL CLIN TRIALS, V10, pS120; BOISSEL JP, 1990, ARCH MAL COEUR VAISS, V83, P1777; BRAUNWALD E, 1990, CIRCULATION, V82, P1510, DOI 10.1161/01.CIR.82.4.1510; BURRELL CJ, 1990, BMJ-BRIT MED J, V300, P237, DOI 10.1136/bmj.300.6719.237; CHAMBERLAIN DA, 1988, LANCET, V1, P545; COLLINS R, 1991, BRIT HEART J, V66, P250; FINEBERG HV, 1987, B CANCER, V74, P333; FRIEDMAN L, 1983, CONTROL CLIN TRIALS, V4, P513, DOI 10.1016/0197-2456(83)90032-6; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; Haigh R, 1991, Health Trends, V23, P154; HENDRA TJ, 1992, BMJ-BRIT MED J, V304, P423, DOI 10.1136/bmj.304.6824.423; HLATKY MA, 1988, AM J CARDIOL, V61, P510, DOI 10.1016/0002-9149(88)90755-2; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; WILCOX RG, 1988, LANCET, V2, P525; 1986, LANCET, V1, P398; 1987, LANCET, V1, P502	20	204	204	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1993	342	8876					891	894		10.1016/0140-6736(93)91945-I	http://dx.doi.org/10.1016/0140-6736(93)91945-I			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105166				2022-12-24	WOS:A1993MA96300009
J	DIXON, M				DIXON, M			ACID, ULCERS, AND HELICOBACTER-PYLORI	LANCET			English	Editorial Material							HELICOBACTER-PYLORI				DIXON, M (corresponding author), UNIV LEEDS,ACAD UNIT PATHOL SCI,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.							CARD WI, 1960, CLIN SCI, V19, P147; DIXON MF, 1991, J GASTROEN HEPATOL, V6, P125, DOI 10.1111/j.1440-1746.1991.tb01451.x; DIXON MF, 1992, IRISH J MED SCI S10, V161, P11; ELOMAR E, 1993, GUT, V34, P1060, DOI 10.1136/gut.34.8.1060; ELOMAR E, 1993, GASTROENTEROLOGY, V104, pA75; Kramling H J, 1987, Adv Exp Med Biol, V216A, P427; MCCOLL KEL, 1993, GUT, V34, P762, DOI 10.1136/gut.34.6.762; MITCHELL HM, 1992, J INFECT DIS, V166, P149, DOI 10.1093/infdis/166.1.149; MOSS SF, 1993, GUT, V34, P888, DOI 10.1136/gut.34.7.888; MOSS SF, 1992, LANCET, V340, P930, DOI 10.1016/0140-6736(92)92816-X; MULHOLLAND G, 1993, GUT, V34, P757, DOI 10.1136/gut.34.6.757; SIPPONEN P, 1989, GUT, V30, P922, DOI 10.1136/gut.30.7.922; WYATT JI, 1987, J CLIN PATHOL, V40, P841, DOI 10.1136/jcp.40.8.841; WYATT JI, 1990, J CLIN PATHOL, V43, P981, DOI 10.1136/jcp.43.12.981; 1992, GUT, V34, P604	15	34	34	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					384	385						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101896				2022-12-24	WOS:A1993LR90000004
J	MORENO, S; BARAIAETXABURU, J; BOUZA, E; PARRAS, F; PEREZTASCON, M; MIRALLES, P; VICENTE, T; ALBERDI, JC; COSIN, J; LOPEZGAY, D				MORENO, S; BARAIAETXABURU, J; BOUZA, E; PARRAS, F; PEREZTASCON, M; MIRALLES, P; VICENTE, T; ALBERDI, JC; COSIN, J; LOPEZGAY, D			RISK FOR DEVELOPING TUBERCULOSIS AMONG ANERGIC PATIENTS INFECTED WITH HIV	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; TUBERCULOSIS; HYPERSENSITIVITY, DELAYED; TUBERCULIN TEST; SKIN TESTS	HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS; EPIDEMIC; SPAIN	Objective: To assess the risk for development of tuberculosis among anergic pa Design: Retrospective cohort study. Setting: Tertiary referral center. Patients: All HIV-infected patients who had a base-line positive protein purified derivative test (PPD) and delayed-type hypersensitivity skin tests. Measurements: Development of active tuberculosis. Results: Of 374 patients, 108 (29%) had positive results of PPD tests, 154 (41%) had negative results of PPD tests but no skin anergy, and 112 (30%) were anergic. Conversion of the PPD to positive was observed in 10 of 67 (15%) patients with previously negative results of PPD tests and no anergy and in 3 of 36 (8%) anergic patients who were retested during the follow-up period (mean, 26 months). The risk for active tuberculosis to develop in patients not receiving isoniazid chemoprophylaxis was similar in patients with a positive PPD test result (10.4 cases per 100 person-years) and in anergic patients (12.4 cases per 100 person-years) and higher in both groups than in nonanergic patients with a negative PPD test result (5.4 cases per 100 person-years). Tuberculosis was more frequent among intravenous drug abusers with no previous isoniazid treatment (63 of 290, 22%) than among homosexual men (0 of 29) or patients in other HIV transmission categories (0 of 31). Preventive therapy with isoniazid reduced tuberculosis development (4% as compared with 31 %; P = 0.008). Among 15 anergic patients who had CD4 counts measured within 3 months of tuberculosis development, only 1 (7%) had more than 500 CD4 cells/mm3. Conclusions: Anergic HIV-infected patients are at high risk for development of tuberculosis. Anergic HIV-infected patients, in addition to HIV-infected patients with positive results of PPD tests, should be offered preventive therapy if they live in areas with a high prevalence of tuberculosis, at least when the CD4 count decreases to less than 500 CD4 cells/mm3.	CONSEJERIA SALUD COMUNIDAD AUTONOMA, MADRID, SPAIN		MORENO, S (corresponding author), HOSP GREGORIO MARANON, SERV MICROBIOL CLIN, DR ESQUERDO 46, E-28007 MADRID, SPAIN.		Bouza, Emilio/D-8661-2014	Bouza, Emilio/0000-0001-6967-9267				AYUELA PD, 1990, REV CLIN ESP, V186, P365; BARNES PF, 1991, NEW ENGL J MED, V325, P1884; BERENGUER J, 1992, NEW ENGL J MED, V326, P668, DOI 10.1056/NEJM199203053261004; BOUZA E, 1988, EUR J CLIN MICROBIOL, V7, P785, DOI 10.1007/BF01975050; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DEVENDRA W, 1991, 7 P INT C AIDS FLOR; DIPERRI G, 1989, LANCET, V2, P1502; DIPERRI G, 1991, NEW ENGL J MED, V325, P1882; GUELAR A, 1991, 31ST INT C ANT AG CH; JORDAN TJ, 1991, JAMA-J AM MED ASSOC, V265, P2987, DOI 10.1001/jama.265.22.2987; PITCHENIK AE, 1990, ANN INTERN MED, V113, P89, DOI 10.7326/0003-4819-113-2-89; PITCHENIK AE, 1987, AM REV RESPIR DIS, V135, P875, DOI 10.1164/arrd.1987.135.4.875; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; Rothman K, 1986, MODERN EPIDEMIOLOGY; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; 1991, MMWR MORB MORTAL WKL, V40, P27; 1989, MMWR MORB MORTAL WKL, V38, P236; 1989, MMWR MORB MORTAL WKL, V38, P243; 1991, VIGILANCIA EPIDEMIOL	21	171	173	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1993	119	3					194	198		10.7326/0003-4819-119-3-199308010-00003	http://dx.doi.org/10.7326/0003-4819-119-3-199308010-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU903	8100693				2022-12-24	WOS:A1993LU90300003
J	SHAPER, AG				SHAPER, AG			WHATS NEW IN ENDOMYOCARDIAL FIBROSIS	LANCET			English	Editorial Material											SHAPER, AG (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON,ENGLAND.							VALIATHAN MS, 1993, ENDOMYOCARDIAL FIBRO, P302	1	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					255	256		10.1016/0140-6736(93)91813-2	http://dx.doi.org/10.1016/0140-6736(93)91813-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101298				2022-12-24	WOS:A1993LQ16300006
J	HARRISON, LC; HONEYMAN, MC; DEAIZPURUA, HJ; SCHMIDLI, RS; COLMAN, PG; TAIT, BD; CRAM, DS				HARRISON, LC; HONEYMAN, MC; DEAIZPURUA, HJ; SCHMIDLI, RS; COLMAN, PG; TAIT, BD; CRAM, DS			INVERSE RELATION BETWEEN HUMORAL AND CELLULAR-IMMUNITY TO GLUTAMIC-ACID DECARBOXYLASE IN SUBJECTS AT RISK OF INSULIN-DEPENDENT DIABETES	LANCET			English	Article							PANCREATIC-ISLETS; LYMPHOCYTE-T; HLA-DR3; CELLS	Glutamic acid decarboxylase (GAD) in pancreatic beta cells is an autoantigen in insulin-dependent diabetes (IDD). We measured immunity to GAD in 31 first-degree relatives of IDD patients judged to be at risk of developing IDD themselves because of the presence of islet-cell antibodies. We found that in most of the subjects GAD autoimmunity was either predominantly humoral or predominantly cellular. High concentrations of circulating autoantibodies that precipitate native GAD activity were associated with low proliferation of peripheral-blood T cells to recombinant GAD; conversely, low concentrations of autoantibody to GAD were associated with high T-cell proliferation to GAD. Although T-cell proliferation was measured in the presence of autologous serum, GAD autoantibodies did not have a blocking effect in vitro. This dichotomy of the immune response to GAD defined heterogeneity within at-risk relatives and could have prognostic importance. We postulate that, if GAD is a pathogenetic autoantigen, sensitisation to beta-cell GAD is more likely to lead to IDD when the immune response deviates towards the expansion of autoreactive T cells rather than towards generation of autoantibodies. This idea is consistent with evidence that beta-cell destruction is mediated by T cells and that high concentrations of GAD antibodies are associated with slower progression to clinical disease.			HARRISON, LC (corresponding author), ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, BURNET CLIN RES UNIT, PARKVILLE, VIC 3050, AUSTRALIA.			Colman, Peter/0000-0001-8718-6175				ALBERS RW, 1959, J BIOL CHEM, V234, P926; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; BONIFACIO E, 1990, LANCET, V335, P147, DOI 10.1016/0140-6736(90)90013-U; BRUSERUD O, 1985, DIABETOLOGIA, V28, P420, DOI 10.1007/BF00280884; CAMPBELL IL, 1991, J CLIN INVEST, V87, P739, DOI 10.1172/JCI115055; CRAM DS, 1991, BIOCHEM BIOPH RES CO, V176, P1239, DOI 10.1016/0006-291X(91)90418-7; DEAIZPURUA HJ, 1992, P NATL ACAD SCI USA, V89, P9841, DOI 10.1073/pnas.89.20.9841; DEAIZPURUA HJ, 1992, J AUTOIMMUN, V5, P759, DOI 10.1016/0896-8411(92)90191-R; DEAIZPURUA HJ, 1992, DIABETES, V41, P1182, DOI 10.2337/diabetes.41.9.1182; DESCHAMPS I, 1988, DIABETOLOGIA, V31, P896; GENOVESE S, 1992, DIABETOLOGIA, V35, P385, DOI 10.1007/BF00401207; GIANANI R, 1992, DIABETES, V41, P347, DOI 10.2337/diabetes.41.3.347; HARRISON LC, 1992, J CLIN INVEST, V89, P1161, DOI 10.1172/JCI115698; HARRISON LC, 1992, IMMUNOL TODAY, V13, P348, DOI 10.1016/0167-5699(92)90170-C; HARRISON LC, 1991, DIABETES, V40, P1128, DOI 10.2337/diabetes.40.9.1128; HARRISON LC, 1990, ADV ENDOCRINOL METAB, V1, P35; HONEYMAN MC, 1993, J EXP MED, V177, P535, DOI 10.1084/jem.177.2.535; KARLSEN AE, 1992, DIABETES, V41, P1355, DOI 10.2337/diabetes.41.10.1355; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; MARTINO GV, 1991, J AUTOIMMUN, V4, P915, DOI 10.1016/0896-8411(91)90054-G; OKADA Y, 1976, SCIENCE, V194, P620, DOI 10.1126/science.185693; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; PFEIFFER C, 1991, IMMUNOL REV, V123, P65, DOI 10.1111/j.1600-065X.1991.tb00606.x; RASANEN L, 1988, CLIN EXP IMMUNOL, V71, P470; ROBERTS E, 1950, J BIOL CHEM, V187, P55; ROWLEY MJ, 1992, DIABETES, V41, P548, DOI 10.2337/diabetes.41.4.548; SCHMNIDLI RS, 1992, P AUST DIABETES SOC, V36; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STREET NE, 1991, FASEB J, V5, P171, DOI 10.1096/fasebj.5.2.1825981; TAIT BD, 1991, BAILLIERE CLIN ENDOC, V5, P211, DOI 10.1016/S0950-351X(05)80124-7; YAMASHITA K, IN PRESS BIOCH BIOPH	31	261	263	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	1993	341	8857					1365	1369		10.1016/0140-6736(93)90940-I	http://dx.doi.org/10.1016/0140-6736(93)90940-I			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098789				2022-12-24	WOS:A1993LE18000003
J	SHARPE, RM; SKAKKEBAEK, NE				SHARPE, RM; SKAKKEBAEK, NE			ARE ESTROGENS INVOLVED IN FALLING SPERM COUNTS AND DISORDERS OF THE MALE REPRODUCTIVE-TRACT	LANCET			English	Article							MULLERIAN INHIBITING SUBSTANCE; TESTICULAR CANCER; ETHINYL ESTRADIOL; SERTOLI CELLS; EXPOSURE; DIETHYLSTILBESTROL; MAMMALS; TESTIS; RISK; CRYPTORCHIDISM	The incidence of disorders of development of the male reproductive tract has more than doubled in the past 30-50 years while sperm counts have declined by about half. Similar abnormalities occur in the sons of women exposed to diethylstilbestrol (DES) during pregnancy and can be induced in animals by brief exposure to exogenous oestrogen/DES during pregnancy. We argue that the increasing incidence of reproductive abnormalities in the human male may be related to increased oestrogen exposure in utero, and identify mechanisms by which this exposure could occur.	UNIV COPENHAGEN,DEPT GROWTH & REPROD,DK-1168 COPENHAGEN,DENMARK	University of Copenhagen	SHARPE, RM (corresponding author), CTR REPROD BIOL,MRC,REPROD BIOL UNIT,37 CHALMERS ST,EDINBURGH EH3 9EW,SCOTLAND.		Sharpe, Richard M/D-2725-2013	Sharpe, Richard M/0000-0003-1686-8085				ADLERCREUTZ H, 1990, ANN NY ACAD SCI, V595, P281, DOI 10.1111/j.1749-6632.1990.tb34302.x; ARAI Y, 1983, INT REV CYTOL, V84, P235, DOI 10.1016/S0074-7696(08)61019-0; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BERNSTEIN L, 1986, J NATL CANCER I, V76, P1035; BROWN LM, 1992, CANCER RES, V46, P4812; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; Colborn T., 1992, CHEM INDUCED ALTERAT; COOKE S, 1992, BIOL REPROD, V46, P146; CORTES D, 1987, INT J ANDROL, V10, P589, DOI 10.1111/j.1365-2605.1987.tb00358.x; DEGRAAFF WE, 1992, LAB INVEST, V66, P166; DEPUE RH, 1984, INT J EPIDEMIOL, V13, P311, DOI 10.1093/ije/13.3.311; FIELD B, 1990, SEMIN REPROD ENDOCR, V8, P44, DOI 10.1055/s-2007-1021422; FOREST MG, 1982, ASPECTS MALE INFERTI, P1; GIWERCMAN A, 1992, INT J ANDROL, V15, P373, DOI 10.1111/j.1365-2605.1992.tb01351.x; HAMON M, 1990, J DAIRY RES, V57, P419, DOI 10.1017/S0022029900027072; HIROBE S, 1992, ENDOCRINOLOGY, V131, P854, DOI 10.1210/en.131.2.854; HUTSON JM, 1990, OXFORD REV REPROD, P1; JACKSON MB, 1988, HORM RES, V30, P153, DOI 10.1159/000181052; KALDAS RS, 1989, REPROD TOXICOL, V3, P81, DOI 10.1016/0890-6238(89)90042-7; KURODA T, 1990, ENDOCRINOLOGY, V127, P1825, DOI 10.1210/endo-127-4-1825; LAMMING GE, 1984, COMMISSION EUROPEAN, V913, P4; MABLY TA, 1992, TOXICOL APPL PHARM, V114, P118, DOI 10.1016/0041-008X(92)90103-Y; McLachlan J. A., 1985, ESTROGENS ENV; MOSS AR, 1986, AM J EPIDEMIOL, V124, P39, DOI 10.1093/oxfordjournals.aje.a114369; ORTH JM, 1988, ENDOCRINOLOGY, V122, P787, DOI 10.1210/endo-122-3-787; OSTERLIND A, 1986, BRIT J CANCER, V53, P501, DOI 10.1038/bjc.1986.79; PRENER A, 1992, CANCER CAUSE CONTROL, V3, P265, DOI 10.1007/BF00124260; RUSSELL LD, 1984, J REPROD FERTIL, V70, P635, DOI 10.1530/jrf.0.0700635; SAGER D, 1991, ENVIRON TOXICOL CHEM, V10, P737, DOI 10.1897/1552-8618(1991)10[737:EPETPS]2.0.CO;2; SHARPE RM, 1993, J ENDOCRINOL, V137, P357; SHEEHAN DM, 1979, ENDOCRINOLOGY, V104, P1442, DOI 10.1210/endo-104-5-1442; SKAKKEBAEK N E, 1987, International Journal of Andrology, V10, P1; STILLMAN RJ, 1982, AM J OBSTET GYNECOL, V142, P905, DOI 10.1016/S0002-9378(16)32540-6; VERDEAL K, 1979, J FOOD PROTECT, V7, P577; WALKER AH, 1990, BRIT J CANCER, V62, P599, DOI 10.1038/bjc.1990.337; YASUDA Y, 1985, TERATOLOGY, V32, P113, DOI 10.1002/tera.1420320115; YASUDA Y, 1985, TERATOLOGY, V32, P210	37	1475	1555	1	74	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1392	1395		10.1016/0140-6736(93)90953-E	http://dx.doi.org/10.1016/0140-6736(93)90953-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098802				2022-12-24	WOS:A1993LE18000016
J	HOGE, CW; SHLIM, DR; RAJAH, R; TRIPLETT, J; SHEAR, M; RABOLD, JG; ECHEVERRIA, P				HOGE, CW; SHLIM, DR; RAJAH, R; TRIPLETT, J; SHEAR, M; RABOLD, JG; ECHEVERRIA, P			EPIDEMIOLOGY OF DIARRHEAL ILLNESS ASSOCIATED WITH COCCIDIAN-LIKE ORGANISM AMONG TRAVELERS AND FOREIGN RESIDENTS IN NEPAL	LANCET			English	Article							CAMPYLOBACTER-JEJUNI; TRAVELERS; CHILDREN	A newly described organism called CLB (coccidian-like or cyanobacterium-like body) has been identified in cases of prolonged diarrhoea. To confirm an association of CLB with disease and identify risk factors for transmission, we conducted a case-control study of travellers and foreign residents at two outpatient clinics in Kathmandu, Nepal. Patients without diarrhoea were matched to CLB cases by clinic and date of visit. For comparison, patients with other causes of diarrhoea were also studied. Stools were examined for enteric pathogens with standard microbiological and molecular genetic techniques. CLB was identified in 108 (11%) of 964 individuals with gastrointestinal symptoms compared with only 1 (1%) of 96 symptom-free controls (p=0.003). 7% of residents in the US Embassy community acquired the infection. The diarrhoeal illness associated with CLB lasted a median of 7 weeks (interquartile range 4-9) compared with 9 days (4-19) for individuals with other causes of diarrhoea (p<0.0001). The prevalence of other enteric pathogens was no higher among CLB cases than among symptom-free controls. Patients with CLB infection were more likely than controls to report consumption of untreated water (odds ratio 3.98; 95% Cl 1.29-13.14); organisms of the same appearance were identified in an epidemiologically implicated water sample. The significant association of CLB with prolonged diarrhoea, and the low rate of other enteropathogens in CLB cases, strongly supports the hypothesis that CLB is a new pathogen. Epidemiological and environmental data suggest that the organism is waterborne.	US EMBASSY, MED CLIN, Kathmandu, NEPAL; CANADIAN INT WATER & ENERGY CONSULTANTS CLIN, Kathmandu, NEPAL		HOGE, CW (corresponding author), USA, MED COMPONENT, ARMED FORCES RES INST MED SCI, DEPT BACTERIOL IMMUNOL & MOLEC GENET, BANGKOK 10400, THAILAND.							CONNOR BA, IN PRESS ANN INTERN; DEAN AG, 1972, J INFECT DIS, V125, P407, DOI 10.1093/infdis/125.4.407; ECHEVERRIA P, 1989, J INFECT DIS, V159, P543, DOI 10.1093/infdis/159.3.543; ECHEVERRIA P, 1990, P95; HART AS, 1990, LANCET, V335, P169, DOI 10.1016/0140-6736(90)90042-4; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; LONG EG, 1991, J INFECT DIS, V164, P199, DOI 10.1093/infdis/164.1.199; ORTEGA YR, 1993, IN PRESS N ENGL J ME; POLLOK RCG, 1992, LANCET, V340, P556, DOI 10.1016/0140-6736(92)91759-2; SACK DA, 1975, INFECT IMMUN, V11, P334, DOI 10.1128/IAI.11.2.334-336.1975; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; SOAVE R, 1986, CLIN RES, V34, pA533; STEELE TW, 1984, PATHOLOGY, V16, P263, DOI 10.3109/00313028409068535; TAYLOR DN, 1988, JAMA-J AM MED ASSOC, V260, P1245, DOI 10.1001/jama.260.9.1245; WANG WLL, 1983, J CLIN MICROBIOL, V18, P803, DOI 10.1128/JCM.18.4.803-807.1983; 1991, MMWR, V40, P325; 1991, 90762 CTR DIS CONTR	17	142	149	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	1993	341	8854					1175	1179		10.1016/0140-6736(93)91002-4	http://dx.doi.org/10.1016/0140-6736(93)91002-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098077				2022-12-24	WOS:A1993LB01700004
J	RIDKER, PM; VAUGHAN, DE; STAMPFER, MJ; MANSON, JE; HENNEKENS, CH				RIDKER, PM; VAUGHAN, DE; STAMPFER, MJ; MANSON, JE; HENNEKENS, CH			ENDOGENOUS TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND RISK OF MYOCARDIAL-INFARCTION	LANCET			English	Article							CORONARY-ARTERY DISEASE; HEART-DISEASE; INHIBITOR; PLASMA; THROMBOEMBOLISM; AGE	Endogenous tissue-type plasminogen activator (tPA) has been hypothesised to be a marker of baseline fibrinolytic capacity. We therefore tested whether tPA antigen is associated with the occurrence of future myocardial infarction (MI) among apparently healthy individuals. tPA antigen concentrations were measured at baseline in plasma samples from 231 apparently healthy men from the Physicians' Health Study cohort who later developed MI, and in an equal number of controls matched for age and smoking habit who remained free of reported cardiovascular disease during a follow-up of 60.2 months. In crude matched-pair analyses, baseline concentrations of tPA antigen were higher in cases than controls (p=0.03) and strongly associated with risk of future MI. Specifically, the relative risks of developing a first MI from lowest (referent) to highest quintiles of tPA antigen were 1.00, 1.27, 1.75, 1.88, and 2.81 (p for trend 0.008, 95% Cl for the relative risk in the fifth as compared with first quintile 1.47 to 5.37, p=0.002). Analyses which adjusted for risk factors that affect progression of atherosclerosis, particularly HDL-cholesterol, abolished the statistical significance of this association, a finding which suggests that elevations of tPA antigen are a result rather than a cause of atherosclerotic coronary disease. These prospective data suggest that endogenous tPA concentrations increase as a consequence of important preclinical atherosclerosis and therefore may be a marker for risk of future MI.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PREVENT MED,BOSTON,MA 02115; W ROXBURY VET ADM HOSP,CTR RES THROMBOSIS,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	RIDKER, PM (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOL,900 COMMONWEALTH AVE E,BOSTON,MA 02115, USA.				NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-26490, HL-34595] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1989, NEW ENGL J MED, V321, P129; AZNAR J, 1988, BRIT HEART J, V59, P535; FUSTER V, 1992, NEW ENGL J MED, V326, P310; HAMSTEN A, 1987, LANCET, V2, P3; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; JANSSON JH, 1991, EUR HEART J, V12, P157, DOI 10.1093/oxfordjournals.eurheartj.a059862; LUSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P887; MEHTA J, 1987, J AM COLL CARDIOL, V9, P263, DOI 10.1016/S0735-1097(87)80373-X; NILSSON TK, 1992, CIRCULATION, V86, P598; OLOFSSON BO, 1989, EUR HEART J, V10, P77; OSEROFF A, 1989, J LAB CLIN MED, V113, P88; PARAMO JA, 1985, BRIT MED J, V291, P573, DOI 10.1136/bmj.291.6495.573; Petrakis N L, 1985, Natl Cancer Inst Monogr, V67, P193; PRINS MH, 1991, ARCH INTERN MED, V151, P1721, DOI 10.1001/archinte.151.9.1721; RANBY M, 1986, CLIN CHEM, V32, P2160; Ridker Paul M., 1992, Circulation, V86, pI325; RIDKER PM, 1992, CIRCULATION, V85, P1822, DOI 10.1161/01.CIR.85.5.1822; RIDKER PM, 1991, CIRCULATION, V83, P1098, DOI 10.1161/01.CIR.83.3.1098; RIDKER PM, 1992, CURR OPIN LIPIDOL, V3, P285; SPRENGERS ED, 1987, BLOOD, V69, P381; VANDEKERCKHOVE Y, 1988, THROMB RES, V50, P449, DOI 10.1016/0049-3848(88)90274-5; WALKER ID, 1977, THROMB RES, V10, P509, DOI 10.1016/0049-3848(77)90160-8; WIMAN B, 1991, PROG CARDIOVASC DIS, V34, P179, DOI 10.1016/0033-0620(91)90012-B; WINN DM, 1990, EPIDEMIOL REV, V12, P56, DOI 10.1093/oxfordjournals.epirev.a036062; 1971, ISCHEMIC HEART DISEA	25	569	575	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1165	1168		10.1016/0140-6736(93)90998-V	http://dx.doi.org/10.1016/0140-6736(93)90998-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098074				2022-12-24	WOS:A1993LB01700001
J	STIRLING, D; LUDLAM, CA				STIRLING, D; LUDLAM, CA			BLEEDING DISORDERS - HEMOPHILIA-B AND FACTOR-IX MUTATIONS	LANCET			English	Editorial Material							HEMOPHILIA-B; PROMOTER; LEYDEN				STIRLING, D (corresponding author), ROYAL EDINBURGH & ASSOCIATED HOSP,DEPT HAEMATOL,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND.							ALBERTS B, 1989, MOL BIOL CELL, P551; BRIET E, 1985, ANN INTERN MED, V103, P225, DOI 10.7326/0003-4819-103-2-225; Brownlee G, 1988, REC ADV HAEMATOL, V5, P251; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; GIANNELLI F, 1991, NUCLEIC ACIDS RES, V19, P2193, DOI 10.1093/nar/19.suppl.2193; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; VELTKAMP JJ, 1970, SCAND J HAEMATOL, V7, P82	9	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1127	1128		10.1016/0140-6736(93)93136-O	http://dx.doi.org/10.1016/0140-6736(93)93136-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097812				2022-12-24	WOS:A1993KZ68700012
J	EIKENBOOM, JCJ; REITSMA, PH; PEERLINCK, KMJ; BRIET, E				EIKENBOOM, JCJ; REITSMA, PH; PEERLINCK, KMJ; BRIET, E			RECESSIVE INHERITANCE OF VONWILLEBRANDS DISEASE TYPE-I	LANCET			English	Article							POLYMERASE CHAIN-REACTION; VON-WILLEBRANDS DISEASE; FACTOR GENE; FACTOR-VIII; POLYMORPHISM; VARIANT; FAMILY; EXPRESSION; MULTIMERS; MUTATION	The inheritance of type I von Willebrand's disease is thought to be autosomally dominant. The laboratory profile may, however, vary between affected people, even within a single family. There is also a large variation in the severity of clinical symptoms. To see if there is an association between the von Willebrand factor genotype, the laboratory profile, and the severity of the clinical symptoms we did a genetic analysis of four families with type I von Willebrand's disease. The proband of each family proved to be a compound heterozygote for defects in the von Willebrand factor gene. Simple heterozygotes in these families were either symptomless or only mildly affected. One of the identified mutations, which was shared by the probands of three of the four families, may have a carrier prevalence of 1:50 in the general population. These results suggest that the inheritance of von Willebrand's disease is often recessive rather than dominant and so have important implications for diagnosis and genetic counselling.	CATHOLIC UNIV LEUVEN,CTR THROMBOSIS & VASC RES,B-3000 LOUVAIN,BELGIUM	KU Leuven	EIKENBOOM, JCJ (corresponding author), UNIV HOSP LEIDEN,AEMOSTASIS & THROMBOSIS RES CTR,DEPT HAEMATOL,BLDG 1C2-R,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Eikenboom, Jeroen/F-9156-2018	Eikenboom, Jeroen/0000-0002-3268-5759				ABILDGAARD CF, 1980, BLOOD, V56, P712; BERNDT MC, 1991, THROMB HAEMOSTASIS, V65, P1180; BLOOM AL, 1979, THROMB RES, V15, P502; CACHERIS PM, 1991, J BIOL CHEM, V266, P13499; DONNER M, 1991, BRIT J HAEMATOL, V78, P403, DOI 10.1111/j.1365-2141.1991.tb04455.x; EIKENBOOM JCJ, 1992, THROMB HAEMOSTASIS, V68, P448; GAUCHER C, 1991, BRIT J HAEMATOL, V78, P506, DOI 10.1111/j.1365-2141.1991.tb04480.x; HOLMBERG L, 1992, CIRCULATION S1, V86, pS416; HOYER LW, 1980, BLOOD, V55, P1056; JORIEUX S, 1992, BLOOD, V79, P563; KRONER PA, 1991, J BIOL CHEM, V266, P19146; KUNKEL GR, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961-a; MANCUSO DJ, 1991, BIOCHEMISTRY-US, V30, P253, DOI 10.1021/bi00215a036; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MILLER CH, 1979, BLOOD, V54, P117; MOHRI H, 1988, J BIOL CHEM, V263, P17901; NICHOLS WC, 1991, P NATL ACAD SCI USA, V88, P3857, DOI 10.1073/pnas.88.9.3857; PEAKE IR, 1990, BLOOD, V76, P555; PEAKE IR, 1990, BLOOD, V75, P654; PEERLINCK K, 1992, BRIT J HAEMATOL, V80, P358, DOI 10.1111/j.1365-2141.1992.tb08145.x; RODEGHIERO F, 1987, BLOOD, V69, P454; RUGGERI ZM, 1987, BLOOD, V70, P895; STANDEN GR, 1990, BRIT J HAEMATOL, V76, P242, DOI 10.1111/j.1365-2141.1990.tb07879.x; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; VANAMSTEL HKP, 1990, NUCLEIC ACIDS RES, V18, P4957, DOI 10.1093/nar/18.16.4957-a; WEISS HJ, 1986, BLOOD, V68, P149	26	112	114	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					982	986		10.1016/0140-6736(93)91070-3	http://dx.doi.org/10.1016/0140-6736(93)91070-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096943				2022-12-24	WOS:A1993KY36800003
J	BADING, H; GINTY, DD; GREENBERG, ME				BADING, H; GINTY, DD; GREENBERG, ME			REGULATION OF GENE-EXPRESSION IN HIPPOCAMPAL-NEURONS BY DISTINCT CALCIUM SIGNALING PATHWAYS	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; IMMEDIATE EARLY GENES; NMDA RECEPTOR ACTIVATION; C-FOS; SYNAPTIC ACTIVATION; DENDRITIC SPINES; NERVOUS-SYSTEM; MESSENGER-RNA; CALMODULIN; CHANNELS	Calcium ions (Ca2+) act as an intracellular second messenger and can enter neurons through various ion channels. Influx of Ca2+ through distinct types of Ca2+ channels may differentially activate biochemical processes. N-Methyl-D-aspartate (NMDA) receptors and L-type Ca2+ channels, two major sites of Ca2+ entry into hippocampal neurons, were found to transmit signals to the nucleus and regulated gene transcription through two distinct Ca2+ signaling pathways. Activation of the multifunctional Ca2+-calmodulin-dependent protein kinase (CaM kinase) was evoked by stimulation of either NMDA receptors or L-type Ca2+ channels; however, activation of CaM kinase appeared to be critical only for propagating the L-type Ca2+ channel signal to the nucleus. Also, the NMDA receptor and L-type Ca2+ channel pathways activated transcription by means of different cis-acting regulatory elements in the c-fos promoter. These results indicate that Ca2+, depending on its mode of entry into neurons, can activate two distinct signaling pathways. Differential signal processing may provide a mechanism by which Ca2+ controls diverse cellular functions.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,200 LONGWOOD AVE,BOSTON,MA 02115	Harvard University; Harvard Medical School					NINDS NIH HHS [NS28829, 2F32 NS 08764] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS028829, R01NS028829, F32NS008764] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BADING H, UNPUB; Bashir Z I, 1992, Curr Opin Neurobiol, V2, P328, DOI 10.1016/0959-4388(92)90124-4; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BLAUSTEIN MP, 1988, TRENDS NEUROSCI, V11, P438, DOI 10.1016/0166-2236(88)90195-6; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DOROSHENKO PA, 1988, NEUROSCIENCE, V27, P1073, DOI 10.1016/0306-4522(88)90211-4; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Ginty D D, 1992, Curr Opin Neurobiol, V2, P312, DOI 10.1016/0959-4388(92)90121-Z; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GORELICK FS, 1988, J BIOL CHEM, V263, P17209; GREENBERG DA, 1987, BRAIN RES, V404, P401, DOI 10.1016/0006-8993(87)91403-X; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LI GD, 1992, MOL PHARMACOL, V42, P489; LOEFFLER JP, 1990, J NEUROCHEM, V54, P1812, DOI 10.1111/j.1471-4159.1990.tb01240.x; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MILLER RJ, 1991, PROG NEUROBIOL, V37, P255, DOI 10.1016/0301-0082(91)90028-Y; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; Misra R, UNPUB; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, UNPUB; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SZEKELY AM, 1989, MOL PHARMACOL, V35, P401; Thomas P, 1992, Curr Opin Neurobiol, V2, P308, DOI 10.1016/0959-4388(92)90120-A; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Treisman R, 1990, Semin Cancer Biol, V1, P47; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; VANBELLE H, 1981, CELL CALCIUM, V2, P483, DOI 10.1016/0143-4160(81)90007-5; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; YUSTE R, 1991, NEURON, V6, P333, DOI 10.1016/0896-6273(91)90243-S	55	994	1008	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 9	1993	260	5105					181	186		10.1126/science.8097060	http://dx.doi.org/10.1126/science.8097060			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8097060				2022-12-24	WOS:A1993KW45200028
J	QARI, SH; SHI, YP; GOLDMAN, IF; UDHAYAKUMAR, V; ALPERS, MP; COLLINS, WE; LAL, AA				QARI, SH; SHI, YP; GOLDMAN, IF; UDHAYAKUMAR, V; ALPERS, MP; COLLINS, WE; LAL, AA			IDENTIFICATION OF PLASMODIUM-VIVAX-LIKE HUMAN MALARIA PARASITE	LANCET			English	Article							CIRCUMSPOROZOITE PROTEIN GENE; IMMUNODOMINANT EPITOPE; FALCIPARUM; POLYMORPHISM; SEQUENCE; VACCINE; VARIANT	There are four species of human malarial parasite and several monkey ones, and in evolutionary terms the human and non-human primate plasmodia may be related. The tools of molecular biology have lately pointed to the existence of two types of Plasmodium vivax. Using specific oligonucleotides we have identified a human malaria parasite resembling P vivax under the microscope but with circumsporozoite (CS) protein differing from those of P vivax types 1 and 2. The CS protein of this ''P vivax-like'' malaria parasite is identical to that of P simiovale, a monkey parasite resembling P ovale, a human one, morphologically. Polyclonal serum raised against a partial repeat sequence of the P vivax-like malaria parasite specifically reacted with P simiovale sporozoites but not with those of P vivax types 1 and 2, P ovale, or P simium. Sera collected from people living in malaria endemic regions of Papua New Guinea and Brazil contained antibodies that specifically reacted with the synthetic peptides representing the repeat sequences of CS protein of this P vivax-like parasite. A comparison of the CS protein gene sequences of P simiovale and the P vivax-like malaria parasites with those of other primate parasites, data on serological cross-reactivity, and 18S ribosomal DNA analyses suggest that the new human malaria parasite described here is distinct from P falciparum, P malariae, P vivax, and P ovale, the four known species of human parasite.	CTR DIS CONTROL, NATL CTR INFECT DIS, MALARIA BRANCH, ATLANTA, GA 30333 USA; PAPUA NEW GUINEA INST MED RES, GOROKA, PAPUA N GUINEA	Centers for Disease Control & Prevention - USA; PNG Institute Of Medical Research				Qari, Shoukat/0000-0002-0016-4414	NIAID NIH HHS [1-Y02-AI-00006-01] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNOT DE, 1985, SCIENCE, V230, P815, DOI 10.1126/science.2414847; ARNOT DE, 1990, MOL BIOCHEM PARASIT, V43, P147, DOI 10.1016/0166-6851(90)90140-H; ARNOT DE, 1988, P NATL ACAD SCI USA, V85, P8102, DOI 10.1073/pnas.85.21.8102; COATNEY GR, 1971, AM J TROP MED HYG, V20, P795, DOI 10.4269/ajtmh.1971.20.795; Coatney GR, 1971, PRIMATE MALARIAS; DELACRUZ VF, 1987, J BIOL CHEM, V262, P11935; Dissanaike A. S., 1965, Ceylon Journal of Medical Science, V14, P27; GALINSKI MR, 1987, CELL, V48, P311, DOI 10.1016/0092-8674(87)90434-X; KAIN KC, 1991, J INFECT DIS, V164, P208, DOI 10.1093/infdis/164.1.208; LAL AA, 1988, J BIOL CHEM, V263, P5495; LAL AA, 1988, MOL BIOCHEM PARASIT, V30, P291, DOI 10.1016/0166-6851(88)90099-0; LAL AA, 1991, J BIOL CHEM, V266, P6686; LOCKYER MJ, 1991, MOL BIOCHEM PARASIT, V45, P179, DOI 10.1016/0166-6851(91)90041-4; LOCKYER MJ, 1987, MOL BIOCHEM PARASIT, V22, P101, DOI 10.1016/0166-6851(87)90073-9; MCCUTCHAN TF, 1992, MOL BIOCHEM PARASIT, V50, P37, DOI 10.1016/0166-6851(92)90242-C; MCCUTCHAN TF, 1985, SCIENCE, V230, P1381, DOI 10.1126/science.2416057; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; OZAKI LS, STRUCTURE PLASMODIUM; QARI SH, 1992, MOL BIOCHEM PARASIT, V55, P105, DOI 10.1016/0166-6851(92)90131-3; QARI SH, 1991, J BIOL CHEM, V266, P16297; ROSENBERG R, 1989, SCIENCE, V245, P973, DOI 10.1126/science.2672336; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHI YP, 1992, AM J TROP MED HYG, V47, P844, DOI 10.4269/ajtmh.1992.47.844; WATERS AP, 1989, LANCET, V1, P1343; YOSHIDA N, 1990, EXP PARASITOL, V71, P386, DOI 10.1016/0014-4894(90)90064-J	25	73	73	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	1993	341	8848					780	783		10.1016/0140-6736(93)90559-Y	http://dx.doi.org/10.1016/0140-6736(93)90559-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8095999				2022-12-24	WOS:A1993KU90000003
J	MURCH, SH; MACDONALD, TT; WALKERSMITH, JA; LEVIN, M; LIONETTI, P; KLEIN, NJ				MURCH, SH; MACDONALD, TT; WALKERSMITH, JA; LEVIN, M; LIONETTI, P; KLEIN, NJ			DISRUPTION OF SULFATED GLYCOSAMINOGLYCANS IN INTESTINAL INFLAMMATION	LANCET			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; CONNECTIVE-TISSUE POLYSACCHARIDES; HEPARAN-SULFATE; CROHNS-DISEASE; ULCERATIVE-COLITIS; LYMPHOCYTES-T; ENDOGLYCOSIDASE; MUCOSUBSTANCES; PATHOGENESIS; ALBUMIN	We have studied the distribution and nature of sulphated glycosaminoglycans (GAGs) within normal and inflamed intestine. There is increasing evidence that these negatively charged polysaccharides, which both regulate the ability of albumin to leave the vasculature and inhibit thrombosis, may be affected by inflammatory cells and their products. We obtained samples of freshly resected intestinal tissue from eight controls, eleven patients with Crohn's disease, and six with ulcerative colitis. Sulphated GAGs were detected by means of a gold-conjugated poly-L-lysine probe, and the tissue density of anionic sites was assessed semiquantitatively by means of a Lennox graticule. In normal intestine there was staining in the vascular endothelium and the subepithelial basal lamina and throughout the extracellular matrix of the lamina propria and submucosa. Tissue from the patients with inflammatory bowel disease showed inflammation macroscopically and on histology. There were profound abnormalities of extracellular matrix GAGs, limited to the mucosa in ulcerative colitis and greatest in the submucosa in Crohn's disease. There was also substantial loss of GAGs from the subepithelial basal lamina in both disorders and from the vascular endothelium in submucosa in Crohn's disease. The extent of local GAG disruption was associated with the distribution of macrophages immunoreactive for tumour necrosis factor alpha and the activation marker RM 3/1. We suggest that inflammatory disruption of vascular and connective tissue GAGs may be an important pathogenetic mechanism, contributing to the leakage of protein and fluid, thrombosis, and tissue remodelling seen in inflammatory bowel disease.	ST MARYS HOSP,DEPT CHILD HLTH,LONDON,ENGLAND	Imperial College London	MURCH, SH (corresponding author), ST BARTHOLOMEWS HOSP,DEPT PAEDIAT GASTROENTEROL,LONDON EC1A 7BE,ENGLAND.		Lionetti, Paolo/AAC-2626-2019	Lionetti, Paolo/0000-0001-8029-3904; Klein, Nigel/0000-0003-3925-9258	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEEKEN WL, 1972, GASTROENTEROLOGY, V62, P207; BORN GVR, 1985, BRIT J EXP PATHOL, V66, P543; BRAEGGER CP, 1992, LANCET, V339, P89, DOI 10.1016/0140-6736(92)90999-J; CHOY MY, 1990, GUT, V31, P1365, DOI 10.1136/gut.31.12.1365; COMPER WD, 1978, PHYSIOL REV, V58, P255, DOI 10.1152/physrev.1978.58.1.255; COMPER WD, 1990, BIOCHEM J, V269, P561, DOI 10.1042/bj2690561; EXLEY AR, 1990, LANCET, V335, P1275, DOI 10.1016/0140-6736(90)91337-A; FILIPE MI, 1970, GUT, V11, P229, DOI 10.1136/gut.11.3.229; FRIDMAN R, 1987, J CELL PHYSIOL, V130, P85, DOI 10.1002/jcp.1041300113; GOTLOIB L, 1988, RESUSCITATION, V16, P179, DOI 10.1016/0300-9572(88)90045-7; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLEIN NJ, 1992, J CELL SCI, V102, P821; KLEIN NJ, 1993, HISTOCHEM J, V25, P291, DOI 10.1007/BF00159120; LEE J C L, 1968, Gastroenterology, V54, P76; LENNOX B, 1975, J CLIN PATHOL, V28, P99, DOI 10.1136/jcp.28.2.99; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MALIK AB, 1989, J INVEST DERMATOL, V93, pS62, DOI 10.1111/1523-1747.ep12581072; MAST BA, 1992, PLAST RECONSTR SURG, V89, P503, DOI 10.1097/00006534-199203000-00019; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; MURCH SH, 1992, LANCET, V339, P381, DOI 10.1016/0140-6736(92)90077-G; NAPARSTEK Y, 1984, NATURE, V310, P241, DOI 10.1038/310241a0; PAPPENHEIMER JR, 1951, AM J PHYSIOL, V167, P13, DOI 10.1152/ajplegacy.1951.167.1.13; POWERS MR, 1989, J CELL PHYSIOL, V141, P558, DOI 10.1002/jcp.1041410314; ROSENZWEIG LJ, 1982, LAB INVEST, V47, P177; SAWYER PN, 1972, B NEW YORK ACAD MED, V48, P235; SHEAHAN DG, 1976, AM J ANAT, V146, P103, DOI 10.1002/aja.1001460202; SMITH JAW, 1988, DISEASES SMALL INTES, P328; SUNERGREN KP, 1987, J APPL PHYSIOL, V63, P1987; WAKEFIELD AJ, 1989, LANCET, V2, P1057	30	141	143	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					711	714		10.1016/0140-6736(93)90485-Y	http://dx.doi.org/10.1016/0140-6736(93)90485-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095623				2022-12-24	WOS:A1993KT36200002
J	ESMONDE, TFG; WILL, RG; SLATTERY, JM; KNIGHT, R; HARRIESJONES, R; DESILVA, R; MATTHEWS, WB				ESMONDE, TFG; WILL, RG; SLATTERY, JM; KNIGHT, R; HARRIESJONES, R; DESILVA, R; MATTHEWS, WB			CREUTZFELDT-JAKOB DISEASE AND BLOOD-TRANSFUSION	LANCET			English	Note							TRANSMISSION; ENGLAND; WALES	Epidemiological surveillance of Creutzfeldt-Jakob disease (CJD) in the UK identified 21 patients who had received a blood transfusion and 29 who had donated blood, out of a total of 202 definite and probable cases. This frequency of blood transfusion or donation did not differ from that in age and sex matched controls, and the clinical features in patients with a history of blood transfusion were similar to those of classical CJD and clearly distinct from CJD in recipients of human growth hormone. This evidence does not suggest that blood transfusion is a major risk factor for CJD.	WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; UNIV OXFORD, RADCLIFFE INFIRM, DEPT CLIN NEUROL, OXFORD OX2 6HE, ENGLAND; POOLE GEN HOSP, DEPT MED ELDERLY, POOLE, DORSET, ENGLAND	University of Edinburgh; Radcliffe Infirmary; University of Oxford; Poole Hospital								BROWN P, 1992, LANCET, V340, P24, DOI 10.1016/0140-6736(92)92431-E; COUSENS SN, 1990, J NEUROL NEUROSUR PS, V53, P459, DOI 10.1136/jnnp.53.6.459; DOI T, 1991, Nagasaki Igakkai Zasshi, V66, P104; GAJDUSEK D C, 1990, P2289; HARRIESJONES R, 1988, J NEUROL NEUROSUR PS, V51, P1113, DOI 10.1136/jnnp.51.9.1113; MANUELIDIS EE, 1985, LANCET, V2, P896; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; TATEISHI J, 1985, LANCET, V2, P1074; WATKINS AM, 1991, BRIT MED J, V302, P1537, DOI 10.1136/bmj.302.6791.1537	9	140	142	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 23	1993	341	8839					205	207		10.1016/0140-6736(93)90068-R	http://dx.doi.org/10.1016/0140-6736(93)90068-R			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093499				2022-12-24	WOS:A1993KJ21900006
J	MILLER, LC; LYNCH, EA; ISA, S; LOGAN, JW; DINARELLO, CA; STEERE, AC				MILLER, LC; LYNCH, EA; ISA, S; LOGAN, JW; DINARELLO, CA; STEERE, AC			BALANCE OF SYNOVIAL-FLUID IL-1-BETA AND IL-1 RECEPTOR ANTAGONIST AND RECOVERY FROM LYME ARTHRITIS	LANCET			English	Note							MONONUCLEAR-CELLS; INTERLEUKIN-1	Borrelia burgdorferi, the causative agent of Lyme disease, is a potent inducer of interleukin-1beta (IL-1beta), a cytokine implicated in the pathogenesis of inflammatory arthritis. The balance between IL-1 and the IL-1 receptor antagonist (IL-1ra), a naturally occurring inhibitor of IL-1, might influence disease expression. To explore this possibility, we have done a retrospective study that compared the clinical course of Lyme arthritis in 83 patients with concentrations of IL-1beta and IL-1ra in the patients' synovial fluid. Patients with high concentrations of IL-1ra and low concentrations of IL-1beta had rapid resolution of attacks of arthritis, whereas patients with the reverse pattern of cytokine concentrations had long intervals to recovery. Thus, the balance between synovial fluid IL-1beta and IL-1ra concentrations relates to the time to recovery from an episode of Lyme arthritis.	TUFTS UNIV,NEW ENGLAND MED CTR,DEPT MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University	MILLER, LC (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,DEPT PEDIAT,BOSTON,MA 02111, USA.			Steere, Allen/0000-0002-5268-9853				AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; AREND WP, 1990, ARTHRITIS RHEUM-US, V33, P305, DOI 10.1002/art.1780330302; COMINELLI F, 1990, J CLIN INVEST, V86, P972, DOI 10.1172/JCI114799; DINARELLO CA, 1991, BLOOD, V77, P1627; ENDRES S, 1988, CLIN IMMUNOL IMMUNOP, V49, P424, DOI 10.1016/0090-1229(88)90130-4; MILLER LC, 1992, J CLIN INVEST, V90, P906, DOI 10.1172/JCI115966; POUTSIAKA DD, 1991, BLOOD, V78, P1275; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1980, ARTHRITIS RHEUM, V23, P591, DOI 10.1002/art.1780230511; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906	10	166	175	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					146	148		10.1016/0140-6736(93)90006-3	http://dx.doi.org/10.1016/0140-6736(93)90006-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093746				2022-12-24	WOS:A1993KG62700006
J	HERMEKING, H; EICK, D				HERMEKING, H; EICK, D			MEDIATION OF C-MYC-INDUCED APOPTOSIS BY P53	SCIENCE			English	Article							TUMOR-SUPPRESSOR P53; CELL-CYCLE; PROTEIN; GROWTH; GENE; FIBROBLASTS; INDUCTION; BINDING; ANTIGEN; TARGET	The cellular proto-oncogene c-myc is involved in cell proliferation and transformation but is also implicated in the induction of programmed cell death (apoptosis). The same characteristics have been described for the tumor suppressor gene p53, the most commonly mutated gene in human cancer. In quiescent mouse fibroblasts expressing wildtype p53 protein, activation of c-Myc was found to induce apoptosis and cell cycle reentry, preceded by stabilization of p53. In contrast, in quiescent p53-null fibroblasts, activation of c-Myc induced cell cycle reentry but not apoptosis. These results suggest that p53 mediates apoptosis as a safeguard mechanism to prevent cell proliferation induced by oncogene activation.	GSF MUNICH,FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health								ASKEW DS, 1991, ONCOGENE, V6, P1915; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARVEY M, 1993, ONCOGENE, V8, P2457; HERMEKING H, IN PRESS P NATL ACAD; HERMEKING H, UNPUB; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Sambrook J., 1989, MOL CLONING LAB MANU; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649	26	718	731	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2091	2093		10.1126/science.8091232	http://dx.doi.org/10.1126/science.8091232			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091232				2022-12-24	WOS:A1994PJ91200029
J	MURRAY, JC; BUETOW, KH; WEBER, JL; LUDWIGSEN, S; SCHERPBIERHEDDEMA, T; MANION, F; QUILLEN, J; SHEFFIELD, VC; SUNDEN, S; DUYK, GM; WEISSENBACH, J; GYAPAY, G; DIB, C; MORRISSETTE, J; LATHROP, GM; VIGNAL, A; WHITE, R; MATSUNAMI, N; GERKEN, S; MELIS, R; ALBERTSEN, H; PLAETKE, R; ODELBERG, S; WARD, D; DAUSSET, J; COHEN, D; CANN, H				MURRAY, JC; BUETOW, KH; WEBER, JL; LUDWIGSEN, S; SCHERPBIERHEDDEMA, T; MANION, F; QUILLEN, J; SHEFFIELD, VC; SUNDEN, S; DUYK, GM; WEISSENBACH, J; GYAPAY, G; DIB, C; MORRISSETTE, J; LATHROP, GM; VIGNAL, A; WHITE, R; MATSUNAMI, N; GERKEN, S; MELIS, R; ALBERTSEN, H; PLAETKE, R; ODELBERG, S; WARD, D; DAUSSET, J; COHEN, D; CANN, H			A COMPREHENSIVE HUMAN LINKAGE WITH CENTIMORGAN DENSITY	SCIENCE			English	Article							FRAGMENT LENGTH POLYMORPHISMS; POLYMERASE CHAIN-REACTION; HUMAN GENOME; HUMAN DNA; HUNTINGTONS-DISEASE; GEL-ELECTROPHORESIS; MYOTONIC-DYSTROPHY; GENETIC-ANALYSIS; MAP; CEPH	In the last few years there have been rapid advances in developing genetic maps for humans, greatly enhancing our ability to localize and identify genes for inherited disorders. Through the collaborative efforts of three large groups generating microsatellite markers and the efforts of the 110 CEPH collaborators, a comprehensive human linkage map is presented here. consists of 5840 loci, of which 970 are uniquely ordered, covering 4000 centimorgans on the sex-averaged map. Of these loci, 3617 are polymerase chain reaction-formatted short tandem repeat polymorphisms, and another 427 are genes. The map has markers at an average density of 0.7 centimorgan, providing a resource for ready transference to physical maps and achieving one of the first goals of the Human Genome Project-a comprehensive, high-density genetic map.	UNIV IOWA,DEPT PEDIAT,IOWA CITY,IA 52245; UNIV IOWA,DEPT BIOL,IOWA CITY,IA 52245; FOX CHASE CANC CTR,PHILADELPHIA,PA 19111; MARSHFIELD MED RES FDN,MARSHFIELD,WI 54449; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; GENETHON,F-91100 EVRY,FRANCE; CHU LAVAL,LAVAL G1K 7P4,PQ,CANADA; INSERM,F-75010 PARIS,FRANCE; UNIV UTAH,ECCLES INST HUMAN GENET,SALT LAKE CITY,UT; YALE UNIV,DEPT GENET,NEW HAVEN,CT 06510; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE	University of Iowa; University of Iowa; Fox Chase Cancer Center; Harvard University; Harvard Medical School; Laval University; Institut National de la Sante et de la Recherche Medicale (Inserm); Utah System of Higher Education; University of Utah; Yale University			Manion, Frank J./I-9373-2019; Vignal, Alain/I-6253-2017	Manion, Frank J./0000-0003-1030-6348; Vignal, Alain/0000-0002-6797-2125				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; ARNHEIM N, 1985, P NATL ACAD SCI USA, V82, P6970, DOI 10.1073/pnas.82.20.6970; ATTWOOD J, 1994, GENOMICS, V19, P203, DOI 10.1006/geno.1994.1049; BANCHS I, 1994, HUM MUTAT, V3, P365, DOI 10.1002/humu.1380030407; Bell J, 1937, PROC R SOC SER B-BIO, V123, P119, DOI 10.1098/rspb.1937.0046; BOEHNKE M, 1994, AM J HUM GENET, V55, P379; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; BOWCOCK AM, 1993, GENOMICS, V16, P486, DOI 10.1006/geno.1993.1215; BOWCOCK AM, 1992, GENOMICS, V14, P833, DOI 10.1016/S0888-7543(05)80101-6; BROOK JD, 1993, NAT GENET, V3, P279; BUETOW KH, 1991, AM J HUM GENET, V49, P985; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; CARDUCCI C, 1992, BIOTECHNIQUES, V13, P735; CHAKRAVARTI A, 1984, AM J HUM GENET, V36, P1239; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; COOPER DN, 1985, HUM GENET, V69, P201, DOI 10.1007/BF00293024; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DRACOPOLI NC, 1991, GENOMICS, V9, P686, DOI 10.1016/0888-7543(91)90362-I; DUYK GM, 1990, P NATL ACAD SCI USA, V87, P8995, DOI 10.1073/pnas.87.22.8995; ELSTON RC, 1971, HUM HERED, V21, P523, DOI 10.1159/000152448; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731; HASHIMOTO L, 1994, NATURE, V371, P160; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; IMBERT G, 1993, NAT GENET, V4, P72, DOI 10.1038/ng0593-72; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JORDE LB, 1994, AM J HUM GENET, V54, P884; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KEATS BJB, 1981, LINKAGE CHROMOSOME M; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; KWOK P, IN PRESS GENOMICS; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MATERA AG, 1992, HUM MOL GENET, V1, P535, DOI 10.1093/hmg/1.7.535; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MONACO AP, 1985, NATURE, V316, P842, DOI 10.1038/316842a0; MORTON NE, 1955, AM J HUM GENET, V7, P277; MURRAY JC, 1984, P NATL ACAD SCI-BIOL, V81, P3486, DOI 10.1073/pnas.81.11.3486; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; OTT J, 1974, AM J HUM GENET, V26, P588; RICHARDS B, 1993, HUM MOL GENET, V2, P159, DOI 10.1093/hmg/2.2.159; SHERRINGTON R, 1991, AM J HUM GENET, V49, P966; SMEETS HJM, 1989, HUM GENET, V83, P245, DOI 10.1007/BF00285165; SPURR NK, 1992, GENOMICS, V14, P1055, DOI 10.1016/S0888-7543(05)80129-6; THEILMANN J, 1989, J MED GENET, V26, P676, DOI 10.1136/jmg.26.11.676; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WHITE RL, 1990, GENOMICS, V6, P393, DOI 10.1016/0888-7543(90)90469-B; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	66	509	532	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2049	2054		10.1126/science.8091227	http://dx.doi.org/10.1126/science.8091227			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091227				2022-12-24	WOS:A1994PJ91200022
J	TAKAHASHI, H; SNOW, BJ; BHATT, MH; PEPPARD, R; EISEN, A; CALNE, DB				TAKAHASHI, H; SNOW, BJ; BHATT, MH; PEPPARD, R; EISEN, A; CALNE, DB			EVIDENCE FOR A DOPAMINERGIC DEFICIT IN SPORADIC AMYOTROPHIC-LATERAL-SCLEROSIS ON POSITRON EMISSION SCANNING	LANCET			English	Article							ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; HYPOTHESIS; DEMENTIA; DISORDERS; GUAM	Although rare, the chronic neurodegenerative disorders amyotrophic lateral sclerosis (ALS) and idiopathic parkinsonism coexist to a greater degree than expected by chance. This suggests that patients with ALS may have subclinical lesions of the nigrostriatal dopaminergic pathway. To study this hypothesis, we did positron emission tomography with 6-fluorodopa on 16 patients with sporadic ALS and without extrapyramidal disease, and compared the results with age-matched controls. We found a significant progressive fall in 6-fluorodopa uptake with time since diagnosis, and reduced dopaminergic function in 3 patients with ALS of long duration. This supports the hypothesis that ALS and IP may share pathogenesis and, perhaps, aetiology.	UNIV BRITISH COLUMBIA,CTR NEURODEGENERAT DISORDERS,VANCOUVER V6T 1W5,BC,CANADA; UBC,TRIUMF,PET PROGRAM,VANCOUVER,BC,CANADA	University of British Columbia; University of British Columbia				Bhatt, Mohit/0000-0002-5233-3371; Eisen, Andrew/0000-0002-1447-2725				APPEL SH, 1981, ANN NEUROL, V10, P499, DOI 10.1002/ana.410100602; BURROW JNC, 1992, AUST NZ J MED, V22, P469; CALNE DB, 1986, LANCET, V2, P1067, DOI 10.1016/S0140-6736(86)90469-1; CALNE DB, 1992, ANN NEUROL, V32, P799, DOI 10.1002/ana.410320615; EISEN A, 1993, MUSCLE NERVE, V16, P27, DOI 10.1002/mus.880160107; EISEN A, 1992, CAN J NEUROL SCI, V19, P117, DOI 10.1017/S0317167100041482; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; HAMMERSTAD J P, 1991, Neurology, V41, P192; HANSEN L, 1990, NEUROLOGY, V40, P1; HEATHFIELD MT, 1990, NEUROSCI LETT, V110, P216; HUDSON AJ, 1981, BRAIN, V104, P217, DOI 10.1093/brain/104.2.217; JELLINGER K, 1989, PARKINSONISM AGING, P35; MARTIN WRW, 1989, ANN NEUROL, V26, P535, DOI 10.1002/ana.410260407; Mendell J R, 1971, Trans Am Neurol Assoc, V96, P284; PATE BD, 1993, ANN NEUROL, V34, P331, DOI 10.1002/ana.410340306; RODGERSJOHNSON P, 1986, NEUROLOGY, V36, P7, DOI 10.1212/WNL.36.1.7; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROWLAND LP, 1991, AMYOTROPH LATERAL SC, P3; SNOW BJ, 1993, ANN NEUROL, V34, P324, DOI 10.1002/ana.410340304; SNOW BJ, 1990, ARCH NEUROL-CHICAGO, V47, P870, DOI 10.1001/archneur.1990.00530080052010	20	84	88	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1016	1018		10.1016/0140-6736(93)92878-W	http://dx.doi.org/10.1016/0140-6736(93)92878-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105264				2022-12-24	WOS:A1993MD06600009
J	BUKRINSKY, MI; HAGGERTY, S; DEMPSEY, MP; SHAROVA, N; ADZHUBEI, A; SPITZ, L; LEWIS, P; GOLDFARB, D; EMERMAN, M; STEVENSON, M				BUKRINSKY, MI; HAGGERTY, S; DEMPSEY, MP; SHAROVA, N; ADZHUBEI, A; SPITZ, L; LEWIS, P; GOLDFARB, D; EMERMAN, M; STEVENSON, M			A NUCLEAR-LOCALIZATION SIGNAL WITHIN HIV-1 MATRIX PROTEIN THAT GOVERNS INFECTION OF NONDIVIDING CELLS	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY SYNDROME; RETROVIRAL DNA; COMPLEX; GENE; INTEGRATION; MONOCYTES; INVITRO; VIRIONS	PERMISSIVENESS of the host cell to productive infection by onco-retroviruses is cell-cycle dependent1, and nuclear localization of viral nucleoprotein preintegration complexes will occur only after cells have passed through mitosis2. In contrast, establishment of an integrated provirus after infection by the lentivirus HIV-1 is independent of host cell proliferation3-5. The ability of HIV-1 to replicate in non-dividing cells is partly accounted for by the karvophilic properties of the viral preintegration complex which, after virus infection, is actively transported to the host cell nucleus. Here we report that the gag matrix protein of HIV-1 contains a nuclear localization sequence which, when conjugated to a heterologous protein, directs its nuclear import. In addition, HIV-1 mutants containing amino-acid substitutions in this nuclear localization signal integrate and replicate within dividing but not growth-arrested cells, and thus display a phenotype more representative of an onco-retrovirus.	UNIV NEBRASKA,MED CTR,DEPT PATHOL & MICROBIOL,OMAHA,NE 68198; IMPERIAL CANC RES FUND,BIOMOLEC MODELLING LAB,LONDON WC2A 3PX,ENGLAND; UNIV NEBRASKA,MED CTR,EPPLEY INST RES,OMAHA,NE 68198; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627; FRED HUTCHINSON CANC RES CTR,PROGRAM MOLEC MED,SEATTLE,WA 98104	University of Nebraska System; University of Nebraska Medical Center; Cancer Research UK; University of Nebraska System; University of Nebraska Medical Center; University of Rochester; Fred Hutchinson Cancer Center					NCRR NIH HHS [R01 RR011589] Funding Source: Medline; NIAID NIH HHS [R21 AI127091, R37 AI037475] Funding Source: Medline; NIMH NIH HHS [R01 MH064411, R01 MH093306] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; ELIOPOULOS E, 1982, INT J BIOL MACROMOL, V4, P263, DOI 10.1016/0141-8130(82)90053-8; FARNET CM, 1991, J VIROL, V65, P1990; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GENDELMAN HE, 1986, J VIROL, V58, P67, DOI 10.1128/JVI.58.1.67-74.1986; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; HAASE AT, 1982, VIROLOGY, V119, P399, DOI 10.1016/0042-6822(82)90099-X; HSU WS, 1990, SCIENCE, V250, P1227; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; MEYERS G, 1992, HUMAN RETROVIRUSES A; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; STEVENSON M, 1990, J VIROL, V64, P3792, DOI 10.1128/JVI.64.8.3792-3803.1990; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089	27	709	741	0	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					666	669		10.1038/365666a0	http://dx.doi.org/10.1038/365666a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	8105392	Green Accepted			2022-12-24	WOS:A1993MB84600065
J	MORRISON, PJ				MORRISON, PJ			TRINUCLEOTIDE REPEAT REPEAT REPEAT	LANCET			English	Editorial Material											MORRISON, PJ (corresponding author), NO IRELAND GENET SERV,BELFAST,NORTH IRELAND.							BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MANDEL JL, 1993, NAT GENET, V4, P8, DOI 10.1038/ng0593-8; NELSON DL, 1993, NAT GENET, V4, P107, DOI 10.1038/ng0693-107; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; REIK W, 1993, J MED GENET, V30, P175; SCHALLING M, 1993, NAT GENET, V4, P135, DOI 10.1038/ng0693-135; SHAW DJ, 1993, J MED GENET, V30, P189, DOI 10.1136/jmg.30.3.189; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; 1993, CELL, V72, P971	10	9	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					385	386						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101897				2022-12-24	WOS:A1993LR90000005
J	AUGARTEN, A; KEREM, BS; YAHAV, Y; NOIMAN, S; RIVLIN, Y; TAL, A; BLAU, H; BENTUR, L; SZEINBERG, A; KEREM, E; GAZIT, E				AUGARTEN, A; KEREM, BS; YAHAV, Y; NOIMAN, S; RIVLIN, Y; TAL, A; BLAU, H; BENTUR, L; SZEINBERG, A; KEREM, E; GAZIT, E			MILD CYSTIC-FIBROSIS AND NORMAL OR BORDERLINE SWEAT TEST IN PATIENTS WITH THE 3849+10 KB C-]T MUTATION	LANCET			English	Note							DELTA-F508; DISEASE; GENE	Different mutations in the cystic fibrosis (CF) gene appear to contribute to heterogeneity of the CF phenotype. We investigated 15 patients with CF who have the 3849+10 kb C-->T mutation. All were Ashkenazi Jews. Their clinical features were compared with those of CF patients with the DELTAF508/DELTAF508, W1282X/W1282X, W1282X/DELTAF508 mutations, which are known to be associated with a severe disease. Patients with the 3849+10 kb mutation were older, had been diagnosed as having CF at a more advanced age, and were in a better nutritional state. Sweat chloride values were normal (below 60 mmol/L) in 5 3849+10 kb patients (33%). 4 of these patients and 6 others (total 66%) had normal pancreatic function. However, age-adjusted pulmonary function did not differ between the two groups. None of the patients with 3849+10 kb C-->T had had meconium ileus or had liver disease or diabetes mellitus. We conclude that this mutation is associated with a mild type of CF.	CHAIM SHEBA MED CTR,TISSUE TYPING LAB,IL-52621 TEL HASHOMER,ISRAEL; SOROKA MED CTR,DEPT PAEDIAT,IL-84101 BEER SHEVA,ISRAEL; BEILINSON MED CTR,DEPT PAEDIAT,IL-49100 PETAH TIQWA,ISRAEL; CHAIM SHEBA MED CTR,DEPT PAEDIAT,IL-52621 TEL HASHOMER,ISRAEL; HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT GENET,JERUSALEM,ISRAEL; SHAARE ZEDEK MED CTR,DEPT PAEDIAT,IL-91000 JERUSALEM,ISRAEL; CARMEL HOSP,DEPT PAEDIAT,HAIFA,ISRAEL; RAMBAM MED CTR,DEPT PAEDIAT,HAIFA,ISRAEL	Chaim Sheba Medical Center; Ben Gurion University; Soroka Medical Center; Rabin Medical Center; Chaim Sheba Medical Center; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Clalit Health Services; Carmel Medical Center; Rambam Health Care Campus; Technion Israel Institute of Technology			Tal, Asher/B-4286-2012	Tal, Asher/0000-0002-5670-8804				ABELIOVICH D, 1992, AM J HUM GENET, V51, P951; GIBSON LE, 1959, PEDIATRICS, V23, P545; Highsmith W.E.B.L., 1991, PEDIATR PULM S, V6, p22A; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; SANTIS G, 1990, LANCET, V335, P1426, DOI 10.1016/0140-6736(90)91448-J; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; STRONG TV, 1991, NEW ENGL J MED, V325, P1630, DOI 10.1056/NEJM199112053252307; TSUI LC, 1985, SCIENCE, V230, P145; VEEZE HJ, 1992, PEDIATR PULM S, V8, P239	10	114	116	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					25	26		10.1016/0140-6736(93)91885-P	http://dx.doi.org/10.1016/0140-6736(93)91885-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	8100293				2022-12-24	WOS:A1993LK98500014
J	TARBELL, NJ; GELBER, RD; WEINSTEIN, HJ; MAUCH, P				TARBELL, NJ; GELBER, RD; WEINSTEIN, HJ; MAUCH, P			SEX-DIFFERENCES IN RISK OF 2ND MALIGNANT-TUMORS AFTER HODGKINS-DISEASE IN CHILDHOOD	LANCET			English	Article							CANCER; COMPLICATIONS; IRRADIATION; THERAPY; CHEMOTHERAPY; CHILDREN; LEUKEMIA; LYMPHOMA	There have been reports of a high incidence of second malignant disorders in survivors of Hodgkin's disease. We studied the cumulative incidence of second tumours in 191 children, who were 16 years or younger at diagnosis, with stage IA-IVB Hodgkin's disease, treated at the Joint Center for Radiation Therapy, Boston, between 1969 and 1988. The 10-year actuarial survival was 89 (SE 2)%. The median follow-up time was 11 (range 3-21) years from diagnosis. 109 children were initially treated with radiotherapy alone, 61 received chemotherapy and radiotherapy, and 21 received chemotherapy alone. Second tumours arose in 15 patients 6-20 years after the diagnosis of Hodgkin's disease. The estimated cumulative incidence of second malignant disorders at 1 5 years was 12 (4)% overall. 10 of the second tumours arose among 66 female patients, compared with 5 among 125 male patients (cumulative incidence 24 [9] vs 5 [3]%). The relative risk of a second tumour for female compared with male patients was 4.5 (95% CI 1.4-15.1; p=0.013). For male patients, the observed incidence of second tumours was 18 times that expected for the normal population (95% CI 6-42), whereas for female patients it was 57 times that expected (27-105). 13 of the second malignant disorders were solid tumours, including 4 breast cancers. Thus, the risk of a child treated for Hodgkin's disease developing a second tumour is higher for girls than for boys. The cumulative incidence of second cancers increases from 10 years after treatment. These findings emphasise the importance of continued surveillance in patients treated for Hodgkin's disease.	HARVARD UNIV,SCH PUBL HLTH,DANA FARBER CANC INST,DEPT BIOSTAT,DIV BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	TARBELL, NJ (corresponding author), JOINT CTR RADIAT THERAPY,DEPT RADIAT ONCOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA.				NCI NIH HHS [CA 06516] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006516] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOICE J, 1992, NEW ENGL J MED, V326, P782; COLEMAN CN, 1977, NEW ENGL J MED, V297, P1249, DOI 10.1056/NEJM197712082972303; COX DR, 1972, J R STAT SOC B, V34, P187; COX DR, 1984, ANAL SURVIVAL DATA, P112; DEVITA VT, 1980, ANN INTERN MED, V92, P587, DOI 10.7326/0003-4819-92-5-587; DONALDSON SS, 1987, J CLIN ONCOL, V5, P742, DOI 10.1200/JCO.1987.5.5.742; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Greenwood M., 1926, REPORTS PUBLIC HLTH, V33, P1; Henry-Amar M, 1992, Ann Oncol, V3 Suppl 4, P117; HORNING SJ, 1981, NEW ENGL J MED, V304, P1377, DOI 10.1056/NEJM198106043042301; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P169; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kaplan HS, 1980, HODGKINS DISEASE, P281; KUSHNER BH, 1988, CANCER-AM CANCER SOC, V62, P1364, DOI 10.1002/1097-0142(19881001)62:7<1364::AID-CNCR2820620721>3.0.CO;2-T; LI FP, 1983, CANCER, V51, P521, DOI 10.1002/1097-0142(19830201)51:3<521::AID-CNCR2820510325>3.0.CO;2-U; MAUCH P, 1978, CANCER-AM CANCER SOC, V42, P1039, DOI 10.1002/1097-0142(197809)42:3<1039::AID-CNCR2820420302>3.0.CO;2-R; MAUCH P, 1988, J CLIN ONCOL, V6, P1576, DOI 10.1200/JCO.1988.6.10.1576; MAUCH PM, 1983, CANCER-AM CANCER SOC, V51, P925, DOI 10.1002/1097-0142(19830301)51:5<925::AID-CNCR2820510527>3.0.CO;2-O; MEADOWS AT, 1989, MED PEDIATR ONCOL, V17, P477; MEFFERD JM, 1989, INT J RADIAT ONCOL, V16, P679, DOI 10.1016/0360-3016(89)90485-9; MILLER AB, 1989, NEW ENGL J MED, V321, P1285, DOI 10.1056/NEJM198911093211902; RODRIGUEZ M, IN PRESS ANN ONCOL; SHERINS RJ, 1973, ANN INTERN MED, V79, P216, DOI 10.7326/0003-4819-79-2-216; TARBELL NJ, 1990, INT J RADIAT ONCOL, V18, P275, DOI 10.1016/0360-3016(90)90089-3; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VALAGUSSA P, 1986, J CLIN ONCOL, V4, P830, DOI 10.1200/JCO.1986.4.6.830; VANLEEUWEN FE, 1989, J CLIN ONCOL, V7, P1046, DOI 10.1200/JCO.1989.7.8.1046; VANRIJSWIJK REN, 1987, J CLIN ONCOL, V5, P1624, DOI 10.1200/JCO.1987.5.10.1624; 1981, NCI MONOGR, V57; [No title captured]	30	56	57	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 5	1993	341	8858					1428	1430		10.1016/0140-6736(93)90880-P	http://dx.doi.org/10.1016/0140-6736(93)90880-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099139				2022-12-24	WOS:A1993LF84100002
J	LOBO, RA				LOBO, RA			HORMONE REPLACEMENT THERAPY - ESTROGEN REPLACEMENT AFTER TREATMENT FOR BREAST-CANCER	LANCET			English	Editorial Material							ESTROGEN; WOMEN				LOBO, RA (corresponding author), UNIV SO CALIF,SCH MED,DIV REPROD ENDOCRINOL & INFERTIL,LOS ANGELES,CA 90033, USA.							BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; DARBRE PD, 1990, J STEROID BIOCHEM, V37, P753, DOI 10.1016/0960-0760(90)90416-I; EDEN JA, 1992, MED J AUSTRALIA, V157, P247, DOI 10.5694/j.1326-5377.1992.tb137129.x; EDEN JA, 1992, MED J AUSTRALIA, V157, P175, DOI 10.5694/j.1326-5377.1992.tb137081.x; LOBO RA, 1991, J CLIN ENDOCR METAB, V73, P925, DOI 10.1210/jcem-73-5-925; ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355; Spicer D, 1990, Oncology (Williston Park), V4, P49; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STOLL BA, 1989, EUR J CANCER CLIN ON, V25, P1909, DOI 10.1016/0277-5379(89)90372-6; VASSILOPOULOUSELLIN R, 1992, AM J MED SCI, V304, P145, DOI 10.1097/00000441-199209000-00001; 1991, TECHNICAL B AM COLLE, V158	11	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 22	1993	341	8856					1313	1314		10.1016/0140-6736(93)90820-7	http://dx.doi.org/10.1016/0140-6736(93)90820-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098453				2022-12-24	WOS:A1993LD25300008
J	GRAY, D; KEATING, NA; MURDOCK, J; SKENE, AM; HAMPTON, JR				GRAY, D; KEATING, NA; MURDOCK, J; SKENE, AM; HAMPTON, JR			IMPACT OF HOSPITAL THROMBOLYSIS POLICY ON OUT-OF-HOSPITAL RESPONSE TO SUSPECTED MYOCARDIAL-INFARCTION	LANCET			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; TRIAL; EDUCATION; PATIENT; DELAY	The treatment of acute myocardial infarction changed when several trials reported that thrombolytic agents given within a few hours of infarction improved outcome. We present data from the Nottingham Heart Attack Register comparing 1982-84, when thrombolysis was not available, and 1989-90, when it was hospital policy to give thrombolysis to all patients who arrived within 6 hours of the onset of symptoms, in the absence of a specific contraindication. The number of patients referred with symptoms suggestive of acute myocardial infarction increased by 75% from 1982 to 1990; a diagnosis of ''possible infarction'' was made in about half of all patients in 1982-84 and 23% in 1989-90. Our current thrombolytic policy has had little impact on patient and general practitioner (GP) behaviour. The GP was contacted by most patients. The median time between the onset of a patient's symptoms and admission to hospital when the GP was involved was 229 min in 1 982-84 and 21 0 min in 1989-90; when he was not involved in arranging the admission median times to admission were 89 min and 75 min, respectively. By 6 hours from symptom onset, 60% of patients had been admitted; by 12 hours, about 70% were in hospital and by 24 hours, 80%. Of 7855 patients admitted with suspected acute myocardial infarction in 1989-90, 4465 were admitted within 6 hours of symptom onset. Of these, 736 (16%) patients received a thrombolytic drug, 389 (9%) patients had a specific, documented contraindication to thrombolysis. Although we estimate that the policy has saved about 8 lives per year, it is not surprising that there has been no improvement in overall case fatality after myocardial infarction.	UNIV NOTTINGHAM, DEPT MATH, BRITISH HEART FDN, CARDIOVASC STAT UNIT, NOTTINGHAM NG7 2RD, ENGLAND	University of Nottingham	GRAY, D (corresponding author), UNIV NOTTINGHAM HOSP, QUEENS MED CTR, DIV CARDIOVASC MED, NOTTINGHAM NG7 2UH, ENGLAND.							ALTHOUSE R, 1990, AM J CARDIOL, V66, P1298, DOI 10.1016/0002-9149(90)91157-2; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; ARMSTRONG A, 1972, BRIT HEART J, V34, P67; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; BOSSAERT L, 1991, EUR HEART J, V12, P965; BOUTEN MJM, 1992, EUR HEART J, V13, P925, DOI 10.1093/oxfordjournals.eurheartj.a060294; BRUGEMANN J, 1992, EUR HEART J, V13, P787; CHAMBERLAIN DA, 1988, LANCET, V1, P545; HERLITZ J, 1989, AM J CARDIOL, V64, P90, DOI 10.1016/0002-9149(89)90659-0; HO MT, 1989, ANN EMERG MED, V18, P727, DOI 10.1016/S0196-0644(89)80004-6; JAGGER JD, 1987, LANCET, V1, P34; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; OROURKE MF, 1989, THROMBOLYSIS CARDIOV, P302; PELL ACH, 1992, BMJ-BRIT MED J, V304, P83, DOI 10.1136/bmj.304.6819.83; RAWLES JM, 1988, BRIT MED J, V296, P882, DOI 10.1136/bmj.296.6626.882; ROWLEY JM, 1992, BRIT HEART J, V67, P255; ROWLEY JM, 1982, BRIT MED J, V284, P1741, DOI 10.1136/bmj.284.6331.1741; SCHOFER J, 1990, AM J CARDIOL, V66, P1429, DOI 10.1016/0002-9149(90)90528-9; WILCOX RG, 1988, LANCET, V2, P525; WILCOX RG, 1992, 14TH C EUR SOC CARD, P2429; 1987, REV FED ARG CARDIOL, V16, P238	22	47	47	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	1993	341	8846					654	657		10.1016/0140-6736(93)90420-L	http://dx.doi.org/10.1016/0140-6736(93)90420-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095570				2022-12-24	WOS:A1993KR61300004
J	ALMOHANA, JMA; LOWE, GDO; MURRAY, GD; BURNS, HG				ALMOHANA, JMA; LOWE, GDO; MURRAY, GD; BURNS, HG			ASSOCIATION OF FIBRINOLYTIC TESTS WITH OUTCOME OF ACUTE UPPER-GASTROINTESTINAL-TRACT BLEEDING	LANCET			English	Article							HEMORRHAGE	Endogenous fibrinolysis may play a part in acute upper-gastrointestinal-tract bleeding by causing digestion of haemostatic plugs. We assessed the predictive value of fibrinolytic tests for hospital outcome in a prospective study of 122 patients with acute upper-gastrointestinal-tract bleeding who Underwent endoscopy. Serum fibrin degradation products (FDP) were above the normal range in 32% (95% CI 21-44%) of patients who survived and did not require transfusion or surgery, in 53% (37-69%) of patients who survived without surgery but required transfusion, and in 100% (82-100%) of patients who required surgery or died. Multivariate analysis showed that after adjustment for the effects of established risk factors (age, pulse rate, blood pressure, haemoglobin, site of bleeding, and stigmata of active bleeding at endoscopy), serum FDP was a powerful independent predictor of outcome (p=0.003). Doubling of serum FDP was associated with a 59% increase in the risk of a poor outcome (95% CI 14-120%). These findings are consistent with roles for endogenous fibrinolysis in gastrointestinal-tract bleeding, for fibrinolytic tests in prediction of adverse outcome, and for fibrinolytic inhibitors in treatment.	UNIV GLASGOW,ROYAL INFIRM,DEPT SURG,GLASGOW G31 2ER,SCOTLAND; UNIV GLASGOW,ROYAL INFIRM,DEPT MED,GLASGOW G31 2ER,SCOTLAND	Royal Infirmary of Edinburgh; University of Glasgow; Royal Infirmary of Edinburgh; University of Glasgow				Murray, Gordon/0000-0001-9866-4734				BERTAGLIA E, 1983, HAEMOSTASIS, V13, P328; BOOTH NA, 1991, BLOOD COAGULATION HA, P115; ELMS MJ, 1983, THROMB HAEMOSTASIS, V50, P591; HARRIS DCH, 1982, MED J AUSTRALIA, V2, P35, DOI 10.5694/j.1326-5377.1982.tb124207.x; HAVERKATE F, 1974, HAEMOSTASIS, V1, P55; HENRY DA, 1989, BMJ-BRIT MED J, V298, P1142, DOI 10.1136/bmj.298.6681.1142; LANGMAN MJS, 1985, GUT, V26, P217, DOI 10.1136/gut.26.3.217; LOWE GDO, 1980, BLOOD COAGULATION HA, P222; LOWE GDO, 1991, BLOOD COAGULATION HA, P177; MACLEOD IA, 1982, BRIT J SURG, V69, P256, DOI 10.1002/bjs.1800690509; NIEUWENHUIZEN W, 1991, BLOOD COAGULATION HA, P151; POLLER L, 1979, J CLIN PATHOL S, V14, P63; STOREY DW, 1981, NEW ENGL J MED, V305, P915, DOI 10.1056/NEJM198110153051603	13	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					518	521		10.1016/0140-6736(93)90278-O	http://dx.doi.org/10.1016/0140-6736(93)90278-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094771				2022-12-24	WOS:A1993KP08300004
J	MILLER, WR				MILLER, WR			HORMONAL FACTORS AND RISK OF BREAST-CANCER	LANCET			English	Editorial Material													Miller, William/AAY-5398-2020					ANBAZHAGAN R, 1992, LANCET, V339, P1056; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; KVALE G, 1987, AM J EPIDEMIOL, V126, P842, DOI 10.1093/oxfordjournals.aje.a114721; SANDSON TA, 1992, LANCET, V339, P523, DOI 10.1016/0140-6736(92)90341-Y; TRICHOPOULOS D, 1972, JNCI-J NATL CANCER I, V48, P605; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z; VESSEY MP, 1989, P ROY SOC EDINB B, V95, P35, DOI 10.1017/S0269727000010538	7	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					25	26		10.1016/0140-6736(93)92489-G	http://dx.doi.org/10.1016/0140-6736(93)92489-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093272				2022-12-24	WOS:A1993KF02700011
J	GUILLEMOT, F; NAGY, A; AUERBACH, A; ROSSANT, J; JOYNER, AL				GUILLEMOT, F; NAGY, A; AUERBACH, A; ROSSANT, J; JOYNER, AL			ESSENTIAL ROLE OF MASH-2 IN EXTRAEMBRYONIC DEVELOPMENT	NATURE			English	Article							EMBRYONIC STEM-CELLS; SCUTE GENE-COMPLEX; NERVOUS-SYSTEM; MOUSE	THE outer layer of the blastocyst, or trophectoderm, is the first cell lineage to differentiate in the mouse embryo(1,2), but little is known about the genetic control of its development. Lineage-specific transcription factors may be important in lineage specification, and the product of the Mash-2 gene(3,4) fulfils the criteria for such a factor. Mash-2 is a mammalian member of the achaete-scute family(5-7) which encodes basic-helix-loop-helix transcription factors(8) and is strongly expressed in the extraembryonic trophoblast lineage. Mash-2 transcripts are found in the female germ line and in the embryo throughout preimplantation development, but are highly expressed later only in the ectoplacental cone, the chorion and their derivatives in the placenta. Mash-2 transcripts are not found in primary and secondary giant cells, yolk sac or allantois at any post-implantation stage, and are present only transiently and at low levels in the embryo during gastrulation. To analyse the role of Mash-2 in development, we have used gene targeting to generate mice having no Mash-2 function. We report here that Mash-2(-1-) embryos die from placental failure at 10 days postcoitum. In mutant placentas, spongiotrophoblast cells and their precursors are absent and chorionic ectoderm is reduced. We have rescued this placental mutant phenotype by constructing chimaeras with tetraploid wild-type embryos which contribute almost exclusively to extraembryonic tissues(9,10). Mash-2(-1-) embryos developed normally and adult Mash-2(-1-) mice were viable, demonstrating that Mash-2 has no major role in the embryo itself. Mash-2 is the first transcription factor shown to play a critical part in the development of the mammalian trophoblast lineage.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO M5G 1X5,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Guillemot, Francois/AAV-1482-2021; Nagy, Andras/G-6465-2013	Nagy, Andras/0000-0003-4311-0413				CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; COLOSI P, 1988, MOL ENDOCRINOL, V2, P579, DOI 10.1210/mend-2-6-579; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FINNERTY H, 1993, ONCOGENE, V8, P2293; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KAUFMAN MH, 1983, BIOL TROPHOBLAST, P23; LESCISIN KR, 1989, GENE DEV, V2, P1639; LINZER DIH, 1985, P NATL ACAD SCI USA, V82, P4356, DOI 10.1073/pnas.82.13.4356; MANO H, 1990, ONCOGENE, V5, P1781; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORRE C, 1989, CELL, V56, P777; NAGY A, 1990, DEVELOPMENT, V110, P815; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; Rossant J., 1986, EXPT APPROACHES MAMM, P97; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WURST W, 1993, GENE TARGETING PRACT, P31	20	503	516	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					333	336		10.1038/371333a0	http://dx.doi.org/10.1038/371333a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	8090202				2022-12-24	WOS:A1994PH25400052
J	MASKELL, K; MINTZER, IM; CALLANDER, BA				MASKELL, K; MINTZER, IM; CALLANDER, BA			BASIC SCIENCE OF CLIMATE-CHANGE	LANCET			English	Article									UNIV MARYLAND,STOCKHOLM ENVIRONM INST,COLL PK,MD 20742; UNIV MARYLAND,CTR GLOBAL CHANGE,COLL PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	MASKELL, K (corresponding author), METEOROL OFF,HADLEY CTR,INTERGOVT PANEL CLIMATE CHANGE TECH SUPPORT UNIT,BRACKNELL RG12 2SY,ENGLAND.							DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Houghton J.T., 1992, CLIMATE CHANGE 1992; Intergovernmental Panel on Climate Change, 1990, IPCC 1 ASS REP POL S, P63; MURPHY JM, 1992, 32 HADL CTR CLIM RES; WJMcG Tegart, 1990, CLIMATE CHANGE IPCC, DOI Australian Government Publishing Service	5	16	19	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1027	1031		10.1016/0140-6736(93)92883-U	http://dx.doi.org/10.1016/0140-6736(93)92883-U			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105268				2022-12-24	WOS:A1993MD06600014
J	MERTENS, TE				MERTENS, TE			ESTIMATING THE EFFECTS OF MISCLASSIFICATION	LANCET			English	Article							RELATIVE RISK; CORRELATED EXPOSURES; BIAS		WHO,GLOBAL PROGRAMME AIDS,CH-1211 GENEVA 27,SWITZERLAND	World Health Organization				Mertens, Thierry Eric/0000-0002-1593-6608				[Anonymous], 1988, BMJ, V297, P319; BENNETT KJ, 1987, JAMA-J AM MED ASSOC, V257, P2451, DOI 10.1001/jama.257.18.2451; COPELAND KT, 1977, AM J EPIDEMIOL, V105, P488, DOI 10.1093/oxfordjournals.aje.a112408; CURTIS V, 1993, B WORLD HEALTH ORGAN, V71, P20; DEKLERK NH, 1989, INT J EPIDEMIOL, V18, P705, DOI 10.1093/ije/18.3.705; DUFFY SW, 1989, STAT MED, V8, P1529, DOI 10.1002/sim.4780081213; FINK AJ, 1989, J ROY SOC MED, V82, P695, DOI 10.1177/014107688908201132; FULLER WA, 1978, J AM STAT ASSOC, V73, P99, DOI 10.2307/2286529; GREENLAND S, 1985, AM J EPIDEMIOL, V122, P495, DOI 10.1093/oxfordjournals.aje.a114131; LILIENFELD AM, 1958, J NATL CANCER I, V27, P713; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MERTENS TE, 1990, TROP MED PARASITOL, V41, P79; PHILLIPS AN, 1992, STAT MED, V11, P953, DOI 10.1002/sim.4780110712; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; SILVERMAN WA, 1985, HUMAN EXPT GUIDED ST; SMITH GD, 1992, LANCET, V340, P709; SURICK I, 1989, 5 INT C AIDS MONTR; TZONOU A, 1986, REV EPIDEMIOL SANTE, V34, P10	18	62	63	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					418	421		10.1016/0140-6736(93)92820-J	http://dx.doi.org/10.1016/0140-6736(93)92820-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101908				2022-12-24	WOS:A1993LR90000016
J	HILGARTNER, MW; BUCKLEY, JD; OPERSKALSKI, EA; PIKE, MC; MOSLEY, JW				HILGARTNER, MW; BUCKLEY, JD; OPERSKALSKI, EA; PIKE, MC; MOSLEY, JW			PURITY OF FACTOR-VIII CONCENTRATES AND SERIAL CD4 COUNTS	LANCET			English	Note							INFECTED HEMOPHILIACS	Whether expensive high-purity factor VIII concentrates are required to slow CD4 decline in HIV-infected haemophiliacs is controversial. We examined CD4 counts among such cases treated with intermediate-purity and high-purity factor VIII. 36 subjects treated with high-purity concentrate for 6 months or more had a smaller decline in CD4 than 72 matched controls on intermediate-purity concentrate (two-sided p=0.08). In a more complex analysis with 226 subjects, CD4 counts declined 3% less per 6 months with high-purity material than with intermediate product (p=0.04). Thus concentrate purity may affect rate of CD4 change.	CORNELL UNIV,NEW YORK HOSP CTR,NEW YORK,NY 10021; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033	Cornell University; University of Southern California					NHLBI NIH HHS [N01-HB-9-7074, N01-HB-4-7003] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB047003, N01HB097074] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CASH JD, 1991, BRIT MED J, V303, P633, DOI 10.1136/bmj.303.6803.633; DEBIASI R, 1991, BLOOD, V78, P1919; FLETCHER MA, 1992, BLOOD, V80, P831; FLETCHER MA, 1989, CLIN IMMUNOL IMMUNOP, V52, P38, DOI 10.1016/0090-1229(89)90191-8; GOLDSMITH JM, 1991, THROMB HAEMOSTASIS, V66, P415; GOMPERTS E D, 1992, Transfusion Medicine Reviews, V6, P44, DOI 10.1016/S0887-7963(92)70155-2; LAIRD NM, 1992, BIOMETRICS, V38, P963; MANNUCCI PM, 1992, THROMB HAEMOSTASIS, V67, P310; MAYNE EE, 1992, BRIT MED J, V304, P319, DOI 10.1136/bmj.304.6822.319-b; MENITOVE JE, 1983, NEW ENGL J MED, V308, P83, DOI 10.1056/NEJM198301133080206	10	40	40	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 29	1993	341	8857					1373	1374		10.1016/0140-6736(93)90943-B	http://dx.doi.org/10.1016/0140-6736(93)90943-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE180	8098792				2022-12-24	WOS:A1993LE18000006
J	STEEL, M				STEEL, M			CELL-DIFFERENTIATION - NEW LIGHT ON G-PROTEINS	LANCET			English	Editorial Material											STEEL, M (corresponding author), WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							HELPER JR, 1992, TRENDS BIOCHEM SCI, V17, P383; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; 1990, LANCET, V336, P1291	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1187	1188		10.1016/0140-6736(93)91010-J	http://dx.doi.org/10.1016/0140-6736(93)91010-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098083				2022-12-24	WOS:A1993LB01700012
J	SAUER, MV; PAULSON, RJ; LOBO, RA				SAUER, MV; PAULSON, RJ; LOBO, RA			PREGNANCY AFTER AGE 50 - APPLICATION OF OOCYTE DONATION TO WOMEN AFTER NATURAL MENOPAUSE	LANCET			English	Article							OVARIAN FAILURE; FERTILITY	The age at which the uterus no longer provides a receptive environment for embryo implantation and development remains unknown. We assessed whether menopausal women between the ages of 50 and 59 years could be prepared for pregnancy with oocyte donation. All potential recipients underwent extensive screening to ensure that they were in excellent physical, reproductive, and psychological health before enrolment. Of 18 patients initially screened (mean [SD] age 52.2 years [2.5]), 14 couples were entered into the study. Oocytes were donated by fertile women (28.1 [2.7] years) who provided gametes after pituitary downregulation with leuprolide acetate and routine ovarian hyperstimulation by human menopausal gonadotropin. 22 donor follicle aspirations resulted in 21 embryo transfers to 14 recipients. Pregnancies were established in 9 women. 1 pregnancy ended in a preclinical loss. The ratio of clinical pregnancies per transfer attempt was 38% (8/21), with an implantation rate per transferred embryo of 19%. Of the 8 clinical pregnancies, 1 spontaneous abortion occurred at 7 weeks' gestation. 3 women have delivered, 2 at 35 weeks' by emergency caesarean section for worsening preeclampsia and 1 at 37 weeks' after a normal vaginal birth. 4 pregnancies continue to progress normally beyond the second trimester. Women may become pregnant after the age of natural menopause by means of in-vitro fertilisation of donated oocytes. However, thorough medical screening before embryo transfer is essential to reduce to a minimum obstetric risks common in this older population.	UNIV SO CALIF, DEPT OBSTET & GYNECOL, DIV REPROD ENDOCRINOL, LOS ANGELES, CA 90089 USA	University of Southern California								BUEHLER JW, 1986, JAMA-J AM MED ASSOC, V255, P53, DOI 10.1001/jama.255.1.53; CNATTINGIUS S, 1992, JAMA-J AM MED ASSOC, V268, P886; HOLINKA CF, 1979, BIOL REPROD, V20, P1201, DOI 10.1095/biolreprod20.5.1201; MAROULIS GB, 1991, SEMIN REPROD ENDOCR, V9, P165, DOI 10.1055/s-2007-1019407; NAVOT D, 1991, LANCET, V337, P1375, DOI 10.1016/0140-6736(91)93060-M; PAULSON RJ, 1992, FERTIL STERIL, V58, P551; SAUER MV, 1992, JAMA-J AM MED ASSOC, V268, P1275, DOI 10.1001/jama.268.10.1275; SAUER MV, 1992, FERTIL STERIL, V58, P16; SAUER MV, 1991, INT J GYNECOL OBSTET, V35, P61, DOI 10.1016/0020-7292(91)90065-D; SAUER MV, 1989, FERTIL STERIL, V52, P433; SAUER MV, 1991, FERTIL STERIL, V55, P39; SAUER MV, 1992, HUM REPROD, V7, P726, DOI 10.1093/oxfordjournals.humrep.a137726; SAUER MV, 1990, NEW ENGL J MED, V323, P1157, DOI 10.1056/NEJM199010253231702; SAUER MV, 1991, GYNECOL OBSTET INVES, V32, P118, DOI 10.1159/000293009; SAUER MV, 1992, 39TH ANN M SOC GYN I; SERHAL PF, 1989, LANCET, V1, P1185; STENE J, 1977, ANN HUM GENET, V40, P299, DOI 10.1111/j.1469-1809.1977.tb00194.x	17	127	130	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 6	1993	341	8841					321	323		10.1016/0140-6736(93)90132-Z	http://dx.doi.org/10.1016/0140-6736(93)90132-Z			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094110				2022-12-24	WOS:A1993KK93900001
J	SCHWARER, AP; JIANG, YZ; BROOKES, PA; BARRETT, AJ; BATCHELOR, JR; GOLDMAN, JM; LECHLER, RI				SCHWARER, AP; JIANG, YZ; BROOKES, PA; BARRETT, AJ; BATCHELOR, JR; GOLDMAN, JM; LECHLER, RI			FREQUENCY OF ANTI-RECIPIENT ALLOREACTIVE HELPER T-CELL PRECURSORS IN DONOR BLOOD AND GRAFT-VERSUS-HOST DISEASE AFTER HLA-IDENTICAL SIBLING BONE-MARROW TRANSPLANTATION	LANCET			English	Article							LEUKEMIA; ALLELES; INVIVO	A substantial proportion of patients undergoing allogeneic bone-marrow transplantation (BMT) develop moderate-to-severe acute graft-versus-host disease (GVHD). Anti-recipient helper (interleukin-2-producing) T-lymphocyte precursors (HTLp) have an important role in the control and amplification of the alloreactive immune response that initiates GVHD. We used a limiting dilution assay to measure the frequency of HTLp in the blood of marrow donors for 25 patients undergoing genotypically HLA-identical BMT for chronic myeloid leukaemia (n = 20), acute myeloid leukaemia (4), or thalassaemia (1). HTLp frequencies in donor blood ranged from 1 in 18 x 10(3) to less than 1 in 500 x 10(3); they were significantly higher (p = 0.02) in patients with grade II-IV acute GVHD than in those with grade 0-I GVHD. The HTLp assay seems sufficiently sensitive to detect clinically significant minor histocompatibility antigen differences between the donor and recipient. The assay should prove valuable in selecting the best donor/recipient combination and could indicate the need to intensify GVHD prophylaxis when the only available donor has a high HTLp frequency.	ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,DU CANE RD,LONDON W12 0NN,ENGLAND; ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0HS,ENGLAND	Imperial College London; Imperial College London								BATCHELOR JR, 1991, TRANSPLANT P, V23, P1711; BEATTY PG, 1985, NEW ENGL J MED, V313, P765, DOI 10.1056/NEJM198509263131301; BIDWELL JL, 1988, TRANSPLANTATION, V45, P640, DOI 10.1097/00007890-198803000-00027; BISHOP DK, 1989, TRANSPLANTATION, V47, P671, DOI 10.1097/00007890-198904000-00020; CIVIN CI, 1990, EXP HEMATOL, V18, P461; CLOUSE KA, 1984, J IMMUNOL, V132, P2961; COHEN J, 1988, BONE MARROW TRANSPL, V3, P193; DEGAST GC, 1992, BONE MARROW TRANSPL, V9, P87; DESTGROTH SF, 1982, J IMMUNOL METHODS, V49, pR11, DOI 10.1016/0022-1759(82)90269-1; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; GOLDMAN JM, 1986, NEW ENGL J MED, V314, P202, DOI 10.1056/NEJM198601233140403; GOULMY E, 1991, BONE MARROW TRANSPL, V7, P49; HOWELL WM, 1991, EUR J IMMUNOGENET, V18, P81, DOI 10.1111/j.1744-313X.1991.tb00008.x; IRLE C, 1985, TRANSPLANTATION, V40, P329, DOI 10.1097/00007890-198509000-00021; KAMINSKI E, 1989, TRANSPLANTATION, V48, P608; PANINABORDIGNON P, 1991, SCIENCE, V252, P1548, DOI 10.1126/science.1710827; PERREAULT C, 1990, BLOOD, V76, P1269; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; STORB R, 1990, EUR J CLIN INVEST, V20, P119, DOI 10.1111/j.1365-2362.1990.tb02258.x	21	136	137	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					203	205		10.1016/0140-6736(93)90067-Q	http://dx.doi.org/10.1016/0140-6736(93)90067-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093498				2022-12-24	WOS:A1993KJ21900005
J	KUMAR, L				KUMAR, L			EPIPODOPHYLLOTOXINS AND SECONDARY LEUKEMIA	LANCET			English	Editorial Material							LEUKEMIA; ETOPOSIDE; CISPLATIN; RADIATION; RISK				KUMAR, L (corresponding author), ALL INDIA INST MED SCI,INST ROTARY CANC HOSP,NEW DELHI 110016,INDIA.							AMYLON MD, 1992, BLOOD S, V80, pA206; BAJORIN DF, 1993, J NATL CANCER I, V85, P60, DOI 10.1093/jnci/85.1.60; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HAWKINS MM, 1992, BRIT MED J, V304, P951, DOI 10.1136/bmj.304.6832.951; LEVINE EG, 1992, SEMIN ONCOL, V19, P47; NICHOLS CR, 1993, J NATL CANCER I, V85, P36, DOI 10.1093/jnci/85.1.36; PEDERSENBJERGAARD J, 1991, LANCET, V338, P359, DOI 10.1016/0140-6736(91)90490-G; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RATAIN MJ, 1987, BLOOD, V70, P1412; THACHUK DC, 1992, CELL, V71, P691; WHITLOCK JA, 1991, CANCER, V68, P600, DOI 10.1002/1097-0142(19910801)68:3<600::AID-CNCR2820680326>3.0.CO;2-F; WINICK NJ, 1993, J CLIN ONCOL, V11, P209, DOI 10.1200/JCO.1993.11.2.209	12	31	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					819	820		10.1016/0140-6736(93)92692-M	http://dx.doi.org/10.1016/0140-6736(93)92692-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104269				2022-12-24	WOS:A1993MA02500006
J	PALMER, CR				PALMER, CR			PROBABILITY OF RECURRENCE OF EXTREME DATA - AN AID TO DECISION-MAKING	LANCET			English	Article								Those, such as public health specialists, who have to assess routinely collected data often find it difficult to decide whether or not extreme results are a matter of chance. I describe here a simple method of measuring one's ''degree of surprise'' for noticeable patterns in ranked data, classified by time and place, to help detect significant departures from random variation. A table of exact probability values is the key to this approach. Designed primarily for reviewing post-hoc data, the method is relevant to published ''league tables'' of performance indicators. The table has to be used cautiously and the method is intended as a preliminary screen where data are limited or as a supplement to traditional analyses where there is more. Areas of application include public health, audit, and health services management and performance monitoring.			PALMER, CR (corresponding author), UNIV CAMBRIDGE,INST PUBL HLTH,DEPT COMMUNITY MED,ROBINSON WAY,CAMBRIDGE CB2 2SR,ENGLAND.							Agresti A., 1992, STAT SCI, V7, P131, DOI [10.1214/ss/1177011454, DOI 10.1214/SS/1177011454]; Fisher RA, 1934, STAT METHODS RES WOR, V5; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; Siegel S., 2009, NONPARAMETRIC STAT B, V2nd; 1991, STATXACT STATISTICAL; 1993, LANCET, V341, P1183	7	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					845	847		10.1016/0140-6736(93)92699-T	http://dx.doi.org/10.1016/0140-6736(93)92699-T			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104276				2022-12-24	WOS:A1993MA02500013
J	DALEY, CL				DALEY, CL			TUBERCULOSIS RECURRENCE IN AFRICA - TRUE RELAPSE OR REINFECTION	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS				DALEY, CL (corresponding author), SAN FRANCISCO GEN HOSP, DIV PULM & CRIT CARE MED, SAN FRANCISCO, CA 94110 USA.		Daley, Charles L./AAC-3231-2021					ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; MUKADI Y, 1991, 7 P INT C AIDS FLOR; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503	9	23	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	1993	342	8874					756	757		10.1016/0140-6736(93)91535-T	http://dx.doi.org/10.1016/0140-6736(93)91535-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103871				2022-12-24	WOS:A1993LY86800004
J	JUDSON, IR; THREADGILL, MD				JUDSON, IR; THREADGILL, MD			POLY(ADP-RIBOSYLATION) AS TARGET FOR CANCER-CHEMOTHERAPY	LANCET			English	Editorial Material							INHIBITORS; SYNTHETASE		UNIV BATH,SCH PHARM & PHARMACOL,BATH BA2 7AY,AVON,ENGLAND	University of Bath	JUDSON, IR (corresponding author), INST CANC RES,SUTTON SM2 5PX,SURREY,ENGLAND.		Threadgill, Michael/C-3925-2009					ALDERSON T, 1990, BIOL REV, V65, P623, DOI 10.1111/j.1469-185X.1990.tb01240.x; ALDERSON T, 1993, BIOL REV, V68, P265, DOI 10.1111/j.1469-185X.1993.tb00997.x; BANASIK M, 1992, J BIOL CHEM, V267, P1569; PURNELL MR, 1980, BIOCHEM J, V185, P775, DOI 10.1042/bj1850775; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SUTO MJ, 1991, ANTI-CANCER DRUG DES, V7, P107; SWINNEN LJ, 1989, CANCER RES, V49, P1383; TSENG A, 1987, P NATL ACAD SCI USA, V84, P1107, DOI 10.1073/pnas.84.4.1107; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73	9	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					632	632		10.1016/0140-6736(93)91756-C	http://dx.doi.org/10.1016/0140-6736(93)91756-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103143				2022-12-24	WOS:A1993LX27200007
J	BLASI, J; CHAPMAN, ER; LINK, E; BINZ, T; YAMASAKI, S; DECAMILLI, P; SUDHOF, TC; NIEMANN, H; JAHN, R				BLASI, J; CHAPMAN, ER; LINK, E; BINZ, T; YAMASAKI, S; DECAMILLI, P; SUDHOF, TC; NIEMANN, H; JAHN, R			BOTULINUM NEUROTOXIN-A SELECTIVELY CLEAVES THE SYNAPTIC PROTEIN SNAP-25	NATURE			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; MOTOR-NERVE TERMINALS; MEMBRANE-PROTEIN; CLOSTRIDIAL NEUROTOXINS; SECRETORY PATHWAY; VESICLES; IDENTIFICATION; SYNAPTOBREVIN; EXOCYTOSIS; RECEPTOR	NEUROTRANSMITTER release is potently blocked by a group of structurally related toxin proteins produced by Clostridium botulinum1. Botulinum neurotoxin type B (BoNT/B) and tetanus toxin (TeTx) are zinc-dependent proteases that specifically cleave synaptobrevin (VAMP), a membrane protein of synaptic vesicles2,3. Here we report that inhibition of transmitter release from synaptosomes caused by botulinum neurotoxin A (BoNT/A) is associated with the selective proteolysis of the synaptic protein SNAP-25. Furthermore, isolated or recombinant L chain of BoNT/A cleaves SNAP-25 in vitro. Cleavage occurred near the carboxyterminus and was sensitive to divalent cation chelators. In addition, a glutamate residue in the BoNT/A L chain, presumably required to stabilize a water molecule in the zinc-containing catalytic centre, was required for proteolytic activity. These findings demonstrate that BoNT/A acts as a zinc-dependent protease that selectively cleaves SNAP-25. Thus, a second component of the putative fusion complex mediating synaptic vesicle exocytosis is targeted by a clostridial neurotoxin.	FED RES CTR VIRUS DIS ANIM,INST MICROBIOL,W-7400 TUBINGEN,GERMANY; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED CTR,DALLAS,TX 75235; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; UNIV BARCELONA,SCH MED,DEPT CELL BIOL & PATHOL,BARCELONA 7,SPAIN	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; Yale University; Yale University; Yale University; University of Barcelona			Blasi, Juan/K-7943-2014	Blasi, Juan/0000-0002-0482-9444; Jahn, Reinhard/0000-0003-1542-3498; Chapman, Edwin/0000-0001-9787-8140				BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BINZ T, 1990, J BIOL CHEM, V265, P9153; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CATSICAS S, 1991, P NATL ACAD SCI USA, V88, P785, DOI 10.1073/pnas.88.3.785; CHAPMAN ER, 1992, J BIOL CHEM, V267, P25233; DREYER F, 1987, N-S ARCH PHARMACOL, V335, P1, DOI 10.1007/BF00165027; GANSEL M, 1987, PFLUG ARCH EUR J PHY, V409, P533, DOI 10.1007/BF00583812; HESS DT, 1992, J NEUROSCI, V12, P4634; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; OLMSTEDT JB, 1987, METHOD ENZYMOL, V134, P467; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUGII S, 1975, INFECT IMMUN, V12, P1262, DOI 10.1128/IAI.12.6.1262-1270.1975; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; [No title captured]	30	959	997	2	87	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					160	163		10.1038/365160a0	http://dx.doi.org/10.1038/365160a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8103915				2022-12-24	WOS:A1993LW44200048
J	KUIPERS, EJ; PENA, AS; VANKAMP, G; UYTERLINDE, AM; PALS, G; PELS, NFM; KURZPOHLMANN, E; MEUWISSEN, SGM				KUIPERS, EJ; PENA, AS; VANKAMP, G; UYTERLINDE, AM; PALS, G; PELS, NFM; KURZPOHLMANN, E; MEUWISSEN, SGM			SEROCONVERSION FOR HELICOBACTER-PYLORI	LANCET			English	Article							CAMPYLOBACTER-PYLORIDIS; GASTRIC-CARCINOMA; DUODENAL-ULCER; INFECTION; ERADICATION; ANTIBODY; RISK; SEROLOGY; CHILDREN; HUMANS	The prevalence of Helicobacter pylori antibodies increases with age, but it is unknown whether this is due to a constant rate of infection in different age groups, or whether most infection occurs in childhood. Follow-up data on infection rates and the course of infection in an untreated population are scarce. We measured H pylori IgG antibody concentrations in patients who were seen at our endoscopy unit between 1979 and 1983. 115 of 164 eligible patients (70%) participated in the study. H pylori IgG antibody concentrations were measured in two serum samples taken with a mean interval of 11.5 years. 56 patients tested positive at the first visit. During follow-up, 2 patients became infected (annual infection rate 0.30%, 95% CI 0.04-1.08%). Evidence of infection disappeared in 6 patients: after gastric surgery in 3 and due to an unknown cause in the remaining 3 patients. A non-significant decrease of infection was shown in different age cohorts during follow-up. Antibody concentrations did not increase with age. These results strongly support the concept of dominant infection rates in childhood. Elimination of infection may occur in a few patients without eradication therapy.	FREE UNIV AMSTERDAM HOSP,DEPT CLIN CHEM,1081 HV AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT PATHOL,1081 HV AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT HUMAN GENET,1081 HV AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	KUIPERS, EJ (corresponding author), FREE UNIV AMSTERDAM HOSP,DEPT GASTROENTEROL,DE BOELELAAN 1117,1081 HV AMSTERDAM,NETHERLANDS.		Kuipers, Ernst J/H-3293-2019; Pals, Gerard/A-5198-2011	Kuipers, Ernst J/0000-0002-0633-3098; Pals, Gerard/0000-0003-4091-7115				FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; GEORGE LL, 1990, MED J AUSTRALIA, V153, P145, DOI 10.5694/j.1326-5377.1990.tb136833.x; GOODWIN CS, 1987, J INFECT DIS, V155, P488, DOI 10.1093/infdis/155.3.488; HO SA, 1991, J CLIN MICROBIOL, V29, P2543, DOI 10.1128/JCM.29.11.2543-2549.1991; JONES DM, 1986, J MED MICROBIOL, V22, P57, DOI 10.1099/00222615-22-1-57; KARNES WE, 1991, GASTROENTEROLOGY, V101, P167, DOI 10.1016/0016-5085(91)90474-Y; KOSUNEN TU, 1992, LANCET, V339, P893, DOI 10.1016/0140-6736(92)90929-W; KUIPERS EJ, 1993, SCAND J GASTROENTERO, V28, P433, DOI 10.3109/00365529309098245; KUIPERS EJ, IN PRESS SCAND J GAS; LOFFELD RJLF, 1992, GUT, V33, P1680, DOI 10.1136/gut.33.12.1680; MEYER B, 1991, GUT, V32, P347, DOI 10.1136/gut.32.4.347; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; ODERDA G, 1992, GUT, V33, P1328, DOI 10.1136/gut.33.10.1328; PARSONNET J, 1992, GASTROENTEROLOGY, V102, P41, DOI 10.1016/0016-5085(92)91782-Y; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PENA AS, 1989, DIGESTION, V44, P131, DOI 10.1159/000199902; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SIERRA R, 1992, CANCER EPIDEM BIOMAR, V1, P449; SOBALA GM, 1991, LANCET, V338, P94, DOI 10.1016/0140-6736(91)90085-4; STEER HW, 1987, SERODIAGN IMMUNOTHER, V1, P253; VANZANTEN SV, 1992, GASTROENTEROLOGY, V102, pA184; VEENENDAAL RA, 1991, GUT, V32, P1291, DOI 10.1136/gut.32.11.1291; VEENENDAAL RA, 1992, GUT, V33, P452, DOI 10.1136/gut.33.4.452	24	208	209	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					328	331		10.1016/0140-6736(93)91473-Y	http://dx.doi.org/10.1016/0140-6736(93)91473-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101585				2022-12-24	WOS:A1993LQ86800011
J	FOWKES, FGR; LOWE, GDO; HOUSLEY, E; RATTRAY, A; RUMLEY, A; ELTON, RA; MACGREGOR, IR; DAWES, J				FOWKES, FGR; LOWE, GDO; HOUSLEY, E; RATTRAY, A; RUMLEY, A; ELTON, RA; MACGREGOR, IR; DAWES, J			CROSS-LINKED FIBRIN DEGRADATION PRODUCTS, PROGRESSION OF PERIPHERAL ARTERIAL-DISEASE, AND RISK OF CORONARY HEART-DISEASE	LANCET			English	Note							MYOCARDIAL-INFARCTION	Haemostatic and rheological factors may predict cardiovascular disease. We studied patients with intermittent claudication to see if the progression of peripheral arterial disease and the risks of coronary events could be predicted by baseline packed cell volume, plasma fibrinogen, blood and plasma viscosites, von Willebrand factor antigen, cross-linked fibrin degradation products (XLFDP), urinary fibrinopeptide A, and plasma leucocyte elastase. In 617 patients with claudication followed up for one year, baseline XLFDP was related most strongly to coronary events, relative risk 4.4 (95% CI 1.3-19.0) between top and bottom quintiles. Plasma fibrinogen was the strongest independent predictor of death from coronary disease. XLFDP was the only factor, in addition to age and cigarette smoking, that was independently associated (p = 0.008) with deterioration in peripheral arterial disease. We conclude that, in patients with peripheral arterial disease, plasma concentration of XLFDP, a measure of ongoing fibrin formation and degradation, is a strong predictor of both disease progression and future coronary risk. These results accord with the hypothesis that fibrin formation contributes to progression of coronary and peripheral atherosclerosis.	UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT MED,HAEMOSTASIS & THROMBOSIS UNIT,GLASGOW,SCOTLAND; UNIV EDINBURGH,DEPT PUBL HLTH SCI,MED STAT UNIT,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; SCOTTISH NATL BLOOD TRANSFUS SERV,NATL SCI LAB,EDINBURGH,SCOTLAND; MRC,SCOTTISH NATL BLOOD TRANSFUS SERV,BLOOD COMPONENTS ASSAY GRP,EDINBURGH,SCOTLAND	University of Glasgow; University of Edinburgh	FOWKES, FGR (corresponding author), UNIV EDINBURGH,DEPT PUBL HLTH SCI,WOLFSON UNIT PREVENT PERIFERAL VASC DIS,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							ALZAHRANI H, 1992, CLIN HEMORHEOL, V12, P867; BANERJEE AK, 1992, THROMB HAEMOSTASIS, V68, P261; FOWKES FGR, 1988, J EPIDEMIOL COMMUN H, V42, P128, DOI 10.1136/jech.42.2.128; HAMSTEN A, 1987, LANCET, V2, P3; LOWE GDO, IN PRESS CIRCULATION; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEADE TW, 1991, LANCET, V337, P850; NIEUWENHUIZEN W, 1991, BLOOD COAGULATION HA, P151; SMITH EB, 1990, ARTERIOSCLEROSIS, V10, P263, DOI 10.1161/01.ATV.10.2.263; SMITH FB, IN PRESS ATHEROSCLER; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; 1976, PUBLIC HLTH EUROPE	13	214	217	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					84	86		10.1016/0140-6736(93)91288-W	http://dx.doi.org/10.1016/0140-6736(93)91288-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100915				2022-12-24	WOS:A1993LL78900012
J	TENCATE, JW				TENCATE, JW			THROMBOLYSIS - THROMBOLYTIC TREATMENT OF PULMONARY-EMBOLISM	LANCET			English	Editorial Material											TENCATE, JW (corresponding author), UNIV AMSTERDAM HOSP,DEPT HAEMATOL,AMSTERDAM,NETHERLANDS.							CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; GOLDHABER SZ, 1993, LANCET, V341, P507, DOI 10.1016/0140-6736(93)90274-K; HUISMAN MV, 1989, CHEST, V95, P498, DOI 10.1378/chest.95.3.498; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; KRUIT WHJ, 1991, J INTERN MED, V230, P333, DOI 10.1111/j.1365-2796.1991.tb00453.x; PRADONI P, 1992, LANCET, V339, P441	6	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 22	1993	341	8856					1315	1316		10.1016/0140-6736(93)90822-X	http://dx.doi.org/10.1016/0140-6736(93)90822-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098455				2022-12-24	WOS:A1993LD25300010
J	BOTS, ML; VANSWIETEN, JC; BRETELER, MMB; DEJONG, PTVM; VANGIJN, J; HOFMAN, A; GROBBEE, DE				BOTS, ML; VANSWIETEN, JC; BRETELER, MMB; DEJONG, PTVM; VANGIJN, J; HOFMAN, A; GROBBEE, DE			CEREBRAL WHITE MATTER LESIONS AND ATHEROSCLEROSIS IN THE ROTTERDAM STUDY	LANCET			English	Article							CAROTID-ARTERY; RISK-FACTORS; SIGNAL ABNORMALITIES; NORMAL INDIVIDUALS; WALL THICKNESS; ULTRASOUND; POPULATION; DISEASE; ULTRASONOGRAPHY; DETERMINANTS	Cerebral white matter lesions (WML) seen on magnetic resonance imaging scans are associated with cardiovascular disease and vascular risk factors. To assess the association between WML and atherosclerosis, we studied 111 people, aged 65 to 85 years, randomly sampled, and stratified by age and sex, from participants in the Rotterdam Study. Cerebral T2-weighted magnetic resonance images in the axial plane were obtained for all subjects. Carotid atherosclerosis was ultrasonographically assessed by the presence of stenosis, measurement of intima to media wall thickness (IMT), and the presence of atherosclerotic plaques. A possible or definite myocardial infarction on an electrocardiogram was used as an indicator of coronary atherosclerosis. The ankle to arm systolic blood pressure ratio (ABI) was determined, and peripheral arterial disease was defined as an ABI lower than 0.90 in at least one side. Carotid atherosclerosis was significantly more pronounced in people with WML. The difference in common carotid IMT was 0.13 mm (95% confidence interval [CI] 0.04-0.21), whereas the odds ratio of WML associated with plaques in the carotid bifurcation was 3.9. The degree of internal carotid artery stenosis was not, however, associated with WML. The mean ABI was significantly lower in people with WML than in those without lesions with a difference of -0.11 (95% CI -0.21 to -0.01). The odds ratio of WML associated with peripheral arterial disease and a possible or definite myocardial infarction was 2.4 and 3.1, respectively. We conclude that atherosclerosis, indicated by increased common carotid IMT, carotid plaques, and a lower ABI, is related to WML.	ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS; UNIV UTRECHT HOSP, DEPT NEUROL, 3511 GV UTRECHT, NETHERLANDS; UNIV HOSP DIJKZIGT, DEPT NEUROL, ROTTERDAM, NETHERLANDS; UNIV HOSP DIJKZIGT, DEPT OPHTHALMOL, ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC			Grobbee, Diederick/C-7651-2014; van Gijn, Jan/A-9444-2008; Breteler, Monique M.B./J-5058-2014	Grobbee, Diederick/0000-0003-4472-4468; Breteler, Monique M.B./0000-0002-0626-9305; van Swieten, John/0000-0001-6278-6844				AWAD IA, 1986, STROKE, V17, P1090, DOI 10.1161/01.STR.17.6.1090; BOONE KB, 1992, ARCH NEUROL-CHICAGO, V49, P549, DOI 10.1001/archneur.1992.00530290141024; BOTS ML, 1993, ARTERIOSCLER THROMB, V13, P64, DOI 10.1161/01.ATV.13.1.64; BOTS ML, 1992, HYPERTENSION, V19, P717, DOI 10.1161/01.HYP.19.6.717; BOWEN BC, 1990, AM J NEURORADIOL, V11, P283; BRAFFMAN BH, 1988, AM J ROENTGENOL, V151, P559, DOI 10.2214/ajr.151.3.559; BRETELER MMB, UNPUB CEREBRAL WHITE; FAZEKAS F, 1988, STROKE, V19, P1285, DOI 10.1161/01.STR.19.10.1285; FEUSSNER JR, 1988, ANN INTERN MED, V109, P805, DOI 10.7326/0003-4819-109-10-805; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; GORELICK PB, 1992, STROKE, V23, P804, DOI 10.1161/01.STR.23.6.804; HAAPANEN A, 1989, CIRCULATION, V80, P10, DOI 10.1161/01.CIR.80.1.10; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; HENDRIE HC, 1989, AM J NEURORADIOL, V10, P703; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; HUNT AL, 1989, NEUROLOGY, V39, P1470, DOI 10.1212/WNL.39.11.1470; JUNGQUIST G, 1991, J CLIN EPIDEMIOL, V44, P347, DOI 10.1016/0895-4356(91)90073-I; JUNQUE C, 1990, ARCH NEUROL-CHICAGO, V47, P151, DOI 10.1001/archneur.1990.00530020047013; KAPPELLE LJ, 1988, STROKE, V19, P1093, DOI 10.1161/01.STR.19.9.1093; KERTESZ A, 1988, ARCH NEUROL-CHICAGO, V45, P404, DOI 10.1001/archneur.1988.00520280050015; LECHNER H, 1988, STROKE, V19, P263, DOI 10.1161/01.STR.19.2.263; MIRSEN TR, 1991, ARCH NEUROL-CHICAGO, V48, P1015, DOI 10.1001/archneur.1991.00530220031015; NORRVING B, 1989, STROKE, V20, P59, DOI 10.1161/01.STR.20.1.59; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; POLI A, 1988, ATHEROSCLEROSIS, V70, P253, DOI 10.1016/0021-9150(88)90176-1; PSATY BM, 1992, JAMA-J AM MED ASSOC, V268, P1287, DOI 10.1001/jama.268.10.1287; ROSEN GA, 1982, CARDIOVASCULAR SURVE; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; SAVAGE RM, 1977, CIRCULATION, V55, P279, DOI 10.1161/01.CIR.55.2.279; SCHNEIDER R, 1987, J NEUROL, V234, P67, DOI 10.1007/BF00314104; SCHROLL M, 1981, J CHRON DIS, V34, P261, DOI 10.1016/0021-9681(81)90031-X; STARY HC, 1992, ARTERIOSCLER THROMB, V12, P120, DOI 10.1161/01.ATV.12.1.120; TAYLOR DC, 1987, J CLIN ULTRASOUND, V15, P635, DOI 10.1002/jcu.1870150906; VANGENT CM, 1977, CLIN CHIM ACTA, V75, P243, DOI 10.1016/0009-8981(77)90195-4; VANSWIETEN JC, 1991, ANN NEUROL, V30, P825, DOI 10.1002/ana.410300612; VANSWIETEN JC, 1991, BRAIN, V114, P761; VOGT MT, 1992, J CLIN EPIDEMIOL, V45, P529, DOI 10.1016/0895-4356(92)90102-S; WENDELHAG I, 1992, ARTERIOSCLER THROMB, V12, P70, DOI 10.1161/01.ATV.12.1.70; WENDELHAG I, 1991, CLIN PHYSIOL, V11, P565, DOI 10.1111/j.1475-097X.1991.tb00676.x	39	310	312	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1993	341	8855					1232	1237		10.1016/0140-6736(93)91144-B	http://dx.doi.org/10.1016/0140-6736(93)91144-B			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098390	Green Submitted			2022-12-24	WOS:A1993LC49700002
J	MARCHIONNI, MA; GOODEARL, ADJ; CHEN, MS; BERMINGHAMMCDONOGH, O; KIRK, C; HENDRICKS, M; DANEHY, F; MISUMI, D; SUDHALTER, J; KOBAYASHI, K; WROBLEWSKI, D; LYNCH, C; BALDASSARE, M; HILES, I; DAVIS, JB; HSUAN, JJ; TOTTY, NF; OTSU, M; MCBURNEY, RN; WATERFIELD, MD; STROOBANT, P; GWYNNE, D				MARCHIONNI, MA; GOODEARL, ADJ; CHEN, MS; BERMINGHAMMCDONOGH, O; KIRK, C; HENDRICKS, M; DANEHY, F; MISUMI, D; SUDHALTER, J; KOBAYASHI, K; WROBLEWSKI, D; LYNCH, C; BALDASSARE, M; HILES, I; DAVIS, JB; HSUAN, JJ; TOTTY, NF; OTSU, M; MCBURNEY, RN; WATERFIELD, MD; STROOBANT, P; GWYNNE, D			GLIAL GROWTH-FACTORS ARE ALTERNATIVELY SPLICED ERBB2 LIGANDS EXPRESSED IN THE NERVOUS-SYSTEM	NATURE			English	Article							SCHWANN-CELL PROLIFERATION; PERIPHERAL-NERVE; NEU ONCOGENE; GENE; ETHYLNITROSOUREA; IDENTIFICATION; REGENERATION; DEGENERATION; MITOGENS; CULTURE	Glial growth factors, proteins that are mitogenic for Schwann cells, and several ligands for the p185erbB2 receptor, are products of the same gene. Alternative splicing of the messenger RNA generates an array of putative membrane-attached, intracellular and secreted signalling proteins, at least some of which are expressed in the developing spinal cord and brain. These factors are probably important in the development and regeneration of the nervous system.	LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Ludwig Institute for Cancer Research; Columbia University; Howard Hughes Medical Institute	MARCHIONNI, MA (corresponding author), CAMBRIDGE NEUROSCI INC,1 KENDALL SQ,BLDG 700,CAMBRIDGE,MA 02139, USA.		Goodearl, Andrew/AAP-5501-2020; Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Bermingham-McDonogh, Olivia/0000-0002-2559-4218				ACHESON A, 1991, NEURON, V7, P265, DOI 10.1016/0896-6273(91)90265-2; Aguayo A.J., 1985, SYNAPTIC PLASTICITY, P457; AGUAYO AJ, 1976, BRAIN RES, V104, P1, DOI 10.1016/0006-8993(76)90643-0; ALTMAN J, 1984, ADV ANATOMY EMBRYOLO, V85; BAEHR M, 1989, EXP NEUROL, V106, P27, DOI 10.1016/0014-4886(89)90141-6; BAICHWAL RR, 1988, P NATL ACAD SCI USA, V85, P1701, DOI 10.1073/pnas.85.5.1701; BHATTACHARYYA A, 1992, J NEUROBIOL, V23, P451, DOI 10.1002/neu.480230410; BROCKES JP, 1984, SCIENCE, V225, P1280, DOI 10.1126/science.6474177; BROCKES JP, 1986, ANN NEUROL, V20, P317, DOI 10.1002/ana.410200308; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; BUNGE RP, 1986, ANNU REV NEUROSCI, V9, P305; BUNGE RP, 1992, DIS NERV SYST, P87; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN JA, 1992, J NEUROSCI RES, V31, P622, DOI 10.1002/jnr.490310406; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; ECCLESTON PA, 1992, EXP CELL RES, V199, P1, DOI 10.1016/0014-4827(92)90455-H; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Jessen K R, 1992, Curr Opin Neurobiol, V2, P575, DOI 10.1016/0959-4388(92)90021-C; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Le Douarin N.M., 1982, NEURAL CREST; LEMKE GE, 1984, J NEUROSCI, V4, P75; LU X, 1991, J NEUROSCI, V11, P972; LUPU R, 1992, J STEROID BIOCHEM, V43, P229, DOI 10.1016/0960-0760(92)90212-2; MATSUOKA I, 1991, J NEUROSCI, V11, P3165; MUIR D, 1989, NEUROCHEM RES, V14, P1003, DOI 10.1007/BF00965935; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; NORDLUND M, 1992, GLIA, V5, P182, DOI 10.1002/glia.440050304; PELLEGRINO RG, 1986, J NEUROCYTOL, V15, P17, DOI 10.1007/BF02057901; PERANTONI AO, 1987, P NATL ACAD SCI USA, V84, P6317, DOI 10.1073/pnas.84.17.6317; RAFF MC, 1978, CELL, V15, P813, DOI 10.1016/0092-8674(78)90266-0; SALZER JL, 1980, J CELL BIOL, V84, P753, DOI 10.1083/jcb.84.3.753; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; Sambrook J., 1989, MOL CLONING LAB MANU; SANDROCK AW, 1987, BRAIN RES, V425, P360, DOI 10.1016/0006-8993(87)90520-8; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	51	716	781	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 25	1993	362	6418					312	318		10.1038/362312a0	http://dx.doi.org/10.1038/362312a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8096067				2022-12-24	WOS:A1993KU17600050
J	ONEILL, P				ONEILL, P			MENINGITIS - HOW LONG TO TREAT BACTERIAL-MENINGITIS	LANCET			English	Editorial Material							CEFTRIAXONE; CHILDREN; CHLORAMPHENICOL; MULTICENTER; CEFUROXIME; AMPICILLIN; THERAPY				ONEILL, P (corresponding author), DUDLEY RD GEN HOSP, DEPT MICROBIOL, BIRMINGHAM B18 7QH, W MIDLANDS, ENGLAND.		Henry, David/AAJ-4332-2020	Henry, David/0000-0003-2934-2242				JADAVJI T, 1986, PEDIATRICS, V78, P21; LIN TY, 1985, JAMA-J AM MED ASSOC, V253, P3559, DOI 10.1001/jama.253.24.3559; MACFARLANE JT, 1979, T ROY SOC TROP MED H, V73, P693, DOI 10.1016/0035-9203(79)90023-3; MARKS WA, 1986, J PEDIATR-US, V109, P123, DOI 10.1016/S0022-3476(86)80591-1; MARTIN E, 1990, INFECTION, V18, P70, DOI 10.1007/BF01641418; MCCRACKEN GH, 1987, PEDIATR INFECT DIS J, V6, P501, DOI 10.1097/00006454-198706000-00001; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; PELTOLA H, 1989, LANCET, V1, P1281; SCHAAD UB, 1990, NEW ENGL J MED, V322, P141, DOI 10.1056/NEJM199001183220301; WALI SS, 1979, T ROY SOC TROP MED H, V73, P698, DOI 10.1016/0035-9203(79)90024-5	10	20	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 27	1993	341	8844					530	530		10.1016/0140-6736(93)90287-Q	http://dx.doi.org/10.1016/0140-6736(93)90287-Q			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094780				2022-12-24	WOS:A1993KP08300013
J	MIDDLETON, SJ; SHORTHOUSE, M; HUNTER, JO				MIDDLETON, SJ; SHORTHOUSE, M; HUNTER, JO			INCREASED NITRIC-OXIDE SYNTHESIS IN ULCERATIVE-COLITIS	LANCET			English	Note							L-ARGININE; NITRATES; CELLS	Nitric oxide (NO) is produced in tissues by NO synthase with the liberation of equimolar amounts of citrulline. Citrulline concentrations were significantly higher in rectal biopsy specimens from patients with active ulcerative colitis than in those from patients with quiescent disease or with normal histology. Incubation of biopsy samples from patients with ulcerative colitis with N(G)-monomethyl-L-arginine (L-NMMA) inhibited citrulline production. These findings suggest that mucosal NO biosynthesis is increased in active colitis and that NO may have a pathogenic role in ulcerative colitis.			MIDDLETON, SJ (corresponding author), ADDENBROOKES HOSP,DEPT GASTROENTEROL,CAMBRIDGE CB2 2QQ,ENGLAND.							EINARSSON S, 1983, J CHROMATOGR, V282, P609, DOI 10.1016/S0021-9673(00)91638-8; HEGESH E, 1982, CLIN CHIM ACTA, V125, P107, DOI 10.1016/0009-8981(82)90187-5; HIBBS JB, 1987, J IMMUNOL, V138, P550; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MCCALL TB, 1989, BIOCHEM J, V261, P293, DOI 10.1042/bj2610293; MIDDLETON SJ, 1991, GUT, V32, pA1248; MONCADA S, 1991, PHARMACOL REV, V43, P109; PARK KGM, 1991, LANCET, V337, P645, DOI 10.1016/0140-6736(91)92456-C; ROEDIGER WEW, 1990, DIS COLON RECTUM, V33, P1034, DOI 10.1007/BF02139219; YEATES RA, 1985, MOL PHARMACOL, V28, P555	10	332	348	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					465	466		10.1016/0140-6736(93)90211-X	http://dx.doi.org/10.1016/0140-6736(93)90211-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094492				2022-12-24	WOS:A1993KN13700008
J	PARKER, SE; DAVEY, PG				PARKER, SE; DAVEY, PG			ANTIMICROBIAL THERAPY - ONCE-DAILY AMINOGLYCOSIDE DOSING	LANCET			English	Editorial Material							CRITICALLY ILL				PARKER, SE (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,PHARMACOECON RES CTR,DUNDEE DD1 9SY,SCOTLAND.							BRUSHWOOD DB, 1992, AM J HOSP PHARM, V49, P1748, DOI 10.1093/ajhp/49.7.1748; FLINT LM, 1985, ARCH SURG-CHICAGO, V120, P99; LABOVITZ E, 1974, ANTIMICROB AGENTS CH, V6, P465, DOI 10.1128/AAC.6.4.465; MARIK PE, 1991, J ANTIMICROB CHEMOTH, V27, P81, DOI 10.1093/jac/27.suppl_C.81; PARKER SE, 1992, PHARMACOECONOMICS, V2, P103; PARKER SE, IN PRESS J ANTIMICRO; SUMMER WR, 1983, CRIT CARE MED, V11, P948, DOI 10.1097/00003246-198312000-00011	7	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					346	347		10.1016/0140-6736(93)90143-5	http://dx.doi.org/10.1016/0140-6736(93)90143-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094120				2022-12-24	WOS:A1993KK93900011
J	HABUCHI, T; TAKAHASHI, R; YAMADA, H; KAKEHI, Y; SUGIYAMA, T; YOSHIDA, O				HABUCHI, T; TAKAHASHI, R; YAMADA, H; KAKEHI, Y; SUGIYAMA, T; YOSHIDA, O			METACHRONOUS MULTIFOCAL DEVELOPMENT OF UROTHELIAL CANCERS BY INTRALUMINAL SEEDING	LANCET			English	Note							BLADDER-CANCER; CLONAL ORIGIN; P53 MUTATIONS	To investigate the clonal origin of multifocal urothelial tumours, we analysed the p53 tumour-suppressor gene in 3 cases with bladder tumours developing after treatment for a renal pelvic or ureteral tumour and in 1 case with a ureteral tumour after treatment for a bladder tumour. For each case, identical p53 gene mutations were detected in all primary and recurrent tumours. The results suggest that heterotopic recurrence by intraluminal seeding from the original tumour is common in urothelial cancer. The data also support the view that multifocal urothelial tumours are derived from a single progenitor cell.	KYOTO UNIV,FAC MED,DEPT UROL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT PATHOL,KYOTO 606,JAPAN	Kyoto University; Kyoto University								HABUCHI T, 1993, CANCER RES, V53, P3795; HARRIS AL, 1992, NEW ENGL J MED, V326, P759, DOI 10.1056/NEJM199203123261108; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LUNEC J, 1992, LANCET, V339, P439, DOI 10.1016/0140-6736(92)90135-P; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; SPRUCK CH, 1993, CANCER RES, V53, P1162	8	170	171	2	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1087	1088		10.1016/0140-6736(93)92066-3	http://dx.doi.org/10.1016/0140-6736(93)92066-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105314				2022-12-24	WOS:A1993ME82200012
J	GOODWIN, CS				GOODWIN, CS			GASTRIC-CANCER AND HELICOBACTER-PYLORI - THE WHISPERING KILLER	LANCET			English	Editorial Material							INFECTION; STOMACH				GOODWIN, CS (corresponding author), UNITED ARAB EMIRATES UNIV, FAC MED, DEPT MED MICROBIOL, AL AIN, U ARAB EMIRATES.							BARKER DJP, 1990, BRIT J CANCER, V61, P575, DOI 10.1038/bjc.1990.129; FORMAN D, 1993, LANCET, V341, P1359; GOODWIN CS, 1992, CURR OPIN GASTROEN, V8, P122; GRAHAM DY, 1993, NEW ENGL J MED, V328, P349, DOI 10.1056/NEJM199302043280512; HALLISSEY MT, 1990, BRIT MED J, V301, P513, DOI 10.1136/bmj.301.6751.513; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; Logan Robert P. H., 1993, P307; Mitchell Hazel M., 1993, P95; NEWELL DG, 1991, J CLIN PATHOL, V44, P385, DOI 10.1136/jcp.44.5.385; PARSONNET J, 1993, GASTROENTEROL CLIN N, V22, P89; QIN DX, 1993, CANCER, V71, P216, DOI 10.1002/1097-0142(19930101)71:1<216::AID-CNCR2820710133>3.0.CO;2-#; RECAVARRENARCE S, 1991, SCAND J GASTROENTERO, V26, P51, DOI 10.3109/00365529109093208; SEDGWICK DM, 1991, BRIT MED J, V302, P1305, DOI 10.1136/bmj.302.6788.1305; Sipponen Pentti, 1993, P37; SOBALA GM, 1991, CARCINOGENESIS, V12, P193, DOI 10.1093/carcin/12.2.193	15	18	18	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1993	342	8870					507	508		10.1016/0140-6736(93)91640-8	http://dx.doi.org/10.1016/0140-6736(93)91640-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102661				2022-12-24	WOS:A1993LU58200003
J	MATUSCHKA, FR; SPIELMAN, A				MATUSCHKA, FR; SPIELMAN, A			RISK OF INFECTION FROM AND TREATMENT OF TICK BITE	LANCET			English	Article							LYME-DISEASE SPIROCHETE; BORRELIA-BURGDORFERI; IXODES-DAMMINI; BABESIA-MICROTI; TRANSMISSION; ATTACHMENT; DURATION		HARVARD UNIV,SCH PUBL HLTH,DEPT TROP PUBL HLTH,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health	MATUSCHKA, FR (corresponding author), FREE UNIV BERLIN,UNIV KLINIKUM RUDOLF VIRCHOW,INST PATHOL,D-12249 BERLIN,GERMANY.							MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; MATUSCHKA FR, 1992, PARASITOL RES, V78, P695, DOI 10.1007/BF00931523; MATUSCHKA FR, 1992, NEW ENGL J MED, V327, P542, DOI 10.1056/NEJM199208203270807; MATUSCHKA FR, 1992, WOOD TICKS LYME DISE; PIESMAN J, 1991, J INFECT DIS, V163, P895, DOI 10.1093/infdis/163.4.895; PIESMAN J, 1986, INT J PARASITOL, V16, P381, DOI 10.1016/0020-7519(86)90118-9; PIESMAN J, 1987, J CLIN MICROBIOL, V25, P557, DOI 10.1128/JCM.25.3.557-558.1987; PIESMAN J, 1986, ACTA TROP, V43, P263; SHAPIRO ED, 1992, NEW ENGL J MED, V327, P1769, DOI 10.1056/NEJM199212173272501; SHIH CM, 1992, J INFECT DIS, V166, P827, DOI 10.1093/infdis/166.4.827	10	17	18	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					529	530		10.1016/0140-6736(93)91650-B	http://dx.doi.org/10.1016/0140-6736(93)91650-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102671				2022-12-24	WOS:A1993LU58200013
J	WANG, PH				WANG, PH			TIGHT GLUCOSE CONTROL AND DIABETIC COMPLICATIONS	LANCET			English	Editorial Material											WANG, PH (corresponding author), HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, BOSTON, MA 02115 USA.							DCCT Res Grp, 1988, DIABETES CARE, V11, P567; KLEIN R, 1992, DIABETES CARE, V15, P1875, DOI 10.2337/diacare.15.12.1875; Prospective U. K., 1991, DIABETOLOGIA, V34, P877; REAVEN GM, 1991, DIABETES CARE, V14, P33, DOI 10.2337/diacare.14.4.33; SAWIN CT, 1993, P ENDOC SOC, P230; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y	6	20	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	1993	342	8864					129	129		10.1016/0140-6736(93)91338-M	http://dx.doi.org/10.1016/0140-6736(93)91338-M			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101249				2022-12-24	WOS:A1993LN04200004
J	LOCKWOOD, CM; THIRU, S; ISAACS, JD; HALE, G; WALDMANN, H				LOCKWOOD, CM; THIRU, S; ISAACS, JD; HALE, G; WALDMANN, H			LONG-TERM REMISSION OF INTRACTABLE SYSTEMIC VASCULITIS WITH MONOCLONAL-ANTIBODY THERAPY	LANCET			English	Note							RESPONSES	Monoclonal antibodies that target T cells offer an alternative to conventional immunosuppressive drugs in the management of autoimmune disease. ''Humanisation'' of such monoclonal antibodies makes their clinical use less likely to be prone to the risk of cross-species sensitisation than treatment with rodent antibodies. We describe humanised monoclonal antibody therapy in four patients with severe systemic vasculitis unresponsive to immunosuppressive drugs. Substantial and sustained benefit was seen in three of the four patients, although one of these three patients developed anti-idiotypic antibodies that had to be removed by plasma exchange.	UNIV CAMBRIDGE,DEPT PATHOL,DIV HISTOPATHOL,CAMBRIDGE,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,DIV IMMUNOL,CAMBRIDGE,ENGLAND	University of Cambridge; University of Cambridge	LOCKWOOD, CM (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2SP,ENGLAND.		waldmann, herman/W-8051-2019	Isaacs, John/0000-0002-6103-7056; Waldmann, Herman/0000-0001-7519-6720; Hale, Geoff/0000-0001-9473-423X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHEN ZH, 1992, EUR J IMMUNOL, V22, P805, DOI 10.1002/eji.1830220326; COBBOLD SP, 1990, J IMMUNOL METHODS, V127, P19, DOI 10.1016/0022-1759(90)90335-S; HOM JT, 1988, EUR J IMMUNOL, V18, P881, DOI 10.1002/eji.1830180608; ISAACS JD, 1992, LANCET, V340, P748, DOI 10.1016/0140-6736(92)92294-P; MATHIESON PW, 1990, NEW ENGL J MED, V323, P250, DOI 10.1056/NEJM199007263230407; MATHIESON PW, 1992, NEW ENGL J MED, V340, P748; SAMPAIO EP, 1992, J EXP MED, V175, P1729, DOI 10.1084/jem.175.6.1729; WALDMANN H, 1989, ANNU REV IMMUNOL, V7, P407, DOI 10.1146/annurev.iy.07.040189.002203; WOFSY D, 1985, J IMMUNOL, V134, P852	9	181	184	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1620	1622		10.1016/0140-6736(93)90759-A	http://dx.doi.org/10.1016/0140-6736(93)90759-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099991				2022-12-24	WOS:A1993LJ72700005
J	VISCOLI, CM; LACHS, MS; HORWITZ, RI				VISCOLI, CM; LACHS, MS; HORWITZ, RI			BLADDER-CANCER AND COFFEE-DRINKING - A SUMMARY OF CASE-CONTROL RESEARCH	LANCET			English	Article							LOWER URINARY-TRACT; RISK-FACTORS; ARTIFICIAL SWEETENERS; EARLY PRECURSORS; TOBACCO SMOKING; DIETARY FACTORS; COLLEGE MEN; OCCUPATION; EPIDEMIOLOGY; CONSUMPTION	An association between coffee drinking and cancer of the lower urinary tract (LUT) was first suggested 20 years ago and has been the subject of many epidemiological studies. We have undertaken a critical review and statistical summary of 35 case-control studies of this association published between 1971 and 1992. Predefined methodological criteria were applied to the available reports. Studies were classified as either meeting the criteria (core studies) or failing to satisfy at least one of the requirements for design or analysis (non-core studies). The summarised data from the 8 core studies showed no evidence of an increase in risk of LUT cancer with coffee drinking in men or women after adjustment for the effects of cigarette smoking (odds ratio 1.07 [95% CI 1.00-1.14] for men, 0.91 [0.81-1.03] for women). The measures of association from the non-core studies were higher on average than those from the core studies, although the inclusion of these data in an overall summarised estimate did not substantially change the findings from the core analysis. We conclude that the best available data do not suggest a clinically important association between the regular use of coffee and development of cancer of the LUT in men or women.	YALE UNIV, SCH MED,DEPT INTERNAL MED,ROOM IE-61 SHM,POB 3333, NEW HAVEN, CT 06510 USA	Yale University								AKDAS A, 1990, EUR UROL, V17, P23; BRAVO MP, 1987, NEOPLASMA, V34, P633; BROSS IDJ, 1973, PREV MED, V2, P445, DOI 10.1016/0091-7435(73)90040-6; CARTWRIGHT RA, 1981, CARCINOGENESIS, V2, P343, DOI 10.1093/carcin/2.4.343; CICCONE G, 1988, CANCER LETT, V41, P45, DOI 10.1016/0304-3835(88)90053-5; CLAUDE J, 1986, AM J EPIDEMIOL, V124, P578, DOI 10.1093/oxfordjournals.aje.a114430; CLAVEL J, 1991, INT J CANCER, V47, P207, DOI 10.1002/ijc.2910470208; COLE P, 1971, NEW ENGL J MED, V284, P129, DOI 10.1056/NEJM197101212840304; COLE P, 1971, LANCET, V1, P1335; DAVANZO B, 1992, EUR J CANCER, V28A, P1480, DOI 10.1016/0959-8049(92)90548-G; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUNHAM LJ, 1968, J NATL CANCER I, V41, P683; FRAUMENI JF, 1971, LANCET, V2, P1204; GONZALES CA, 1988, AM J IND MED, V14, P673, DOI 10.1002/ajim.4700140607; GONZALEZ CA, 1985, CANCER, V55, P2031, DOI 10.1002/1097-0142(19850501)55:9<2031::AID-CNCR2820550934>3.0.CO;2-I; HARTGE P, 1983, J NATL CANCER I, V70, P1021; HOWE GR, 1980, JNCI-J NATL CANCER I, V64, P701; HOWE GR, 1977, LANCET, V2, P578, DOI 10.1016/S0140-6736(77)91428-3; ISCOVICH J, 1987, INT J CANCER, V40, P734, DOI 10.1002/ijc.2910400604; JACOBSEN BK, 1986, J NATL CANCER I, V76, P823; JENSEN OM, 1986, INT J CANCER, V37, P651, DOI 10.1002/ijc.2910370503; JENSEN OM, 1983, INT J CANCER, V32, P577; KABAT GC, 1986, CANCER-AM CANCER SOC, V57, P362, DOI 10.1002/1097-0142(19860115)57:2<362::AID-CNCR2820570229>3.0.CO;2-F; KANTOR AF, 1985, INT J CANCER, V35, P703, DOI 10.1002/ijc.2910350602; KANTOR AF, 1988, CANCER RES, V48, P3853; KUNZE E, 1992, CANCER-AM CANCER SOC, V69, P1776, DOI 10.1002/1097-0142(19920401)69:7<1776::AID-CNCR2820690721>3.0.CO;2-P; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LAVECCHIA C, 1989, NUTR CANCER, V12, P93, DOI 10.1080/01635588909514006; MARRETT LD, 1983, AM J EPIDEMIOL, V117, P113, DOI 10.1093/oxfordjournals.aje.a113522; METTLIN C, 1979, AM J EPIDEMIOL, V110, P255, DOI 10.1093/oxfordjournals.aje.a112810; MILLER AB, 1977, CANCER RES, V37, P2939; MILLER CT, 1978, J CHRON DIS, V31, P51, DOI 10.1016/0021-9681(78)90080-2; MILLS PK, 1991, AM J EPIDEMIOL, V133, P230, DOI 10.1093/oxfordjournals.aje.a115867; MOMMSEN S, 1982, EUR J CANCER CLIN ON, V18, P1205, DOI 10.1016/0277-5379(82)90103-1; MOMMSEN S, 1983, EUR J CANCER CLIN ON, V19, P725, DOI 10.1016/0277-5379(83)90005-6; MORGAN RW, 1974, CAN MED ASSOC J, V111, P1067; MORRISON AS, 1982, JNCI-J NATL CANCER I, V68, P91; MORRISON AS, 1980, NEW ENGL J MED, V302, P537, DOI 10.1056/NEJM198003063021001; NAJEM GR, 1982, INT J EPIDEMIOL, V11, P212, DOI 10.1093/ije/11.3.212; NOMURA A, 1986, JNCI-J NATL CANCER I, V76, P587, DOI 10.1093/jnci/76.4.587; Ohno Y, 1985, Natl Cancer Inst Monogr, V69, P229; PIPER JM, 1986, AM J EPIDEMIOL, V123, P1033, DOI 10.1093/oxfordjournals.aje.a114331; REBELAKOS A, 1985, JNCI-J NATL CANCER I, V75, P455; RISCH HA, 1988, AM J EPIDEMIOL, V127, P1179, DOI 10.1093/oxfordjournals.aje.a114911; SCHULTE PA, 1986, CANCER, V58, P2156, DOI 10.1002/1097-0142(19861101)58:9<2156::AID-CNCR2820580933>3.0.CO;2-Y; SIMON D, 1975, J NATL CANCER I, V54, P587; SLATTERY ML, 1988, CANCER, V61, P402, DOI 10.1002/1097-0142(19880115)61:2<402::AID-CNCR2820610233>3.0.CO;2-U; SLATTERY ML, 1988, INT J CANCER, V42, P17, DOI 10.1002/ijc.2910420105; SNOWDON DA, 1984, AM J PUBLIC HEALTH, V74, P820, DOI 10.2105/AJPH.74.8.820; SULLIVAN JW, 1982, J UROLOGY, V128, P281, DOI 10.1016/S0022-5347(17)52886-4; VINEIS P, 1984, INT J CANCER, V34, P165, DOI 10.1002/ijc.2910340205; WHITTEMORE AS, 1984, J UROLOGY, V132, P1256, DOI 10.1016/S0022-5347(17)50118-4; WHITTEMORE AS, 1985, JNCI-J NATL CANCER I, V74, P43; WYNDER EL, 1977, CANCER-AM CANCER SOC, V40, P1246, DOI 10.1002/1097-0142(197709)40:3<1246::AID-CNCR2820400340>3.0.CO;2-5; WYNDER EL, 1977, CANCER RES, V37, P4608; WYNDER EL, 1985, ENVIRON RES, V37, P475, DOI 10.1016/0013-9351(85)90129-X; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	57	41	41	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	1993	341	8858					1432	1437		10.1016/0140-6736(93)90881-G	http://dx.doi.org/10.1016/0140-6736(93)90881-G			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099140				2022-12-24	WOS:A1993LF84100003
J	KOOT, M; KEET, IPM; VOS, AHV; DEGOEDE, REY; ROOS, MTL; COUTINHO, RA; MIEDEMA, F; SCHELLEKENS, PTA; TERSMETTE, M				KOOT, M; KEET, IPM; VOS, AHV; DEGOEDE, REY; ROOS, MTL; COUTINHO, RA; MIEDEMA, F; SCHELLEKENS, PTA; TERSMETTE, M			PROGNOSTIC VALUE OF HIV-1 SYNCYTIUM-INDUCING PHENOTYPE FOR RATE OF CD4+ CELL DEPLETION AND PROGRESSION TO AIDS	ANNALS OF INTERNAL MEDICINE			English	Article						ANTIGENS, CD4; HUMAN IMMUNODEFICIENCY VIRUS TYPE-1; HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; GIANT CELLS; ACQUIRED IMMUNODEFICIENCY SYNDROME	HUMAN-IMMUNODEFICIENCY-VIRUS; SEROPOSITIVE HOMOSEXUAL MEN; REPLICATIVE CAPACITY; NATURAL-HISTORY; IMMUNE-SYSTEM; INFECTION; VARIANTS; TROPISM; TYPE-1; PATHOGENESIS	Objective: To investigate the relation between detection of syncytium-inducing (SI), human immunodeficiency virus type 1 (HIV-1) variants, rate of CD4+ cell decline, and clinical progression. Design: Prospective study during a 2.5-year follow-up period; cohort study with pairwise matched controls. Setting: The Amsterdam cohort study on the course of HIV-1 infection in homosexual men. Participants: Asymptomatic HIV-1-infected men (n = 225) were tested for the presence of SI variants and were studied prospectively for CD4+ cell decline and clinical progression. In addition, 45 men with a defined moment of appearance of SI variants and 45 matched controls without SI variants were compared for CD4+ cell decline. Measurements: Syncytium-inducing variants were detected by cocultivation of peripheral blood mononuclear cells with the MT-2 T-cell line. Results: During a 30-month period, 70.8% of the men with SI variants progressed to AIDS, compared with 15.8% of men without SI variants at entry (P <0.0001). Multivariable Cox proportional hazard analysis, controlling for CD4+ cell count and HIV-p24 antigenemia, showed a relative hazard for SI variants of 6.7 (95% Cl, 3.5 to 12.7). In the matched control study, before the appearance of SI variants, CD4+ cell counts of 45 men with SI variants and their controls were compared. Syncytium-inducing variants emerged at a mean CD4+ cell count of 0.48 x 10(9)/L (Cl, 0.42 to 0.54), coinciding with the onset of a threefold increased rate of CD4+ cell decline. Men developing AIDS with SI variants had decreased CD4+ cell counts (0.08 x 10(9)/L; 95% Cl, 0.05 to 0.12) at the time of diagnosis compared with persons progressing to AIDS without SI variants (0.25 x 10(9)/L; 95% Cl, 0.15 to 0.41) (P = 0.0035). Conclusions: The HIV-1 biological phenotype is a practical, binary marker for progression to AIDS, which is independent of decreased CD4+ cell counts and antigenemia. Appearance of SI variants, occurring 2 years before progression to AIDS on the average, is predictive for a significantly increased rate of CD4+ cell decline.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV,CENT LAB, DEPT CLIN VIROIMMUNOL,POB 9406, 1006 AK AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, AMSTERDAM, NETHERLANDS; MUNICIPAL HLTH SERV, DEPT PUBL HLTH & ENVIRONM, 1000 HE AMSTERDAM, NETHERLANDS	University of Amsterdam								ASJO B, 1986, LANCET, V2, P660; BOUCHER CAB, 1992, AIDS, V6, P1259, DOI 10.1097/00002030-199211000-00003; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; COREY L, 1992, NEW ENGL J MED, V326, P484, DOI 10.1056/NEJM199202133260710; DEWOLF F, 1988, J INFECT DIS, V158, P615, DOI 10.1093/infdis/158.3.615; EVANS LA, 1987, J IMMUNOL, V138, P3415; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; FENYO EM, 1989, AIDS, V3, pS5, DOI 10.1097/00002030-198901001-00002; GROENINK M, 1991, J VIROL, V65, P1968, DOI 10.1128/JVI.65.4.1968-1975.1991; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; MIEDEMA F, 1990, IMMUNOL TODAY, V11, P293, DOI 10.1016/0167-5699(90)90116-Q; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; PHILLIPS AN, 1991, LANCET, V337, P389; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; SCHELLEKENS PTA, 1992, AIDS, V6, P665, DOI 10.1097/00002030-199207000-00008; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; TERSMETTE M, 1990, AIDS (London), V4, pS57; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TERSMETTE M, 1989, LANCET, V1, P983; VANGRIENSVEN GJP, 1989, BMJ-BRIT MED J, V298, P218, DOI 10.1136/bmj.298.6668.218; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; VONBRIESEN H, 1987, J MED VIROL, V23, P51, DOI 10.1002/jmv.1890230107; VONGEGERFELT A, 1991, VIROLOGY, V185, P162, DOI 10.1016/0042-6822(91)90764-3; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; 1987, MMWR S, V36, pS1	36	753	766	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1993	118	9					681	688		10.7326/0003-4819-118-9-199305010-00004	http://dx.doi.org/10.7326/0003-4819-118-9-199305010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY502	8096374				2022-12-24	WOS:A1993KY50200004
J	BLASCZYK, R; WESTHOFF, U; GROSSEWILDE, H				BLASCZYK, R; WESTHOFF, U; GROSSEWILDE, H			SOLUBLE CD4, CD8, AND HLA MOLECULES IN COMMERCIAL IMMUNOGLOBULIN PREPARATIONS	LANCET			English	Note							LINKED-IMMUNOSORBENT-ASSAY; ADHESION; BINDING; CELL	CD4 and CD8 exist in membrane-bound and soluble forms. These antigens are the physiological ligands for molecules of HLA classes I and II, which we have found in soluble form in commercial immunoglobulin preparations. We measured concentrations of soluble CD4 and CD8, as well as soluble HLA-ABC and HLA-RQP in sixteen immunoglobulin preparations by enzyme immunosorbent assays. Only two preparations contained detectable CD8, and nine had soluble CD4 in varying amounts. There was great variation in concentrations of soluble HLA molecules. It is possible that the immunomodulating effects of immunoglobulin therapy in disorders with immune aetiology are due, at least partly, to these contaminating molecules.	UNIV ESSEN GESAMTHSCH KLINIKUM,INST IMMUNOL,VIRCHOWSTR 171,W-4300 ESSEN 1,GERMANY	University of Duisburg Essen				Djukanovic, Ratko/0000-0001-6039-5612; Blasczyk, Rainer/0000-0003-3875-3190				CHIA D, 1991, TISSUE ANTIGENS, V37, P49, DOI 10.1111/j.1399-0039.1991.tb01845.x; DOXIADIS I, 1989, BLUT, V59, P449, DOI 10.1007/BF00349066; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; GROSSEWILDE H, 1992, TISSUE ANTIGENS, V39, P74, DOI 10.1111/j.1399-0039.1992.tb01910.x; LENERT P, 1990, SCIENCE, V248, P1639, DOI 10.1126/science.2363051; ROSENSTEIN Y, 1990, J IMMUNOL, V144, P526; ROSENSTEIN Y, 1989, J EXP MED, V169, P149, DOI 10.1084/jem.169.1.149; SULLIVAN KM, 1990, NEW ENGL J MED, V323, P705, DOI 10.1056/NEJM199009133231103; WESTHOFF U, 1991, VOX SANG, V61, P106, DOI 10.1111/j.1423-0410.1991.tb00255.x; 1991, NEW ENGL J MED, V325, P73	10	152	154	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					789	790		10.1016/0140-6736(93)90563-V	http://dx.doi.org/10.1016/0140-6736(93)90563-V			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096001				2022-12-24	WOS:A1993KU90000006
J	SCHECHTER, MT; CRAIB, KJP; GELMON, KA; MONTANER, JSG; LE, TN; OSHAUGHNESSY, MV				SCHECHTER, MT; CRAIB, KJP; GELMON, KA; MONTANER, JSG; LE, TN; OSHAUGHNESSY, MV			HIV-1 AND THE ETIOLOGY OF AIDS	LANCET			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; DISEASE	The belief that HIV-1 infection causes AIDS has been questioned, and the suggestion made that to know the correct cause of AIDS the incidence of disease in patients with and without risk behaviours and with and without antibody to HIV-1 must be known. We describe findings in such a cohort. In 715 homosexual men followed for a median of 8-6 years, all 136 AIDS cases occurred in the 365 individuals with pre-existing HIV-1 antibody. Most men negative for HIV-1 antibody reported risk behaviours but none developed any AIDS illnesses. CD4 counts fell in anti-HIV-1-positive men but remained stable in antibody-negative men, whether or not risk behaviours were present. The hypothesis that AIDS in homosexual men is caused not by HIV-1 infection but by drugs and sexual activity is rejected by these data. HIV-1 has an integral role in the pathogenesis of AIDS.	BRITISH COLUMBIA CTR EXCELLENCE HIV AIDS,VANCOUVER,BC,CANADA; BRITISH COLUMBIA CANC AGCY,VANCOUVER,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER V6T 1W5,BC,CANADA; ST PAULS HOSP,VANCOUVER V6Z 1Y6,BC,CANADA	B.C. Centre for Excellence in HIV/AIDS; British Columbia Cancer Agency; University of British Columbia; St. Paul's Hospital; University of Saskatchewan	SCHECHTER, MT (corresponding author), UNIV BRITISH COLUMBIA,FAC MED,DEPT HLTH CARE & EPIDEMIOL,5804 FAIRVIEW AVE,VANCOUVER V6T 1Z3,BC,CANADA.		Montaner, Julio/K-7621-2012	Schechter, Martin/0000-0001-6063-2155				DEAN M, 1992, LANCET, V339, P1286, DOI 10.1016/0140-6736(92)91604-7; DUESBERG P, 1988, SCIENCE, V242, P997, DOI 10.1126/science.242.4881.997-b; DUESBERG PH, 1987, CANCER RES, V47, P1199; DUESBERG PH, 1991, P NATL ACAD SCI USA, V88, P1575, DOI 10.1073/pnas.88.4.1575; DUESBERG PH, 1990, RES IMMUNOL, V141, P5, DOI 10.1016/0923-2494(90)90097-I; DUESBERG PH, 1989, P NATL ACAD SCI USA, V86, P755, DOI 10.1073/pnas.86.3.755; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; SCHECHTER MT, 1991, AIDS, V5, P373, DOI 10.1097/00002030-199104000-00003	8	25	25	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					658	659		10.1016/0140-6736(93)90421-C	http://dx.doi.org/10.1016/0140-6736(93)90421-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095571				2022-12-24	WOS:A1993KR61300005
J	BRILLANTI, S; FOLI, M; GAIANI, S; MASCI, C; MIGLIOLI, M; BARBARA, L				BRILLANTI, S; FOLI, M; GAIANI, S; MASCI, C; MIGLIOLI, M; BARBARA, L			PERSISTENT HEPATITIS-C VIREMIA WITHOUT LIVER-DISEASE	LANCET			English	Note							NON-B-HEPATITIS; LONG-TERM; NON-A; VIRUS; VIREMIA	In viral infections persistence of the virus is not always associated with virus-induced disease. To find out if active hepatitis C virus (HCV) infection can persist without liver disease we selected four symptom-free individuals with antibodies to HCV but normal aminotransferase levels. They were followed up for 3 years by monthly serology and a liver biopsy was done. At presentation, all four had both antibodies to HCV and circulating HCV RNA. During follow-up their sera remained persistently positive for all HCV antibodies and RNA yet aminotransferase levels did not increase and liver biopsy was normal. These findings indicate that persistent hepatitis C viraemia is not invariably associated with liver damage.	UNIV BOLOGNA,DEPT INTERNAL MED & GASTROENTEROL,I-40126 BOLOGNA,ITALY	University of Bologna			Brillanti, Stefano/E-8970-2010	Brillanti, Stefano/0000-0003-4181-795X				ALBERTI A, 1992, LANCET, V340, P697, DOI 10.1016/0140-6736(92)92234-7; BRILLANTI S, 1992, HEPATOLOGY, V15, P998, DOI 10.1002/hep.1840150604; BRILLANTI S, 1991, J MED VIROL, V34, P136, DOI 10.1002/jmv.1890340213; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; GARSON JA, 1990, LANCET, V336, P1022, DOI 10.1016/0140-6736(90)92487-3; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J; ZIGNEGO AL, 1992, J HEPATOL, V15, P382, DOI 10.1016/0168-8278(92)90073-X	9	204	206	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					464	465		10.1016/0140-6736(93)90210-8	http://dx.doi.org/10.1016/0140-6736(93)90210-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094491				2022-12-24	WOS:A1993KN13700007
J	CORRAL, J; MARTIN, C; PEREZ, R; SANCHEZ, I; MORIES, MT; MILLAN, JLS; MIRALLES, JM; GONZALEZSARMIENTO, R				CORRAL, J; MARTIN, C; PEREZ, R; SANCHEZ, I; MORIES, MT; MILLAN, JLS; MIRALLES, JM; GONZALEZSARMIENTO, R			THYROGLOBULIN GENE POINT MUTATION ASSOCIATED WITH NONENDEMIC SIMPLE GOITER	LANCET			English	Note							SEQUENCE; ACID	Simple goitre is defined as an enlargement of the thyroid gland that is not the result of an inflammatory or neoplastic process and is not associated with thyrotoxicosis or myxoedema; the cause is unknown in most cases. Structural or regulatory defects in the proteins involved in thyroid metabolism might be involved in the functional abnormality that brings about the disorder. We have found a mutation within exon 10 of the thyroglobulin gene in 25 of 56 members of three families affected by simple goitre; 14 of the gene carriers had the disorder. DNA sequencing showed a mis-sense mutation within thyroglobulin gene exon 10, resulting in a glutamine to histidine substitution. Thus, some cases of non-endemic simple goitre are associated with a mutation at the thyroglobulin locus.	UNIV SALAMANCA,DEPT MED,UNIDAD GENET MOLEC,SALAMANCA,SPAIN; UNIV SALAMANCA,HOSP CLIN,SERV ENDOCRINOL,SALAMANCA,SPAIN; HOSP RAMON Y CAJAL,UNIDAD GENET MOLEC,MADRID,SPAIN	University of Salamanca; University of Salamanca; Hospital Universitario Ramon y Cajal			Gonzalez-Sarmiento, Rogelio/V-5526-2019; San-Millán, José L./F-9944-2015; Perez-Canaveras, Rosa M./N-4108-2014	Gonzalez-Sarmiento, Rogelio/0000-0002-2726-6795; MORIES, MARIA TERESA/0000-0002-0658-7514; Corral, Javier/0000-0003-0288-1107; Perez-Canaveras, Rosa M./0000-0002-8541-2412				ELTE JWF, 1981, NETH J MED, V24, P79; GREIG WR, 1967, Q J MED, V36, P175; LEIRI T, 1991, J CLIN INVEST, V88, P1901; LEVER EG, 1983, ENDOCR REV, V4, P213, DOI 10.1210/edrv-4-3-213; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; MALTHIERY Y, 1989, BIOCHIMIE, V71, P195, DOI 10.1016/0300-9084(89)90057-6; MORIES T, 1991, CLIN SCI, V80, P301, DOI 10.1042/cs0800301; OHMIYA Y, 1990, J BIOL CHEM, V265, P9066; TARGOVNIK H, 1989, J CLIN ENDOCR METAB, V69, P1137, DOI 10.1210/jcem-69-6-1137; TARGOVNIK HM, 1984, EUR J BIOCHEM, V141, P271, DOI 10.1111/j.1432-1033.1984.tb08188.x	10	55	60	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					462	464		10.1016/0140-6736(93)90209-Y	http://dx.doi.org/10.1016/0140-6736(93)90209-Y			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094490				2022-12-24	WOS:A1993KN13700006
J	DAHLITZ, M; PARKES, JD				DAHLITZ, M; PARKES, JD			SLEEP PARALYSIS	LANCET			English	Note							NARCOLEPSY; PREVALENCE	Sleep paralysis is a common condition with a prevalence of 5-62%. Although most affected people have single or infrequent episodes, sleep paralysis may be recurrent, or occur in association with the narcoleptic syndrome. In a study of 22 subjects with frequent sleep paralysis and also excessive daytime sleepiness, episodes continued for between 5 and 35 years. In contrast to subjects with the narcoleptic syndrome, these patients did not have cataplexy, daytime sleepiness and insomnia were less severe, and there was no HLA DR2(15) or DQ1(6) association. Sleep paralysis was familial in 19 of these subjects. A non-HLA linked genetic factor, in addition to environmental factors, may thus predispose to sleep paralysis.	UNIV LONDON,INST PSYCHIAT,DEPT NEUROL,DENMARK HILL,LONDON SE5 8AF,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,LONDON WC2R 2LS,ENGLAND	University of London; University of London; King's College London								Adie WJ, 1926, BRAIN, V49, P257, DOI 10.1093/brain/49.3.257; ANDREASZIETZ A, 1986, LANCET, V2, P684; BELL CC, 1984, J NATL MED ASSOC, V76, P501; DALY DD, 1974, HDB CLIN NEUROL, V15, P836; Firestone M., 1985, J PSYCHOANALYTIC ANT, V8, P47; FUKUDA K, 1987, SLEEP, V10, P279, DOI 10.1093/sleep/10.3.279; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; MACFARLANE AW, 1891, LANCET, V1, P824; Mitchell SW, 1876, VIRGINIA MED MONTHLY, V2, P769; MITLER MM, 1986, SLEEP, V9, P260, DOI 10.1093/sleep/9.1.260; NEELY S, 1987, NEUROLOGY, V37, P1858, DOI 10.1212/WNL.37.12.1858; NESS R C, 1978, Culture Medicine and Psychiatry, V2, P15, DOI 10.1007/BF00052448; SIEGEL JM, 1991, SCIENCE, V252, P1315, DOI 10.1126/science.1925546	13	59	59	0	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					406	407		10.1016/0140-6736(93)92992-3	http://dx.doi.org/10.1016/0140-6736(93)92992-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094172				2022-12-24	WOS:A1993KM41600007
J	DELCOUR, AH; TSIEN, RW				DELCOUR, AH; TSIEN, RW			ALTERED PREVALENCE OF GATING MODES IN NEUROTRANSMITTER INHIBITION OF N-TYPE CALCIUM CHANNELS	SCIENCE			English	Article							RAT SYMPATHETIC NEURONS; CHICK SENSORY NEURONS; VOLTAGE DEPENDENCE; BINDING PROTEIN; CELL-LINE; MODULATION; ACTIVATION; CURRENTS; GTP; NORADRENALINE	G protein-mediated inhibition of voltage-activated calcium channels by neurotransmitters has important consequences for the control of synaptic strength. Single-channel recordings of N-type calcium channels in frog sympathetic neurons reveal at least three distinct patterns of gating, designated low-P(o), medium-P(o), and high-P(o) modes according to their probability of being open (P(o)) at -10 millivolts. The high-P(o) mode is responsible for the bulk of divalent cation entry in the absence of neurotransmitter. Norepinephrine greatly decreased the prevalence of high-P(o) gating and increased the proportion of time a channel exhibited low-P(o) behavior or no activity at all, which thereby reduced the overall current. Directly observed patterns of transition between the various modes suggest that activated G protein alters the balance between modal behaviors that freely interconvert even in the absence of modulatory signaling.	STANFORD UNIV,MED CTR,BECKMAN CTR,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Stanford University					NHLBI NIH HHS [HL13156] Funding Source: Medline; NINDS NIH HHS [NS24607] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BEECH DJ, 1992, NEURON, V8, P97, DOI 10.1016/0896-6273(92)90111-P; BEVAN JA, 1984, FED PROC, V43, P1365; BOLAND LM, 1993, J NEUROSCI, V13, P516; CARBONE E, 1989, PROG BIOPHYS MOL BIO, V54, P31, DOI 10.1016/0079-6107(89)90008-4; DELCOUR AH, IN PRESS J NEUROSCI; DOLPHIN AC, 1987, J PHYSIOL-LONDON, V386, P1; DOLPHIN AC, 1990, ANNU REV PHYSIOL, V52, P243; DUNLAP K, 1981, J PHYSIOL-LONDON, V317, P519, DOI 10.1113/jphysiol.1981.sp013841; DUNLAP K, 1978, NATURE, V276, P837, DOI 10.1038/276837a0; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; EWALD DA, 1988, P NATL ACAD SCI USA, V85, P3633, DOI 10.1073/pnas.85.10.3633; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; FORSCHER P, 1986, J PHYSIOL-LONDON, V379, P131, DOI 10.1113/jphysiol.1986.sp016244; GALVAN M, 1982, BRAIN RES, V244, P135, DOI 10.1016/0006-8993(82)90911-8; GRASSI F, 1989, NEUROSCI LETT, V105, P113, DOI 10.1016/0304-3940(89)90021-9; GROSS RA, 1987, P NATL ACAD SCI USA, V84, P5469, DOI 10.1073/pnas.84.15.5469; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HESS P, 1984, NATURE, V311, P538, DOI 10.1038/311538a0; HOLZ GG, 1986, NATURE, V319, P670, DOI 10.1038/319670a0; IKEDA SR, 1991, J PHYSIOL-LONDON, V439, P181, DOI 10.1113/jphysiol.1991.sp018663; JONES SW, 1991, BIOPHYS J, V60, P502, DOI 10.1016/S0006-3495(91)82077-X; KASAI H, 1992, J PHYSIOL-LONDON, V448, P189, DOI 10.1113/jphysiol.1992.sp019036; KASAI H, 1989, PFLUEGERS ARCH, V414, P415; KURACHI Y, 1990, PFLUG ARCH EUR J PHY, V416, P216, DOI 10.1007/BF00370247; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; LOPEZ HS, 1991, NEURON, V7, P1061, DOI 10.1016/0896-6273(91)90350-9; MARCHETTI C, 1989, BIOPHYS J, V56, P1267, DOI 10.1016/S0006-3495(89)82774-2; MARCHETTI C, 1986, PFLUG ARCH EUR J PHY, V406, P104, DOI 10.1007/BF00586670; MARKS TN, 1992, J GEN PHYSIOL, V99, P367, DOI 10.1085/jgp.99.3.367; MATHIE A, 1992, NEURON, V8, P907, DOI 10.1016/0896-6273(92)90205-R; MCMANUS OB, 1988, J PHYSIOL-LONDON, V402, P79, DOI 10.1113/jphysiol.1988.sp017195; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PLUMMER MR, 1991, J NEUROSCI, V11, P2339; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; WANKE E, 1987, P NATL ACAD SCI USA, V84, P4313, DOI 10.1073/pnas.84.12.4313; YUE DT, 1990, P NATL ACAD SCI USA, V87, P753, DOI 10.1073/pnas.87.2.753	39	90	91	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					980	984		10.1126/science.8094902	http://dx.doi.org/10.1126/science.8094902			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8094902				2022-12-24	WOS:A1993KL80000046
J	VANTRAPPEN, G				VANTRAPPEN, G			GASTROENTEROLOGY - ACUTE COLONIC PSEUDOOBSTRUCTION	LANCET			English	Editorial Material							PSEUDOOBSTRUCTION OGILVIES SYNDROME				VANTRAPPEN, G (corresponding author), CATHOLIC UNIV LEUVEN,DEPT MED,B-3000 LOUVAIN,BELGIUM.							BONACINI M, 1991, J CLIN GASTROENTEROL, V13, P475, DOI 10.1097/00004836-199108000-00024; FAULK DL, 1978, GASTROENTEROLOGY, V74, P922; HEIMBACH DM, 1971, SURGERY, V69, P582; HUTCHINSON R, 1992, ANN ROY COLL SURG, V74, P364; MACCOLL C, 1990, GASTROENTEROLOGY, V98, P773, DOI 10.1016/0016-5085(90)90301-G; SLOYER AF, 1988, DIGEST DIS SCI, V33, P1391, DOI 10.1007/BF01536993; VANEK VW, 1986, DIS COLON RECTUM, V29, P203, DOI 10.1007/BF02555027	7	22	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					152	153		10.1016/0140-6736(93)90010-E	http://dx.doi.org/10.1016/0140-6736(93)90010-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093750				2022-12-24	WOS:A1993KG62700010
J	WOOSTER, R; NEUHAUSEN, SL; MANGION, J; QUIRK, Y; FORD, D; COLLINS, N; NGUYEN, K; SEAL, S; TRAN, T; AVERILL, D; FIELDS, P; MARSHALL, G; NAROD, S; LENOIR, GM; LYNCH, H; FEUNTEUN, J; DEVILEE, P; CORNELISSE, CJ; MENKO, FH; DALY, PA; ORMISTON, W; MCMANUS, R; PYE, C; LEWIS, CM; CANNONALBRIGHT, LA; PETO, J; PONDER, BAJ; SKOLNICK, MH; EASTON, DF; GOLDGAR, DE; STRATTON, MR				WOOSTER, R; NEUHAUSEN, SL; MANGION, J; QUIRK, Y; FORD, D; COLLINS, N; NGUYEN, K; SEAL, S; TRAN, T; AVERILL, D; FIELDS, P; MARSHALL, G; NAROD, S; LENOIR, GM; LYNCH, H; FEUNTEUN, J; DEVILEE, P; CORNELISSE, CJ; MENKO, FH; DALY, PA; ORMISTON, W; MCMANUS, R; PYE, C; LEWIS, CM; CANNONALBRIGHT, LA; PETO, J; PONDER, BAJ; SKOLNICK, MH; EASTON, DF; GOLDGAR, DE; STRATTON, MR			LOCALIZATION OF A BREAST-CANCER SUSCEPTIBILITY GENE, BRCA2, TO CHROMOSOME 13Q12-13	SCIENCE			English	Article							ANDROGEN RECEPTOR GENE; FAMILIAL BREAST; LINKAGE ANALYSIS; ATAXIA-TELANGIECTASIA; OVARIAN-CANCER; P53 GENE; MUTATIONS; HETEROZYGOSITY; CARCINOMA; LOCUS	A small proportion oi breast cancer, in particular those cases arising at a young age, is due to the inheritance of dominant susceptibility genes conferring a high risk of the disease. A genomic linkage search was performed with 15 high-risk breast cancer families that were unlinked to the BRCA1 locus on chromosome 17q21. This analysis localized a second breast cancer susceptibility locus, BRCA2, to a 6-centimorgan interval on chromosome 13q12-13. Preliminary evidence suggests that BRCA2 confers a high risk of breast cancer but, unlike BRCA1, does not confer a substantially elevated risk of ovarian cancer.	INST CANC RES, EPIDEMIOL SECT, SUTTON SM2 5NG, SURREY, ENGLAND; INST CANC RES, MOLEC CARCINOGENESIS SECT, SUTTON SM2 5NG, SURREY, ENGLAND; MCGILL UNIV, DIV HUMAN GENET, MONTREAL H3G 1A4, PQ, CANADA; MCGILL UNIV, DEPT MED, DIV MED GENET, MONTREAL H3G 1A4, PQ, CANADA; CREIGHTON UNIV, SCH MED, DEPT PREVENT MED & PUBL HLTH, OMAHA, NE 68178 USA; INT AGCY RES CANC, F-69372 LYON 08, FRANCE; INST GUSTAVE ROUSSY, VILLEJUIF, FRANCE; LEIDEN UNIV, DEPT PATHOL, 2333 AL LEIDEN, NETHERLANDS; LEIDEN UNIV, DEPT HUMAN GENET, 2333 AL LEIDEN, NETHERLANDS; FREE UNIV AMSTERDAM, DEPT CLIN GENET, 1007 MB AMSTERDAM, NETHERLANDS; UNIV IRELAND TRINITY COLL, ST JAMES HOSP, SCH MED, DEPT MED, DUBLIN 8, IRELAND; UNIV CAMBRIDGE, DEPT PATHOL, CRC, HUMAN CANC GENET GRP, CAMBRIDGE CB2 1QP, ENGLAND; UNIV UTAH, DEPT INTERNAL MED, SALT LAKE CITY, UT 84132 USA	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; McGill University; McGill University; Creighton University; World Health Organization; International Agency for Research on Cancer (IARC); UNICANCER; Gustave Roussy; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam; Trinity College Dublin; University of Cambridge; Utah System of Higher Education; University of Utah			Lewis, Cathryn M/A-5225-2010; Narod, Steven A/AAA-6112-2022; DEVILEE, PETER/ABR-2140-2022; Feunteun, Jean/AAZ-1267-2020; Lewis, Cathryn/M-8766-2019; McManus, Ross/AAE-9236-2020	Lewis, Cathryn M/0000-0002-8249-8476; Lewis, Cathryn/0000-0002-8249-8476; Feunteun, Jean/0000-0003-1212-9189; albright, lisa/0000-0003-2602-3668; McManus, Ross/0000-0002-0529-9617	NATIONAL CANCER INSTITUTE [P01CA048711] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000571] Funding Source: NIH RePORTER; NCI NIH HHS [CA-48711, CN-05222] Funding Source: Medline; NHGRI NIH HHS [HG-00571] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BIRCH JM, 1994, CANCER RES, V54, P1298; BISHOP DT, 1988, GENET EPIDEMIOL, V5, P151, DOI 10.1002/gepi.1370050303; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CLAUS EB, 1993, AM J HUM GENET, V53, P787; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DENG G, 1994, CANCER RES, V54, P499; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EASTON D, UNPUB; EASTON DF, 1993, AM J HUM GENET, V52, P678; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; KHO CJ, 1992, P NATL ACAD SCI USA, V89, P2200, DOI 10.1073/pnas.89.6.2200; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LOBACCARO JM, 1993, NAT GENET, V5, P109, DOI 10.1038/ng1093-109; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; NAROD SA, 1991, LANCET, V338, P82; OTT J, 1985, ANAL HUMAN GENETIC L, P200; PROSSER J, 1991, BRIT J CANCER, V63, P181, DOI 10.1038/bjc.1991.44; ROSNET O, 1993, ONCOGENE, V8, P173; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRATTON MR, 1994, NAT GENET, V7, P103, DOI 10.1038/ng0594-103; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1993, GENOMICS, V17, P535, DOI 10.1006/geno.1993.1368; WARREN W, 1992, ONCOGENE, V7, P1043; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WOOSTER R, 1992, NAT GENET, V2, P132, DOI 10.1038/ng1092-132; WOOSTER R, 1993, HUM GENET, V92, P91, DOI 10.1007/BF00216153; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	31	1458	1524	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	1994	265	5181					2088	2090		10.1126/science.8091231	http://dx.doi.org/10.1126/science.8091231			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091231				2022-12-24	WOS:A1994PJ91200028
J	BRANDEIS, M; FRANK, D; KESHET, I; SIEGFRIED, Z; MENDELSOHN, M; NEMES, A; TEMPER, V; RAZIN, A; CEDAR, H				BRANDEIS, M; FRANK, D; KESHET, I; SIEGFRIED, Z; MENDELSOHN, M; NEMES, A; TEMPER, V; RAZIN, A; CEDAR, H			SP1 ELEMENTS PROTECT A CPG ISLAND FROM DE-NOVO METHYLATION	NATURE			English	Article							DNA METHYLATION; TRANSCRIPTION FACTOR; DENOVO METHYLATION; MOUSE EMBRYO; GENE; PROMOTER; CELLS; DEMETHYLATION; PATTERNS; TISSUES	ANIMAL somatic cell DNA is characterized by a bimodal pattern of methylation: tissue-specific genes are methylated in most cell types whereas housekeeping genes have 5' CpG islands which are constitutively unmethylated(1,2). Because methyl moieties derived from the gametes are erased in the morula and early blastula(3), this profile must be re-established in every generation; this is apparently accomplished by a wave of non-CpG island de novo methylation that occurs at implantation(4). Using transfection into embryonic stem cells and transgenic mice as a model system, we now show that Sp1 elements play a key role in protecting a CpG island in the adenine phosphoribosyltransferase (APRT) gene from de novo methylation. This recognition mechanism represents a critical step in embryogenesis; as it is responsible for setting up the correct genome methylation pattern which, in turn, is involved in regulating basal gene expression in the organism(5).	TECHNION ISRAEL INST TECHNOL, BRUCE RAPPAPORT FAC MED, DEPT BIOCHEM, IL-31096 HAIFA, ISRAEL; COLUMBIA UNIV, SCH MED, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Columbia University	BRANDEIS, M (corresponding author), HEBREW UNIV JERUSALEM, SCH MED, DEPT CELLULAR BIOCHEM, IL-91120 JERUSALEM, ISRAEL.							BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CEDAR H, 1982, COLD SPRING HARB SYM, V47, P605, DOI 10.1101/SQB.1983.047.01.071; CHOI YC, 1993, MOL CELL BIOL, V13, P5538, DOI 10.1128/MCB.13.9.5538; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANK D, 1991, NATURE, V351, P239, DOI 10.1038/351239a0; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Hogan B., 1986, MANIPULATING MOUSE E; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KOLSTO AB, 1986, NUCLEIC ACIDS RES, V14, P9667; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; LOWY I, 1980, CELL, V22, P817, DOI 10.1016/0092-8674(80)90558-9; MACLEOD D, IN PRESS GENES DEV; MONK M, 1987, DEVELOPMENT, V99, P371; MUMMANENI P, 1993, J BIOL CHEM, V268, P552; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; SHEMER R, 1991, J BIOL CHEM, V266, P23676; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; VANDERPLOEG LHT, 1980, CELL, V19, P947, DOI 10.1016/0092-8674(80)90086-0; YISRAELI J, 1984, DNA METHYLATION BIOC, P353	28	630	645	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	1994	371	6496					435	438		10.1038/371435a0	http://dx.doi.org/10.1038/371435a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	8090226				2022-12-24	WOS:A1994PJ28500048
J	ELLIS, SJ				ELLIS, SJ			FUNCTIONAL MAGNETIC-RESONANCE - NEUROLOGICAL ENLIGHTENMENT	LANCET			English	Editorial Material							POSITRON EMISSION TOMOGRAPHY; BRAIN				ELLIS, SJ (corresponding author), UNIV OXFORD, DEPT CLIN NEUROL, OXFORD, ENGLAND.			Ellis, Simon/0000-0002-9131-6427				FRACKOWIAK RSJ, 1989, SEMIN NEUROL, V9, P275, DOI 10.1055/s-2008-1041334; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; JAMIESON DG, 1989, COMPUT MED IMAG GRAP, V13, P61, DOI 10.1016/0895-6111(89)90079-7; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; Poeck K, 1984, Adv Neurol, V42, P71; SMITH FW, 1988, J CEREBRAL BLOOD FLO, V8, pS166; WEISSLEDER R, 1992, Magnetic Resonance Quarterly, V8, P55	7	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1993	342	8876					882	882		10.1016/0140-6736(93)91942-F	http://dx.doi.org/10.1016/0140-6736(93)91942-F			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105163				2022-12-24	WOS:A1993MA96300006
J	POIRIER, J; DAVIGNON, J; BOUTHILLIER, D; KOGAN, S; BERTRAND, P; GAUTHIER, S				POIRIER, J; DAVIGNON, J; BOUTHILLIER, D; KOGAN, S; BERTRAND, P; GAUTHIER, S			APOLIPOPROTEIN-E POLYMORPHISM AND ALZHEIMERS-DISEASE	LANCET			English	Article							RAT SCIATIC-NERVE; CHOLESTEROL TRANSPORT; IMMUNOREACTIVITY; PROTEIN; CORTEX; LOCUS	Apolipoprotein E (apoE) is associated with Alzheimer's neurofibrillary tangles and beta-amyloid protein in senile plaques. It also appears to play an important part in the redistribution of lipids that follows deafferentation and neurodegeneration in the brain. The gene for apoE is on chromosome 19, within the genomic region previously associated with late-onset familial Alzheimer's disease (AD). We have studied apoE phenotype expression and the corresponding allele frequencies (epsilon2, epsilon3, epsilon4) in 91 patients with sporadic AD and 74 controls. There was a significant association between epsilon4 and sporadic AD (epsilon4 frequency 0.380 in AD and 0.122 in controls, p <0.01). Analysis of epsilon4 allele frequency as a function of age revealed a bimodal distribution, with peaks at 65 and 75 years. In bearers of epsilon4 in whom AD develops this tended to happen earlier in life than in those with epsilon3 or epsilon2. The epsilon4/AD association was more pronounced in women. Octogenarians with AD had an epsilon4 allele frequency that was 3 times higher than one reported, in a different study, in healthy octogenarians. ApoE may be an important susceptibility factor in the aetiopathology of sporadic AD.	MCGILL UNIV,DEPT PSYCHIAT,MONTREAL H3A 2T5,QUEBEC,CANADA; CLIN RES INST MONTREAL,MONTREAL H2W 1R7,QUEBEC,CANADA; UNIV MONTREAL,MONTREAL H3C 3J7,QUEBEC,CANADA	McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal	POIRIER, J (corresponding author), DOUGLAS HOSP,RES CTR,MCGILL CTR STUDIES AGING,6575 LASALLE BLVD,VERDUN H4H 1R3,PQ,CANADA.				NIA NIH HHS [AG-10003] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010003] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOUTHILLIER D, 1983, J LIPID RES, V24, P1060; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; CUMMING AM, 1984, CLIN GENET, V25, P310; DAVIES CA, 1987, J NEUROL SCI, V78, P151, DOI 10.1016/0022-510X(87)90057-8; Davignon J, 1988, Trans Am Clin Climatol Assoc, V99, P100; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; GUIBILEI F, 1989, ACTA NEUROL SCAND, V81, P84; HALLMAN DM, 1991, AM J HUM GENET, V49, P338; HONER WG, 1992, NEUROBIOL AGING, V13, P375, DOI 10.1016/0197-4580(92)90111-A; LEBLANC AC, 1990, J NEUROSCI RES, V25, P162, DOI 10.1002/jnr.490250203; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MASLIAH E, 1989, NEUROSCI LETT, V103, P234, DOI 10.1016/0304-3940(89)90582-X; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MUCJKLE TJ, 1985, LANCET, V1, P1191; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; POIRIER J, 1991, BASIC THERAPEUTIC ST, P191; RANSMAYR G, 1989, NEUROSCIENCE, V32, P701, DOI 10.1016/0306-4522(89)90291-1; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHELLENBERG GD, 1992, ANN NEUROL, V31, P223, DOI 10.1002/ana.410310214; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423; YAMADA N, 1980, BIOCHEM BIOPH RES CO, V94, P710, DOI 10.1016/0006-291X(80)91290-5	25	1142	1176	4	53	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					697	699		10.1016/0140-6736(93)91705-Q	http://dx.doi.org/10.1016/0140-6736(93)91705-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103819				2022-12-24	WOS:A1993LX46900006
J	DALBAGNI, G; PRESTI, J; REUTER, V; FAIR, WR; CORDONCARDO, C				DALBAGNI, G; PRESTI, J; REUTER, V; FAIR, WR; CORDONCARDO, C			GENETIC ALTERATIONS IN BLADDER-CANCER	LANCET			English	Note							ALTERED EXPRESSION; ALLELOTYPE; CARCINOMA	To see whether genetic alterations follow a sequence of events leading to bladder cancer progression, 60 paired bladder tumours and normal tissues were analysed with polymorphic DNA markers, correlating loss of heterozygosity (LOH) at candidate tumour suppressor gene sites with pathological indices of poor clinical outcome. Distinct genotypic patterns were associated with early and late stages of bladder cancer. 9q deletions were observed in all superficial papillary tumours (Ta) and almost all tumours invading the lamina propria (T1), suggesting that this event associates with the development of superficial bladder tumours. However, 3p, 5q, and 17p deletions were absent in the Ta tumours but were identified in invasive bladder cancers. Two genetic pathways characterise the evolution of superficial bladder tumours. 9qLOH was detected in most Ta tumours, but in only 43% of muscle invasive neoplasms. Our hypothesis is that certain chromosomal abnormalities have a defined role in bladder tumour development, whereas others correlate with pathological indices of poor clinical outcome.	MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,1275 YORK AVE,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT SURG,UROL SERV,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [NCI CA-47538] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA047538, R01CA047538] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; DEVILEE P, 1991, ONCOGENE, V6, P1705; FARNDON PA, 1992, LANCET, V339, P581, DOI 10.1016/0140-6736(92)90868-4; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOSS L, 1992, DIAGNOSTIC CYTOLOGY, P934; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; PRESTI JC, 1991, CANCER RES, V51, P5405; TYRKUS M, 1992, J UROLOGY, V148, P44, DOI 10.1016/S0022-5347(17)36504-7; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047	10	220	221	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					469	471		10.1016/0140-6736(93)91595-D	http://dx.doi.org/10.1016/0140-6736(93)91595-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102431				2022-12-24	WOS:A1993LU07500012
J	BLATT, SP; HENDRIX, CW; BUTZIN, CA; FREEMAN, TM; WARD, WW; HENSLEY, RE; MELCHER, GP; DONOVAN, DJ; BOSWELL, RN				BLATT, SP; HENDRIX, CW; BUTZIN, CA; FREEMAN, TM; WARD, WW; HENSLEY, RE; MELCHER, GP; DONOVAN, DJ; BOSWELL, RN			DELAYED-TYPE HYPERSENSITIVITY SKIN TESTING PREDICTS PROGRESSION TO AIDS IN HIV-INFECTED PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; ACQUIRED IMMUNODEFICIENCY SYNDROME; HYPERSENSITIVITY, DELAYED; SKIN TESTS; IMMUNITY, CELLULAR	HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-MEDIATED-IMMUNITY; PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED-IMMUNODEFICIENCY; HOMOSEXUAL MEN; T-HELPER; BETA-2-MICROGLOBULIN LEVEL; CUTANEOUS HYPERSENSITIVITY; LYMPHOCYTE COUNT; KAPOSIS SARCOMA	Objective: To evaluate the prognostic significance of cutaneous delayed-type h Design: Cohort study. Setting: United States Air Force (USAF) Medical Center. Patients: Consecutive sample of 889 HIV-infected USAF personnel or dependents undergoing their first staging evaluation from 1985 through August 1990 in the USAF HIV Natural History Study. Measurements: All patients were evaluated with DTH skin testing including purified protein derivative and four control skin test antigens: mumps, candida, tetanus toxoid, and trichophyton. In addition, all patients underwent CD4+ T-cell surface marker determinations. The relation between DTH skin test response at first evaluation and progression to Walter Reed stage 6 (presence of an AIDS-defining opportunistic infection) was evaluated using Kaplan-Meier survival analysis. Results: Patients with more than 400 CD4+ T cells/mm3 are more likely than those having fewer than 400 CD4+ T cells per mm3 to respond to at least one (94% compared with 67%, P < 0.001) or at least two (86% compared with 45%, P < 0.001) DTH skin tests. Mean CD4 counts are lower for anergic compared with nonanergic patients and for patients responding to a single control skin test compared with those responding to two or more skin tests (P < 0.05). The DTH skin test response at first evaluation was also found to predict progression to AIDS; the relative risk at 5 years of follow-up was 2.5 (95% CI, 1.2 to 5.2) for anergy compared with a single positive skin test and 3.0 (CI, 1.4 to 6.2) for a single compared with two or more skin test responses. The DTH skin test response at first evaluation was a predictor of progression (P < 0.001) when controlling for initial CD4 count and Walter Reed stage in a Cox proportional hazards regression analysis. Conclusions: The DTH skin test response, a functional measure of cellular immunity, is an independent predictor of progression to AIDS in persons with HIV.			BLATT, SP (corresponding author), WILFORD HALL USAF MED CTR, CTR AIDS RES,SW FDN BIOMED RES,PSMI-H, 2200 BERGQUIST DR, STE 1, LACKLAND AFB, TX 78236 USA.		Hendrix, Craig W/G-4182-2014	Hendrix, Craig W/0000-0002-5696-8665				AHMED AR, 1983, ARCH DERMATOL, V119, P934, DOI 10.1001/archderm.119.11.934; ANDERSON RE, 1990, ARCH INTERN MED, V150, P73, DOI 10.1001/archinte.150.1.73; ANDERSON RE, 1991, AIDS, V5, P213, DOI 10.1097/00002030-199102000-00013; CANESSA PA, 1989, CHEST, V96, P1215, DOI 10.1378/chest.96.5.1215; FAHEY JL, 1984, AM J MED, V76, P95, DOI 10.1016/0002-9343(84)90756-3; FAIRSHTER RD, 1980, J ALLERGY CLIN IMMUN, V66, P452, DOI 10.1016/0091-6749(80)90005-6; FRENCH MAH, 1990, CLIN IMMUNOL IMMUNOP, V55, P86, DOI 10.1016/0090-1229(90)90070-7; GORDON EH, 1983, J ALLERGY CLIN IMMUN, V72, P487, DOI 10.1016/0091-6749(83)90586-9; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369; HOFMANN B, 1990, AIDS, V4, P207, DOI 10.1097/00002030-199003000-00005; HUEBNER RE, 1992, JAMA-J AM MED ASSOC, V267, P409, DOI 10.1001/jama.267.3.409; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KNIKER WT, 1984, ANN ALLERGY, V52, P75; LAMBIN P, 1988, CLIN CHEM, V34, P1367; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LEVY JA, 1989, JAMA-J AM MED ASSOC, V261, P2997, DOI 10.1001/jama.261.20.2997; LUCEY DR, 1991, J ACQ IMMUN DEF SYND, V4, P24; LUCEY DR, 1991, J INFECT DIS, V164, P631, DOI 10.1093/infdis/164.4.631; MALONE JL, 1990, J ACQ IMMUN DEF SYND, V3, P144; MARKOWITZ N, 1990, American Review of Respiratory Disease, V141, pA617; MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402; MORRIS DL, 1979, CANCER RES, V39, P219; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MUNOZ A, 1988, J ACQ IMMUN DEF SYND, V1, P396; PITCHENIK AE, 1983, ANN INTERN MED, V98, P277, DOI 10.7326/0003-4819-98-3-277; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; RENZULLO PO, 1990, J ACQ IMMUN DEF SYND, V3, P266; REUBEN JM, 1984, ANN ALLERGY, V53, P390; ROBERT CF, 1989, NEW ENGL J MED, V321, P1268; SCHROFF RW, 1983, CLIN IMMUNOL IMMUNOP, V27, P300, DOI 10.1016/0090-1229(83)90083-1; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SIEGAL FP, 1981, NEW ENGL J MED, V305, P1439, DOI 10.1056/NEJM198112103052403; STIMPSON PG, 1976, SOUTHERN MED J, V69, P424, DOI 10.1097/00007611-197604000-00013; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; 1991, MMWR, V40, P27; 1990, MMWR, V39, P645; 1990, MMWR, V39, P638	39	120	120	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1993	119	3					177	184		10.7326/0003-4819-119-3-199308010-00001	http://dx.doi.org/10.7326/0003-4819-119-3-199308010-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU903	8100691				2022-12-24	WOS:A1993LU90300001
J	DAVENPORT, A; JONES, SR; GOEL, S; ASTLEY, JP; HARTOG, M				DAVENPORT, A; JONES, SR; GOEL, S; ASTLEY, JP; HARTOG, M			DIFFERENTIATION OF ACUTE FROM CHRONIC RENAL IMPAIRMENT BY DETECTION OF CARBAMYLATED HEMOGLOBIN	LANCET			English	Article							HEMOGLOBIN; CYANATE; UREMIA; UREA	Detection of carbamylated haemoglobin, measured as valine hydantoin per g haemoglobin (VH/g Hb), may be useful in differentiating between patients with acute or chronic renal failure. To assess this test, we measured carbamylated haemoglobin prospectively in 42 consecutive patients referred to the regional renal unit with a serum creatinine in excess of 500 mumol/L and a provisional diagnosis of acute renal failure (ARF). Patients were subsequently classed on clinical criteria as having ARF (20) or acute on chronic renal failure (AonCRF, 22). 24 patients with stable chronic renal failure (CRF), matched for degree of renal impairment, were also studied. Standard biochemical tests and haemoglobin were similar among the three groups. Patients with ARF of 10 or less days duration had a lower median (interquartile range [IQR]) carbamylated haemoglobin concentration than those with a longer duration of ARF (29 [27-35] vs 72 [60-83] mug VH/g Hb; p < 0.01). Carbamylated haemoglobin concentration was lower in the ARF group than in the AonCRF or CRF groups (42 [31-67], 116 [83-119], and 148 [122-210] mug VH/g Hb, respectively; p < 0.001). All patients with a degree of acute and potentially, reversible renal failure (ARF and AonCRF) had a carbamylated haemoglobin concentration below 190 mug VH/g Hb (sensitivity 100%, positive predictive value 62% for this cut-off). When the ratio of carbamylated haemoglobin to serum creatinine was calculated, to correct for degree of renal failure, a value of less than 0.2 had a 100% sensitivity and 80% positive predictive value for dividing patients with potentially reversible renal failure from those with CRF. Measurement of carbamylated haemoglobin was useful in identifying patients with acute and potentially reversible forms of renal failure. This test could be of clinical value in deciding which patients require urgent referral for further management and treatment in hospitals without specialist neuphrological care.	SOUTHMEAD GEN HOSP,DEPT CLIN CHEM,BRISTOL BS10 5NB,AVON,ENGLAND; UNIV BRISTOL,SOUTHMEAD HOSP,DEPT MED,BRISTOL BS10 5NB,AVON,ENGLAND	Southmead Hospital; Southmead Hospital; University of Bristol	DAVENPORT, A (corresponding author), SOUTHMEAD GEN HOSP,DEPT RENAL MED,BRISTOL BS10 5NB,AVON,ENGLAND.							BASTL CP, 1980, CONTEMP ISS NEPHROL, V6, P17; BUNN HF, 1981, DIABETES, V30, P613; CASSIDY MJD, 1990, BRIT MED J, V301, P329, DOI 10.1136/bmj.301.6747.329; DELGRECO F, 1981, ANN CLIN LAB SCI, V11, P283; DIRNHUBER P, 1948, BIOCHEM J, V42, P628, DOI 10.1042/bj0420628; FEEST TG, 1993, BMJ-BRIT MED J, V306, P481, DOI 10.1136/bmj.306.6876.481; FLUCKIGER R, 1981, NEW ENGL J MED, V304, P823, DOI 10.1056/NEJM198104023041406; JENSEN M, 1973, J BIOL CHEM, V248, P8057; KANIS JA, 1987, OXFORD TXB MED, V1; KWAN JTC, 1990, CLIN CHEM, V36, P607; KWAN JTC, 1991, NEPHROL DIAL TRANSPL, V6, P38, DOI 10.1093/ndt/6.1.38; KWAN JTC, 1992, 29TH C EUR DIAL TRAN; LEE CK, 1973, J BIOL CHEM, V248, P5861; LEE JA, 1991, LANCET, V338, P1438, DOI 10.1016/0140-6736(91)92733-I; MARSHALL WJ, 1988, ILLUSTRATED TXB CLIN, P6; MUEHRCKE RC, 1969, ACUTE RENAL FAILURE; OLIVER DO, 1987, OXFORD TXB MED, V2; SMITH WGJ, 1988, CLIN CHIM ACTA, V178, P297, DOI 10.1016/0009-8981(88)90238-0; STARK GR, 1960, J BIOL CHEM, V235, P3177	19	47	48	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1614	1617		10.1016/0140-6736(93)90757-8	http://dx.doi.org/10.1016/0140-6736(93)90757-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099989				2022-12-24	WOS:A1993LJ72700003
J	COULTER, A				COULTER, A			GYNECOLOGY - MANAGING MENORRHAGIA WITH ENDOMETRIAL RESECTION	LANCET			English	Editorial Material							ABLATION				COULTER, A (corresponding author), UNIV OXFORD,HLTH SERV RES UNIT,OXFORD,ENGLAND.		Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				COULTER A, 1991, BRIT J OBSTET GYNAEC, V98, P789, DOI 10.1111/j.1471-0528.1991.tb13484.x; DWYER N, 1993, BRIT J OBSTET GYNAEC, V100, P237, DOI 10.1111/j.1471-0528.1993.tb15237.x; FRASER IS, 1984, AM J OBSTET GYNECOL, V149, P788, DOI 10.1016/0002-9378(84)90123-6; GANNON MJ, 1991, BRIT MED J, V303, P1362, DOI 10.1136/bmj.303.6814.1362; GARRY R, 1991, BRIT J OBSTET GYNAEC, V98, P357, DOI 10.1111/j.1471-0528.1991.tb13425.x; MACDONALD R, 1990, BRIT J OBSTET GYNAEC, V97, P3, DOI 10.1111/j.1471-0528.1990.tb01709.x; MAGOS AL, 1991, LANCET, V337, P1473; MILSOM I, 1991, AM J OBSTET GYNECOL, V164, P879, DOI 10.1016/S0002-9378(11)90533-X; PHIPPS JH, 1990, LANCET, V335, P374, DOI 10.1016/0140-6736(90)90207-L; SCULPHER MJ, 1993, BRIT J OBSTET GYNAEC, V100, P244, DOI 10.1111/j.1471-0528.1993.tb15238.x; SLADE RJ, 1991, LANCET, V337, P1473, DOI 10.1016/0140-6736(91)93159-7; VESSEY MP, 1992, BRIT J OBSTET GYNAEC, V99, P402, DOI 10.1111/j.1471-0528.1992.tb13758.x	12	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1185	1186		10.1016/0140-6736(93)91008-A	http://dx.doi.org/10.1016/0140-6736(93)91008-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	8098081				2022-12-24	WOS:A1993LB01700010
J	SPIETH, J; BROOKE, G; KUERSTEN, S; LEA, K; BLUMENTHAL, T				SPIETH, J; BROOKE, G; KUERSTEN, S; LEA, K; BLUMENTHAL, T			OPERONS IN C-ELEGANS - POLYCISTRONIC MESSENGER-RNA PRECURSORS ARE PROCESSED BY TRANSSPLICING OF SL2 TO DOWNSTREAM CODING REGIONS	CELL			English	Article							CAENORHABDITIS-ELEGANS; LEADER SEQUENCE; ADENOSINE-TRIPHOSPHATASE; POLYADENYLATION SIGNAL; TRIMETHYLGUANOSINE CAP; POLYMERASE-II; GENE FAMILY; INVITRO; TRANSCRIPTION; PROTEIN	The MRNAs of six C. elegans genes are known to be trans-spliced to SL2. We report here that a similarly oriented gene is located 100-300 bp upstream of each. We present evidence that the genes in these clusters are cotranscribed and downstream mRNAs are formed by cleavage at the polyadenylation site and trans-splicing. From one three-gene cluster we isolated cDNA clones representing both polycistronic RNAs and mRNAs polyadenylated at the free 3' end created by trans-splicing, suggesting that polycistronic RNAs can be processed by trans-splicing. Several experiments indicate that SL2 trans-splicing is a consequence of a gene's downstream location in an operon. In particular, when an SL1-accepting gene was moved to a downstream location, its mRNA was trans-spliced largely to SL2. The possible regulatory significance of cotranscription of C. elegans genes is discussed.			SPIETH, J (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042432, F32GM013595, R56GM042432, R01GM030870] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM13595, GM30870, GM42432] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BEKTESH SL, 1988, NUCLEIC ACIDS RES, V16, P5692, DOI 10.1093/nar/16.12.5692; BONNEVILLE JM, 1989, CELL, V59, P1135, DOI 10.1016/0092-8674(89)90769-1; BRENNER S, 1974, GENETICS, V77, P71; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; CONRAD R, 1993, EMBO J, V12, P1249, DOI 10.1002/j.1460-2075.1993.tb05766.x; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; FIRE A, 1989, EMBO J, V8, P3419, DOI 10.1002/j.1460-2075.1989.tb08506.x; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FRANGIONE B, 1981, P NATL ACAD SCI-BIOL, V78, P7403, DOI 10.1073/pnas.78.12.7403; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HANNON GJ, 1992, SCIENCE, V258, P1775, DOI 10.1126/science.1465612; HANNON GJ, 1991, J BIOL CHEM, V266, P22792; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HU E, 1991, J BIOL CHEM, V266, P19796; Huang X Y, 1992, Genet Eng (N Y), V14, P211; HUANG XY, 1989, J MOL BIOL, V206, P411, DOI 10.1016/0022-2836(89)90490-7; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KUWABARA PE, 1992, MOL BIOL CELL, V3, P461, DOI 10.1091/mbc.3.4.461; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LEE YH, 1992, GENE, V121, P227, DOI 10.1016/0378-1119(92)90126-A; LEWIN B, 1990, GENES, V4; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NILSEN TW, 1989, MOL CELL BIOL, V9, P3543, DOI 10.1128/MCB.9.8.3543; NIWA M, 1992, NATURE, V360, P277, DOI 10.1038/360277a0; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; NIWA M, 1991, GENE EXPRESSION, V1, P5; OKKEMA PG, 1991, EMBO J, V10, P171, DOI 10.1002/j.1460-2075.1991.tb07933.x; SANDRIGOLDIN RM, 1992, GENE DEV, V6, P848, DOI 10.1101/gad.6.5.848; SHEETS MD, 1987, MOL CELL BIOL, V7, P1518, DOI 10.1128/MCB.7.4.1518; SPIETH J, 1985, MOL CELL BIOL, V5, P2495, DOI 10.1128/MCB.5.10.2495; SPIETH J, 1991, MOL CELL BIOL, V11, P4651, DOI 10.1128/MCB.11.9.4651; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TAKACS AM, 1988, P NATL ACAD SCI USA, V85, P7932, DOI 10.1073/pnas.85.21.7932; THOMAS J, 1990, NUCLEIC ACIDS RES, V18, P2633, DOI 10.1093/nar/18.9.2633; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; TSCHUDI C, 1988, EMBO J, V7, P455, DOI 10.1002/j.1460-2075.1988.tb02833.x; ULLU E, 1993, MOL CELL BIOL, V13, P720, DOI 10.1128/MCB.13.1.720; VANDOREN K, 1990, MOL CELL BIOL, V10, P1769, DOI 10.1128/MCB.10.4.1769; VANDOREN K, 1988, NATURE, V335, P556; WALKER JE, 1987, BIOCHEMISTRY-US, V26, P8613, DOI 10.1021/bi00400a018	52	256	282	3	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					521	532		10.1016/0092-8674(93)90139-H	http://dx.doi.org/10.1016/0092-8674(93)90139-H			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8098272				2022-12-24	WOS:A1993LA74300013
J	TANABE, KK; ELLIS, LM; SAYA, H				TANABE, KK; ELLIS, LM; SAYA, H			EXPRESSION OF CD44R1 ADHESION MOLECULE IN COLON CARCINOMAS AND METASTASES	LANCET			English	Note							CELLS	CD44 is a cell surface adhesion molecule postulated to control lymphocyte recirculation by facilitating entry into lymphoid tissue. Tumour cells transfected to overexpress the epithelial variant CD44R1 readily gain access to lymph nodes and distant metastatic sites in animal models, possibly by mimicking circulating lymphocytes.. To investigate if human tumours display altered CD44 expression we performed reverse transcriptase a polymerase chain reaction (PCR) analysis of CD44 in 49 specimens from normal colonic mucosa, primary colon and rectal tumours, normal liver, and metastases of 20 patients. The haematopoietic variant CD44H was the principal isoform amplified in all of the specimens, However, 12/14 primary tumours and 16/16 metastatic tumours expressed CD44R1, compared with only 2 of 13 normal mucosa specimens. This increase in CD44R1 relative to CD44H expressed by human colon carcinoma cells may increase their metastatic potential. Moreover, the relative increase in PCR amplification of CD44R1 compared with that of CD44H may provide a sensitive method for detecting primary and metastatic colon carcinoma cells in small biopsy specimens.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	TANABE, KK (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT GEN SURG,BOX 106,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.		Saya, Hideyuki/J-4325-2013		NATIONAL CANCER INSTITUTE [P30CA016672, T32CA009599] Funding Source: NIH RePORTER; NCI NIH HHS [5T32-CA09599-04, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; BIRCH M, 1991, CANCER RES, V51, P6660; DOUGHERTY GJ, 1992, P AM ASSOC CANC RES, V33, P34; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; JACKSON BG, 1992, J BIOL CHEM, V267, P4732; JALKANEN S, 1986, SCIENCE, V233, P556, DOI 10.1126/science.3726548; JALKANEN S, 1991, J CLIN INVEST, V87, P1835, DOI 10.1172/JCI115205; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x	10	301	308	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					725	726		10.1016/0140-6736(93)90490-8	http://dx.doi.org/10.1016/0140-6736(93)90490-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095628				2022-12-24	WOS:A1993KT36200007
J	NIEHRS, C; KELLER, R; CHO, KWY; DEROBERTIS, EM				NIEHRS, C; KELLER, R; CHO, KWY; DEROBERTIS, EM			THE HOMEOBOX GENE GOOSECOID CONTROLS CELL-MIGRATION IN XENOPUS EMBRYOS	CELL			English	Article							ECTOPIC EXPRESSION; LAEVIS; AXIS; GASTRULA; MESODERM; LINEAGE; ORGANIZER; INDUCTION; LAYER; FATE	goosecoid (gsc), a homeobox gene expressed specifically in the dorsal blastopore lip of the Xenopus gastrula, is considered to play an important role in Spemann's organizer phenomenon. Lineage tracing and time-lapse microscopy were used to follow the fate of embryonic cells microinjected with gsc mRNA. Microinjected gsc has non-cell autonomous effects, recruiting neighboring uninjected cells into a twinned dorsal axis. Ectopic expression of gsc mRNA in ventral blastomeres as well as overexpression of gsc in dorsal blastomeres leads to cell movement toward the anterior of the embryo. The results suggest a function for gsc in the control of gastrulation movements in groups of cells, but not in dissociated cells, and demonstrate that a vertebrate homeobox gene can regulate region-specific cell migration.	UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV CELL & DEV BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Los Angeles; University of California System; University of California Berkeley	NIEHRS, C (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA.			De Robertis, Edward/0000-0002-7843-1869	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD025594, R01HD025594, R01HD021502, R37HD021502] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21502-08, HD25594] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BELOUSSOV LV, 1988, CELL DIFFER DEV, V25, P165, DOI 10.1016/0922-3371(88)90113-X; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; DALE L, 1987, DEVELOPMENT, V99, P527; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; GERHART J, 1991, BOD MAR LAB, P57; GIMLICH RL, 1985, DEV BIOL, V109, P509, DOI 10.1016/0012-1606(85)90476-2; GIMLICH RL, 1983, NATURE, V306, P471, DOI 10.1038/306471a0; GOULD AP, 1992, DEVELOPMENT, V116, P1163; GRABA Y, 1992, EMBO J, V11, P3375, DOI 10.1002/j.1460-2075.1992.tb05416.x; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GURDON JB, 1988, NATURE, V336, P772, DOI 10.1038/336772a0; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; KELLER R, 1988, DEVELOPMENT, V103, P193; Keller R, 1992, DEVELOPMENT S, V116, P81; KELLER R, 1991, CELL CELL INTERACTIO, P31; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KLEIN SL, 1987, DEV BIOL, V120, P299, DOI 10.1016/0012-1606(87)90127-8; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; MOODY SA, 1987, DEV BIOL, V122, P300, DOI 10.1016/0012-1606(87)90296-X; MOON RT, 1992, CELL, V71, P709, DOI 10.1016/0092-8674(92)90545-N; NAKATSUJI N, 1986, J CELL SCI, V86, P109; NAKATSUJI N, 1983, J CELL SCI, V59, P43; NIEHRS C, 1991, EMBO J, V10, P3621, DOI 10.1002/j.1460-2075.1991.tb04928.x; REPRESA J, 1989, International Journal of Developmental Biology, V33, P397; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; SHIH J, 1992, DEVELOPMENT, V116, P901; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STEWART RM, 1990, DEVELOPMENT, V109, P363; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WINKLBAUER R, 1990, DEV BIOL, V142, P155, DOI 10.1016/0012-1606(90)90159-G; WINKLBAUER R, 1991, DEV BIOL, V148, P573, DOI 10.1016/0012-1606(91)90275-8; WINKLBAUER R, 1991, BOD MAR LAB, P147	44	168	170	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 26	1993	72	4					491	503		10.1016/0092-8674(93)90069-3	http://dx.doi.org/10.1016/0092-8674(93)90069-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8095000				2022-12-24	WOS:A1993KP16500005
J	EDWARDS, CRW; BENEDIKTSSON, R; LINDSAY, RS; SECKL, JR				EDWARDS, CRW; BENEDIKTSSON, R; LINDSAY, RS; SECKL, JR			DYSFUNCTION OF PLACENTAL GLUCOCORTICOID BARRIER - LINK BETWEEN FETAL ENVIRONMENT AND ADULT HYPERTENSION	LANCET			English	Article							BLOOD-PRESSURE; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; PROTEIN-TURNOVER; BODY-WEIGHT; GROWTH; RATS; CORTISONE; EXPOSURE; DISEASE; INFANCY	Low birthweight is associated with the subsequent development of common disorders of adult life, especially hypertension; maternal malnutrition has been suggested as the cause. We suggest an alternative aetiology-increased fetal exposure to maternal glucocorticoids. This hypothesis is supported by our findings that in rats decreased activity of the enzyme that acts as a placental barrier to maternal glucocorticoids (11beta-hydroxysteroid dehydrogenase) is associated with low birthweight. Furthermore, increased exposure of the fetus to exogenous glucocorticoids leads to low birthweight and subsequent hypertension in the offspring. Glucocorticoids acting during critical periods of prenatal development may, like other steroid hormones, exert organisational effects or imprint patterns of response that persist throughout life. Thus, the lifetime risk of common disorders may be partly determined by the intrauterine environment.			EDWARDS, CRW (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Seckl, Jonathan R/C-3555-2013; Benediktsson, Rafn/R-2457-2018	Benediktsson, Rafn/0000-0002-2954-9801; Lindsay, Robert/0000-0002-9868-5217	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAGGIA S, 1990, ENDOCRINOLOGY, V126, P2742, DOI 10.1210/endo-126-5-2742; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BEITINS IZ, 1973, PEDIATR RES, V7, P509, DOI 10.1203/00006450-197305000-00004; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; BERNAL AL, 1980, J STEROID BIOCHEM, V13, P1081, DOI 10.1016/0022-4731(80)90140-5; BUTLER NR, 1969, 2ND 1958 BRIT PER MO; CAMPBELL AG, 1967, CIRC RES, V21, P229, DOI 10.1161/01.RES.21.2.229; CANAVAN JP, 1988, DIABETES, V37, P1671, DOI 10.2337/diabetes.37.12.1671; CSABA G, 1980, HORM METAB RES, V12, P28, DOI 10.1055/s-2007-996189; CSABA G, 1979, ACTA PHYSIOL HUNG, V53, P487; ECKLES CH, 1919, RES B MIN AGR EXP ST, P35; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; GUNBERG DL, 1957, ANAT RECORD, V129, P133, DOI 10.1002/ar.1091290202; GUSTAFSSON JA, 1974, J BIOL CHEM, V249, P711; GUSTAFSSON JA, 1974, J BIOL CHEM, V249, P719; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hammond J., 1944, PROC NUTRITION SOC [CAMBRIDGE], V2, P8; HAZON N, 1990, J ENDOCRINOL, V127, P243, DOI 10.1677/joe.0.1270243; HELLER CL, 1988, J STEROID BIOCHEM, V31, P119, DOI 10.1016/0022-4731(88)90214-2; HUGGETT AS, 1944, P NUTR SOC, V2, P20; KROGER H, 1970, AM J OBSTET GYNECOL, V106, P586; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LEVER AF, 1992, J HYPERTENS, V10, P101, DOI 10.1097/00004872-199202000-00001; MAYER JS, 1985, PHYSL DEV, V65, P1020; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MILLER HC, 1974, PEDIATR RES, V8, P960, DOI 10.1203/00006450-197412000-00009; MOISAN MP, 1992, ENDOCRINOLOGY, V130, P400, DOI 10.1210/en.130.1.400; MONDER C, 1984, STEROIDS, V44, P383, DOI 10.1016/S0039-128X(84)80001-X; MURPHY BEP, 1974, AM J OBSTET GYNECOL, V118, P538, DOI 10.1016/S0002-9378(16)33697-3; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; REINISCH JM, 1978, SCIENCE, V202, P436, DOI 10.1126/science.705336; ROBINSON J, 1988, DIABETES, V37, P1665, DOI 10.2337/diabetes.37.12.1665; RUDOLPH AM, 1984, J DEV PHYSIOL, V6, P11; SANCHIS R, 1986, ALCOHOL ALCOHOLISM, V21, P295; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; Spira A, 1975, J Perinat Med, V3, P237, DOI 10.1515/jpme.1975.3.4.237; STEIN Z, 1975, DUTCH HUNGER WINTER, P119; TANNER JM, 1956, ARCH DIS CHILD, V31, P372, DOI 10.1136/adc.31.159.372; TONOLO G, 1988, J HYPERTENS, V6, P25; WALKER BR, 1992, CLIN SCI, V82, P597, DOI 10.1042/cs0820597; WALKER BR, IN PRESS CLIN ENDOCR; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; 1942, LANCET, V243, P10	47	488	493	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					355	357		10.1016/0140-6736(93)90148-A	http://dx.doi.org/10.1016/0140-6736(93)90148-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094124				2022-12-24	WOS:A1993KK93900016
J	BOWSHER, D				BOWSHER, D			CEREBROVASCULAR-DISEASE - SENSORY CONSEQUENCES OF STROKE	LANCET			English	Editorial Material							PAIN				BOWSHER, D (corresponding author), WALTON HOSP,PAIN RES INST,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND.							ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; AWERBUCH GI, 1990, INT J NEUROSCI, V55, P129, DOI 10.3109/00207459008985960; LEIJON G, 1989, PAIN, V38, P187, DOI 10.1016/0304-3959(89)90237-6; LEIJON G, 1990, PAIN S, V5, pS468; VERDUGO R, 1992, BRAIN, V115, P893, DOI 10.1093/brain/115.3.893	5	29	30	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					156	156		10.1016/0140-6736(93)90015-9	http://dx.doi.org/10.1016/0140-6736(93)90015-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093755				2022-12-24	WOS:A1993KG62700015
J	CLAYTON, RH; MURRAY, A; HIGHAM, PD; CAMPBELL, RWF				CLAYTON, RH; MURRAY, A; HIGHAM, PD; CAMPBELL, RWF			SELF-TERMINATING VENTRICULAR TACHYARRHYTHMIAS - A DIAGNOSTIC DILEMMA	LANCET			English	Article							TACHYCARDIA; POINTES	Ventricular fibrillation is generally regarded as being lethal unless promptly halted. There have been reports of self-terminating ventricular fibrillation, but similar events are described by some cardiologists as polymorphic ventricular tachycardia or even torsade de pointes. To examine how experienced cardiologists would diagnose such tachyarrhythmias, electrocardiograms of self-terminating ventricular tachyarrhythmias compatible with accepted definitions of ventricular fibrillation (rate >300/min) were sent to 22 cardiologists. During the study period of 19 months, 2462 patients treated in a 10-bed coronary-care unit were monitored by use of a single bipolar chest lead. 45 (2%) had episodes of ventricular fibrillation that were terminated by direct current (DC) shock. 12 self-terminating tachyarrhythmias (duration 5.2-49.5 s) were recorded from 8 patients, 3 of whom also had sustained ventricular fibrillation terminated by DC shock. The cardiologists offered 264 diagnoses for the self-terminating events; 42 (15.9%) ventricular fibrillation, 99 (37.5%) polymorphic ventricular tachycardia, 98 (37.1%) torsade de pointes, and 25 (9.5%) ''other''. The cardiologists differed (p<0.01 in their response patterns. The findings show that rapid self-terminating ventricular tachyarrhythmias are not uncommon in coronary-care unit patients, and that the diagnostic categorisation of these important events is highly subjective and inconsistent.	FREEMAN RD HOSP,DEPT ACAD CARDIOL,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND	Newcastle Freeman Hospital	CLAYTON, RH (corresponding author), FREEMAN RD HOSP,DEPT REG MED PHYS,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND.		Clayton, Richard/CAF-3400-2022	Clayton, Richard/0000-0002-8438-7518; Murray, Alan/0000-0003-2621-4632				BARDY GH, 1990, CARDIAC ELECTROPHYSI; BECHGAARD P, 1948, ACTA MED SCAND, V132, P9; CLAYTON RH, 1992, COMPUTER CARDIOLOGY, P685; DELUNA AB, 1989, J AMB MON, V2, P3; JOSEPHSON ME, 1979, AM J CARDIOL, V44, P623, DOI 10.1016/0002-9149(79)90279-0; JULIAN DG, 1980, J ROY COLL PHYS LOND, V14, P17; KRIKLER DM, 1976, BRIT HEART J, V38, P117; Murray A., 1985, Computers in Cardiology (Cat. No.85CH2217-8), P275; SCHWARTZ SP, 1932, ARCH INTERN MED, V49, P450; TZIVONI D, 1983, AM J CARDIOL, V52, P639, DOI 10.1016/0002-9149(83)90043-7; Zilcher H, 1980, Eur Heart J, V1, P63; ZIPES DP, 1975, CIRCULATION S, V3, P120	12	36	36	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					93	95		10.1016/0140-6736(93)92567-D	http://dx.doi.org/10.1016/0140-6736(93)92567-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	8093413				2022-12-24	WOS:A1993KF87000014
J	NIGHTINGALE, SL				NIGHTINGALE, SL			RECOMMENDATION TO IMMEDIATELY WITHDRAWN PATIENTS FROM TREATMENT WITH FELBAMATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	22	22	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					995	995		10.1001/jama.272.13.995	http://dx.doi.org/10.1001/jama.272.13.995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089899				2022-12-24	WOS:A1994PH77500007
J	WOLDEGABRIEL, G; WHITE, TD; SUWA, G; RENNE, P; DEHEINZELIN, J; HART, WK; HEIKEN, G				WOLDEGABRIEL, G; WHITE, TD; SUWA, G; RENNE, P; DEHEINZELIN, J; HART, WK; HEIKEN, G			ECOLOGICAL AND TEMPORAL PLACEMENT OF EARLY PLIOCENE HOMINIDS AT ARAMIS, ETHIOPIA	NATURE			English	Article							MIDDLE-AWASH-VALLEY; STRATIGRAPHY; DISCOVERIES; HADAR; AFAR	SEDIMENTARY deposits in the Middle Awash research area of Ethiopia's Afar depression have yielded vertebrate fossils including the most ancient hominids known. Radioisotopic dating, geochemical analysis of interbedded volcanic ashes and biochronological considerations place the hominid-bearing deposits at around 4.4 million years of age. Sedimentological, botanical and faunal evidence suggests a wooded habitat for the Aramis hominids.	UNIV CALIF BERKELEY,HUMAN EVOLUTIONARY STUDIES LAB,BERKELEY,CA 94720; LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545; UNIV TOKYO,DEPT ANTHROPOL,BUNKYO KU,TOKYO 113,JAPAN; BERKELEY GEOCHRONOL CTR,BERKELEY,CA 94709; INST ROYAL SCI NAT BELGIQUE,B-1040 BRUSSELS,BELGIUM; MIAMI UNIV,DEPT GEOL,OXFORD,OH 45056	University of California System; University of California Berkeley; United States Department of Energy (DOE); Los Alamos National Laboratory; University of Tokyo; Berkeley Geochronolgy Center; University System of Ohio; Miami University			Klein, Richard G/B-5910-2009	Renne, Paul/0000-0003-1769-5235				ADAMSON DA, 1987, J HUM EVOL, V16, P597, DOI 10.1016/0047-2484(87)90015-7; ANDREWS PJ, 1989, J HUM EVOL, V18, P173, DOI 10.1016/0047-2484(89)90071-7; ASFAW B, 1987, J HUM EVOL, V16, P611, DOI 10.1016/0047-2484(87)90016-9; BONNEFILLE R, 1987, PALAEOGEOGR PALAEOCL, V60, P249, DOI 10.1016/0031-0182(87)90035-6; CLARK JD, 1984, NATURE, V307, P423, DOI 10.1038/307423a0; DEINO A, 1990, J GEOPHYS RES-SOLID, V95, P8453, DOI 10.1029/JB095iB06p08453; GORTANI M, 1973, MISSIONE GEOLOGICA A; HAILEAB B, 1992, J HUM EVOL, V22, P453, DOI 10.1016/0047-2484(92)90080-S; HILGEN FJ, 1991, EARTH PLANET SC LETT, V107, P349, DOI 10.1016/0012-821X(91)90082-S; Kalb J.E., 1982, Newsletters on Stratigraphy, V11, P95; KALB JE, 1982, NATURE, V298, P25, DOI 10.1038/298025a0; KALB JE, 1993, T AM PHILOS SOC, V83, P1; KALB JE, 1982, NATURE, V298, P17, DOI 10.1038/298017a0; LEAKEY M.D., 1987, LAETOLI PLIOCENE SIT; TAJEB M, 1974, THESIS U PARIS 6; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0; WHITE TD, 1993, NATURE, V366, P261, DOI 10.1038/366261a0	17	201	207	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					330	333		10.1038/371330a0	http://dx.doi.org/10.1038/371330a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PH254	8090201				2022-12-24	WOS:A1994PH25400051
J	COX, TM				COX, TM			GAUCHERS-DISEASE - A BRAND LEADER	LANCET			English	Editorial Material							GLUCOCEREBROSIDASE				COX, TM (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND.							ACHORD DT, 1978, CELL, V15, P269, DOI 10.1016/0092-8674(78)90102-2; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; DEDUVE C, 1964, FED PROC, V23, P1045; FRATANTONI JC, 1968, SCIENCE, V163, P570; MISTRY PK, 1992, Q J MED, V84, P541; MOULLIER P, 1993, NAT GENET, V4, P154, DOI 10.1038/ng0693-154; OHASHI T, 1992, P NATL ACAD SCI USA, V89, P11332, DOI 10.1073/pnas.89.23.11332; SATO Y, 1993, J CLIN INVEST, V91, P1909, DOI 10.1172/JCI116409; ZIMRAN A, 1993, BLOOD, V82, P1107	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					694	695		10.1016/0140-6736(93)91703-O	http://dx.doi.org/10.1016/0140-6736(93)91703-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103817				2022-12-24	WOS:A1993LX46900004
J	HORWICH, AL; LOW, KB; FENTON, WA; HIRSHFIELD, IN; FURTAK, K				HORWICH, AL; LOW, KB; FENTON, WA; HIRSHFIELD, IN; FURTAK, K			FOLDING IN-VIVO OF BACTERIAL CYTOPLASMIC PROTEINS - ROLE OF GROEL	CELL			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI K-12; HEAT-SHOCK PROTEINS; ORNITHINE TRANSCARBAMYLASE; MOLECULAR CHAPERONE; YEAST MITOCHONDRIA; HSP60; GENE; DNAK; MUTAGENESIS	A general role for chaperonin ring structures in mediating folding of newly translated proteins has been suggested. Here we have directly examined the role of the E. coli chaperonin GroEL in the bacterial cytoplasm by production of temperature-sensitive lethal mutations in this essential gene. After shift to nonpermissive temperature, the rate of general translation in the mutant cells was reduced, but, more specifically, a defined group of cytoplasmic proteins - including citrate synthase, ketoglutarate dehydrogenase, and polynucleotide phosphorylase - were translated but failed to reach native form. Similarly, a monomeric test protein, maltose-binding protein, devoid of its signal domain, was translated but failed to fold to its native conformation. We conclude that GroEL indeed is a machine at the distal end of the pathway of transfer of genetic information, assisting a large and specific set of newly translated cytoplasmic proteins to reach their native tertiary structures.	YALE UNIV, SCH MED, DEPT THERAPEUT RADIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; ST JOHNS UNIV, DEPT BIOL SCI, JAMAICA, NY 11439 USA	Yale University; Howard Hughes Medical Institute; Yale University; Saint John's University	HORWICH, AL (corresponding author), YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA.							Bachmann B.J., 1987, ESCHERICHIA COLI SAL, P1190; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BUSBY S, 1982, J MOL BIOL, V154, P197, DOI 10.1016/0022-2836(82)90060-2; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; DONNELLY CE, 1992, J BACTERIOL, V174, P3133, DOI 10.1128/jb.174.10.3133-3139.1992; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS C P, 1974, Journal of Supramolecular Structure, V2, P349, DOI 10.1002/jss.400020224; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HOOGENRAAD NJ, 1980, ANAL BIOCHEM, V101, P97, DOI 10.1016/0003-2697(80)90045-7; HORWICH A, 1980, J VIROL, V36, P125, DOI 10.1128/JVI.36.1.125-132.1980; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; KALOUSEK F, 1978, J BIOL CHEM, V253, P3939; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEE SC, 1992, J BIOL CHEM, V267, P2849; LOW B, 1971, J BACTERIOL, V108, P742, DOI 10.1128/JB.108.2.742-750.1971; LOW B, 1973, J BACTERIOL, V113, P798, DOI 10.1128/JB.113.2.798-812.1973; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; SCHELLHORN HE, 1991, J BACTERIOL, V173, P6192, DOI 10.1128/jb.173.19.6192-6198.1991; STERNBERG N, 1973, J MOL BIOL, V76, P45; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VANBOGELEN RA, 1992, ELECTROPHORESIS, V13, P1014, DOI 10.1002/elps.11501301203; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; WANG Z, 1992, PROTEIN SCI, V1, P522; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; WYNN RM, 1992, J BIOL CHEM, V267, P12400; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	56	299	304	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 10	1993	74	5					909	917		10.1016/0092-8674(93)90470-B	http://dx.doi.org/10.1016/0092-8674(93)90470-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8104102				2022-12-24	WOS:A1993LX29200016
J	WEISSKOPF, MG; ZALUTSKY, RA; NICOLL, RA				WEISSKOPF, MG; ZALUTSKY, RA; NICOLL, RA			THE OPIOID PEPTIDE DYNORPHIN MEDIATES HETEROSYNAPTIC DEPRESSION OF HIPPOCAMPAL MOSSY FIBER SYNAPSES AND MODULATES LONG-TERM POTENTIATION (VOL 362, PG 423, 1993)	NATURE			English	Correction, Addition																		DERRICK BE, 1991, BRAIN RES BULL, V27, P219, DOI 10.1016/0361-9230(91)90071-Q; KUPFERMANN I, 1991, PHYSIOL REV, V71, P683, DOI 10.1152/physrev.1991.71.3.683; WEISSKOPF MG, 1993, NATURE, V362, P423, DOI 10.1038/362423a0	3	35	35	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					188	188		10.1038/365188a0	http://dx.doi.org/10.1038/365188a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8103916	Bronze			2022-12-24	WOS:A1993LW44200056
J	PRAYITNO, SW; ADDY, M; WADE, WG				PRAYITNO, SW; ADDY, M; WADE, WG			DOES GINGIVITIS LEAD TO PERIODONTITIS IN YOUNG-ADULTS	LANCET			English	Note								It has been assumed that poor oral hygiene predisposes to gingivitis with progression to periodontitis and tooth loss. However, a high prevalence of gingivitis occurs in some populations in which severe periodontitis is rare. To assess whether gingivitis is a reliable predictor of periodontitis, we compared the periodontal health of tea pickers and university students aged between 18 and 30 in Indonesia. Oral hygiene and gingival health was significantly better in students than in tea pickers. However, the prevalence and the severity of chronic periodontitis were similar in the two groups. Our findings suggest that gingivitis is a poor predictor of periodontitis in subjects younger than 30 years. Attempts to prevent periodontitis in young adults through antigingivitis measures. such as plaque control may be unsuccessful.	DENT SCH, DEPT PERIODONTOL, JAKARTA, INDONESIA; UNIV WALES COLL MED, SCH DENT, DEPT PERIODONTOL, CARDIFF CF4 4XY, WALES	Cardiff University				Wade, William/0000-0003-2685-826X				Addy M, 1988, Community Dent Health, V5, P345; BAELUM V, 1986, J PERIODONTAL RES, V21, P221, DOI 10.1111/j.1600-0765.1986.tb01454.x; CUTRESS TW, 1982, COMMUNITY DENT ORAL, V10, P193, DOI 10.1111/j.1600-0528.1982.tb00378.x; LOE H, 1965, J PERIODONTOL, V36, P177, DOI 10.1902/jop.1965.36.3.177; LOVDAL A., 1958, JOUR AMER DENTAL ASSOC, V56, P21; MARSHALLDAY CD, 1955, J PERIODONTOL, V26, P185; PAPAPANOU PN, 1988, J CLIN PERIODONTOL, V15, P469, DOI 10.1111/j.1600-051X.1988.tb01602.x; PRAYITNO SW, 1990, THESIS U WALES CARDI; Sheiham A, 1969, Dent Pract Dent Rec, V19, P232; SILNESS J, 1964, Acta Odontol Scand, V22, P121, DOI 10.3109/00016356408993968	10	20	20	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	1993	342	8869					471	472		10.1016/0140-6736(93)91596-E	http://dx.doi.org/10.1016/0140-6736(93)91596-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102432				2022-12-24	WOS:A1993LU07500013
J	BOTKER, HE; MOLLER, N; OVESEN, P; MENGEL, A; SCHMITZ, O; ORSKOV, H; BAGGER, JP				BOTKER, HE; MOLLER, N; OVESEN, P; MENGEL, A; SCHMITZ, O; ORSKOV, H; BAGGER, JP			INSULIN-RESISTANCE IN MICROVASCULAR ANGINA (SYNDROME-X)	LANCET			English	Article							NORMAL CORONARY-ARTERIES; ESSENTIAL-HYPERTENSION; MUSCLE; DISEASE; DISORDER; OBESITY; NIDDM	Patients with microvascular angina (syndrome X) may be insulin resistant. We designed a study to establish whether this is the case. 11 patients with microvascular angina were compared with 9 matched subjects with noncardiac chest pain. Patients and controls were evaluated by coronary sinus catheterisation, and by isotopic measurement of glucose turnover, indirect calorimetry, and forearm technique during a 3 h baseline period after overnight fast and during a 2 h hyperinsulinaemic euglycaemic clamp. Pace-induced increase in coronary sinus blood flow was less in patients than in controls, whereas forearm blood flow did not differ between groups. Baseline measures of glucose metabolism were normal. During the clamp, glucose production and lipolysis were equally suppressed in both groups. Mean (SE) total insulin-induced glucose uptake was significantly impaired in patients compared with controls (3.9 [0.7] vs 6.4 [0.7] mg/kg per min; p < 0.01), and insulin-stimulated glucose uptake in the forearm was significantly reduced in patients (0.88 [0-101 vs 1.6 [0.301 mmol/L; p < 0.001). Reduced oxidative and nonoxidative metabolism accounted for the defect in overall glucose uptake in patients. No correlation between changes in coronary sinus blood flow and total body glucose uptake was seen. We found that microvascular angina was associated with substantial insulin resistance. Whether this relation is causal or coincidental is as yet unsettled.	AARHUS UNIV,INST EXPTL CLIN RES,DK-8000 AARHUS,DENMARK; AARHUS UNIV HOSP,AARHUS KOMMUNEHOSP,DEPT MED ENDOCRINOL & DIABET M,DK-8000 AARHUS,DENMARK	Aarhus University; Aarhus University	BOTKER, HE (corresponding author), UNIV HOSP AARHUS,SKEJBY HOSP,DEPT CARDIOL,DK-8200 AARHUS N,DENMARK.		Moller, Niels/E-5091-2011	Moller, Niels/0000-0001-5627-7322; Botker, Hans Erik/0000-0001-6358-8962				BAGGER JP, 1985, CARDIOVASC RES, V19, P27, DOI 10.1093/cvr/19.1.27; BARON AD, 1990, J CLIN ENDOCR METAB, V70, P1525, DOI 10.1210/jcem-70-6-1525; BRESSLER P, 1992, DIABETES S1, V41, pA24; CANNON RO, 1990, AM J MED, V88, P217, DOI 10.1016/0002-9343(90)90145-4; CANNON RO, 1992, CIRCULATION, V85, P883, DOI 10.1161/01.CIR.85.3.883; CANNON RO, 1988, AM J CARDIOL, V61, P1338, DOI 10.1016/0002-9149(88)91180-0; CANNON RO, 1990, CIRCULATION, V82, P2011, DOI 10.1161/01.CIR.82.6.2011; DEAN JD, 1991, LANCET, V337, P456; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DETEJADA IS, 1989, NEW ENGL J MED, V320, P1025, DOI 10.1056/NEJM198904203201601; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FISHER BM, 1986, DIABETOLOGIA, V29, P706, DOI 10.1007/BF00870280; HOTHERNIELSEN O, 1987, DIABETOLOGIA, V30, P834; KEMP HG, 1973, AM J CARDIOL, V32, P375, DOI 10.1016/S0002-9149(73)80150-X; KOIVISTO V A, 1986, Diabetes Metabolism Reviews, V1, P445; LILLIOJA S, 1987, J CLIN INVEST, V80, P415, DOI 10.1172/JCI113088; MOLLER N, 1990, J CLIN ENDOCR METAB, V70, P1179, DOI 10.1210/jcem-70-4-1179; OPERK D, 1989, CIRCULATION, V80, P1610; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RICHARDSON PJ, 1974, LANCET, V2, P677; SAX FL, 1987, NEW ENGL J MED, V317, P1366, DOI 10.1056/NEJM198711263172202; STALDER M, 1982, DIABETOLOGIA, V21, P544; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x	26	88	92	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					136	140						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101255				2022-12-24	WOS:A1993LN04200010
J	CLARK, SG; CHISHOLM, AD; HORVITZ, HR				CLARK, SG; CHISHOLM, AD; HORVITZ, HR			CONTROL OF CELL FATES IN THE CENTRAL BODY REGION OF C-ELEGANS BY THE HOMEOBOX GENE LIN-39	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; POST-EMBRYONIC DEVELOPMENT; PATTERN-FORMATION; DROSOPHILA; EXPRESSION; SEQUENCES; SYSTEM; SPECIFICATION; LINEAGES; CLUSTER	Cells in the mid-body region of the nematode C. elegans develop differently from their anterior or posterior homologs. The gene lin-39 is required for mid-body region-specific development. In lin-39 mutants, midbody cells express fates characteristic of more anterior or posterior homologs, and the migration of a neuroblast through the mid-body is defective. lin-39 acts cell autonomously in these mid-body cells and in the migrating neuroblast. lin-39 encodes a protein with an Antennapedia class homeodomain, most similar to those of the Drosophila homeotic genes Deformed and Sex combs reduced, and is located in a homeotic gene cluster with two other regional homeotic genes, mab-5 and egl-5. lin-39 and mab-5 function combinatorially in 2 ectodermal cells and have redundant functions in gonad development.	MIT,DEPT BIOL,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)				Chisholm, Andrew/0000-0001-5091-0537	NIGMS NIH HHS [GM24943, GM24663] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024663, R01GM024663, R01GM024943] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROIAN RV, 1993, MOL CELL BIOL, V13, P626, DOI 10.1128/MCB.13.1.626; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; BURGLIN TR, 1993, IN PRESS GUIDEBOOK H; CHALFIE M, 1983, SCIENCE, V221, P61, DOI 10.1126/science.6857263; CHISHOLM A, 1991, DEVELOPMENT, V111, P921; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLARK SG, 1992, THESIS MIT CAMBRIDGE; COSTA M, 1988, CELL, V55, P747, DOI 10.1016/0092-8674(88)90131-6; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; ELLIS H, 1985, THESIS MIT CAMBRIDGE; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FIXSEN W, 1985, COLD SPRING HARB SYM, V50, P99, DOI 10.1101/SQB.1985.050.01.014; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HIRSH D, 1976, DEV BIOL, V49, P200, DOI 10.1016/0012-1606(76)90267-0; HODGKIN J, 1979, GENETICS, V91, P67; HODGKIN J, 1988, NEMATODE CAENORHABDI, P491; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KENYON C, 1991, SCIENCE, V253, P516, DOI 10.1126/science.1677487; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LEMOTTE PK, 1989, EMBO J, V8, P219, DOI 10.1002/j.1460-2075.1989.tb03367.x; LI C, 1990, NEURON, V4, P681, DOI 10.1016/0896-6273(90)90195-L; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; ROSENBLUTH RE, 1985, GENETICS, V109, P493; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; SCHALLER D, 1990, NUCLEIC ACIDS RES, V18, P2033, DOI 10.1093/nar/18.8.2033; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STROEHER VL, 1986, MOL CELL BIOL, V6, P4667, DOI 10.1128/MCB.6.12.4667; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; White J., 1988, NEMATODE CAENORHABDI, V17, P81; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; White T.J., 1990, PCR PROTOCOLS GUIDE, P315	50	216	232	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					43	55		10.1016/0092-8674(93)90293-Y	http://dx.doi.org/10.1016/0092-8674(93)90293-Y			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8101475				2022-12-24	WOS:A1993LN62500006
J	DAY, CP; JAMES, OFW; BUTLER, TJ; CAMPBELL, RWF				DAY, CP; JAMES, OFW; BUTLER, TJ; CAMPBELL, RWF			QT PROLONGATION AND SUDDEN CARDIAC DEATH IN PATIENTS WITH ALCOHOLIC LIVER-DISEASE	LANCET			English	Article							MYOCARDIAL-INFARCTION; CIRRHOSIS; CARDIOMYOPATHY; CONSUMPTION; DISPERSION	Cardiovascular death is the most important cause of mortality in alcoholics, yet alcohol may protect against ischaemic heart disease. This could be explained if deaths were a consequence of alcohol-related arrhythmias rather than of coronary atheroma. In many conditions, abnormalities of the QT interval are markers of arrhythmia and for risk of sudden death. We examined the relation between QT intervals and mortality in patients with alcoholic liver disease. Simultaneous 12-lead electrocardiographic recordings were obtained from 69 patients with histologically proven alcoholic liver disease (without evidence of structural heart disease), and from 40 healthy non-drinking controls matched for age and sex. Patients were abstinent for at least 7 days before investigation to exclude acute effects of alcohol. QT intervals were corrected for rate with Bazett's and cube root formulae to define QT(c) and QT(cub), respectively. Unlike QT(c), QT(cub) was independent of rate. Patients were followed for up to four years. For those who died, the cause was determined from case records and postmortem reports. Maximum QT intervals were longer in alcoholics than in controls (QT(cub) 450 vs 439, p = 0.016). This difference was not explained by variations in electrolytes. QT intervals were prolonged in the 14 patients who died compared with survivors (QT(cub) 471 vs 446, p = 0.007). This difference was mainly due to the long QT intervals in the 6 patients with sudden cardiac deaths (QT(cub) 493). The only other factor independently associated with death was sex. QT interval prolongation occurs in some patients with alcoholic liver disease and is associated with an adverse prognosis, especially sudden cardiac death. QT measurement should be included in the initial assessment of alcoholic patients, particularly in those considered for liver transplantation.	UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT MED, NEWCASTLE UPON TYNE NE2 4HH, ENGLAND; UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT MED STAT, NEWCASTLE UPON TYNE NE2 4HH, ENGLAND	Newcastle University - UK; Newcastle University - UK	DAY, CP (corresponding author), UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT ACAD CARDIOL, NEWCASTLE UPON TYNE NE2 4HH, ENGLAND.		Day, Christopher/Z-3305-2019					AHMED SS, 1984, J AM COLL CARDIOL, V3, P696, DOI 10.1016/S0735-1097(84)80245-4; AHNVE S, 1980, ACTA MED SCAND, V208, P55; ALGRA A, 1991, CIRCULATION, V83, P1888, DOI 10.1161/01.CIR.83.6.1888; ASHLEY MJ, 1980, J STUD ALCOHOL, V41, P1040, DOI 10.15288/jsa.1980.41.1040; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; Child CG., 1964, LIVER PORTAL HYPERTE; COHEN EJ, 1988, AM J CARDIOL, V62, P971, DOI 10.1016/0002-9149(88)90906-X; COWAN JC, 1988, AM J CARDIOL, V61, P83, DOI 10.1016/0002-9149(88)91309-4; DAY CP, 1991, HEPATOLOGY, V14, P798, DOI 10.1002/hep.1840140509; DAY CP, 1992, BRIT HEART J, V67, P39; DAY CP, 1991, EUR HEART J, V12, P423, DOI 10.1093/oxfordjournals.eurheartj.a059911; DYER AR, 1977, CIRCULATION, V56, P1067, DOI 10.1161/01.CIR.56.6.1067; ETTINGER PO, 1978, AM HEART J, V95, P555, DOI 10.1016/0002-8703(78)90296-X; EVANS W, 1959, BRIT HEART J, V31, P445; GREENSPON AJ, 1979, NEW ENGL J MED, V301, P1049, DOI 10.1056/NEJM197911083011906; HAYES PC, 1990, LANCET, V336, P153, DOI 10.1016/0140-6736(90)91668-Z; JACKMAN WM, 1988, PROG CARDIOVASC DIS, V31, P115, DOI 10.1016/0033-0620(88)90014-X; KELBAEK H, 1984, AM J CARDIOL, V54, P852, DOI 10.1016/S0002-9149(84)80220-9; KINO M, 1981, BRIT HEART J, V46, P545; KOIDE T, 1981, JPN HEART J, V22, P151; KOIDE T, 1972, JPN HEART J, V13, P418; KOSKINEN P, 1987, BRIT HEART J, V57, P468, DOI 10.1136/hrt.57.5.468; KRAMER K, 1968, ANN INTERN MED, V69, P273, DOI 10.7326/0003-4819-69-2-273; KRASNER N, 1977, BRIT MED J, V1, P1497, DOI 10.1136/bmj.1.6075.1497; KUO CS, 1983, CARDIOVASC RES, V17, P152, DOI 10.1093/cvr/17.3.152; LEFKOWITCH JH, 1983, HUM PATHOL, V14, P457, DOI 10.1016/S0046-8177(83)80293-7; PANOS RJ, 1988, PACE, V11, P423, DOI 10.1111/j.1540-8159.1988.tb06002.x; SCHLICHTING P, 1983, HEPATOLOGY, V3, P889; SCHWARTZ PJ, 1975, AM HEART J, V89, P378, DOI 10.1016/0002-8703(75)90089-7; TURNER TB, 1981, JOHNS HOPKINS MED J, V148, P53	30	178	182	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	1993	341	8858					1423	1428						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099138				2022-12-24	WOS:A1993LF84100001
J	GOUGEON, ML; MONTAGNIER, L				GOUGEON, ML; MONTAGNIER, L			APOPTOSIS IN AIDS	SCIENCE			English	Editorial Material							MATURE T-CELLS; DEATH; RECEPTOR; SUPERANTIGEN; MECHANISMS; ANTIGEN; VIRUS				GOUGEON, ML (corresponding author), INST PASTEUR, DEPT AIDS & RETROVIRUSES, 28 RUE DR ROUX, F-75724 PARIS, FRANCE.							ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COLE BC, 1991, IMMUNOL TODAY, V12, P271, DOI 10.1016/0167-5699(91)90125-D; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P287, DOI 10.1089/aid.1993.9.287; GOUGEON ML, IN PRESS AIDS RES HU; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HABESHAW J, 1992, IMMUNOL TODAY, V13, P207, DOI 10.1016/0167-5699(92)90155-Z; KAZIKI H, 1989, J IMMUNOL, V43, P1790; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LAURENTCRAWFORD AG, IN PRESS AIDS RES HU; LEMAITRE M, 1992, INFECT IMMUN, V60, P742; LO SC, 1989, AM J TROP MED HYG, V41, P601, DOI 10.4269/ajtmh.1989.41.601; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MONTAGNIER L, IN PRESS NEW CONCEPT; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; PAU X, COMMUNICATION; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112	26	341	359	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1993	260	5112					1269	1270		10.1126/science.8098552	http://dx.doi.org/10.1126/science.8098552			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8098552				2022-12-24	WOS:A1993LE02500031
J	COELHO, HLL; TEIXEIRA, AC; SANTOS, AP; FORTE, EB; MORAIS, SM; LAVECCHIA, C; TOGNONI, G; HERXHEIMER, A				COELHO, HLL; TEIXEIRA, AC; SANTOS, AP; FORTE, EB; MORAIS, SM; LAVECCHIA, C; TOGNONI, G; HERXHEIMER, A			MISOPROSTOL AND ILLEGAL ABORTION IN FORTALEZA, BRAZIL	LANCET			English	Article								Misoprostol, a prostaglandin E1 analogue indicated for ulcer treatment, has been widely used as an abortifacient by women in Brazil, where abortion is legal only in cases of rape or incest, or to save the woman's life. Because misoprostol is an inefficient abortifacient, many women who use it have incomplete abortions and need uterine evacuation. We reviewed the records of women admitted to the main obstetric hospital of Fortaleza, capital of Ceara state, Brazil, between January, 1990, and July, 1992, for uterine evacuation after induced abortion. The number of incomplete abortions induced by misoprostol increased substantially during the first half of 1990, and declined thereafter. Of the 593 cases in 1991, 75% were related to misoprostol, 10% to the use of other specified drugs, and 6% to unspecified drugs. For the remaining 9% the procedure used was not recorded; these included 3% in whom abortion had been induced by a clandestine abortionist. The number of uterine evacuations per month fell from 89 in August, 1990, to 62 in July, 1991, when sales of misoprostol in Ceara state were suspended. The fall continued after the sale of misoprostol ceased, to about 20 cases in December, 1991 numbers remained around this level until June, 1992, sustained by clandestine sales. The lack of access to contraception is the main reason for the large numbers of unplanned pregnancies and is a major public health issue for Brazilian women. The prohibition of abortion creates a void in which misuse of medicines is one extra complication, mainly because of the poor control of drug marketing.	FED UNIV CEARA,DEPT PHARM,PREVENCAO USO INDEVIDO MEDICAMENTOS GRP,FORTALEZA,BRAZIL; UNIV MILAN,IST BIOMETRIA & STAT MED,I-20122 MILAN,ITALY; COCHRANE CTR,NHS RES & DEV PROGRAMME,OXFORD,ENGLAND	Universidade Federal do Ceara; University of Milan; Cochrane Centre	COELHO, HLL (corresponding author), MARIO NEGRI INST PHARMACOL RES,VIA ERITREA 62,I-20157 MILAN,ITALY.			La Vecchia, Carlo/0000-0003-1441-897X; Araujo Teixeira, Ana Claudia de/0000-0003-2851-5260				BAIRD DT, 1992, LANCET, V339, P313, DOI 10.1016/0140-6736(92)91392-L; COELHO HLL, 1991, LANCET, V338, P247, DOI 10.1016/0140-6736(91)90379-4; COELHO HLL, 1991, CIENCIA HOJE, V13, P60; FONSECA W, 1991, LANCET, V338, P1594, DOI 10.1016/0140-6736(91)92414-W; FONSECA W, 1991, LANCET, V338, P56, DOI 10.1016/0140-6736(91)90046-R; LAGUARDIA K, 1990, OBSTET GYNECOL, V75, P28; MUMFORD SD, 1984, AM J OBSTET GYNECOL, V149, P639, DOI 10.1016/0002-9378(84)90249-7; NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; PAUMGARTTEN FJR, 1992, RISK ASSESSMENT PREN, P163; PINOTTI JA, 1989, INT J GYNECOL OBSTET, V3, P97; RABE T, 1987, GEBURTSH FRAUENHEILK, V47, P324, DOI 10.1055/s-2008-1035830; Schonhofar P S, 1991, Lancet, V337, P1534, DOI 10.1016/0140-6736(91)93212-R; SCHOR N, 1990, REV SAUDE PUBL, V24, P1444	13	77	82	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1261	1263		10.1016/0140-6736(93)91157-H	http://dx.doi.org/10.1016/0140-6736(93)91157-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LC497	8098403				2022-12-24	WOS:A1993LC49700015
J	MCCORMICK, J				MCCORMICK, J			OLFACTION - IN PRAISE OF STINKS	LANCET			English	Editorial Material											MCCORMICK, J (corresponding author), UNIV DUBLIN TRINITY COLL,DEPT COMMUNITY HLTH & GEN PRACTICE,DUBLIN 2,IRELAND.							FANGER PO, 1988, P INDOOR AMBIENT AIR, P365; SHUSTERMAN D, 1992, AM J PUBLIC HEALTH, V82, P1566, DOI 10.2105/AJPH.82.11.1566	2	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1126	1127		10.1016/0140-6736(93)93134-M	http://dx.doi.org/10.1016/0140-6736(93)93134-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KZ687	8097810				2022-12-24	WOS:A1993KZ68700010
J	ZENZ, M; WILLWEBERSTRUMPF, A				ZENZ, M; WILLWEBERSTRUMPF, A			OPIOPHOBIA AND CANCER PAIN IN EUROPE	LANCET			English	Article											ZENZ, M (corresponding author), UNIV HOSP BERGMANNSHEIL,DEPT ANAESTHESIOL INTENS CARE & PAIN THERAPY,W-4630 BOCHUM 1,GERMANY.							AGENAS I, 1982, LAKARTIDNINGEN, V5, P287; ANGAROLA RT, 1990, J PAIN SYMPT MANAGEM, V2, P6; Loeser J., 1990, MANAGEMENT PAIN, P2040; PORTER J, 1980, NEW ENGL J MED, V302, P123; Sorge J, 1990, Schmerz, V4, P151, DOI 10.1007/BF02527878; Twycross RG, 1983, SYMPTOM CONTROL FAR; Willweber-Strumpf A, 1992, Schmerz, V6, P255, DOI 10.1007/BF02527815; 1986, CANCER PAIN RELIEF	8	146	148	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1075	1076		10.1016/0140-6736(93)92425-S	http://dx.doi.org/10.1016/0140-6736(93)92425-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	8096970				2022-12-24	WOS:A1993KZ01800017
J	LEFF, JA; PARSONS, PE; DAY, CE; TANIGUCHI, N; JOCHUM, M; FRITZ, H; MOORE, FA; MOORE, EE; MCCORD, JM; REPINE, JE				LEFF, JA; PARSONS, PE; DAY, CE; TANIGUCHI, N; JOCHUM, M; FRITZ, H; MOORE, FA; MOORE, EE; MCCORD, JM; REPINE, JE			SERUM ANTIOXIDANTS AS PREDICTORS OF ADULT RESPIRATORY-DISTRESS SYNDROME IN PATIENTS WITH SEPSIS	LANCET			English	Article							TUMOR NECROSIS FACTOR; SUPEROXIDE-DISMUTASE; FACTOR-VIII; GLUTATHIONE; DEFICIENCY; ELASTASE; ANTIGEN; PROTEIN; INJURY	Adult respiratory distress syndrome (ARDS) can develop as a complication of various disorders, including sepsis, but it has not been possible to identify which of the patients at risk will develop this serious disorder. We have investigated the ability of six markers, measured sequentially in blood, to predict development of ARDS in 26 patients with sepsis. At the initial diagnosis of sepsis (6-24 h before the development of ARDS), serum manganese superoxide dismutase concentration and catalase activity were higher in the 6 patients who subsequently developed ARDS than in 20 patients who did not develop ARDS. These changes in antioxidant enzymes predicted the development of ARDS in septic patients with the same sensitivity, specificity, and efficiency as simultaneous assessments of serum lactate dehydrogenase activity and factor VIII concentration. By contrast, serum glutathione peroxidase activity and alpha1Pi-elastase complex concentration did not differ at the initial diagnosis of sepsis between patients who did and did not subsequently develop ARDS, and were not as effective in predicting the development of ARDS. Measurement of manganese superoxide dismutase and catalase, in addition to the other markers, should facilitate identification of patients at highest risk of ARDS and allow prospective treatment.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,OSAKA,JAPAN; UNIV MUNICH,DEPT CLIN BIOCHEM,W-8000 MUNICH 2,GERMANY; UNIV COLORADO,DENVER GEN HOSP,DEPT MED,DENVER,CO 80202; UNIV COLORADO,DENVER GEN HOSP,DEPT SURG,DENVER,CO 80202	Osaka University; University of Munich; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center; University of Colorado System; University of Colorado Denver	LEFF, JA (corresponding author), WEBB WARING INST BIOMED RES,4200 E 9TH AVE,BOX C322,DENVER,CO 80262, USA.		Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL040784, R01HL045582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 40784, HL-01849, HL 45582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beutler E., 1984, RED CELL METABOLISM, P1; BROWN JM, 1990, P NATL ACAD SCI USA, V87, P5026, DOI 10.1073/pnas.87.13.5026; BUHL R, 1989, LANCET, V2, P1294; CARVALHO ACA, 1982, NEW ENGL J MED, V307, P1113, DOI 10.1056/NEJM198210283071803; CEJKA J, 1982, CLIN CHEM, V28, P1356; DUSWALD KH, 1985, SURGERY, V98, P892; DWENGER A, 1991, ADULT RESPIRATORY DI, P91; HILGENFELDT U, 1990, EUR J CLIN PHARMACOL, V38, P125; KAWAGUCHI T, 1990, BIOCHEM BIOPH RES CO, V171, P1378, DOI 10.1016/0006-291X(90)90838-E; LEFF JA, 1992, FREE RADICAL BIO MED, V13, P143, DOI 10.1016/0891-5849(92)90076-S; LEFF JA, 1993, INFLAMMATION, V17, P199, DOI 10.1007/BF00916105; LEFF JA, 1992, AM REV RESPIR DIS, V146, P985, DOI 10.1164/ajrccm/146.4.985; PACHT ER, 1991, CHEST, V100, P1397, DOI 10.1378/chest.100.5.1397; PARSONS PE, 1989, AM REV RESPIR DIS, V140, P294, DOI 10.1164/ajrccm/140.2.294; REPINE JE, 1992, LANCET, V339, P466, DOI 10.1016/0140-6736(92)91067-I; ROCKER GM, 1989, LANCET, V1, P120; RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; TANIGUCHI N, 1992, ADV CLIN CHEM, V29, P1, DOI 10.1016/S0065-2423(08)60221-8; WHITE CW, 1989, J APPL PHYSIOL, V66, P1003, DOI 10.1152/jappl.1989.66.2.1003; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703	21	103	111	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					777	780		10.1016/0140-6736(93)90558-X	http://dx.doi.org/10.1016/0140-6736(93)90558-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8095998	Green Submitted			2022-12-24	WOS:A1993KU90000002
J	KALACHE, A; MAGUIRE, A; THOMPSON, SG				KALACHE, A; MAGUIRE, A; THOMPSON, SG			AGE AT LAST FULL-TERM PREGNANCY AND RISK OF BREAST-CANCER	LANCET			English	Article							REPRODUCTIVE FACTORS; 1ST BIRTH; PARITY; EPIDEMIOLOGY; POPULATION; WOMEN	Age at first full-term pregnancy (FTP) has long been thought to be the major reproductive risk factor in breast cancer but a Norwegian study suggested that age at last FTP might be more important. In Norway ''high parity'' means 4 or more deliveries. Does this finding hold in an area with a much broader distribution of parity? Data from a case-control study done in 1980-82 in Fortaleza and Recife, two cities in Brazil's impoverished north-east, have been used to explore further the influence of age at last FTP. The cases were 509 women with histologically diagnosed breast cancer who were matched with hospital controls for age and area of residence. The analysis was based on case-control pairs interviewed by the same person. High breast cancer risk was associated with low parity; after adjustment for parity, breast cancer risk was related both to late age at first FTP (odds ratio [OR] 1.21 for each 5 year increase, p = 0.008) and to late age at last FTP (OR 1.24, p = 0.0007). However, multivariate analysis revealed that the effect of age at last FTP dominated that of age at first FTP: once age at last FTP was taken into account the effect of age at first FTP was no longer significant (OR 1.08, p = 0.38) while the association with parity became more striking. These results challenge the view that age at first FTP is the principal reproductive variable related to breast cancer risk. Moreover, they suggest that high parity is protective independent of ages at first and last FTP. Given recent worldwide reductions in fertility rates, breast cancer incidence may be expected to increase. Balancing that may be the willingness of some women to complete their families by, say, age 35 if they were to be told that this might reduce their risk of breast cancer.	UNIV LONDON LONDON SCH HYG & TROP MED, MED STAT UNIT, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine	KALACHE, A (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, HLTH PROMOT SCI UNIT, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.							ADAMI HO, 1980, BRIT J CANCER, V42, P651, DOI 10.1038/bjc.1980.298; ARRUDA JM, 1987, PESQUISA NACIONAL SA; Breslow N, 1980, STATISTICAL METHODS, V32; BRINTON LA, 1983, BRIT J CANCER, V47, P757, DOI 10.1038/bjc.1983.128; CHOI NW, 1978, AM J EPIDEMIOL, V107, P510, DOI 10.1093/oxfordjournals.aje.a112570; EWERTZ M, 1988, BRIT J CANCER, V58, P99, DOI 10.1038/bjc.1988.172; HLAING T, 1978, INT J CANCER, V21, P432, DOI 10.1002/ijc.2910210406; Kalache A., 1990, Health Policy and Planning, V5, P1, DOI 10.1093/heapol/5.1.1; KALCHE A, 1992, THESIS U LONDON; Kelsey J L, 1979, Epidemiol Rev, V1, P74; KVALE G, 1987, AM J EPIDEMIOL, V126, P842, DOI 10.1093/oxfordjournals.aje.a114721; KVALE G, 1987, AM J EPIDEMIOL, V126, P831, DOI 10.1093/oxfordjournals.aje.a114720; LAVECCHIA C, 1987, INT J EPIDEMIOL, V16, P347, DOI 10.1093/ije/16.3.347; LAYDE PM, 1986, AM J EPIDEMIOL, V124, P516; LIPNICK R, 1984, CANCER-AM CANCER SOC, V53, P1020, DOI 10.1002/1097-0142(19840215)53:4<1020::AID-CNCR2820530433>3.0.CO;2-G; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209; MACMAHON B, 1982, JNCI-J NATL CANCER I, V69, P1035; MILLER A, 1984, TRENDS CANCER INCIDE, P231; MILLER AB, 1986, INT J CANCER, V37, P173, DOI 10.1002/ijc.2910370202; MIRRA AP, 1971, CANCER RES, V31, P77; PATHAK DR, 1986, INT J CANCER, V37, P21, DOI 10.1002/ijc.2910370105; PIKE MC, 1981, BANBURY REPORT, V8, P3; SOINI I, 1977, INT J EPIDEMIOL, V6, P365, DOI 10.1093/ije/6.4.365; TRAPIDO EJ, 1983, CANCER, V51, P946, DOI 10.1002/1097-0142(19830301)51:5<946::AID-CNCR2820510530>3.0.CO;2-2; TRICHOPOULOS D, 1983, INT J CANCER, V31, P701, DOI 10.1002/ijc.2910310604; TULINIUS H, 1982, INT J CANCER, V29, P365; VESSEY M, 1983, BRIT J CANCER, V47, P455, DOI 10.1038/bjc.1983.74; WYNDER EL, 1978, CANCER-AM CANCER SOC, V41, P2341, DOI 10.1002/1097-0142(197806)41:6<2341::AID-CNCR2820410637>3.0.CO;2-N; 1992, 1992 WORLD BANK WORL	29	69	71	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 2	1993	341	8836					33	36		10.1016/0140-6736(93)92497-H	http://dx.doi.org/10.1016/0140-6736(93)92497-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093279				2022-12-24	WOS:A1993KF02700018
J	BEKENSTEIN, JW; LOTHMAN, EW				BEKENSTEIN, JW; LOTHMAN, EW			DORMANCY OF INHIBITORY INTERNEURONS IN A MODEL OF TEMPORAL-LOBE EPILEPSY	SCIENCE			English	Article							HIPPOCAMPAL PYRAMIDAL CELLS; INDUCED EPILEPTIFORM ACTIVITY; LIMBIC STATUS EPILEPTICUS; SYNAPTIC REORGANIZATION; POSTSYNAPTIC RESPONSES; FEEDFORWARD INHIBITION; RAT HIPPOCAMPUS; NEURON LOSS; INVITRO; SEIZURES	In humans temporal lobe epilepsy (TLE) is characterized by recurrent seizures, neuronal hyperexcitability, and selective loss of certain neuronal populations in the hippocampus. Animal models of the condition indicate that a diminution of inhibition mediated by gamma-aminobutyric acid (GABA) accounts for the altered function, and it has been hypothesized that the diminution arises because GABAergic basket interneurons are ''dormant'' as a result of their being disconnected from excitatory inputs. In hippocampal slices, inhibitory postsynaptic potentials (IPSPs) were elicited in CA1 pyramidal cells by activation of basket cells; responses from an animal model of TLE were compared to those from control tissue. IPSPs evoked indirectly by activation of terminals that then excited basket cells were reduced in the epileptic tissue, whereas IPSPs evoked by direct activation of basket cells, when excitatory neurotransmission was blocked, were not different from controls. These results provide support for the ''dormant basket cell'' hypothesis and have implications for the pathophysiology and treatment of human TLE.	UNIV VIRGINIA,HLTH SCI CTR,DEPT NEUROL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,NEUROSCI PROGRAM,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia								ALGER BE, 1982, J PHYSIOL-LONDON, V328, P105, DOI 10.1113/jphysiol.1982.sp014255; ANDERSEN P, 1969, INTERNEURON, P415; ASHWOOD TJ, 1986, BRAIN RES, V367, P390, DOI 10.1016/0006-8993(86)91625-2; ASHWOOD TJ, 1984, BRAIN RES, V293, P279, DOI 10.1016/0006-8993(84)91235-6; AVOLI M, 1992, EUR J NEUROSCI, V4, P16, DOI 10.1111/j.1460-9568.1992.tb00105.x; BABB TL, 1984, EPILEPSIA, V25, P721, DOI 10.1111/j.1528-1157.1984.tb03483.x; BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7; BERTRAM EH, 1990, ANN NEUROL, V27, P43, DOI 10.1002/ana.410270108; BUZSAKI G, 1984, PROG NEUROBIOL, V22, P131, DOI 10.1016/0301-0082(84)90023-6; CRONIN J, 1992, BRAIN RES, V573, P305, DOI 10.1016/0006-8993(92)90777-7; CURTIS DR, 1970, BRIT J PHARMACOL, V40, P881, DOI 10.1111/j.1476-5381.1970.tb10663.x; DAM AM, 1982, ACTA NEUROL SCAND, V66, P601, DOI 10.1111/j.1600-0404.1982.tb04528.x; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DICHTER M, 1969, J NEUROPHYSIOL, V32, P649, DOI 10.1152/jn.1969.32.5.649; DINGLEDINE R, 1980, J PHYSIOL-LONDON, V305, P297, DOI 10.1113/jphysiol.1980.sp013364; FALCONER MA, 1974, LANCET, V2, P767; FRANCK JE, 1985, BRAIN RES, V329, P309, DOI 10.1016/0006-8993(85)90540-2; FRANCK JE, 1988, J NEUROSCI, V8, P1991; HABLITZ JJ, 1984, J NEUROPHYSIOL, V51, P1011, DOI 10.1152/jn.1984.51.5.1011; JENSEN MS, 1988, ANN NEUROL, V24, P591, DOI 10.1002/ana.410240502; KAPUR J, 1989, J NEUROPHYSIOL, V61, P427, DOI 10.1152/jn.1989.61.2.427; LACAILLE JC, 1988, J NEUROSCI, V8, P1411; LOTHMAN EW, 1990, EPILEPSY RES, V6, P110, DOI 10.1016/0920-1211(90)90085-A; LOTHMAN EW, 1991, PROG NEUROBIOL, V37, P1, DOI 10.1016/0301-0082(91)90011-O; LOTHMAN EW, 1989, EPILEPSY RES, V3, P107, DOI 10.1016/0920-1211(89)90038-7; MAGIERSON JH, 1966, BRAIN, V89, P499; MILES R, 1987, J PHYSIOL-LONDON, V388, P611, DOI 10.1113/jphysiol.1987.sp016634; MILES R, 1987, NATURE, V329, P724, DOI 10.1038/329724a0; Nakajima S, 1991, Hippocampus, V1, P67, DOI 10.1002/hipo.450010107; NEWBERRY NR, 1984, J PHYSIOL-LONDON, V348, P239, DOI 10.1113/jphysiol.1984.sp015107; RIBAK CE, 1987, SCIENCE, V238, P1292, DOI 10.1126/science.3685980; SAGAR HJ, 1987, ANN NEUROL, V22, P334, DOI 10.1002/ana.410220309; SCHWARTZKROIN PA, 1975, BRAIN RES, V85, P423, DOI 10.1016/0006-8993(75)90817-3; SCHWARTZKROIN PA, 1978, BRAIN RES, V147, P117, DOI 10.1016/0006-8993(78)90776-X; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; SLOVITER RS, 1987, SCIENCE, V238, P1292, DOI 10.1126/science.238.4831.1292-a; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; TRAYNELIS SF, 1988, J NEUROPHYSIOL, V59, P259, DOI 10.1152/jn.1988.59.1.259; VANLANDINGHAM KE, 1991, NEUROLOGY, V41, P1942, DOI 10.1212/WNL.41.12.1942; VANLANDINGHAM KE, 1991, NEUROLOGY, V41, P1950, DOI 10.1212/WNL.41.12.1950; WIESER HG, IN PRESS SURGICAL TR; WONG RKS, 1982, J NEUROPHYSIOL, V48, P938, DOI 10.1152/jn.1982.48.4.938; WONG RKS, 1979, SCIENCE, V204, P1228, DOI 10.1126/science.451569; WOODBURY DM, 1980, ANTIEPILEPTIC DRUGS, P249	47	185	187	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					97	100		10.1126/science.8093417	http://dx.doi.org/10.1126/science.8093417			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8093417				2022-12-24	WOS:A1993KE60100038
J	RINGWALD, M; BALDOCK, R; BARD, J; KAUFMAN, M; EPPIG, JT; RICHARDSON, JE; NADEAU, JH; DAVIDSON, D				RINGWALD, M; BALDOCK, R; BARD, J; KAUFMAN, M; EPPIG, JT; RICHARDSON, JE; NADEAU, JH; DAVIDSON, D			A DATABASE FOR MOUSE DEVELOPMENT	SCIENCE			English	Editorial Material							COMPUTER		WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT ANAT,EDINBURGH,SCOTLAND	University of Edinburgh; University of Edinburgh	RINGWALD, M (corresponding author), JACKSON LAB,600 MAIN ST,BAR HARBOR,ME 04609, USA.			Baldock, Richard/0000-0003-0332-6877	Medical Research Council [MC_U127527203] Funding Source: Medline; MRC [MC_U127527203] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ASHBURNER M, 1994, DEVELOPMENT, V120, P2077; BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3093, DOI 10.1093/nar/21.13.3093; BALDOCK R, 1992, BIOESSAYS, V14, P501, DOI 10.1002/bies.950140713; BARAITSER M, 1993, DYSMORPHOLOGY DATABA; BARKER W, 1993, NUCLEIC ACIDS RES, V21, P3089, DOI 10.1093/nar/21.13.3089; BENSON D, 1993, NUCLEIC ACIDS RES, V21, P2936; BUCHER P, 1993, EUKARYOTIC PROMOTER; BUYSE ML, 1987, AM J PERINAT, V4, P8, DOI 10.1055/s-2007-999728; CUTICCHIA AJ, 1993, NUCLEIC ACIDS RES, V21, P3003, DOI 10.1093/nar/21.13.3003; Davisson MT, 1989, GENETIC VARIANTS STR, P432; DURBIN R, 1993, 1ST P INT C INT SYST, P411; GOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117; HARTENSTEIN V, 1993, DEV DROSOPHILA; JACOBS RE, 1994, SCIENCE, V263, P681, DOI 10.1126/science.7508143; Kaufman M.H., 1992, ATLAS MOUSE DEV; RICE CM, 1993, NUCLEIC ACIDS RES, V21, P2967, DOI 10.1093/nar/21.13.2967; SCHATZ BR, 1994, SCIENCE, V265, P895, DOI 10.1126/science.265.5174.895; SIKELA JM, 1993, NAT GENET, V3, P189, DOI 10.1038/ng0393-189; SMITH BR, 1994, P NATL ACAD SCI USA, V91, P3530, DOI 10.1073/pnas.91.9.3530; TAKAHASHI JS, 1994, SCIENCE, V264, P1724, DOI 10.1126/science.8209253	20	87	88	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2033	2034		10.1126/science.8091224	http://dx.doi.org/10.1126/science.8091224			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091224				2022-12-24	WOS:A1994PJ91200019
J	KOJIMA, T; SASAI, M; KOBAYASHI, Y				KOJIMA, T; SASAI, M; KOBAYASHI, Y			INCREASED SOLUBLE ICAM-1 IN TRACHEAL ASPIRATES OF INFANTS WITH BRONCHOPULMONARY DYSPLASIA	LANCET			English	Note							ADHESION MOLECULE-1 ICAM-1; CIRCULATING ICAM-1	Raised concentrations of soluble intercellular adhesion molecule 1 (sICAM-1) in tracheal aspirates from premature infants may predict development of bronchopulmonary dysplasia (BPD). We measured sICAM-1 in tracheal aspirates and serum samples from 15 newborn babies (9 with BPD, 6 without BPD) at 2-4, 6-7, and 12-14 days of age. sICAM-1 concentrations in tracheal aspirates were significantly raised at 6-7 and 12-14 days of age in infants who later developed BPD compared with infants who did not develop BPD. Serum samples from the two groups did not differ significantly in sICAM-1. Raised sICAM-1 in tracheal aspirate was a good predictor of lung injury in infants who later developed BPD.			KOJIMA, T (corresponding author), KANSAI MED UNIV,DEPT PAEDIAT,FUMIZONOCHO 1,MORIGUCHI,OSAKA 570,JAPAN.							CLEMENT A, 1988, PEDIATR RES, V23, P470, DOI 10.1203/00006450-198805000-00007; DUSTIN ML, 1986, J IMMUNOL, V137, P245; JACOBSON W, 1992, EUR J PEDIATR, V151, P204, DOI 10.1007/BF01954385; KUSTER H, 1993, LANCET, V341, P506, DOI 10.1016/0140-6736(93)90272-I; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; NORTHWAY WH, 1992, PEDIATRICS, V89, P969; OGDEN BE, 1984, AM REV RESPIR DIS, V130, P817; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; SETH R, 1991, LANCET, V338, P83, DOI 10.1016/0140-6736(91)90077-3; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851	10	36	36	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1023	1024		10.1016/0140-6736(93)92880-3	http://dx.doi.org/10.1016/0140-6736(93)92880-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105265				2022-12-24	WOS:A1993MD06600011
J	WEINER, TM; LIU, ET; CRAVEN, RJ; CANCE, WG				WEINER, TM; LIU, ET; CRAVEN, RJ; CANCE, WG			EXPRESSION OF FOCAL ADHESION KINASE GENE AND INVASIVE CANCER	LANCET			English	Note							PROTEIN-TYROSINE KINASE; PHOSPHORYLATION; INTEGRINS	The focal adhesion kinase (FAK) gene produces a tyrosine kinase that localises to contact points between cells and extracellular matrix. It is believed to be an important signal molecule in cell adhesion. We have isolated a human homologue of the FAK gene from primary sarcomas and looked for FAK mRNA in 49 human tissue samples, including paired normal and neoplastic samples. We found increased levels of FAK in 1 of 8 adenomatous tissues, in 17 of 20 invasive tumours, and in all 15 metastatic tumours. There was no detectable FAK mRNA in 6 normal tissue samples. These observations suggest that FAK overexpression may accompany changes in signal pathways involved in tumour cell invasion.	UNIV N CAROLINA,SCH MED,DEPT SURG,3010 OLD CLIN BLDG,CB 7210,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Liu, Edison/C-4141-2008		NCI NIH HHS [1-P50-CA-58223-01, CA-09688, KO8-CA-01635] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009688, P50CA058223] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; TIERNEY RP, 1990, SURG GYNECOL OBSTET, V171, P81; WEINER TM, IN PRESS ANN SURG ON; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	10	308	321	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1024	1025		10.1016/0140-6736(93)92881-S	http://dx.doi.org/10.1016/0140-6736(93)92881-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105266				2022-12-24	WOS:A1993MD06600012
J	BOGREN, HG; BUONOCORE, MH				BOGREN, HG; BUONOCORE, MH			MEASUREMENT OF CORONARY-ARTERY FLOW RESERVE BY MAGNETIC-RESONANCE VELOCITY MAPPING IN THE AORTA	LANCET			English	Note							BLOOD-FLOW	Coronary artery flow occurs predominantly in diastole via retrograde flow in the ascending aorta, some of which supplies the coronary arteries while the remainder recirculates in the ascending aorta. We used magnetic resonance velocity mapping to measure global coronary artery diastolic flow in the ascending aorta. In eight normal subjects and in four patients with possible ischaemic heart disease but with normal perfusion scans, the mean coronary flow reserve (CFR) was 269 ml/min. CFR was zero in seven patients with coronary artery disease. We have shown that CFR can be measured non-invasively with this technique.			BOGREN, HG (corresponding author), UNIV CALIF DAVIS,SACRAMENTO MED CTR,DEPT RADIOL,TICON 11 BLDG,SACRAMENTO,CA 95817, USA.							BOGREN HG, 1989, AM HEART J, V117, P1214, DOI 10.1016/0002-8703(89)90399-2; BUONOCORE MH, 1992, MAGNET RESON MED, V26, P141, DOI 10.1002/mrm.1910260115; GOULD KL, 1988, CIRCULATION, V78, P237, DOI 10.1161/01.CIR.78.2.237; HOFFMAN JIE, 1984, CIRCULATION, V70, P153, DOI 10.1161/01.CIR.70.2.153; LENTNER C, 1990, GEIGY SCI TABLES, V5, P124; VOGEL RA, 1984, ARCH INTERN MED, V144, P1773, DOI 10.1001/archinte.144.9.1773; WILSON RF, 1988, PROG CARDIOVASC DIS, V31, P95, DOI 10.1016/0033-0620(88)90013-8	7	13	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 9	1993	342	8876					899	900		10.1016/0140-6736(93)91948-L	http://dx.doi.org/10.1016/0140-6736(93)91948-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105169				2022-12-24	WOS:A1993MA96300012
J	CARSWELL, W				CARSWELL, W			HIV IN SOUTH-AFRICA	LANCET			English	Editorial Material																			0	4	4	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					132	132		10.1016/0140-6736(93)91342-J	http://dx.doi.org/10.1016/0140-6736(93)91342-J			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101253				2022-12-24	WOS:A1993LN04200008
J	HILLIS, WS; MACINTYRE, PD				HILLIS, WS; MACINTYRE, PD			DRUG-REACTIONS - SUMATRIPTAN AND CHEST PAIN	LANCET			English	Editorial Material											HILLIS, WS (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,GARDINER INST,DEPT MED & THERAPEUT,GLASGOW G11 6NT,SCOTLAND.							CURTIN T, 1992, BRIT MED J, V305, P713, DOI 10.1136/bmj.305.6855.713-d; INMAN W, 1992, BRIT MED J, V305, P714, DOI 10.1136/bmj.305.6855.714; KASKI JC, 1991, J AM COLL CARDIOL, V17, P627, DOI 10.1016/S0735-1097(10)80175-5; MACINTYRE PD, 1992, BRIT J CLIN PHARMACO, V34, P541; MACINTYRE PD, 1993, CIRCULATION, V87, P401, DOI 10.1161/01.CIR.87.2.401; MCFADDEN EP, 1991, NEW ENGL J MED, V324, P6348; OTTERVANGER JP, 1993, LANCET, V341, P861, DOI 10.1016/0140-6736(93)93064-8; TANSEY MJB, 1993, J NEUROL SCI, V114, P109, DOI 10.1016/0022-510X(93)90057-6; WILLETT F, 1992, BRIT MED J, V304, P1415, DOI 10.1136/bmj.304.6839.1415	9	49	49	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 19	1993	341	8860					1564	1565		10.1016/0140-6736(93)90700-Q	http://dx.doi.org/10.1016/0140-6736(93)90700-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099643				2022-12-24	WOS:A1993LH55000007
J	SCOTT, J				SCOTT, J			LIPID-METABOLISM - NATURE, NURTURE, AND HYPERCHOLESTEROLEMIA	LANCET			English	Editorial Material											SCOTT, J (corresponding author), ROYAL POSTGRAD MED SCH,LONDON W12 0HS,ENGLAND.							BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; DUELAND S, 1992, J BIOL CHEM, V267, P22695; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; HOBBS HH, 1989, J CLIN INVEST, V84, P656, DOI 10.1172/JCI114212; MITSURU E, 1991, ARTERIOSCL THROMB, V11, P1349; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; ZAMBON A, 1993, LANCET, V341, P1119, DOI 10.1016/0140-6736(93)93129-O	7	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 22	1993	341	8856					1312	1313		10.1016/0140-6736(93)90819-3	http://dx.doi.org/10.1016/0140-6736(93)90819-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098452				2022-12-24	WOS:A1993LD25300007
J	COLLINS, P; ROSANO, GMC; JIANG, CW; LINDSAY, D; SARREL, PM; POOLEWILSON, PA				COLLINS, P; ROSANO, GMC; JIANG, CW; LINDSAY, D; SARREL, PM; POOLEWILSON, PA			CARDIOVASCULAR PROTECTION BY ESTROGEN - A CALCIUM-ANTAGONIST EFFECT	LANCET			English	Article							CORONARY ATHEROSCLEROSIS; ESTROGEN; ARTERY; PROGRESSION; NIFEDIPINE; THERAPY; DISEASE; TRIAL	During their Premenopausal years, women have a lower risk than men of getting cardiovascular disease. This protection continues after the menopause if women receive oestrogen replacement. Based on new experimental evidence we propose that some of the cardiovascular benefits of oestrogen replacement therapy may be due to a long-term calcium antagonist effect of oestrogen.	YALE UNIV,SCH MED,NEW HAVEN,CT 06520	Yale University	COLLINS, P (corresponding author), NATL HEART & LUNG INST,DEPT CARDIAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.		Rosano, Giuseppe M. C./K-8718-2018	Rosano, Giuseppe M. C./0000-0003-4023-2263				ADAMS MR, 1990, OVARIAN SECRETIONS C, P151; BRASS LM, 1990, J CARDIOVASC TECHNOL, V9, P68; CHELSKY R, 1990, CIRCULATION, V82, P111; COLLINS P, 1993, CIRCULATION, V87, P80, DOI 10.1161/01.CIR.87.1.80; GANGAR KF, 1991, LANCET, V338, P839; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; HENRY PD, 1981, J CLIN INVEST, V68, P1366, DOI 10.1172/JCI110384; JIANG C, 1992, BRIT J PHARMACOL, V106, P739, DOI 10.1111/j.1476-5381.1992.tb14403.x; JIANG CW, 1992, AM J PHYSIOL, V263, pH271, DOI 10.1152/ajpheart.1992.263.1.H271; JIANG CW, 1991, BRIT J PHARMACOL, V104, P1033, DOI 10.1111/j.1476-5381.1991.tb12545.x; LICHTLEN PR, 1990, LANCET, V335, P1109, DOI 10.1016/0140-6736(90)91121-P; MAGNESS RR, 1989, AM J PHYSIOL, V256, pE536, DOI 10.1152/ajpendo.1989.256.4.E536; OPIE LH, 1987, DRUGS HEART, P34; SARREL P, 1989, CIRCULATION FEMALE C, P117; SARREL PM, 1990, MATURITAS, V12, P287, DOI 10.1016/0378-5122(90)90008-T; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STICE SL, 1987, BIOL REPROD, V36, P361, DOI 10.1095/biolreprod36.2.361; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; VANBUREN G, 1992, AM J OBSTET GYNECOL, V16, P828; WATERS D, 1990, CIRCULATION, V82, P1940, DOI 10.1161/01.CIR.82.6.1940; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680	21	262	268	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 15	1993	341	8855					1264	1265		10.1016/0140-6736(93)91158-I	http://dx.doi.org/10.1016/0140-6736(93)91158-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC497	8098404				2022-12-24	WOS:A1993LC49700016
J	BURTON, JL				BURTON, JL			DERMATOLOGY - EPIDEMIC BLACK SPOTS ON THE SCALP	LANCET			English	Editorial Material											BURTON, JL (corresponding author), BRISTOL ROYAL INFIRM & GEN HOSP,DEPT DERMATOL,BRISTOL BS2 8HW,AVON,ENGLAND.							COBB N, 1993, WESTERN J MED, V158, P139; Spitzer W O, 1987, Trans Assoc Am Physicians, V100, P40	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1127	1127		10.1016/0140-6736(93)93135-N	http://dx.doi.org/10.1016/0140-6736(93)93135-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097811				2022-12-24	WOS:A1993KZ68700011
J	OGAWA, O; ECCLES, MR; SZETO, J; MCNOE, LA; YUN, K; MAW, MA; SMITH, PJ; REEVE, AE				OGAWA, O; ECCLES, MR; SZETO, J; MCNOE, LA; YUN, K; MAW, MA; SMITH, PJ; REEVE, AE			RELAXATION OF INSULIN-LIKE GROWTH FACTOR-II GENE IMPRINTING IMPLICATED IN WILMS-TUMOR	NATURE			English	Article							WIEDEMANN-BECKWITH SYNDROME; CARCINOGENESIS; DISOMY	GENOMIC imprinting has been implicated in the onset of several embryonal tumours but the mechanism is not well understood1-3. Maternal chromosome 11p15 loss of heterozygosity4 and paternal chromosome 11 isodisomy 5,6 suggest that imprinted genes are involved in the onset of Wilms' tumour and the Beckwith-Wiedemann syndrome. The insulin-like growth factor II (IGF2) gene located at 11p15.5 has been put forward as a candidate gene as it is maternally imprinted (paternally expressed) in the mouse7, and is expressed at high levels in Wilms' tumours8,9. We report here that the IGF2 gene is expressed from the paternal allele in human fetal tissue, but that in Wilms' tumour expression can occur biallelically. These results provide, to our knowledge, the first evidence that relaxation of imprinting may play a role in the onset of disease and suggest a new genetic mechanism involved in the development of cancer.	UNIV OTAGO,DEPT BIOCHEM,CANC GENET LAB,DUNEDIN,NEW ZEALAND; UNIV OTAGO,DEPT PATHOL,DUNEDIN,NEW ZEALAND; UNIV QUEENSLAND,DEPT PATHOL,HERSTON,QLD 4006,AUSTRALIA	University of Otago; University of Otago; University of Queensland								ALECK KA, 1989, AM J MED GENET, V33, P155, DOI 10.1002/ajmg.1320330202; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; GRUNDY P, 1991, LANCET, V338, P1079, DOI 10.1016/0140-6736(91)91937-P; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; JUNIEN C, 1992, GENOMICS, V12, P620, DOI 10.1016/0888-7543(92)90461-Z; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LITTLE M, 1991, NATURE, V351, P609, DOI 10.1038/351609a0; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; MOUTOU C, 1992, J MED GENET, V29, P217, DOI 10.1136/jmg.29.4.217; OLSHAN AF, 1986, CANCER GENET CYTOGEN, V21, P303, DOI 10.1016/0165-4608(86)90209-8; PONDER B, 1989, NATURE, V340, P264, DOI 10.1038/340264a0; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; REIK W, 1989, NATURE, V338, P112, DOI 10.1038/338112a0; REIK W, 1989, TRENDS GENET, V5, P331, DOI 10.1016/0168-9525(89)90138-8; Sambrook J., 1989, MOL CLONING LAB MANU; SCOTT J, 1985, NATURE, V317, P261; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; VIJOEN D, 1992, J MED GENET, V29, P221; WILKINS RJ, 1988, LANCET, V1, P329	21	682	698	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 22	1993	362	6422					749	751		10.1038/362749a0	http://dx.doi.org/10.1038/362749a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY450	8097018				2022-12-24	WOS:A1993KY45000056
J	JACOBY, GC; WAGNER, WS				JACOBY, GC; WAGNER, WS			DENDOCHRONOLOGY - TREE-RING ANALYSIS - BRIDGING NOW AND THEN	LANCET			English	Editorial Material											JACOBY, GC (corresponding author), LAMONT DOHERTY EARTH OBSERV,TREE RING LAB,PALISADES,NY, USA.							Baillie M.G.L., 1982, TREE RING DATING ARC; CHRISTENSEN DJ, 1977, FORESTS PEOPLE, V27, P3; Cook E., 1992, Holocene, V2, P205, DOI 10.1177/095968369200200302; JACOBY GC, 1989, CLIMATIC CHANGE, V14, P39, DOI 10.1007/BF00140174; JACOBY GC, 1988, SCIENCE, V241, P196, DOI 10.1126/science.241.4862.196; JACOBY GC, 1992, SCIENCE, V258, P1621, DOI 10.1126/science.258.5088.1621; YAMAGUCHI DK, 1983, QUATERNARY RES, V20, P246, DOI 10.1016/0033-5894(83)90080-7	7	1	1	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					666	667		10.1016/0140-6736(93)90428-J	http://dx.doi.org/10.1016/0140-6736(93)90428-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	8095577				2022-12-24	WOS:A1993KR61300012
J	LEE, A				LEE, A			PEPTIC-ULCERATION - H-PYLORI-INITIATED ULCEROGENESIS - LOOK TO THE HOST	LANCET			English	Editorial Material											LEE, A (corresponding author), UNIV NEW S WALES,SCH MICROBIOL & IMMUNOL,SYDNEY,NSW,AUSTRALIA.							AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P5137, DOI 10.1093/nar/20.19.5137; MITCHELL HM, 1992, J INFECT DIS, V166, P149, DOI 10.1093/infdis/166.1.149; NWOKOLO CU, 1992, GUT, V33, P1323, DOI 10.1136/gut.33.10.1323; SOLNICK J, IN PRESS INFECT AGEN; TAYLOR DE, 1992, ANNU REV MICROBIOL, V46, P35, DOI 10.1146/annurev.micro.46.1.35	5	39	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					280	281		10.1016/0140-6736(93)92624-3	http://dx.doi.org/10.1016/0140-6736(93)92624-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093924				2022-12-24	WOS:A1993KK24500012
J	BLEI, AT; OLAFSSON, S; WEBSTER, S; LEVY, R				BLEI, AT; OLAFSSON, S; WEBSTER, S; LEVY, R			COMPLICATIONS OF INTRACRANIAL-PRESSURE MONITORING IN FULMINANT HEPATIC-FAILURE	LANCET			English	Article								In patients with fulminant hepatic failure, brain oedema and the resulting intracranial hypertension often lead to death; intracranial pressure (ICP) monitoring may therefore be valuable. However, there is uncertainty about the hazards of implanting ICP monitoring devices. We carried out a survey of complications associated with ICP monitoring among centres performing liver transplantation in the USA (n=262 patients). Epidural transducers were the most commonly used devices and had the lowest complication rate (3.8%); subdural bolts and parenchymal monitors (fibreoptic pressure transducers in direct contact with brain parenchyma and intraventricular catheters) were associated with complication rates of 20% and 22%, respectively. Fatal haemorrhage occurred in 1% of patients undergoing epidural ICP monitoring, whereas subdural and intraparenchymal devices had fatal haemorrhage rates of 5% and 4%. Thus, in the setting of fulminant hepatic failure, epidural transducers may be the safest choice for ICP monitoring, even though they are known to be less precise than the other devices.	NORTHWESTERN UNIV,SCH MED,DEPT MED,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT NEUROSURG,CHICAGO,IL 60611	Northwestern University; Northwestern University								BLEI AT, 1991, HEPATOLOGY, V13, P376, DOI 10.1016/0270-9139(91)92455-H; INAGAKI M, 1992, Gastroenterology, V102, pA826; Kanter M J, 1991, Neurosurg Clin N Am, V2, P257; LIDOFSKY SD, 1992, HEPATOLOGY, V16, P1, DOI 10.1002/hep.1840160102; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; SCHAFER DF, 1989, SEMIN LIVER DIS, V9, P189, DOI 10.1055/s-2008-1040512; STONE JL, 1989, SEMIN NEUROL, V9, P218, DOI 10.1055/s-2008-1041328; 1991, LANCET, V338, P156	9	173	177	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					157	158		10.1016/0140-6736(93)90016-A	http://dx.doi.org/10.1016/0140-6736(93)90016-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093756				2022-12-24	WOS:A1993KG62700016
J	HEATON, KW; EMMETT, PM; SYMES, CL; BRADDON, FEM				HEATON, KW; EMMETT, PM; SYMES, CL; BRADDON, FEM			AN EXPLANATION FOR GALLSTONES IN NORMAL-WEIGHT WOMEN - SLOW INTESTINAL TRANSIT	LANCET			English	Article							DANISH POPULATION; GALL-STONES; DEOXYCHOLIC-ACID; CHOLESTEROL; DISEASE; BILE; PATHOGENESIS; METABOLISM; LIPIDS; DIET	Many cases of gallstones can be explained in terms of the established risk factors, especially obesity. However, gallstones develop in some women who are not obese, and the causes are unknown. Biochemical studies have shown that slow intestinal transit is associated with lithogenic bile. We have tested the hypothesis that intestinal transit is abnormally slow in normal-weight women with gallstones. In a population survey, 1058 women aged 25-69 years, registered with general practitioners in Bristol, UK, underwent cholecystosonography. Gallstones were identified in 48 women, of whom 15 were of normal weight (body mass index less-than-or-equal-to 25 kg/m2). These women and age-matched controls with healthy gallbladders then underwent measurement of whole-gut transit time (WGTT); the measurement was done directly when possible, or calculated from records of three defaecations. The mean WGTT was significantly longer in the women with gallstones than in the controls (82 vs 63 h; mean difference 19, 95% CI 2-37 h). Stool output was also lower in the women with gallstones (74 [SD 54] vs 141 [56] g per 24 h, p = 0.015). There was no significant difference between cases and controls in body mass index, waist-hip circumference ratio, parity, plasma triglyceride concentration, or alcohol intake. Normal-weight women with gallstones tend to have slow intestinal transit and this feature could explain why they have gallstones.			HEATON, KW (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,BRISTOL BS2 8HW,AVON,ENGLAND.		Emmett, Pauline/AAL-6815-2021	Emmett, Pauline/0000-0003-1076-4779				BARBARA L, 1987, HEPATOLOGY, V7, P913, DOI 10.1002/hep.1840070520; EMMETT P, 1992, J HUM NUTR DIET, V5, P245, DOI 10.1111/j.1365-277X.1992.tb00159.x; EVERSON GT, 1991, J CLIN INVEST, V87, P237, DOI 10.1172/JCI114977; Garrow J. S., 1983, Nutrition Abstracts and Reviews, A, V53, P697; HAFFNER SM, 1989, AM J EPIDEMIOL, V129, P587, DOI 10.1093/oxfordjournals.aje.a115171; HAY DW, 1990, SEMIN LIVER DIS, V10, P159, DOI 10.1055/s-2008-1040470; HEAETON KW, 1992, GUT, V33, P818; HEATON KW, 1991, GUT, V32, P316, DOI 10.1136/gut.32.3.316; HEATON KW, 1991, EUR J GASTROEN HEPAT, V3, P745; HERTZ AF, 1909, CONSTIPATION ALLIED; HUSSAINI SH, 1992, GUT, V33, pS57; JORGENSEN T, 1989, GUT, V30, P528, DOI 10.1136/gut.30.4.528; JORGENSEN T, 1989, SCAND J GASTROENTERO, V24, P916, DOI 10.3109/00365528909089235; JORGENSEN T, 1988, J BIOSOC SCI, V20, P111; JORGENSEN T, 1988, GUT, V29, P433, DOI 10.1136/gut.29.4.433; LEIJD B, 1980, CLIN SCI, V59, P203, DOI 10.1042/cs0590203; LEWIS B, 1976, HYPERLIPIDAEMIAS CLI, P131; LOWBEER TS, 1978, LANCET, V2, P1063; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; MARCUS SN, 1988, GUT, V29, P522, DOI 10.1136/gut.29.4.522; MARCUS SN, 1986, GUT, V27, P550, DOI 10.1136/gut.27.5.550; ODONNELL LJD, 1990, BMJ-BRIT MED J, V300, P439, DOI 10.1136/bmj.300.6722.439; OSLER W, 1982, PRINCIPLES PRACTICE, P432; PETTITI DB, 1981, NEW ENGL J MED, V304, P1396; PROBERT CJS, IN PRESS J EPIDEMIOL; RADBERG G, 1989, SCAND J GASTROENTERO, V25, P97; REUBEN A, 1985, CLIN SCI, V69, P71, DOI 10.1042/cs0690071; SCRAGG RKR, 1984, BRIT MED J, V288, P1113, DOI 10.1136/bmj.288.6424.1113; STONE BG, 1992, HEPATOLOGY, V15, P785; THIJS C, 1990, GASTROENTEROLOGY, V99, P843, DOI 10.1016/0016-5085(90)90978-A	30	96	98	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					8	10		10.1016/0140-6736(93)92479-D	http://dx.doi.org/10.1016/0140-6736(93)92479-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093323				2022-12-24	WOS:A1993KF02700003
J	SILBERMAN, G; CROSSE, MG; PETERSON, EA; WESTON, RC; HOROWITZ, MM; APPELBAUM, FR; CHESON, BD				SILBERMAN, G; CROSSE, MG; PETERSON, EA; WESTON, RC; HOROWITZ, MM; APPELBAUM, FR; CHESON, BD			AVAILABILITY AND APPROPRIATENESS OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA IN 10 COUNTRIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; T-CELL DEPLETION; INCREASING UTILIZATION; CHRONIC PHASE; DONORS	Background. Allogeneic bone marrow transplantation, a sophisticated and expensive procedure, is the only curative therapy for chronic myeloid leukemia (CML). We examined the availability and appropriateness of allogeneic bone marrow transplantation for CML in 10 economically advanced countries with diverse health care systems. For each country we obtained data on the likelihood of transplantation to treat CML in patients under the age of 55 years, the length of time from diagnosis to transplantation, and the stage of disease at the time of transplantation. Methods. Data were collected on 9873 allogeneic bone marrow transplantations performed at 208 centers in 10 countries from 1989 th rough 1991. Data were acquired from transplantation registries and by means of a mailed survey of all centers and teams that did not contribute data to registries. Data on the incidence of disease were drawn from national and regional cancer registries. Results. Among the 10 countries there was a twofold difference between the lowest and highest rates of transplantation to treat CML (0.26 to 0.54 per 100,000 population per year); Swedish patients were the most likely to receive a transplant, and German patients the least likely. The median length of time from diagnosis to transplantation ranged from 6.8 to 15.4 months. In all countries, most transplantations were performed in the chronic phase of the disease, but as many as a third of patients received transplants in the less favorable accelerated or blast phase. The values for the United States fell near the middle of those for the 10 countries on all measures. Conclusions. Our findings challenge the assumption that the United States is unique in providing broad access to high-technology treatments. On no measure of the availability or appropriateness of transplantation for CML did it surpass the other nine countries studied.	MED COLL WISCONSIN,INST HLTH POLICY,INT BONE MARROW TRANSPLANT REGISTRY,MILWAUKEE,WI; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA; NCI,CANC THERAPY EVALUAT PROGRAM,BETHESDA,MD	Medical College of Wisconsin; Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SILBERMAN, G (corresponding author), US GEN ACCOUNTING OFF,DIV PROGRAM EVALUAT & METHODOL,WASHINGTON,DC 20548, USA.		horowitz, Mary/ABH-2173-2021		NATIONAL CANCER INSTITUTE [P01CA040053] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-40053] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASH RC, 1991, BONE MARROW TRANSPL, V7, P443; BORTIN MM, 1989, TRANSPLANTATION, V48, P453, DOI 10.1097/00007890-198909000-00021; BORTIN MM, 1992, ANN INTERN MED, V116, P505, DOI 10.7326/0003-4819-116-6-505; BORTIN MM, 1986, TRANSPLANTATION, V42, P229, DOI 10.1097/00007890-198609000-00001; GOLDMAN JM, 1993, BLOOD, V82, P2235; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; GRATWOHL A, 1991, BONE MARROW TRANSPL, V8, P197; GRATWOHL A, 1993, J INTERN MED, V233, P333, DOI 10.1111/j.1365-2796.1993.tb00681.x; HEATH CW, 1982, CANCER EPIDEMIOL, P728; HOROWITZ MM, 1992, BONE MARROW TRANSPL, P367; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; MCGLAVE PB, 1990, BLOOD, V75, P1728; MCGLAVE PB, 1990, BLOOD, V76, P654; SEGEL GB, 1986, BLOOD, V68, P1055; SOKAL JE, 1985, BLOOD, V66, P1352; SPECK B, 1984, LANCET, V1, P665; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; THOMAS ED, 1989, BLOOD, V73, P861; 1988, BRIT J HAEMATOL, V69, P463; 1994, NEW ENGL J MED, V330, P820	20	48	48	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	1994	331	16					1063	1067		10.1056/NEJM199410203311606	http://dx.doi.org/10.1056/NEJM199410203311606			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL560	8090167				2022-12-24	WOS:A1994PL56000006
J	STARK, MR; JOHNSON, AD				STARK, MR; JOHNSON, AD			INTERACTION BETWEEN 2 HOMEODOMAIN PROTEINS IS SPECIFIED BY A SHORT C-TERMINAL TAIL	NATURE			English	Article							HOMEO DOMAIN; ALPHA-2 REPRESSOR; CRYSTAL-STRUCTURE; DNA INTERACTIONS; MCM1 PROTEIN; YEAST A1; BINDING; OPERATOR; POLYMERASE; COMPLEX	TWO yeast homeodomain proteins, a1 and alpha 2, interact and cooperatively bind the haploid-specific gene (Hsg) operator, resulting in the repression of a set of genes involved in the determination of cell type(1-5). The cooperative binding of a1 and alpha 2 to DNA can be reconstituted in vitro using purified fragments of a1 and alpha 2. Only the homeodomain is needed for a1, but for alpha 2 a C-terminal 22-amino-acid tail is required as well(4,6-9). As most of the specificity of DNA binding appears to derive from a1, we proposed(4) that alpha 2 functions in the a1/alpha 2 heterodimer to contact a1 with its tail. By construction and analysis of several chimaeric proteins, we investigate how two DNA-binding proteins, one with low intrinsic specificity (alpha 2) and one with no apparent intrinsic DNA-binding ability (a1), can together create a highly specific DNA-binding activity(4). We show that the 22-amino-acid region of alpha 2 immediately C-terminal to the homeodomain, when grafted onto the a1 homeodomain, converts a1 to a strong DNA-binding protein. This alpha 2 tail can also be attached to the Drosophila engrailed homeodomain, and the chimaeric protein now binds cooperatively to DNA with a1, showing how a simple change can create a new homeodomain combination that specifically recognizes a new DNA operator.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT IMMUNOL & MICROBIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	STARK, MR (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							CHAN SK, 1993, GENE DEV, V7, P796, DOI 10.1101/gad.7.5.796; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; GOUTTE C, 1994, EMBO J, V13, P1434, DOI 10.1002/j.1460-2075.1994.tb06397.x; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GOUTTE C, 1993, J MOL BIOL, V233, P359, DOI 10.1006/jmbi.1993.1517; GOUTTE C, 1992, COMBINATORIAL CONTRO; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; PHILLIPS CL, 1994, BIOCHEMISTRY-US, V33, P9294, DOI 10.1021/bi00197a033; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STRATHERN J, 1988, GENETICS, V120, P75; STRATHERN J, 1981, J MOL BIOL, V147, P357, DOI 10.1016/0022-2836(81)90488-5; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	23	60	62	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 29	1994	371	6496					429	432		10.1038/371429a0	http://dx.doi.org/10.1038/371429a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	8090224				2022-12-24	WOS:A1994PJ28500046
J	TSAI, LH; DELALLE, I; CAVINESS, VS; CHAE, T; HARLOW, E				TSAI, LH; DELALLE, I; CAVINESS, VS; CHAE, T; HARLOW, E			P35 IS A NEURAL-SPECIFIC REGULATORY SUBUNIT OF CYCLIN-DEPENDENT KINASE-5	NATURE			English	Article							PROTEIN-KINASE; CELL-CYCLE; BRAIN	CYCLIN-dependent kinase 5 (Cdk5) was originally isolated through its structural homology to human Cdc2(1), a key regulator of cell-cycle progression(2-6). In tissue samples from adult mice, Cdk5 protein is found at the highest level in brain, at an intermediate level in testis, and at low or undetectable levels in all other tissues, but brain is the only tissue that shows Cdk5 histone H1 kinase activity(7). No equivalent kinase activity has been found in tissue culture cell lines despite high levels of Cdk5 This raised the possibility that a Cdk5 regulatory subunit was responsible for the activation of Cdk5 in brain. Here we describe the cloning and characterization of a regulatory subunit for Cdk5 known as p35. p35 displays a neuronal cell-specific pattern of expression, it associates physically with Cdk5 in vivo and activates the Cdk5 kinase. p35 differs from the mammalian cyclins and thus represents a new type of regulatory subunit for cyclin-dependent kinase activity.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital				Delalle, Ivana/0000-0002-1873-3064				CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1990, New Biologist, V2, P389; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TSAI LH, 1993, DEVELOPMENT, V119, P1029; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; YAMAMOTO M, 1981, J CELL BIOL, V91, P142, DOI 10.1083/jcb.91.1.142	18	809	837	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 29	1994	371	6496					419	423		10.1038/371419a0	http://dx.doi.org/10.1038/371419a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	8090221				2022-12-24	WOS:A1994PJ28500043
J	WALMRATH, D; SCHNEIDER, T; PILCH, J; GRIMMINGER, F; SEEGER, W				WALMRATH, D; SCHNEIDER, T; PILCH, J; GRIMMINGER, F; SEEGER, W			AEROSOLIZED PROSTACYCLIN IN ADULT-RESPIRATORY-DISTRESS-SYNDROME	LANCET			English	Note							INHALED NITRIC-OXIDE; PULMONARY-HYPERTENSION	We studied the effects of aerosolised prostacyclin (PGI2) in three patients with acute severe adult respiratory distress syndrome. 17-50 ng/kg per min, nebulised into the afferent limb of the ventilator circuit, decreased mean pulmonary artery pressure (SEM) from 40.3 (13.5) to 32.0 (3.8) mm Hg (pulmonary vascular resistance fell by 30%); systemic arterial pressure decreased slightly from 76.8 (2.2) to 74.5 (6.1) mm Hg. Concomitantly, the ratio of arterial oxygen partial pressure to the fraction of inspired oxygen increased from 120 (19) to 173 (18), mainly due to redistribution of blood flow from shunt areas to regions of normal ventilation-perfusion. All effects were reversed on drug withdrawal.	UNIV GIESSEN,DEPT INTERNAL MED,KLIN STR 36,W-6300 GIESSEN,GERMANY	Justus Liebig University Giessen				Grimminger, Friedrich/0000-0001-8725-6276; Seeger, Werner/0000-0003-1946-0894				BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; HARDY CC, 1988, J APPL PHYSIOL, V64, P1567, DOI 10.1152/jappl.1988.64.4.1567; HIGENBOTTAM T, 1987, AM REV RESPIR DIS, V136, P782, DOI 10.1164/ajrccm/136.3.782; KINSELLA JP, 1992, LANCET, V340, P819, DOI 10.1016/0140-6736(92)92687-B; MELOT C, 1989, AM REV RESPIR DIS, V139, P106, DOI 10.1164/ajrccm/139.1.106; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; RADERMACHER P, 1990, INTENS CARE MED, V16, P227, DOI 10.1007/BF01705156; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; WAGNER PD, 1974, J APPL PHYSIOL, V36, P588, DOI 10.1152/jappl.1974.36.5.588	10	232	239	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					961	962		10.1016/0140-6736(93)92004-D	http://dx.doi.org/10.1016/0140-6736(93)92004-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105216				2022-12-24	WOS:A1993MC00500011
J	CALNE, RY				CALNE, RY			RESECTION OF LARGE LIVER-TUMORS - LESSONS FROM TRANSPLANTATION SURGERY	LANCET			English	Editorial Material											CALNE, RY (corresponding author), UNIV CAMBRIDGE,SCH CLIN,DEPT SURG,CAMBRIDGE,ENGLAND.							FORTNER JG, 1974, ANN SURG, V180, P644; PICHLMAYR R, 1990, BRIT J SURG, V77, P21, DOI 10.1002/bjs.1800770107; YANAGA K, 1993, SURGERY, V113, P637	3	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					386	386						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101898				2022-12-24	WOS:A1993LR90000006
J	ROS, E; NAVARRO, S; BRU, C; GILABERT, R; BIANCHI, L; BRUGUERA, M				ROS, E; NAVARRO, S; BRU, C; GILABERT, R; BIANCHI, L; BRUGUERA, M			URSODEOXYCHOLIC ACID TREATMENT OF PRIMARY HEPATOLITHIASIS IN CAROLIS SYNDROME	LANCET			English	Note							INTRAHEPATIC CHOLESTEROL STONES; DISSOLUTION THERAPY; GALLSTONES; DISEASE	Congenital cystic dilation of the intrahepatic bile ducts (Caroli's syndrome) is a rare cause of chronic cholestasis and hepatolithiasis in young adults. Long-term prognosis is poor even with surgical drainage. We treated twelve patients who had Caroli's syndrome and intrahepatic stones with ursodeoxycholic acid (UDCA), 10-20 mg/kg daily. The duodenal bile of these patients contained cholesterol crystals, which suggests that the stones were cholesterol rich. UDCA led to sustained clinical remission, return to normal liver function, and dissolution of intrahepatic stones on ultrasound in all patients (nine partial, three complete) after 48 (range 12-114) months' follow-up. Litholytic therapy is indicated for intrahepatic stones in Caroli's syndrome.	HOSP CLIN BARCELONA,DEPT RADIOL,E-08036 BARCELONA,SPAIN; HOSP CLIN BARCELONA,LIVER UNIT,E-08036 BARCELONA,SPAIN	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona	ROS, E (corresponding author), HOSP CLIN BARCELONA,GASTROENTEROL SERV,C VILLARROEL 170,E-08036 BARCELONA,SPAIN.		Navarro, Samuel/AAD-2021-2020	Navarro, Samuel/0000-0001-5016-5653; Ros, Emilio/0000-0002-2573-1294				BENHAMOU JP, 1987, DISEASES LIVER, P1461; CAROLI J, 1958, Sem Hop, V34, P488; DAYTON MT, 1983, AM J SURG, V145, P41, DOI 10.1016/0002-9610(83)90164-2; DECAESTECKER JS, 1991, GUT, V32, P1061, DOI 10.1136/gut.32.9.1061; HEUMAN DM, 1991, HEPATOLOGY, V14, P920, DOI 10.1002/hep.1840140527; OKUDA K, 1984, INTRAHEPATIC CALCULI; ROS E, 1986, GASTROENTEROLOGY, V91, P703, DOI 10.1016/0016-5085(86)90642-6; SCHILLIO Y, 1992, DIGEST DIS SCI, V37, P1460, DOI 10.1007/BF01296020; SEDAGHAT A, 1980, NEW ENGL J MED, V302, P1274, DOI 10.1056/NEJM198006053022302; STRICHARTZ SD, 1991, GASTROENTEROLOGY, V100, P228, DOI 10.1016/0016-5085(91)90605-K	10	72	77	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					404	406		10.1016/0140-6736(93)92817-D	http://dx.doi.org/10.1016/0140-6736(93)92817-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101905				2022-12-24	WOS:A1993LR90000013
J	VANDERWAALS, FW; MOHRS, J; FOETS, M				VANDERWAALS, FW; MOHRS, J; FOETS, M			SEX-DIFFERENCES AMONG RECIPIENTS OF BENZODIAZEPINES IN DUTCH GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							SEDATIVE DRUG-USE; PREVALENCE; DURATION	Objective-To analyse sex differences among recipients of benzodiazepines in Dutch general practice. Design-Study of consultations and associated interventions as recorded in the Dutch national survey of general practice. Setting-Practices of 45 general practitioners monitored during 1 April to 30 June 1987. Subjects-61249 patients (29035 (47.4%) men in the age groups 19-44, 45-64, and 65 years and over. Main outcome measures-Symptoms among recipients of repeat as well as new benzodiazepine prescriptions stratified by sex and age. Results-Prescriptions for benzodiazepines were found to be significantly more common among women than among men, (a) after correcting for the sex distribution of the total patient population, and (b) in the two oldest age groups after correcting for the number of consultations. Of all prescriptions for benzodiazepines, 89% (6055/6777) were repeats and 70% (4759/6777) requests. Only 9% (439/4759) of these were authorised by the general practitioner, the rest being issued by the general practitioner's assistant after he or she had referred to the diagnosis in the patient's record. In contrast, only three (1%) of the 492 first time recipients of benzodiazepines had requested a prescription and were not seen by the general practitioner. Women (43/96; 45%) aged 45-64 years received their first prescription for benzodiazepines almost twice as often as men (15/63; 24%) without symptoms or a diagnosis being an indication (female to male relative risk 1.88 (95% confidence interval 1.15 to 3.08)). Conclusions-The sex difference among first time recipients of benzodiazepines seems to be due to general practitioners being less stringent when prescribing this drug for women. The difference continues in repeat prescriptions, physicians failing to check adequately the need for these.	NETHERLANDS INST PRIMARY HLTH CARE,3500 BN UTRECHT,NETHERLANDS; UNIV AMSTERDAM,FAC MED,DEPT GEN PRACTICE,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam	VANDERWAALS, FW (corresponding author), UNIV AMSTERDAM,FAC MED,1105 AZ AMSTERDAM,NETHERLANDS.							BALTER MB, 1974, NEW ENGL J MED, V290, P769, DOI 10.1056/NEJM197404042901404; BALTER MB, 1984, CURR MED RES OPIN, V8, P5; Bensing JM, 1991, HUISARTS WETENSCHAP, V34, P51; BLIJENBERGRUIS B, 1986, TIJDSCHRIFT SOCIALE, V64, P491; CATALAN J, 1988, BRIT J PSYCHIAT, V152, P399, DOI 10.1192/bjp.152.3.399; HAAFKENS J, 1992, CONT DRUG PROBLE FAL, P505; HERINGS RMC, 1989, EFFECTEN CHRONISCH G; Lamberts H., 1987, ICPC INT CLASSIFICAT; MELLINGER GD, 1984, CURR MED RES OPIN, V8, P21, DOI 10.1185/03007998409109542; MELLINGER GD, 1984, JAMA-J AM MED ASSOC, V251, P375, DOI 10.1001/jama.251.3.375; MORGAN K, 1988, BRIT MED J, V296, P601, DOI 10.1136/bmj.296.6622.601; NIJLAND A, 1991, THESIS RIJKS U GRONI; NOLAN L, 1988, EUR J CLIN PHARMACOL, V35, P225, DOI 10.1007/BF00558257; POST D, 1988, PHARM WEEKBLAD, V123, P522; RODRIGO EK, 1988, BMJ-BRIT MED J, V296, P603, DOI 10.1136/bmj.296.6622.603; SWINKELS H, 1990, HUISARTS WET, V33, P504; TIMMERMANS AJG, 1983, MED CONTACT, V38, P1331; VANASSELT JW, 1989, SLAAPVERWEKKEND ONDE; VANDENBREKEL EJG, 1987, MAANDBERICHTEN GEZON, V3, P5; VANDERVELDEN J, 1989, INT CLASSIFICATION P; WOODS JH, 1987, PHARMACOL REV, V39, P251; 1993, VADEMECUM GEZONDHEID; 1989, DIAGNOSE INFORMATIE; 1989, VODEMECUM GEZONDHEID	24	80	82	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1993	307	6900					363	366		10.1136/bmj.307.6900.363	http://dx.doi.org/10.1136/bmj.307.6900.363			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR768	8104066	Green Published, Bronze			2022-12-24	WOS:A1993LR76800022
J	JURKOVIC, D; JAUNIAUX, E; CAMPBELL, S; PANDYA, P; CARDY, DL; NICOLAIDES, KH				JURKOVIC, D; JAUNIAUX, E; CAMPBELL, S; PANDYA, P; CARDY, DL; NICOLAIDES, KH			COELOCENTESIS - A NEW TECHNIQUE FOR EARLY PRENATAL-DIAGNOSIS	LANCET			English	Note							AMNIOCENTESIS	Chorionic villus sampling and amniocentesis have disadvantages. In 100 women undergoing termination of pregnancy, coelomic fluid was successfully aspirated in 96% of cases at 6-10 weeks' gestation, 42% at 11, and 10% at 12 weeks. Cytogenetic analysis always failed with coelomic fluid, but fetal sexing was always successful with fluorescence in-situ hybridisation and polymerase chain reaction, and the results agreed with those obtained from chorionic villi and amniotic fluid in all cases. Coelocentesis may be suitable for prenatal diagnosis in the first trimester.	KINGS COLL,SCH MED & DENT,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON SE5 8RX,ENGLAND; CYOCELL LTD,LEWKNOR,OXON,ENGLAND	University of London; King's College London	JURKOVIC, D (corresponding author), KINGS COLL,SCH MED & DENT,DEPT OBSTET & GYNAECOL,LONDON SE5 8RX,ENGLAND.			Nicolaides, Kypros/0000-0003-1266-0711				[Anonymous], 1991, LANCET, V337, P1491; BYRNE D, 1991, ULTRASOUND OBST GYN, V1, P235, DOI 10.1046/j.1469-0705.1991.01040235.x; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; JAUNIAUX E, 1991, OBSTET GYNECOL, V78, P1124; JORGENSEN FS, 1992, PRENATAL DIAG, V12, P277, DOI 10.1002/pd.1970120407; RODECK CH, 1993, LANCET, V341, P468, DOI 10.1016/0140-6736(93)90213-Z; TABOR A, 1986, LANCET, V1, P1287; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6	8	58	61	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1623	1624		10.1016/0140-6736(93)90761-5	http://dx.doi.org/10.1016/0140-6736(93)90761-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099993				2022-12-24	WOS:A1993LJ72700007
J	MACKIE, RM; MCHENRY, P; HOLE, D				MACKIE, RM; MCHENRY, P; HOLE, D			ACCELERATED DETECTION WITH PROSPECTIVE SURVEILLANCE FOR CUTANEOUS MALIGNANT-MELANOMA IN HIGH-RISK GROUPS	LANCET			English	Article							MELANOCYTIC NEVI; NUMBER	In 1983 a classification scheme was proposed for patients with atypical naevi, according to their personal and family history of melanoma and atypical naevi. To assess the predictive value of these features we undertook prospective surveillance of patients at high risk of primary melanoma. We followed up 116 patients each with 3 or more clinically atypical naevi for at least 5 years. Patients are examined and naevi are photographed every 3-6 months; lesions showing disturbing change are excised for histopathology. Among 85 patients with no personal or family history of melanoma, 5 invasive (level 2 or deeper) melanomas developed during 583 person-years of follow up. The expected number of invasive melanomas in this population would be 0.054; the increased risk is significant (p < 0.001; relative risk 92 [95% CI 30-216]). There was a similarly increased risk of new melanoma also among 24 patients with atypical naevi plus a history of previous melanoma (observed 2, expected 0.022, p < 0.001; relative risk 91 [11-328]). By comparison, no second melanoma developed among 25 patients with previous melanoma but a normal naevus pattern during 213 person-years of similarly intensive follow-up. The risk of melanoma was highest among 7 patients with atypical naevi and a family history of melanoma (observed 6, expected 0.009, p < 0.001; relative risk 444 [121-1138]). The median thickness of surveillance-detected melanomas was 0.75 mm (range 0.40-1.05 mm) in this group. This study shows the value of clinical follow-up of high-risk patients to detect early thin melanomas.			MACKIE, RM (corresponding author), UNIV GLASGOW,DEPT DERMATOL,ROBERTSON BLDG,GLASGOW G12 8QQ,SCOTLAND.							BRESLOW NE, 1987, STATISTICAL METHODS, V11; GALLAGHER RP, 1990, ARCH DERMATOL, V126, P770, DOI 10.1001/archderm.126.6.770; GOLDGAR DE, 1991, J NATL CANCER I, V83, P1726, DOI 10.1093/jnci/83.23.1726; GROB JJ, 1990, CANCER, V66, P387, DOI 10.1002/1097-0142(19900715)66:2<387::AID-CNCR2820660232>3.0.CO;2-J; HOLLY EA, 1987, J AM ACAD DERMATOL, V17, P459, DOI 10.1016/S0190-9622(87)70230-8; MACKIE R, 1992, LANCET, V339, P971, DOI 10.1016/0140-6736(92)91539-K; MACKIE RM, 1989, LANCET, V2, P487; MILTON GW, 1984, RISK FACTORS MULTIPL, P353; OSTERLIND A, 1988, INT J CANCER, V42, P200, DOI 10.1002/ijc.2910420210; POPE DJ, 1992, ARCH DERMATOL, V128, P1201, DOI 10.1001/archderm.128.9.1201	10	85	85	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1618	1620		10.1016/0140-6736(93)90758-9	http://dx.doi.org/10.1016/0140-6736(93)90758-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099990				2022-12-24	WOS:A1993LJ72700004
J	AGARD, DA				AGARD, DA			TO FOLD OR NOT TO FOLD	SCIENCE			English	Editorial Material							ALPHA-LYTIC PROTEASE; CLASS-I; PROTEINS; SUBTILISIN		UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,STRUCT BIOL UNIT,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	AGARD, DA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; FLAJNIK MF, 1991, IMMUNOGENETICS, V33, P295, DOI 10.1007/BF00216688; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GETHING MJ, UNPUB; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; SABIL HR, 1993, CURR BIOL, V3, P265; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SILEN JL, 1988, GENE, V69, P237, DOI 10.1016/0378-1119(88)90434-9; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WELLS JA, 1983, NUCLEIC ACIDS RES, V11, P7911, DOI 10.1093/nar/11.22.7911; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	27	94	100	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1903	1904		10.1126/science.8100365	http://dx.doi.org/10.1126/science.8100365			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8100365				2022-12-24	WOS:A1993LJ34900031
J	GIAID, A; MICHEL, RP; STEWART, DJ; SHEPPARD, M; CORRIN, B; HAMID, Q				GIAID, A; MICHEL, RP; STEWART, DJ; SHEPPARD, M; CORRIN, B; HAMID, Q			EXPRESSION OF ENDOTHELIN-1 IN LUNGS OF PATIENTS WITH CRYPTOGENIC FIBROSING ALVEOLITIS	LANCET			English	Article							IDIOPATHIC PULMONARY FIBROSIS; LOWER RESPIRATORY-TRACT; SMOOTH-MUSCLE CELLS; FIBROBLAST INTERACTIONS; CHRONIC INFLAMMATION; UNKNOWN CAUSE; C-FOS; VASOCONSTRICTOR; MITOGENESIS; DISEASES	The vasoconstrictor and mitogenic peptide endothelin-1 (ET-1) is believed to play a part in fibrosis and collagen production. We examined expression of ET-1 in lung tissue from 52 patients with interstitial lung fibrosis, of whom 45 had cryptogenic fibrosing alveolitis (CFA), 10 had CFA and concomitant pulmonary hypertension, and 7 had non-specific focal fibrosis. 17 normal unused donor lungs were studied as controls. Immunohistochemistry and in-situ hybridisation were done with polyclonal antisera to ET-1 and its precursor big ET-1, and complementary RNA probes for preproET-1. Normal lung tissue and that from patients with focal fibrosis expressed very little ET-1. By contrast, there was striking expression of ET-1 in lung tissue from patients with CFA. Immunostains for ET-1 and big ET-1 and expression of ET-1 mRNA were most prominent in airway epithelium and type II pneumocytes, particularly those lining areas of young granulation tissue. ET-1-like immunoreactivity and mRNA were also present in pulmonary vascular endothelial cells, particularly in specimens from patients with pulmonary hypertension. In all patients, there was a significant correlation between ET-1 -like immunoreactivity and histological parameters of disease activity (r = 0.78, 95% Cl 0-65-0.87, p < 0.001). These findings suggest a possible role for cell-specific expression of ET-1 in the pathogenesis of CFA and associated pulmonary hypertension.	MCGILL UNIV,MONTREAL GEN HOSP,DEPT MED,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT PATHOL,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT MED,MONTREAL H3A 1A1,QUEBEC,CANADA; BROMPTON HOSP,NATL HEART & LUNG INST,DEPT LUNG PATHOL,LONDON SW3 6HP,ENGLAND	McGill University; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; Imperial College London; Royal Brompton Hospital	GIAID, A (corresponding author), MCGILL UNIV,MONTREAL GEN HOSP,DEPT PATHOL,1650 CEDAR AVE,MONTREAL H3G 1A4,QUEBEC,CANADA.		Sheppard, Mary N/AAB-3364-2019	Sheppard, Mary N/0000-0003-2724-3881				ADAMSON IYR, 1990, AM J PATHOL, V137, P385; ADAMSON IYR, 1991, EXP LUNG RES, V17, P821, DOI 10.3109/01902149109062880; CHERNIACK RM, 1991, AM REV RESPIR DIS, V143, P680, DOI 10.1164/ajrccm/143.3.680; CORRIN B, 1985, J PATHOL, V147, P107, DOI 10.1002/path.1711470206; CROUCH E, 1990, AM J PHYSIOL, V259, pL159, DOI 10.1152/ajplung.1990.259.4.L159; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P235, DOI 10.1056/NEJM198401263100406; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P154, DOI 10.1056/NEJM198401193100304; ENDO T, 1992, BIOCHEM BIOPH RES CO, V186, P1594, DOI 10.1016/S0006-291X(05)81590-6; GIAID A, 1991, AM J RESP CELL MOL, V4, P50, DOI 10.1165/ajrcmb/4.1.50; GIAID A, 1992, American Review of Respiratory Disease, V145, pA717; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; HYDE DM, 1992, AM REV RESPIR DIS, V146, P1042, DOI 10.1164/ajrccm/146.4.1042; KAHALEH MB, 1991, ARTHRITIS RHEUM, V34, P978, DOI 10.1002/art.1780340807; KANSE SM, 1991, LIFE SCI, V48, P1379, DOI 10.1016/0024-3205(91)90434-D; KHALIL N, 1991, AM J RESP CELL MOL, V5, P155, DOI 10.1165/ajrcmb/5.2.155; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; MASAKI T, 1991, CIRCULATION, V84, P1457, DOI 10.1161/01.CIR.84.4.1457; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; NASH JRG, 1993, HISTOPATHOLOGY, V22, P343, DOI 10.1111/j.1365-2559.1993.tb00133.x; PANOS RJ, 1991, IMMUNOLOGICALLY MEDI, P1; Reeves JT, 1984, PULMONARY HYPERTENSI, P1; SHINMI O, 1989, BIOCHEM BIOPH RES CO, V162, P340, DOI 10.1016/0006-291X(89)92001-9; SIMONSON MS, 1992, J LAB CLIN MED, V119, P622; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; Sokal RR, 1981, BIOMETRY PRINCIPLES; SPRINGALL DR, 1991, LANCET, V337, P697, DOI 10.1016/0140-6736(91)90279-X; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; VITTORI E, 1992, AM REV RESPIR DIS, V146, P1320, DOI 10.1164/ajrccm/146.5_Pt_1.1320; YAMANE K, 1991, ARTHRITIS RHEUM, V34, P243, DOI 10.1002/art.1780340220; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; 1990, AM REV RESPIR DIS, V141, pS166	31	238	243	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 19	1993	341	8860					1550	1554						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099638				2022-12-24	WOS:A1993LH55000002
J	VERBANCK, JJ; DEMOL, JW; GHILLEBERT, GL; RUTGEERTS, LJ; SURMONT, IP				VERBANCK, JJ; DEMOL, JW; GHILLEBERT, GL; RUTGEERTS, LJ; SURMONT, IP			ULTRASOUND-GUIDED PUNCTURE OF THE GALLBLADDER FOR ACUTE CHOLECYSTITIS	LANCET			English	Article							TRANS-HEPATIC CHOLECYSTOSTOMY; PERCUTANEOUS CHOLECYSTOSTOMY	In 18 high-risk patients with acute cholecystitis and severe concurrent disease, we aspirated the gallbladder by using a percutaneous technique under ultrasound guidance. 17 of the 18 improved after aspiration, the only complication being local pain in 2.13 of the 17 who improved remained free from biliary infections during a mean follow-up period of 14 months. 4 had an uncomplicated cholecystectomy 6-10 weeks later for recurrent cholecystitis. Percutaneous transhepatic gallbladder aspiration is a safe and effective procedure in critically ill patients with acute cholecystitis.			VERBANCK, JJ (corresponding author), HEILIG HARTZIEKENHUIS,DEPT GASTROENTEROL & BACTERIOL,B-8800 ROESELARE,BELGIUM.							DUNHAM F, 1985, ENDOSCOPY, V17, P153, DOI 10.1055/s-2007-1018487; EGGERMONT AM, 1985, ARCH SURG-CHICAGO, V120, P1354; KISS J, 1988, INT SURG, V73, P35; MCGAHAN JP, 1989, RADIOLOGY, V173, P481, DOI 10.1148/radiology.173.2.2678261; VANSONNENBERG E, 1984, RADIOLOGY, V151, P377, DOI 10.1148/radiology.151.2.6709906; VERBANCK J, 1991, EUR J GASTROEN HEPAT, V3, P753	6	27	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 1	1993	341	8853					1132	1133		10.1016/0140-6736(93)93138-Q	http://dx.doi.org/10.1016/0140-6736(93)93138-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ687	8097814				2022-12-24	WOS:A1993KZ68700014
J	BASTA, SS				BASTA, SS			ARCHITECTURAL MEDICINE - MALNUTRITION BY DESIGN	LANCET			English	Editorial Material											BASTA, SS (corresponding author), UNICEF,GENEVA,SWITZERLAND.							BASTA SS, 1979, AM J CLIN NUTR, V32, P916, DOI 10.1093/ajcn/32.4.916; BASTA SS, 1982, URBAN PLANNING PRACT; BASTA SS, 1977, ECOL FOOD NUTR, V6, P13; WHARTON BA, 1992, INT CHILD HLTH, V3, P2	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					934	934		10.1016/0140-6736(93)91222-8	http://dx.doi.org/10.1016/0140-6736(93)91222-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096275				2022-12-24	WOS:A1993KW98100014
J	MINTY, A; CHALON, P; DEROCQ, JM; DUMONT, X; GUILLEMOT, JC; KAGHAD, M; LABIT, C; LEPLATOIS, P; LIAUZUN, P; MILOUX, B; MINTY, C; CASELLAS, P; LOISON, G; LUPKER, J; SHIRE, D; FERRARA, P; CAPUT, D				MINTY, A; CHALON, P; DEROCQ, JM; DUMONT, X; GUILLEMOT, JC; KAGHAD, M; LABIT, C; LEPLATOIS, P; LIAUZUN, P; MILOUX, B; MINTY, C; CASELLAS, P; LOISON, G; LUPKER, J; SHIRE, D; FERRARA, P; CAPUT, D			INTERLEUKIN-13 IS A NEW HUMAN LYMPHOKINE REGULATING INFLAMMATORY AND IMMUNE-RESPONSES	NATURE			English	Article							T-CELL CLONE; HUMAN-MONOCYTES; SEQUENCE; TH1; IDENTIFICATION; LYMPHOCYTES; CYTOKINES; RECEPTOR; ANTIGEN; SIGNAL	THE discovery of new cytokines normally relies on a prior knowledge of at least one of their biological effects, which is used as a criterion either for the purification of the protein or for the isolation of the complementary DNA by expression cloning. However, the redundancy of cytokine activities complicates the discovery of novel cytokines in this way, and the pleiotropic nature of many cytokines means that the principal activities of a new cytokine may bear little relation to that used for its isolation. We have adopted an alternative approach which relies on differential screening of an organized subtracted cDNA library from activated peripheral blood mononuclear cells, using the inducibility of lymphokine messenger RNAs by anti-CD28 as a primary screening criterion. The ligation of the CD28 antigen on the T lymphocyte by a surface antigen, B7/BB-1, expressed on activated B lymphocytes and monocytes1,2 is a key step in the activation of T lymphocytes and the accumulation of lymphokine mRNAs3. Here we report the discovery by molecular cloning of a new interleukin (interleukin-13 or IL-13) expressed in activated human T lymphocytes. Recombinant IL-13 protein inhibits inflammatory cytokine production induced by lipopolysaccharide in human peripheral blood monocytes. Moreover, it synergizes with IL-2 in regulating interferon-gamma synthesis in large granular lymphocytes. Recent mapping of the IL-13 gene shows that it is closely linked to the IL-4 gene on chromosome 5q 23-31 (ref. 4). Interleukin-13 may be critical in regulating inflammatory and immune responses.	SANOFI ELF BIO RECH,F-31676 LABEGE,FRANCE; SANOFI RECH,F-34184 MONTPELLIER,FRANCE	Sanofi-Aventis; Sanofi-Aventis; Sanofi France								AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; BOOM WH, 1988, J EXP MED, V167, P1350, DOI 10.1084/jem.167.4.1350; BRAKE AJ, 1990, METHOD ENZYMOL, V185, P408; BROWN KD, 1989, J IMMUNOL, V142, P679; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHER DJ, 1987, J IMMUNOL, V138, P3688; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; KOYANAGI Y, 1988, SCIENCE, V241, P1673, DOI 10.1126/science.3047875; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; MALEFYT RD, 1991, J EXP MED, V174, P1209; MONTANER LJ, 1993, J CELL BIOCH B S, V17, P94; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; MORRISON BW, 1992, J BIOL CHEM, V267, P11957; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; POWERS R, 1992, SCIENCE, V256, P1673, DOI 10.1126/science.256.5064.1673; SCOTT P, 1991, J IMMUNOL, V147, P3149; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; TIMONEN T, 1982, J IMMUNOL METHODS, V51, P269, DOI 10.1016/0022-1759(82)90393-3; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; ZLOTNIK A, 1991, CYTOKINE, V3, P366, DOI 10.1016/1043-4666(91)90039-G	28	870	949	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 18	1993	362	6417					248	250		10.1038/362248a0	http://dx.doi.org/10.1038/362248a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	8096327				2022-12-24	WOS:A1993KT02600057
J	CZEIZEL, AE; ELEK, C; GUNDY, S; METNEKI, J; NEMES, E; REIS, A; SPERLING, K; TIMAR, L; TUSNADY, G; VIRAGH, Z				CZEIZEL, AE; ELEK, C; GUNDY, S; METNEKI, J; NEMES, E; REIS, A; SPERLING, K; TIMAR, L; TUSNADY, G; VIRAGH, Z			ENVIRONMENTAL TRICHLORFON AND CLUSTER OF CONGENITAL-ABNORMALITIES	LANCET			English	Article							INSECTICIDES; ABERRATIONS	Of 15 live births in one Hungarian village in 1989-90, 11 (73%) were affected by congenital abnormalities and 6 were twins. Of the 11, 4 had Down syndrome. Likely causes of such clusters (known teratogenic factors, familial inheritance, consanguinity) were excluded. A case-control study and environmental investigations pointed the finger of suspicion at the excessive use of trichlorfon at local fish farms. The content of this chemical was very high in fish (100 mg/kg) and several pregnant women, including all mothers of babies with Down syndrome, had consumed contaminated fish in the critical period for the congenital abnormalities observed.	NATL INST HYG,WHO COLLABORATING CTR COMMUNITY CONTROL HEREDITARY DIS,BUDAPEST,HUNGARY; DEPT PUBL HLTH,KAPOSVAR,HUNGARY; HUNGARIAN ACAD SCI,INST MATH,H-1361 BUDAPEST 5,HUNGARY; INST HUMAN GENET,BERLIN,GERMANY	Hungarian Academy of Sciences; Hungarian Alfred Renyi Institute of Mathematics			Reis, André/D-2309-2009	Reis, André/0000-0002-6301-6363				BERGE GN, 1986, ARCH TOXICOL, V59, P26, DOI 10.1007/BF00263953; COURTNEY KD, 1986, J ENVIRON SCI HEAL B, V21, P207, DOI 10.1080/03601238609372519; CZEIZEL A, 1988, ACTA MORPHOL HUNG, V36, P63; CZEIZEL AE, 1993, BRIT MED J, V306, P499, DOI 10.1136/bmj.306.6876.499; CZEIZEL AE, 1988, MULTIPLE CONGENITAL; DEGRAEVE N, 1984, ARCH TOXICOL, V56, P66, DOI 10.1007/BF00316356; DEGRAEVE N, 1984, TOXICOL LETT, V21, P315, DOI 10.1016/0378-4274(84)90090-0; DEGRAEVE N, 1984, FOOD CHEM TOXICOL, V22, P683, DOI 10.1016/0278-6915(84)90280-1; DZWONKOWSKA A, 1986, ARCH TOXICOL, V58, P152, DOI 10.1007/BF00340974; JENEY Z, 1986, AQUACULTURA HUNGARIC, V5, P79; JENEY Z, 1985, ARCH TOXICOL S, V8, P299; KALLEN B, 1986, ACTA GENET MED GEMEL, V35, P167; MARTSON LV, 1979, GIG SANIT, V7, P70; MOUTSCHENDAHMEN J, 1981, ACTA PHARMACOL TOX, V49, P29; NEHEZ M, 1987, ECOTOX ENVIRON SAFE, V13, P216, DOI 10.1016/0147-6513(87)90010-8; SHEEHAN PME, 1983, BRIT MED J, V287, P1428, DOI 10.1136/bmj.287.6403.1428; STAPLES RE, 1979, ENVIRON HEALTH PERSP, V30, P105, DOI 10.2307/3429110; VANBAO T, 1974, HUMANGENETIK, V24, P33; 1986, WHO ENV HLTH CRITERI, V63, P181; 1991, HLTH SAFETY GUIDE	20	78	79	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					539	542		10.1016/0140-6736(93)90293-P	http://dx.doi.org/10.1016/0140-6736(93)90293-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094783				2022-12-24	WOS:A1993KP08300016
J	RAYMOND, LA; BLACKSTONE, CD; HUGANIR, RL				RAYMOND, LA; BLACKSTONE, CD; HUGANIR, RL			PHOSPHORYLATION AND MODULATION OF RECOMBINANT GLUR6 GLUTAMATE RECEPTORS BY CAMP-DEPENDENT PROTEIN-KINASE	NATURE			English	Article							RETINAL HORIZONTAL CELLS; AMINO-ACID RECEPTORS; HIPPOCAMPAL-NEURONS; NERVOUS-SYSTEM; KAINATE; ENHANCEMENT; QUISQUALATE; ACTIVATION	GLUTAMATE-GATED ion channels mediate most excitatory synaptic transmission in the central nervous system and play crucial roles in synaptic plasticity, neuronAL development and some neuropathological conditions1-3. These ionotropic glutamate receptors have been classified according to their preferred agonists as NMDA (N-methyL-D-aspartate), AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) and KA (kainate) receptors4. On the basis of sequence similarity and pharmacological properties, the recently cloned glutamate receptor subunits have been assigned as components of NMDA (NMDAR1, 2A-D), AMPA (GluR1-4) and KA (GluR5-7, KA1, KA2) receptors5-7. Protein phosphorylation of glutamate receptors by protein kinase C and cyclic AMP-dependent protein kinase (PKA) has been suggested to regulate their function8-18, possibly playing a prominent role in certain forms of synaptic plasticity such as long-term potentiation19 and long-term depression9. Here we report that the GluR6 glutamate receptor, transiently expressed in mammalian cells, is directly phosphorylated by PKA, and that intracellularly applied PKA increases the amplitude of the glutamate response. Site-specific mutagenesis of the serine residue (Ser 684) representing a PKA consensus site completely eliminates PKA-mediated phosphorylation of this site as well as the potentiation of the glutamate response. These results provide evidence that direct phosphorylation of glutamate receptors modulates their function.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROL,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University			Raymond, Lynn A./R-6707-2016; Raymond, Lynn A/A-6664-2010	Raymond, Lynn A./0000-0002-8610-1042; Raymond, Lynn A/0000-0002-8610-1042				BETTLER B, 1992, NEURON, V8, P257, DOI 10.1016/0896-6273(92)90292-L; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; CHAVEZNORIEGA LE, 1992, BRAIN RES, V574, P85, DOI 10.1016/0006-8993(92)90803-H; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; GERBER G, 1989, J NEUROSCI, V9, P3606; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; KELLER BU, 1992, EMBO J, V11, P891, DOI 10.1002/j.1460-2075.1992.tb05127.x; KNAPP AG, 1987, NATURE, V325, P437, DOI 10.1038/325437a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LIMAN ER, 1989, BRAIN RES, V481, P399, DOI 10.1016/0006-8993(89)90822-6; LINDEN DJ, 1991, SCIENCE, V254, P1656, DOI 10.1126/science.1721243; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OLNEY JW, 1990, ANNU REV PHARMACOL, V30, P47; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WANG LY, IN PRESS SCIENCE	29	253	254	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 18	1993	361	6413					637	641		10.1038/361637a0	http://dx.doi.org/10.1038/361637a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	8094892				2022-12-24	WOS:A1993KM77600064
J	DIEPPE, PA; FRANKEL, SJ; TOTH, B				DIEPPE, PA; FRANKEL, SJ; TOTH, B			IS RESEARCH INTO THE TREATMENT OF OSTEOARTHRITIS WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS MISDIRECTED	LANCET			English	Editorial Material							OSTEO-ARTHRITIS; KNEE; ACETAMINOPHEN; EPIDEMIOLOGY; MANAGEMENT		UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH,BRISTOL BS8 1TH,AVON,ENGLAND	University of Bristol	DIEPPE, PA (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,RHEUMATOL UNIT,BRISTOL BS2 8HW,AVON,ENGLAND.			Toth, Ben/0000-0002-8465-4145				ALLISON MC, 1992, NEW ENGL J MED, V327, P749, DOI 10.1056/NEJM199209103271101; AMADIO P, 1983, CURR THER RES CLIN E, V34, P59; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; BRADLOW J, 1992, PATTERNS REFERRAL ST; CUSHNAGHAN J, 1990, ANN RHEUM DIS, V49, P768, DOI 10.1136/ard.49.10.768; DONOVAN J, 1992, EPIDEMIOLOGICALLY BA; FELSON DT, 1988, EPIDEMIOL REV, V10, P1; FRANKEL S, 1991, J EPIDEMIOL COMMUN H, V45, P257, DOI 10.1136/jech.45.4.257; FRANKEL SJ, 1989, HLTH TRENDS, V21, P54; KEYS J, 1992, J ROY SOC MED, V85, P442; MCALINDON T, 1990, BRIT J RHEUMATOL, V29, P471; PARR G, 1989, BRIT J CLIN PHARMACO, V27, P235, DOI 10.1111/j.1365-2125.1989.tb05356.x; ROBBINS M, 1992, EPIDEMIOLOGICALLY BA; SOMERVILLE K, 1986, LANCET, V1, P462; SWIFT GL, 1992, BRIT J CLIN PRACT, V46, P92; WILLIAMS M, 1992, EPIDEMIOLOGICALLY BA; WRIGHT V, 1989, BRIT MED J, V299, P1476, DOI 10.1136/bmj.299.6714.1476; WYLES M, 1992, ARTHRITIS; 1988, OPCS PREVALENCE DISA	19	52	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					353	354		10.1016/0140-6736(93)90147-9	http://dx.doi.org/10.1016/0140-6736(93)90147-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094123				2022-12-24	WOS:A1993KK93900015
J	BROWN, P; KAUR, P; SULIMA, MP; GOLDFARB, LG; GIBBS, CJ; GAJDUSEK, DC				BROWN, P; KAUR, P; SULIMA, MP; GOLDFARB, LG; GIBBS, CJ; GAJDUSEK, DC			REAL AND IMAGINED CLINICOPATHOLOGICAL LIMITS OF PRION DEMENTIA	LANCET			English	Article							CREUTZFELDT-JAKOB DISEASE; PROTEINS	The term ''prion dementia'' has been proposed to replace ''spongiform encephalopathy'', to accommodate the existence of atypical forms of these ''prion protein'' (PrP) cerebral amyloidoses that may not show spongiform changes in the brain. We tested brain tissue extracts for the presence of PrP from 46 cases (including 13 familial cases) of non-spongiform dementias with a variety of associated neurological signs, referred to our laboratory for primate transmission studies. None of the cases transmitted disease to primates, and none had PrP detectable by western immunoblots of extracted brain tissue. We conclude that prion dementias are not lurking undetected within the larger landscape of neurodegenerative disorders, and that their clinicopathological limits are, except for a small number of previously reported familial cases, essentially those of spongiform encephalopathy.			BROWN, P (corresponding author), NINCDS,CNS STUDIES LAB,BLDG 36,ROOM 5B21,BETHESDA,MD 20892, USA.							BOCKMAN JM, 1985, NEW ENGL J MED, V312, P73, DOI 10.1056/NEJM198501103120202; BROWN P, 1986, NEW ENGL J MED, V314, P547, DOI 10.1056/NEJM198602273140904; BROWN P, 1992, NEUROLOGY, V42, P422, DOI 10.1212/WNL.42.2.422; BROWN P, 1985, P WORKSHOP SLOW TRAN, P27; COLLINGE J, 1992, BRAIN, V115, P687, DOI 10.1093/brain/115.3.687; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; GOLDFARB LG, 1991, P NATL ACAD SCI USA, V88, P10926, DOI 10.1073/pnas.88.23.10926; HILMERT H, 1984, BIOSCIENCE REP, V4, P165, DOI 10.1007/BF01120313; JENDROSKA K, 1991, NEUROLOGY, V41, P1482, DOI 10.1212/WNL.41.9.1482; KITAMOTO T, 1989, J GEN VIROL, V70, P3371, DOI 10.1099/0022-1317-70-12-3371; KITAMOTO T, 1992, AM J PATHOL, V140, P1285; MANETTO V, 1992, NEUROLOGY, V42, P312, DOI 10.1212/WNL.42.2.312; PETERSEN RB, 1992, NEUROLOGY, V42, P1859, DOI 10.1212/WNL.42.10.1859; POWERS JM, 1991, ACTA NEUROPATHOL, V83, P95, DOI 10.1007/BF00294437; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110	15	37	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 16	1993	341	8838					127	129		10.1016/0140-6736(93)90001-W	http://dx.doi.org/10.1016/0140-6736(93)90001-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093741				2022-12-24	WOS:A1993KG62700001
J	EDWARDS, G; LOGAN, R; COPELAND, M; REINISCH, L; DAVIDSON, J; JOHNSON, B; MACIUNAS, R; MENDENHALL, M; OSSOFF, R; TRIBBLE, J; WERKHAVEN, J; ODAY, D				EDWARDS, G; LOGAN, R; COPELAND, M; REINISCH, L; DAVIDSON, J; JOHNSON, B; MACIUNAS, R; MENDENHALL, M; OSSOFF, R; TRIBBLE, J; WERKHAVEN, J; ODAY, D			TISSUE ABLATION BY A FREE-ELECTRON LASER TUNED TO THE AMIDE-II BAND	NATURE			English	Article							ABSORPTION; DAMAGE	EFFORTS to ablate soft tissue with conventional lasers have been limited by collateral damage and by concern over potential photochemical effects(1-5). Motivated by the thermal-confinement model(6), past infrared investigations targeted the OH-stretch mode of water with fast pulses from lasers emitting near 3,000 nm (refs 1, 7-9). What does a free-electron laser offer for the investigation of tissue ablation? Operating at non-photochemical single-photon energies, these infrared sources can produce trains of picosecond pulses tunable to the vibrational modes of proteins, lipids and/or water. We report here that targeting free-electron laser radiation to the amide II band of proteins leads to tissue ablation characterized by minimal collateral damage while maintaining a substantial ablation rate. To account for these observations we propose a novel ablation mechanism based on compromising tissue through resonant denaturation of structural proteins.	VANDERBILT UNIV,SCH MED,DEPT OPHTHALMOL & VISUAL SCI,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT NEUROSURG,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT OTOLARYNGOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PATHOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	EDWARDS, G (corresponding author), VANDERBILT UNIV,DEPT PHYS & ASTRON,NASHVILLE,TN 37235, USA.		Mendenhall, Marcus/M-4996-2017; Reinisch, Lou/L-2638-2019	Mendenhall, Marcus/0000-0001-6236-8212; 				ALFANO RR, 1984, IEEE J QUANTUM ELECT, V20, P1342, DOI 10.1109/JQE.1984.1072330; ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297; AUSTIN RH, 1989, PHYS REV LETT, V62, P1912, DOI 10.1103/PhysRevLett.62.1912; BERMAN ER, 1991, BIOCH EYE; BRAU CA, 1988, SCIENCE, V239, P1115, DOI 10.1126/science.239.4844.1115; BRAU CA, 1992, NUCL INSTRUM METH A, V319, P47, DOI 10.1016/0168-9002(92)90529-D; Brewer R. G., 1964, PHYS REV LETT, V13, P334; DLOTT DD, 1989, J OPT SOC AM B, V6, P977, DOI 10.1364/JOSAB.6.000977; EDWARDS GS, 1993, OPT ENG, V32, P314, DOI 10.1117/12.60753; FANN W, 1990, PHYS REV LETT, V64, P607, DOI 10.1103/PhysRevLett.64.607; Flory P., 1969, STATISTICAL MECHANIC; GRAENER H, 1991, PHYS REV LETT, V66, P2092, DOI 10.1103/PhysRevLett.66.2092; Joly M., 1965, PHYSICOCHEMICAL APPR, P153; LIEBMAN SA, 1984, PYROLYSIS GC POLYM A; MADEY JMJ, 1971, J APPL PHYS, V42, P1906, DOI 10.1063/1.1660466; MCCLAIN PE, 1972, J BIOL CHEM, V247, P692; PRIVALOV PL, 1989, J MOL BIOL, V205, P737, DOI 10.1016/0022-2836(89)90318-5; PULIAFITO CA, 1985, OPHTHALMOLOGY, V92, P741; ROBERTSON JH, 1988, LASERS NEUROSURGERY; SRINIVASAN R, 1986, SCIENCE, V234, P559, DOI 10.1126/science.3764428; STEM D, 1988, OPHTHALMOLOGY, V95, P1434; TUNCEL E, 1993, PHYS REV LETT, V70, P4146, DOI 10.1103/PhysRevLett.70.4146; WALSH JT, 1989, LASER SURG MED, V9, P314, DOI 10.1002/lsm.1900090403; WEISSBLUTH M, 1989, PHOTON ATOM INTERACT, P376; WOLBARSHT ML, 1984, IEEE J QUANTUM ELECT, V20, P1427, DOI 10.1109/JQE.1984.1072328; ZIMDARS D, 1993, PHYS REV LETT, V70, P2718, DOI 10.1103/PhysRevLett.70.2718; ZYSSET B, 1989, LASER SURG MED, V9, P193, DOI 10.1002/lsm.1900090302	27	210	231	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 29	1994	371	6496					416	419		10.1038/371416a0	http://dx.doi.org/10.1038/371416a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	8090220				2022-12-24	WOS:A1994PJ28500042
J	NEUMANN, HPH; BERGER, DP; SIGMUND, G; BLUM, U; SCHMIDT, D; PARMER, RJ; VOLK, B; KIRSTE, G				NEUMANN, HPH; BERGER, DP; SIGMUND, G; BLUM, U; SCHMIDT, D; PARMER, RJ; VOLK, B; KIRSTE, G			PHEOCHROMOCYTOMAS, MULTIPLE ENDOCRINE NEOPLASIA TYPE-2, AND VONHIPPEL-LINDAU DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHROMOGRANIN-A; FAMILIAL PHEOCHROMOCYTOMA; MR; NEUROFIBROMATOSIS; FEATURES; MEMBERS; LESIONS; COMPLEX; TUMOR; CT	Background. Pheochromocytoma is a feature of two disorders with an autosomal dominant pattern of inheritance - multiple endocrine neoplasia type 2 (MEN-2) (with medullary thyroid carcinoma and hyperparathyroidism) and von Hippel-Lindau disease (with angioma of the retina, hemangioblastoma of the central nervous system, renal-cell carcinoma, pancreatic cysts, and epididymal cystadenoma). The frequency of these syndromes in patients with pheochromocytoma is not known. Methods. In an unselected group of patients with pheochromocytoma, we performed pentagastrin tests, parathyroid hormone assays, computed tomography (CT) or magnetic resonance imaging (MRI) of the brain, ophthalmoscopy, CT imaging of the abdomen, and ultrasonography of the testes. We also screened members of families with MEN-2 or von Hippel-Lindau disease for pheochromocytoma by measuring plasma and urine catecholamines and plasma chromogranin A and by performing abdominal ultrasonography, CT and MRI, and metaiodobenzylguanidine scintigraphy. Results. Nineteen of 82 unselected patients with pheochromocytomas (23 percent) were carriers of familial disorders; 19 percent had von Hippel-Lindau disease and 4 percent had MEN-2. Prospectively, in 36 of 79 subjects at risk for pheochromocytoma (46 percent), 42 unsuspected pheochromocytomas were found. Overall, there were 130 patients with 185 pheochromocytomas; 43 had von Hippel-Lindau disease, 24 had MEN-2, and 63 had sporadic tumors. The patients with familial and those with sporadic pheochromocytomas differed in mean age at diagnosis (32 vs. 46 years, P<0.001), multifocal localization (55 vs. 8 percent, P<0.001), and cancer (0 vs. 11 percent, P = 0.005); but not in the frequency of extraadrenal tumors (24 vs. 16 percent). Thirty-eight percent of carriers of von Hippel-Lindau disease and 24 percent of carriers of MEN-2 had pheochromocytoma as the only manifestation of their syndrome. Conclusions. All patients with pheochromocytomas should be screened for MEN-2 and von Hippel-Lindau disease to avert further morbidity and mortality in the patients and their families. All patients in families with MEN-2 or von Hippel-Lindau disease should be screened for pheochromocytoma, even if they are asymptomatic.	UNIV FREIBURG,DEPT RADIOL,W-7800 FREIBURG,GERMANY; UNIV FREIBURG,DEPT OPHTHALMOL,W-7800 FREIBURG,GERMANY; UNIV FREIBURG,DEPT SURG,W-7800 FREIBURG,GERMANY; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103	University of Freiburg; University of Freiburg; University of Freiburg; University of California System; University of California San Diego	NEUMANN, HPH (corresponding author), UNIV FREIBURG,DEPT MED,DIV NEPHROL & HYPERTENS,HUGSTETTERSTR 55,D-79106 FREIBURG,GERMANY.							ATUK NO, 1979, MEDICINE, V58, P209, DOI 10.1097/00005792-197905000-00001; BRAVO EL, 1991, KIDNEY INT, V40, P544, DOI 10.1038/ki.1991.244; CARMAN CT, 1960, NEW ENGL J MED, V263, P419, DOI 10.1056/NEJM196009012630901; CHATAL JF, 1985, J CLIN ENDOCR METAB, V61, P769, DOI 10.1210/jcem-61-4-769; EASTON DF, 1989, AM J HUM GENET, V44, P208; GLOWNIAK JV, 1985, ARCH INTERN MED, V145, P257, DOI 10.1001/archinte.145.2.257; GREEN JS, 1986, CAN MED ASSOC J, V134, P133; GRIFFITHS DFR, 1987, Q J MED, V64, P769; HORTON WA, 1976, ARCH INTERN MED, V136, P769, DOI 10.1001/archinte.136.7.769; HSIAO RJ, 1990, AM J MED, V88, P607, DOI 10.1016/0002-9343(90)90526-J; LAMIELL JM, 1989, MEDICINE, V68, P1; Landsberg L., 1992, WILLIAMS TXB ENDOCRI, P621; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEVINE E, 1982, AM J ROENTGENOL, V139, P505, DOI 10.2214/ajr.139.3.505; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NEUMANN HPH, 1987, VASA-J VASCULAR DIS, V16, P220; NEUMANN HPH, 1992, J NEUROL NEUROSUR PS, V55, P898, DOI 10.1136/jnnp.55.10.898; NEUMANN HPH, 1991, LANCET, V337, P1052, DOI 10.1016/0140-6736(91)91705-Y; NEUMANN HPH, 1991, GASTROENTEROLOGY, V101, P465, DOI 10.1016/0016-5085(91)90026-H; OCONNOR DT, 1986, NEW ENGL J MED, V314, P1145, DOI 10.1056/NEJM198605013141803; OCONNOR DT, 1989, CLIN CHEM, V35, P1631; QUINT LE, 1987, RADIOLOGY, V165, P89, DOI 10.1148/radiology.165.1.3628794; REINIG JW, 1986, RADIOLOGY, V158, P81, DOI 10.1148/radiology.158.1.3940403; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; SATO Y, 1988, RADIOLOGY, V166, P241, DOI 10.1148/radiology.166.1.3336687; SCHIMKE RN, 1990, AM J MED GENET, V37, P375, DOI 10.1002/ajmg.1320370317; STEIN PP, 1990, MEDICINE, V70, P46; VASEN HFA, 1987, AM J MED, V83, P847, DOI 10.1016/0002-9343(87)90641-3; WILSON RA, 1978, HUM PATHOL, V9, P181, DOI 10.1016/S0046-8177(78)80109-9; YEH HC, 1980, AM J ROENTGENOL, V135, P1167, DOI 10.2214/ajr.135.6.1167	32	356	364	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1993	329	21					1531	1538		10.1056/NEJM199311183292103	http://dx.doi.org/10.1056/NEJM199311183292103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG188	8105382				2022-12-24	WOS:A1993MG18800003
J	HERTOG, MGL; FESKENS, EJM; HOLLMAN, PCH; KATAN, MB; KROMHOUT, D				HERTOG, MGL; FESKENS, EJM; HOLLMAN, PCH; KATAN, MB; KROMHOUT, D			DIETARY ANTIOXIDANT FLAVONOIDS AND RISK OF CORONARY HEART-DISEASE - THE ZUTPHEN ELDERLY STUDY	LANCET			English	Article							DENSITY-LIPOPROTEIN; QUERCETIN; CHOLESTEROL; INHIBITION	Flavonoids are polyphenolic antioxidants naturally present in vegetables, fruits, and beverages such as tea and wine. In vitro, flavonoids inhibit oxidation of low-density lipoprotein and reduce thrombotic tendency, but their effects on atherosclerotic complications in human beings are unknown. We measured the content in various foods of the flavonoids quercetin, kaempferol, myricetin, apigenin, and luteolin. We then assessed the flavonoid intake of 805 men aged 65-84 years in 1985 by a cross-check dietary history; the men were then followed up for 5 years. Mean baseline flavonoid intake was 25.9 mg daily. The major sources of intake were tea (61%), onions (13%), and apples (10%). Between 1985 and 1990, 43 men died of coronary heart disease. Fatal or non-fatal myocardial infarction occurred in 38 of 693 men with no history of myocardial infarction at baseline. Flavonoid intake (analysed in tertiles) was significantly inversely associated with mortality from coronary heart disease (p for trend = 0.015) and showed an inverse relation with incidence of myocardial infarction, which was of borderline significance (p for trend = 0 08). The relative risk of coronary heart disease mortality in the highest versus the lowest tertile of flavonoid intake was 0.42 (95% Cl 0.20-0.88). After adjustment for age, body-mass index, smoking, serum total and high-density-lipoprotein cholesterol, blood pressure, physical activity, coffee consumption, and intake of energy, vitamin C, vitamin E, beta-carotene, and dietary fibre, the risk was still significant (0.32 [0.15-0.71]). Intakes of tea, onions, and apples were also inversely related to coronary heart disease mortality, but these associations were weaker. Flavonoids in regularly consumed foods may reduce the risk of death from coronary heart disease in elderly men.	AGR UNIV WAGENINGEN,6700 HB WAGENINGEN,NETHERLANDS; STATE INST QUAL CONTROL AGR PROD,WAGENINGEN,NETHERLANDS	Wageningen University & Research	HERTOG, MGL (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT CHRON DIS & ENVIRONM EPIDEMIOL,POB 1,3720 BA BILTHOVEN,NETHERLANDS.		Ibrahim, Essam Hassan/G-1960-2018; Hollman, Peter C.H./I-7446-2013; Feskens, Edith JM/A-3757-2012; Kromhout, Daan/A-8566-2014; Feskens, Edith/ABI-1446-2020	Ibrahim, Essam Hassan/0000-0003-0130-2257; Hollman, Peter C.H./0000-0002-7510-6809; Feskens, Edith/0000-0001-5819-2488				BLOEMBERG BPM, 1989, AM J EPIDEMIOL, V130, P1047, DOI 10.1093/oxfordjournals.aje.a115405; CASPERSEN CJ, 1991, AM J EPIDEMIOL, V133, P1078, DOI 10.1093/oxfordjournals.aje.a115821; CONNEY AH, 1992, PREV MED, V21, P361, DOI 10.1016/0091-7435(92)90043-H; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; GUGLER R, 1975, EUR J CLIN PHARMACOL, V9, P229, DOI 10.1007/BF00614022; HERTOG MGL, 1993, NUTR CANCER, V20, P21, DOI 10.1080/01635589309514267; HERTOG MGL, 1992, J AGR FOOD CHEM, V40, P1591, DOI 10.1021/jf00021a023; HERTOG MGL, 1992, J AGR FOOD CHEM, V40, P2379, DOI 10.1021/jf00024a011; HERTOG MGL, 1993, J AGR FOOD CHEM, V41, P1242, DOI 10.1021/jf00032a015; HUSAIN SR, 1987, PHYTOCHEMISTRY, V26, P2489, DOI 10.1016/s0031-9422(00)83860-1; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KATIYAR SK, 1992, NUTR CANCER, V18, P73, DOI 10.1080/01635589209514207; KEYS A, 1967, ACTA MED SCAND, P1; KLELIJNEN J, 1992, LANCET, V340, P1136; Kuhnau J, 1976, World Rev Nutr Diet, V24, P117; LAUGHTON MJ, 1991, BIOCHEM PHARMACOL, V42, P1673, DOI 10.1016/0006-2952(91)90501-U; NEGRESALVAYRE A, 1992, FREE RADICAL BIO MED, V12, P101, DOI 10.1016/0891-5849(92)90002-X; Robak J, 1998, BIOCHEM PHARMACOL, V37, P83; Rose G, 1968, CARDIOVASCULAR SURVE; SIEDEL J, 1981, J CLIN CHEM CLIN BIO, V19, P838; SORATA Y, 1984, BIOCHIM BIOPHYS ACTA, V799, P313, DOI 10.1016/0304-4165(84)90276-9; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TAKAHAMA U, 1985, PHYTOCHEMISTRY, V24, P1443, DOI 10.1016/S0031-9422(00)81040-7; UENO I, 1983, JPN J EXP MED, V53, P41; VANBUCHEM FSP, 1967, ACTA MED SCAND  S460, P191; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WILSON PWF, 1989, ARCH INTERN MED, V149, P1169, DOI 10.1001/archinte.149.5.1169; 1985, UCV TABEL UITGEBREID	29	3468	3615	8	512	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1007	1011		10.1016/0140-6736(93)92876-U	http://dx.doi.org/10.1016/0140-6736(93)92876-U			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105262				2022-12-24	WOS:A1993MD06600007
J	MITCHISON, TJ				MITCHISON, TJ			LOCALIZATION OF AN EXCHANGEABLE GTP-BINDING SITE AT THE PLUS END OF MICROTUBULES	SCIENCE			English	Article							MECHANISM; DYNAMICS; TUBULINS; INVITRO	Microtubule polarity arises from the head-to-tall orientation of alpha-beta tubulin heterodimers in the microtubule lattice. The identity of the polypeptide at each end of the microtubule is unknown, but structural models predict that the beta-tubulin end contains an exchangeable guanosine triphosphate (GTP) binding site. When GTP-coated fluorescent beads were incubated with microtubules, they bound specifically to plus ends, suggesting that tubulin is oriented in microtubules with beta-tubulin toward the plus end.			MITCHISON, TJ (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.				NIGMS NIH HHS [GM-39565] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039565, R37GM039565] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOS LA, 1974, J CELL SCI, V14, P523; BEESE L, 1987, J MOL BIOL, V194, P257, DOI 10.1016/0022-2836(87)90373-1; BERGEN LG, 1980, J CELL BIOL, V84, P151, DOI 10.1083/jcb.84.1.151; BURNS RG, 1991, CELL MOTIL CYTOSKEL, V20, P181, DOI 10.1002/cm.970200302; CAPLOW M, 1990, J BIOL CHEM, V265, P8935; CARLIER MF, 1989, INT REV CYTOL, V115, P139; GELFAND VI, 1991, ANNU REV CELL BIOL, V7, P93, DOI 10.1146/annurev.cb.07.110191.000521; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1991, J CELL SCI, P125; JACKSON RJ, 1973, BIOCHEM BIOPH RES CO, V51, P428, DOI 10.1016/0006-291X(73)91275-8; Kirschner M W, 1978, Int Rev Cytol, V54, P1, DOI 10.1016/S0074-7696(08)60164-3; MANDELKOW E, 1989, CELL MOVEMENT, V2, P23; MANDELKOW EM, 1985, J MOL BIOL, V181, P123, DOI 10.1016/0022-2836(85)90330-4; NATH JP, 1985, BIOCHEMISTRY-US, V24, P1555, DOI 10.1021/bi00327a040; Oakley B R, 1992, Trends Cell Biol, V2, P1, DOI 10.1016/0962-8924(92)90125-7; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER RA, 1989, J CELL BIOL, V108, P931, DOI 10.1083/jcb.108.3.931; WEISENBERG RC, 1968, BIOCHEMISTRY-US, V7, P4466, DOI 10.1021/bi00852a043	18	138	141	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	1993	261	5124					1044	1047		10.1126/science.8102497	http://dx.doi.org/10.1126/science.8102497			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT747	8102497				2022-12-24	WOS:A1993LT74700034
J	BLACKWELL, AL; THOMAS, PD; WAREHAM, K; EMERY, SJ				BLACKWELL, AL; THOMAS, PD; WAREHAM, K; EMERY, SJ			HEALTH GAINS FROM SCREENING FOR INFECTION OF THE LOWER GENITAL-TRACT IN WOMEN ATTENDING FOR TERMINATION OF PREGNANCY	LANCET			English	Article							PELVIC INFLAMMATORY DISEASE; CHLAMYDIA-TRACHOMATIS INFECTION; 1ST TRIMESTER ABORTION; NON-SPECIFIC VAGINITIS; THERAPEUTIC-ABORTION; BACTERIAL VAGINOSIS; DOUBLE-BLIND; METRONIDAZOLE; FLORA	Infection of the upper genital tract after abortion is well recognised, but routine screening for infection before termination is rare, and few centres are aware of the prevalence of post-abortion complications in their population. We undertook a study to assess the prevalence and sequelae of genital-tract infection in patients undergoing termination of pregnancy and to estimate the costs and potential benefits of introducing screening and prophylaxis for the most commonly found organisms. The study in Swansea, UK, was of 401 consecutive patients attending for termination of pregnancy; only 1 patient refused to take part. Immediately before the termination procedure vaginal and cervical swabs were taken for microscopic examination and culture of Trichomonas vaginalis, Neisseria gonorrhoeae, and candida species. We sought Chlamydia trachomatis by enzyme-linked immunosorbent assay. 112 (28%) women had the typical bacterial flora of anaerobic (bacterial) vaginosis, 95 (24%) had candidal infection, 32 (8%) chlamydial infection, 3 (0.75%) trichomonas infection, and 1 (0.25%) gonorrhoea. Postoperative follow-up of 30 of the women with chlamydial infection showed that pelvic infection developed in 19 (63%), of whom 7 were readmitted to hospital. 9 male partners of women with chlamydial (plus gonococcal in 1 case) infection were examined; 8 were symptom-free, 3 had C trachomatis infection, and 1 N gonorrhoeae. Estimated costs of hospital admissions for complications of chlamydial infection were more than double the costs of providing a routine chlamydia screening programme and prophylactic treatment. Screening for chlamydial infection before termination of pregnancy is essential. Prophylactic treatment for both chlamydial infection and anaerobic vaginosis should also be considered. Male partners of women infected with chlamydia are often symptom-free, but they must be traced to avoid reinfections.	SINGLETON HOSP TRUST,PUBL HLTH LAB SERV,SWANSEA SA2 8QA,WALES; SINGLETON HOSP TRUST,DEPT OBSTET & GYNAECOL,SWANSEA SA2 8QA,WALES; MORRISTON HOSP,SCH POSTGRAD STUDIES MED & HLTH CARE,SWANSEA,W GLAM,WALES	Singleton Hospital; Singleton Hospital; Morriston Hospital; Swansea University	BLACKWELL, AL (corresponding author), SINGLETON HOSP TRUST,DEPT GENITOURINARY MED,SWANSEA SA2 8QA,WALES.							BLACKWELL A, 1982, BRIT J VENER DIS, V58, P387; BLACKWELL AL, 1983, LANCET, V2, P1379; CATES W, 1990, EPIDEMIOL REV, V12, P199, DOI 10.1093/oxfordjournals.epirev.a036054; DUTHIE SJ, 1987, GENITOURIN MED, V63, P183; FISH ANJ, 1989, EUR J OBSTET GYN R B, V31, P67, DOI 10.1016/0028-2243(89)90027-0; GUIJON F, 1992, INT J GYNECOL OBSTET, V37, P185, DOI 10.1016/0020-7292(92)90379-W; HEISTERBERG L, 1985, OBSTET GYNECOL, V65, P371; HILLIER SL, 1992, OBSTET GYNECOL, V79, P369, DOI 10.1097/00006250-199203000-00008; HILLIER SL, 1992, AM J OBSTET GYNECOL, V166, P938, DOI 10.1016/0002-9378(92)91368-K; LARSSON PG, 1989, ACTA OBSTET GYN SCAN, V68, P217, DOI 10.3109/00016348909020992; LARSSON PG, 1992, AM J OBSTET GYNECOL, V166, P100, DOI 10.1016/0002-9378(92)91838-2; MARTIUS J, 1990, ARCH GYNECOL OBSTET, V247, P1, DOI 10.1007/BF02390649; MAZULLI T, 1990, J CLIN MICROBIOL, V28, P1506; MOLLER BR, 1982, OBSTET GYNECOL, V59, P210; MORTON K, 1990, EUR J OBSTET GYN R B, V37, P231, DOI 10.1016/0028-2243(90)90029-Z; PETERSON HB, 1990, MED CLIN N AM, V74, P1603, DOI 10.1016/S0025-7125(16)30497-7; QVIGSTAD E, 1983, BRIT J VENER DIS, V59, P189; RIDGWAY GL, 1983, BRIT MED J, V286, P1478, DOI 10.1136/bmj.286.6376.1478-a; SCHULTZ R, 1991, BRIT MED J, V303, P1369, DOI 10.1136/bmj.303.6814.1369; SHIOOTZ H, 1985, ANN CLIN RES, V17, P60; SKJELDESTAD FE, 1988, ACTA OBSTET GYN SCAN, V67, P525, DOI 10.3109/00016348809029864; SPIEGEL CA, 1989, CLIN LAB MED, V9, P525, DOI 10.1016/S0272-2712(18)30616-4; THIN RN, 1989, GENITOURIN MED, V65, P157; VEJTORP M, 1988, BRIT J OBSTET GYNAEC, V95, P920, DOI 10.1111/j.1471-0528.1988.tb06581.x; WESTROM L, 1987, CONTRACEPTION, V36, P111, DOI 10.1016/0010-7824(87)90064-3; WOOD SM, 1989, LANCET, V2, P928; 1991, SEX TRANSM DIS, V18, P46; 1991, REPORT RCOG WORKING	28	112	114	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					206	210		10.1016/0140-6736(93)92299-9	http://dx.doi.org/10.1016/0140-6736(93)92299-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100930				2022-12-24	WOS:A1993LN62200012
J	SHANN, F				SHANN, F			AUSTRALIAN VIEW OF PEDIATRIC INTENSIVE-CARE IN BRITAIN	LANCET			English	Editorial Material											SHANN, F (corresponding author), ROYAL CHILDRENS HOSP,PAEDIAT INTENS CARE UNIT,PARKVILLE,VIC 3052,AUSTRALIA.		Shann, Frank/C-9510-2011					EDGE WE, 1992, CRIT CARE MED, V20, pS38; FARLEY DE, 1992, MED CARE, V30, P77, DOI 10.1097/00005650-199201000-00009; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; POLLACK MM, 1991, CRIT CARE MED, V19, P150, DOI 10.1097/00003246-199102000-00007; RAMSEY CB, 1993, TXB PEDIATRIC CRITIC, P1108; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; YEH TS, 1992, CRIT CARE CLIN, V8, P23, DOI 10.1016/S0749-0704(18)30265-3; 1987, REPORT WORKING PARTY; 1982, MANAGEMENT SERIOUSLY	9	19	19	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					68	68		10.1016/0140-6736(93)91282-Q	http://dx.doi.org/10.1016/0140-6736(93)91282-Q			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100909				2022-12-24	WOS:A1993LL78900006
J	STLOUIS, ME; KAMENGA, M; BROWN, C; NELSON, AM; MANZILA, T; BATTER, V; BEHETS, F; KABAGABO, U; RYDER, RW; OXTOBY, M; QUINN, TC; HEYWARD, WL				STLOUIS, ME; KAMENGA, M; BROWN, C; NELSON, AM; MANZILA, T; BATTER, V; BEHETS, F; KABAGABO, U; RYDER, RW; OXTOBY, M; QUINN, TC; HEYWARD, WL			RISK FOR PERINATAL HIV-1 TRANSMISSION ACCORDING TO MATERNAL IMMUNOLOGICAL, VIROLOGICAL, AND PLACENTAL FACTORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACQUIRED IMMUNODEFICIENCY; SEROPOSITIVE MOTHERS; PREGNANT-WOMEN; INFECTION; TYPE-1; INFANTS; CELLS; AIDS; CHORIOAMNIONITIS	Objective.-To evaluate how maternal and obstetric factors interact to influence mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission. Design.-Prospective, observational cohort study of children born to HIV-infected women to determine child's HIV infection status. The analysis then compared peripartum maternal, placental, and obstetric variables between HIV-1 transmitter and nontransmitter women. Setting.-Two large maternity wards in Kinshasa, Zaire. Participants.-Consecutive sample of 324 HIV-1-infected women at delivery, with 254 HIV-seronegative women followed up as control subjects. Principal Outcome Measures.-HIV infection status of children, to classify each woman as an HIV-1 transmitter or nontransmitter. Results.-The highest transmission risk (TR) was associated with maternal p24 antigenemia (TR, 71 %; relative risk [RR], 3.0; 95% confidence interval [CI], 1.7 to 5.2) and maternal CD8+ lymphocyte counts of at least 1.80 X 10(9)/L (1800/muL) (TR, 50%; RR, 2.2; 95% CI, 1.2 to 4.2). Among women with CD8+ lymphocyte counts of less than 1.80 X 10(9)/L, CD4+ lymphocyte counts of less than 0.60 x 10(9)/L were a risk factor (TR, 29%; RR, 2.2; 95% CI, 1.2 to 4.2). In women with neither high CD8+ nor low CD4+ lymphocyte counts, placental membrane inflammation was associated with perinatal transmission (TR, 40%; RR, 4.2; 95% CI, 1.3 to 13.7). In women with neither p24 antigenemia, high CD8+ or low CD4+ lymphocyte counts, nor placental membrane inflammation, the transmission risk was only 7%. Additional correlates of transmission included maternal anemia and fever, but not maternal sexually transmitted diseases. Conclusions.-Identifiable subgroups of HIV-1-infected women based on maternal and placental characteristics had between a 7% and 71% risk of perinatal HIV-1 transmission. Not only the overall rate of transmission but the impact of different risk factors for transmission appear to vary over the course of HIV infection.	PROJET SIDA, KINSHASA, DEM REP CONGO; NIAID, BETHESDA, MD 20892 USA; ARMED FORCES INST PATHOL, WASHINGTON, DC 20306 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); United States Department of Defense	STLOUIS, ME (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV HIV AIDS, 1600 CLIFTON RD, MAILSTOP E-50, ATLANTA, GA 30333 USA.		Quinn, Thomas/A-2494-2010					ALIMENTI A, 1992, J INFECT DIS, V166, P1146, DOI 10.1093/infdis/166.5.1146; BELL SJD, 1992, CLIN IMMUNOL IMMUNOP, V64, P254, DOI 10.1016/0090-1229(92)90208-6; Blanc W A, 1981, Monogr Pathol, P67; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; BLANCO JD, 1983, J INFECT DIS, V147, P650, DOI 10.1093/infdis/147.4.650; BROWN C, 1991, AIDS, V5, P89, DOI 10.1097/00002030-199101000-00013; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; BURGARD M, 1992, NEW ENGL J MED, V327, P1192, DOI 10.1056/NEJM199210223271702; CAMERON DW, 1989, LANCET, V2, P403; CHANDWANI S, 1991, J INFECT DIS, V163, P1134, DOI 10.1093/infdis/163.5.1134; CLERICI M, 1992, P NATL ACAD SCI USA, V89, P8424, DOI 10.1073/pnas.89.18.8424; CLIFFORD SH, 1954, J PEDIATR-US, V44, P1, DOI 10.1016/S0022-3476(54)80085-0; COLEBUNDERS R, 1987, LANCET, V1, P492; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DINSMOOR MJ, 1992, AM J OBSTET GYNECOL, V167, P1575, DOI 10.1016/0002-9378(92)91743-T; EHRNST A, 1991, LANCET, V338, P203, DOI 10.1016/0140-6736(91)90347-R; FOX H, 1978, PATHOLOGY PLACENTA, P286; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GOEDERT JJ, 1989, LANCET, V2, P1351; GUZICK DS, 1985, OBSTET GYNECOL, V65, P11; HALSEY NA, 1990, JAMA-J AM MED ASSOC, V264, P2088, DOI 10.1001/jama.264.16.2088; HANDSFIELD HH, 1973, JAMA-J AM MED ASSOC, V225, P697; HERZENBERG LA, 1979, P NATL ACAD SCI USA, V76, P1453, DOI 10.1073/pnas.76.3.1453; HILLIER SL, 1988, NEW ENGL J MED, V319, P972, DOI 10.1056/NEJM198810133191503; HIRA SK, 1990, J PEDIATR-US, V117, P421, DOI 10.1016/S0022-3476(05)81084-4; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HUNZIKER RD, 1984, J IMMUNOL, V133, P667; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; JAUNIAUX E, 1988, PLACENTA, V9, P633, DOI 10.1016/0143-4004(88)90007-0; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; LEWIS SH, 1990, LANCET, V335, P565, DOI 10.1016/0140-6736(90)90349-A; MARTIN AW, 1992, HUM PATHOL, V23, P411, DOI 10.1016/0046-8177(92)90088-K; MAYERS MM, 1991, PEDIATRICS, V88, P1248; MERCER BM, 1992, AM J OBSTET GYNECOL, V166, P794, DOI 10.1016/0002-9378(92)91336-9; MIOTTI PG, 1992, J INFECT DIS, V165, P1116, DOI 10.1093/infdis/165.6.1116; MUSHER DM, 1990, ANN INTERN MED, V113, P872, DOI 10.7326/0003-4819-113-11-872; NELSON AM, 1991, MAR ANN M US CAN AC; NEWELL ML, 1992, LANCET, V339, P1007; OU CY, 1990, AIDS RES HUM RETROV, V6, P1323, DOI 10.1089/aid.1990.6.1323; OXTOBY MJ, 1990, PEDIATR INFECT DIS J, V9, P609; POLLACK H, 1990, 30TH INT C ANT AG CH; PRINCE HE, 1991, J ACQ IMMUN DEF SYND, V4, P1227; QUINN TC, 1993, J INFECT DIS, V167, P1193, DOI 10.1093/infdis/167.5.1193; QUINN TC, 1987, JAMA-J AM MED ASSOC, V257, P2617, DOI 10.1001/jama.257.19.2617; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SEAGE GR, 1989, AM J PUBLIC HEALTH, V79, P1638, DOI 10.2105/AJPH.79.12.1638; SIEGAL FP, 1981, NEW ENGL J MED, V305, P1439, DOI 10.1056/NEJM198112103052403; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; VORHERR H, 1975, AM J OBSTET GYNECOL, V123, P67, DOI 10.1016/0002-9378(75)90951-5; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; 1990, BMDP STATISTICAL SOF; 1985, SAS PROCEDURES GUIDE	59	246	251	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2853	2859		10.1001/jama.269.22.2853	http://dx.doi.org/10.1001/jama.269.22.2853			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE936	8098783				2022-12-24	WOS:A1993LE93600020
J	HAUSSINGER, D; ROTH, E; LANG, F; GEROK, W				HAUSSINGER, D; ROTH, E; LANG, F; GEROK, W			CELLULAR HYDRATION STATE - AN IMPORTANT DETERMINANT OF PROTEIN CATABOLISM IN HEALTH AND DISEASE	LANCET			English	Article							RAT SKELETAL-MUSCLE; GLUTAMINE; INJURY; NUTRITION; TURNOVER; PLASMA; SEPSIS; WATER	There is evidence that cellular hydration state is an important factor controlling cellular protein turnover, protein synthesis and protein degradation are affected in opposite directions by cell swelling and shrinking. An increase in cellular hydration (swelling) acts as an anabolic proliferative signal, whereas cell shrinkage is catabolic and antiproliferative. The cellular hydration state is mainly determined by the activity of ion and substrate transport systems in the plasma membrane. Hormones, substrates, and oxidative stress can change the cellular hydration state within minutes, thereby affecting protein turnover. We postulate that a decrease in cellular hydration in liver and skeletal muscle triggers the protein catabolic states that accompany various diseases.	UNIV VIENNA,CHIRURG KLIN,A-1010 VIENNA,AUSTRIA; UNIV TUBINGEN,INST PHYSIOL,W-7400 TUBINGEN 1,GERMANY	University of Vienna; Eberhard Karls University of Tubingen	HAUSSINGER, D (corresponding author), UNIV FREIBURG,MED KLIN,HUGSTETTERSTR 55,W-7800 FREIBURG,GERMANY.							BERGSTROM J, 1974, J APPL PHYSIOL, V36, P693, DOI 10.1152/jappl.1974.36.6.693; BERGSTROM JP, 1987, ACTA CHIR SCAND, V153, P261; CUNNINGHAM JN, 1971, J CLIN INVEST, V50, P49, DOI 10.1172/JCI106483; ELWYN DH, 1975, ANN SURG, V182, P76, DOI 10.1097/00000658-197507000-00015; FURST P, 1990, JPEN-PARENTER ENTER, V14, pS118, DOI 10.1177/014860719001400417; HALLBRUCKER C, 1993, EUR J BIOCHEM, V211, P449, DOI 10.1111/j.1432-1033.1993.tb17570.x; HAUSSINGER D, 1992, TRENDS PHARMACOL SCI, V13, P371, DOI 10.1016/0165-6147(92)90114-L; HAUSSINGER D, 1991, BIOCHIM BIOPHYS ACTA, V1071, P331, DOI 10.1016/0304-4157(91)90001-D; HAUSSINGER D, 1990, EUR J BIOCHEM, V188, P689, DOI 10.1111/j.1432-1033.1990.tb15451.x; HAUSSINGER D, 1991, FEBS LETT, V283, P470; JAMES JH, 1990, METABOLISM, V39, P335, DOI 10.1016/0026-0495(90)90245-8; JEPSON MM, 1988, AM J PHYSIOL, V255, pE155; KARNER J, 1981, J PARENT EUR NUTR, V5, P102; MACLENNAN PA, 1988, FEBS LETT, V237, P133, DOI 10.1016/0014-5793(88)80186-8; MORTIMORE GE, 1987, ANNU REV NUTR, V7, P539, DOI 10.1146/annurev.nu.07.070187.002543; RENNIE MJ, 1986, LANCET, V2, P1008; RENNIE MJ, 1985, BRIT MED BULL, V41, P257, DOI 10.1093/oxfordjournals.bmb.a072060; ROTH E, 1990, JPEN-PARENTER ENTER, V14, pS130, DOI 10.1177/014860719001400419; Roth E, 1982, Clin Nutr, V1, P25, DOI 10.1016/0261-5614(82)90004-8; ROTH E, 1985, CLIN CHEM, V31, P1305; ROTH E, 1984, ADV HEPATIC ENCEPHAL, P527; SMITH R, 1983, TRENDS BIOCHEM SCI, V4, P142; STOLL B, 1992, BIOCHEM J, V287, P217, DOI 10.1042/bj2870217; TRACEY KJ, 1986, J EXP MED, V164, P1368, DOI 10.1084/jem.164.4.1368; VONDAHL S, 1991, BIOCHEM J, V280, P105; WATFORD M, 1989, TRENDS BIOCHEM SCI, V14, P1, DOI 10.1016/0968-0004(89)90074-1; WILKINSON HW, 1976, METABOLISM RESPONSE	27	360	365	3	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 22	1993	341	8856					1330	1332		10.1016/0140-6736(93)90828-5	http://dx.doi.org/10.1016/0140-6736(93)90828-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098459				2022-12-24	WOS:A1993LD25300015
J	ATKIN, WS; CUZICK, J; NORTHOVER, JMA; WHYNES, DK				ATKIN, WS; CUZICK, J; NORTHOVER, JMA; WHYNES, DK			PREVENTION OF COLORECTAL-CANCER BY ONCE-ONLY SIGMOIDOSCOPY	LANCET			English	Article							OCCULT BLOOD-TESTS; FLEXIBLE SIGMOIDOSCOPY; ASYMPTOMATIC PATIENTS; FIBEROPTIC SIGMOIDOSCOPY; SCREENING-PROCEDURE; COLONIC POLYPS; FOLLOW-UP; NEOPLASMS; RISK; COLONOSCOPY	There is no national screening programme for colorectal cancer in the UK despite the fact that the annual death toll from this disease exceeds that of breast and cervical cancer. Faecal occult blood testing (FOBT) is under evaluation for screening, but screening by sigmoidoscopy is not considered viable. This situation contrasts with the USA where both annual FOBT and screening by flexible sigmoidoscopy every 3 to 5 years are recommended from 50 years old. We seek to demonstrate that most of the benefit from the US screening policy would accrue from a single flexible sigmoidoscopy examination at age 55 to 60 years with appropriate colonoscopic surveillance for the 3% to 5% found to have high-risk adenomas (greater-than-or-equal-to 1 cm or villous histology). If applied nationally, this screening regimen could prevent about 5500 colorectal cancer cases and 3500 deaths in the UK each year, thus saving 40 000 years of life. We estimate that there would be little net cost to the National Health Service because savings obtained from treating fewer patients would largely off set the cost of screening. We recommend that a randomised trial to evaluate screening by single flexible sigmoidoscopy should start without delay. Such a trial would involve about 120000 participants, and 15 years of follow-up would be required to obtain a clear answer on mortality, although information on incidence reduction would be available sooner.	IMPERIAL CANC RES FUND,DEPT MATH STAT & EPIDEMIOL,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; ST MARKS HOSP,IMPERIAL CANC RES FUND,COLORECTAL UNIT,LONDON EC1V 2PS,ENGLAND; UNIV NOTTINGHAM,DEPT ECON,NOTTINGHAM NG7 2RD,ENGLAND	Cancer Research UK; Cancer Research UK; Imperial College London; University of Nottingham				Atkin, Wendy/0000-0001-9073-9658				ALLISON JE, 1990, ANN INTERN MED, V112, P328, DOI 10.7326/0003-4819-112-5-328; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; DAY NE, 1985, LANCET, V1, P280; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; FOLEY DP, 1987, GUT, V28, pA1367; FOUTCH PG, 1991, DIGEST DIS SCI, V36, P924, DOI 10.1007/BF01297142; FRIEDMAN GD, 1986, J CHRON DIS, V39, P453, DOI 10.1016/0021-9681(86)90112-8; GATTESCHI B, 1991, INT J CANCER, V49, P509, DOI 10.1002/ijc.2910490406; GILBERTSEN VA, 1978, CANCER, V41, P1137, DOI 10.1002/1097-0142(197803)41:3<1137::AID-CNCR2820410350>3.0.CO;2-G; GROSSMAN S, 1989, GASTROENTEROLOGY, V96, P299, DOI 10.1016/0016-5085(89)91551-5; HOFF G, 1985, SCAND J GASTROENTERO, V20, P351, DOI 10.3109/00365528509091663; JOHNSON DA, 1990, AM J GASTROENTEROL, V85, P969; KEWENTER J, 1991, CANCER SCREENING, P116; KRONBORG O, 1987, SCAND J GASTROENTERO, V22, P677, DOI 10.3109/00365528709011142; LIEBERMAN DA, 1988, ARCH INTERN MED, V148, P473, DOI 10.1001/archinte.148.2.473; MARKS G, 1979, DIS COLON RECTUM, V22, P162, DOI 10.1007/BF02586809; MAULE WF, 1990, GUT, V31, pA1203; MCCALLUM RW, 1984, AM J GASTROENTEROL, V79, P433; MILLER AB, 1991, CANCER SCREENING UIC, P135; MORSON BC, 1976, CLIN GASTROENTEROL, V5, P505; NEUGUT AI, 1988, GASTROENTEROLOGY, V95, P492, DOI 10.1016/0016-5085(88)90511-2; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; REX DK, 1991, GASTROENTEROLOGY, V100, P64, DOI 10.1016/0016-5085(91)90583-7; ROSEVELT J, 1984, DIGEST DIS SCI, V29, P161, DOI 10.1007/BF01317059; ROZEN P, 1987, CANCER-AM CANCER SOC, V60, P2553, DOI 10.1002/1097-0142(19871115)60:10<2553::AID-CNCR2820601034>3.0.CO;2-S; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SELBY JV, 1988, J CLIN EPIDEMIOL, V41, P427, DOI 10.1016/0895-4356(88)90043-1; SHIDA H, 1989, DIS COLON RECTUM, V32, P404, DOI 10.1007/BF02563693; STEPHENSON BM, 1991, BRIT J SURG, V78, P1162, DOI 10.1002/bjs.1800781005; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; THOMAS W, 1991, CANCER SCREENING, P106; TRIPP MR, 1987, CANCER, V60, P1599, DOI 10.1002/1097-0142(19871001)60:7<1599::AID-CNCR2820600730>3.0.CO;2-I; WALKER AR, 1991, J CLIN EPIDEMIOL, V44, P907, DOI 10.1016/0895-4356(91)90053-C; WHERRY DC, 1981, DIS COLON RECTUM, V24, P521, DOI 10.1007/BF02604312; 1990, HLTH PERSONAL SOCIAL; 1988, GASTROINTEST ENDOSC, V34, pS6; 1993, CANCER STATISTIC MB1, V20	37	319	322	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					736	740		10.1016/0140-6736(93)90499-7	http://dx.doi.org/10.1016/0140-6736(93)90499-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095636				2022-12-24	WOS:A1993KT36200016
J	COTTON, DWK; ROGERS, S				COTTON, DWK; ROGERS, S			MOLECULAR MEDICINE - AGING, CANCER, AND MITOCHONDRIAL DETERIORATION	LANCET			English	Editorial Material											COTTON, DWK (corresponding author), UNIV SHEFFIELD,SCH MED,DEPT PATHOL,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND.							COTTON DWK, 1990, HISTOPATHOLOGY, V16, P507; de Duve, 1991, BLUEPRINT CELL; KADENBACH B, 1990, NATURWISSENSCHAFTEN, V77, P221, DOI 10.1007/BF01138485; Margulis L., 1991, SYMBIOSISOURCE EVO; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; SHARP MGF, 1992, J PATHOL, V168, P163, DOI 10.1002/path.1711680203; TROLL W, 1991, FREE RADICAL RES COM, V12-3, P751	7	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					281	282		10.1016/0140-6736(93)92625-4	http://dx.doi.org/10.1016/0140-6736(93)92625-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093925				2022-12-24	WOS:A1993KK24500013
J	COLLIER, JD; GUO, KD; BURT, AD; BASSENDINE, MF; MAJOR, GN				COLLIER, JD; GUO, KD; BURT, AD; BASSENDINE, MF; MAJOR, GN			DEFICIENT REPAIR OF DNA LESION O6-METHYLGUANINE IN CIRRHOSIS	LANCET			English	Article							O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE	Cirrhosis is a risk factor for hepatocellular carcinoma. O6-methylguanine is a promutagenic and potentially carcinogenic DNA lesion produced by environmental alkylating agents. If it is not repaired, DNA replication can lead to a G-to-A transition mutation, which is a known mechanism of oncogene activation. We have found that the activity of the repairing methyltransferase enzyme is significantly lower in cirrhotic tissue than in non-cirrhotic diseased liver or in normal liver. This finding suggests a mechanism for cirrhosis being a risk factor for cancer of the liver: increased cellular proliferation together with persistence of O6-methylguanine might lead to malignant transformation of liver cells through mutation and oncogene activation.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,MED MOLEC BIOL GRP,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PATHOL,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK			Burt, Alastair D/D-3634-2013	Burt, Alastair D/0000-0002-3011-7774				BASSENDINE MF, 1987, BAILLIERE CLIN GASTR, V1, P1, DOI 10.1016/0950-3528(87)90031-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CESARONE C, 1979, ANAL BIOCHEM, V102, P188; CHALLEN C, IN PRESS HEPATOLOGY; CHENG KK, 1992, LANCET, V339, P1314, DOI 10.1016/0140-6736(92)91960-G; CRADDOCK VM, 1986, RELATIVE IMPORTANCE, P242; KYRTOPOULOS SA, 1990, CARCINOGENESIS, V11, P431, DOI 10.1093/carcin/11.3.431; MAJOR GN, 1991, BIOCHEM J, V277, P89, DOI 10.1042/bj2770089; OHGAKI H, 1992, CANCER RES, V52, P2995; PEGG AE, 1990, CANCER RES, V50, P6119	10	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					207	208		10.1016/0140-6736(93)90069-S	http://dx.doi.org/10.1016/0140-6736(93)90069-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093500				2022-12-24	WOS:A1993KJ21900007
J	HARPER, PS				HARPER, PS			INSURANCE AND GENETIC TESTING	LANCET			English	Editorial Material											HARPER, PS (corresponding author), UNIV WALES COLL MED,INST MED GENET,HEATH PK,CARDIFF CF4 4XN,S GLAM,WALES.							ABBING HDCR, 1991, HEALTH POLICY, V18, P197; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; BRANDON RM, 1992, INT J HLTH SERV, V21, P265; HARPER PS, 1992, J ROY COLL PHYS LOND, V26, P184; MADDOX J, 1991, NATURE, V352, P11, DOI 10.1038/352011a0; NATOWICZ MR, 1992, AM J HUM GENET, V50, P465; POKORSKI R, 1989, POTENTIAL ROLE GENET, P8; TYLER A, 1992, BRIT J PSYCHIAT, V161, P481, DOI 10.1192/bjp.161.4.481; 1989, GENETICS SCI SOC; 1992, CYSTIC FIBROSIS DNA, P189; 1992, GENETIC TESTS HLTH I	11	40	41	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 23	1993	341	8839					224	227		10.1016/0140-6736(93)90080-Z	http://dx.doi.org/10.1016/0140-6736(93)90080-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	8093510				2022-12-24	WOS:A1993KJ21900017
J	ALLAART, CF; POORT, SR; ROSENDAAL, FR; REITSMA, PH; BERTINA, RM; BRIET, E				ALLAART, CF; POORT, SR; ROSENDAAL, FR; REITSMA, PH; BERTINA, RM; BRIET, E			INCREASED RISK OF VENOUS THROMBOSIS IN CARRIERS OF HEREDITARY PROTEIN-C DEFICIENCY DEFECT	LANCET			English	Article							PURPURA FULMINANS; DUTCH FAMILIES; NEWBORN-INFANT; FACTOR-V; DISEASE; INACTIVATION; FREQUENCY; ABSENCE	The relevance of heterozygosity for hereditary protein C deficiency as a risk factor for venous thrombosis has been disputed because heterozygotes without symptoms have been identified among blood donors and relatives of homozygotes. As a result, clinicians do not know whether to offer prophylaxis or not. We have compared thrombosis-free survival in 161 heterozygous and normal members of the families of 24 heterozygotes for protein C deficiency referred from several centres in the Netherlands and with a history of symptoms. We studied the influence of heterozygosity and of putative additional risk factors on the occurrence of thrombotic events noted when a medical history was taken. Protein C activities were measured but a diagnosis of heterozygosity was based on the presence of the specific mutation in one of the protein C genes identified in the proband of the family. We found a significant difference in the thrombosis-free survival of the 77 heterozygotes and 84 normals: by age 45, 50% of heterozygotes and 10% of normal relatives can be expected to have had a manifestation of venous thromboembolism. The presence of such a mutation was clearly associated with an increased risk of venous thrombotic events. Thrombotic events occurred more often in years in which the patient had been immobile for more than a week or had had surgery. Other putative risk factors showed no significant effect in the incidence of thrombotic events. About 50% of all first episodes and 65% of recurrences of venous thromboembolism in the heterozygotes were spontaneous-ie, there was no predisposing event such as surgery or pregnancy. There was no increased risk for arterial occlusions in heterozygotes. We conclude that members of the family of a symptomatic heterozygote proband who are heterozygous for the mutation in the protein C gene have an increased risk of venous thrombotic events compared with their normal family members. For such individuals prophylactic anticoagulation should be considered; the decision will need to be taken on an individual basis.	LEIDEN UNIV HOSP, DEPT CLIN EPIDEMIOL, 2333 AA LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	ALLAART, CF (corresponding author), UNIV HOSP LEIDEN, DEPT HEMATOL, THROMBOSIS & HAEMOSTASIS RES UNIT, POB 9600, 2300 RC LEIDEN, NETHERLANDS.		Bertina, Rogier/AGQ-5246-2022; Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496				BENTAL O, 1989, THROMB HAEMOSTASIS, V61, P50; BERTINA RM, 1982, THROMB HAEMOSTASIS, V48, P1; BRANSON HE, 1983, LANCET, V2, P1165; BROEKMANS AW, 1983, NEW ENGL J MED, V309, P340, DOI 10.1056/NEJM198308113090604; BROEKMANS AW, 1983, THROMB HAEMOSTASIS, V50, P350; Broekmans AW, 1988, PROTEIN C RELATED PR, V3, P160; COX DR, 1972, J R STAT SOC B, V34, P187; ESMON CT, 1983, BLOOD, V62, P1155; ESTELLES A, 1984, THROMB HAEMOSTASIS, V52, P53; FULCHER CA, 1984, BLOOD, V63, P486; GLADSON CL, 1988, THROMB HAEMOSTASIS, V59, P18; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HORELLOU MH, 1984, BRIT MED J, V289, P1285, DOI 10.1136/bmj.289.6454.1285; MALLAR RA, 1989, J PEDIATR, V114, P528; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARCINIAK E, 1985, BLOOD, V65, P15; MILETICH J, 1987, NEW ENGL J MED, V317, P991, DOI 10.1056/NEJM198710153171604; PABINGERFASCHING I, 1983, THROMB HAEMOSTASIS, V50, P810; REITSMA PH, 1991, BLOOD, V78, P890, DOI 10.1182/blood.V78.4.890.bloodjournal784890; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; VANDENBROUCKE JP, 1982, AM J EPIDEMIOL, V115, P303, DOI 10.1093/oxfordjournals.aje.a113306; WALKER FJ, 1981, J BIOL CHEM, V256, P1128	25	332	338	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 16	1993	341	8838					134	138		10.1016/0140-6736(93)90003-Y	http://dx.doi.org/10.1016/0140-6736(93)90003-Y			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG627	8093743	Green Submitted			2022-12-24	WOS:A1993KG62700003
J	MORGAN, RE; PALINKAS, LA; BARRETTCONNOR, EL; WINGARD, DL				MORGAN, RE; PALINKAS, LA; BARRETTCONNOR, EL; WINGARD, DL			PLASMA-CHOLESTEROL AND DEPRESSIVE SYMPTOMS IN OLDER MEN	LANCET			English	Article							WEIGHT CHANGE; MORTALITY; POPULATION; RISK	In several clinical trials of interventions designed to lower plasma cholesterol, reductions in coronary heart disease mortality have been offset by an unexplained rise in suicides and other violent deaths. We have tried to find out whether depressive illness is related to low plasma cholesterol concentrations in men of 50 years and older. In 1985-87, Beck depression inventories were obtained from 1020 white men, aged 50-89 years, in the Rancho Bernardo, California, cohort. Disease history and behaviours were assessed by standard questionnaires. Plasma cholesterol and weight were measured at this time, as they had been in 1972-74. Among men aged 70 years and older, categorically defined depression was three times more common in the group with low plasma cholesterol (<4.14 mmol/L) than in those with higher concentrations (5/31 [16%] vs 22/363 [6%]; p=0.033). Depressive symptom scores correlated significantly and inversely with plasma cholesterol concentrations, even after adjustment for age, health status, number of chronic illnesses, number of medications, and exercise, as well as measured weight loss and change in plasma cholesterol in the previous 13 years. Our finding that low plasma cholesterol is associated with depressive symptoms in elderly men is compatible with observations that a very low total cholesterol may be related to suicide and violent death. Since cholesterol lowering in the general population is widely recommended, this observation warrants further investigation.	UNIV CALIF SAN DIEGO,SCH MED,DEPT COMMUNITY & FAMILY MED,DIV EPIDEMIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT COMMUNITY & FAMILY MED,DIV FAMILY MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG007181] Funding Source: NIH RePORTER; NIA NIH HHS [R37 AG07181-05] Funding Source: Medline; NIDDK NIH HHS [R01-DK31801] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHLEY FW, 1974, J CHRON DIS, V27, P103, DOI 10.1016/0021-9681(74)90079-4; BAKER LL, 1985, PREV MED, V14, P155, DOI 10.1016/0091-7435(85)90030-1; Beck A. T., 1960, ARCH GEN PSYCHIAT, V4, P53, DOI DOI 10.1001/ARCHPSYC.1961.01710120031004; BECK AT, 1972, POSTGRAD MED, V52, P81, DOI 10.1080/00325481.1972.11713319; BLAZER D, 1980, AM J PSYCHIAT, V137, P439; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; CRIQUI MH, 1978, AM J EPIDEMIOL, V108, P267; DAPRADA M, 1988, EXPERIENTIA, V44, P115; EISON MS, 1989, PSYCHOPATHOLOGY, V22, P13, DOI 10.1159/000284622; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; FORETTE B, 1989, LANCET, V1, P868; GALLAGHER D, 1982, J CONSULT CLIN PSYCH, V50, P152, DOI 10.1037/0022-006X.50.1.152; GUICHENEY P, 1988, J HYPERTENS, V6, P873, DOI 10.1097/00004872-198811000-00005; HOLINGER PC, 1982, SOC SCI MED, V16, P1929, DOI 10.1016/0277-9536(82)90392-6; KAPLAN JR, 1991, PSYCHOSOM MED, V53, P634, DOI 10.1097/00006842-199111000-00005; MCGEER EG, 1976, AGING-US, V3, P389; MELTZER H, 1989, BRIT J PSYCHIAT, V155, P25, DOI 10.1192/S0007125000291733; MENOTTI A, 1989, ANN MED, V21, P175, DOI 10.3109/07853898909149929; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; MURPHY JM, 1989, SOC PSYCH PSYCH EPID, V24, P134, DOI 10.1007/BF01788022; NIELSEN AC, 1980, ARCH GEN PSYCHIAT, V37, P999; OLIVER MF, 1992, BMJ-BRIT MED J, V304, P393, DOI 10.1136/bmj.304.6824.393; OSTER P, 1981, KLIN WOCHENSCHR, V59, P857, DOI 10.1007/BF01721056; PALINKAS LA, 1990, J CLIN EPIDEMIOL, V43, P1131, DOI 10.1016/0895-4356(90)90014-G; THOMPSON MP, 1991, J AM GERIATR SOC, V39, P497, DOI 10.1111/j.1532-5415.1991.tb02496.x; VANDOORNEN LJP, 1987, J PSYCHOSOM RES, V31, P239, DOI 10.1016/0022-3999(87)90081-X; WEISSENBURGER J, 1986, PSYCHIAT RES, V17, P275, DOI 10.1016/0165-1781(86)90075-2; YOUNG SN, 1988, CLIN NEUROPHARMACOL, V11, pS207; 1992, ARCH INTERN MED, V152, P1490	29	259	261	1	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					75	79		10.1016/0140-6736(93)92556-9	http://dx.doi.org/10.1016/0140-6736(93)92556-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KF870	8093404				2022-12-24	WOS:A1993KF87000003
J	STRAIN, EC; MUMFORD, GK; SILVERMAN, K; GRIFFITHS, RR				STRAIN, EC; MUMFORD, GK; SILVERMAN, K; GRIFFITHS, RR			CAFFEINE DEPENDENCE SYNDROME - EVIDENCE FROM CASE-HISTORIES AND EXPERIMENTAL EVALUATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MAJOR DEPRESSION; PHYSICAL-DEPENDENCE; NORMAL VOLUNTEERS; DISCRIMINATION; HUMANS; WITHDRAWAL; CESSATION; NICOTINE; SMOKING	Objective.-The extent to which daily caffeine use is associated with a substance dependence syndrome similar to that associated with other psychoactive drugs is unknown. The purpose of this study was to assess volunteers who reported problems with their use of caffeine for evidence suggesting a diagnosis of caffeine dependence based on the generic criteria for substance dependence from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Design.-Case-series evaluations. Setting.-An academic research center. Participants.-Self-identified adults who believed they were psychologically or physically dependent on caffeine. Main Outcome Measure.-Diagnoses made by a psychiatrist using a structured clinical interview that included a section on caffeine dependence based on generic criteria for DSM-IV substance dependence. Secondary Outcome Measure.-Double-blind caffeine-withdrawal evaluation. Results.-Ninety-nine subjects were screened for the study, and 16 were identified as having a diagnosis of caffeine dependence. Median daily caffeine intake was 357 mg, and 19% of subjects consumed less than the national (US) daily average of caffeine. Criteria used for making diagnoses (and rates of their prevalence) were as follows: withdrawal (94%), use continued despite knowledge of a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by caffeine use (94%), persistent desire or unsuccessful efforts to cut down or control use (81%), and tolerance (75%). Eleven subjects underwent the double-blind caffeine-withdrawal evaluation portion of the study, and nine (82%) of the 11 showed objective evidence of caffeine withdrawal, including eight of 11 with functional impairment. Conclusions.-These results, together with other experimental evidence, suggest that caffeine exhibits the features of a typical psychoactive substance of dependence. It is valuable to recognize caffeine dependence as a clinical syndrome, since some people feel compelled to continue caffeine use despite desires and recommendations to the contrary.	JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205	Johns Hopkins University			/ABG-5735-2021	Silverman, Kenneth/0000-0003-2724-1413	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003890, K20DA000166] Funding Source: NIH RePORTER; NIDA NIH HHS [K20 DA 00166, R01 DA 03890] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		[Anonymous], 1971, EITS MANUAL PROFILE; Barone JJ, 1984, CAFFEINE PERSPECTIVE, P59, DOI 10.1007/978-3-642-69823-1_4; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Beck AT., 1996, BECK DEPRESSION INVE; BRESLAU N, 1993, ARCH GEN PSYCHIAT, V50, P31; CHAIT LD, 1992, BEHAV PHARMACOL, V3, P219; EVANS SM, 1991, BEHAV PHARMACOL, V2, P345; GILBERT RM, 1984, METHYLXANTHINE BEVER, P185; GLASSMAN AH, 1990, JAMA-J AM MED ASSOC, V264, P1546, DOI 10.1001/jama.264.12.1546; GRAHAM DM, 1978, NUTR REV, V36, P97, DOI 10.1111/j.1753-4887.1978.tb03717.x; Graham H N, 1984, Prog Clin Biol Res, V158, P29; GREDEN JF, 1992, SUBSTANCE ABUSE COMP, P357; GRIFFITHS RR, 1990, J PHARMACOL EXP THER, V255, P1123; GRIFFITHS RR, 1988, PSYCHOPHARMACOLOGY, V94, P437, DOI 10.1007/BF00212836; GRIFFITHS RR, 1990, J PHARMACOL EXP THER, V252, P970; GRIFFITHS RR, 1988, J PHARMACOL EXP THER, V246, P21; GRIFFITHS RR, PSYCHOPHARMACOLOGY 4; HUGHES JR, 1992, AM J PSYCHIAT, V149, P33; Hughes JR, 1993, NIDA RES MONOGR, V132, P194; JACOB P, 1981, J CHROMATOGR, V222, P61, DOI 10.1016/S0378-4347(00)81033-6; JAMES JE, 1991, CAFFEINE HLTH; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P36; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KOZLOWSKI LT, 1993, J SUBST ABUSE TREAT, V10, P171, DOI 10.1016/0740-5472(93)90042-Z; SILVERMAN K, 1992, NEW ENGL J MED, V327, P1109, DOI 10.1056/NEJM199210153271601; SILVERMAN K, 1992, J EXP ANAL BEHAV, V57, P91, DOI 10.1901/jeab.1992.57-91; Spitzer R., 1985, STRUCTURED CLIN INTE; Yesair D W, 1984, Prog Clin Biol Res, V158, P215; 1987, DIAGNOSTIC STATISTIC; 1994, DIAGNOSTIC STATISTIC	30	124	128	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					1043	1048		10.1001/jama.272.13.1043	http://dx.doi.org/10.1001/jama.272.13.1043			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089887				2022-12-24	WOS:A1994PH77500030
J	BARDWELL, AJ; BARDWELL, L; TOMKINSON, AE; FRIEDBERG, EC				BARDWELL, AJ; BARDWELL, L; TOMKINSON, AE; FRIEDBERG, EC			SPECIFIC CLEAVAGE OF MODEL RECOMBINATION AND REPAIR INTERMEDIATES BY THE YEAST RAD1-RAD10 DNA ENDONUCLEASE	SCIENCE			English	Article							PIGMENTOSUM GROUP-F; SACCHAROMYCES-CEREVISIAE; MITOTIC RECOMBINATION; RAD10 CONSTITUTE; GENETIC-CONTROL; PROTEINS RAD1; EXCISION; PURIFICATION; PATHWAY; ERCC1	The RAD1 and RAD10 genes of Saccharomyces cerevisiae are required for both nucleotide excision repair and certain mitotic recombination events. Here, model recombination and repair intermediates were used to show that Rad1-Rad10-mediated cleavage occurs at duplex-single-strand junctions. Moreover, cleavage occurs only on the strand containing the 3' single-stranded tail. Thus, both biochemical and genetic evidence indicate a role for the Rad1-Rad10 complex in the cleavage of specific recombination intermediates. Furthermore, these data suggest that Rad1-Rad10 endonuclease incises DNA 5' to damaged bases during nucleotide excision repair.	UNIV TEXAS,SW MED CTR,MOLEC PATHOL LAB,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Health San Antonio			Bardwell, Lee/I-8284-2019	Bardwell, Lee/0000-0002-2393-8363	NATIONAL CANCER INSTITUTE [R37CA012428, R01CA012428] Funding Source: NIH RePORTER; NCI NIH HHS [CA12428] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AQUILERA A, 1989, GENETICS, V123, P683; BAILIS AM, 1992, MOL CELL BIOL, V12, P4988, DOI 10.1128/MCB.12.11.4988; BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; BARDWELL L, 1990, BIOCHEMISTRY-US, V29, P3119, DOI 10.1021/bi00464a031; BARDWELL L, 1994, P NATL ACAD SCI USA, V91, P3926, DOI 10.1073/pnas.91.9.3926; BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FISHMANLOBELL J, 1992, SCIENCE, V258, P480, DOI 10.1126/science.1411547; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; KLEIN HL, 1988, GENETICS, V120, P367; LIN FL, 1984, MOL CELL BIOL, V4, P1020, DOI 10.1128/MCB.4.6.1020; OZENBERGER BA, 1991, MOL CELL BIOL, V11, P1222, DOI 10.1128/MCB.11.3.1222; SCHIESTL RH, 1990, MOL CELL BIOL, V10, P2485, DOI 10.1128/MCB.10.6.2485; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; SUNG P, 1993, J BIOL CHEM, V268, P26391; THOMAS BJ, 1989, GENETICS, V123, P725; TOMKINSON AE, 1994, BIOCHEMISTRY-US, V33, P5305, DOI 10.1021/bi00183a038; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; ZEHFUS BR, 1990, GENETICS, V126, P41	26	231	242	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2082	2085		10.1126/science.8091230	http://dx.doi.org/10.1126/science.8091230			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091230				2022-12-24	WOS:A1994PJ91200026
J	JOHNSTON, M; ANDREWS, S; BRINKMAN, R; COOPER, J; DING, H; DOVER, J; DU, Z; FAVELLO, A; FULTON, L; GATTUNG, S; GEISEL, C; KIRSTEN, J; KUCABA, T; HILLIER, L; JIER, M; JOHNSTON, L; LANGSTON, Y; LATREILLE, P; LOUIS, EJ; MACRI, C; MARDIS, E; MENEZES, S; MOUSER, L; NHAN, M; RIFKIN, L; RILES, L; STPETER, H; TREVASKIS, E; VAUGHAN, K; VIGNATI, D; WILCOX, L; WOHLDMAN, P; WATERSTON, R; WILSON, R; VAUDIN, M				JOHNSTON, M; ANDREWS, S; BRINKMAN, R; COOPER, J; DING, H; DOVER, J; DU, Z; FAVELLO, A; FULTON, L; GATTUNG, S; GEISEL, C; KIRSTEN, J; KUCABA, T; HILLIER, L; JIER, M; JOHNSTON, L; LANGSTON, Y; LATREILLE, P; LOUIS, EJ; MACRI, C; MARDIS, E; MENEZES, S; MOUSER, L; NHAN, M; RIFKIN, L; RILES, L; STPETER, H; TREVASKIS, E; VAUGHAN, K; VIGNATI, D; WILCOX, L; WOHLDMAN, P; WATERSTON, R; WILSON, R; VAUDIN, M			COMPLETE NUCLEOTIDE-SEQUENCE OF SACCHAROMYCES-CEREVISIAE CHROMOSOME-VIII	SCIENCE			English	Article							PHYSICAL MAPS; YEAST; GENES	The complete nucleotide sequence of Saccharomyces cerevisiae chromosome VIII reveals that it contains 269 predicted or known genes (300 base pairs or larger). Fifty-nine of these genes (22 percent) were previously identified. Of the 210 novel genes, 65 are predicted to encode proteins that are similar to other proteins of known or predicted function. Sixteen genes appear to be relatively recently duplicated. On average, there is one gene approximately every 2 kilobases. Although the coding density and base composition across the chromosome are not uniform, no regular pattern of variation is apparent.	WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL)	JOHNSTON, M (corresponding author), WASHINGTON UNIV,SCH MED,CTR GENOME SEQUENCING,ST LOUIS,MO 63110, USA.		Johnston, Mark/K-3543-2019; Louis, Edward/B-7920-2008; Johnston, Mark/R-6156-2019; Brinkman, Ryan/B-1108-2008; Mardis, Elaine/W-2202-2019; Wilson, Richard K./AAF-4139-2019; Cooper, John/D-4448-2014	Johnston, Mark/0000-0002-4932-7229; Louis, Edward/0000-0003-1157-3608; Brinkman, Ryan/0000-0002-9765-2990; Wilson, Richard K./0000-0002-1992-1358; Cooper, John/0000-0002-0933-4571				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; [Anonymous], UNPUB; BUSSEY H, COMMUNICATION; BUTT TR, 1987, MICROBIOL REV, V51, P351, DOI 10.1128/MMBR.51.3.351-364.1987; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; DUJON B, COMMUNICATION; DURBIN R, UNPUB; ERICKSON JR, 1993, GENETICS, V134, P151; FICHANT GA, 1991, J MOL BIOL, V220, P659, DOI 10.1016/0022-2836(91)90108-I; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HILLIER L, UNPUB; LALO D, 1993, CR ACAD SCI III-VIE, V316, P367; LOUIS EJ, 1994, YEAST, V10, P271, DOI 10.1002/yea.320100214; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OLSON MV, 1991, MOL CELLULAR BIOL YE, V1, P1; RILES L, 1993, GENETICS, V134, P81; RILES L, UNPUB; RYMOND BC, 1992, MOL CELLULAR BIOL YE, V2, P142; SHARP PM, 1993, NUCLEIC ACIDS RES, V21, P179, DOI 10.1093/nar/21.2.179; STEENSMA HY, 1989, CURR GENET, V16, P131; VOYTAS DF, 1992, NATURE, V358, P717, DOI 10.1038/358717a0; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	23	268	619	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2077	2082		10.1126/science.8091229	http://dx.doi.org/10.1126/science.8091229			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	8091229				2022-12-24	WOS:A1994PJ91200025
J	TANJI, J; SHIMA, K				TANJI, J; SHIMA, K			ROLE FOR SUPPLEMENTARY MOTOR AREA CELLS IN PLANNING SEVERAL MOVEMENTS AHEAD	NATURE			English	Article							NEURONAL-ACTIVITY; VOLUNTARY MOVEMENTS; CORTICAL AREAS; ARM MOVEMENTS; CORTEX; MONKEY; ACTIVATION; POTENTIALS; PRIMATES; PREMOTOR	To achieve a volitional goal, we need to execute multiple movements in a specific temporal order. After repetitive performance of a particular sequence of movements, we are able to memorize and execute the whole sequence without external guidance. Where and how in the brain do we store information necessary for the orderly performance of multiple movements? We have found a group of cells in the cerebral cortex of monkeys whose activity is exclusively related to a sequence of multiple movements performed in a particular order. Such cellular activity exists in the supplementary motor area(1,2), but not in the primary motor cortex(3,4). We propose that these cells contribute a signal about the order of forthcoming multiple movements, and are useful for planning and coding of several movements ahead.			TANJI, J (corresponding author), TOHOKU UNIV,SCH MED,DEPT PHYSIOL,AOBA KU,2-1 SEIRYO CHO,SENDAI,MIYAGI 980,JAPAN.							BRINKMAN C, 1979, J NEUROPHYSIOL, V42, P681, DOI 10.1152/jn.1979.42.3.681; BRINKMAN C, 1984, J NEUROSCI, V4, P918; CHEN DF, 1991, SOMATOSENS MOT RES, V8, P27; COLEBATCH JG, 1991, J NEUROPHYSIOL, V65, P1392, DOI 10.1152/jn.1991.65.6.1392; CRUTCHER MD, 1990, J NEUROPHYSIOL, V64, P151, DOI 10.1152/jn.1990.64.1.151; DEECKE L, 1976, BIOL CYBERN, V23, P99, DOI 10.1007/BF00336013; DEIBER MP, 1991, EXP BRAIN RES, V84, P393; Dick J P, 1986, Mov Disord, V1, P255, DOI 10.1002/mds.870010405; HALSBAND U, 1993, BRAIN, V116, P243, DOI 10.1093/brain/116.1.243; IKEDA A, 1992, BRAIN, V115, P1017, DOI 10.1093/brain/115.4.1017; LANG W, 1990, EXP BRAIN RES, V79, P504; LAPLANE D, 1977, J NEUROL SCI, V34, P301, DOI 10.1016/0022-510X(77)90148-4; LUPPINO G, 1991, J COMP NEUROL, V311, P463, DOI 10.1002/cne.903110403; MATELLI M, 1993, NEUROREPORT, V4, P1295, DOI 10.1097/00001756-199309150-00002; MATSUZAKA Y, 1992, J NEUROPHYSIOL, V68, P653, DOI 10.1152/jn.1992.68.3.653; MUSHIAKE H, 1991, J NEUROPHYSIOL, V66, P705, DOI 10.1152/jn.1991.66.3.705; ORGOGOZO JM, 1979, SCIENCE, V206, P847, DOI 10.1126/science.493986; Passingham RE., 1993, FRONTAL LOBES VOLUNT; Porter R, 1993, CORTICOSPINAL FUNCTI; RIZZOLATTI G, 1990, EXP BRAIN RES, V82, P337; ROLAND PE, 1980, J NEUROPHYSIOL, V43, P118, DOI 10.1152/jn.1980.43.1.118; TANJI J, 1994, NEUROSCI RES, V19, P251, DOI 10.1016/0168-0102(94)90038-8; TANJI J, 1988, J NEUROPHYSIOL, V60, P325, DOI 10.1152/jn.1988.60.1.325; TANJI J, 1987, NATURE, V327, P618, DOI 10.1038/327618a0; TANJI J, 1985, J NEUROPHYSIOL, V53, P129, DOI 10.1152/jn.1985.53.1.129; TANJI J, 1982, J NEUROPHYSIOL, V48, P633, DOI 10.1152/jn.1982.48.3.633; WIESENDANGER M, 1986, REV PHYSIOL BIOCH P, V103, P1	27	478	484	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 29	1994	371	6496					413	416		10.1038/371413a0	http://dx.doi.org/10.1038/371413a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	8090219				2022-12-24	WOS:A1994PJ28500041
J	MANSFIELD, S; SINGH, S				MANSFIELD, S; SINGH, S			WHO SHOULD FILL THE CARE GAP IN HIV DISEASE	LANCET			English	Editorial Material							GENERAL-PRACTITIONER; INFECTION; AIDS; ATTITUDES		ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH & PRIMARY CARE,ROWLAND HILL ST,LONDON NW3 2PF,ENGLAND; WESTMINSTER MED SCH & HOSP,LONDON SW1P 2AP,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Imperial College London								ANDERSON P, 1988, BRIT MED J, V296, P535, DOI 10.1136/bmj.296.6621.535; BARTON S, 1992, BRIT MED J, V305, P902, DOI 10.1136/bmj.305.6859.902; BOYTON R, 1988, BRIT MED J, V296, P538, DOI 10.1136/bmj.296.6621.538; HASLAR J, 1984, CONTINUING CARE MANA; HIGGINSON I, 1991, HLTH TRENDS, V23, P59; KING E, 1992, HIV PREVENTION GAY M; KING MB, 1988, BRIT MED J, V297, P182, DOI 10.1136/bmj.297.6642.182; LANDE R, 1989, ROLE GP CARE PEOPLE; MANSFIELD S, 1992, INT J STD AIDS, V3, P248, DOI 10.1177/095646249200300403; MANSFIELD SJ, 1989, J ROY COLL GEN PRACT, V39, P104; MILNE RIG, 1988, BMJ, V296, P280; PINCHING AJ, 1989, AIDS S1, V3, P209; SHAPIRO J, 1991, BR J GEN PRACT, V41, P401; Singh S, 1991, Health Trends, V23, P55; SINGH S, 1990, IN PRESS BR J GEN PR; SMITS A, 1990, BRIT MED J, V300, P241, DOI 10.1136/bmj.300.6719.241; STRANG J, 1992, BMJ, V304, P1129; WADSWORTH E, 1992, BRIT J GEN PRACT, V42, P107; 1992 REPORT MINISTER; 1992, C REPORT ROLE GENERA	20	16	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					726	728						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103828				2022-12-24	WOS:A1993LX46900015
J	MICHAEL, AE; GREGORY, L; WALKER, SM; ANTONIW, JW; SHAW, RW; EDWARDS, CRW; COOKE, BA				MICHAEL, AE; GREGORY, L; WALKER, SM; ANTONIW, JW; SHAW, RW; EDWARDS, CRW; COOKE, BA			OVARIAN 11-BETA-HYDROXYSTEROID DEHYDROGENASE - POTENTIAL PREDICTOR OF CONCEPTION BY IN-VITRO FERTILIZATION AND EMBRYO-TRANSFER	LANCET			English	Note							FLUID	Cortisol is converted to the inactive glucocorticoid, cortisone, in several tissues by 11beta-hydroxysteroid dehydrogenase (11betaHSD). We have recently measured 11betaHSD activity in cultured human granulosa-lutein cells recovered from patients undergoing in-vitro fertilisation and embryo transfer (IVF-ET). We now report an association between the outcome of IVF-ET and 11betaHSD activity in these cells. Of the 64 patients studied, 32 had detectable 11betaHSD activity and none became pregnant; whereas 76% of the remaining ''11betaHSD-negative'' patients achieved pregnancies. Hence 11betaHSD activity may predict the outcome of IVF-ET.	ROYAL FREE HOSP,SCH MED,DEPT BIOCHEM,ROWLAND HILL ST,LONDON NW3 2PF,ENGLAND; UNIV HOSP WALES,ACAD DEPT OBSTET & GYNAECOL,FERTIL UNIT,CARDIFF,WALES; UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Cardiff University; University of Edinburgh								ANDERSEN CY, 1990, J CLIN ENDOCR METAB, V71, P1375, DOI 10.1210/jcem-71-5-1375; BENEDIKTSSON R, 1992, J ENDOCRINOL, V135, P53, DOI 10.1677/joe.0.1350053; FATEH M, 1989, FERTIL STERIL, V51, P538; LAKSHMI V, 1985, ENDOCRINOLOGY, V116, P552, DOI 10.1210/endo-116-2-552; MICHAEL AE, 1993, CLIN ENDOCRINOL, V38, P641, DOI 10.1111/j.1365-2265.1993.tb02147.x; MURPHY BEP, 1981, J STEROID BIOCHEM, V14, P811; TANNIN GM, 1991, J BIOL CHEM, V266, P16653	7	63	65	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					711	712		10.1016/0140-6736(93)91710-4	http://dx.doi.org/10.1016/0140-6736(93)91710-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103824				2022-12-24	WOS:A1993LX46900011
J	CORTELLARO, M; COFRANCESCO, E; BOSCHETTI, C				CORTELLARO, M; COFRANCESCO, E; BOSCHETTI, C			CARDIOLIPIN ANTIBODIES IN SURVIVORS OF MYOCARDIAL-INFARCTION	LANCET			English	Editorial Material							ANTIPHOSPHOLIPID ANTIBODIES				CORTELLARO, M (corresponding author), UNIV MILAN,IST MED INTERNA MALATTIE INFETT & IMMUNOPATOL,I-20122 MILAN,ITALY.							CORTELLARO M, 1992, LANCET, V339, P929, DOI 10.1016/0140-6736(92)90966-7; HAMSTEN A, 1986, LANCET, V1, P113; PHADKE KV, 1993, BRIT HEART J, V69, P391; SLETNES KE, 1992, LANCET, V339, P451, DOI 10.1016/0140-6736(92)91057-F; TRIPLETT DA, 1993, ARCH PATHOL LAB MED, V117, P78	5	2	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					192	192		10.1016/0140-6736(93)92294-4	http://dx.doi.org/10.1016/0140-6736(93)92294-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100926				2022-12-24	WOS:A1993LN62200007
J	ROBERTS, JM; REDMAN, CWG				ROBERTS, JM; REDMAN, CWG			PREECLAMPSIA - MORE THAN PREGNANCY-INDUCED HYPERTENSION	LANCET			English	Article							MATERNAL MORTALITY; REMOTE PROGNOSIS; PREECLAMPSIA; WOMEN		JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND	University of Oxford	ROBERTS, JM (corresponding author), UNIV PITTSBURGH,MAGEE WOMENS HOSP,DEPT OBSTET GYNECOL & REPROD SCI,FORBES AVE,PITTSBURGH,PA 15213, USA.		Roberts, James/AAI-3283-2020	Roberts, James/0000-0002-2671-3207				ASSALI NS, 1950, J CLIN INVEST, V29, P1354, DOI 10.1172/JCI102373; AUGENSEN K, 1984, ACTA OBSTET GYN SCAN, V63, P115, DOI 10.3109/00016348409154645; AUGUST P, 1990, AM J OBSTET GYNECOL, V163, P1612, DOI 10.1016/0002-9378(90)90639-O; BRANCH DW, 1992, PROSTAG LEUKOTR ESS, V45, P191, DOI 10.1016/0952-3278(92)90112-V; BRANCH DW, 1991, LANCET, V337, P943, DOI 10.1016/0140-6736(91)91572-C; Brosens I A, 1972, Obstet Gynecol Annu, V1, P177; CHESLEY LC, 1980, KIDNEY INT, V18, P234, DOI 10.1038/ki.1980.131; COMBS A, IN PRESS AM J OBSTET; COOPER DW, 1988, BRIT J OBSTET GYNAEC, V95, P644, DOI 10.1111/j.1471-0528.1988.tb06524.x; DEBOER K, 1989, AM J OBSTET GYNECOL, V160, P95, DOI 10.1016/0002-9378(89)90096-3; ENDRESEN MJ, 1992, AM J OBSTET GYNECOL, V167, P440, DOI 10.1016/S0002-9378(11)91426-4; FISHER KA, 1981, MEDICINE, V60, P267, DOI 10.1097/00005792-198107000-00002; FRIEDMAN SA, 1988, OBSTET GYNECOL, V71, P122; GALLERY EDM, 1980, PREGNANCY HYPERTENSI; GANT NF, 1973, J CLIN INVEST, V52, P2682, DOI 10.1172/JCI107462; GIFFORD RW, 1990, AM J OBSTET GYNECOL, V163, P1691; KAUNITZ AM, 1985, OBSTET GYNECOL, V65, P605; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; KITZMILL.JL, 1973, AM J OBSTET GYNECOL, V115, P248, DOI 10.1016/0002-9378(73)90293-7; MALEE MP, 1992, J CLIN ENDOCR METAB, V74, P1095, DOI 10.1210/jc.74.5.1095; RAMSEY E M, 1966, Carnegie Institution of Washington Publication, V38, P59; REDMAN CWG, 1978, BRIT MED J, V1, P467, DOI 10.1136/bmj.1.6111.467; Roberts J.M., 1989, MATERNAL FETAL MED P, P777; ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0; ROBERTS JM, 1991, AM J HYPERTENS, V4, P700, DOI 10.1093/ajh/4.8.700; ROBERTS JM, 1992, AM J REPROD IMMUNOL, V27, P101, DOI 10.1111/j.1600-0897.1992.tb00735.x; SPARGO BH, 1976, HYPERTENS PREGNANCY, P129; TAYLOR RN, 1991, AM J OBSTET GYNECOL, V165, P1705, DOI 10.1016/0002-9378(91)90019-N; TAYLOR RN, 1990, J CLIN ENDOCR METAB, V71, P1675, DOI 10.1210/jcem-71-6-1675; TAYLOR RN, 1991, AM J OBSTET GYNECOL, V165, P895, DOI 10.1016/0002-9378(91)90435-T; TSUKIMORI K, 1992, OBSTET GYNECOL, V80, P229; Wallenburg HCS., 1988, HDB HYPERTENSION, P66; WEINER CP, 1982, AM J OBSTET GYNECOL, V142, P275, DOI 10.1016/0002-9378(82)90730-X; 1991, 1985 87 DEP HLTH REP, P17; 1957, 1952 54 MIN HLTH REP	35	1044	1065	1	35	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 5	1993	341	8858					1447	1451		10.1016/0140-6736(93)90889-O	http://dx.doi.org/10.1016/0140-6736(93)90889-O			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099148				2022-12-24	WOS:A1993LF84100011
J	MOORE, PS; MARFIN, AA; QUENEMOEN, LE; GESSNER, BD; AYUB, YS; MILLER, DS; SULLIVAN, KM; TOOLE, MJ				MOORE, PS; MARFIN, AA; QUENEMOEN, LE; GESSNER, BD; AYUB, YS; MILLER, DS; SULLIVAN, KM; TOOLE, MJ			MORTALITY-RATES IN DISPLACED AND RESIDENT POPULATIONS OF CENTRAL SOMALIA DURING 1992 FAMINE	LANCET			English	Article							REFUGEE; THAILAND	Famine and civil war have resulted in high mortality rates and large population displacements in Somalia. To assess mortality rates and risk factors for mortality, we carried out surveys in the central Somali towns of Afgoi and Baidoa in November and December, 1992. In Baidoa we surveyed displaced persons living in camps; the average daily crude mortality rate was 16.8 (95% CI 14.6-19.1) per 10 000 population during the 232 days before the survey. An estimated 74% of children under 5 years living in displaced persons camps died during this period. In Afgoi, where both displaced and resident populations were surveyed, the crude mortality rate was 4.7 (3.9-5.5) deaths per 10 000 per day. Although mortality rates for all displaced persons were high, people living in temporary camps were at highest risk of death. As in other famine-related disasters, preventable infectious diseases such as measles and diarrhoea were the primary causes of death in both towns. These mortality rates are among the highest documented for a civilian population ver a long period. Community-based public health interventions to prevent and control common infectious diseses are needed to reduce these exceptionally high mortality rates in Somalia.	CTR DIS CONTROL, NATL CTR ENVIRONM HLTH, DIV ENVIRONM HAZARDS & HLTH EFFECTS, ATLANTA, GA 30333 USA; CTR DIS CONTROL, EPIDEMIOL PROGRAM OFF, DIV FIELD SERV, ATLANTA, GA 30333 USA; CTR DIS CONTROL, NATL CTR CHRON DIS PREVENT & HLTH PROMOT, ATLANTA, GA 30333 USA; CTR DIS CONTROL, INT HLTH PROGRAMME OFF, ATLANTA, GA 30333 USA; UNICEF, SOMALI CTY OFF, NAIROBI, KENYA; EMORY UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, ATLANTA, GA 30322 USA; EMORY UNIV, SCH PUBL HLTH, CTR INT HLTH, ATLANTA, GA 30322 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University; Emory University	MOORE, PS (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VECTOR BORNE INFECT DIS, POB 2087, FT COLLINS, CO 80522 USA.		Moore, Patrick S./F-3960-2011; Moore, Patrick/GVR-8294-2022	Moore, Patrick S./0000-0002-8132-858X; 				DEAN AG, 1991, AM J PREV MED, V7, P178, DOI 10.1016/S0749-3797(18)30936-X; ELIAS CJ, 1990, AM J PUBLIC HEALTH, V80, P824, DOI 10.2105/AJPH.80.7.824; GLASS RI, 1980, LANCET, V1, P868; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HAKEWILL PA, 1991, TROP DOCT, V21, P24, DOI 10.1177/00494755910210S106; Lemeshow S, 1985, World Health Stat Q, V38, P65; MANONCOURT S, 1992, LANCET, V340, P176, DOI 10.1016/0140-6736(92)93252-I; NEIBERG P, 1988, B WORLD HEALTH ORGAN, V66, P689; NICHOLS BL, 1977, AM J CLIN NUTR, V30, P1457, DOI 10.1093/ajcn/30.9.1457; TOOLE M J, 1989, Bulletin of the World Health Organization, V67, P381; TOOLE MJ, 1988, B WORLD HEALTH ORGAN, V66, P237; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; TOOLE MJ, 1992, MMWR-MORBID MORTAL W, V41, P1; 1992, MMWR, V41, P913; 1993, MMWR, V42, P9; 1992, STATE WORLDS CHILDRE	16	61	62	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 10	1993	341	8850					935	938		10.1016/0140-6736(93)91223-9	http://dx.doi.org/10.1016/0140-6736(93)91223-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096276	Green Submitted			2022-12-24	WOS:A1993KW98100015
J	TOMASEK, L; DARBY, SC; SWERDLOW, AJ; PLACEK, V; KUNZ, E				TOMASEK, L; DARBY, SC; SWERDLOW, AJ; PLACEK, V; KUNZ, E			RADON EXPOSURE AND CANCERS OTHER THAN LUNG-CANCER AMONG URANIUM MINERS IN WEST-BOHEMIA	LANCET			English	Article							MORTALITY; RATES	Recent observations have suggested that radon in the ambient air may cause cancers at sites other than the lung, but the evidence is indirect. We have studied site-specific cancer mortality in 4320 uranium miners in West Bohemia who have been followed-up for an average of 25 years, and in whom a four-fold radon-related excess of lung cancer has already been established. For all cancers other than lung cancer the number of deaths observed was slightly greater than that expected from national rates, but the increase was not significant statistically (ratio of observed to expected deaths [O/E]=1.11, 95% confidence interval [CI]=0.98-1.24) and mortality did not increase with duration of employment underground or with cumulative exposure to radon. Non-lung cancer mortality was significantly raised among men who started mining work aged under 25 but the increase was not related to cumulative radon exposure. When twenty-eight individual sites and types of cancer were examined, significantly increased risks were found for cancers of the liver (O/E=1.67) and gallbladder and extrahepatic bileducts (O/E=2.26). For liver cancer, mortality did not increase with duration of employment underground or with cumulative radon exposure. For cancer of the gallbladder and extrahepatic bileducts, mortality did not increase with duration of employment, but increased with cumulative exposure to radon. Mortality from multiple myeloma, although not significantly increased overall (O/E=1.08), increased with cumulative exposure to radon. Mortality from leukaemia was not increased overall (O/E=0.91) and was not related to cumulative radon exposure, but did increase with increasing duration of employment in the mines. There is no evidence in these miners that a radon-rich atmosphere increases the risk of any cancer other than lung cancer. Possible exceptions are cancer of the gallbladder and extrahepatic bileducts and multiple myeloma but further study is needed before it can be concluded that the associations found are causal.	UNIV OXFORD, RADCLIFFE INFIRM,IMPERIAL CANC RES FUND, CANC EPIDEMIOL UNIT,GIBSON BLDG, OXFORD OX2 6HE, ENGLAND; NATL INST PUBL HLTH, PRAGUE, CZECHOSLOVAKIA; UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND; HLTH INST URANIUM IND, PRIBRAM, CZECHOSLOVAKIA	Radcliffe Infirmary; University of Oxford; National Institute of Public Health (SZU) - Czech Republic; University of London; London School of Hygiene & Tropical Medicine				Swerdlow, Anthony/0000-0001-5550-4159				ANDERSSON M, 1992, J NATL CANCER I, V84, P1318, DOI 10.1093/jnci/84.17.1318; [Anonymous], 1988, SOURCES EFFECTS RISK; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; BRIDGES BA, 1991, LANCET, V337, P1187, DOI 10.1016/0140-6736(91)92859-Z; CHARLES M, 1990, INT J RADIAT BIOL, V58, P859, DOI 10.1080/09553009014552231; DARBY S, 1990, RAD PROTECTION AUSTR, V8, P83; DARBY SC, 1987, BRIT J CANCER, V55, P179, DOI 10.1038/bjc.1987.35; EATOUGH JP, 1990, LANCET, V335, P1292, DOI 10.1016/0140-6736(90)91371-G; EATOUGH JP, 1992, PHYS MED BIOL, V37, P955, DOI 10.1088/0031-9155/37/4/010; EATOUGH JP, 1991, RADIAT PROT DOSIM, V39, P33; FOX AJ, 1976, LANCET, V2, P416; FOX AJ, 1976, BRIT J PREV SOC MED, V30, P225; HENSHAW DL, 1990, LANCET, V335, P1008, DOI 10.1016/0140-6736(90)91071-H; JAMES AC, IN PRESS 29TH P HANF; MORRISON HI, 1988, AM J EPIDEMIOL, V128, P1266, DOI 10.1093/oxfordjournals.aje.a115080; PLACEK V, 1966, EXPOSURE EXTERNAL GA; RADFORD EP, 1984, NEW ENGL J MED, V310, P1485, DOI 10.1056/NEJM198406073102302; RICHARDSON RB, 1991, BRIT J RADIOL, V64, P608, DOI 10.1259/0007-1285-64-763-608; ROCKETTE HE, 1977, J OCCUP ENVIRON MED, V19, P795, DOI 10.1097/00043764-197712000-00004; SECOVA M, 1978, HEALTH PHYS, V35, P803; SEVC J, 1976, HEALTH PHYS, V30, P433, DOI 10.1097/00004032-197606000-00001; SEVC J, IN PRESS HLTH PHYS; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; TIRMARCHE M, IN PRESS BR J CANCER; VANKAICK G, 1989, RISKS RADIUM THOROTR; XIANGZHEN X, 1933, HEALTH PHYS, P120; 1988, MONOGRAPHS EVALUATIO, V44; 1988, HLTH RISKS RADON OTH; 1991, COMP DOSIMETRY RADON; 1990, DOCUMENTS NRPB, V1	30	82	83	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 10	1993	341	8850					919	923		10.1016/0140-6736(93)91212-5	http://dx.doi.org/10.1016/0140-6736(93)91212-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096265				2022-12-24	WOS:A1993KW98100004
J	WATIER, H; AURIAULT, C; CAPRON, A				WATIER, H; AURIAULT, C; CAPRON, A			DOES EPSTEIN-BARR-VIRUS INFECTION CONFER SELECTIVE ADVANTAGE TO MALARIA-INFECTED CHILDREN	LANCET			English	Note							PLASMODIUM-FALCIPARUM MALARIA; TUMOR-NECROSIS FACTOR; PROTECTION		INST PASTEUR,CTR IMMUNOL & BIOL PARASITAIRE,F-59000 LILLE,FRANCE; FAC MED TOURS,IMMUNOL LAB,F-37032 TOURS,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille								BIGGAR RJ, 1978, INT J CANCER, V22, P239, DOI 10.1002/ijc.2910220304; BURDIN N, 1992, 8TH INT C IMM BUD, P201; CARTER R, 1992, PARASITOL TODAY, V8, P41, DOI 10.1016/0169-4758(92)90077-F; CHIZZOLINI C, 1990, CLIN EXP IMMUNOL, V79, P95, DOI 10.1111/j.1365-2249.1990.tb05133.x; CLARK IA, 1987, PARASITOL TODAY, V3, P300, DOI 10.1016/0169-4758(87)90187-6; GAZZINELLI RT, 1992, J IMMUNOL, V148, P1792; GRAU GE, 1989, IMMUNOL REV, V112, P49, DOI 10.1111/j.1600-065X.1989.tb00552.x; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; KARUNAWEERA ND, 1992, CLIN EXP IMMUNOL, V88, P499, DOI 10.1111/j.1365-2249.1992.tb06478.x; KERN P, 1989, AM J MED, V87, P139, DOI 10.1016/S0002-9343(89)80688-6; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; LAM KMC, 1991, LANCET, V337, P876, DOI 10.1016/0140-6736(91)90203-2; WATIER H, 1992, INFECT IMMUN, V60, P136, DOI 10.1128/IAI.60.1.136-142.1992	15	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					612	613		10.1016/0140-6736(93)90364-M	http://dx.doi.org/10.1016/0140-6736(93)90364-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094840				2022-12-24	WOS:A1993KQ23400016
J	HARRISON, BC; MARCHESERAGONA, SP; GILBERT, SP; CHENG, NQ; STEVEN, AC; JOHNSON, KA				HARRISON, BC; MARCHESERAGONA, SP; GILBERT, SP; CHENG, NQ; STEVEN, AC; JOHNSON, KA			DECORATION OF THE MICROTUBULE SURFACE BY ONE KINESIN HEAD PER TUBULIN HETERODIMER	NATURE			English	Article							MOTILITY; ATPASE; IDENTIFICATION	KINESIN, a microtubule-dependent ATPase, is believed to be involved in anterograde axonal transport. The kinesin head, which contains both microtubule and ATP binding sites, has the necessary components for the generation of force and motility1. We have used saturation binding and electron microscopy to examine the interaction of the kinesin motor domain with the microtubule surface and found that binding saturated at one kinesin head per tubulin heterodimer. Both negative staining and cryo-electron microscopy revealed a regular pattern of kinesin bound to the microtubule surface, with an axial repeat of 8 nm. Optical diffraction analysis of decorated microtubules showed a strong layer-line at this spacing, confirming that one kinesin head binds per tubulin heterodimer. The addition of Mg-ATP to the microtubule-kinesin complex resulted in the complete dissociation of kinesin from the microtubule surface.	PENN STATE UNIV,DEPT MOLEC & CELL BIOL,UNIV PK,PA 16802; NIAMSD,STRUCT BIOL LAB,BETHESDA,MD 20892	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)								AMOS LA, 1974, J CELL SCI, V14, P523; BOOY FP, 1991, CELL, V64, P1007, DOI 10.1016/0092-8674(91)90324-R; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; GILBERT SP, IN PRESS BIOCHEMISTR; GRIMSTONE AV, 1966, J CELL SCI, V1, P351; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; STEVEN AC, 1980, P NATL ACAD SCI-BIOL, V77, P4721, DOI 10.1073/pnas.77.8.4721; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	13	75	75	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					73	75		10.1038/362073a0	http://dx.doi.org/10.1038/362073a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	8095324				2022-12-24	WOS:A1993KP97600064
J	ASSICOT, M; GENDREL, D; CARSIN, H; RAYMOND, J; GUILBAUD, J; BOHUON, C				ASSICOT, M; GENDREL, D; CARSIN, H; RAYMOND, J; GUILBAUD, J; BOHUON, C			HIGH SERUM PROCALCITONIN CONCENTRATIONS IN PATIENTS WITH SEPSIS AND INFECTION	LANCET			English	Article							GENE-RELATED PEPTIDE; CALCITONIN; PLASMA	High concentrations of calcitonin-like immunoreactivity have been found in the blood of patients with various extrathyroid diseases. By means of a monoclonal immunoradiometric assay for calcitonin precursors, we have measured serum concentrations of procalcitonin in patients with various bacterial and viral infections. 79 children (newborn to age 12 years) in hospital with suspected infections were investigated prospectively. 19 patients with severe bacterial infections had very high serum concentrations of procalcitonin at diagnosis (range 6-53 ng/mL) in comparison with 21 children found to have no signs of infection (baseline concentrations < 0.1 ng/m L). Serum procalcitonin values decreased rapidly during antibiotic therapy. 11 patients with peripheral bacterial colonisation or local infections without invasive sepsis and 18 (86%) of 21 patients with viral infections had concentrations within or slightly above the normal range (0.1-1.5 ng/mL). Among 9 severely burned patients studied in an intensive care unit, the post-traumatic course of procalcitonin concentrations (range 0.1-120 ng/mL) was closely related to infectious complications and acute septic episodes. Concentrations of mature calcitonin were normal in all subjects, whatever procalcitonin concentrations were found. Concentrations of a substance immunologically identical to procalcitonin are raised during septic conditions. Serum concentrations seem to be correlated with the severity of microbial invasion.	INST GUSTAVE ROUSSY,DEPT BIOL CLIN,F-94805 VILLEJUIF,FRANCE; HOP ST VINCENT DE PAUL,DEPT PEDIAT,PARIS,FRANCE; HOP ST VINCENT DE PAUL,MICROBIOL LAB,PARIS,FRANCE; HOP INSTRUCT ARMEES PERCY,CTR TRAITEMENT BRULES,F-92141 CLAMART,FRANCE	UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite								BECKER KL, 1981, CHEST, V79, P211, DOI 10.1378/chest.79.2.211; BECKER KL, 1980, ARCH PATHOL LAB MED, V104, P196; BORN W, 1991, REGUL PEPTIDES, V32, P311, DOI 10.1016/0167-0115(91)90024-B; CANALE DD, 1975, J CLIN ENDOCR METAB, V40, P738, DOI 10.1210/jcem-40-4-738; Colon JM, 1988, BIOCHEMISTRY-US, V256, P245; COOMBES RC, 1974, LANCET, V1, P1080; DEFTOS LJ, 1975, J CLIN ENDOCR METAB, V40, P409, DOI 10.1210/jcem-40-3-409; FAUCHALD P, 1985, SCAND J CLIN LAB INV, V45, P229, DOI 10.3109/00365518509161000; GHILLANI PP, 1989, CANCER RES, V49, P6845; GILLQUIST J, 1977, SCAND J GASTROENTERO, V12, P21, DOI 10.1080/00365521.1977.12031105; HEATH H, 1979, J LAB CLIN MED, V93, P390; JOYCE CD, 1990, SURGERY, V108, P1097; MALLET E, 1983, LANCET, V1, P294; MILHAUD G, 1974, LANCET, V1, P462; MINVIELLE S, 1991, J BIOL CHEM, V266, P24627; ROOS BA, 1983, J CLIN ENDOCR METAB, V56, P802, DOI 10.1210/jcem-56-4-802; SILVA OL, 1977, NEPHRON, V19, P12, DOI 10.1159/000180860	17	1441	1627	3	125	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					515	518		10.1016/0140-6736(93)90277-N	http://dx.doi.org/10.1016/0140-6736(93)90277-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094770	Green Published			2022-12-24	WOS:A1993KP08300003
J	BULL, RH; COBURN, PR; MORTIMER, PS				BULL, RH; COBURN, PR; MORTIMER, PS			PRETIBIAL MYXEDEMA - A MANIFESTATION OF LYMPHEDEMA	LANCET			English	Note							ISOTOPE LYMPHOGRAPHY; LYMPHATICS; MYXEDEMA; LIMB	Pretibial myxoedema (PTM) in its most extreme form clinically resembles lymphoedema. Studies with quantitative lymphoscintigraphy and fluorescence microlymphography in two patients with extensive PTM confirmed the presence of both functional and structural changes in the lymphatic system. We suggest that mucin deposition in the dermis causes compression of the dermal lymphatics, which results in dermal oedema and the clinical features of lymphoedema.	ROYAL W SUSSEX HOSP,CHICHESTER,W SUSSEX,ENGLAND		BULL, RH (corresponding author), ST GEORGE HOSP,DEPT DERMATOL,BLACKSHAW RD,LONDON SW17 0QT,ENGLAND.							ALEVIZAKIHARHALAKI M, 1983, J NUCL MED, V24, P174; CHEUNG HS, 1978, J INVEST DERMATOL, V71, P12, DOI 10.1111/1523-1747.ep12543646; ELTE JWF, 1983, NETH J MED, V26, P220; JAGER K, 1983, INT ANGIOL, V2, P129; MORTIMER PS, 1983, BRIT J DERMATOL, V108, P561, DOI 10.1111/j.1365-2133.1983.tb01057.x; PROBY CM, 1990, BRIT J DERMATOL, V123, P29, DOI 10.1111/j.1365-2133.1990.tb01821.x; ROBERTS SOB, 1986, TXB DERMATOLOGY, P2343; STEWART G, 1985, BRIT J SURG, V72, P906, DOI 10.1002/bjs.1800721120; STEWART G, 1984, ANN ROY COLL SURG, V66, P391; WORSTMAN J, 1981, ARCH DERMATOL, V117, P635	10	38	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					403	404		10.1016/0140-6736(93)92990-B	http://dx.doi.org/10.1016/0140-6736(93)92990-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094170				2022-12-24	WOS:A1993KM41600005
J	CUTTS, FT				CUTTS, FT			MEASLES CONTROL IN YOUNG INFANTS - WHERE DO WE GO FROM HERE	LANCET			English	Editorial Material							IMMUNIZATION				CUTTS, FT (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,COMMUNICABLE DIS EPIDEMIOL UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.							BECKER RA, 1984, B PAN AM HLTH ORGAN, V18, P397; Boerma J. T., 1990, IMMUNIZATION LEVELS; CUTTS FT, 1991, B WORLD HEALTH ORGAN, V69, P1; DABIS F, 1988, AM J EPIDEMIOL, V127, P171, DOI 10.1093/oxfordjournals.aje.a114778; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; KAMBARAMI RA, 1991, B WORLD HEALTH ORGAN, V69, P213; PANNUTI CS, 1991, B WORLD HEALTH ORGAN, V69, P557; TAYLOR WR, 1988, AM J EPIDEMIOL, V127, P788, DOI 10.1093/oxfordjournals.aje.a114860; WEISS R, 1992, SCIENCE, V258, P5546; 1989, WEEKLY EPIDEMIOL REC, V64, P5; 1992, LANCET, V340, P232; 1991, JAMA-J AM MED ASSOC, V266, P1547	12	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					290	291		10.1016/0140-6736(93)92629-8	http://dx.doi.org/10.1016/0140-6736(93)92629-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093929				2022-12-24	WOS:A1993KK24500017
J	CLARKE, IMC				CLARKE, IMC			MANAGEMENT OF POSTOPERATIVE PAIN	LANCET			English	Editorial Material																		[Anonymous], 1992, ACUTE PAIN MANAGEMEN; AVERYJONES F, 1961, PYES SURGICAL HANDIC, V1, P197; GOULD TH, 1992, BRIT MED J, V305, P1187, DOI 10.1136/bmj.305.6863.1187; PAPPER EM, 1952, SURGERY, V32, P107; READY LB, 1988, ANESTHESIOLOGY, V68, P100, DOI 10.1097/00000542-198801000-00016; Ready LB, 1992, MANAGEMENT ACUTE PAI; 1990, REPORT WORKING PARTY	7	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					27	27		10.1016/0140-6736(93)92492-C	http://dx.doi.org/10.1016/0140-6736(93)92492-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093275				2022-12-24	WOS:A1993KF02700014
J	CONRAD, B; WEIDMANN, E; TRUCCO, G; RUDERT, WA; BEHBOO, R; RICORDI, C; RODRIQUEZRILO, H; FINEGOLD, D; TRUCCO, M				CONRAD, B; WEIDMANN, E; TRUCCO, G; RUDERT, WA; BEHBOO, R; RICORDI, C; RODRIQUEZRILO, H; FINEGOLD, D; TRUCCO, M			EVIDENCE FOR SUPERANTIGEN INVOLVEMENT IN INSULIN-DEPENDENT DIABETES-MELLITUS ETIOLOGY	NATURE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; POLYMERASE CHAIN-REACTION; RENAL GRAFT-SURVIVAL; MAMMARY-TUMOR VIRUS; MOLECULAR COMPATIBILITY; T-CELLS; ISLETS; USAGE; MICE; MLS	INSULIN-DEPENDENT diabetes mellitus (IDDM) is a T-cell-mediated autoimmune disease whose onset is believed to be triggered by unknown environmental factors acting on a predisposing genetic background. Islet-infiltrating T (IIT) cells from two IDDM patients, who had died at the onset of the disease from brain swelling as a complication of ketoacidosis, were analysed. The results provided evidence for the involvement of a pancreatic islet cell membrane-bound superantigen(1,2) as a diabetes aetiopathogenetic factor. There was a selective expansion of a T-cell receptor (TCR) variable segment of the beta-chain (V beta 7) in these IIT cells in association with unselected V alpha-chain segments; extensive junctional diversity of the TCR V beta 7 chains; and evidence of positive selection, after exposure to diabetic islet cell membrane preparations, of V beta 7(+) T-cell clones among peripheral blood lymphocytes from non-diabetic individuals.	CHILDRENS HOSP PITTSBURGH,RANGOS RES CTR,DEPT PEDIAT,DIV IMMUNOGENET,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT SURG,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			RICORDI, CAMILLO/AAA-4740-2019	Ricordi, Camillo/0000-0001-8092-7153; Finegold, David/0000-0001-9901-2578				ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; BULUWELA L, 1989, NUCLEIC ACIDS RES, V17, P452, DOI 10.1093/nar/17.1.452; CALLAN MFC, 1993, P NATL ACAD SCI USA, V90, P10454, DOI 10.1073/pnas.90.22.10454; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; GENEVEE C, 1992, EUR J IMMUNOL, V22, P1261, DOI 10.1002/eji.1830220522; GIORDA R, 1991, LANCET, V338, P1469, DOI 10.1016/0140-6736(91)92781-V; GORGA JC, 1987, J BIOL CHEM, V262, P16087; HAND SL, 1993, TUMOUR IMMUNOBIOLOGY, P143; HSIA S, 1993, TRANSPLANTATION, V55, P395, DOI 10.1097/00007890-199302000-00030; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; KARALAINEN J, 1992, NEW ENGL J MED, V327, P302; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KOHSAKA H, 1993, EUR J IMMUNOL, V23, P1895, DOI 10.1002/eji.1830230825; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MALISSEN M, 1992, IMMUNOL TODAY, V13, P315, DOI 10.1016/0167-5699(92)90044-8; Maniatis T., 1982, MOL CLONING; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; NOTKINS AL, 1984, CONCEPTS VIRAL PATHO, P241; RICORDI C, 1992, TRANSPLANTATION, V53, P407, DOI 10.1097/00007890-199202010-00027; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; TONG JY, 1993, TRANSPLANTATION, V55, P390, DOI 10.1097/00007890-199302000-00029; TRUCCO M, 1992, DIABETES CARE, V15, P705, DOI 10.2337/diacare.15.5.705; WEIDMANN E, 1992, CANCER RES, V52, P5913	26	298	303	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					351	355		10.1038/371351a0	http://dx.doi.org/10.1038/371351a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	8090207				2022-12-24	WOS:A1994PH25400058
J	VAINIO, S; KARAVANOVA, I; JOWETT, A; THESLEFF, I				VAINIO, S; KARAVANOVA, I; JOWETT, A; THESLEFF, I			IDENTIFICATION OF BMP-4 AS A SIGNAL MEDIATING SECONDARY INDUCTION BETWEEN EPITHELIAL AND MESENCHYMAL TISSUES DURING EARLY TOOTH DEVELOPMENT	CELL			English	Article							BONE MORPHOGENETIC PROTEIN; GROWTH-FACTOR-BETA; HOMEOBOX GENE; EMBRYONIC-DEVELOPMENT; MOUSE EMBRYO; EXPRESSION PATTERNS; MESODERM INDUCTION; CELL-PROLIFERATION; DENTAL MESENCHYME; RNA EXPRESSION	Growth factor-mediated signaling has been implicated in the regulation of epithelial-mesenchymal interactions during organogenesis. Bone morphogenetic protein 4 (BMP-4), a member of the transforming growth factor beta superfamily, is expressed in the presumptive dental epithelium at the initiation of tooth development. Subsequently, epithelial signaling leads to mesenchymal induction of BMP-4 expression. To address the role of this factor, BMP-4-releasing agarose beads were added to dental mesenchyme in culture. These beads induced a translucent mesenchymal zone similar to that induced by dental epithelium. Moreover, three transcription factors (Msx-1, Msx-2, and Egr-1) whose expression is governed by epithelial signaling were induced in response to BMP-4. In addition, BMP-4 induced its own mesenchymal expression. These findings support the hypothesis that BMP-4 mediates epithelial-mesenchymal interactions during early tooth development.	UNIV HELSINKI,INST DENT,DEPT PEDODONT & ORTHODONT,SF-00014 HELSINKI,FINLAND	University of Helsinki				Vainio, Seppo/0000-0001-9319-3566	NIDCR NIH HHS [DE-09399] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALTABA ARI, 1989, NATURE, V341, P945; BEQUEKIRN C, 1992, INT J DEV BIOL, V36, P491; BESSHO K, 1990, J ORAL MAXIL SURG, V48, P162, DOI 10.1016/S0278-2391(10)80204-6; Bienz Mariann, 1992, Current Opinion in Cell Biology, V4, P955, DOI 10.1016/0955-0674(92)90124-U; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CRICK F, 1970, NATURE, V225, P420, DOI 10.1038/225420a0; DOLLE P, 1992, DIFFERENTIATION, V49, P93, DOI 10.1111/j.1432-0436.1992.tb00773.x; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRENZ DA, 1992, DEV BIOL, V153, P324, DOI 10.1016/0012-1606(92)90117-Y; GILBERT S, 1992, DEV BIOL; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GROBSTEIN C, 1953, NATURE, V172, P869, DOI 10.1038/172869a0; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; GURDON JB, 1992, CURR BIOL, V3, P1; HAYAMIZU TF, 1991, DEV BIOL, V145, P164, DOI 10.1016/0012-1606(91)90222-O; HAYEK A, 1987, BIOCHEM BIOPH RES CO, V147, P876, DOI 10.1016/0006-291X(87)91011-4; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; INGHAM P, 1992, CURR BIOL, V9, P465; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JONES CM, 1991, DEVELOPMENT, V111, P531; JONES CM, 1992, DEVELOPMENT, V115, P639; JOWETT AK, 1993, DEVELOPMENT, V117, P461; KARAVANOVA I, 1992, MECH DEVELOP, V39, P41, DOI 10.1016/0925-4773(92)90024-E; KAWAI T, 1989, J DENT RES, V68, P1069, DOI 10.1177/00220345890680060301; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; LEHNERT SA, 1988, DEVELOPMENT, V104, P263; LUMSDEN AGS, 1979, J BIOL BUCCALE, V7, P77; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; MACKENZIE A, 1991, DEVELOPMENT, V111, P269; MACKENZIE A, 1992, DEVELOPMENT, V115, P403; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MINA M, 1987, ARCH ORAL BIOL, V32, P123, DOI 10.1016/0003-9969(87)90055-0; MOON RT, 1992, CELL, V71, P709, DOI 10.1016/0092-8674(92)90545-N; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; ORRURTREGER A, 1992, DEVELOPMENT, V115, P1045; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PELTON RW, 1990, DEVELOPMENT, V110, P609; ROS MA, 1992, DEVELOPMENT, V116, P811; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; Ruch J V, 1987, Revis Biol Celular, V14, P1; RUNYAN RB, 1992, MOL REPROD DEV, V32, P152, DOI 10.1002/mrd.1080320211; SAXEN L, 1976, NATURE, V259, P662, DOI 10.1038/259662a0; SAXEN L, 1980, DEV MAMMALS, V4, P161; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; THESLEFF I, 1988, DEV BIOL, V129, P565, DOI 10.1016/0012-1606(88)90401-0; THESLEFF I, 1990, J BIOL BUCCALE, V18, P179; THESLEFF I, 1981, DIFFERENTIATION, V18, P75, DOI 10.1111/j.1432-0436.1981.tb01107.x; THESLEFF I, 1979, DEV BIOL, V70, P116, DOI 10.1016/0012-1606(79)90011-3; THESLEFF I, 1992, CHEM BIOL MINERALIZE, P369; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TREMML G, 1992, DEVELOPMENT, V116, P447; VAAHTOKARI A, 1991, DEVELOPMENT, V113, P985; VAINIO S, 1989, J CELL BIOL, V108, P1945, DOI 10.1083/jcb.108.5.1945; VAINIO S, 1992, DIFFERENTIATION, V50, P97, DOI 10.1111/j.1432-0436.1992.tb00490.x; VAINIO S, 1992, DEV DYNAM, V194, P105, DOI 10.1002/aja.1001940204; VAINIO S, 1992, THESIS U HELSINKI HE; VAINIO S, 1991, DEV BIOL, V147, P323; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; Williams J, 1991, CURR OPIN CELL BIOL, V3, P925, DOI 10.1016/0955-0674(91)90108-B; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212	71	819	847	1	35	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 8	1993	75	1					45	58		10.1016/S0092-8674(05)80083-2	http://dx.doi.org/10.1016/S0092-8674(05)80083-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8104708				2022-12-24	WOS:A1993MB66700007
J	STEWART, TA; HULTGREN, B; HUANG, X; PITTSMEEK, S; HULLY, J; MACLACHLAN, NJ				STEWART, TA; HULTGREN, B; HUANG, X; PITTSMEEK, S; HULLY, J; MACLACHLAN, NJ			INDUCTION OF TYPE-I DIABETES BY INTERFERON-ALPHA IN TRANSGENIC MICE	SCIENCE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; PANCREATIC-ISLET CELLS; INTERLEUKIN-1 PRODUCTION; AUTOIMMUNE-DISEASE; CHRONIC HEPATITIS; BETA-INTERFERON; CYTO-TOXICITY; MELLITUS; INSULIN; THERAPY	Type I diabetes is an autoimmune disease involving an interaction between an epigenetic event (possibly a viral infection), the pancreatic beta cells, and the immune system in a genetically susceptible host. The possibility that the type I interferons could mediate this interaction was tested with transgenic mice in which the insulin-producing beta cells expressed an interferon-alpha. These mice developed a hypoinsulinemic diabetes associated with a mixed inflammation centered on the islets. The inflammation and the diabetes were prevented with a neutralizing antibody to the interferon-alpha. Thus, the expression of interferon-alpha by the beta cells could be causal in the development of type I diabetes, which suggests a therapeutic approach to this disease.	UNIV CALIF DAVIS,DEPT VET PATHOL,DAVIS,CA 95616	University of California System; University of California Davis	STEWART, TA (corresponding author), GENENTECH INC,DEPT ENDOCRINE RES,S SAN FRANCISCO,CA 94080, USA.							ALLISON J, 1992, EUR J IMMUNOL, V22, P1115, DOI 10.1002/eji.1830220503; APPELS B, 1989, J IMMUNOL, V142, P3803; BOHOSLAWEC O, 1986, J INTERFERON RES, V6, P207, DOI 10.1089/jir.1986.6.207; BURMAN P, 1986, J CLIN ENDOCR METAB, V63, P1086, DOI 10.1210/jcem-63-5-1086; CANDLER RV, 1985, J INTERFERON RES, V5, P179, DOI 10.1089/jir.1985.5.179; CHEN SA, 1988, J INTERFERON RES, V8, P597, DOI 10.1089/jir.1988.8.597; COLLINS AR, 1990, ADV EXP MED BIOL, V276, P497; CONLON KC, 1990, CANCER, V65, P2237, DOI 10.1002/1097-0142(19900515)65:10<2237::AID-CNCR2820651013>3.0.CO;2-5; CONTI P, 1988, INT J IMMUNOPHARMACO, V10, P907, DOI 10.1016/0192-0561(88)90035-5; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DEMAEYER E, 1988, INTERFERONS OTHER RE, P39; EBERHARDT MS, 1985, DIABETES, V34, P1247, DOI 10.2337/diabetes.34.12.1247; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; ELLERMANNERIKSEN S, 1989, J GEN VIROL, V70, P2139, DOI 10.1099/0022-1317-70-8-2139; ERLICH HA, 1990, DIABETES, V39, P96, DOI 10.2337/diabetes.39.1.96; EVANS SS, 1987, J IMMUNOL, V138, P2451; FATTOVICH G, 1991, J MED VIROL, V34, P132, DOI 10.1002/jmv.1890340212; FINKELMAN FD, 1991, J EXP MED, V174, P1179, DOI 10.1084/jem.174.5.1179; FOULIS AK, 1987, J PATHOL, V152, P141, DOI 10.1002/path.1711520302; FOULIS AK, 1987, LANCET, V2, P1423; FRISK G, 1992, J INFECTION, V24, P13, DOI 10.1016/0163-4453(92)90814-M; FRISK G, 1985, J MED VIROL, V17, P219, DOI 10.1002/jmv.1890170303; GENDELMAN HE, 1992, J IMMUNOL, V148, P422; GEPTS W, 1985, DIABETIC PANCREAS, P337; GERRARD TL, 1987, J IMMUNOL, V138, P2535; GINGERICH RL, 1979, DIABETES, V28, P276, DOI 10.2337/diabetes.28.4.276; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HIGUCHI Y, 1992, J EXP MED, V176, P1719, DOI 10.1084/jem.176.6.1719; HOLAN V, 1991, J INTERFERON RES, V11, P319, DOI 10.1089/jir.1991.11.319; HORN GT, 1988, P NATL ACAD SCI USA, V85, P6012, DOI 10.1073/pnas.85.16.6012; KASAIAN MT, 1990, J EXP MED, V171, P245; KATO T, 1981, J GEN VIROL, V54, P293, DOI 10.1099/0022-1317-54-2-293; LI BL, 1990, CANCER RES, V50, P5328; MACCARI S, 1991, CLIN RHEUMATOL, V10, P452, DOI 10.1007/BF02206672; MACKAY P, 1986, J CLIN INVEST, V77, P916, DOI 10.1172/JCI112390; MAYET WJ, 1989, HEPATOLOGY, V10, P24, DOI 10.1002/hep.1840100106; OLMOS P, 1988, DIABETOLOGIA, V31, P747, DOI 10.1007/BF00274777; OZES ON, 1992, J INTERFERON RES, V12, P55, DOI 10.1089/jir.1992.12.55; PETERS M, 1986, J IMMUNOL, V137, P3163; PICARELLA DE, 1992, P NATL ACAD SCI USA, V89, P10036, DOI 10.1073/pnas.89.21.10036; PICHERT G, 1990, BRIT J CANCER, V62, P100, DOI 10.1038/bjc.1990.237; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PUKEL C, 1987, DIABETES, V36, P1217, DOI 10.2337/diabetes.36.11.1217; Pyke D A, 1988, Adv Exp Med Biol, V246, P255; RHODES J, 1986, EUR J IMMUNOL, V16, P370, DOI 10.1002/eji.1830160410; RONNBLOM LE, 1991, ACTA ONCOL, V30, P537; RONNBLOM LE, 1990, J INTERN MED, V227, P207; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SARZOTTI M, 1989, NAT IMMUN CELL GROW, V8, P66; SAUTER NP, 1992, AM J MED, V92, P441, DOI 10.1016/0002-9343(92)90278-J; SCALZO S, 1990, EUR J CANCER, V26, P1152, DOI 10.1016/0277-5379(90)90275-X; SCHATTNER A, 1986, CLIN IMMUNOL IMMUNOP, V38, P327, DOI 10.1016/0090-1229(86)90242-4; SCHILLING PJ, 1991, CANCER, V68, P1536, DOI 10.1002/1097-0142(19911001)68:7<1536::AID-CNCR2820680713>3.0.CO;2-B; SCHWIZER RW, 1984, TRANSPLANTATION, V37, P539, DOI 10.1097/00007890-198406000-00002; SEMENZATO G, 1986, BLOOD, V68, P293; STAEHELIN T, 1981, P NATL ACAD SCI-BIOL, V78, P1848, DOI 10.1073/pnas.78.3.1848; STEWART T, UNPUB; TABATA Y, 1988, JPN J CANCER RES, V79, P636, DOI 10.1111/j.1349-7006.1988.tb00034.x; TANIGUCHI Y, 1992, INTERNAL MED, V31, P373, DOI 10.2169/internalmedicine.31.373; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; TUVEMO T, 1988, DIABETES RES CLIN EX, V9, P125; VERHAGEN A, 1990, NAT IMMUN CELL GROW, V9, P325; VILCEK J, 1990, HDB EXPT PHARM, V95, P1	63	262	277	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1942	1946		10.1126/science.8100367	http://dx.doi.org/10.1126/science.8100367			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8100367				2022-12-24	WOS:A1993LJ34900043
J	THOMAS, DL; MAHLEY, RW; BADUR, S; PALAOGLU, KE; QUINN, TC				THOMAS, DL; MAHLEY, RW; BADUR, S; PALAOGLU, KE; QUINN, TC			EPIDEMIOLOGY OF HEPATITIS-E VIRUS-INFECTION IN TURKEY	LANCET			English	Note							NON-B HEPATITIS; TRANSMITTED NON-A; TRANSMISSION	The seroprevalence and risk factors for infection with hepatitis E virus (HEV) were analysed in five regions of Turkey, where one-third of acute hepatitis cases are non-A, non-B. Antibodies to HEV (anti-HEV) were found in 80 (5.9%) of 1350 subjects. Independent predictors of anti-HEV were age over 25 years, less than elementary education, antibodies to hepatitis C virus, and residence in the warmest region (Adana). Whereas none of 105 subjects in the second decade of life were HEV seropositive, 17 (3.7%) of 464 and 28 (9.1%) of 308 of those in the third and fourth decades of life, respectively, had anti-HEV (p < 0.001). These data demonstrate that in Turkey HEV is more prevalent in warmer regions and in adults, beginning in the third decade of life.	ISTANBUL FAC MED,DEPT MICROBIOL,ISTANBUL,TURKEY; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; AMER BRISTOL HOSP,GLADSTONE RES INST,ISTANBUL,TURKEY	Istanbul University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Amerikan Hospital	THOMAS, DL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,1155 ROSS BLDG,720 RUTLAND AVE,BALTIMORE,MD 21205, USA.							BABACAN F, 1990, J TURK MICROBIOL SOC, V20, P131; BADUR S, 1985, APR P INT C INF DIS; BALAYAN MS, 1983, INTERVIROLOGY, V20, P23, DOI 10.1159/000149370; BRADLEY DW, 1990, BRIT MED BULL, V46, P442, DOI 10.1093/oxfordjournals.bmb.a072409; BRADLEY DW, 1988, LANCET, V1, P819; GOLDSMITH R, 1992, LANCET, V339, P328, DOI 10.1016/0140-6736(92)91647-Q; KANE MA, 1984, JAMA-J AM MED ASSOC, V252, P3140, DOI 10.1001/jama.252.22.3140; KHUROO MS, 1980, AM J MED, V68, P818, DOI 10.1016/0002-9343(80)90200-4; SKIDMORE SJ, 1992, J MED VIROL, V37, P58, DOI 10.1002/jmv.1890370110; VELAZQUEZ O, 1990, JAMA-J AM MED ASSOC, V263, P3281, DOI 10.1001/jama.263.24.3281	10	79	81	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 19	1993	341	8860					1561	1562		10.1016/0140-6736(93)90698-G	http://dx.doi.org/10.1016/0140-6736(93)90698-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH550	8099641				2022-12-24	WOS:A1993LH55000005
J	WYATT, J; VOGELSANG, H; HUBL, W; WALDHOER, T; LOCHS, H				WYATT, J; VOGELSANG, H; HUBL, W; WALDHOER, T; LOCHS, H			INTESTINAL PERMEABILITY AND THE PREDICTION OF RELAPSE IN CROHNS-DISEASE	LANCET			English	Article							INDEX	To see whether intestinal permeability (IP) predicted relapse in Crohn's disease, we measured IP in 72 patients with quiescent Crohn's disease using the lactulose-mannitol test. The permeability index (lactulose/mannitol) was significantly higher in patients than in controls (0.046 [SEM 0.005] vs 0.018 [SEM 0.002], respectively). Patients were followed for 1 year after the test. 26 of the 37 patients with raised permeability, but only 6 of the 35 with normal permeability relapsed within 1 year after the test (p<0.001). The sensitivity of the permeability test as a predictor for relapse was 81%. A significant correlation was found between the value of the permeability index and the probability of relapse (p<0.01). These results show that increases in intestinal permeability precede clinical relapses in Crohn's disease and so are an indicator of subclinical disease. The measurement of intestinal permeability may lead to a better understanding of the pathogenesis of Crohn's disease.	INST TUMOR BIOL, A-1090 VIENNA, AUSTRIA		WYATT, J (corresponding author), CLIN INTERNAL MED 4, DEPT GASTROENTEROL & HEPATOL, WAHRINGER GURTEL 18-20, A-1090 VIENNA, AUSTRIA.		Waldhoer, Thomas Johannes/I-1215-2019	Waldhoer, Thomas Johannes/0000-0003-2043-8299				Albert A., 1987, MULTIVARIATE INTERPR; ANDRE F, 1988, GUT, V29, P511, DOI 10.1136/gut.29.4.511; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BRIGNOLA C, 1986, GASTROENTEROLOGY, V91, P1490, DOI 10.1016/0016-5085(86)90206-4; CAMPBELL CA, 1982, J PEDIATR GASTR NUTR, V1, P193, DOI 10.1097/00005176-198201020-00007; Cox DR., 1970, ANAL BINARY DATA; DAMBOISE M, 1980, CLIN CHEM, V26, P1348; DELAHUNTY T, 1986, CLIN CHEM, V32, P1542; GROSS V, 1992, GASTROENTEROLOGY, V102, P514, DOI 10.1016/0016-5085(92)90098-J; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MALCHOW H, 1986, GASTROENTEROLOGY, V2, P249; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MURPHY MS, 1989, ARCH DIS CHILD, V64, P321, DOI 10.1136/adc.64.3.321	14	499	506	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	1993	341	8858					1437	1439		10.1016/0140-6736(93)90882-H	http://dx.doi.org/10.1016/0140-6736(93)90882-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF841	8099141				2022-12-24	WOS:A1993LF84100004
J	MOORJANI, S; ROY, M; TORRES, A; BETARD, C; GAGNE, C; LAMBERT, M; BRUN, D; DAVIGNON, J; LUPIEN, P				MOORJANI, S; ROY, M; TORRES, A; BETARD, C; GAGNE, C; LAMBERT, M; BRUN, D; DAVIGNON, J; LUPIEN, P			MUTATIONS OF LOW-DENSITY-LIPOPROTEIN-RECEPTOR GENE, VARIATION IN PLASMA-CHOLESTEROL, AND EXPRESSION OF CORONARY HEART-DISEASE IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA	LANCET			English	Article							LOCUS	Variation in plasma-cholesterol concentration and the expression of coronary heart disease in patients with homozygous familial hypercholesterolaemia (FH) is well documented, but the underlying reasons for variation are not clearly defined. Because FH is caused by mutations at the low-density-lipoprotein-gene locus, we compared plasma-cholesterol concentrations in 21 FH homozygotes with either the greater than 10 kb deletion (promoter region and exon 1) (11 subjects) or the exon 3 missense (trp66-->gly) mutation (1 0 subjects) of the low-density-lipoprotein gene. Subjects with the greater than 10 kb deletion had a higher mean plasma-cholesterol concentration than those with the exon 3 mutations (26.7 vs 16.1 mmol/L; p=0.000006), and there was no overlap in individual plasma-cholesterol concentrations between subjects in the two groups. Although the frequency of coronary heart disease was similar in the two groups, age-of-onset was earlier in subjects with the greater than 10 kb deletion (p=0.059). Also, coronary deaths were more frequent (p=0.044) and occurred at an earlier age (p=0.009) in subjects with the greater than 10 kb deletion. Our results provide evidence that there is less variation in plasma-cholesterol concentrations among FH homozygotes when they are subdivided into groups according to low-density-lipoprotein-receptor-gene defect. Furthermore, differences in plasma-cholesterol concentrations are reflected in the severity of coronary heart disease expression.	UNIV LAVAL,MED RES CTR,QUEBEC CITY G1K 7P4,QUEBEC,CANADA; CLIN RES INST MONTREAL,MONTREAL H2W 1R7,QUEBEC,CANADA; ST JUSTINE HOSP,MONTREAL,PQ,CANADA	Laval University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine								BETARD C, 1992, HUM GENET, V88, P529, DOI 10.1007/BF00219339; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1982, MED CLIN N AM, V66, P335, DOI 10.1016/S0025-7125(16)31424-9; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; LEHRMAN MA, 1987, J BIOL CHEM, V262, P401; LEITERSDORF E, 1989, J CLIN INVEST, V84, P954, DOI 10.1172/JCI114258; LEITERSDORF E, 1990, J CLIN INVEST, V85, P1014, DOI 10.1172/JCI114531; MA YH, 1989, CLIN GENET, V36, P219; MEINER V, 1991, AM J HUM GENET, V49, P443; MOORJANI S, 1989, ARTERIOSCLEROSIS, V9, P211, DOI 10.1161/01.ATV.9.2.211; SPRECHER DL, 1985, METABOLISM, V34, P294, DOI 10.1016/0026-0495(85)90015-0; Thompson GR, 1989, ARTERIOSCLER, V9, P175; YAMAMOTO A, 1989, ARTERIOSCLEROSIS S, V9, P66	15	132	143	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 22	1993	341	8856					1303	1306		10.1016/0140-6736(93)90815-X	http://dx.doi.org/10.1016/0140-6736(93)90815-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098448				2022-12-24	WOS:A1993LD25300003
J	SMALL, PM; SHAFER, RW; HOPEWELL, PC; SINGH, SP; MURPHY, MJ; DESMOND, E; SIERRA, MF; SCHOOLNIK, GK				SMALL, PM; SHAFER, RW; HOPEWELL, PC; SINGH, SP; MURPHY, MJ; DESMOND, E; SIERRA, MF; SCHOOLNIK, GK			EXOGENOUS REINFECTION WITH MULTIDRUG-RESISTANT MYCOBACTERIUM-TUBERCULOSIS IN PATIENTS WITH ADVANCED HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPIDEMIOLOGY; SEQUENCES; TOOL	Background. In the United States there have been recent outbreaks of multidrug-resistant tuberculosis. These outbreaks have primarily involved persons infected with the human immunodeficiency virus (HIV). Methods. We collected clinical information on 17 patients seen at a New York City hospital who had repeatedly positive cultures for Mycobacterium tuberculosis. Analysis of restriction-fragment-length polymorphisms (RFLPs) was performed on serial isolates of M. tuberculosis obtained from these patients. Results. Six patients had isolates that remained drug-susceptible, and the RFLP patterns of these isolates did not change over time. Eleven patients had isolates that became resistant to antimicrobial agents. The RFLP patterns of the isolates from six of these patients remained essentially unchanged (two strains showed one additional band) despite the development of drug resistance. In five other patients, however, the RFLP patterns of the isolates changed dramatically at the time that drug resistance was detected. The change in the RFLP pattern of the isolate from one patient appeared to be the result of contamination during processing in the laboratory. In the remaining four patients, all of whom had advanced HIV disease, the clinical and microbiologic evidence was consistent with the presence of active tuberculosis caused by a new strain of M. tuberculosis. Conclusions. Resistance to antituberculous drugs can develop not only in the strain that caused the initial disease, but also as a result of reinfection with a new strain of M. tuberculosis that is drug-resistant. Exogenous reinfection with multidrug-resistant M. tuberculosis can occur either during therapy for the original infection or after therapy has been completed.	STANFORD UNIV,DEPT MED,DIV INFECT DIS & GEOG MED,STANFORD,CA 94306; STANFORD UNIV,CTR AIDS RES,DEPT MED,STANFORD,CA 94306; SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; SUNY HLTH SCI CTR,DEPT MED,DIV INFECT DIS,BROOKLYN,NY; SUNY HLTH SCI CTR,DEPT PATHOL,BROOKLYN,NY; CALIF DEPT HLTH SERV,MICROBIAL DIS LAB,BERKELEY,CA 94704	Stanford University; Stanford University; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; California Department of Health Care Services	SMALL, PM (corresponding author), STANFORD UNIV,HOWARD HUGHES MED INST,RM 251,BECKMAN CTR,STANFORD,CA 94306, USA.		Sierra, Maria/GYU-1134-2022		NIAID NIH HHS [AI27762-03, AI07089-11] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027762, T32AI007089] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; EISENACH KD, 1988, J CLIN MICROBIOL, V26, P2240, DOI 10.1128/JCM.26.11.2240-2245.1988; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; GODFREYFAUSSETT P, 1992, BRIT MED J, V305, P221, DOI 10.1136/bmj.305.6847.221; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; JONES WD, 1988, TUBERCLE, V69, P43, DOI 10.1016/0041-3879(88)90039-6; MAZUREK GH, 1991, J CLIN MICROBIOL, V29, P2030, DOI 10.1128/JCM.29.9.2030-2033.1991; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; OTAL E, 1992, J CLIN MICROBIOL, V29, P1252; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; REVES R, 1981, AM J EPIDEMIOL, V113, P423, DOI 10.1093/oxfordjournals.aje.a113110; RICH AR, 1944, PATHOGENESIS TUBERCU, P779; ROMEYN JA, 1970, AM REV RESPIR DIS, V101, P923; SHAFER RW, 1991, MEDICINE, V70, P384, DOI 10.1097/00005792-199111000-00004; SHAFER RW, 1991, AIDS, V5, P399, DOI 10.1097/00002030-199104000-00007; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; STEAD WW, 1967, AM REV RESPIR DIS, V95, P729; VANEMBDEN JDA, 1992, RES MICROBIOL, V143, P385, DOI 10.1016/0923-2508(92)90051-O; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; 1991, MMWR MORB MORTAL WKL, V40, P585; 1991, MMWR MORB MORTAL WKL, V40, P129; 1992, MMWR MORB MORTAL WKL, V41, P61; 1992, MMWR MORB MORTAL WKL, V41, P5; 1990, NCCLS M24P NAT COMM; 1984, DEFINITIONS DRUG RES, P7; 1990, MMWR MORB MORTAL WKL, V39, P718	31	460	471	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 22	1993	328	16					1137	1144		10.1056/NEJM199304223281601	http://dx.doi.org/10.1056/NEJM199304223281601			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY447	8096066				2022-12-24	WOS:A1993KY44700001
J	VAARALA, O; ALFTHAN, G; JAUHIAINEN, M; LEIRISALOREPO, M; AHO, K; PALOSUO, T				VAARALA, O; ALFTHAN, G; JAUHIAINEN, M; LEIRISALOREPO, M; AHO, K; PALOSUO, T			CROSS-REACTION BETWEEN ANTIBODIES TO OXIDIZED LOW-DENSITY-LIPOPROTEIN AND TO CARDIOLIPIN IN SYSTEMIC LUPUS-ERYTHEMATOSUS	LANCET			English	Note							OXIDATIVE MODIFICATION	Serum lipoproteins contain phospholipids and modified low-density lipoprotein (LDL) may thus act as a target for antiphospholipid antibodies. Raised concentrations of IgG antibodies against oxidised LDL were found in 47 of 61 (80%) patients with systemic lupus erythematosus (SLE). 46% of patients also had raised concentrations of IgG anticardiolipin antibodies. Binding of anticardiolipin antibodies to solid-phase cardiolipin was inhibited by oxidised LDL but not by native LDL in 16 of 21 sera from SLE patients. These observations suggest crossreactivity between antiphospholipid antibodies, which are closely associated with thrombosis in SLE, and antibodies to oxidised LDL, thus providing a possible link between thrombotic and atherosclerotic complications in SLE.	NATL PUBL HLTH INST,DEPT IMMUNOBIOL,MANNERHEIMINTIE 166,SF-00300 HELSINKI,FINLAND; NATL PUBL HLTH INST,DEPT NUTR,SF-00300 HELSINKI,FINLAND; NATL PUBL HLTH INST,DEPT BIOCHEM,SF-00300 HELSINKI,FINLAND; UNIV HELSINKI,CENT HOSP,DEPT MED 2,SF-00100 HELSINKI 10,FINLAND	Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital								HARRIS EN, 1987, CLIN EXP IMMUNOL, V68, P215; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; MENEIL HP, 1991, ADV IMMUNOL, V49, P193; MORTON KE, 1986, LANCET, V2, P1353; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PALINSKI W, 1990, ARTERIOSCLEROSIS, V10, P325, DOI 10.1161/01.ATV.10.3.325; PARUMS DV, 1990, ARCH PATHOL LAB MED, V114, P383; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; VAARALA O, 1991, J AUTOIMMUN, V8, P419; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	10	336	346	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					923	925		10.1016/0140-6736(93)91213-6	http://dx.doi.org/10.1016/0140-6736(93)91213-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	8096266				2022-12-24	WOS:A1993KW98100005
J	PIATAK, M; SAAG, MS; YANG, LC; CLARK, SJ; KAPPES, JC; LUK, KC; HAHN, BH; SHAW, GM; LIFSON, JD				PIATAK, M; SAAG, MS; YANG, LC; CLARK, SJ; KAPPES, JC; LUK, KC; HAHN, BH; SHAW, GM; LIFSON, JD			HIGH-LEVELS OF HIV-1 IN PLASMA DURING ALL STAGES OF INFECTION DETERMINED BY COMPETITIVE PCR	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; T-CELL RECEPTOR; HTLV-III; LEUKEMIA-VIRUS; SAN-FRANCISCO; MESSENGER-RNA; AIDS; DISEASE; QUANTITATION	Quantitative competitive polymerase chain reaction (QC-PCR) methods were used to quantify virion-associated human immunodeficiency virus type-1 (HIV-1) RNA in plasma from 66 patients with Centers for Disease Control stage I to IVC1 infection. HIV-1 RNA, ranging from 100 to nearly 22,000,000 copies per milliliter of plasma (corresponding to 50 to 11,000,000 virions per milliliter), was readily quantified in all subjects, was significantly associated with disease stage and CD4+ T cell counts, and decreased by as much as 235-fold with resolution of primary infection or institution of antiretroviral therapy. Plasma virus levels determined by QC-PCR correlated with, but exceeded by an average of 60,000-fold, virus titers measured by endpoint dilution culture. Quantitation of HIV-1 in plasma by QC-PCR may be useful in assessing the efficacy of antiretroviral agents, especially in early stage disease when conventional viral markers are often negative.	GENELABS TECHNOL INC,DIV HIV & EXPLORATORY RES,REDWOOD CITY,CA 94063; UNIV ALABAMA,DEPT MED,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MED,DIV INFECT DIS,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham				Hahn, Beatrice/0000-0002-9400-9887	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI027290, U01AI025922, U01AI032775] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27290, AI25922, AI32775] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMADORI A, 1990, AIDS RES HUM RETROV, V6, P581, DOI 10.1089/aid.1990.6.581; AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; ANDERSON RM, 1988, J ACQ IMMUN DEF SYND, V1, P241; AOKISEI S, 1992, AIDS RES HUM RETROV, V8, P1263, DOI 10.1089/aid.1992.8.1263; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0; BAGNARELLI P, 1992, J VIROL, V66, P7328, DOI 10.1128/JVI.66.12.7328-7335.1992; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BECKERANDRE M, 1989, NUCLEIC ACIDS RES, V17, P9437, DOI 10.1093/nar/17.22.9437; BOURINBAIAR AS, 1991, NATURE, V349, P111, DOI 10.1038/349111b0; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLERICI M, 1991, J INFECT DIS, V164, P178, DOI 10.1093/infdis/164.1.178; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; COHEN J, 1992, SCIENCE, V258, P388, DOI 10.1126/science.1357750; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DICKOVER RE, 1990, J CLIN MICROBIOL, V28, P2130, DOI 10.1128/JCM.28.9.2130-2133.1990; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; GRAZIOSI C, 1992, CLIN RES, V40, P333; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOLODNIY M, 1991, J CLIN INVEST, V88, P1755, DOI 10.1172/JCI115494; HOLODNIY M, 1992, BIOTECHNIQUES, V12, P36; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; JURRIAANS S, 1992, AIDS, V6, P635, DOI 10.1097/00002030-199207000-00004; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LAYNE SP, 1992, VIROLOGY, V189, P695, DOI 10.1016/0042-6822(92)90593-E; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; LINETTE GP, 1988, SCIENCE, V241, P573, DOI 10.1126/science.2899908; MANN DL, 1987, J IMMUNOL, V138, P2640; MARGOLICK JB, 1987, J IMMUNOL, V138, P1719; MCKEATING JA, 1991, NATURE, V349, P660, DOI 10.1038/349660b0; MENZO S, 1992, J CLIN MICROBIOL, V30, P1752, DOI 10.1128/JCM.30.7.1752-1757.1992; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; MITTLER RS, 1989, SCIENCE, V245, P1380, DOI 10.1126/science.2571187; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; MURAKAWA GJ, 1988, DNA CELL BIOL, V239, P295; MYERS G, 1991, HUMAN RETROVIRUSES A; NARA PL, 1991, FASEB J, V5, P2437, DOI 10.1096/fasebj.5.10.1712328; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; OTTMANN M, 1991, J VIROL METHODS, V31, P273, DOI 10.1016/0166-0934(91)90165-V; OVERBAUGH J, 1988, SCIENCE, V239, P906, DOI 10.1126/science.2893454; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PIATAK M, 1993, BIOTECHNIQUES, V14, P70; PIATAK M, UNPUB; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; ROBERTGUROFF M, 1985, NATURE, V316, P72, DOI 10.1038/316072a0; SAAG MS, 1991, J INFECT DIS, V164, P72, DOI 10.1093/infdis/164.1.72; SCADDEN DT, 1992, J INFECT DIS, V165, P1119, DOI 10.1093/infdis/165.6.1119; SCHNITTMAN SM, 1991, AIDS RES HUM RETROV, V7, P361, DOI 10.1089/aid.1991.7.361; SHALABY MR, 1987, CELL IMMUNOL, V110, P140, DOI 10.1016/0008-8749(87)90108-0; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; STIEGER M, 1991, J VIROL METHODS, V34, P149, DOI 10.1016/0166-0934(91)90095-H; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TERSMETTE M, 1989, LANCET, V1, P983; WEISS RA, 1985, NATURE, V316, P69, DOI 10.1038/316069a0; 1986, MORBID MORTAL WEEKLY, V35, P334	71	1144	1189	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1749	1754		10.1126/science.8096089	http://dx.doi.org/10.1126/science.8096089			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	8096089				2022-12-24	WOS:A1993KT81000036
J	HARDINGPINK, D				HARDINGPINK, D			OPIOID TOXICITY - METHADONE - ONE PERSONS MAINTENANCE DOSE IS ANOTHERS POISON	LANCET			English	Editorial Material											HARDINGPINK, D (corresponding author), DELEGAT INT COMM RED CROSS,PRETORIA,SOUTH AFRICA.							BADEN MM, 1970, INT J ADDICT, V5, P489, DOI 10.3109/10826087009057014; BIETER RN, 1948, ANN NY ACAD SCI, V51, P137, DOI 10.1111/j.1749-6632.1948.tb27258.x; DOLE VP, 1968, J AMER MED ASSOC, V206, P2708, DOI 10.1001/jama.206.12.2708; DRUMMER OH, 1992, AM J FOREN MED PATH, V13, P346, DOI 10.1097/00000433-199212000-00017; Greene M H, 1974, J Forensic Sci, V19, P575; HARDINGPINK D, 1991, J TOXICOL CLIN EXPER, V11, P31; MOLYNEUX E, 1991, BRIT MED J, V303, P922, DOI 10.1136/bmj.303.6807.922-a; NAEVE W, 1955, ARCH TOXICOL, V73, P96; ORDING J, 1988, METHADONE MANAGEMENT, P100; ZIMMEY EL, 1981, J FORENSIC SCI, V26, P462; 1951, LANCET, V2, P156	11	42	42	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					665	666		10.1016/0140-6736(93)90427-I	http://dx.doi.org/10.1016/0140-6736(93)90427-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KR613	8095576				2022-12-24	WOS:A1993KR61300011
J	MACFARLANE, JK; RYALL, RDH; HEALD, RJ				MACFARLANE, JK; RYALL, RDH; HEALD, RJ			MESORECTAL EXCISION FOR RECTAL-CANCER	LANCET			English	Article							ADJUVANT THERAPY; CARCINOMA; RADIOTHERAPY; RISK	Concern about world wide local recurrence rates for rectal cancer of 20-45%, together with anxiety at the recent proliferation of adjuvant therapies, led us to review the efficacy of total mesorectal excision (TME) with which no adjuvant therapy had been combined. Precise, sharp dissection is undertaken around the integral mesentery of the hind gut, which envelopes the entire mid rectum. This procedure adds to operative time and complications but has been' claimed to eliminate virtually all locally recurrent disease after ''curative'' surgery. Independent analysis (J. K. M.) of prospective follow-up data extended over a 13-year interval (1978-91; mean 7.5 years). The actuarial local recurrence rate after curative anterior resection at 5 years is 4% (95% CI 0-7.5%) and the overall recurrence rate is 18% (10-25%). 10-year figures are 4% (0-11%) and 19% (7-32%). In view of the high-risk classification used for the North Central Cancer Treatment G roup (NCCTG), which has led to a trend to chemoradiotherapy, a similar group of high-risk Basingstoke cases was constructed for comparison purposes. This group included 135 consecutive Dukes' B (B2) and Dukes' C cancer operations, both anterior resection and abdominal-perineal excision, for tumours below 12 cm from the anal verge. Results from TM E alone are substantially superior to the best reported (NCCTG) from conventional surgery plus radiotherapy or combination chemoradiotherapy: 5% local recurrence at 5 years compared with 25% and 13.5%, respectively; and 22% overall recurrence compared with 62.7% and 41.5%, respectively (Dukes' B cases [B2], 15%; Dukes' C cases, 32%). Meticulous TME, which encompasses the whole field of tumour spread, can improve cure rates and reduce the variability of outcomes between surgeons. Far more genuine ''cures'' of rectal cancer are possible by surgery alone than have generally been believed or are currently accepted. Better surgical results are an essential background for the more selective use of adjuvant therapy in the future.	BASINGSTOKE DIST GEN HOSP, COLORECTAL RES UNIT, ALDERMASTON RD, BASINGSTOKE RG24 9NA, HANTS, ENGLAND; WESSEX RADIOTHERAPY CTR, SOUTHAMPTON, ENGLAND; UNIV BRITISH COLUMBIA, VANCOUVER V6T 1W5, BC, CANADA	University of British Columbia								[Anonymous], 1985, NEW ENGL J MED, V312, P1465; FISHER B, 1988, JNCI-J NATL CANCER I, V80, P21, DOI 10.1093/jnci/80.1.21; GALANDIUK S, 1992, SURG GYNECOL OBSTET, V174, P27; GERARD A, 1988, ANN SURG, V208, P606, DOI 10.1097/00000658-198811000-00011; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; HEALD RJ, 1986, LANCET, V1, P1479; HEALD RJ, 1988, J ROY SOC MED, V81, P503, DOI 10.1177/014107688808100904; HEALD RJ, 1982, BRIT J SURG, V69, P613, DOI 10.1002/bjs.1800691019; ISBISTER WH, 1990, AUST NZ J SURG, V60, P243, DOI 10.1111/j.1445-2197.1990.tb07361.x; IZAR F, 1992, WORLD J SURG, V16, P106, DOI 10.1007/BF02067122; KARANJIA ND, 1991, BRIT J SURG, V78, P196, DOI 10.1002/bjs.1800780221; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; NILSSON E, 1992, ONKOLOGISK FORUM NOV; PAHLMAN L, 1985, BRIT J SURG, V72, P961, DOI 10.1002/bjs.1800721209; Silen W, 1983, YB SURGERY, P368	16	1293	1343	1	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 20	1993	341	8843					457	460		10.1016/0140-6736(93)90207-W	http://dx.doi.org/10.1016/0140-6736(93)90207-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	8094488				2022-12-24	WOS:A1993KN13700004
J	OHOY, KL; TSILFIDIS, C; MAHADEVAN, MS; NEVILLE, CE; BARCELO, J; HUNTER, AGW; KORNELUK, RG				OHOY, KL; TSILFIDIS, C; MAHADEVAN, MS; NEVILLE, CE; BARCELO, J; HUNTER, AGW; KORNELUK, RG			REDUCTION IN SIZE OF THE MYOTONIC-DYSTROPHY TRINUCLEOTIDE REPEAT MUTATION DURING TRANSMISSION	SCIENCE			English	Article							DNA; RECOMBINATION; CHROMOSOME-19; CONVERSION; EVOLUTION; REGION; GENES; LOCUS	Myotonic dystrophy (DM) is an autosomal-dominant disorder that affects 1 in 8000 individuals. Amplification of an unstable trinucleotide CTG repeat, located within the 3' untranslated region of a gene, correlates with a more severe DM phenotype. In three cases, the number of CTG repeats was reduced during the transmission of the DM allele; in one of these cases, the number was reduced to within the normal range and correlated at least with a delay in the onset of clinical signs of DM. Haplotype data of six polymorphic markers in the DM gene region indicate that, in this latter case, two stretches of the affected chromosome had been exchanged with that region of the wild-type chromosome.	UNIV OTTAWA,DEPT MICROBIOL & IMMUNOL,OTTAWA K1H 8M5,ONTARIO,CANADA; CHILDRENS HOSP EASTERN ONTARIO,DIV GENET,OTTAWA K1H 8L1,ONTARIO,CANADA	University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario								BISHOP DK, 1986, MOL CELL BIOL, V6, P3401, DOI 10.1128/MCB.6.10.3401; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1991, CELL, V67, P1; Harper P.S., 1989, MYOTONIC DYSTROPHY; HASTINGS PJ, 1988, GENETIC RECOMBINATIO, P397; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; HUNTER A, 1992, J MED GENET, V29, P774, DOI 10.1136/jmg.29.11.774; HUNTER AGW, 1993, AM J MED GENET, V45, P401, DOI 10.1002/ajmg.1320450330; JOHNSON K, 1990, AM J HUM GENET, V46, P1073; KORNELUK RG, 1989, GENOMICS, V5, P596, DOI 10.1016/0888-7543(89)90028-1; MAEDA N, 1986, ANNU REV GENET, V20, P81; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MICHELSON AM, 1983, J BIOL CHEM, V258, P5245; NEVILLE CE, UNPUB; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; ORRWEAVER TL, 1985, MICROBIOL REV, V49, P33, DOI 10.1128/MMBR.49.1.33-58.1985; SHELBOURNE P, 1992, HUM MOL GENET, V1, P467, DOI 10.1093/hmg/1.7.467; SHUTLER G, 1992, GENOMICS, V13, P518, DOI 10.1016/0888-7543(92)90119-D; STOECKERT CJ, 1984, NUCLEIC ACIDS RES, V12, P4469, DOI 10.1093/nar/12.11.4469; SYMINGTON LS, 1988, MOL CELL BIOL, V8, P595, DOI 10.1128/MCB.8.2.595; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; TSILFIDIS C, UNPUB; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	25	108	108	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 5	1993	259	5096					809	812		10.1126/science.8094260	http://dx.doi.org/10.1126/science.8094260			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8094260				2022-12-24	WOS:A1993KL11000032
J	MING, XF; BURGERING, BMT; WENNSTROM, S; CLAESSONWELSH, L; HELDIN, CH; BOS, JL; KOZMA, SC; THOMAS, G				MING, XF; BURGERING, BMT; WENNSTROM, S; CLAESSONWELSH, L; HELDIN, CH; BOS, JL; KOZMA, SC; THOMAS, G			ACTIVATION OF P70/P85 S6 KINASE BY A PATHWAY INDEPENDENT OF P21(RAS)	NATURE			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE; SIGNALING PATHWAYS; TYROSINE KINASE; RAS; PHOSPHORYLATION; MOLECULES; P70(S6K); MUTANT; RAF-1	THE enzymes p70(s6k) and p85(s6k) two isoforms of the same kinase(1,2) and are important in mitogenesis(2-4). Both isoforms are activated by a complex phosphorylation event(5) and lie on a common signalling pathway(4), distinct from that of the p42(mapk)/p44(mapk) kinases(6). Activation of p42(mapk)/p44(mapk) is triggered by sequential activation of the GDP-GTP exchange factor Sos, the GTP-binding protein p21(ras), and protein kinases p74(raf) and p47(mek) (refs 7-10). As p21(ras) transformed cells have increased S6 phosphorylation(11), we tested whether the p70(s6k)/p85(s6k) signalling pathway bifurcates between p21(ras) and p42(mapk)/p44(mapk). We found that mutants of p74(raf) and p21(ras) blocked activation of epitope-tagged p44(mapk) but not epitope-tagged p70(s6k). Moreover, in cells expressing human platelet-derived growth factor receptors lacking the kinase-insert domain, the growth factor activates p21(ras) but not p70(s6k)/p85(s6k). The critical autophosphorylation site for p70(s6k)/p85(s6k) activation within this domain is a tyrosine at residue 751. Our results show that the p70(s6k)/p85(s6k) signalling pathway is independent of p21(ras), that it bifurcates from the p21(ras) pathway at the receptor, and that it is initiated by autophosphorylation at a specific site.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; UNIV UTRECHT, PHYSIOL CHEM LAB, 3584 CG UTRECHT, NETHERLANDS; BIOMED CTR, LUDWIG INST CANC RES, S-75124 UPPSALA, SWEDEN	Friedrich Miescher Institute for Biomedical Research; Utrecht University; Ludwig Institute for Cancer Research								ARVIDSSON AK, IN PRESS MOL CELL BI; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BLENIS J, 1984, J VIROL, V50, P966, DOI 10.1128/JVI.50.3.966-969.1984; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BURGERING BM, 1994, CELL GROWTH DIFFER, V5, P1; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRARI S, 1993, J BIOL CHEM, V268, P16091; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOZMA SC, IN PRESS PROTEIN KIN; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PELECH SL, 1993, CURR BIOL, V3, P513, DOI 10.1016/0960-9822(93)90043-N; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; WENNSTROM S, 1994, ONCOGENE, V9, P651; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	30	207	210	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	1994	371	6496					426	429		10.1038/371426a0	http://dx.doi.org/10.1038/371426a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	8090223				2022-12-24	WOS:A1994PJ28500045
J	ROSCH, PJ				ROSCH, PJ			STRESSFUL LIFE EVENTS AND GRAVES-DISEASE	LANCET			English	Editorial Material											ROSCH, PJ (corresponding author), AMER INST STRESS,NEW YORK,NY, USA.							HADDEN DR, 1974, LANCET, V2, P577; MEANS JH, 1948, THYROID ITS DISEASES, P295; ORTHGOMER K, 1990, PSYCHOSOM MED, V52, P59, DOI 10.1097/00006842-199001000-00005; ROSCH PJ, 1992, LANCET, V339, P428; SONINO N, 1993, ACTA ENDOCRINOL-COP, V128, P293, DOI 10.1530/acta.0.1280293; UTIGER RD, 1991, NEW ENGL J MED, V325, P278, DOI 10.1056/NEJM199107253250410; WINSA B, 1991, LANCET, V338, P1475, DOI 10.1016/0140-6736(91)92298-G	7	12	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					566	567		10.1016/0140-6736(93)91402-8	http://dx.doi.org/10.1016/0140-6736(93)91402-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102712				2022-12-24	WOS:A1993LV96300002
J	HARRIES, AD				HARRIES, AD			MALARIA - KEEPING THE MOSQUITOS AT BAY	LANCET			English	Editorial Material							TREATED BED NETS; GAMBIAN CHILDREN; AFRICA				HARRIES, AD (corresponding author), UNIV MALAWI, DEPT MED, BLANTYRE, MALAWI.							ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; GREENWOOD BM, 1988, LANCET, V1, P1121; GREENWOOD BM, 1993, T R SOC TROP MED S2, V87; SNOW RW, 1988, T ROY SOC TROP MED H, V82, P212, DOI 10.1016/0035-9203(88)90414-2; SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4; SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9; SPENCER H C, 1987, Annals of Tropical Medicine and Parasitology, V81, P36; STURCHLER D, 1989, PARASITOL TODAY, V5, P39, DOI 10.1016/0169-4758(89)90188-9	8	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1993	342	8870					506	507		10.1016/0140-6736(93)91639-4	http://dx.doi.org/10.1016/0140-6736(93)91639-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102660				2022-12-24	WOS:A1993LU58200002
J	BARLOW, DH				BARLOW, DH			MANAGING THE MENOPAUSE - FROM PUMPKINS TO HRT	LANCET			English	Editorial Material											BARLOW, DH (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND.		Barlow, David/F-8738-2011					BARLOW DH, 1989, BRIT J OBSTET GYNAEC, V96, P1192, DOI 10.1111/j.1471-0528.1989.tb03195.x; BARLOW DH, 1992, BRIT MED BULL, V48, P356, DOI 10.1093/oxfordjournals.bmb.a072551; BUNGAY GT, 1980, BRIT MED J, V2, P181; CHAKRAVARTI S, 1977, BRIT J OBSTET GYNAEC, V84, P769, DOI 10.1111/j.1471-0528.1977.tb12491.x; GARNETT T, 1991, J ROY SOC MED, V84, P128, DOI 10.1177/014107689108400304; GATH D, 1990, HRT AND OSTEOPOROSIS, P35; OLDENHAVE A, 1993, AM J OBSTET GYNECOL, V168, P765, DOI 10.1016/S0002-9378(12)90816-9; OLDENHAVE A, 1993, AM J OBSTET GYNECOL, V168, P772, DOI 10.1016/S0002-9378(12)90817-0; SPECTOR TD, 1989, BRIT MED J, V299, P1434, DOI 10.1136/bmj.299.6713.1434	9	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 10	1993	342	8863					66	67		10.1016/0140-6736(93)91280-Y	http://dx.doi.org/10.1016/0140-6736(93)91280-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL789	8100907				2022-12-24	WOS:A1993LL78900004
J	ZHUO, M; SMALL, SA; KANDEL, ER; HAWKINS, RD				ZHUO, M; SMALL, SA; KANDEL, ER; HAWKINS, RD			NITRIC-OXIDE AND CARBON-MONOXIDE PRODUCE ACTIVITY-DEPENDENT LONG-TERM SYNAPTIC ENHANCEMENT IN HIPPOCAMPUS	SCIENCE			English	Article							CYCLIC-GMP; CELLULAR MECHANISM; SENSORY NEURONS; RAT HIPPOCAMPUS; POTENTIATION; TRANSMISSION; MESSENGER; PROTOPORPHYRIN; INHIBITION; ACTIVATION	Nitric oxide (NO) and carbon monoxide (CO) may act as retrograde messages for long-term potentiation (LTP) in the hippocampus. Zinc protoporphyrin IX, an inhibitor of the enzyme that produces CO, blocked induction of LTP in the CA1 region of hippocampal slices. Application of either NO or CO to slices produced a rapid and long-lasting increase in the size of evoked synaptic potentials if, and only if, the application occurred at the same time as weak tetanic stimulation. This long-term enhancement was spatially restricted to synapses from active presynaptic fibers and appeared to involve mechanisms utilized by LTP, occluding the subsequent induction of LTP by strong tetanic stimulation. The enhancement by NO and CO was not blocked by an N-methyl-D-aspartate (NMDA) receptor blocker, suggesting that NO and CO act downstream from the NMDA receptor. Also, CO produced long-term enhancement when paired with low-frequency stimulation. These results are consistent with the hypothesis that NO and CO, either alone or in combination, serve as retrograde messages that produce activity-dependent presynaptic enhancement during LTP.	COLUMBIA UNIV COLL PHYS & SURG,NEW YORK STATE PSYCHIAT INST,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; New York State Psychiatry Institute; Howard Hughes Medical Institute			Zhuo, Min/A-2072-2008	Zhuo, Min/0000-0001-9062-3241	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045923, R37MH045923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG008702] Funding Source: NIH RePORTER; NIA NIH HHS [AG08702] Funding Source: Medline; NIMH NIH HHS [MH45923] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSEN P, 1977, NATURE, V266, P736, DOI 10.1038/266736a0; ANIKSZTEJN L, 1991, NATURE, V349, P67, DOI 10.1038/349067a0; Bohme G. A., 1992, Society for Neuroscience Abstracts, V18, P640; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREEN CA, 1983, NATURE, V303, P716, DOI 10.1038/303716a0; CHAPMAN PF, 1992, NEUROREPORT, V3, P567, DOI 10.1097/00001756-199207000-00005; Chetkovich D. M., 1992, Society for Neuroscience Abstracts, V18, P761; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; COLINO A, 1992, J NEUROSCI, V12, P180; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GRIBKOFF VK, 1992, J NEUROPHYSIOL, V68, P639, DOI 10.1152/jn.1992.68.2.639; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HAWKINS RD, 1990, SEMIN NEUROSCI, V2, P391; HUANG YY, 1993, J NEUROSCI, V13, P568; LI YG, 1992, SOC NEUR ABSTR, V18, P343; MACINTYRE I, 1991, P NATL ACAD SCI USA, V88, P2936, DOI 10.1073/pnas.88.7.2936; MAINES MD, 1981, BIOCHIM BIOPHYS ACTA, V673, P339, DOI 10.1016/0304-4165(81)90465-7; MARKS GS, 1991, TRENDS PHARMACOL SCI, V12, P185, DOI 10.1016/0165-6147(91)90544-3; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; ODELL TT, COMMUNICATION; QATO MK, 1985, BIOCHEM J, V226, P51, DOI 10.1042/bj2260051; SCHUMAN E M, 1991, Society for Neuroscience Abstracts, V17, P2; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SMALL SA, 1989, SCIENCE, V243, P1603, DOI 10.1126/science.2538924; STEVENS CF, IN PRESS NATURE; SWEATT JD, COMMUNICATION; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WALTERS ET, 1983, SCIENCE, V219, P405, DOI 10.1126/science.6294834; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; WOODY CD, 1978, BRAIN RES, V158, P373, DOI 10.1016/0006-8993(78)90682-0; ZHUO M, UNPUB	40	503	514	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1946	1950		10.1126/science.8100368	http://dx.doi.org/10.1126/science.8100368			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8100368				2022-12-24	WOS:A1993LJ34900044
J	VANDENBROECK, J; EECKELS, R; VUYLSTEKE, J				VANDENBROECK, J; EECKELS, R; VUYLSTEKE, J			INFLUENCE OF NUTRITIONAL-STATUS ON CHILD-MORTALITY IN RURAL ZAIRE	LANCET			English	Article							RISK; DEATH; MALNUTRITION; GUINEA; GROWTH; AGE	Although the association between nutritional status and mortality risk is obvious for extreme malnutrition, the issue is not so clear for mild to moderate undernutrition. We have investigated this association in children of 0-5 years in the rural area of Bwamanda, Zaire, where an integrated development project, with good medical facilities, has operated for 20 years. A random cluster sample of 5167 children was taken; newborn infants and immigrants were included at six quarterly survey rounds from October, 1989, until February, 1991. All surveys included clinical and anthropometric assessment of nutritional status. Deaths were recorded up to April, 1992; there were 246 deaths. Marasmus, kwashiorkor, and other causes of death were defined by the verbal autopsy method and checked against medical records kept at the central hospital and the peripheral dispensaries. As expected, we found an increased risk of death in severe malnutrition. When deaths directly attributed to marasmus or kwashiorkor were excluded, mild to moderate stunting or wasting were not associated with higher mortality in the short term (within 3 months of the previous study round) or in the long term (from 3-30 months after study entry). The commonest causes of death were malaria and anaemia. Extreme marasmus and kwashiorkor caused 16% of deaths, and are important causes of death even in this favoured area with an integrated development project. Nutritional interventions should be targeted more selectively so that children with moderate malnutrition can be protected from progression to marasmus or kwashiorkor.	INST TROP MED,ANTWERP,BELGIUM; CATHOLIC UNIV LEUVEN,DEPT PAEDIAT,B-3000 LOUVAIN,BELGIUM	Institute of Tropical Medicine (ITM); KU Leuven	VANDENBROECK, J (corresponding author), CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,HERESTR 49,B-3000 LOUVAIN,BELGIUM.							ALAM N, 1989, AM J CLIN NUTR, V49, P884, DOI 10.1093/ajcn/49.5.884; BRIEND A, 1989, BRIT MED J, V298, P1607, DOI 10.1136/bmj.298.6688.1607; CHEN LC, 1980, AM J CLIN NUTR, V33, P1836, DOI 10.1093/ajcn/33.8.1836; HEYWOOD P, 1982, J FOOD NUTR, V39, P13; KALTER HD, 1991, INT J EPIDEMIOL, V20, P192; KATZ J, 1989, AM J EPIDEMIOL, V130, P1219, DOI 10.1093/oxfordjournals.aje.a115450; KIELMANN AA, 1978, LANCET, V1, P1247; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; LINDSKOG U, 1988, ACTA PAEDIATR SCAND, V77, P260, DOI 10.1111/j.1651-2227.1988.tb10640.x; MORRIS JA, 1989, STAT CONFIDENCE, P50; SMEDMAN L, 1987, AM J CLIN NUTR, V46, P369, DOI 10.1093/ajcn/46.2.369; SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4; SOMMER A, 1975, AM J CLIN NUTR, V28, P287, DOI 10.1093/ajcn/28.3.287; SUZAWAL S, 1992, LANCET, V340, P528; VANLERBERGHE W, 1989, KASONGO CHILD MORTAL; VANLOON H, 1989, COMP ELEMENTARY EPID; VANLOON H, 1987, THESIS U LEUVEN BELG; Waterlow JC, 1992, PROTEIN ENERGY MALNU; 1976, MONTHLY VITAL STAT S, V25; 1986, B WORLD HEALTH ORGAN, V64, P707; 1988, SAS USERS GUIDE STAT	21	87	87	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1491	1495		10.1016/0140-6736(93)90632-Q	http://dx.doi.org/10.1016/0140-6736(93)90632-Q			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099378				2022-12-24	WOS:A1993LG24200002
J	TUCKER, G				TUCKER, G			PHARMACOLOGY - DRUG DELIVERY - LYMPHING ALONG	LANCET			English	Editorial Material											TUCKER, G (corresponding author), UNIV SHEFFIELD,DEPT MED & PHARMACOL,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND.							AUNGST BJ, 1992, PHARM RES-DORDR, V9, P1507, DOI 10.1023/A:1015831517800; BARNWELL SG, 1992, INT J PHARMACEUT, V88, P423, DOI 10.1016/0378-5173(92)90342-Y; BARNWELL SG, 1993, INT S RECENT ADV DRU; CHARMAN WNA, 1986, INT J PHARM, V34, P175, DOI 10.1016/0378-5173(86)90027-X; Muranishi S., 1991, ADV DRUG RES, P1; WHITE DG, 1991, INT J PHARM, V69, P169, DOI 10.1016/0378-5173(91)90221-9	6	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 22	1993	341	8856					1314	1315		10.1016/0140-6736(93)90821-W	http://dx.doi.org/10.1016/0140-6736(93)90821-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	8098454				2022-12-24	WOS:A1993LD25300009
J	BOOTH, IW; MAGNAY, AR				BOOTH, IW; MAGNAY, AR			PEDIATRICS - PEPTIC DISEASE AND CHILDHOOD DIABETES	LANCET			English	Editorial Material							CHILDREN; GASTRITIS; ULCER				BOOTH, IW (corresponding author), UNIV BIRMINGHAM,INST CHILD HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							BARNETT JL, 1988, GASTROENTEROLOGY, V94, P739, DOI 10.1016/0016-5085(88)90248-X; BURGHEN GA, 1992, AM J DIS CHILD, V146, P718, DOI 10.1001/archpedi.1992.02160180078021; DIXON MF, 1986, J CLIN PATHOL, V39, P524, DOI 10.1136/jcp.39.5.524; DOTEVALL G, 1959, ACTA MED SCAND, V164, P463; EASTHAM EJ, 1991, PEDIATRIC GASTROINTE, P438; FIEDOREK SC, 1991, PEDIATRICS, V88, P578; KILBRIDGE PM, 1988, AM J DIS CHILD, V142, P1149, DOI 10.1001/archpedi.1988.02150110027012; TAM PKH, 1986, J PEDIATR SURG, V21, P15, DOI 10.1016/S0022-3468(86)80642-X	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					868	868		10.1016/0140-6736(93)93071-8	http://dx.doi.org/10.1016/0140-6736(93)93071-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096572				2022-12-24	WOS:A1993KV81100014
J	MOYA, FR; HOFFMAN, DR; ZHAO, B; JOHNSTON, JM				MOYA, FR; HOFFMAN, DR; ZHAO, B; JOHNSTON, JM			PLATELET-ACTIVATING-FACTOR IN SURFACTANT PREPARATIONS	LANCET			English	Note							LUNG	Surfactant administration is used for treatment of neonatal respiratory distress syndrome. We studied whether currently used surfactant preparations contain platelet-activating factor (PAF), a potent lipid mediator produced by fetal lungs. Three surfactant preparations from animal sources contained between 36 and 218 pmol of PAF per mL, whereas PAF was undetectable in an artificial surfactant. Based on current recommendations, about 144-654 pmol PAF would be administered per dose of natural surfactant, sufficient to exert possible physiological effects on the lung. The action of PAF may be exacerbated by low activity of PAF-acetylhydrolase, which inactivates PAF, in tracheal fluid from infants with respiratory distress syndrome.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT OBSTET & GYNECOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NICHD NIH HHS [HD13912] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013912] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGLE MJ, 1987, LAB INVEST, V57, P321; BOURBON JR, 1991, EXP LUNG RES, V17, P789, DOI 10.3109/01902149109062878; CAPLAN MS, 1990, J PEDIATR-US, V116, P960, DOI 10.1016/S0022-3476(05)80661-4; CAPLAN MS, 1990, AM REV RESPIR DIS, V142, P1258, DOI 10.1164/ajrccm/142.6_Pt_1.1258; HOFFMAN DR, 1988, J BIOL CHEM, V263, P9316; HOFFMAN DR, 1987, BIOCHIM BIOPHYS ACTA, V879, P88; JOHNSTON JM, 1989, PAF HLTH DISEASE, P297; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; YEE WFH, 1991, PEDIATR PULM, V11, P65, DOI 10.1002/ppul.1950110111	10	38	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 3	1993	341	8849					858	860						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV811	8096563				2022-12-24	WOS:A1993KV81100005
J	DEMPSTER, DW; LINDSAY, R				DEMPSTER, DW; LINDSAY, R			PATHOGENESIS OF OSTEOPOROSIS	LANCET			English	Article							GLUCOCORTICOID-INDUCED OSTEOPOROSIS; BLOOD MONONUCLEAR-CELLS; GROWTH FACTOR-I; BONE; RELEASE; CALVARIAE; AGE		COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; HELEN HAYES HOSP,DEPT MED,W HAVERSTRAW,NY 10993	Columbia University; Columbia University	DEMPSTER, DW (corresponding author), HELEN HAYES HOSP,REG BONE CTR,ROUTE 9W,W HAVERSTRAW,NY 10993, USA.				NIAMS NIH HHS [AR39191] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039191] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOYCE RW, 1991, J BONE MINER RES  S1, V6, pS218; COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; DEMPSTER DW, 1989, J BONE MINER RES, V4, P137; EPSTEIN S, 1986, BONE, V7, P421, DOI 10.1016/8756-3282(86)90001-3; ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021; ERNST M, 1989, ENDOCRINOLOGY, V125, P825, DOI 10.1210/endo-125-2-825; FEYEN JHM, 1987, ENDOCRINOLOGY, V121, P819, DOI 10.1210/endo-121-2-819; HEANEY RP, 1993, NEW ENGL J MED, V328, P503, DOI 10.1056/NEJM199302183280710; JILJA R, 1992, SCIENCE, V257, P88; JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204; KIMBLE RB, 1992, J BONE MINER RES, V7, pS116; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MELLISH RWE, 1989, BONE MINER, V6, P331, DOI 10.1016/0169-6009(89)90038-X; MELTON LJ, 1987, CALCIFIED TISSUE INT, V41, P57; MOHAN S, 1991, CLIN ORTHOP RELAT R, V263, P30; OURSLER MJ, 1991, P NATL ACAD SCI USA, V88, P6613, DOI 10.1073/pnas.88.15.6613; PACIFICI R, 1992, CALCIFIED TISSUE INT, V50, P295, DOI 10.1007/BF00301625; PACIFICI R, 1987, P NATL ACAD SCI USA, V84, P4616, DOI 10.1073/pnas.84.13.4616; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; PARFITT AM, 1992, BONE, V13, pS41, DOI 10.1016/8756-3282(92)90196-4; PARFITT AM, 1988, OSTEOPOROSIS ETIOLOG, P355; PARISIEN M, 1992, J BONE MINER RES, V7, P913; RALSTON SH, 1990, J BONE MINER RES, V5, P983; RIGGS BL, 1988, CECIL TXB MED, P1510; STEVENSON JC, 1983, VITAMIN D, P43; [No title captured]; [No title captured]; 1991, OSTEOPOROSIS INT, V1, P114; [No title captured]	30	224	227	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					797	801		10.1016/0140-6736(93)90570-7	http://dx.doi.org/10.1016/0140-6736(93)90570-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	8096008				2022-12-24	WOS:A1993KU90000013
J	STRAUSS, WM; DAUSMAN, J; BEARD, C; JOHNSON, C; LAWRENCE, JB; JAENISCH, R				STRAUSS, WM; DAUSMAN, J; BEARD, C; JOHNSON, C; LAWRENCE, JB; JAENISCH, R			GERM LINE TRANSMISSION OF A YEAST ARTIFICIAL CHROMOSOME SPANNING THE MURINE ALPHA(1)(I) COLLAGEN LOCUS	SCIENCE			English	Article							GENETIC-LINKAGE MAP; ALPHA-1(I) COLLAGEN; INSITU HYBRIDIZATION; MAMMALIAN-CELLS; MOUSE; INTERPHASE; CLONING; GENOME; DNA; RNA	Molecular complementation of mutant phenotypes by transgenic technology is a potentially important tool for gene identification. A technology was developed that allows the transfer of a physically intact yeast artificial chromosome (YAC) into the germ line of the mouse. A purified 150-kilobase YAC encompassing the murine gene Col1a1 was efficiently introduced into embryonic stem (ES) cells via lipofection. Chimeric founder mice were derived from two transfected ES cell clones. These chimeras transmitted the full length transgene through the germ line, generating two transgenic mouse strains. Transgene expression was visualized as nascent transcripts in interphase nuclei and quantitated by ribonuclease protection analysis. Both assays indicated that the transgene was expressed at levels comparable to the endogenous collagen gene.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA; UNIV MASSACHUSETTS, SCH MED, WORCESTER, MA 01655 USA	Massachusetts Institute of Technology (MIT); University of Massachusetts System; University of Massachusetts Worcester	STRAUSS, WM (corresponding author), MIT, WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Lawrence, Jeanne/0000-0001-6572-3128	NCI NIH HHS [5 R35 CA44339-05] Funding Source: Medline; NHGRI NIH HHS [HG00198-01] Funding Source: Medline; NIGMS NIH HHS [5 F32 GM13756-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000198, R37HG000198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013756] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHOI T, IN PRESS NATURE; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DIETRICH W, 1992, GENETICS, V131, P423; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DURSO M, 1990, GENOMICS, V7, P531, DOI 10.1016/0888-7543(90)90196-2; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GNIRKE A, 1991, EMBO J, V10, P1629, DOI 10.1002/j.1460-2075.1991.tb07685.x; GNIRKE A, 1991, SOMAT CELL MOLEC GEN, V17, P573, DOI 10.1007/BF01233622; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOOSLEHNER K, 1988, NUCLEIC ACIDS RES, V16, P773, DOI 10.1093/nar/16.2.773; MUNKE M, 1986, CYTOGENET CELL GENET, V43, P140, DOI 10.1159/000132312; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; PAVAN WJ, 1990, MOL CELL BIOL, V10, P4163, DOI 10.1128/MCB.10.8.4163; RAAP AK, 1991, EXP CELL RES, V197, P319, DOI 10.1016/0014-4827(91)90439-2; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; SCHEDL A, 1992, NUCLEIC ACIDS RES, V20, P3073, DOI 10.1093/nar/20.12.3073; SCHNIEKE A, 1983, NATURE, V304, P315, DOI 10.1038/304315a0; STRAUSS WM, 1992, MAMM GENOME, V2, P150, DOI 10.1007/BF00302873; STRAUSS WM, UNPUB; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WU H, 1990, MOL CELL BIOL, V10, P1452, DOI 10.1128/MCB.10.4.1452; XING Y, 1991, METHOD CELL BIOL, V35, P75; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0	35	108	147	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	1993	259	5103					1904	1907		10.1126/science.8096090	http://dx.doi.org/10.1126/science.8096090			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8096090				2022-12-24	WOS:A1993KU17200034
J	WILLETT, WC; STAMPFER, MJ; MANSON, JE; COLDITZ, GA; SPEIZER, FE; ROSNER, BA; SAMPSON, LA; HENNEKENS, CH				WILLETT, WC; STAMPFER, MJ; MANSON, JE; COLDITZ, GA; SPEIZER, FE; ROSNER, BA; SAMPSON, LA; HENNEKENS, CH			INTAKE OF TRANS-FATTY-ACIDS AND RISK OF CORONARY HEART-DISEASE AMONG WOMEN	LANCET			English	Article							UNITED-STATES; HIGH-DENSITY; DIET; EMPHASIS; ISOMERS; TISSUE; FOOD; CIS	Trans isomers of fatty acids, formed by the partial hydrogenation of vegetable oils to produce margarine and vegetable shortening, increase the ratio of plasma low-density-lipoprotein to high-density-lipoprotein cholesterol, so it is possible that they adversely influence risk of coronary heart disease (CHD). To investigate this possibility, we studied dietary data from participants in the Nurses' Health Study. We calculated intake of trans fatty acids from dietary questionnaires completed by 85 095 women without diagnosed CHD, stroke, diabetes, or hypercholesterolaemia in 1980. During 8 years of follow-up, there were 431 cases of new CHD (non-fatal myocardial infarction or death from CHD). After adjustment for age and total energy intake, intake of trans isomers was directly related to risk of CHD (relative risk for highest vs lowest quintile 1.50 [95% CI 1.12-2.00], p for trend=0.001). Additional control for established CHD risk factors, multivitamin use, and intakes of saturated fat, monounsaturated fat, and linoleic acid, dietary cholesterol, vitamins E or C, carotene, or fibre did not change the relative risk substantially. The association was stronger for the 69 181 women whose margarine consumption over the previous 10 years had been stable (1.67 [1.05-2.66], p for trend=0.002). Intakes of foods that are major sources of trans isomers (margarine, cookies [biscuits], cake, and white bread) were each significantly associated with higher risks of CHD. These findings support the hypothesis that consumption of partially hydrogenated vegetable oils may contribute to occurrence of CHD.	HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHANNING LAB,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	WILLETT, WC (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOOYENS J, 1986, MED HYPOTHESES, V21, P387, DOI 10.1016/0306-9877(86)90034-4; EMKEN EA, 1984, ANNU REV NUTR, V4, P339, DOI 10.1146/annurev.nu.04.070184.002011; ENIG MG, 1983, J AM OIL CHEM SOC, V60, P1788, DOI 10.1007/BF02680357; HUNTER JE, 1991, AM J CLIN NUTR, V54, P363, DOI 10.1093/ajcn/54.2.363; KINSELLA JE, 1981, AM J CLIN NUTR, V34, P2307, DOI 10.1093/ajcn/34.10.2307; KUMMEROW FA, 1979, AM J CLIN NUTR, V32, P58, DOI 10.1093/ajcn/32.1.58; LAGROST L, 1992, BIOCHIM BIOPHYS ACTA, V1124, P159, DOI 10.1016/0005-2760(92)90092-A; LONDON SJ, 1991, AM J CLIN NUTR, V54, P340, DOI 10.1093/ajcn/54.2.340; MENSINK RP, 1987, LANCET, V1, P122, DOI 10.1016/S0140-6736(87)91965-9; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1992, J LIPID RES, V33, P1493; NESTEL P, 1992, J LIPID RES, V33, P1029; PARODI PW, 1976, J DAIRY SCI, V50, P1870; PARTHASARATHY S, 1990, P NATL ACAD SCI USA, V87, P3894, DOI 10.1073/pnas.87.10.3894; PEACOCK LIL, 1988, BIOCHEM SOC T, V16, P291, DOI 10.1042/bst0160291; ROSENTHAL MD, 1983, BIOCHIM BIOPHYS ACTA, V753, P450, DOI 10.1016/0005-2760(83)90070-X; SENTI FRE, 1988, HLTH ASPECTS DIETARY; SLOVER HT, 1985, J AM OIL CHEM SOC, V62, P775, DOI 10.1007/BF03028753; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STEPHEN AM, 1990, AM J CLIN NUTR, V52, P457, DOI 10.1093/ajcn/52.3.457; THOMAS LH, 1983, J EPIDEMIOL COMMUN H, V37, P16, DOI 10.1136/jech.37.1.16; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WILLETT WC, 1989, NUTRITONAL EPIDEMIOL; ZOCK PL, 1992, J LIPID RES, V33, P399; 1971, WHO IHD 5TH REP; 1963, AGR HDB SERIES, V8	28	770	790	2	81	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					581	585		10.1016/0140-6736(93)90350-P	http://dx.doi.org/10.1016/0140-6736(93)90350-P			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	8094827				2022-12-24	WOS:A1993KQ23400002
J	HEATH, CW				HEATH, CW			PASSIVE SMOKING - ENVIRONMENTAL TOBACCO-SMOKE AND LUNG-CANCER	LANCET			English	Editorial Material											HEATH, CW (corresponding author), AMER CANC SOC,DEPT EPIDEMIOL & STAT,ATLANTA,GA, USA.							[Anonymous], 1986, ENV TOBACCO SMOKE ME; FONTHAM ETH, 1991, CANCER EPIDEM BIOMAR, V1, P35; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; 1986, EVALUATION CARCINOGE, V38, P303; 1986, HLTH CONSEQUENCES IN; 1992, RESPIRATORY HLTH EFF	6	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 27	1993	341	8844					526	526		10.1016/0140-6736(93)90282-L	http://dx.doi.org/10.1016/0140-6736(93)90282-L			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP083	8094775				2022-12-24	WOS:A1993KP08300008
J	ALLEMANN, Y; HORBER, FF; COLOMBO, M; FERRARI, P; SHAW, S; JAEGER, P; WEIDMANN, P				ALLEMANN, Y; HORBER, FF; COLOMBO, M; FERRARI, P; SHAW, S; JAEGER, P; WEIDMANN, P			INSULIN SENSITIVITY AND BODY-FAT DISTRIBUTION IN NORMOTENSIVE OFFSPRING OF HYPERTENSIVE PARENTS	LANCET			English	Article							MINIMAL MODEL METHOD; DIABETES-MELLITUS; ADIPOSE-TISSUE; OBESITY; GLUCOSE; RESISTANCE; METABOLISM; HYPERINSULINEMIA; WOMEN; PROFILES	Lean, healthy normotensive sons of essential hypertensive parents (OHyp) have lower insulin sensitivity (S(l)) than sons of normotensive parents (ONorm). We have tried to find out whether this disturbance in insulin metabolism is related to altered body fat distribution, fuel metabolism, or both. 21 OHyp and 21 ONorm of similar age and body-mass index were investigated after fasting overnight. Body composition was assessed by dual-energy X-ray absorptiometry and fuel metabolism by indirect calorimetry and urinary nitrogen excretion. Plasma insulin and glucose concentrations were measured during the frequent sampling intravenous glucose tolerance test, and S(l) was calculated by the minimum model method. Systolic blood pressure and heart rate were slightly but not significantly higher in OHyp than ONorm but the groups did not differ in fasting plasma insulin or glucose concentrations, carbohydrate or lipid oxidation, lean and fat mass, bone mineral content, or distribution of body fat. By contrast, S(l) was significantly lower in OHyp than ONorm (8.2 (0.7] vs 13.4 [1.5] 10(-4) L mU-1 min-1, p<0.01). Within the whole study population upper-body fat mass was positively correlated with fasting plasma insulin (r=0.33, p<0.03) and lipid oxidation was positively correlated with S(l)(r=0.35, p<0.04) and negatively correlated with subscapular/triceps skinfold thickness (r= -0.43, p<0.01 ). Thus, impairment of S(l) precedes both the development of overt hypertension and gain or redistribution of body fat. Therefore, the concept that S(l) is low as a result of altered fat distribution has to be reconsidered, at least in young male offspring of hypertensive parents.	UNIV BERN,MED POLIKLIN,FREIBURGSTR 3,CH-3010 BERN,SWITZERLAND	University of Bern			horber, Fritz/AAL-5419-2020	Ferrari, Paolo/0000-0002-9619-3104				AEBI H, 1984, ZWEITER SCHWEIZERISC, P76; ASHWELL M, 1985, BRIT MED J, V290, P1692, DOI 10.1136/bmj.290.6483.1692; BAUMGARTNER RN, 1987, AM J EPIDEMIOL, V126, P614, DOI 10.1093/oxfordjournals.aje.a114701; BEARD JC, 1986, DIABETES, V35, P362, DOI 10.2337/diabetes.35.3.362; BERGMAN RN, 1987, J CLIN INVEST, V79, P790, DOI 10.1172/JCI112886; BJORNTORP P, 1988, DIABETES METAB REV, V4, P615, DOI 10.1002/dmr.5610040607; Bjorntorp P, 1988, Horm Metab Res Suppl, V19, P23; BLAIR D, 1984, AM J EPIDEMIOL, V119, P526, DOI 10.1093/oxfordjournals.aje.a113770; CARO JF, 1991, J CLIN ENDOCR METAB, V73, P691, DOI 10.1210/jcem-73-4-691; ENDRE T, 1992, J HYPERTENS       S4, V10, P36; EVANS DJ, 1984, METABOLISM, V33, P68, DOI 10.1016/0026-0495(84)90164-1; FACCHINI FS, 1992, LANCET, V339, P1128, DOI 10.1016/0140-6736(92)90730-Q; FELDMAN R, 1969, DIABETES, V18, P478, DOI 10.2337/diab.18.7.478; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FERRANNINI E, 1983, J CLIN INVEST, V72, P1737, DOI 10.1172/JCI111133; FERRARI P, 1991, AM J MED, V91, P589, DOI 10.1016/0002-9343(91)90211-F; FERRARI P, 1991, DIABETOLOGIA, V34, P527, DOI 10.1007/BF00403291; HORBER FF, 1992, BRIT J RADIOL, V65, P895, DOI 10.1259/0007-1285-65-778-895; HORBER FF, 1991, DIABETES, V40, P141, DOI 10.2337/diabetes.40.1.141; HORBER FF, 1987, J CLIN INVEST, V79, P1181, DOI 10.1172/JCI112935; JENSEN MD, 1989, J CLIN INVEST, V83, P1168, DOI 10.1172/JCI113997; JENSEN MD, 1991, AM J CLIN NUTR, V53, P172, DOI 10.1093/ajcn/53.1.172; KISSEBAH AH, 1976, DIABETOLOGIA, V12, P563, DOI 10.1007/BF01220632; KROTKIEWSKI M, 1990, J INTERN MED, V228, P385, DOI 10.1111/j.1365-2796.1990.tb00250.x; LANDIN K, 1990, EUR J CLIN INVEST, V20, P530, DOI 10.1111/j.1365-2362.1990.tb01897.x; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; NUTTALL FQ, 1985, J AM COLL NUTR, V4, P437, DOI 10.1080/07315724.1985.10720086; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; PEIRIS AN, 1988, J CLIN ENDOCR METAB, V67, P760, DOI 10.1210/jcem-67-4-760; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SIMONSON DC, 1990, AM J PHYSIOL, V258, pE399, DOI 10.1152/ajpendo.1990.258.3.E399; STROMBLAD G, 1986, METABOLISM, V35, P323, DOI 10.1016/0026-0495(86)90148-4; YANG YJ, 1987, AM J PHYSIOL, V253, pE595, DOI 10.1152/ajpendo.1987.253.6.E595	33	116	121	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					327	331		10.1016/0140-6736(93)90135-4	http://dx.doi.org/10.1016/0140-6736(93)90135-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	8094112				2022-12-24	WOS:A1993KK93900003
J	DRIVER, CR; VALWAY, SE; MORGAN, WM; ONORATO, IM; CASTRO, KG				DRIVER, CR; VALWAY, SE; MORGAN, WM; ONORATO, IM; CASTRO, KG			TRANSMISSION OF MYCOBACTERIUM-TUBERCULOSIS ASSOCIATED WITH AIR-TRAVEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES-NAVY; OUTBREAK; INFECTION; FLIGHTS	Objective.-To investigate potential transmission of Mycobacterium tuberculosis in aircraft from a crew member with tuberculosis. Design.-Retrospective cohort study and survey. Setting.-A large US airline carrier. Participants.-A total of 212 crew members and 59 passengers who were exposed to a crew member with tuberculosis during a potentially infectious period (May through October 1992). Comparison volunteer sample of 247 unexposed crew members. Main Outcome Measures.-Positive tuberculin skin test (TST) result or tuberculosis. Results.-Rates of positive TST results were higher among foreign-born persons in all study groups. Among US-born comparisons and contacts, rates of positive TST results did not differ between comparisons and contacts exposed from May through July (5.3% vs 5.9%, respectively). However, contacts exposed from August through October had significantly higher rates of positive TST results than did contacts exposed from May through July (30% vs 5.8%, respectively; P<.001); two had documented TST conversions between September 1992 and February 1993. The risk of infection increased with increasing hours of exposure to the index case. Four (6.7%) of 59 frequent flyers were TST-positive; all flew in October. Conclusions.-Data support the conclusion that M tuberculosis was transmitted from an infectious crew member to other Grew members on an aircraft. Because of the clustering of TST-positive frequent flyers in October when the index patient was most infectious, transmission of M tuberculosis to passengers cannot be excluded.	CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	DRIVER, CR (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,DIV TB ELIMINAT,ATLANTA,GA 30333, USA.		Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				AMLER RW, 1982, JAMA-J AM MED ASSOC, V248, P2129, DOI 10.1001/jama.248.17.2129; CLAYTON AJ, 1976, AVIAT SPACE ENVIR MD, V47, P471; COMSTOCK GW, 1974, AM REV RESPIR DIS, V110, P572; CROSS ER, 1990, AM J PUBLIC HEALTH, V80, P435, DOI 10.2105/AJPH.80.4.435; DRAKE JW, 1990, AVIAT SPACE ENVIR MD, V61, P531; EISENBERG MS, 1975, LANCET, V2, P595; HARDLE W, 1990, APPLIED NONPARAMETRI, P4; HEDBERG CW, 1992, JAMA-J AM MED ASSOC, V268, P3208, DOI 10.1001/jama.268.22.3208; MCFARLAND JW, 1993, LANCET, V342, P112, DOI 10.1016/0140-6736(93)91311-9; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; NAGDA NL, 1989, DOTP15895 US DEP TRA; PALMER CE, 1956, PUBLIC HEALTH REP, V71, P633, DOI 10.2307/4589488; PEFFERS ASR, 1973, LANCET, V1, P143; RUBEN FL, 1977, AM REV RESPIR DIS, V115, P23; RUST P, 1975, AM J EPIDEMIOL, V101, P311, DOI 10.1093/oxfordjournals.aje.a112099; SNIDER DE, 1992, AM REV RESPIR DIS, V145, P494, DOI 10.1164/ajrccm/145.2_Pt_1.494; SUTHERLAND I, 1968, 10 YEAR INCIDENCE CL; SUTTON RGA, 1974, J HYG-CAMBRIDGE, V72, P441, DOI 10.1017/S0022172400023688; TAUXE RV, 1987, AM J EPIDEMIOL, V125, P150, DOI 10.1093/oxfordjournals.aje.a114498; TRUMP DH, 1993, ARCH INTERN MED, V153, P211, DOI 10.1001/archinte.153.2.211; 1983, MMWR-MORBID MORTAL W, V32, P210; 1990, MMWR-MORBID MORTAL W, V39, P1; 1976, MMWR-MORBID MORTAL W, V25, P332; 1976, MMWR-MORBID MORTAL W, V25, P317; 1990, AM REV RESPIR DIS, V142, P725; 1992, MMWR-MORBID MORTAL W, V41, P134; 1983, MMWR-MORBID MORTAL W, V32, P215	27	110	112	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					1031	1035		10.1001/jama.272.13.1031	http://dx.doi.org/10.1001/jama.272.13.1031			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089885				2022-12-24	WOS:A1994PH77500028
J	NGHIEM, P; OLLICK, T; GARDNER, P; SCHULMAN, H				NGHIEM, P; OLLICK, T; GARDNER, P; SCHULMAN, H			INTERLEUKIN-2 TRANSCRIPTIONAL BLOCK BY MULTIFUNCTIONAL CA2+/CALMODULIN KINASE	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; LYMPHOCYTE-T ACTIVATION; CALMODULIN KINASE; CLONAL ANERGY; CAM KINASE; CALCIUM; EXPRESSION; CALCINEURIN; TRANSACTIVATION; PROMOTER	IN the presence of costimulation(1), Ca2+ influx in T cells leads to activation (transcription of interleukin-2; ref 2) via calcineurin(3,4). In the absence of costimulation, Ca2+ influx results in anergy (interleukin-2 transcriptional block(5)) through an unknown mechanism. Specific attenuation of interleukin-2 transcriptional induction occurs in Jurkat T cells following pretreatment with a Ca2+ ionophore. A >90% block of inducible interleukin-2 reporter gene activity was initiated by transfection of a constitutively active mutant of multifunctional Ca2+/calmodulin-dependent protein kinase (CaM kinase or CaM kinase II)(6), but not by constitutive mutants of CaM kinase IV, calcineurin or protein kinase C. The block was complete six hours after kinase transfection and showed specificity for interleukin-2; there was no change in beta-actin transcription or in c-fos transcription induced by phorbol myristyl acetate, and a Rous sarcoma virus promoter was stimulated threefold. Multifunctional CaM kinase also attenuated interleukin-2 activation by calcineurin plus phorbol ester. T-cell receptor signalling activates multifunctional CaM kinase. These findings suggest that two Ca2+/calmodulin-responsive enzymes, multifunctional CaM kinase and calcineurin, could mediate the divergent effects of Ca2+ signals in T-lymphocyte regulation.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT MOLEC PHARMACOL & MED,STANFORD,CA 94305	Stanford University; Stanford University			Nghiem, Paul T/A-9210-2011	Nghiem, Paul T/0000-0003-2784-963X				CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HANSON PI, 1992, REV BIOCH, V61, P559; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; LI X, 1994, CYTOGENET CELL GENET, V66, P113, DOI 10.1159/000133679; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; SCHULMAN H, 1992, CELL CALCIUM, V13, P401, DOI 10.1016/0143-4160(92)90053-U; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRAYSTMAN MD, 1991, CLIN EXP IMMUNOL, V86, P291, DOI 10.1111/j.1365-2249.1991.tb05812.x	30	94	94	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					347	350		10.1038/371347a0	http://dx.doi.org/10.1038/371347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	8090206				2022-12-24	WOS:A1994PH25400057
J	FANG, FC; MCCLELLAND, M; GUINEY, DG; JACKSON, MM; HARTSTEIN, AI; MORTHLAND, VH; DAVIS, CE; MCPHERSON, DC; WELSH, J				FANG, FC; MCCLELLAND, M; GUINEY, DG; JACKSON, MM; HARTSTEIN, AI; MORTHLAND, VH; DAVIS, CE; MCPHERSON, DC; WELSH, J			VALUE OF MOLECULAR EPIDEMIOLOGIC ANALYSIS IN A NOSOCOMIAL METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS OUTBREAK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMID ANALYSIS; ARBITRARY PRIMERS; STRAINS; INFECTIONS; DNA; EPIDERMIDIS; EVOLUTION; MARKERS	Objective.-To evaluate two molecular epidemiologic methods used in the analysis of a nosocomial methicillin-resistant Staphylococcus aureus (MRSA) outbreak. Design.-Restriction endonuclease analysis of plasmid DNA (REAP) was used in the analysis of 45 MRSA isolates. After termination of the outbreak, isolates were retrospectively analyzed in a blind fashion using the newly described technique of arbitrarily primed polymerase chain reaction (AP-PCR). Molecular analyses were compared with epidemiologic and antimicrobial susceptibility data. Setting.-Tertiary care university hospital. Subjects.-Twenty-eight patients and 12 employees infected or colonized with MRSA during a 6-week period. Results.-A clonal relationship demonstrated among isolates from burn unit patients and staff was clearly distinguishable from MRSA isolates arising from other hospital wards. The combination of REAP and AP-PCR provided complementary information in several instances. Aggressive measures to isolate infected patients and eradicate colonization from patients and staff terminated the outbreak. Conclusions.-Although traditional epidemiologic methods retain their central role in modem hospital infection control, molecular epidemiologic analysis can significantly enhance the ability of infection control officers to analyze and terminate hospital epidemics. The combination of AP-PCR and REAP may prove to be a particularly informative means of tracking the nosocomial spread of microbial strains and their mobile genetic elements.	CALIF INST BIOL RES, LA JOLLA, CA USA; OREGON HLTH SCI UNIV, DEPT PATHOL, PORTLAND, OR 97201 USA; UNIV CALIF SAN DIEGO, MED CTR, DIV INFECT DIS, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, MED CTR, EPIDEMIOL UNIT, LA JOLLA, CA 92093 USA	Oregon Health & Science University; University of California System; University of California San Diego; University of California System; University of California San Diego			McClelland, Michael/A-8583-2011	Fang, Ferric/0000-0002-3243-110X; McClelland, Michael/0000-0003-1788-9347				[Anonymous], 1961, BMJ-BRIT MED J, V1, P113; ARCHER GL, 1983, J CLIN MICROBIOL, V18, P395, DOI 10.1128/JCM.18.2.395-399.1983; BENNER EJ, 1968, LANCET, V2, P741; BOYCE JM, 1991, INFECT CONT HOSP EP, V12, P46, DOI 10.2307/30147088; BOYCE JM, 1983, JAMA-J AM MED ASSOC, V249, P2803, DOI 10.1001/jama.249.20.2803; BRANGER C, 1987, J MED MICROBIOL, V24, P275, DOI 10.1099/00222615-24-3-275; BRANGER C, 1990, J CLIN MICROBIOL, V28, P150, DOI 10.1128/JCM.28.1.150-151.1990; BRAUDE AI, 1955, ANTIBIOT ANNU, P1133; BRUMFITT W, 1989, NEW ENGL J MED, V320, P1188, DOI 10.1056/NEJM198905043201806; Chambers H.F., 1988, CLIN MICROBIOL REV, V1, P173, DOI DOI 10.1128/CMR.1.2.173; COHEN ML, 1982, ANTIMICROB AGENTS CH, V21, P210, DOI 10.1128/AAC.21.2.210; CRISTINO JAGM, 1989, J HOSP INFECT, V13, P133, DOI 10.1016/0195-6701(89)90019-4; EISENSTEIN BI, 1990, J INFECT DIS, V161, P595, DOI 10.1093/infdis/161.4.595; FRENCH GL, 1990, J HOSP INFECT, V15, P117, DOI 10.1016/0195-6701(90)90120-D; HALL LMC, 1989, EPIDEMIOL INFECT, V103, P183, DOI 10.1017/S095026880003048X; HARTSTEIN AI, 1989, J CLIN MICROBIOL, V27, P1874, DOI 10.1128/JCM.27.8.1874-1879.1989; KOZARSKY PE, 1986, INFECT CONT HOSP EP, V7, P577, DOI 10.1017/S0195941700065413; KREISWIRTH B, 1993, SCIENCE, V259, P227, DOI 10.1126/science.8093647; LACEY RW, 1973, J MED MICROBIOL, V6, P511, DOI 10.1099/00222615-6-4-511; LOCKSLEY RM, 1982, ANN INTERN MED, V97, P317, DOI 10.7326/0003-4819-97-3-317; LUPSKI JR, 1987, REV INFECT DIS, V9, P357; LYON BR, 1987, MICROBIOL REV, V51, P88, DOI 10.1128/MMBR.51.1.88-134.1987; MCDONNELL RW, 1983, ANTIMICROB AGENTS CH, V23, P151, DOI 10.1128/AAC.23.1.151; MCMANUS AT, 1989, ARCH SURG-CHICAGO, V124, P1456; MUDER RR, 1991, ANN INTERN MED, V114, P107, DOI 10.7326/0003-4819-114-2-1-107; MULLIGAN ME, 1991, INFECT CONT HOSP EP, V12, P20, DOI 10.2307/30147085; PEACOCK JE, 1980, ANN INTERN MED, V93, P526, DOI 10.7326/0003-4819-93-4-526; PFALLER MA, 1991, DIAGN MICR INFEC DIS, V14, P209, DOI 10.1016/0732-8893(91)90034-D; PFALLER MA, 1991, MANUAL CLIN MICROBIO, P171; RALPH D, 1993, J BACTERIOL, V175, P973, DOI 10.1128/JB.175.4.973-981.1993; REBOLI AC, 1990, INFECT CONT HOSP EP, V11, P291, DOI 10.1086/646174; RHINEHART E, 1987, ARCH INTERN MED, V147, P521, DOI 10.1001/archinte.147.3.521; RUTALA WA, 1983, J CLIN MICROBIOL, V18, P683, DOI 10.1128/JCM.18.3.683-688.1983; Sambrook J., 1989, MOL CLONING LAB MANU; SCHABERG DR, 1986, REV INFECT DIS, V8, P705; STEWART G T, 1963, Br Med J, V1, P308; WACHSMUTH K, 1986, REV INFECT DIS, V8, P682; WAKEFIELD DS, 1988, AM J INFECT CONTROL, V16, P185, DOI 10.1016/0196-6553(88)90058-2; WELSH J, 1992, INT J SYST BACTERIOL, V42, P370, DOI 10.1099/00207713-42-3-370; WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213; Welsh John, 1993, P595; WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531	42	32	33	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1323	1328		10.1001/jama.270.11.1323	http://dx.doi.org/10.1001/jama.270.11.1323			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8103118				2022-12-24	WOS:A1993LW34500029
J	JAMIL, S; KEER, JT; LUCAS, SB; DOCKRELL, HM; CHIANG, TJ; HUSSAIN, R; STOKER, NG				JAMIL, S; KEER, JT; LUCAS, SB; DOCKRELL, HM; CHIANG, TJ; HUSSAIN, R; STOKER, NG			USE OF POLYMERASE CHAIN-REACTION TO ASSESS EFFICACY OF LEPROSY CHEMOTHERAPY	LANCET			English	Article							MYCOBACTERIUM-LEPRAE; BIOPSIES; THERAPY; PCR	The assessment of chemotherapy efficacy in leprosy is difficult, since the only reliable method for determining whether the causative organism, Mycobacterium leprae, is viable depends on its growth in mouse foot pads. In an attempt to replace this expensive, time-consuming test, methods based on the polymerase chain reaction (PCR) have been developed. These methods depend on detection of DNA, which is more susceptible to degradation on cell death than are other cell components, so should be a more accurate indicator of viability. We have used a specific PCR assay to detect M leprae DNA in skin biopsy samples from leprosy patients. By use of limiting dilution PCR (LD-PCR), the concentration of M leprae DNA in the original sample could be measured. The DNA concentration was more closely correlated with the morphological index (derived from a staining technique that distinguishes morphologically intact and damaged bacteria) than with the number of bacteria visible (bacterial index, BI, which counts both alive and dead bacteria). In a longitudinal study of multibacillary patients on multi-drug therapy, skin biopsy samples were collected before treatment and 3, 6, 12, and 24 months after the start of therapy. While the BI showed little or no change during treatment, the number of genomes detected by PCR fell sharply, in parallel with the MI. We propose that PCR can be used as a rapid measure of M leprae viability and that this approach can be used for monitoring individual leprosy patients and for assessment of existing and new regimens. The method may be applicable to other infectious diseases in which culture of the causative organism is slow or impossible.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT CLIN SCI, KEPPEL ST, LONDON WC1E 7HT, ENGLAND; AGA KHAN UNIV, DEPT MICROBIOL, KARACHI, PAKISTAN; MARIE ADELAIDE LEPROSY CTR, KARACHL, PAKISTAN; UNIV LONDON UNIV COLL, SCH MED, DEPT HISTOPATHOL, LONDON WC1E 6BT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine; Aga Khan University; University of London; University College London; UCL Medical School			Stoker, Neil G/L-8812-2016; Hussain, Rabia/E-9982-2015	Stoker, Neil G/0000-0001-7055-6184; Dockrell, Hazel/0000-0003-1869-9107				BANCROFT JD, 1984, MAUAL HISTOLOGICAL T, P207; BAOHONG J, 1987, International Journal of Leprosy and Other Mycobacterial Diseases, V55, P830; BECXBLEUMINCK M, 1989, INT J LEPROSY, V57, P540; COLSTON M J, 1987, International Journal of Leprosy and Other Mycobacterial Diseases, V55, P859; DEWIT MYL, 1991, J CLIN MICROBIOL, V29, P906, DOI 10.1128/JCM.29.5.906-910.1991; Grosset J H, 1986, Lepr Rev, V57 Suppl 3, P223; GROSSET JH, 1988, INT J LEPROSY, V56, P259; Haas M, 1993, Int J Antimicrob Agents, V2, P117, DOI 10.1016/0924-8579(93)90050-F; HARTSKEERL RA, 1989, J GEN MICROBIOL, V135, P2357; HONORE N, 1993, ANTIMICROB AGENTS CH, V37, P414, DOI 10.1128/AAC.37.3.414; Leiker D L, 1971, Lepr Rev, V42, P121; MCCULLAGH P, 1984, GENERALIZED LINEAR M, P1; MCRAE DH, 1971, INFECT IMMUN, V3, P116, DOI 10.1128/IAI.3.1.116-120.1971; REES RJW, 1985, LEPROSY, P31; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; RIDLEY D. S., 1958, LEPROSY REV, V29, P45; RIDLEY D. S., 1955, TRANS ROY SOC TROP MED AND HYG, V49, P449, DOI 10.1016/0035-9203(55)90010-9; Ridley D S, 1967, Int J Lepr Other Mycobact Dis, V35, P184; Ridley M J, 1971, Lepr Rev, V42, P88; SHEPARD CC, 1974, AM J TROP MED HYG, V23, P1120, DOI 10.4269/ajtmh.1974.23.1120; Sheppard CC, 1985, LEPROSY, P269; VEGALOPEZ F, 1993, INFECT IMMUN, V61, P2145; Waters M F, 1974, Lepr Rev, V45, P288; WATERS M F, 1962, Int J Lepr, V30, P266; WILLIAMS DL, 1990, J INFECT DIS, V162, P193, DOI 10.1093/infdis/162.1.193; WILLIAMS DL, 1992, MOL CELL PROBE, V6, P401, DOI 10.1016/0890-8508(92)90034-U; WOODS SA, 1989, FEMS MICROBIOL LETT, V65, P305; WHO82 TECH REP, P675; 1987, INT J LEPROSY, V55, P864	29	37	40	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 31	1993	342	8866					264	268		10.1016/0140-6736(93)91816-5	http://dx.doi.org/10.1016/0140-6736(93)91816-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101301				2022-12-24	WOS:A1993LQ16300009
J	BRESTERS, D; MAUSERBUNSCHOTEN, EP; REESINK, HW; ROOSENDAAL, G; VANDERPOEL, CL; CHAMULEAU, RAFM; JANSEN, PLM; WEEGINK, CJ; CUYPERS, HTM; LELIE, PN; VANDENBERG, HM				BRESTERS, D; MAUSERBUNSCHOTEN, EP; REESINK, HW; ROOSENDAAL, G; VANDERPOEL, CL; CHAMULEAU, RAFM; JANSEN, PLM; WEEGINK, CJ; CUYPERS, HTM; LELIE, PN; VANDENBERG, HM			SEXUAL TRANSMISSION OF HEPATITIS-C VIRUS	LANCET			English	Note							SPOUSES; SEMEN	We tested 50 heterosexual partners of hepatitis C viraemic (HCV) individuals, using second generation HCV antibody assays and a validated polymerase chain reaction assay. In none of them were HCV antibodies or HCV-RNA detected. The median duration of the sexual relationship was 13 years. This study, with the most sensitive techniques for detection of HCV, indicates that the risk of sexual transmission of HCV is absent or very low.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,1105 AZ AMSTERDAM,NETHERLANDS; UNIV UTRECHT HOSP,VAN CREVELD CLIN,3511 GV UTRECHT,NETHERLANDS; PRINSENGRACHT HOSP,AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Utrecht University Medical Center	BRESTERS, D (corresponding author), RED CROSS BLOOD BANK,POB 9137,1006 AC AMSTERDAM,NETHERLANDS.		Jansen, Peter LM/I-4509-2013; Valente, Guido/B-9714-2013					AKAHANE Y, 1992, LANCET, V339, P1059, DOI 10.1016/0140-6736(92)90585-Q; BRETTLER DB, 1992, BLOOD, V80, P540; CYPERS HTM, 1992, J CLIN MICROBIOL, V30, P3220; HSU HH, 1991, HEPATOLOGY, V14, P763, DOI 10.1002/hep.1840140504; JENISON SA, 1987, J INFECT DIS, V156, P299, DOI 10.1093/infdis/156.2.299; KAO JH, 1992, J INFECT DIS, V166, P900, DOI 10.1093/infdis/166.4.900; KELLOGG DE, 1990, PCR PROTOCOLS GUIDE, P343; OSMOND DH, 1993, JAMA-J AM MED ASSOC, V269, P361, DOI 10.1001/jama.269.3.361; TERADA S, 1992, ANN INTERN MED, V117, P171, DOI 10.7326/0003-4819-117-2-171_2; Urdea M S, 1991, Nucleic Acids Symp Ser, P197; ZAAIJER HL, 1993, LANCET, V341, P722, DOI 10.1016/0140-6736(93)90488-3	11	189	189	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 24	1993	342	8865					210	211		10.1016/0140-6736(93)92300-I	http://dx.doi.org/10.1016/0140-6736(93)92300-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN622	8100931				2022-12-24	WOS:A1993LN62200013
J	LANDRY, SJ; ZEILSTRARYALLS, J; FAYET, O; GEORGOPOULOS, C; GIERASCH, LM				LANDRY, SJ; ZEILSTRARYALLS, J; FAYET, O; GEORGOPOULOS, C; GIERASCH, LM			CHARACTERIZATION OF A FUNCTIONALLY IMPORTANT MOBILE DOMAIN OF GROES	NATURE			English	Article							ESCHERICHIA-COLI; PROTEIN; CHAPERONIN; ATP	ALTHOUGH genetic1 and biochemical2,3 evidence has established that GroES is required for the full function of the molecular chaperone, GroEL, little is known about the molecular details of their interaction. GroES enhances the cooperativity of ATP binding and hydrolysis by GroEL (refs 4, 5) and is necessary for release and folding of several GroEL substrates6. Here we report that native GroES has a highly mobile and accessible polypeptide loop whose mobility and accessibility are lost upon formation of the GroES/GroEL complex. In addition, lesions present in eight independently isolated mutant groES alleles map in the mobile loop. Studies with synthetic peptides suggest that the loop binds in a hairpin conformation at a site on GroEL that is distinct from the substrate-binding site. Flexibility may be required in the mobile loops on the GroES seven-mer to allow them to bind simultaneously to sites on seven GroEL subunits, which may themselves be able to adopt different arrangements, and thus to modulate allosterically GroEL/substrate affinity.	UNIV TEXAS,SW MED CTR,DALLAS,TX 75235; UNIV GENEVA,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND; UNIV UTAH,MED CTR,SALT LAKE CITY,UT 84132	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Geneva; Utah System of Higher Education; University of Utah			Landry, Samuel/AAK-5778-2020; Gierasch, Lila M/D-1494-2009	Landry, Samuel/0000-0002-4082-0543; 				BERTSCH U, 1992, P NATL ACAD SCI USA, V89, P8696, DOI 10.1073/pnas.89.18.8696; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P45; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; NILSSON B, 1991, ANNU REV MICROBIOL, V45, P607; OHTAKA C, 1992, J BACTERIOL, V174, P1869, DOI 10.1128/jb.174.6.1869-1874.1992; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TILLY K, 1982, J BACTERIOL, V149, P1082, DOI 10.1128/JB.149.3.1082-1088.1982; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K., 1986, NMR PROTEINS NUCL AC	24	212	214	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					255	258		10.1038/364255a0	http://dx.doi.org/10.1038/364255a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8100614				2022-12-24	WOS:A1993LM68300063
J	GURNEY, H; GRILL, V; MARTIN, TJ				GURNEY, H; GRILL, V; MARTIN, TJ			PARATHYROID HORMONE-RELATED PROTEIN AND RESPONSE TO PAMIDRONATE IN TUMOR-INDUCED HYPERCALCEMIA	LANCET			English	Article							MALIGNANCY-ASSOCIATED HYPERCALCEMIA; SERUM-CALCIUM; BISPHOSPHONATE; THRESHOLD; SINGLE	To find out if the concentration of parathyroid hormone-related protein (PTHrP) predicts the response of tumour-inducing hypercalcaemia (TIH) to pamidronate, we studied 44 patients. Pretreatment measurements of serum PTHrP, calcium and phosphate, nephrogenous cyclic AMP, tubular threshold for calcium and phosphate (TmP), and the presence of bone metastases were correlated with response to pamidronate. Response was considered good (normal calcium concentration corrected for albumin [CCa] for > 14 days), or poor (failure of CCa to fall, or a rise above normal less-than-or-equal-to 14 days). PTHrP correlated significantly with response (good vs poor, p = 0.02). Undetectable PTHrP (< 2 pmol/L) was associated with a good response in all seven treatments, PTHrP in the range 2-12 pmol/L was associated with good response in 10 of 14 treatments, while PTHrP greater-than-or-equal-to 12 pmol/L was associated with a poor response in all 11 treatments. Tubular threshold for calcium correlated with the fall in CCa by day 6 after treatment (p = 0.02). Urinary clearance estimations in poor responders suggested that there was an incomplete reversal of the renal tubular component of hypercalcaemia. Serum PTHrP correlates with response to pamidronate in the treatment of TIH; which may be associated with a renal tubular mechanism not significantly affected by currently available treatment. Drugs that inhibit tubular reabsorption of calcium or PTHrP secretion may help in patients who do not respond to pamidronate.	ST VINCENTS HOSP,DEPT MED,FITZROY,VIC 3065,AUSTRALIA; ST VINCENTS HOSP,INST MED RES,FITZROY,VIC 3065,AUSTRALIA	St Vincent's Hospital Melbourne; St Vincent's Hospital Melbourne; University of Sydney; Westmead Institute for Medical Research	GURNEY, H (corresponding author), WESTMEAD HOSP,DEPT MED ONCOL & PALLIAT CARE,WESTMEAD,NSW 2145,AUSTRALIA.		Gurney, Howard/ABF-6924-2020	Gurney, Howard/0000-0003-0217-5261				BILEZIKIAN JP, 1992, NEW ENGL J MED, V326, P1196; BROADUS AE, 1977, ADV CYCLIC NUCLEOTID, P509; FLEISCH H, 1982, BONE MINERAL RES ANN, P319; GOLDMAN ME, 1988, ENDOCRINOLOGY, V123, P2597, DOI 10.1210/endo-123-5-2597; GRILL V, 1991, J CLIN ENDOCR METAB, V73, P1309, DOI 10.1210/jcem-73-6-1309; GRILL V, 1992, J CLIN ENDOCR METAB, V74, P1468, DOI 10.1210/jc.74.6.1468; GURNEY H, 1989, LANCET, V2, P241; KLEEREKOPER M, 1974, CLIN CHEM, V20, P369; KUKREJA SC, 1988, J CLIN INVEST, V82, P1798, DOI 10.1172/JCI113794; MARTIN TJ, 1991, CRIT REV BIOCHEM MOL, V26, P377, DOI 10.3109/10409239109114073; MUNDY GR, 1982, METABOLISM, V31, P1247, DOI 10.1016/0026-0495(82)90012-9; Nordin B.E.C., 1976, CALCIUM PHOSPHATE MA; POWELL GJ, 1991, CANCER RES, V51, P3059; RALSTON SH, 1987, BONE MINER, V2, P227; RALSTON SH, 1989, LANCET, V2, P617; THIEBAUD D, 1988, J CLIN ONCOL, V6, P762, DOI 10.1200/JCO.1988.6.5.762; VANBREUKELEN FJM, 1982, CALCIFIED TISSUE INT, V34, P321, DOI 10.1007/BF02411261; WALTON RJ, 1975, LANCET, V2, P309, DOI 10.1016/S0140-6736(75)92736-1; WARRELL RP, 1988, J CLIN ONCOL, V6, P759, DOI 10.1200/JCO.1988.6.5.759; WIRSCHEL SS, 1985, J CLIN INVEST, V76, P1851; YATES AJP, 1987, AUST NZ J MED, V17, P387, DOI 10.1111/j.1445-5994.1987.tb00070.x	21	78	78	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 26	1993	341	8861					1611	1613		10.1016/0140-6736(93)90756-7	http://dx.doi.org/10.1016/0140-6736(93)90756-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ727	8099988				2022-12-24	WOS:A1993LJ72700002
J	BERAL, V				BERAL, V			BREAST-CANCER - MAMMOGRAPHIC SCREENING	LANCET			English	Editorial Material											BERAL, V (corresponding author), ICRF,CANC EPIDEMIOL UNIT,OXFORD,ENGLAND.							MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; PEETERS PHM, 1989, BRIT J CANCER, V59, P929, DOI 10.1038/bjc.1989.196; Shapiro S, 1985, Natl Cancer Inst Monogr, V67, P65; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; [No title captured]	6	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 12	1993	341	8859					1509	1510		10.1016/0140-6736(93)90639-X	http://dx.doi.org/10.1016/0140-6736(93)90639-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG242	8099384				2022-12-24	WOS:A1993LG24200008
J	BOOTH, IW				BOOTH, IW			PEDIATRIC GASTROENTEROLOGY - DIETARY-MANAGEMENT OF ACUTE DIARRHEA IN CHILDHOOD	LANCET			English	Editorial Material							CHILDREN; MILK				BOOTH, IW (corresponding author), UNIV BIRMINGHAM,INST CHILD HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							ARMITSTEAD J, 1989, J PEDIATR GASTR NUTR, V8, P240, DOI 10.1097/00005176-198902000-00019; BOUDRAA G, 1990, J PEDIATR GASTR NUTR, V11, P509, DOI 10.1097/00005176-199011000-00011; BROWN KH, 1988, J PEDIATR-US, V112, P191, DOI 10.1016/S0022-3476(88)80055-6; CHUNG AW, 1948, J PEDIATR-US, V33, P1, DOI 10.1016/S0022-3476(48)80147-2; FILHO LAD, 1993, LANCET, V341, P194; GODARD C, 1989, J PEDIATR GASTR NUTR, V9, P473, DOI 10.1097/00005176-198911000-00014; REES L, 1979, LANCET, V1, P770; WHARTON BA, 1988, BMJ-BRIT MED J, V296, P450, DOI 10.1136/bmj.296.6620.450; 1987, LANCET, V1, P23	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					996	997		10.1016/0140-6736(93)91079-2	http://dx.doi.org/10.1016/0140-6736(93)91079-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	8096951				2022-12-24	WOS:A1993KY36800011
J	BENNETT, G				BENNETT, G			PEST-CONTROL - COCKROACHES AS CARRIERS OF BACTERIA	LANCET			English	Editorial Material											BENNETT, G (corresponding author), PURDUE UNIV,DEPT ENTOMOL,W LAFAYETTE,IN 47907, USA.							ALCAMO IE, 1980, J ENVIRON HEALTH, V42, P263; Bennett G. W., 1986, ADV URBAN PEST MANAG; CLOAREC A, 1992, EPIDEMIOL INFECT, V109, P483, DOI 10.1017/S0950268800050470; GRAFFAR M, 1950, ANN I PASTEUR PARIS, V79, P654; Roth Louis M., 1957, MED VET IMPORTANCE C	5	16	18	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 20	1993	341	8847					732	732		10.1016/0140-6736(93)90497-5	http://dx.doi.org/10.1016/0140-6736(93)90497-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT362	8095634				2022-12-24	WOS:A1993KT36200014
J	RUCKLEY, CV				RUCKLEY, CV			VENOUS DISEASE - DOES VENOUS REFLUX MATTER	LANCET			English	Editorial Material							ULCERATION; LEG				RUCKLEY, CV (corresponding author), ROYAL EDINBURGH & ASSOCIATED HOSP,VASC SURG UNIT,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND.							CALLAM MJ, 1987, BRIT MED J, V295, P1382, DOI 10.1136/bmj.295.6610.1382; CALLAM MJ, 1985, BRIT MED J, V290, P1855, DOI 10.1136/bmj.290.6485.1855; Dale J J, 1983, Health Bull (Edinb), V41, P310; LAING W, 1992, CHRONIC VENOUS DISEA, P25; SETHIA KK, 1984, BRIT J SURG, V71, P754, DOI 10.1002/bjs.1800711006	5	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 13	1993	341	8842					411	412		10.1016/0140-6736(93)92997-8	http://dx.doi.org/10.1016/0140-6736(93)92997-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM416	8094177				2022-12-24	WOS:A1993KM41600012
J	STEWART, GSAB				STEWART, GSAB			BIOSENSORS - BACTERIAL LUMINESCENCE - DEVELOPMENT AND APPLICATION	LANCET			English	Editorial Material							ESCHERICHIA-COLI; BIOLUMINESCENCE; GENE				STEWART, GSAB (corresponding author), UNIV NOTTINGHAM,DEPT APPL BIOCHEM & FOOD SCI,NOTTINGHAM NG7 2RD,ENGLAND.							GUZZO A, 1991, APPL ENVIRON MICROB, V57, P2255, DOI 10.1128/AEM.57.8.2255-2259.1991; HEITZER A, 1992, APPL ENVIRON MICROB, V58, P1839, DOI 10.1128/AEM.58.6.1839-1846.1992; JASSIM SAA, 1990, J BIOLUM CHEMILUM, V5, P115, DOI 10.1002/bio.1170050207; KORPELA M, 1989, J BIOLUM CHEMILUM, V4, P551, DOI 10.1002/bio.1170040172; LILIUS EM, 1986, BIOLUMINESCENCE CHEM, P431; MEIGHEN EA, 1988, ANNU REV MICROBIOL, V42, P151, DOI 10.1146/annurev.mi.42.100188.001055; MOELDERS H, 1990, Patent No. 239981; RYCHERT R, 1991, ENVIRON TOXIC WATER, V6, P415, DOI 10.1002/tox.2530060406; SHAW JJ, 1986, BIO-TECHNOL, V4, P560, DOI 10.1038/nbt0686-560; STEWART GSAB, 1992, J GEN MICROBIOL, V138, P1289, DOI 10.1099/00221287-138-7-1289	10	5	5	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 30	1993	341	8840					279	280		10.1016/0140-6736(93)92622-Z	http://dx.doi.org/10.1016/0140-6736(93)92622-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK245	8093923				2022-12-24	WOS:A1993KK24500010
J	BATES, C				BATES, C			VITAMIN-A AND INFANT IMMUNITY	LANCET			English	Editorial Material							DEFICIENCY											BENDICH A, 1990, ANN NY ACAD SCI, V587, P168, DOI 10.1111/j.1749-6632.1990.tb00144.x; MEYDANI SN, 1991, AM J CLIN NUTR, V53, P1275, DOI 10.1093/ajcn/53.5.1275; SEMBA RD, 1992, J NUTR, V122, P101, DOI 10.1093/jn/122.1.101; THURNHAM DI, 1989, T ROY SOC TROP MED H, V83, P721, DOI 10.1016/0035-9203(89)90308-8	5	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 2	1993	341	8836					28	28		10.1016/0140-6736(93)92494-E	http://dx.doi.org/10.1016/0140-6736(93)92494-E			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	8093277				2022-12-24	WOS:A1993KF02700016
